0001090872-20-000020.txt : 20201218 0001090872-20-000020.hdr.sgml : 20201218 20201217195621 ACCESSION NUMBER: 0001090872-20-000020 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 139 CONFORMED PERIOD OF REPORT: 20201031 FILED AS OF DATE: 20201218 DATE AS OF CHANGE: 20201217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AGILENT TECHNOLOGIES, INC. CENTRAL INDEX KEY: 0001090872 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 770518772 STATE OF INCORPORATION: DE FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15405 FILM NUMBER: 201397647 BUSINESS ADDRESS: STREET 1: 5301 STEVENS CREEK BLVD CITY: SANTA CLARA STATE: CA ZIP: 95051 BUSINESS PHONE: (408) 345-8886 MAIL ADDRESS: STREET 1: 5301 STEVENS CREEK BLVD, MS 1A-LC STREET 2: P.O. BOX 58059 CITY: SANTA CLARA STATE: CA ZIP: 95052-8059 FORMER COMPANY: FORMER CONFORMED NAME: AGILENT TECHNOLOGIES INC DATE OF NAME CHANGE: 19990816 FORMER COMPANY: FORMER CONFORMED NAME: HP MEASUREMENT INC DATE OF NAME CHANGE: 19990716 10-K 1 a-20201031.htm 10-K a-20201031
0001090872false2020FY00010908722019-11-012020-10-31iso4217:USD00010908722020-04-30xbrli:shares00010908722020-12-100001090872us-gaap:ProductMember2019-11-012020-10-310001090872us-gaap:ProductMember2018-11-012019-10-310001090872us-gaap:ProductMember2017-11-012018-10-310001090872us-gaap:ServiceOtherMember2019-11-012020-10-310001090872us-gaap:ServiceOtherMember2018-11-012019-10-310001090872us-gaap:ServiceOtherMember2017-11-012018-10-3100010908722018-11-012019-10-3100010908722017-11-012018-10-31iso4217:USDxbrli:shares00010908722020-10-3100010908722019-10-3100010908722018-10-3100010908722017-10-310001090872us-gaap:CommonStockMember2017-10-310001090872us-gaap:AdditionalPaidInCapitalMember2017-10-310001090872us-gaap:RetainedEarningsMember2017-10-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-10-310001090872us-gaap:ParentMember2017-10-310001090872us-gaap:NoncontrollingInterestMember2017-10-310001090872us-gaap:RetainedEarningsMember2017-11-012018-10-310001090872us-gaap:ParentMember2017-11-012018-10-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-11-012018-10-310001090872us-gaap:CommonStockMember2017-11-012018-10-310001090872us-gaap:AdditionalPaidInCapitalMember2017-11-012018-10-310001090872us-gaap:CommonStockMember2018-10-310001090872us-gaap:AdditionalPaidInCapitalMember2018-10-310001090872us-gaap:RetainedEarningsMember2018-10-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-10-310001090872us-gaap:ParentMember2018-10-310001090872us-gaap:NoncontrollingInterestMember2018-10-310001090872us-gaap:RetainedEarningsMembersrt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember2018-10-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMembersrt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember2018-10-310001090872us-gaap:ParentMembersrt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember2018-10-310001090872srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember2018-10-310001090872us-gaap:RetainedEarningsMember2018-11-012019-10-310001090872us-gaap:ParentMember2018-11-012019-10-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-11-012019-10-310001090872us-gaap:NoncontrollingInterestMember2018-11-012019-10-310001090872us-gaap:CommonStockMember2018-11-012019-10-310001090872us-gaap:AdditionalPaidInCapitalMember2018-11-012019-10-310001090872us-gaap:CommonStockMember2019-10-310001090872us-gaap:AdditionalPaidInCapitalMember2019-10-310001090872us-gaap:RetainedEarningsMember2019-10-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-10-310001090872us-gaap:ParentMember2019-10-310001090872us-gaap:NoncontrollingInterestMember2019-10-310001090872us-gaap:RetainedEarningsMember2019-11-012020-10-310001090872us-gaap:ParentMember2019-11-012020-10-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-11-012020-10-310001090872us-gaap:CommonStockMember2019-11-012020-10-310001090872us-gaap:AdditionalPaidInCapitalMember2019-11-012020-10-310001090872us-gaap:CommonStockMember2020-10-310001090872us-gaap:AdditionalPaidInCapitalMember2020-10-310001090872us-gaap:RetainedEarningsMember2020-10-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-10-310001090872us-gaap:ParentMember2020-10-310001090872us-gaap:NoncontrollingInterestMember2020-10-310001090872us-gaap:NonUsMember2020-10-31a:numberOfCustomers0001090872us-gaap:AccountsReceivableMember2020-10-310001090872us-gaap:MachineryAndEquipmentMembersrt:MinimumMember2019-11-012020-10-310001090872us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2019-11-012020-10-310001090872us-gaap:SoftwareDevelopmentMembersrt:MinimumMember2019-11-012020-10-310001090872us-gaap:SoftwareDevelopmentMembersrt:MaximumMember2019-11-012020-10-310001090872srt:MinimumMember2019-11-012020-10-310001090872srt:MaximumMember2019-11-012020-10-310001090872a:LasergenMember2018-11-012019-10-310001090872us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2020-10-310001090872us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2019-10-310001090872us-gaap:AccountingStandardsUpdate201602Member2019-11-0100010908722019-11-010001090872a:BioTekMember2019-08-232019-08-230001090872a:BioTekMember2019-08-230001090872a:BioTekMemberus-gaap:DevelopedTechnologyRightsMember2019-08-230001090872srt:MinimumMembera:BioTekMemberus-gaap:DevelopedTechnologyRightsMember2019-08-232019-08-230001090872srt:MaximumMembera:BioTekMemberus-gaap:DevelopedTechnologyRightsMember2019-08-232019-08-230001090872us-gaap:CustomerRelationshipsMembera:BioTekMember2019-08-230001090872srt:MinimumMemberus-gaap:CustomerRelationshipsMembera:BioTekMember2019-08-232019-08-230001090872srt:MaximumMemberus-gaap:CustomerRelationshipsMembera:BioTekMember2019-08-232019-08-230001090872us-gaap:OrderOrProductionBacklogMembera:BioTekMember2019-08-230001090872us-gaap:OrderOrProductionBacklogMembera:BioTekMember2019-08-232019-08-230001090872us-gaap:TrademarksAndTradeNamesMembera:BioTekMember2019-08-230001090872us-gaap:TrademarksAndTradeNamesMembera:BioTekMember2019-08-232019-08-230001090872a:BioTekMember2020-10-310001090872a:BioTekMember2019-10-310001090872a:ACEABiosciencesInc.Member2018-11-142018-11-140001090872srt:AmericasMembera:LifeSciencesandAppliedMarketsMember2019-11-012020-10-310001090872a:AgilentCrossLabMembersrt:AmericasMember2019-11-012020-10-310001090872a:DiagnosticsAndGenomicsMembersrt:AmericasMember2019-11-012020-10-310001090872srt:AmericasMember2019-11-012020-10-310001090872srt:EuropeMembera:LifeSciencesandAppliedMarketsMember2019-11-012020-10-310001090872a:AgilentCrossLabMembersrt:EuropeMember2019-11-012020-10-310001090872srt:EuropeMembera:DiagnosticsAndGenomicsMember2019-11-012020-10-310001090872srt:EuropeMember2019-11-012020-10-310001090872a:LifeSciencesandAppliedMarketsMembersrt:AsiaPacificMember2019-11-012020-10-310001090872a:AgilentCrossLabMembersrt:AsiaPacificMember2019-11-012020-10-310001090872a:DiagnosticsAndGenomicsMembersrt:AsiaPacificMember2019-11-012020-10-310001090872srt:AsiaPacificMember2019-11-012020-10-310001090872a:LifeSciencesandAppliedMarketsMember2019-11-012020-10-310001090872a:AgilentCrossLabMember2019-11-012020-10-310001090872a:DiagnosticsAndGenomicsMember2019-11-012020-10-310001090872srt:AmericasMembera:LifeSciencesandAppliedMarketsMember2018-11-012019-10-310001090872a:AgilentCrossLabMembersrt:AmericasMember2018-11-012019-10-310001090872a:DiagnosticsAndGenomicsMembersrt:AmericasMember2018-11-012019-10-310001090872srt:AmericasMember2018-11-012019-10-310001090872srt:EuropeMembera:LifeSciencesandAppliedMarketsMember2018-11-012019-10-310001090872a:AgilentCrossLabMembersrt:EuropeMember2018-11-012019-10-310001090872srt:EuropeMembera:DiagnosticsAndGenomicsMember2018-11-012019-10-310001090872srt:EuropeMember2018-11-012019-10-310001090872a:LifeSciencesandAppliedMarketsMembersrt:AsiaPacificMember2018-11-012019-10-310001090872a:AgilentCrossLabMembersrt:AsiaPacificMember2018-11-012019-10-310001090872a:DiagnosticsAndGenomicsMembersrt:AsiaPacificMember2018-11-012019-10-310001090872srt:AsiaPacificMember2018-11-012019-10-310001090872a:LifeSciencesandAppliedMarketsMember2018-11-012019-10-310001090872a:AgilentCrossLabMember2018-11-012019-10-310001090872a:DiagnosticsAndGenomicsMember2018-11-012019-10-310001090872a:PharmaceuticalandBiopharmaceuticalMarketMember2019-11-012020-10-310001090872a:PharmaceuticalandBiopharmaceuticalMarketMember2018-11-012019-10-310001090872a:ChemicalandEnergyMarketMember2019-11-012020-10-310001090872a:ChemicalandEnergyMarketMember2018-11-012019-10-310001090872a:DiagnosticsandClinicalMarketMember2019-11-012020-10-310001090872a:DiagnosticsandClinicalMarketMember2018-11-012019-10-310001090872a:FoodMarketMember2019-11-012020-10-310001090872a:FoodMarketMember2018-11-012019-10-310001090872a:AcademiaandGovernmentMarketMember2019-11-012020-10-310001090872a:AcademiaandGovernmentMarketMember2018-11-012019-10-310001090872a:EnvironmentalandForensicsMarketMember2019-11-012020-10-310001090872a:EnvironmentalandForensicsMarketMember2018-11-012019-10-310001090872a:InstrumentationMember2019-11-012020-10-310001090872a:InstrumentationMember2018-11-012019-10-310001090872a:NonInstrumentationandOtherMember2019-11-012020-10-310001090872a:NonInstrumentationandOtherMember2018-11-012019-10-310001090872us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member2018-11-012018-11-01xbrli:pure0001090872us-gaap:EmployeeStockMember2020-10-310001090872us-gaap:EmployeeStockOptionMember2019-11-012020-10-310001090872us-gaap:RestrictedStockUnitsRSUMember2019-11-012020-10-310001090872us-gaap:CostOfSalesMember2019-11-012020-10-310001090872us-gaap:CostOfSalesMember2018-11-012019-10-310001090872us-gaap:CostOfSalesMember2017-11-012018-10-310001090872us-gaap:ResearchAndDevelopmentExpenseMember2019-11-012020-10-310001090872us-gaap:ResearchAndDevelopmentExpenseMember2018-11-012019-10-310001090872us-gaap:ResearchAndDevelopmentExpenseMember2017-11-012018-10-310001090872us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-11-012020-10-310001090872us-gaap:SellingGeneralAndAdministrativeExpensesMember2018-11-012019-10-310001090872us-gaap:SellingGeneralAndAdministrativeExpensesMember2017-11-012018-10-310001090872us-gaap:InventoriesMember2019-11-012020-10-310001090872us-gaap:InventoriesMember2018-11-012019-10-310001090872a:LtppMember2019-11-012020-10-310001090872a:LtppMember2018-11-012019-10-310001090872a:LtppMember2017-11-012018-10-310001090872a:LTPPRSUMember2019-11-012020-10-310001090872a:LTPPRSUMember2018-11-012019-10-310001090872a:LTPPRSUMember2017-11-012018-10-310001090872a:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange01Member2019-11-012020-10-310001090872a:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange01Member2020-10-310001090872a:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange02Member2019-11-012020-10-310001090872a:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange02Member2020-10-310001090872a:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange03Member2020-10-310001090872a:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange03Member2019-11-012020-10-310001090872us-gaap:EmployeeStockOptionMember2020-10-31utr:Y0001090872us-gaap:ForeignCountryMember2019-11-012020-10-310001090872us-gaap:ForeignCountryMember2020-10-310001090872us-gaap:DomesticCountryMember2020-10-310001090872us-gaap:CaliforniaFranchiseTaxBoardMember2020-10-310001090872us-gaap:OtherNoncurrentAssetsMember2020-10-310001090872us-gaap:OtherNoncurrentAssetsMember2019-10-310001090872us-gaap:OtherNoncurrentLiabilitiesMember2020-10-310001090872us-gaap:OtherNoncurrentLiabilitiesMember2019-10-310001090872a:TaxInterestandPenaltiesMember2019-11-012020-10-310001090872a:TaxInterestandPenaltiesMember2018-11-012019-10-310001090872a:TaxInterestandPenaltiesMember2017-11-012018-10-310001090872us-gaap:OtherAssetsMember2020-10-310001090872us-gaap:OtherCurrentLiabilitiesMember2020-10-310001090872a:OtherAccruedAndLongTermLiabilitiesMember2020-10-310001090872a:LifeSciencesandAppliedMarketsMember2018-10-310001090872a:DiagnosticsAndGenomicsMember2018-10-310001090872a:AgilentCrossLabMember2018-10-310001090872a:LifeSciencesandAppliedMarketsMember2019-10-310001090872a:DiagnosticsAndGenomicsMember2019-10-310001090872a:AgilentCrossLabMember2019-10-310001090872a:LifeSciencesandAppliedMarketsMember2020-10-310001090872a:DiagnosticsAndGenomicsMember2020-10-310001090872a:AgilentCrossLabMember2020-10-310001090872us-gaap:DevelopedTechnologyRightsMember2019-10-310001090872us-gaap:OrderOrProductionBacklogMember2019-10-310001090872us-gaap:TrademarksMember2019-10-310001090872us-gaap:CustomerRelationshipsMember2019-10-310001090872a:ThirdPartyTechnologyandLicensesMember2019-10-310001090872us-gaap:DevelopedTechnologyRightsMember2020-10-310001090872us-gaap:TrademarksMember2020-10-310001090872us-gaap:CustomerRelationshipsMember2020-10-310001090872a:ThirdPartyTechnologyandLicensesMember2020-10-310001090872a:BioTekandACEAMembera:LifeSciencesandAppliedMarketsMember2018-11-012019-10-310001090872a:DiagnosticsAndGenomicsMembera:AdvancedAnalyticalTechnologiesIncAATIMember2018-11-012019-10-310001090872a:EquitySecuritiesWithReadilyDeterminableFairValueMember2019-11-012020-10-310001090872a:EquitySecuritiesWithReadilyDeterminableFairValueMember2018-11-012019-10-310001090872a:EquitySecuritiesWithoutReadilyDeterminableFairValueMember2019-11-012020-10-310001090872a:EquitySecuritiesWithoutReadilyDeterminableFairValueMember2018-11-012019-10-310001090872us-gaap:AccountingStandardsUpdate201601Member2018-11-010001090872us-gaap:FairValueMeasurementsRecurringMember2020-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMember2019-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-10-310001090872us-gaap:TreasuryLockMembera:SeniorNotes2022Member2012-07-010001090872us-gaap:TreasuryLockMembera:SeniorNotes2022Member2020-10-310001090872us-gaap:CashFlowHedgingMemberus-gaap:TreasuryLockMembera:SeniorNotes2026Member2016-02-010001090872us-gaap:CashFlowHedgingMemberus-gaap:TreasuryLockMembera:SeniorNotes2026Member2016-09-142016-09-150001090872us-gaap:CashFlowHedgingMemberus-gaap:TreasuryLockMembera:SeniorNotes2026Member2020-10-310001090872a:SeniorNotes2029Memberus-gaap:TreasuryLockMember2019-08-010001090872a:SeniorNotes2029Memberus-gaap:TreasuryLockMember2019-09-062019-09-060001090872a:SeniorNotes2029Memberus-gaap:TreasuryLockMember2020-10-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2019-11-012020-10-31a:contracts0001090872us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-10-310001090872us-gaap:NondesignatedMember2020-10-310001090872us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2020-10-310001090872us-gaap:ForwardContractsMemberus-gaap:ShortMemberus-gaap:CashFlowHedgingMembercurrency:EURus-gaap:DesignatedAsHedgingInstrumentMember2020-10-310001090872us-gaap:ForwardContractsMemberus-gaap:ShortMembercurrency:EURus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2020-10-310001090872us-gaap:ForwardContractsMembercurrency:EURus-gaap:NondesignatedMemberus-gaap:LongMember2020-10-310001090872us-gaap:ForwardContractsMemberus-gaap:ShortMembercurrency:GBPus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-10-310001090872us-gaap:ForwardContractsMembercurrency:GBPus-gaap:NondesignatedMemberus-gaap:LongMember2020-10-310001090872us-gaap:ForwardContractsMemberus-gaap:ShortMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:CAD2020-10-310001090872us-gaap:ForwardContractsMemberus-gaap:ShortMembercurrency:CADus-gaap:NondesignatedMember2020-10-310001090872us-gaap:ForwardContractsMemberus-gaap:ShortMemberus-gaap:CashFlowHedgingMembercurrency:JPYus-gaap:DesignatedAsHedgingInstrumentMember2020-10-310001090872us-gaap:ForwardContractsMemberus-gaap:ShortMembercurrency:JPYus-gaap:NondesignatedMember2020-10-310001090872us-gaap:ForwardContractsMemberus-gaap:ShortMemberus-gaap:CashFlowHedgingMembercurrency:KRWus-gaap:DesignatedAsHedgingInstrumentMember2020-10-310001090872us-gaap:ForwardContractsMemberus-gaap:ShortMembercurrency:KRWus-gaap:NondesignatedMember2020-10-310001090872us-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LongMembercurrency:SGD2020-10-310001090872us-gaap:ForwardContractsMemberus-gaap:NondesignatedMemberus-gaap:LongMembercurrency:SGD2020-10-310001090872us-gaap:ForwardContractsMembercurrency:CNYus-gaap:ShortMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-10-310001090872us-gaap:ForwardContractsMembercurrency:CNYus-gaap:ShortMemberus-gaap:NondesignatedMember2020-10-310001090872us-gaap:ForwardContractsMemberus-gaap:ShortMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:SEK2020-10-310001090872us-gaap:ForwardContractsMemberus-gaap:ShortMemberus-gaap:NondesignatedMembercurrency:SEK2020-10-310001090872us-gaap:ForwardContractsMemberus-gaap:ShortMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:TWD2020-10-310001090872us-gaap:ForwardContractsMemberus-gaap:ShortMemberus-gaap:NondesignatedMembercurrency:TWD2020-10-310001090872us-gaap:ForwardContractsMembercurrency:INRus-gaap:ShortMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-10-310001090872us-gaap:ForwardContractsMembercurrency:INRus-gaap:ShortMemberus-gaap:NondesignatedMember2020-10-310001090872us-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMembercurrency:XXXus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LongMember2020-10-310001090872us-gaap:ForwardContractsMembercurrency:XXXus-gaap:NondesignatedMemberus-gaap:LongMember2020-10-310001090872us-gaap:ForwardContractsMemberus-gaap:ShortMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-10-310001090872us-gaap:ForwardContractsMemberus-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2020-10-310001090872us-gaap:ForwardContractsMemberus-gaap:ShortMemberus-gaap:NondesignatedMember2020-10-310001090872us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-10-310001090872us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-10-310001090872us-gaap:ForeignExchangeContractMemberus-gaap:AccruedLiabilitiesMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-10-310001090872us-gaap:ForeignExchangeContractMemberus-gaap:AccruedLiabilitiesMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-10-310001090872us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2020-10-310001090872us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2019-10-310001090872us-gaap:ForeignExchangeContractMemberus-gaap:AccruedLiabilitiesMemberus-gaap:NondesignatedMember2020-10-310001090872us-gaap:ForeignExchangeContractMemberus-gaap:AccruedLiabilitiesMemberus-gaap:NondesignatedMember2019-10-310001090872us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherComprehensiveIncomeMemberus-gaap:InterestRateSwapMember2019-11-012020-10-310001090872us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherComprehensiveIncomeMemberus-gaap:InterestRateSwapMember2018-11-012019-10-310001090872us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherComprehensiveIncomeMemberus-gaap:InterestRateSwapMember2017-11-012018-10-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-11-012020-10-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2018-11-012019-10-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2017-11-012018-10-310001090872us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-11-012020-10-310001090872us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2018-11-012019-10-310001090872us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2017-11-012018-10-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2018-11-012019-10-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2017-11-012018-10-310001090872us-gaap:OtherIncomeMemberus-gaap:NondesignatedMember2019-11-012020-10-310001090872us-gaap:OtherIncomeMemberus-gaap:NondesignatedMember2018-11-012019-10-310001090872us-gaap:OtherIncomeMemberus-gaap:NondesignatedMember2017-11-012018-10-3100010908722018-11-012019-01-310001090872us-gaap:DeferredProfitSharingMember2020-10-310001090872us-gaap:DeferredProfitSharingMember2019-10-310001090872srt:MinimumMemberus-gaap:PensionPlansDefinedBenefitMember2019-11-012020-10-310001090872us-gaap:PensionPlansDefinedBenefitMember2019-11-012020-10-310001090872srt:MaximumMemberus-gaap:PensionPlansDefinedBenefitMember2019-11-012020-10-310001090872us-gaap:PensionPlansDefinedBenefitMembercountry:US2019-11-012020-10-310001090872us-gaap:PensionPlansDefinedBenefitMembercountry:US2018-11-012019-10-310001090872us-gaap:PensionPlansDefinedBenefitMembercountry:US2017-11-012018-10-310001090872us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-11-012020-10-310001090872us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2018-11-012019-10-310001090872us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2017-11-012018-10-310001090872us-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2019-11-012020-10-310001090872us-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2018-11-012019-10-310001090872us-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2017-11-012018-10-310001090872us-gaap:PensionPlansDefinedBenefitMembercountry:US2019-10-310001090872us-gaap:PensionPlansDefinedBenefitMembercountry:US2018-10-310001090872us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-10-310001090872us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2018-10-310001090872us-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2019-10-310001090872us-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2018-10-310001090872us-gaap:PensionPlansDefinedBenefitMembercountry:US2020-10-310001090872us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872us-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2020-10-310001090872us-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherAssetsMembercountry:US2020-10-310001090872us-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherAssetsMembercountry:US2019-10-310001090872us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherAssetsMember2020-10-310001090872us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherAssetsMember2019-10-310001090872us-gaap:DefinedBenefitPostretirementHealthCoverageMemberus-gaap:OtherAssetsMembercountry:US2020-10-310001090872us-gaap:DefinedBenefitPostretirementHealthCoverageMemberus-gaap:OtherAssetsMembercountry:US2019-10-310001090872a:EmployeecompensationandbenefitsMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2020-10-310001090872a:EmployeecompensationandbenefitsMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-10-310001090872a:EmployeecompensationandbenefitsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872a:EmployeecompensationandbenefitsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-10-310001090872us-gaap:DefinedBenefitPostretirementHealthCoverageMembera:EmployeecompensationandbenefitsMembercountry:US2020-10-310001090872us-gaap:DefinedBenefitPostretirementHealthCoverageMembera:EmployeecompensationandbenefitsMembercountry:US2019-10-310001090872a:RetirementandpostretirementbenefitsMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2020-10-310001090872a:RetirementandpostretirementbenefitsMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-10-310001090872a:RetirementandpostretirementbenefitsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872a:RetirementandpostretirementbenefitsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-10-310001090872a:RetirementandpostretirementbenefitsMemberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2020-10-310001090872a:RetirementandpostretirementbenefitsMemberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2019-10-310001090872us-gaap:EquitySecuritiesMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-10-310001090872us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:EquitySecuritiesMembercountry:US2019-10-310001090872us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:EquitySecuritiesMembercountry:US2020-10-310001090872us-gaap:EquitySecuritiesMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2020-10-310001090872us-gaap:FixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2020-10-310001090872us-gaap:FixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-10-310001090872us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMembercountry:US2020-10-310001090872us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FixedIncomeSecuritiesMembercountry:US2019-10-310001090872us-gaap:EquitySecuritiesMembercountry:USus-gaap:DeferredProfitSharingMember2020-10-310001090872us-gaap:EquitySecuritiesMembercountry:USus-gaap:DeferredProfitSharingMember2019-10-310001090872us-gaap:FixedIncomeSecuritiesMembercountry:USus-gaap:DeferredProfitSharingMember2020-10-310001090872us-gaap:FixedIncomeSecuritiesMembercountry:USus-gaap:DeferredProfitSharingMember2019-10-310001090872a:OtherPlanAssetsMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-10-310001090872us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembera:OtherPlanAssetsMembercountry:US2019-10-310001090872a:OtherPlanAssetsMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2020-10-310001090872us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembera:OtherPlanAssetsMembercountry:US2020-10-310001090872us-gaap:EquitySecuritiesMembersrt:MinimumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872us-gaap:EquitySecuritiesMembersrt:MaximumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872srt:MinimumMemberus-gaap:FixedIncomeSecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872srt:MaximumMemberus-gaap:FixedIncomeSecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872srt:MinimumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:RealEstateMember2020-10-310001090872srt:MaximumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:RealEstateMember2020-10-310001090872us-gaap:PensionPlansDefinedBenefitMembercountry:USus-gaap:CashAndCashEquivalentsMember2020-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMembercountry:USus-gaap:CashAndCashEquivalentsMember2020-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMembercountry:USus-gaap:CashAndCashEquivalentsMember2020-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMembercountry:USus-gaap:CashAndCashEquivalentsMember2020-10-310001090872us-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:FixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:FixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:FixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel1Membera:OtherPlanAssetsMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2020-10-310001090872a:OtherPlanAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel3Membera:OtherPlanAssetsMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMembercountry:US2020-10-310001090872us-gaap:PensionPlansDefinedBenefitMembercountry:USus-gaap:CashAndCashEquivalentsMember2019-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMembercountry:USus-gaap:CashAndCashEquivalentsMember2019-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMembercountry:USus-gaap:CashAndCashEquivalentsMember2019-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMembercountry:USus-gaap:CashAndCashEquivalentsMember2019-10-310001090872us-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-10-310001090872us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:FixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:FixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:FixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel1Membera:OtherPlanAssetsMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-10-310001090872a:OtherPlanAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel3Membera:OtherPlanAssetsMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMembercountry:US2018-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-11-012020-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMembercountry:US2018-11-012019-10-310001090872us-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:USus-gaap:CashAndCashEquivalentsMember2020-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:USus-gaap:CashAndCashEquivalentsMember2020-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:USus-gaap:CashAndCashEquivalentsMember2020-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:USus-gaap:CashAndCashEquivalentsMember2020-10-310001090872us-gaap:EquitySecuritiesMemberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2020-10-310001090872us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMemberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2020-10-310001090872us-gaap:DefinedBenefitPostretirementHealthCoverageMemberus-gaap:FixedIncomeSecuritiesMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMemberus-gaap:FixedIncomeSecuritiesMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMemberus-gaap:FixedIncomeSecuritiesMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMemberus-gaap:FixedIncomeSecuritiesMembercountry:US2020-10-310001090872a:OtherPlanAssetsMemberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel1Membera:OtherPlanAssetsMemberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2020-10-310001090872a:OtherPlanAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel3Membera:OtherPlanAssetsMemberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2020-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2020-10-310001090872us-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:USus-gaap:CashAndCashEquivalentsMember2019-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:USus-gaap:CashAndCashEquivalentsMember2019-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:USus-gaap:CashAndCashEquivalentsMember2019-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:USus-gaap:CashAndCashEquivalentsMember2019-10-310001090872us-gaap:EquitySecuritiesMemberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2019-10-310001090872us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMemberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2019-10-310001090872us-gaap:DefinedBenefitPostretirementHealthCoverageMemberus-gaap:FixedIncomeSecuritiesMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMemberus-gaap:FixedIncomeSecuritiesMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMemberus-gaap:FixedIncomeSecuritiesMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMemberus-gaap:FixedIncomeSecuritiesMembercountry:US2019-10-310001090872a:OtherPlanAssetsMemberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel1Membera:OtherPlanAssetsMemberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2019-10-310001090872a:OtherPlanAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel3Membera:OtherPlanAssetsMemberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2019-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2018-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2019-11-012020-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPostretirementHealthCoverageMembercountry:US2018-11-012019-10-310001090872us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2020-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2020-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2020-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2020-10-310001090872us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872us-gaap:FixedIncomeSecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:FixedIncomeSecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:FixedIncomeSecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:FixedIncomeSecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872a:OtherPlanAssetsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872us-gaap:FairValueInputsLevel1Membera:OtherPlanAssetsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872a:OtherPlanAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872us-gaap:FairValueInputsLevel3Membera:OtherPlanAssetsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2019-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2019-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2019-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2019-10-310001090872us-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2019-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2019-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2019-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2019-10-310001090872us-gaap:FixedIncomeSecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:FixedIncomeSecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:FixedIncomeSecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:FixedIncomeSecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-10-310001090872a:OtherPlanAssetsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-10-310001090872us-gaap:FairValueInputsLevel1Membera:OtherPlanAssetsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-10-310001090872a:OtherPlanAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-10-310001090872us-gaap:FairValueInputsLevel3Membera:OtherPlanAssetsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-10-310001090872us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-10-310001090872us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-10-310001090872us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-10-310001090872us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembercountry:US2020-10-310001090872srt:MinimumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-11-012020-10-310001090872srt:MaximumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-11-012020-10-310001090872srt:MinimumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2018-11-012019-10-310001090872srt:MaximumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2018-11-012019-10-310001090872srt:MinimumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2017-11-012018-10-310001090872srt:MaximumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2017-11-012018-10-310001090872srt:MinimumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872srt:MaximumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-10-310001090872srt:MinimumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-10-310001090872srt:MaximumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-10-310001090872a:PenaltyreduceoverperiodoftimeMember2020-10-310001090872a:A5YrUnsecuredCreditFacilityMemberus-gaap:LineOfCreditMember2019-03-132019-03-130001090872a:A5YrUnsecuredCreditFacilityMemberus-gaap:LineOfCreditMember2020-10-310001090872a:A5YrUnsecuredCreditFacilityMemberus-gaap:LineOfCreditMember2019-11-012020-10-310001090872a:ShortTermLoanFacilityMemberus-gaap:LineOfCreditMember2019-08-232019-08-230001090872a:ShortTermLoanFacilityMemberus-gaap:LineOfCreditMember2019-08-070001090872a:ShortTermLoanFacilityMemberus-gaap:LineOfCreditMember2019-11-012020-10-310001090872a:AdditionalIncrementalTermLoanFacilityMemberus-gaap:LineOfCreditMember2019-10-210001090872a:AdditionalIncrementalTermLoanFacilityMemberus-gaap:LineOfCreditMember2020-10-310001090872us-gaap:CommercialPaperMemberus-gaap:LineOfCreditMember2020-05-260001090872us-gaap:CommercialPaperMemberus-gaap:LineOfCreditMember2020-10-310001090872us-gaap:CommercialPaperMemberus-gaap:LineOfCreditMember2019-11-012020-10-310001090872a:SeniorNotes2020Member2010-07-122010-07-130001090872a:SeniorNotes2020Member2010-07-130001090872a:SeniorNotes2020Member2011-08-082011-08-090001090872a:SeniorNotes2020Member2011-08-090001090872a:SeniorNotes2020Member2019-09-172019-09-170001090872a:SeniorNotes2022Member2020-10-310001090872a:SeniorNotes2022Member2019-10-310001090872a:SeniorNotes2023Member2020-10-310001090872a:SeniorNotes2023Member2019-10-310001090872a:SeniorNotes2026Member2020-10-310001090872a:SeniorNotes2026Member2019-10-310001090872a:SeniorNotes2029Member2020-10-310001090872a:SeniorNotes2029Member2019-10-310001090872a:SeniorNotes2030Member2020-10-310001090872a:SeniorNotes2030Member2019-10-310001090872a:SeniorNotes2022Member2012-09-132012-09-130001090872a:SeniorNotes2022Member2012-09-130001090872a:SeniorNotes2023Member2013-06-212013-06-210001090872a:SeniorNotes2023Member2013-06-210001090872a:SeniorNotes2026Member2016-09-222016-09-220001090872a:SeniorNotes2026Member2016-09-220001090872us-gaap:CashFlowHedgingMemberus-gaap:TreasuryLockMembera:SeniorNotes2026Member2016-09-150001090872a:SeniorNotes2029Member2019-09-162019-09-160001090872a:SeniorNotes2029Member2019-09-160001090872a:SeniorNotes2030Member2020-06-042020-06-040001090872a:SeniorNotes2030Member2020-06-040001090872a:A2015RepurchaseProgramMember2015-05-280001090872a:A2015RepurchaseProgramMember2017-11-012018-10-310001090872a:A2015RepurchaseProgramMember2019-10-310001090872a:A2019RepurchaseProgramMember2018-11-190001090872a:A2019RepurchaseProgramMember2018-11-012019-10-310001090872a:A2019RepurchaseProgramMember2019-11-012020-10-310001090872a:A2019RepurchaseProgramMember2020-10-310001090872us-gaap:SubsequentEventMember2020-11-182020-11-180001090872srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMemberus-gaap:AccumulatedTranslationAdjustmentMember2018-11-010001090872srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2018-11-012018-11-010001090872srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2018-11-012018-11-010001090872srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMemberus-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2018-11-012018-11-010001090872srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember2018-11-012018-11-0100010908722018-11-01a:segment0001090872a:SegmentTotalMember2019-11-012020-10-310001090872a:SegmentTotalMember2018-11-012019-10-310001090872a:LifeSciencesandAppliedMarketsMember2017-11-012018-10-310001090872a:DiagnosticsAndGenomicsMember2017-11-012018-10-310001090872a:AgilentCrossLabMember2017-11-012018-10-310001090872a:SegmentTotalMember2017-11-012018-10-310001090872a:SegmentTotalMember2020-10-310001090872a:SegmentTotalMember2019-10-310001090872country:US2019-11-012020-10-310001090872country:CN2019-11-012020-10-310001090872a:RestOfWorldMember2019-11-012020-10-310001090872country:US2018-11-012019-10-310001090872country:CN2018-11-012019-10-310001090872a:RestOfWorldMember2018-11-012019-10-310001090872country:US2017-11-012018-10-310001090872country:CN2017-11-012018-10-310001090872a:RestOfWorldMember2017-11-012018-10-310001090872country:US2020-10-310001090872country:DE2020-10-310001090872a:RestOfWorldMember2020-10-310001090872country:US2019-10-310001090872country:DE2019-10-310001090872a:RestOfWorldMember2019-10-310001090872us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2019-10-310001090872us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2019-11-012020-10-310001090872us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2020-10-310001090872us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2018-10-310001090872us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2018-11-012019-10-310001090872us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2017-10-310001090872us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2017-11-012018-10-31
Table of Contents            
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________
Form 10-K
_____________________________________________________________

(MARK ONE) 
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 
For the fiscal year ended October 31, 2020 
or 
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 
For transition period from to

Commission File Number: 001-15405
_____________________________________________________________
Agilent Technologies, Inc.
(Exact name of registrant as specified in its charter)

Delaware77-0518772
(State or other jurisdiction of incorporation or organization)(IRS Employer Identification No.)
Address of principal executive offices: 5301 Stevens Creek Blvd., Santa Clara, California 95051
Registrant's telephone number, including area code: (800) 227-9770
Securities registered pursuant to Section 12(b) of the Act:
Title of each ClassTrading SymbolName of each Exchange on which registered
Common Stock, $0.01 par valueANew York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None
_____________________________________________________________
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐Non-accelerated filer☐
Smaller reporting company☐Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The aggregate market value of the registrant's common equity held by non-affiliates as of April 30, 2020, was approximately $18.0 billion. Shares of stock held by officers, directors and 5 percent or more stockholders have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.
As of December 10, 2020 there were 306,849,526 outstanding shares of common stock, par value $0.01 per share.
_____________________________________________________________
DOCUMENTS INCORPORATED BY REFERENCE
Document Description
10-K Part 
Portions of the Proxy Statement for the Annual Meeting of Stockholders (the "Proxy Statement") to be held on March 17, 2021, and to be filed pursuant to Regulation 14A within 120 days after registrant's fiscal year ended October 31, 2020 are incorporated by reference into Part III of this ReportIII
1

TABLE OF CONTENTS
  Page


2
Table of Contents            
Forward-Looking Statements

This report contains forward-looking statements including, without limitation, statements regarding growth opportunities, including for revenue and our end markets, strength and drivers of the markets we sell into, sales funnels, our strategic direction, new product and service introductions and the position of our current products and services, market demand for and adoption of our products, the ability of our products and solutions to address customer needs and meet industry requirements, our focus on differentiating our product solutions, improving our customers’ experience and growing our earnings, future financial results, our operating margin, mix, our investments, including in manufacturing infrastructure, research and development and expanding and improving our applications and solutions portfolios, expanding our position in developing countries and emerging markets, our focus on balanced capital allocation, our contributions to our pension and other defined benefit plans, impairment of goodwill and other intangible assets, the impact of foreign currency movements, our hedging programs and other actions to offset the effects of tariffs and foreign currency movements, our future effective tax rate, tax valuation allowance and unrecognized tax benefits, the impact of local government regulations on our ability to pay vendors or conduct operations, our ability to satisfy our liquidity requirements, including through cash generated from operations, the potential impact of adopting new accounting pronouncements, indemnification, source and supply of materials used in our products, our sales, our purchase commitments, our capital expenditures, the integration and effects of our acquisitions and other transactions, our stock repurchase program and dividends and the potential or anticipated direct or indirect impact of COVID-19 on our business that involve risks and uncertainties. Our actual results could differ materially from the results contemplated by these forward-looking statements due to various factors, including those discussed in Part I Item 1A and elsewhere in this Form 10-K.

PART I


Item 1.    Business

Overview

Agilent Technologies Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.

For fiscal year ended October 31, 2020, we have three business segments comprised of the life sciences and applied markets business, the diagnostics and genomics business and the Agilent CrossLab business.

Our life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. Our diagnostics and genomics business is comprised of six areas of activity providing active pharmaceutical ingredients ("APIs") for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio, which is designed to improve customer outcomes. In addition, we conduct centralized order fulfillment and supply chain operations for our businesses through the order fulfillment and supply chain organization ("OFS"). OFS provides resources for manufacturing, engineering and strategic sourcing to our respective businesses. Each of our businesses, together with OFS and Agilent Technologies Research Laboratories, is supported by our global infrastructure organization, which provides shared services in the areas of finance, information technology, legal, certain procurement services, workplace services and human resources.

We sell our products primarily through direct sales, but we also utilize distributors, resellers, manufacturer's representatives and electronic commerce. As of October 31, 2020, we employed approximately 16,400 people worldwide. Our primary research and development and manufacturing sites are in California, Colorado, Delaware, Massachusetts, Texas and Vermont in the U.S. and in Australia, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore and the United Kingdom.

3
Table of Contents            
Life Sciences and Applied Markets Business
Our life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. Key product categories include: liquid chromatography ("LC") systems and components; liquid chromatography mass spectrometry ("LCMS") systems; gas chromatography ("GC") systems and components; gas chromatography mass spectrometry ("GCMS") systems; inductively coupled plasma mass spectrometry ("ICP-MS") instruments; atomic absorption ("AA") instruments; microwave plasma-atomic emission spectrometry ("MP-AES") instruments; inductively coupled plasma optical emission spectrometry ("ICP-OES") instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software for sample tracking; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps and measurement technologies.

We employed approximately 5,300 people as of October 31, 2020 in our life sciences and applied markets business.

Life Sciences and Applied Markets
Our life sciences and applied markets business focuses primarily on the following five markets:
The Pharmaceutical, Biopharmaceutical, CRO & CMO Market. This market consists of “for-profit” companies who participate across the pharmaceutical value chain in the areas of therapeutic research, discovery & development, clinical trials, manufacturing and quality assurance and quality control. One sub-segment of this market is core and emerging pharmaceutical companies ("pharma"). A second sub-segment includes biopharmaceutical companies ("biopharma"), contract research organizations ("CROs") and contract manufacturing organizations ("CMOs"). Biopharma companies and, to a somewhat lesser extent, CROs and CMOs typically participate in specific points in the pharmaceutical industry value chain. Additionally, due to the relatively low drug efficacy within oncology, pharma companies are partnering with diagnostic companies to bring validated tests to the market with their new drugs.
The Academic and Government Market. This market consists primarily of “not-for-profit” organizations and includes academic institutions, large government institutes and privately funded organizations. The academic and government market plays an influential role in technology adoption and therapeutic developments for pharmaceutical and molecular diagnostics companies. After decades of investment in basic biomedical research by government funding bodies, the focus has widened to include translational research - multidisciplinary scientific efforts directed at accelerating therapy development.
The Chemical & Energy Market. Our products and solutions are used throughout the chemicals sector in the development, manufacturing, and quality control of commodity chemicals, specialty and agrochemicals, and fine chemicals. Chemical market customers use our products to determine chemical composition, perform impurity analysis, qualify raw materials, conduct materials characterization, and verify and ensure the environmental safety of operations and employees. The natural gas and petroleum exploration and refining markets use our products to analyze crude oil composition, perform intermediate material analysis, verify and improve refining processes and ensure the overall quality of gasoline, fuels, lubricants and other products.
The Environmental & Forensics Market. Our instruments, software and workflow solutions are used by the environmental market for applications such as laboratory and field analysis of chemical pollutants in air, water, soil and solid waste. Environmental industry customers include all levels of government, the industrial and manufacturing sectors, engineering and consulting companies, commercial testing laboratories and colleges and universities. Drug testing and forensics laboratories use our instruments, software and workflow solutions for applications such as analyzing evidence associated with crime, screening athletes for performance enhancing drugs, analyzing samples for recreational drugs, or detecting and identifying biological and chemical warfare agents. Some of our instruments are used in mobile laboratories as well. Customers include local, state, federal, and international law enforcement agencies and health laboratories.
The Food Market.  Our instruments, software, and workflow solutions are used throughout the food production chain, including incoming inspection, new product development, quality control and assurance, and packaging. For example, our mass spectrometer portfolio is used to analyze contaminants and residual pesticides in food. There is also a significant food safety market involved in analyzing food for pathogen contamination, accurate verification of species type and evidence of genetically modified content.

4
Table of Contents            
Life Sciences and Applied Markets Products and Applications
Our products fall into eight main areas of work: liquid chromatography, gas chromatography, mass spectrometry, spectroscopy, software and informatics, lab automation and robotics, vacuum technology and cell analysis.
Our key products and applications include the following technologies:
Liquid Chromatography
A liquid chromatograph ("LC") or a high-performance liquid chromatograph ("HPLC") is used to separate molecules of a liquid mixture to determine the quantity and identity of the molecules present. The Agilent LC portfolio is modular in construction and can be configured as analytical and preparative systems. These systems can be stepwise upgraded to highly sophisticated, automated workflow solutions such as method development, multi‑method/walk-up, high-capacity/high-throughput or multi‑dimensional LC and can be extended to application‑based analyzers (e.g., for bio-molecular separations, chiral analysis or size exclusion chromatography). As a leader in liquid chromatography, we continue to expand our application space with new HPLC columns, new services and diagnostics offerings and ongoing instrument and software product enhancements.
Gas Chromatography

Agilent is the world's leading provider of gas chromatographs ("GC"), both laboratory and portable models. GCs are used to separate any gas, liquid or solid that can be vaporized and then detect the molecules present to determine their identity and quantity. Agilent provides custom or standard analyzers configured for specific chemical analysis applications, such as detailed speciation of a complex hydrocarbon stream, calculation of gas calorific values in the field, or analysis of a new bio-fuel formulation. We also offer related software, accessories and consumable products for these and other similar instruments.

Mass Spectrometry

A mass spectrometer (“MS”) identifies and quantifies chemicals based on a chemical's molecular mass and characteristic patterns of fragment ion masses that result when a molecule is broken apart. Liquid chromatography is commonly used to separate compounds and introduce them to the MS system. The combined use of LC and MS is frequently used both to identify and quantify chemical compounds. Mass spectrometry is an important tool in analyzing small molecules and can also be used to characterize and quantify proteins and other biological entities. Agilent's LCMS portfolio includes instruments built around four main analyzer types - single quadrupole, triple quadrupole, time-of-flight ("TOF") and quadrupole time-of-flight ("QTOF"). Agilent's GC/MS portfolio includes instruments built around three main analyzer types - single quadrupole, triple quadrupole, and quadrupole time-of-flight ("QTOF"). We significantly expanded our mass spectrometry portfolio in recent years with a focus on improving performance, sensitivity, and ease of use.

Spectroscopy

Spectroscopy is a technique for analyzing the individual chemical components of substances based on the absorption or emission of electromagnetic radiation of specific wavelengths of light. Our spectroscopy instruments include AA spectrometers, microwave plasma-atomic emission spectrometers ("MP-AES"), ICP-OES, ICP-MS, fluorescence spectrophotometers, ultraviolet-visible ("UV-Vis") spectrophotometers, Fourier Transform infrared ("FT-IR" spectrophotometers, near-infrared ("NIR") spectrophotometers, raman spectrometers and sample automation products. We also offer related software, accessories and consumable products for these and other similar instruments.

Software and Informatics

We provide software for instrument control, data acquisition, data analysis, laboratory content and business process management, and informatics. Our software facilitates the compliant use of instruments in pharmaceutical quality assurance/quality control environments. With our OpenLab Laboratory Software Suite, Agilent has a scalable, open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise.

Lab Automation and Robotics

We offer a comprehensive suite of workflow solutions to our life science customers with the addition of automated liquid handling and robotics that range from standalone instrumentation to bench-top automation solutions. These solutions strengthen our offering of automated sample preparation solutions across a broad range of applications.
5
Table of Contents            

Vacuum Technology

Our vacuum technologies products are used to create, control, measure and test vacuum environments in life science, industrial and scientific applications where ultra-clean, high-vacuum environments are needed. Vacuum technologies' customers are typically OEMs that manufacture equipment for these applications, or government and research organizations that require vacuum solutions in their facilities. Products include a wide range of high and ultra-high vacuum pumps (diffusion, turbomolecular and ion getter), intermediate vacuum pumps (rotary vane, sorption and dry scroll), vacuum instrumentation (vacuum control instruments, sensor gauges and meters) and vacuum components (valves, flanges and other mechanical hardware). These products also include helium mass spectrometry and helium-sensing leak detection instruments used to identify and measure leaks in hermetic or vacuum environments. In addition to product sales, we also offer a wide range of services including an exchange and rebuild program, assistance with the design and integration of vacuum systems, applications support and training in basic and advanced vacuum technologies.

Cell Analysis

Our cell analysis tools are used to study cell signaling pathways, general cell function and behavior through metabolic profile analysis, real-time cellular impedance measurements, and traditional cytometry techniques. Characterizing cellular behavior and function is an increasingly critical step in understanding normal behavior versus diseased states, advancements of those diseases, and response to therapies, providing researchers with a more targeted approach for drug discovery and ultimately more effective therapeutics. Our cell analysis portfolio includes cell analysis plate-based assays, flow cytometer, real-time cell analyzer, microplate reader, cell imaging system and related consumables. Cell analysis customers are typically academic institutions and pharma and biopharma companies.

Life Sciences and Applied Markets Customers
We had approximately 25,400 customers for our life sciences and applied markets business in fiscal 2020. No single customer represented a material amount of the net revenue of the life sciences and applied markets business. A significant number of our life sciences and applied markets customers are also customers of our Agilent CrossLab business.
The life sciences and applied markets business is susceptible to seasonality in its orders and revenues primarily related to U.S. and foreign government budgets, chemical and energy and environmental customers and large pharmaceutical company budgets. Historically, the result is that our first and fourth fiscal quarters tend to deliver the strongest profits for this group. However, general economic trends, new product introductions and competition might overshadow this trend in any given year.
Life Sciences and Applied Markets Sales, Marketing and Support
The life sciences and applied markets channels focus on the therapeutics and human disease research customer base (pharma, biopharma, CRO, CMO and generics), clinical customer base (high complexity clinical testing labs), emerging life sciences opportunities in life science research institutes and applied markets (chemical and energy, food, environmental and forensics). We deploy a multi-channel approach, marketing products to our customers through direct sales, electronic commerce, resellers, manufacturers' representatives and distributors. We primarily use direct sales to market our solutions to our pharmaceutical, biopharmaceutical, clinical, life science research and applied market accounts. Sales agents supplement direct sales by providing broader geographic coverage and coverage of smaller accounts. Our active reseller program augments our ability to provide more complete solutions to our customers. We sell our consumable products through distributors, electronic commerce and direct sales.
Our products typically come with standard warranties, and extended warranties are available for additional cost.
Life Sciences and Applied Markets Manufacturing
Our manufacturing supports our diverse product range and customer‑centric focus. We assemble highly configurable products to individual customer orders and make standard products to stock. We employ advanced manufacturing techniques and supply chain management systems to reduce costs and manufacturing cycle times. Our manufacturing process then converts these designs into standard as well as custom products for shipment to customers. We selectively use third parties to provide some supply chain processes for manufacturing, warehousing and logistics. Inside the U.S., we have manufacturing facilities in California, Delaware, Massachusetts and Vermont. Outside of the U.S., we have manufacturing facilities in Germany, Malaysia and Singapore. We have FDA registered sites in California, Vermont, Germany and Singapore.
6
Table of Contents            
Life Sciences and Applied Markets Competition
The markets for analytical instruments in which we compete are characterized by evolving industry standards and intense competition. Our principal competitors in the life sciences and applied markets arena include: Danaher Corporation, PerkinElmer Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc. and Waters Corporation. Agilent competes on the basis of product performance, reliability, support quality, applications expertise, global channel coverage and price.

Diagnostics and Genomics Business

Our diagnostics and genomics business includes the genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership and biomolecular analysis businesses.

Our diagnostics and genomics business is comprised of six areas of activity providing active pharmaceutical ingredients ("APIs") for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our genomics business includes arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as next generation sequencing ("NGS") target enrichment and genetic data management and interpretation support software. This business also includes solutions that enable clinical labs to identify DNA variants associated with genetic disease and help direct cancer therapy. Second, our nucleic acid solutions business provides equipment and expertise focused on production of synthesized oligonucleotides under pharmaceutical good manufacturing practices ("GMP") conditions for use as API in an emerging class of drugs that utilize nucleic acid molecules for disease therapy. Third, our pathology solutions business is focused on product offerings for cancer diagnostics and anatomic pathology workflows. The broad portfolio of offerings includes immunohistochemistry ("IHC"), in situ hybridization ("ISH"), hematoxylin and eosin ("H&E") staining and special staining. Fourth, we also collaborate with a number of major pharmaceutical companies to develop new potential pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. Fifth, the reagent partnership business is a provider of reagents used for turbidimetry and flow cytometry. Finally, our biomolecular analysis business provides complete workflow solutions, including instruments, consumables and software, for quality control analysis of nucleic acid samples. Samples are analyzed using quantitative and qualitative techniques to ensure accuracy in further genomics analysis techniques utilized in clinical and life science research applications.

We employed approximately 2,700 people as of October 31, 2020 in our diagnostics and genomics business.

Diagnostics and Genomics Market

Within the diagnostics and genomics business, we focus primarily on the diagnostics and clinical market. Our high-quality, automated pathology tissue staining platforms and solutions are used most heavily by the large labs located in hospitals, medical centers, and reference labs. The market is skewed towards mature economies, with most of the market in North America, Western Europe and Japan. The mix is changing, however, as emerging markets increase spending on human health.

The clinical market for genomics consists of high complexity clinical labs performing patient testing, including “for-profit” reference laboratories, hospital labs, and molecular diagnostic companies. While these labs primarily purchase in vitro diagnostics ("IVD") labeled testing kits, they often develop and validate their own molecular based tests. Analyte Specific Reagents ("ASRs") are often used by these labs.

Diagnostics and Genomics Products

Our products fall into eight main areas of work: pathology products, specific proteins and flow reagents, companion diagnostics, target enrichment, cytogenetic research solutions and microarrays, PCR and qPCR instrumentation and molecular biology reagents, nucleic acid solutions and automated electrophoresis and microfluidics.

Pathology

This area consists of routine clinical solutions for tissue-based cancer diagnostics with solutions that comprise antibodies, reagents, instruments and software targeting both primary and advanced cancer diagnostics. Our CoverStainer and Artisan based product families target primary cancer diagnostics through hematoxylin and eosin staining as well as special stains for additional insights and detection of potentially carcinogenic tissue. Dako Omnis and Autostainer based IHC solution and Instant Quality Fluorescence In Situ Hybridization ("IQFISH") technologies provide advanced tumor typing through
7
Table of Contents            
investigation of protein and gene expression. These products also include companion diagnostic tests that are used to help identify patients most likely to benefit from a specific targeted therapy.
Specific Proteins and Flow Reagents

Our reagent OEM business is a provider of clinical diagnostic products within the areas of specific proteins for turbidimetry and reagents for flow cytometry. These are sold to OEM customers as customized reagent solutions supplied to top IVD companies or through retail partners.

Companion Diagnostics

In our companion diagnostics business, we partner with a number of major pharmaceutical companies to develop new potential pharmacodiagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. We support pharmaceutical companies during each phase of their drug development process, from early pre-clinical through commercial launch activities. Companion diagnostics has a history of developing clinically relevant and validated tests, with accurate and effective scoring and interpretation guidelines, that enable successful regulatory approvals in our worldwide markets.

Target Enrichment

We provide a target enrichment portfolio composed of two main platforms, SureSelect and HaloPlex, both enabling customers to select specific target regions of the genome for sequencing. Customers can customize our products for their regions of interest using the SureDesign software, or they can choose from a wide range of catalog products, including gene panels for specific applications and Exome designs, which allow analysis of the entire coding sequences of the genome. The technologies provide an easy sample prep workflow that can be automated with the Agilent Bravo platform for scalability. HaloPlex provides less-than-24-hours fast workflow, which makes it suitable for labs that require fast turnaround time from sample to results. These products are used for mutation detection and genotyping. Results can be easily analyzed using Agilent software solutions GeneSpring or SureCall. Our solutions also enable clinical labs to identify DNA variants associated with genetic diseases and help direct cancer therapy.

Cytogenetic Research Solutions and Microarrays

We provide microarrays for comparative genomic hybridization (“CGH”), mostly used by customers in cytogenetic laboratories. The arrays allow customers to detect genome-wide copy number alterations, with high levels of resolution (from entire chromosomal copy number changes to specific microdeletions or duplications). The arrays are offered in many formats allowing the customers to choose from different levels of resolution and number of samples per arrays. Arrays can also be customized using the SureDesign software. In addition to the microarrays, Agilent's solution includes reagents for sample processing, hardware for reading the microarrays, and software to help users view the data in a meaningful way. In addition to the CGH portfolio, the cytogenetics solution comprises a line of oligonucleotide probes for fluorescent in situ hybridization ("FISH") called SureFISH. Additionally, Agilent provides a wide range of microarrays to the research market for different types of applications: gene expression, microRNA, methylation, splice variants, and chromatin immunoprecipitation applications. Arrays are offered as catalog designs or customizable designs, with no minimum order size and short delivery time, which differentiates us from other vendors and enables researchers the maximum flexibility in their studies.

PCR and qPCR Instrumentation and Molecular Biology Reagents

Polymerase chain reaction ("PCR") is a standard laboratory method used to amplify the amount of genetic material of a given sample to enable further interrogation. Quantitative PCR ("qPCR") or real time PCR is also a standard method used in genomic research facilities to measure the amount of a specific nucleic acid sequence within a sample. There are several applications for qPCR; among the most common are identifying the expression level of a specific gene or calculating the amount of a specific pathogen present in a sample. Agilent offers a complete portfolio of PCR & qPCR instruments, as well as specialty enzymes for amplifying difficult sample types. In addition to PCR and qPCR enzymes, Agilent offers a wide range of molecular biology reagents including tools for cloning and mutagenesis applications.

Nucleic Acid Solutions

Our nucleic acid solutions business is a contract manufacturing and development services business with equipment and expertise focused on mid to large scale production of synthesized oligonucleotide APIs under pharmaceutical GMP conditions for an emerging class of drugs that utilize oligonucleotide molecules for disease therapy. These drugs have advanced from
8
Table of Contents            
single strand DNA molecules to complex, highly modified molecules including antisense, aptamers, double-stranded RNA, and RNA mixtures. These advancements in the technology have greatly improved the efficacy of delivery and stability of the oligos in-vivo. Our nucleic acid solutions business offers industry leading experience to efficiently advance our customers' oligo drug candidates from clinical trials to commercial launch with a common goal of patient health and safety.  

Automated Electrophoresis and Microfluidics

Automated electrophoresis is a separation technique for bio molecules such as proteins, peptides and nucleic acids (RNA and DNA) and is used to determine the identity of a molecule by either size or charge. It is widely used as a QC tool to check sample integrity prior to subsequent analysis. Prominent examples are nucleic acid preparation products in front of polymerase chain reaction, NGS and microarrays.

Diagnostics and Genomics Customers

We had approximately 10,900 customers for our diagnostics and genomics business in fiscal 2020. No single customer represented a material amount of the net revenue of the diagnostics and genomics business.

Diagnostics and Genomics Sales, Marketing and Support

The diagnostics and genomics channels focus on the therapeutics and human disease research customer base (pharma, biopharma, CRO, CMO and generics), clinical customer base (pathology labs and high complexity clinical testing labs) and on emerging life sciences opportunities in life science research institutes. We deploy a multi-channel approach, marketing products to our customers through direct sales, electronic commerce, resellers, manufacturers' representatives and distributors. We primarily use direct sales to market our solutions to our pharmaceutical, biopharmaceutical and clinical accounts. Sales agents supplement direct sales by providing broader geographic coverage and coverage of smaller accounts. Our active reseller program augments our ability to provide more complete solutions to our customers. We sell our consumable products through distributors, telesales, electronic commerce and direct sales. We utilize telesales for more mature product lines, as well as for reorders of reagent products.
Diagnostics and Genomics Manufacturing

Our manufacturing supports our diverse product range and customer-centric focus. We assemble highly configurable products to individual customer orders and make standard products to stock. We employ advanced manufacturing techniques and supply chain management systems to reduce costs and manufacturing cycle times. We selectively use third parties to provide some supply chain processes for manufacturing, warehousing and logistics. In the U.S., we have manufacturing facilities in California, Colorado and Texas. Outside of the U.S., we have manufacturing facilities in Denmark and Malaysia. Our FDA registered sites include California, Colorado, Texas and Denmark.

Diagnostics and Genomics Competition

The markets for diagnostics and genomics analytical products in which we compete are characterized by evolving industry standards and intense competition. Our principal competitors in the diagnostics and genomics arena include: Roche Ventana Medical Systems, Inc., a member of the Roche Group, Leica Biosystems, Inc., a division of Danaher Corporation, Abbott Laboratories, Illumina, Inc. and Affymetrix, Inc., a division of Thermo Fisher Scientific Inc. Agilent competes on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price.

Diagnostics and Genomics Government Regulation
Some of the products the diagnostics and genomics business sells are subject to regulatory approval by the FDA and other regulatory bodies throughout the world. These regulations govern a wide variety of product related activities, from quality management, design and development to labeling, manufacturing, promotion, sales and distribution. We continually invest in our manufacturing infrastructure to gain and maintain certifications necessary for the level of clearance.

9
Table of Contents            
Agilent CrossLab Business

The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio, which is designed to improve customer outcomes. The majority of the portfolio is vendor neutral, meaning Agilent can serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries and supplies to services and software helping to connect the entire lab. Key product categories in consumables include GC and LC columns, sample preparation products, custom chemistries, and a large selection of laboratory instrument supplies. Services include startup, operational, training and compliance support, software as a service, as well as asset management and consultative services that help increase customer productivity. Custom service and consumable bundles are tailored to meet the specific application needs of various industries and to keep instruments fully operational and compliant with the respective industry requirements.

Our Agilent CrossLab business employed approximately 5,800 people as of October 31, 2020.

Agilent CrossLab Markets

The Pharmaceutical, Biopharmaceutical, CRO & CMO Market. Our services and consumable products support customers in this market that consists of “for-profit” companies who participate across the pharmaceutical value chain in the areas of therapeutic research, discovery and development, clinical trials, manufacturing and quality assurance and quality control. One sub-segment of this market is core and emerging pharmaceutical companies ("pharma"). A second sub-segment includes biopharmaceutical companies ("biopharma"), contract research organizations ("CROs") and contract manufacturing organizations ("CMOs"). Biopharma companies and, to a somewhat lesser extent, CROs and CMOs typically participate in specific points in the pharmaceutical industry value chain. Additionally, due to the relatively low drug efficacy within oncology, pharma companies are partnering with diagnostic companies to bring validated tests to the market with their new drugs.
The Academic and Government Market. Our services and consumable products support customers in this market that consists primarily of “not-for-profit” organizations and includes academic institutions, large government institutes and privately funded organizations. The academic and government market plays an influential role in technology adoption and therapeutic developments for pharmaceutical and molecular diagnostics companies. After decades of investment in basic biomedical research by government funding bodies, the focus has widened to include translational research - multidisciplinary scientific efforts directed at accelerating therapy development.
The Chemical & Energy Market. Our services, software, technical support, and consumables are used throughout the chemicals sector in the development, manufacturing, and quality control of commodity chemicals, specialty and agrochemicals, and fine chemicals. Chemical market customers use our services, software, technical support, and consumables to maintain, optimize, and enable higher productivity and profitability for labs, and support quality control and compliance with environmental and safety regulations. The natural gas and petroleum exploration and refining markets use our services, software, technical support, and consumables to support quality control, environmental safety reviews, analysis of crude oil composition, and improve their refining processes and quality of products.
The Environmental & Forensics Market.  Our services and consumable products support the environmental industry customers that perform laboratory and field analysis of chemical pollutants in air, water, soil and solid waste. Environmental industry customers include all levels of government, the industrial and manufacturing sectors, engineering and consulting companies, commercial testing laboratories and colleges and universities. Our services and consumable products also support drug testing and forensics laboratories that are involved with analyzing evidence associated with crime, screening athletes for performance enhancing drugs, analyzing samples for recreational drugs, or detecting and identifying biological and chemical warfare agents. Customers include local, state, federal, and international law enforcement agencies and commercial testing laboratories.

The Food Market.  Our services and consumable products support the food production chain, including incoming inspection, new product development, quality control and assurance, and packaging. Our services and consumable products also support the food safety market in their work to analyze food for concerns ranging from pathogen contamination, genetic modification, species verification and others.

The Diagnostics and Clinical Market. Our services and consumable products support clinical diagnostic customers in pathology labs throughout the world. The market is skewed towards the mature economies, with most of the market in North America, Western Europe and Japan. The mix is changing, however, as emerging markets increase spending on human health.
10
Table of Contents            
Agilent CrossLab Products and Applications

Chemistries and Supplies

We offer a broad range of market specific consumables and supplies to complete customers' analytical workflows from sample preparation through separation and analysis to storage, with the support of our technology platforms. This includes sample preparation consumables such as solid phase extraction ("SPE") and filtration products, self-manufactured GC and LC columns, chemical standards, and instrument replacement parts. Consumable products also include scientific instrument parts and supplies such as filters and fittings for GC systems; xenon lamps and cuvettes for UV-Vis-NIR, fluorescence, FT-IR and raman spectroscopy instruments; and graphite furnace tubes, hollow cathode lamps and specialized sample introduction glassware for our AA, ICP-OES and ICP-MS products.

Services and Support

We offer a wide range of startup, operational, educational and compliance support services for our measurement and data handling systems. Our support services include maintenance, troubleshooting, repair and training for all of our chemical and bioanalytical instrumentation hardware and software products. With advances in digital and virtual support technologies, many of those services can be offered remotely. Special service bundles have also been designed to meet the specific application needs of various industries. As customers continue to outsource laboratory operations and consolidate suppliers, our enterprise services consist of a broad portfolio of integrated laboratory management services including instrument services, lab supply management, asset management, procurement, informatics and scientific services. Advancements in our offering software and service solutions will help our customers operate a more digitally connected smart lab that can derive more value out of data analytics, artificial intelligence and robotics.

Remarketed Instruments

We refurbish and resell certified pre-owned instruments to value-oriented customers who demand Agilent quality and performance at a budget conscious price.

Agilent CrossLab Customers

We had approximately 54,600 Agilent CrossLab customers in fiscal 2020 and no single customer represented a material amount of the net revenue of the Agilent CrossLab business. A significant number of our Agilent CrossLab customers are also customers of our life sciences and applied markets business.

The service and consumables business is mostly recurring in nature and is not as susceptible to market seasonality and industry cycles in comparison to our instrument businesses. The vendor neutral portion of the portfolio allows the business to perform relatively independent from our instrument business.

Agilent CrossLab Sales, Marketing and Support

We deploy a multi-channel approach, marketing products and services to our customers through direct sales, electronic commerce, resellers, manufacturers' representatives and distributors. We primarily use direct sales to market our solutions to our large accounts. Sales agents supplement direct sales by providing broader geographic coverage and coverage of smaller accounts. Our active reseller program augments our ability to provide more complete solutions to our customers. A substantial portion of consumable sales are processed by our digital commerce infrastructure. All channels are supported by technical product and application specialists to meet our customers' specific requirements.

We deliver our support services to customers in a variety of ways, including on-site assistance with repair or exchange of returned products, as well as a growing number of remote service delivery options. In addition to the traditional telephone support and on-site service, our teams remotely engage customers through various digital tools and omni-channel platforms. We also offer special industry-focused service bundles that are designed to meet the specific needs of hydrocarbon processing, environmental, pharmaceutical and biopharmaceutical customers to keep instruments fully operational and compliant with the respective industry requirements. Our products typically come with standard warranties, and extended warranties are available for additional cost.

11
Table of Contents            
Agilent CrossLab Manufacturing

Our primary manufacturing sites for the consumables business are in California and Delaware in the U.S., and in the Netherlands and the United Kingdom outside of the U.S. Our direct service delivery organization is regionally based operating in 28 countries.

Agilent CrossLab Competition

Our principal competitors in the services and consumable products arena include many of our competitors from the instrument business, such as: Danaher Corporation, PerkinElmer, Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc. and Waters Corporation, as well as numerous niche consumables and service providers. Agilent competes on the basis of product performance, reliability, support quality, applications expertise, global channel coverage and price.

Agilent Technologies Research Laboratories

Agilent Technologies Research Laboratories ("Agilent Labs") is our central research organization based in Santa Clara, California. The Research Labs create competitive advantage through high-impact technology, driving market leadership and growth in Agilent's core businesses and expanding Agilent's footprint into adjacent markets. At the cross-roads of the organization, the Research Labs are able to identify and enable synergies across Agilent's businesses to create competitive differentiation and compelling customer value.

The technical staff have advanced degrees that cover a wide range of scientific and engineering fields, including molecular and cell biology, chemistry, physics, pathology, mathematics, software and informatics, artificial intelligence, deep and machine learning, image processing, nano/microfabrication, and fluidics.

Global Infrastructure Organization

We provide support to our businesses through our global infrastructure organization. This support includes services in the areas of finance, tax, treasury, legal, real estate, insurance services, workplace services, human resources, information technology services, order administration and other corporate infrastructure expenses. Generally, these organizations are managed from Santa Clara, California, with operations and services provided worldwide. As of October 31, 2020, our global infrastructure organization employed approximately 2,600 people worldwide.

Agilent Order Fulfillment Organizations

Our order fulfillment and supply chain organization (“OFS”) focuses on order fulfillment and supply chain operations in our businesses. OFS provides resources for manufacturing, engineering and strategic sourcing to our respective businesses. In general, OFS employees are dedicated to specific businesses and the associated costs are directly allocated to those businesses.

        The following discussions of Research and Development, Backlog, Intellectual Property, Materials, Environmental, Regulatory Affairs and Human Capital Management include information common to each of our businesses.

Research and Development

We anticipate that we will continue to have significant research and development expenditures in order to maintain our competitive position with a continuing flow of innovative, high-quality products and services. Our research and development efforts focus on potential new products and product improvements covering a wide variety of technologies, none of which is individually significant to our operations. Our research seeks to improve on various technical competencies in software, systems and solutions, life sciences and diagnostics. In each of these research fields, we conduct research that is focused on specific product development for release in the short-term as well as other research that is intended to be the foundation for future products over a longer time-horizon. Most of our product development research is designed to improve products already in production, focus on major new product releases, and develop new product segments for the future. We remain committed to invest significantly in research and development and have focused our development efforts on key strategic opportunities to align our business with available markets and position ourselves to capture market share.

12
Table of Contents            
Backlog

We believe that backlog is not a meaningful indicator of future business prospects for our business segments since a significant portion of our revenue for a given quarter is derived from the current quarter's orders. Therefore, we believe that backlog information is not material to an understanding of our business.

Intellectual Property

We generate patent and other intellectual property rights covering significant inventions and other innovations in order to create a competitive advantage. While we believe that our licenses, patents and other intellectual property rights have value, in general no single license, patent or other intellectual property right is in itself material. In addition, our intellectual property rights may be challenged, invalidated or circumvented or may otherwise not provide significant competitive advantage.

Materials

Our life sciences and applied markets, diagnostics and genomics and Agilent CrossLab businesses all purchase materials from thousands of suppliers on a global basis. Some of the parts that require custom design work are not readily available from alternate suppliers due to their unique design or the length of time necessary for design work. Our long-term relationships with suppliers allow us to proactively manage technology road maps and product discontinuance plans and monitor their financial health. To address any potential disruption in our supply chain, we use a number of techniques, including qualifying multiple sources of supply and redesign of products for alternative components. In addition, while we generally attempt to keep our inventory at minimal levels, we do purchase incremental inventory as circumstances warrant to protect the supply chain.

Environmental

Our R&D, manufacturing and distribution operations involve the use of hazardous substances and are regulated under international, federal, state and local laws governing health and safety and the environment. We apply strict standards for protection of the environment and occupational health and safety to sites inside and outside the U.S., even if not subject to regulation imposed by foreign governments. We believe that our properties and operations at our facilities comply in all material respects with applicable environmental laws and occupational health and safety laws. We are also regulated under a number of international, federal, state, and local laws regarding recycling, product packaging and product content requirements. We believe we are substantially in compliance with such environmental, product content/disposal and recycling laws.

We maintain a comprehensive Environmental Site Liability insurance policy which may cover certain clean-up costs or legal claims related to environmental contamination. This policy covers specified active, inactive and divested locations.

Regulatory Affairs

A number of our products and services are subject to regulation by the FDA and certain similar foreign regulatory agencies. These regulations govern a wide variety of product and service related activities, from quality management, design and development to labeling, manufacturing, promotion, sales and distribution. If we fail to comply with FDA and other applicable regulatory requirements or are perceived to potentially have failed to comply, we may face, among other things, warning letters; adverse publicity; investigations or notices of non-compliance, fines, injunctions, and civil penalties; import or export restrictions; partial suspensions or total shutdown of production facilities or the imposition of operating restrictions; increased difficulty in obtaining required FDA clearances or approvals or foreign equivalents; seizures or recalls of our products or those of our customers; or the inability to sell our products. In Europe, the European Union is going to enforce new requirements, known as the EU In Vitro Diagnostic Regulation (the “EU IVDR”), which imposes stricter requirements for the marketing and sale of in vitro diagnostics in the European Union. These new regulations are more stringent in a variety of areas, including clinical requirements, quality systems and post-market surveillance activities. We will have until May 2022 to meet the new EU IVDR requirements.

We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government contracts could harm our business by leading to a reduction in revenue associated with these customers. We have agreements relating to the sale of our products to government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government. We are also subject to investigation for compliance with the regulations governing government contracts. A failure to comply with these regulations could result in suspension of these contracts, criminal, civil and administrative penalties or debarment.

We are also subject to various significant international, federal, state and local regulations in the areas of health and safety, packaging, product content, employment, labor and immigration, import/export controls, trade restrictions and anti-
13
Table of Contents            
competition. Violations of these laws and regulations could result in fines and penalties, criminal sanctions, restrictions on our business conduct and on our ability to offer our products in one or more countries, and could also materially affect our brand, our ability to attract and retain employees, our international operations, our business and our operating results.

In addition, as a global organization, we are subject to data privacy and security laws, regulations, and customer-imposed controls in numerous jurisdictions as a result of having access to and processing confidential, personal, sensitive and/or patient health data in the course of our business. The EU's General Data Protection Regulation ("GDPR"), which became effective in May 2018, applies to all of our activities related to products and services that we offer to EU customers and workers. The GDPR established new requirements regarding the handling of personal data and includes significant penalties for non-compliance (including possible fines of up to 4 percent of total company revenue). Other governmental authorities around the world have passed or are considering similar types of legislative and regulatory proposals concerning data protection. Each of these privacy, security and data protection laws and regulations could impose significant limitations and increase our cost of providing our products and services where we process end user personal data and could harm our results of operations and expose us to significant fines, penalties and other damages.

While we believe we are in compliance in all material respects with such laws and regulations, any noncompliance could result in substantial fines or otherwise restrict our ability to operate and thereby have an adverse effect on our financial condition. To date, none has had a material impact on our operations.

Human Capital Management

As of October 31, 2020, we employed approximately 16,400 persons, of whom approximately 5,600 were employed in the United States and approximately 10,800 were employed outside of the United States. We also leverage temporary workers to provide flexibility for our business and manufacturing needs.

We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. We provide our employees with competitive salaries and bonuses, opportunities for equity ownership, development programs that enable continued learning and growth and a robust employment package that promotes well-being across all aspects of their lives, including health care, retirement planning and paid time off. As part of our promotion and retention efforts, we also invest in ongoing leadership development through programs such as our Emerging Leader Program, our Managing at Agilent programs and our experienced managers’ Accelerate program. In addition, we regularly conduct an employee survey to gauge employee engagement and identify areas of focus.

As a global company, much of our success is rooted in the diversity of our teams and our commitment to inclusion. We value diversity at all levels and continue to focus on extending our diversity and inclusion initiatives across our entire workforce, from working with managers to develop strategies for building diverse teams to promoting the advancement of leaders from different backgrounds.

Information about our Executive Officers
The names of our current executive officers and their ages, titles and biographies appear below:

Henrik Ancher-Jensen, 55, has served as our Senior Vice President, Agilent and President, Order Fulfillment since September 2013. From September 2012 to September 2013, Mr. Ancher-Jensen served as our Vice President, Global Product Supply, Diagnostics and Genomics Group.  From September 2010 to September 2012 he served as Corporate Vice President, Global Operations of Dako A/S, a Danish diagnostics company, and as Dako’s Vice President, Supply Chain and Chief Information Officer from 2006 to September 2010.  Prior to joining Dako, he spent more than 15 years in senior management roles and management consulting with Chr. Hansen, Deloitte Consulting and NVE.

Rodney Gonsalves, 55, has served as our Vice President, Corporate Controllership and Chief Accounting Officer since May 2015. From September 2009 to May 2015, Mr. Gonsalves served as Vice President and operational CFO for various business groups within the company, most recently for the Life Sciences and Applied Markets Group. Prior to that, Mr. Gonsalves served in various capacities for Agilent, including as vice president of Investor Relations, controller, corporate governance and customer financing in Agilent’s Global Infrastructure Organization, and controller for the Photonics Systems Business Unit.  Before joining Agilent, Mr. Gonsalves held a variety of positions in finance with Hewlett-Packard Company.  

Dominique P. Grau, 61, has served as our Senior Vice President, Human Resources and Global Communications since November 2018. From August 2014 to October 2018 he served as Senior Vice President, Human Resources. From May 2012 to August 2014 Mr. Grau served as Vice President, Worldwide Human Resources. Prior to that, he served as Vice President,
14
Table of Contents            
Compensation, Benefits and HR Services from May 2006 to May 2012. Mr. Grau had previously served in various capacities for Agilent and Hewlett-Packard Company.

Padraig McDonnell, 49, has served as our Senior Vice President, Agilent and President, Agilent CrossLab Group since May 2020. From November 2016 to April 2020, Mr. McDonnell served as our Vice President and General Manager of the Chemistries and Supplies Division. Prior to that, he served as our Vice President and General Manager of EMEAI Laboratory Solutions Sales. Mr. McDonnell has previously held a variety of positions with Agilent and Hewlett-Packard Company.

Robert W. McMahon, 52, has served as our Senior Vice President since August 2018 and Chief Financial Officer since September 2018. He previously served as the Chief Financial Officer of Hologic, Inc., a medical technology company from May 2014 to August 2018.  Prior to Hologic, Mr. McMahon spent 20 years with Johnson & Johnson most recently as Worldwide Vice President of Finance and Business Development for Ortho Clinical Diagnostics a division of Johnson & Johnson's Medical Device and Diagnostics Group.

Michael R. McMullen, 59, has served as Chief Executive Officer since March 2015 and as President since September 2014. From September 2014 to March 2015 he also served as Chief Operating Officer. From September 2009 to September 2014, he served as Senior Vice President, Agilent and President, Chemical Analysis Group. Prior to that, he served in various capacities for Agilent, including as our Vice President and General Manager of the Chemical Analysis Solutions Unit of the Life Sciences and Chemical Analysis Group and Country Manager for Agilent's China, Japan and Korea Life Sciences and Chemical Analysis Group. Prior to that, Mr. McMullen served as Controller for the Hewlett‑Packard Company and Yokogawa Electric Joint Venture from July 1996 to March 1999. Since September 2018, Mr. McMullen has served as a member of the Board of Directors of Coherent, Inc.

Samraat S. Raha, 48, has served as our Senior Vice President, Agilent and President, Diagnostics and Genomics Group since April 2018. From May 2017 to April 2018, Mr. Raha served as our Senior Vice President, Strategy and Corporate Development. From June 2013 to January 2017 he served as Vice President, Global Marketing for Illumina, Inc. and from 2008 to 2012 he served as Vice President and General Manager, Genomic Assays / NextGen qPCR for Life Technologies, Inc. 

Michael Tang, 46, has served as our Senior Vice President, General Counsel and Secretary since January 2016. From May 2015 to January 2016 he served as Vice President, Assistant General Counsel and Secretary and from November 2013 to April 2015 he served as Vice President, Assistant General Counsel and Assistant Secretary. From March 2012 to October 2013 he served as Business Development Manager in Agilent’s Corporate Development group. Prior to that, Mr. Tang served in various capacities in Agilent's legal department. Before joining Agilent, Mr. Tang worked at Wilson Sonsini Goodrich & Rosati, a California law firm and Fenwick & West LLP, a California law firm.

Jacob Thaysen, 45, has served as our Senior Vice President, Agilent and President, Life Sciences and Applied Markets Group, since April 2018. From November 2014 to April 2018 he served as Senior Vice President, Agilent and President, Diagnostics and Genomics Group.  From October 2013 to November 2014 he served as Vice President and General Manager of the Diagnostics and Genomics business. Prior to that he served as Vice President and General Manager of the Genomics Solutions unit from January 2013 to October 2013. Before joining Agilent, he served in various capacities at Dako A/S, a Danish diagnostics company, including as Corporate Vice President of R&D, Vice President, System Development, R&D, Vice President, Strategic Marketing and Vice President, Global Sales Operations. Prior to Dako, Mr. Thaysen worked as a management consultant and Chief Technical Officer and founder of a high-tech start-up company.

Investor Information
We are subject to the informational requirements of the Securities Exchange Act of 1934 (“Exchange Act”). Therefore, we file periodic reports, proxy statements and other information with the Securities and Exchange Commission (“SEC”). The SEC maintains an Internet site (https://www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers that file electronically.
Our financial and other information can be accessed at our Investor Relations website. The address is www.investor.agilent.com. We make available, free of charge, copies of our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after filing such material electronically or otherwise furnishing it to the SEC.
Our Amended and Restated Bylaws, Corporate Governance Standards, the charters of our Audit and Finance Committee, our Compensation Committee, our Executive Committee and our Nominating/Corporate Governance Committee, as well as our
15
Table of Contents            
Standards of Business Conduct (including code of ethics provisions that apply to our principal executive officer, principal financial officer, principal accounting officer and senior financial officers) are available on our website at www.investor.agilent.com under “Corporate Governance”. These items are also available in print to any stockholder in the United States and Canada who requests them by calling (877) 942-4200. This information is also available by writing to the company at the address on the cover of this Annual Report on Form 10-K.

Item 1A.  Risk Factors

Risks, Uncertainties and Other Factors Specific to Our Company That May Affect Future Results
The COVID-19 pandemic has adversely impacted, and continues to pose risks to, our business, results of operations and financial condition, the nature and extent of which are highly uncertain and unpredictable.

Our global operations expose us to risks associated with public health crises, including epidemics and pandemics such as COVID-19. The global spread of COVID-19 had, and may continue to have, an adverse impact on our operations, sales and delivery and supply chains. Many countries including the United States implemented measures such as quarantine, shelter-in-place, curfew, travel and activity restrictions and similar isolation measures, including government orders and other restrictions on the conduct of business operations. Due to these measures we experienced significant and unpredictable reductions or increases in demand for certain of our products. Moreover, these measures caused delays in installations and significantly impacted our ability to service our customers on site. If the COVID-19 pandemic continues or worsens, we may again experience a decline in sales activities and customer orders in certain of our businesses. Continuing travel restrictions, prolonged quarantines or other government orders in response to the pandemic may significantly impact our ability to support our sites and service customers in those locations. The COVID-19 pandemic has also impacted our supply chain as we experienced disruptions or delays in shipments of certain materials or components of our products. If the pandemic continues or worsens, our manufacturing facilities, our distribution centers where inventory is managed and the operations of our logistics and other service providers may be significantly impacted. Accordingly, COVID-19 has negatively affected our revenue growth in certain of our businesses. It is uncertain how materially COVID-19 will affect our global operations generally if these impacts persist, worsen or re-emerge over an extended period of time. The extent and duration of these impacts are dependent in part on customers returning to work and economic activity continuing to ramp up. The impact on our business also depends in part on the pace at which our customers resume non-COVID-19 related patient care and testing, as well as the timing of when research performed by laboratories and other institutions returns to normal levels. 

Additionally, the COVID-19 pandemic caused significant volatility and uncertainty in U.S. and international markets. A disruption of global financial markets or resulting economic downturn may reduce our ability to incur debt or access capital and increase the cost of doing so. There are no assurances that the credit markets or the capital markets will be available to us in the future or that the lenders participating in our credit facilities will be able to provide financing in accordance with their contractual obligations.

We cannot reasonably estimate the length or severity of the COVID-19 pandemic or the related response, or the extent to which the disruption may impact our business, financial position, results of operations and cash flows. Ultimately, the COVID-19 pandemic could have a material adverse impact on our business, financial position, results of operations and cash flows. To the extent COVID-19 conditions improve, the duration and sustainability of any such improvements will be uncertain and continuing adverse impacts and/or the degree of improvement may vary dramatically by geography and by business. The actions we take in response to any improvements in conditions may also vary widely by geography and by business and will likely be made with incomplete information; pose the risk that such actions may prove to be premature, incorrect or insufficient; and could have a material, adverse impact on our business and results of operations.

Our operating results and financial condition could be harmed if the markets into which we sell our products decline or do not grow as anticipated.

Visibility into our markets is limited. Our quarterly sales and operating results are highly dependent on the volume and timing of orders received during the fiscal quarter, which are difficult to forecast and may be cancelled by our customers. In addition, our revenue and earnings forecasts for future fiscal quarters are often based on the expected seasonality of our markets. However, the markets we serve do not always experience the seasonality that we expect as customer spending policies and budget allocations, particularly for capital items, may change. Any decline in our customers' markets or in general economic conditions would likely result in a reduction in demand for our products and services. Also, if our customers' markets decline, we may not be able to collect on outstanding amounts due to us. Such declines could harm our consolidated financial position, results of operations, cash flows and stock price, and could limit our profitability. Also, in such an environment, pricing pressures could intensify. Since a significant portion of our operating expenses is relatively fixed in nature due to sales,
16
Table of Contents            
research and development and manufacturing costs, if we were unable to respond quickly enough these pricing pressures could further reduce our operating margins.

If we do not introduce successful new products and services in a timely manner to address increased competition through frequent new product and service introductions, rapid technological changes and changing industry standards, our products and services may become obsolete, and our operating results may suffer.

We generally sell our products in industries that are characterized by increased competition through frequent new product and service introductions, rapid technological changes and changing industry standards. Without the timely introduction of new products, services and enhancements, our products and services may become technologically obsolete over time, in which case our revenue and operating results could suffer. The success of our new products and services will depend on several factors, including our ability to:

•properly identify customer needs and predict future needs;
•innovate and develop new technologies, services and applications;
•appropriately allocate our research and development spending to products and services with higher growth prospects;
•successfully commercialize new technologies in a timely manner;
•manufacture and deliver new products in sufficient volumes and on time;
•differentiate our offerings from our competitors' offerings;
•price our products competitively;
•anticipate our competitors' development of new products, services or technological innovations; and
•control product quality in our manufacturing process.

In addition, if we fail to accurately predict future customer needs and preferences or fail to produce viable technologies, we may invest in research and development of products and services that do not lead to significant revenue, which would adversely affect our profitability. Even if we successfully innovate and develop new and enhanced products and services, we may incur substantial costs in doing so, and our operating results may suffer. In addition, promising new products may fail to reach the market or realize only limited commercial success because of real or perceived concerns of our customers. Furthermore, as we collaborate with pharmaceutical customers to develop drugs such as companion diagnostics assays or provide drug components like active pharmaceutical ingredients, we face risks that those drug programs may be cancelled upon clinical trial failures.

General economic conditions may adversely affect our operating results and financial condition.

Our business is sensitive to negative changes in general economic conditions, both inside and outside the United States. Slower global economic growth and uncertainty in the markets in which we operate may adversely impact our business resulting in:

•reduced demand for our products, delays in the shipment of orders, or increases in order cancellations;
•increased risk of excess and obsolete inventories;
•increased price pressure for our products and services; and
•greater risk of impairment to the value, and a detriment to the liquidity, of our investment portfolio.

Failure to adjust our purchases due to changing market conditions or failure to accurately estimate our customers' demand could adversely affect our income.

Our income could be harmed if we are unable to adjust our purchases to reflect market fluctuations, including those caused by the seasonal nature of the markets in which we operate. The sale of our products and services are dependent, to a large degree, on customers whose industries are subject to seasonal trends in the demand for their products. During a market upturn, we may not be able to purchase sufficient supplies or components to meet increasing product demand, which could materially affect our results. In the past, we have experienced a shortage of parts for some of our products. In addition, some of the parts that require custom design are not readily available from alternate suppliers due to their unique design or the length of time necessary for design work. Should a supplier cease manufacturing such a component, we would be forced to reengineer our product. In addition to discontinuing parts, suppliers may also extend lead times, limit supplies or increase prices due to capacity constraints or other factors. In order to secure components for the production of products, we may continue to enter into non-cancelable purchase commitments with vendors, or at times make advance payments to suppliers, which could impact our ability to adjust our inventory to declining market demands. If demand for our products is less than we expect, we may experience additional excess and obsolete inventories and be forced to incur additional expenses.
17
Table of Contents            

Demand for some of our products and services depends on the capital spending policies of our customers, research and development budgets and on government funding policies.

Our customers include pharmaceutical companies, laboratories, universities, healthcare providers, government agencies and public and private research institutions. Many factors, including public policy spending priorities, available resources, mergers and consolidations, institutional and governmental budgetary policies and spending priorities, and product and economic cycles, have a significant effect on the capital spending policies of these entities. Fluctuations in the research and development budgets at these organizations could have a significant effect on the demand for our products and services. Research and development budgets fluctuate due to changes in available resources, consolidation, spending priorities, general economic conditions and institutional and governmental budgetary policies. The timing and amount of revenue from customers that rely on government funding or research may vary significantly due to factors that can be difficult to forecast, including changes in spending authorizations and budgetary priorities for our products and services. If demand for our products and services is adversely affected, our revenue and operating results would suffer.

Economic, political, foreign currency and other risks associated with international sales and operations could adversely affect our results of operations.

Because we sell our products worldwide, our business is subject to risks associated with doing business internationally. We anticipate that revenue from international operations will continue to represent a majority of our total revenue. International revenue and costs are subject to the risk that fluctuations in foreign currency exchange rates could adversely affect our financial results when translated into U.S. dollars for financial reporting purposes. Foreign currency movements for the year ended October 31, 2020 had an overall unfavorable impact on revenue of approximately 1 percentage point when compared to the same period last year. When movements in foreign currency exchange rates have a negative impact on revenue, they will also have a positive impact by reducing our costs and expenses. In addition, many of our employees, contract manufacturers, suppliers, job functions, outsourcing activities and manufacturing facilities are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including:

•interruption to transportation flows for delivery of parts to us and finished goods to our customers;
•changes in a specific country's or region's political, economic or other conditions;
•changes in diplomatic and trade relationships, such as the United Kingdom's exit from the European Union and the increased uncertainty around its implementation caused by COVID-19, as well as, new tariffs, trade protection measures, import or export licensing requirements, new or different customs duties, trade embargoes and sanctions and other trade barriers;
•tariffs imposed by the U.S. on goods from other countries and tariffs imposed by other countries on U.S. goods, including the tariffs enacted and proposed by the U.S. government on various imports from China and by the Chinese government on certain U.S. goods;
•negative consequences from changes in or differing interpretations of laws and regulations, including those related to tax and import/export;
•difficulty in staffing and managing widespread operations;
•differing labor regulations;
•differing protection of intellectual property;
•unexpected changes in regulatory requirements;
•geopolitical uncertainty or turmoil, terrorism and war; and
•impact of public health crises, including pandemics and epidemics, such as COVID-19 on the global economy.

We sell our products into many countries and we also source many components and materials for our products from and manufacture our products in various countries. Future tariffs and tariffs already implemented could have negative impact on our business, results of operations and financial condition. It may be time-consuming and expensive for us to alter our business operations in order to adapt to any such change. Further, additional tariffs, the scope and duration of which, if implemented, remains uncertain, which have been proposed or threatened and the potential escalation of a trade war and retaliatory measures could have a material adverse effect on our business, results of operations and financial condition.

Most of our accounting and tax processes including general accounting, cost accounting, accounts payable, accounts receivable and tax functions are centralized at locations in India and Malaysia. If conditions change in those countries, it may adversely affect operations, including impairing our ability to pay our suppliers and collect our receivables. Our results of operations, as well as our liquidity, may be adversely affected and possible delays may occur in reporting financial results.

18
Table of Contents            
In addition, although the majority of our products are priced and paid for in U.S. dollars, a significant amount of certain types of expenses, such as payroll, utilities, tax, and marketing expenses, are paid in local currencies. Our hedging programs reduce, but do not always entirely eliminate, within any given twelve-month period, the impact of currency exchange rate movements, and therefore fluctuations in exchange rates, including those caused by currency controls, could impact our business, operating results and financial condition by resulting in lower revenue or increased expenses. For expenses beyond that twelve-month period, our hedging strategy does not mitigate our exposure. In addition, our currency hedging programs involve third-party financial institutions as counterparties. The weakening or failure of financial institution counterparties may adversely affect our hedging programs and our financial condition through, among other things, a reduction in available counterparties, increasingly unfavorable terms, and the failure of the counterparties to perform under hedging contracts.

Our strategic initiatives to adjust our cost structure could have long-term adverse effects on our business, and we may not realize the operational or financial benefits from such actions.

We have implemented multiple strategic initiatives across our businesses to adjust our cost structure, and we may engage in similar activities in the future. These strategic initiatives and our regular ongoing cost reduction activities may distract management, could slow improvements in our products and services and limit our ability to increase production quickly if demand for our products increases. In addition, delays in implementing our strategic initiatives, unexpected costs or failure to meet targeted improvements may diminish the operational and financial benefits we realize from such actions. Any of the above circumstances could have an adverse effect on our business and operating results and financial condition.

Our business will suffer if we are not able to retain and hire key personnel.

Our future success depends partly on the continued service of our key research, engineering, sales, marketing, manufacturing, executive and administrative personnel. If we fail to retain and hire a sufficient number of these personnel, we will not be able to maintain or expand our business. The markets in which we operate are very dynamic, and our businesses continue to respond with reorganizations, workforce reductions and site closures. We believe our pay levels are very competitive within the regions that we operate. However, there is intense competition for certain highly technical specialties in geographic areas where we continue to recruit, and it may become more difficult to hire and retain our key employees.

Our acquisitions, strategic investments and alliances, joint ventures, exiting of businesses and divestitures may result in financial results that are different than expected.

In the normal course of business, we frequently engage in discussions with third parties relating to possible acquisitions, strategic investments and alliances, joint ventures and divestitures, and generally expect to complete several transactions per year. In addition, we may decide to exit a particular business within our product portfolio. As a result of such transactions, our financial results may differ from our own or the investment community's expectations in a given fiscal quarter or over the long term. We may have difficulty developing, manufacturing and marketing the products of a newly acquired company in a way that enhances the performance of our combined businesses or product lines. Acquired businesses may also expose us to new risks and new markets, and we may have difficulty addressing these risks in a cost effective and timely manner. Transactions such as acquisitions have resulted, and may in the future result in, unexpected significant costs and expenses. In the future, we may be required to record charges to earnings during the period if we determine there is an impairment of goodwill or intangible assets, up to the full amount of the value of the assets, or, in the case of strategic investments and alliances, consolidate results, including losses, of third parties or write down investment values or loans and convertible notes related to the strategic investment.

Integrating the operations of acquired businesses within Agilent could be a difficult, costly and time-consuming process that involves a number of risks. Acquisitions and strategic investments and alliances may require us to integrate and collaborate with a different company culture, management team, business model, business infrastructure and sales and distribution methodology and assimilate and retain geographically dispersed, decentralized operations and personnel. Depending on the size and complexity of an acquisition, our successful integration of the entity depends on a variety of factors, including introducing new products and meeting revenue targets as expected, the retention of key employees and key customers, increased exposure to certain governmental regulations and compliance requirements and increased costs and use of resources. Further, the integration of acquired businesses is likely to result in our systems and internal controls becoming increasingly complex and more difficult to manage. Any difficulties in the assimilation of acquired businesses into our control system could harm our operating results or cause us to fail to meet our financial reporting obligations.

Even if we are able to successfully integrate acquired businesses within Agilent, we may not be able to realize the revenue and other synergies and growth that we anticipated from the acquisition in the time frame that we expected, and the costs of achieving these benefits may be higher than what we expected. As a result, the acquisition and integration of acquired
19
Table of Contents            
businesses may not contribute to our earnings as expected, we may not achieve our operating margin targets when expected, or at all, and we may not achieve the other anticipated strategic and financial benefits of such transactions.

A successful divestiture depends on various factors, including our ability to effectively transfer liabilities, contracts, facilities and employees to the purchaser, identify and separate the intellectual property to be divested from the intellectual property that we wish to keep and reduce fixed costs previously associated with the divested assets or business. In addition, if customers of the divested business do not receive the same level of service from the new owners, this may adversely affect our other businesses to the extent that these customers also purchase other Agilent products. In exiting a business, we may still retain liabilities associated with the support and warranty of those businesses and other indemnification obligations. All of these efforts require varying levels of management resources, which may divert our attention from other business operations. If we do not realize the expected benefits or synergies of such transactions, our consolidated financial position, results of operations, cash flows and stock price could be negatively impacted.

If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results, which could lead to a loss of investor confidence in our financial statements and have an adverse effect on our stock price.

Effective internal controls are necessary for us to provide reliable and accurate financial statements and to effectively prevent fraud. We devote significant resources and time to comply with the internal control over financial reporting requirements of the Sarbanes Oxley Act of 2002 and continue to enhance our controls. However, we cannot be certain that we will be able to prevent future significant deficiencies or material weaknesses. Inadequate internal controls could cause investors to lose confidence in our reported financial information, which could have a negative effect on investor confidence in our financial statements, the trading price of our stock and our access to capital.

Our customers and we are subject to various governmental regulations. Compliance with or changes in such regulations may cause us to incur significant expenses, and if we fail to maintain satisfactory compliance with certain regulations, we may be forced to recall products and cease their manufacture and distribution, and we could be subject to civil or criminal penalties.

Our customers and we are subject to various significant international, federal, state and local regulations, including but not limited to regulations in the areas of health and safety, packaging, product content, employment, labor and immigration, import/export controls, trade restrictions and anti-competition. In addition, as a global organization, we are subject to data privacy and security laws, regulations, and customer-imposed controls in numerous jurisdictions as a result of having access to and processing confidential, personal, sensitive and/or patient health data in the course of our business. The EU's General Data Protection Regulation ("GDPR"), which became effective in May 2018, applies to all of our activities related to products and services that we offer to EU customers and workers. The GDPR established new requirements regarding the handling of personal data and includes significant penalties for non-compliance (including possible fines of up to 4 percent of total company revenue). Other governmental authorities around the world have passed or are considering similar types of legislative and regulatory proposals concerning data protection. Each of these privacy, security and data protection laws and regulations could impose significant limitations and increase our cost of providing our products and services where we process end user personal data and could harm our results of operations and expose us to significant fines, penalties and other damages.

We must also comply with complex foreign and U.S. laws and regulations, such as the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, and other local laws prohibiting corrupt payments to governmental officials, anti-competition regulations and sanctions imposed by the U.S. Office of Foreign Assets Control and other similar laws and regulations. Violations of these laws and regulations could result in fines and penalties, criminal sanctions, restrictions on our business conduct and on our ability to offer our products in one or more countries, and could also materially affect our brand, our ability to attract and retain employees, our international operations, our business and our operating results. Although we have implemented policies and procedures designed to ensure compliance with these laws and regulations, there can be no assurance that our employees, contractors, or agents will not violate our policies.

These regulations are complex, change frequently and have tended to become more stringent over time. We may be required to incur significant expenses to comply with these regulations or to remedy any violations of these regulations. Any failure by us to comply with applicable government regulations could also result in the cessation of our operations or portions of our operations, product recalls or impositions of fines and restrictions on our ability to carry on or expand our operations. In addition, because many of our products are regulated or sold into regulated industries, we must comply with additional regulations in marketing our products. We develop, configure and market our products to meet customer needs created by these regulations. Any significant change in these regulations could reduce demand for our products, force us to modify our products to comply with new regulations or increase our costs of producing these products. If demand for our products is adversely
20
Table of Contents            
affected or our costs increase, our operating results and business would suffer.

Our products and operations are also often subject to the rules of industrial standards bodies, like the International Standards Organization, as well as regulation by other agencies such as the FDA. We also must comply with work safety rules. If we fail to adequately address any of these regulations, our businesses could be harmed.

We are subject to extensive regulation by the FDA and certain similar foreign regulatory agencies, and failure to comply with such regulations could harm our reputation, business, financial condition and results of operations.

A number of our products and services are subject to regulation by the FDA and certain similar foreign regulatory agencies. In addition, a number of our products and services may in the future be subject to regulation by the FDA and certain similar foreign regulatory agencies. These regulations govern a wide variety of product and service-related activities, from quality management, design and development to labeling, manufacturing, promotion, sales and distribution. If we or any of our suppliers or distributors fail to comply with FDA and other applicable regulatory requirements or are perceived to potentially have failed to comply, we may face, among other things, warning letters; adverse publicity affecting both us and our customers; investigations or notices of non-compliance, fines, injunctions, and civil penalties; import or export restrictions; partial suspensions or total shutdown of production facilities or the imposition of operating restrictions; increased difficulty in obtaining required FDA clearances or approvals or foreign equivalents; seizures or recalls of our products or those of our customers; or the inability to sell our products. Any such FDA or other regulatory agency actions could disrupt our business and operations, lead to significant remedial costs and have a material adverse impact on our financial position and results of operations. In addition, the global regulatory environment has become increasingly stringent for our products and services. For example, the EU is going to enforce new requirements, known as the EU In Vitro Diagnostic Regulation (the “EU IVDR”), which imposes stricter requirements for the marketing and sale of in vitro diagnostics in the European Union. These new regulations are more stringent in a variety of areas, including clinical requirements, quality systems and post-market surveillance activities. We will have until May 2022 to meet the new EU IVDR requirements. Failure to meet these requirements could adversely impact our business in the EU and other regions that tie their product registrations to the EU requirements.

Some of our products are subject to particularly complex regulations such as regulations of toxic substances, and failure to comply with such regulations could harm our business.

Some of our products and related consumables are used in conjunction with chemicals whose manufacture, processing, distribution and notification requirements are regulated by the U.S. Environmental Protection Agency (“EPA”) under the Toxic Substances Control Act and by regulatory bodies in other countries under similar laws. The Toxic Substances Control Act regulations govern, among other things, the testing, manufacture, processing and distribution of chemicals, the testing of regulated chemicals for their effects on human health and safety and the import and export of chemicals. The Toxic Substances Control Act prohibits persons from manufacturing any chemical in the United States that has not been reviewed by the EPA for its effect on health and safety and placed on an EPA inventory of chemical substances. We must ensure conformance of the manufacturing, processing, distribution of and notification about these chemicals to these laws and adapt to regulatory requirements in all applicable countries as these requirements change. If we fail to comply with the notification, record-keeping and other requirements in the manufacture or distribution of our products, then we could be subject to civil penalties, criminal prosecution and, in some cases, prohibition from distributing or marketing our products until the products or component substances are brought into compliance.

Our business may suffer if we fail to comply with government contracting laws and regulations.

We derive a portion of our revenue from direct and indirect sales to U.S. federal, state, local, and foreign governments and their respective agencies. Such contracts are subject to various procurement laws and regulations and contract provisions relating to their formation, administration and performance. Failure to comply with these laws, regulations or provisions in our government contracts could result in the imposition of various civil and criminal penalties, termination of contracts, forfeiture of profits, suspension of payments, increased pricing pressure or suspension from future government contracting. If our government contracts are terminated, if we are suspended from government work, or if our ability to compete for new contracts is adversely affected, our business could suffer.

21
Table of Contents            
Our reputation, ability to do business and financial statements may be harmed by improper conduct by any of our employees, agents or business partners.

We cannot provide assurance that our internal controls and compliance systems will always protect us from acts committed by employees, agents or business partners of ours (or of businesses we acquire or partner with) that would violate U.S. and/or non-U.S. laws, including the laws governing payments to government officials, bribery, fraud, kickbacks and false claims, pricing, sales and marketing practices, conflicts of interest, competition, employment practices and workplace behavior, export and import compliance, money laundering and data privacy. In particular, the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act and similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments to government officials for the purpose of obtaining or retaining business, and we operate in many parts of the world that have experienced governmental corruption to some degree. Any such improper actions or allegations of such acts could damage our reputation and subject us to civil or criminal investigations in the United States and in other jurisdictions, and related shareholder lawsuits could lead to substantial civil and criminal, monetary and non-monetary penalties and could cause us to incur significant legal and investigatory fees. In addition, the government may seek to hold us liable as a successor for violations committed by companies in which we invest or that we acquire. We also rely on our suppliers to adhere to our supplier standards of conduct, and material violations of such standards of conduct could occur that could have a material effect on our business, reputation and financial statements.

Our retirement and post retirement pension plans are subject to financial market risks that could adversely affect our future results of operations and cash flows.

We have significant retirement and post retirement pension plan assets and obligations. The performance of the financial markets and interest rates impact our plan expenses and funding obligations. Significant decreases in market interest rates, decreases in the fair value of plan assets and investment losses on plan assets will increase our funding obligations and adversely impact our results of operations and cash flows.

The impact of consolidation and acquisitions of competitors is difficult to predict and may harm our business.

The life sciences industry is intensely competitive and has been subject to increasing consolidation. Consolidation in our industries could result in existing competitors increasing their market share through business combinations and result in stronger competitors, which could have a material adverse effect on our business, financial condition and results of operations. We may not be able to compete successfully in increasingly consolidated industries and cannot predict with certainty how industry consolidation will affect our competitors or us.

If we are unable to successfully manage the consolidation and streamlining of our manufacturing operations, we may not achieve desired efficiencies, and our ability to deliver products to our customers could be disrupted.

Although we utilize manufacturing facilities throughout the world, we have consolidated, and may further consolidate, our manufacturing operations to certain of our plants to achieve efficiencies and gross margin improvements. Additionally, we typically consolidate the production of products from our acquisitions into our supply chain and manufacturing processes, which are technically complex and require expertise to operate. If we are unable to establish processes to efficiently and effectively produce high quality products in the consolidated locations, we may not achieve the anticipated synergies and production may be disrupted, which could adversely affect our business and operating results.

Our operating results may suffer if our manufacturing capacity does not match the demand for our products.

Because we cannot immediately adapt our production capacity and related cost structures to rapidly changing market conditions, when demand does not meet our expectations, our manufacturing capacity may exceed our production requirements. If during an economic downturn we had excess manufacturing capacity, then our fixed costs associated with excess manufacturing capacity would adversely affect our gross margins and operating results. If, during a general market upturn or an upturn in one of our segments, we cannot increase our manufacturing capacity to meet product demand, we may not be able to fulfill orders in a timely manner which could lead to order cancellations, contract breaches or indemnification obligations. This inability could materially and adversely limit our ability to improve our results.

22
Table of Contents            
Dependence on contract manufacturing and outsourcing other portions of our supply chain, including logistics and third-party package delivery services, may adversely affect our ability to bring products to market and damage our reputation. Dependence on outsourced information technology and other administrative functions may impair our ability to operate effectively.

As part of our efforts to streamline operations and to manage costs, we outsource aspects of our manufacturing processes and other functions and continue to evaluate additional outsourcing. If our contract manufacturers or other outsourcers fail to perform their obligations in a timely manner or at satisfactory quality levels, our ability to bring products to market and our reputation could suffer. For example, during a market upturn, our contract manufacturers may be unable to meet our demand requirements, which may preclude us from fulfilling our customers' orders on a timely basis. The ability of these manufacturers to perform is largely outside of our control. If one or more of the third-party package delivery providers experiences a significant disruption in services or institutes a significant price increase, we may have to seek alternative providers, our costs could increase, and the delivery of our products could be prevented or delayed. Additionally, changing or replacing our contract manufacturers, logistics providers or other outsourcers could cause disruptions or delays. In addition, we outsource significant portions of our information technology ("IT") and other administrative functions. Since IT is critical to our operations, any failure to perform on the part of our IT providers could impair our ability to operate effectively. In addition to the risks outlined above, problems with manufacturing or IT outsourcing could result in lower revenue and unexecuted efficiencies and impact our results of operations and our stock price.

Environmental contamination from past and ongoing operations could subject us to substantial liabilities.

Certain properties we have previously owned or leased are undergoing remediation for subsurface contamination.  Although we are indemnified for liability relating to the required remediation at some of those properties, we may be subject to liability if these indemnification obligations are not fulfilled.  In other cases, we have agreed to indemnify the current owners of certain properties for liabilities related to contamination, including companies with which we have previously been affiliated such as HP, Inc., Hewlett-Packard Enterprise (formerly Hewlett-Packard Company) and Varian Medical Systems, Inc.  Further, other properties we have previously owned or leased at which we have operated in the past, or for which we have otherwise contractually assumed, or provided indemnities for, certain actual or contingent environmental liabilities may or do require remediation. While we are not aware of any material liabilities associated with any potential environmental contamination at any of those properties or facilities, we may be exposed to material liability if environmental contamination at material levels is found to exist. In addition, in connection with the acquisition of certain companies, we have assumed other costs and potential or contingent liabilities for environmental matters.  Any significant costs or liabilities could have an adverse effect on results of operations.

Our current and historical manufacturing processes and operations involve, or have involved, the use of certain substances regulated under various foreign, federal, state and local environment protection and health and safety laws and regulations. As a result, we may become subject to liabilities for environmental contamination, and these liabilities may be substantial. Although our policy is to apply strict standards for environmental protection and health and safety at our sites inside and outside the United States, we may not be aware of all conditions that could subject us to liability. Further, in the event that any future climate change legislation would require that stricter standards be imposed by domestic or international environmental regulatory authorities, we may be required to make certain changes and adaptations to our manufacturing processes. Failure to comply with these environmental protection and health and safety laws and regulations could result in civil, criminal, regulatory, administrative or contractual sanction, including fines, penalties or suspensions. If we have any violations of, or incur liabilities pursuant to these laws or regulations, our financial condition and operating results could be adversely affected.

Third parties may claim that we are infringing their intellectual property, and we could suffer significant litigation or licensing expenses or be prevented from selling products or services.

From time to time, third parties may claim that one or more of our products or services infringe their intellectual property rights. We analyze and take action in response to such claims on a case by case basis. Any dispute or litigation regarding patents or other intellectual property could be costly and time-consuming due to the complexity of our technology and the uncertainty of intellectual property litigation and could divert our management and key personnel from our business operations. A claim of intellectual property infringement could force us to enter into a costly or restrictive license agreement, which might not be available under acceptable terms or at all, could require us to redesign our products, which would be costly and time-consuming, and/or could subject us to significant damages or to an injunction against the development and sale of certain of our products or services. Our intellectual property portfolio may not be useful in asserting a counterclaim, or negotiating a license, in response to a claim of intellectual property infringement. In certain of our businesses, we rely on third-party intellectual
23
Table of Contents            
property licenses, and we cannot ensure that these licenses will continue to be available to us in the future or can be expanded to cover new products on favorable terms or at all.

Third parties may infringe our intellectual property, and we may suffer competitive injury or expend significant resources enforcing our rights.

Our success depends in large part on our proprietary technology, including technology we obtained through acquisitions. We rely on various intellectual property rights, including patents, copyrights, trademarks and trade secrets, as well as confidentiality provisions and licensing arrangements, to establish our proprietary rights. If we do not enforce our intellectual property rights successfully, our competitive position may suffer, which could harm our operating results.

Our pending patent, copyright and trademark registration applications may not be allowed, or competitors may challenge the validity or scope of our patents, copyrights or trademarks. In addition, our patents, copyrights, trademarks and other intellectual property rights may not provide us with a significant competitive advantage.

We may need to spend significant resources monitoring and enforcing our intellectual property rights, and we may not be aware of or able to detect or prove infringement by third parties. Our competitive position may be harmed if we cannot detect infringement and enforce our intellectual property rights quickly or at all. In some circumstances, we may choose to not pursue enforcement because an infringer has a dominant intellectual property position or for other business reasons. In addition, competitors might avoid infringement by designing around our intellectual property rights or by developing non-infringing competing technologies. Intellectual property rights and our ability to enforce them may be unavailable or limited in some countries, which could make it easier for competitors to capture market share and could result in lost revenues. Furthermore, some of our intellectual property is licensed to others which may allow them to compete with us using that intellectual property.

Changes in tax laws, unfavorable resolution of tax examinations, or exposure to additional tax liabilities could have a material adverse effect on our results of operations, financial condition and liquidity.

We are subject to taxes in the U.S., Singapore and various foreign jurisdictions. Governments in the jurisdictions in which we operate implement changes to tax laws and regulations periodically. Any implementation of tax laws that fundamentally change the taxation of corporations in the U.S. or Singapore could materially impact our effective tax rate and could have a significant adverse impact on our financial results.

The U.S. Tax Cuts and Job Act ("the Tax Act") significantly changed the taxation of U.S. based multinational corporations. Our compliance with the Tax Act requires the use of estimates in our financial statements and exercise of significant judgment in accounting for its provisions. The implementation of the Tax Act requires interpretations and implementing regulations by the Internal Revenue Service ("IRS"), as well as state tax authorities. The legislation could be subject to potential amendments and technical corrections, any of which could materially lessen or increase certain adverse impacts of the legislation. As regulations and guidance evolve with respect to the Tax Act, and as we gather information and perform more analysis, our results may differ from previous estimates and may materially affect our financial position.

We are also subject to examinations of our tax returns by tax authorities in various jurisdictions around the world. We regularly assess the likelihood of adverse outcomes resulting from ongoing tax examinations to determine the adequacy of our provision for taxes. These assessments can require a high degree of judgment and estimation. Intercompany transactions associated with the sale of inventory, services, intellectual property and cost share arrangements are complex and affect our tax liabilities. The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in multiple jurisdictions. There can be no assurance that the outcomes from ongoing tax examinations will not have an adverse effect on our operating results and financial condition. A difference in the ultimate resolution of tax uncertainties from what is currently estimated could have an adverse effect on our financial results and condition.

If tax incentives change or cease to be in effect, our income taxes could increase significantly.

We benefit from tax incentives extended to our foreign subsidiaries to encourage investment or employment. Several jurisdictions have granted us tax incentives which require renewal at various times in the future. The incentives are conditioned on achieving various thresholds of investments and employment or specific types of income. Our taxes could increase if the incentives are not renewed upon expiration. If we cannot or do not wish to satisfy all or parts of the tax incentive conditions, we may lose the related tax incentive and could be required to refund tax incentives previously realized. As a result, our effective tax rate could be higher than it would have been had we maintained the benefits of the tax incentives.
24
Table of Contents            

We have outstanding debt and may incur other debt in the future, which could adversely affect our financial condition, liquidity and results of operations.

We are party to a $1 billion five-year unsecured credit facility that will expire on March 13, 2024. As of October 31, 2020, the company had no borrowings outstanding under the credit facility. On August 7, 2019, we entered into an amendment to the credit agreement, which provided for a $500 million short-term loan facility that was used in full to complete the acquisition of BioTek and was repaid in full as of October 31, 2020. On October 21, 2019, we entered into a second amendment to the credit agreement, which refreshed the amount available for additional incremental term loan facilities under the credit agreement to permit additional incremental facilities of up to $500 million. We had no borrowings under the additional incremental facilities as of October 31, 2020. On May 1, 2020, we entered into a new $1.0 billion commercial paper program, and as of October 31, 2020 we had $75 million of commercial paper outstanding. We also have outstanding an aggregate principal amount of $2.3 billion in senior unsecured notes. We may borrow additional amounts in the future and use the proceeds from any future borrowing for general corporate purposes, future acquisitions, expansion of our business or repurchases of our outstanding shares of common stock.

Our incurrence of this debt, and increases in our aggregate levels of debt, may adversely affect our operating results and financial condition by, among other things:

•increasing our vulnerability to downturns in our business, to competitive pressures and to adverse economic and industry conditions; 
•requiring the dedication of an increased portion of our expected cash flows from operations to service our indebtedness, thereby reducing the amount of expected cash flows available for other purposes, including capital expenditures, acquisitions, stock repurchases and dividends; and 
•limiting our flexibility in planning for or reacting to changes in our business and our industry.

Our credit facility imposes restrictions on us, including restrictions on our ability to create liens on our assets and engage in certain types of sale and leaseback transactions and the ability of our subsidiaries to incur indebtedness, and requires us to maintain compliance with specified financial ratios. Our ability to comply with these ratios may be affected by events beyond our control. In addition, the indentures governing our senior notes contain covenants that may adversely affect our ability to incur certain liens or engage in certain types of sale and leaseback transactions. If we breach any of the covenants and do not obtain a waiver from the lenders or noteholders, then, subject to applicable cure periods, our outstanding indebtedness could be declared immediately due and payable.

If we suffer a loss to our factories, facilities or distribution system due to catastrophe, our operations could be seriously harmed.

Our factories, facilities and distribution system are subject to catastrophic loss due to fire, flood, terrorism, public health crises, increasing severity or frequency of extreme weather events, or other natural or man-made disasters. For example, in the first quarter of fiscal year 2020, the outbreak of COVID-19 in China led to an extension of the Lunar New Year holiday, which impacted our business and results, reduced the number of selling days and otherwise impacted our supply chain. As described above, the COVID-19 pandemic continued to impact our business operations, supply chain and financial results and may have a material adverse effect on our business and results of operations. In addition, several of our facilities could be subject to a catastrophic loss caused by earthquake due to their locations. Our production facilities, headquarters and laboratories in California, and our production facilities in Japan, are all located in areas with above-average seismic activity. If any of our facilities were to experience a catastrophic loss, it could disrupt our operations, delay production, shipments and revenue and result in large expenses to repair or replace the facility. If such a disruption were to occur, we could breach agreements, our reputation could be harmed, and our business and operating results could be adversely affected. In addition, because we have consolidated our manufacturing facilities and we may not have redundant manufacturing capability readily available, we are more likely to experience an interruption to our operations in the event of a catastrophe in any one location. Although we carry insurance for property damage and business interruption, we do not carry insurance or financial reserves for interruptions or potential losses arising from earthquakes or terrorism. Also, our third-party insurance coverage will vary from time to time in both type and amount depending on availability, cost and our decisions with respect to risk retention. Economic conditions and uncertainties in global markets may adversely affect the cost and other terms upon which we are able to obtain third-party insurance. If our third-party insurance coverage is adversely affected or to the extent we have elected to self-insure, we may be at a greater risk that our financial condition will be harmed by a catastrophic loss.

25
Table of Contents            
If we experience a significant disruption in, or breach in security of, our information technology systems, or if we fail to implement new systems and software successfully, our business could be adversely affected.

We rely on several centralized information technology systems throughout our company to provide products and services, keep financial records, process orders, manage inventory, process shipments to customers and operate other critical functions. Our information technology systems may be susceptible to damage, disruptions or shutdowns due to power outages, hardware failures, computer viruses, attacks by computer hackers, telecommunication failures, user errors, catastrophes or other unforeseen events. Our information technology systems also may experience interruptions, delays or cessations of service or produce errors in connection with system integration, software upgrades or system migration work that takes place from time to time. If we were to experience a prolonged system disruption in the information technology systems that involve our interactions with customers or suppliers, it could result in the loss of sales and customers and significant incremental costs, which could adversely affect our business. In addition, security breaches of our information technology systems could result in the misappropriation or unauthorized disclosure of confidential information belonging to us or to our employees, partners, customers or suppliers, which could result in our suffering significant financial or reputational damage.

We cannot assure that we will continue to pay dividends on our common stock.

Since the first quarter of fiscal year 2012, we have paid a quarterly dividend on our common stock. The timing, declaration, amount and payment of any future dividends fall within the discretion of our Board of Directors and will depend on many factors, including our available cash, estimated cash needs, earnings, financial condition, operating results, capital requirements, as well as limitations in our contractual agreements, applicable law, regulatory constraints, industry practice and other business considerations that our Board of Directors considers relevant. A change in our dividend program could have an adverse effect on the market price of our common stock.

General Risks

Adverse conditions in the global banking industry and credit markets may adversely impact the value of our cash investments or impair our liquidity.

As of October 31, 2020, we had cash and cash equivalents of approximately $1,441 million invested or held in a mix of money market funds, time deposit accounts and bank demand deposit accounts. Disruptions in the financial markets may, in some cases, result in an inability to access assets such as money market funds that traditionally have been viewed as highly liquid. Any failure of our counterparty financial institutions or funds in which we have invested may adversely impact our cash and cash equivalent positions and, in turn, our operating results and financial condition.

Regulations related to “conflict minerals” may cause us to incur additional expenses and could limit the supply and increase the cost of certain metals used in manufacturing our products.

We are subject to the rules of the SEC which require disclosures by public companies of specified minerals, known as conflict minerals, that are necessary to the functionality or production of products manufactured or contracted to be manufactured. The rule, which requires an annual disclosure report to be filed with the SEC by May 31st of each year, requires companies to perform due diligence, disclose and report whether or not such minerals originate from the Democratic Republic of Congo or an adjoining country. Our ongoing implementation of these rules could affect sourcing at competitive prices and availability in sufficient quantities of certain minerals used in the manufacture of our products, including tin, tantalum, gold and tungsten. The number of suppliers who provide conflict-free minerals may be limited. In addition, there may be material costs associated with complying with the disclosure requirements, such as costs related to the due diligence process of determining the source of certain minerals used in our products, as well as costs of possible changes to products, processes, or sources of supply as a consequence of such verification activities. As our supply chain is complex and we use contract manufacturers for some of our products, we may not be able to sufficiently verify the origins of the relevant minerals used in our products through the due diligence procedures that we implement, which may harm our reputation. We may also encounter challenges to satisfy those customers who require that all of the components of our products be certified as conflict-free, which could place us at a competitive disadvantage if we are unable to do so.

Item 1B.    Unresolved Staff Comments

None.

26
Table of Contents            
Item 2. Properties
As of October 31, 2020, we owned or leased a total of approximately 6.6 million square feet of space worldwide. Of that, we owned approximately 4.6 million square feet and leased the remaining 2.0 million square feet. Our sales and support facilities occupied a total of approximately 0.8 million square feet. Our manufacturing plants, R&D facilities and warehouse and administrative facilities occupied approximately 5.8 million square feet. All of our businesses share sales offices throughout the world.

Information about each of our businesses appears below:

Life Sciences & Applied Markets Business. Our life sciences and applied markets business has manufacturing and R&D facilities in Australia, China, Germany, Italy, Malaysia, Singapore, United Kingdom and the United States.

Diagnostics and Genomics Business. Our diagnostics and genomics business has manufacturing and R&D facilities in Belgium, Denmark, Germany, Malaysia and the United States.

Agilent CrossLab Business. Our Agilent CrossLab business has manufacturing and R&D facilities in Australia, China, Germany, Japan, Netherlands, Singapore, United Kingdom and the United States.

Item 3. Legal Proceedings
We are involved in lawsuits, claims, investigations and proceedings, including, but not limited to, intellectual property, commercial, real estate, environmental and employment matters, which arise in the ordinary course of business. There are no matters pending that we currently believe are probable and reasonably possible of having a material impact to our business, consolidated financial condition, results of operations or cash flows.

Item 4. Mine Safety Disclosures
Not applicable.


27
Table of Contents            
PART II

Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our common stock is listed on the New York Stock Exchange with the ticker symbol “A”. As of December 2, 2020, there were 20,173 common stockholders of record.

The information required by this item with respect to equity compensation plans is included under the caption "Equity Compensation Plans" in our Proxy Statement for the Annual Meeting of Stockholders to be held March 17, 2021, to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, and is incorporated herein by reference.



STOCK PRICE PERFORMANCE GRAPH

The graph below shows the cumulative total stockholder return on our common stock with the cumulative total return of the S&P 500 Index and our peer group, consisting of all companies in the Health Care and Materials Indexes of the S&P 500, assuming an initial investment of $100 on October 31, 2015 and the reinvestment of all dividends.

Agilent’s stock price performance shown in the following graph is not indicative of future stock price performance. The data for this performance graph was compiled for us by Standard and Poor’s.

a-20201031_g1.jpg

        INDEXED RETURNS
Base            Years Ending
Period
Company Name / Index10/31/201510/31/201610/31/201710/31/201810/31/201910/31/2020
Agilent Technologies100116.63 183.87 176.70 208.42 283.31 
S&P 500100104.51 129.21 138.70 158.57 173.97 
Peer Group10099.21 123.71 134.82 147.29 163.88 

28
Table of Contents            
ISSUER PURCHASES OF EQUITY SECURITIES

The table below summarizes information about the company’s purchases, based on trade date, of its equity securities registered pursuant to Section 12 of the Exchange Act during the quarterly period ended October 31, 2020. The total number of shares of common stock purchased by the company during the fiscal year ended October 31, 2020 was 5,227,273 shares.
PeriodTotal Number of
Shares of Common
Stock Purchased(1)		Weighted Average
Price Paid per Share of
Common Stock(2)		Total
Number of
Shares of Common
Stock Purchased as
Part of Publicly
Announced Plans or
Programs(1)		Maximum
Approximate Dollar
Value of Shares of
Common Stock that
May Yet Be
Purchased Under the
Plans or Programs
(in millions)(1)
 
August 1, 2020 through
August 31, 2020
526,247 $98.38 526,247 $756 
September 1, 2020 through
September 30, 2020
1,041,643 $98.98 1,041,643 $653 
October 1, 2020 through
October 31, 2020
908,745 $104.62 908,745 $558 
Total2,476,635 $100.92 2,476,635  

(1)On November 19, 2018 we announced that our board of directors had approved a new share repurchase program (the "2019 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2019 repurchase program authorizes the purchase of up to $1.75 billion of our common stock at the company's discretion and has no fixed termination date. As of October 31, 2020, we had remaining authorization to repurchase up to $558 million of our common stock under this program. The 2019 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. As of October 31, 2020, all repurchased shares have been retired.

(2)The weighted average price paid per share of common stock does not include the cost of commissions.


29
Table of Contents            
Item 6.    Selected Financial Data
SELECTED FINANCIAL DATA
(Unaudited)

 Years Ended October 31,
 20202019201820172016
 (in millions, except per share data)
Consolidated Statement of Operations Data:
Net revenue (1)
$5,339 $5,163 $4,914 $4,472 $4,202 
Income before taxes$842 $919 $946 $803 $544 
Net income (2)
$719 $1,071 $316 $684 $462 
Net income per share - Basic$2.33 $3.41 $0.98 $2.12 $1.42 
Net income per share - Diluted$2.30 $3.37 $0.97 $2.10 $1.40 
Weighted average shares used in computing net income per share:
Basic309 314 321 322 326 
Diluted312 318 325 326 329 
Cash dividends declared per common share$0.720 $0.656 0.596 $0.528 $0.460 

(1) In 2019 we adopted ASC Topic 606, Revenue from Contracts with Customers, using the modified retrospective approach. Results for reporting periods for 2019 and after are presented under ASC 606, while prior period amounts were not adjusted and continue to be reported in accordance with ASC Topic 605, Revenue Recognition.
(2) Net income for the year ended October 31, 2019 was impacted by a tax benefit of $299 million related to the extension of tax incentives in Singapore. Net income for the year ended October 31, 2018 was impacted by a tax expense of $552 million related to the enactment of the U.S Tax Cuts and Jobs Act of 2017 (the "Tax Act").
 

 October 31,
 20202019201820172016
 (in millions)
Consolidated Balance Sheet Data (1):
Cash and cash equivalents$1,441 $1,382 $2,247 $2,678 $2,289 
Working capital$1,948 $1,109 $2,677 $2,906 $2,690 
Total assets$9,627 $9,452 $8,541 $8,426 $7,794 
Long-term debt$2,284 $1,791 $1,799 $1,801 $1,904 
Stockholders' equity$4,873 $4,748 $4,567 $4,831 $4,243 

(1) In 2020, we adopted ASC Topic 842, Leases, using the modified retrospective method. Results for reporting periods beginning November 1, 2019 are presented under ASC 842, while prior period amounts were not adjusted and are reported under ASC 840.

30
Table of Contents            

Item 7.    Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with the consolidated financial statements and notes thereto included elsewhere in this Annual Report on Form 10-K. This report contains forward-looking statements including, without limitation, statements regarding growth opportunities, including for revenue and our end markets, strength and drivers of the markets into which we sell, sales funnels, our strategic direction, new product and service introductions and the position of our current products and services, market demand for and adoption of our products, the ability of our products and solutions to address customer needs and meet industry requirements, our focus on differentiating our product solutions, improving our customers’ experience and growing our earnings, future financial results, our operating margin, mix, our investments, including in manufacturing infrastructure, research and development and expanding and improving our applications and solutions portfolios, expanding our position in developing countries and emerging markets, our focus on balanced capital allocation, our contributions to our pension and other defined benefit plans, impairment of goodwill and other intangible assets, the impact of foreign currency movements, our hedging programs and other actions to offset the effects of tariffs and foreign currency movements, our future effective tax rate, tax valuation allowance and unrecognized tax benefits, the impact of local government regulations on our ability to pay vendors or conduct operations, our ability to satisfy our liquidity requirements, including through cash generated from operations, the potential impact of adopting new accounting pronouncements, indemnification, source and supply of materials used in our products, our sales, our purchase commitments, our capital expenditures, the integration and effects of our acquisitions and other transactions, our stock repurchase program and dividends and the potential or anticipated direct or indirect impact of COVID-19 on our business that involve risks and uncertainties. Our actual results could differ materially from the results contemplated by these forward-looking statements due to various factors, including those discussed in Part I Item 1A and elsewhere in this Form 10-K.

Overview and Executive Summary

Agilent Technologies Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.

COVID-19 Pandemic

Both our domestic and international operations have been and continue to be affected by the ongoing global pandemic of a novel strain of coronavirus (“COVID-19”) and the resulting volatility and uncertainty it has caused in the U.S. and international markets. Many countries, including the United States, implemented measures such as quarantine, shelter-in-place, curfew, travel and activity restrictions and similar isolation measures, including government orders and other restrictions on the conduct of business operations at different times. Due to these measures, we experienced unpredictable reductions or increases in demand for certain of our products, disruptions or delays in shipments of certain materials or components of our products, and delays in installations and services due to the inability to access customer sites, primarily in the latter part of our second quarter.

As an essential business throughout the COVID-19 pandemic, we have remained open with our top priority being the health and safety of our employees, customers and community. At every stage of the pandemic, we have taken decisive and appropriate precautions, including a mandatory work from home policy for all employees with the exception of manufacturing, distribution, and certain laboratory environments, as well as restrictions on all non-essential travel and visitors into our facilities. At this time, our factories continue to operate around the world in accordance with the guidance issued by local, state and national government authorities. Our digital workplace strategy and strategic technology investments have enabled us to provide modern connectivity and collaboration tools to our employees to meet remote working needs as this situation has escalated. We have taken and continue to take proactive measures to ensure the health and safety of our global employee base. We designed a multi-phase return-to-office process for the safe return of our employees to our sites. We developed and implemented rigorous return-to-office protocols to promote a safe work environment in all locations for employees who have been working on-site throughout the pandemic and for employees who will be returning in the future, as well as, for the safety of all customer and vendor interactions.

At this time, the COVID-19 pandemic has not significantly impacted our manufacturing facilities or third parties to whom we outsource certain manufacturing processes, the distribution centers where our inventory is managed or the operations of our logistics and other service providers. We continue working with our customers and suppliers to understand the existing and potential future negative impacts to our delivery and supply chain and take actions in an effort to mitigate such impacts. The majority of the markets we serve, such as the pharmaceutical, biopharmaceutical, food, environmental and diagnostics and clinical markets, have continued to operate at various levels throughout the pandemic, and we continue working closely with
31
Table of Contents            
our customers to ensure their seamless operations. From a customer-facing perspective, we continue leveraging digital demand generation activities, including virtual demonstrations across all regions, remote instrument repairs, virtual sales seminars, online product training, and rapid one-on-one communications over emails, phone and video conferencing.

Despite the economic challenges due to the COVID-19 pandemic, we ended fiscal year 2020 with revenue growth of 3 percent year over year with revenue growth from most of our key end markets. In the latter part of the fiscal year, our Agilent CrossLab business began to see an increase in revenue for our on-demand services and installation services due to the re-opening of laboratories around the world, especially in Europe. While we began to see elective medical procedures resume in the fourth quarter, revenue from our diagnostics and genomics business continues to be negatively impacted by the COVID-19 pandemic. In our life sciences and applied markets business, we saw an increase in demand for some of our products for use in the COVID-19 testing, vaccine and therapeutic drug development. We also benefited from our cost savings actions which included reduction in travel and non-essential spending.

The COVID-19 pandemic continues to be dynamic, and near-term challenges across the economy remain. Although we anticipate there will be vaccines distributed widely in the near future, we expect continued volatility and unpredictability related to the impact of COVID-19 on our business results. We continue to actively monitor the pandemic and we will continue to take appropriate steps to mitigate the adverse impacts on our business posed by the on-going spread of COVID-19.

2030 Senior Notes

On June 4, 2020, we issued an aggregate principal amount of $500 million in senior notes ("2030 senior notes"). The 2030 senior notes were issued at 99.812% of their principal amount. The 2030 senior notes will mature on June 4, 2030, and bear interest at a fixed rate of 2.10% per annum. The interest is payable semi-annually on June 4th and December 4th of each year and payments commenced on December 4, 2020.

Acquisitions

In 2019, we acquired 100 percent of the stock of ACEA Biosciences Inc. ("ACEA"), a developer of cell analysis tools, for $250 million. In addition, we completed the acquisition of privately-owned Lionheart Technologies LLC ("BioTek"), a leader in the design, manufacture and distribution of innovative life science instrumentation for $1.17 billion. The financial results of these businesses have been included in our financial results from the date of the close.

Actual Results

Agilent's net revenue of $5,339 million in 2020 increased 3 percent when compared to 2019. Foreign currency movements for 2020 had an overall unfavorable impact on revenue of approximately 1 percentage point compared to 2019. In 2020, acquisitions from 2019 had an overall favorable impact of 3 percentage points when compared to 2019. Revenue in the life sciences and applied markets business increased 4 percent in 2020 when compared to 2019. In 2020 acquisitions from 2019 had an overall favorable impact of 7 percentage points when compared to 2019. Foreign currency movements had no overall impact on revenue in 2020 when compared to 2019. Revenue in the diagnostics and genomics business increased 2 percent in 2020 when compared to 2019. Foreign currency movements had an overall unfavorable impact on revenue of 1 percentage point in 2020 when compared to 2019. Revenue in the Agilent CrossLab business increased 3 percent in 2020 when compared to 2019. Foreign currency movements had an overall unfavorable impact on revenue of 1 percentage point in 2020 when compared to 2019.

Agilent's net revenue of $5,163 million increased 5 percent in 2019 when compared to 2018. Foreign currency movements for 2019 had an overall unfavorable impact on revenue of approximately 2 percentage points compared to 2018. In 2019, acquisitions from 2018 had an overall favorable impact of 2 percentage points when compared to 2018. Revenue in the life sciences and applied markets business increased 1 percent in 2019 when compared to 2018. Foreign currency movements had an overall unfavorable impact on revenue of 2 percentage points in 2019 when compared to 2018. Revenue in the diagnostics and genomics business increased 8 percent in 2019 when compared to 2018. Foreign currency movements had an overall unfavorable impact of 3 percentage points on revenue in 2019 when compared to 2018. Revenue in the Agilent CrossLab business increased 8 percent in 2019 when compared to 2018. Foreign currency movements had an overall unfavorable impact on revenue of 3 percentage points in 2019 when compared to 2018.

Net income was $719 million in 2020 compared to net income of $1,071 million and $316 million in 2019 and 2018, respectively. Net income in 2020 was impacted by revenue declines in certain of our businesses associated with the COVID-19 pandemic and increased costs and expenses which included an impairment charge of $98 million related to the closure of our
32
Table of Contents            
sequencer development program. Net income for the year ended October 31, 2019 was impacted by a discrete tax benefit of $299 million related to the extension of the company's tax incentives in Singapore. Net income for the year ended October 31, 2018 was impacted by a discrete tax charge of $552 million related to the enactment of the Tax Act that was passed on December 22, 2017. As of October 31, 2020 and 2019, we had cash and cash equivalents balances of $1,441 million and $1,382 million, respectively.

On May 28, 2015 we announced that our board of directors had approved a share repurchase program (the "2015 repurchase program"). The 2015 share repurchase program authorizes the purchase of up to $1.14 billion of our common stock at the company's discretion through and including November 1, 2018. The 2015 repurchase program did not require the company to acquire a specific number of shares and could have been suspended or discontinued at any time. During the year ended October 31, 2018, we repurchased and retired approximately 6.4 million shares for $422 million under this authorization. As of October 31, 2018, we had remaining authorization to repurchase up to $188 million of our common stock under this program which expired on November 1, 2018.

On November 19, 2018 we announced that our board of directors had approved a new share repurchase program (the "2019 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2019 share repurchase program authorizes the purchase of up to $1.75 billion of our common stock at the company's discretion and has no fixed termination date. The 2019 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. During the year ended October 31, 2019, we repurchased and retired 10.4 million shares for $723 million under this authorization. During the year ended October 31, 2020, we repurchased and retired approximately 5.2 million shares for $469 million under this authorization. As of October 31, 2020, we had remaining authorization to repurchase up to $558 million of our common stock under this program.

During the year ended October 31, 2020, cash dividends of 0.720 per share, or $222 million were declared and paid on the company's outstanding common stock. During the year ended October 31, 2019, cash dividends of 0.656 per share, or $206 million were declared and paid on the company's outstanding common stock. During the year ended October 31, 2018, cash dividends of 0.596 per share, or $191 million were declared and paid on the company's outstanding common stock.

On November 18, 2020 we declared a quarterly dividend of $0.194 per share of common stock, or approximately $59 million which will be paid on January 27, 2021 to shareholders of record as of the close of business on January 5, 2021. The timing and amounts of any future dividends are subject to determination and approval by our board of directors.

Looking forward, our top priority continues to be the health and safety of our employees, customers and community, as well as supporting our customers' operations. We also remain focused on improving our customers’ experience, differentiating product solutions and productivity especially during these extraordinary times. Our focus on meeting our customers’ needs supported several aspects of the COVID-19 research and testing along with therapeutic and vaccine development. While uncertainties remain as the spread of COVID-19 begins to rise, we are cautiously optimistic that in the short-term our financial results can continue to improve as the global economy continues its path towards recovery.

Critical Accounting Policies and Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made and if different estimates that reasonably could have been used or changes in the accounting estimate that are reasonably likely to occur could materially change the financial statements. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, inventory valuation, retirement and post-retirement plan assumptions, valuation of goodwill and purchased intangible assets and accounting for income taxes.

Revenue Recognition.  On November 1, 2018, we adopted Accounting Standard Codification Topic 606, Revenue from Contracts with Customers ("ASC 606").

We enter into contracts to sell products, services or combinations of products and services. Products may include hardware or software and services may include one-time service events or services performed over time.
33
Table of Contents            

We derive revenue primarily from the sale of analytical and diagnostics products and services. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606. Revenue is recognized when control of the promised products or services is transferred to our customers and the performance obligation is fulfilled in an amount that reflects the consideration that we expect to be entitled in exchange for those products or services, the transaction price. For equipment, consumables, and most software licenses, control transfers to the customer at a point in time. We use present right to payment, legal title, physical possession of the asset, and risks and rewards of ownership as indicators to determine the transfer of control to the customer. Where acceptance is not a formality, the customer must have documented their acceptance of the product or service. For products that include installation, if the installation meets the criteria to be considered a separate performance obligation, product revenue is recognized when control has passed to the customer, and recognition of installation revenue occurs once completed. Product revenue, including sales to resellers and distributors is reduced for provisions for warranties, returns, and other adjustments in the period the related sales are recorded.

Service revenue includes extended warranty, customer and software support including: Software as a Service, post contract support, consulting including companion diagnostics, and training and education. Instrument service contracts and software maintenance contracts are typically annual contracts, which are billed at the beginning of the contract or maintenance period. Revenue for these contracts is recognized on a straight-line basis to revenue over the service period, as a time-based measure of progress best reflects our performance in satisfying this obligation. There are no deferred costs associated with the service contract, as the cost of the service is recorded when the service is performed. Service calls not included in a support contract are recognized to revenue at the time a service is performed.

We have sales from standalone software. These arrangements typically include software licenses and maintenance contracts, both of which we have determined are distinct performance obligations. We determine the amount of the transaction price to allocate to the license and maintenance contract based on the relative standalone selling price of each performance obligation. Software license revenue is recognized at the point in time when control has been transferred to the customer. The revenue allocated to the software maintenance contract is recognized on a straight-line basis over the maintenance period, which is the contractual term of the contract, as a time-based measure of progress best reflects our performance in satisfying this obligation. Unspecified rights to software upgrades are typically sold as part of the maintenance contract on a when-and-if-available basis.

Our multiple-element arrangements are generally comprised of a combination of instruments, installation or other start-up services, and/or software, and/or support or services. Hardware and software elements are typically delivered at the same time and revenue is recognized when control passes to the customer. Service revenue is deferred and recognized over the contractual period or as services are rendered and accepted by the customer. Our arrangements generally do not include any provisions for cancellation, termination, or refunds that would significantly impact recognized revenue.

For contracts with multiple performance obligations, we allocate the consideration to which we expect to be entitled to each performance obligation based on relative standalone selling prices and recognize the related revenue when or as control of each individual performance obligation is transferred to customers. We estimate the standalone selling price by calculating the average historical selling price of our products and services per country for each performance obligation. Stand-alone selling prices are determined for each distinct good or service in the contract and then we allocate the transaction price in proportion to those standalone selling prices by performance obligations.

A portion of our revenue relates to lease arrangements. Standalone lease arrangements are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 842, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type capital lease using the current lease classification guidance. In a lease arrangement that is a multiple-element arrangement that contains equipment leases and the supply of consumables, the revenue associated with the instrument rental is treated under the lease accounting standard ASC 842, whereas the revenue associated with the consumables, the non-lease component, is recognized in accordance with the ASC 606 revenue standard.

Inventory Valuation.  We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based upon estimates about future demand and actual usage. Such estimates are difficult to make under most economic conditions. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with manufacturing to maximize recovery of excess inventory. If actual market conditions are less favorable than those projected by management, additional write-downs may be required. If actual market conditions are more favorable than anticipated, inventory previously written down may be sold to customers, resulting in lower cost of sales and higher income from operations than expected in that period.
34
Table of Contents            

Retirement and Post-Retirement Benefit Plan Assumptions.  Retirement and post-retirement benefit plan costs are a significant cost of doing business. They represent obligations that will ultimately be settled sometime in the future and therefore are subject to estimation. Pension accounting is intended to reflect the recognition of future benefit costs over the employees' average expected future service to Agilent based on the terms of the plans and investment and funding decisions. To estimate the impact of these future payments and our decisions concerning funding of these obligations, we are required to make assumptions using actuarial concepts within the framework of accounting principles generally accepted in the U.S. Two critical assumptions are the discount rate and the expected long-term return on plan assets. Other important assumptions include, expected future salary increases, expected future increases to benefit payments, expected retirement dates, employee turnover, retiree mortality rates, and portfolio composition. We evaluate these assumptions at least annually.

The discount rate is used to determine the present value of future benefit payments at the measurement date - October 31 for both U.S. and non-U.S. plans. For 2020 and 2019, the U.S. discount rates were based on the results of matching expected plan benefit payments with cash flows from a hypothetically constructed bond portfolio. In 2020, discount rates for the U.S. plans decreased compared to the previous year due to the decrease in the corporate bond rates. For 2020 and 2019, the discount rates for non-U.S. plans were generally based on published rates for high quality corporate bonds and in 2020, decreased marginally compared to the previous year. If we changed our discount rate by 1 percent, the impact would be less than $1 million in U.S. pension expense and $17 million on non-U.S. pension expense. Lower discount rates increase present values of the pension benefit obligation and subsequent year pension expense; higher discount rates decrease present values of the pension benefit obligation and subsequent year pension expense.

The company uses alternate methods of amortization as allowed by the authoritative guidance which amortizes the actuarial gains and losses on a consistent basis for the years presented. For U.S. Plans, gains and losses are amortized over the average future lifetime of participants using the corridor method. For most Non-U.S. Plans and U.S. Post-Retirement Benefit Plans, gains and losses are amortized using a separate layer for each year's gains and losses.

In the U.S., target asset allocations for our retirement and post-retirement benefit plans are approximately 80 percent to equities and approximately 20 percent to fixed income investments. Our Deferred Profit-Sharing Plan target asset allocation is approximately 60 percent to equities and approximately 40 percent to fixed income investments. Approximately 1 percent of the retirement and post-retirement plans consists of limited partnerships. Outside the U.S., our target asset allocation ranges from 24 percent to 60 percent to equities, from 38 percent to 65 percent to fixed income investments, and from zero to 25 percent to real estate, depending on the plan. All plans' assets are broadly diversified. Due to fluctuations in equity markets, our actual allocations of plan assets at October 31, 2020 and 2019 differ from the target allocation. Our policy is to bring the actual allocation in line with the target allocation.

Equity securities include exchange-traded common stock and preferred stock of companies from broadly diversified industries. Fixed income securities include a global portfolio of corporate bonds of companies from diversified industries, government securities, mortgage-backed securities, asset-backed securities, derivative instruments and other. Other investments include a group trust consisting primarily of private equity partnerships.

The expected long-term return on plan assets is estimated using current and expected asset allocations as well as historical and expected returns. Plan assets are valued at fair value. If we changed our estimated return on assets by 1 percent, the impact would be $4 million on U.S. pension expense and $9 million on non-U.S. pension expense. The net periodic pension and post-retirement benefit costs recorded were a $22 million expense in 2020, $10 million expense in 2019 and $3 million benefit in 2018. The year ended October 31, 2020 included a loss on settlement of $4 million. The year ended October 31, 2018 included a settlement gain of $5 million.

Goodwill and Purchased Intangible Assets. Under the authoritative guidance, we have the option to perform a qualitative assessment to determine whether further impairment testing is necessary. The accounting standard gives an entity the option to first assess qualitative factors to determine whether performing the two-step test is necessary. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not (i.e., greater than 50% chance) that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test will be required. Otherwise, no further testing will be required.

The guidance includes examples of events and circumstances that might indicate that a reporting unit's fair value is less than its carrying amount. These include macro-economic conditions such as deterioration in the entity's operating environment or industry or market considerations; entity-specific events such as increasing costs, declining financial performance, or loss of key personnel; or other events such as an expectation that a reporting unit will be sold or a sustained decrease in the stock price on either an absolute basis or relative to peers.

35
Table of Contents            
If it is determined, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, the provisions of authoritative guidance require that we perform a two-step impairment test on goodwill. In the first step, we compare the fair value of each reporting unit to its carrying value. The second step (if necessary) measures the amount of impairment by applying fair-value-based tests to the individual assets and liabilities within each reporting unit. As defined in the authoritative guidance, a reporting unit is an operating segment, or one level below an operating segment. We aggregate components of an operating segment that have similar economic characteristics into our reporting units.

In fiscal year 2020, we assessed goodwill impairment for our three reporting units which consisted of three segments: life sciences and applied markets, diagnostics and genomics and Agilent CrossLab. We performed a qualitative test for goodwill impairment of the three reporting units as of September 30, 2020. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair value of each reporting unit is greater than its respective carrying value. Each quarter we review the events and circumstances to determine if goodwill impairment is indicated. There was no impairment of goodwill during the years ended October 31, 2020, 2019 and 2018.

Purchased intangible assets consist primarily of acquired developed technologies, proprietary know-how, trademarks, and customer relationships and are amortized using the best estimate of the asset's useful life that reflect the pattern in which the economic benefits are consumed or used up or a straight-line method ranging from 6 months to 15 years. Our determination of the fair value of the intangible assets acquired involves the use of significant estimates and assumptions. Specifically, our determination of the fair value of the developed product technology and in-process research and development ("IPR&D") acquired involves significant estimates and assumptions related to revenue growth rates and discount rates. Our determination of the fair value of customer relationships acquired involves significant estimates and assumptions related to revenue growth rates, discount rates, and customer attrition rates. Our determination of the fair value of the tradename acquired involves the use of significant estimates and assumptions related to revenue growth rates, royalty rates and discount rates. The company believes that the fair value assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that marketplace participants would use. Actual results could differ materially from these estimates. IPR&D is initially capitalized at fair value as an intangible asset with an indefinite life and assessed for impairment thereafter. When the IPR&D project is complete, it is reclassified as an amortizable purchased intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, we will record a charge for the value of the related intangible asset to our consolidated statement of operations in the period it is abandoned.

We continually monitor events and changes in circumstances that could indicate carrying amounts of finite-lived intangible assets may not be recoverable. When such events or changes in circumstances occur, we assess the recoverability of finite-lived intangible assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the undiscounted future cash flows is less than the carrying amount of those assets, we recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets. During 2018, we recorded an impairment charge of $21 million related to purchased intangible assets within the diagnostics and genomics segment that were deemed unrecoverable.

Our indefinite-lived intangible assets are IPR&D intangible assets. The accounting guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the issued impairment testing guidance for goodwill and allows the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset to determine whether it is more-likely-than-not (i.e., greater than 50% chance) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value. We performed a qualitative test for impairment of indefinite-lived intangible assets as of September 30, 2020. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair value of these indefinite-lived intangible assets is greater than their respective carrying values. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible assets is indicated. During fiscal year 2020, we recorded an impairment of in-process research and development of $90 million related to the shutdown of our sequencer development program in our diagnostics and genomics segment. During the year ended October 31, 2019 and 2018 there were no impairments of indefinite-lived intangible assets.

Accounting for Income Taxes. We must make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of tax credits, benefits and deductions, and in the calculation of certain tax assets and liabilities which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes, as well as interest and penalties related to uncertain tax positions. Significant changes to these estimates may result in an increase or decrease to our tax provision in a subsequent period. On a quarterly basis, we provide for income taxes based upon an estimated annual effective tax rate. The effective tax rate is highly dependent
36
Table of Contents            
upon the geographic composition of worldwide earnings, tax regulations governing each region, availability of tax credits and the effectiveness of our tax planning strategies. We monitor the changes in many factors and adjust our effective income tax rate on a timely basis. If actual results differ from these estimates, this could have a material effect on our financial condition and results of operations.

Significant management judgment is also required in determining whether deferred tax assets will be realized in full or in part. When it is more-likely-than-not that all or some portion of deferred tax assets may not be realized, a valuation allowance must be established against such deferred tax assets. We consider all available positive and negative evidence on a jurisdiction-by-jurisdiction basis when assessing whether it is more likely than not that deferred tax assets are recoverable. We consider evidence such as our past operating results, the existence of losses in recent years and our forecast of future taxable income.

The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax law and regulations in a multitude of jurisdictions. Although the guidance on the accounting for uncertainty in income taxes prescribes the use of a recognition and measurement model, the determination of whether an uncertain tax position has met those thresholds will continue to require significant judgment by management. In accordance with the guidance on the accounting for uncertainty in income taxes, for all U.S. and other tax jurisdictions, we recognize potential liabilities for anticipated tax audit issues based on our estimate of whether, and the extent to which, additional taxes and interest will be due. The ultimate resolution of tax uncertainties may differ from what is currently estimated, which could result in a material impact on income tax expense. If our estimate of income tax liabilities proves to be less than the ultimate assessment, a further charge to expense would be required. If events occur and the payment of these amounts ultimately proves to be unnecessary, the reversal of the liabilities would result in tax benefits being recognized in the period when we determine the liabilities are no longer necessary. We include interest and penalties related to unrecognized tax benefits within the provision for income taxes on the consolidated statements of operations.

Adoption of New Pronouncements

See Note 2, "New Accounting Pronouncements," to the consolidated financial statements for a description of new accounting pronouncements.

Foreign Currency

Our revenues, costs and expenses, and monetary assets and liabilities are exposed to changes in foreign currency exchange rates as a result of our global operating and financing activities. Foreign currency movements for the year ended October 31, 2020 had an overall unfavorable impact on revenue of 1 percentage point when compared to the same period last year. The unfavorable effects of changes in foreign currency exchange rates have decreased revenue by approximately 2 percentage points for the year ended October 31, 2019. When movements in foreign currency exchange rates have a negative impact on revenue, they will also have a positive impact on our costs and expenses. We calculate the impact of movements in foreign currency exchange rates by applying the actual foreign currency exchange rates in effect during the last month of each quarter of the current year to both the applicable current and prior year periods. We hedge revenues, expenses and balance sheet exposures that are not denominated in the functional currencies of our subsidiaries on a short term and anticipated basis. We do experience some fluctuations within individual lines of the consolidated statement of operations and balance sheet because our hedging program is not designed to offset the currency movements in each category of revenues, expenses, monetary assets and liabilities. Our hedging program is designed to hedge currency movements on a relatively short-term basis (up to a rolling thirteen-month period). We may also hedge equity balances denominated in foreign currency on a long-term basis. To the extent that we are required to pay for all, or portions, of an acquisition price in foreign currencies, we may enter into foreign exchange contracts to reduce the risk that currency movements will impact the U.S. dollar cost of the transaction.

 



37
Table of Contents            
Results from Operations

Net Revenue

 Years Ended October 31,2020 over 2019
Change		2019 over 2018 Change
 202020192018
 (in millions)  
Net revenue:     
Products$3,993 $3,877 $3,746 3%3%
Services and other$1,346 $1,286 $1,168 5%10%
Total net revenue$5,339 $5,163 $4,914 3%5%
 
 Years Ended October 31,2020 over 2019
Change		2019 over 2018 Change
 202020192018
% of total net revenue:     
Products75 %75 %76 %—(1) ppt
Services and other25 %25 %24 %—1 ppt
Total100 %100 %100 %  

Agilent's net revenue of $5,339 million for the year ended October 31, 2020 increased 3 percent when compared to 2019. Foreign currency movements for 2020 had an unfavorable impact of approximately 1 percentage point when compared to 2019. Agilent's net revenue of $5,163 million increased 5 percent in 2019 when compared to 2018. Foreign currency movements for 2019 had an unfavorable impact of approximately 2 percentage points when compared to 2018.

Product revenue includes revenue generated from the sales of our analytical instrumentation, software and consumables. Revenue from products increased 3 percent for the year ended October 31, 2020, when compared to 2019. Revenue in 2020 was impacted by the global COVID-19 pandemic within most of our product lines as customers curtailed equipment spending at various times when countries around the world were in the lockdown phase of the COVID-19 pandemic. Growth was due to our cell analysis business, automation products and our nucleic acid solutions business. The increase in the cell analysis business is primarily due to the contributions from our acquisitions and the increased demand for our products for use in COVID-19 testing and vaccine research.

Revenue from products increased 3 percent for the year ended October 31, 2019, when compared to 2018. The growth in product revenue was impacted by increased sales within our cell analysis business, mainly due to contributions from our recent acquisitions. In addition, product revenue growth was impacted by strong sales in our consumables and nucleic acid solutions businesses partially offset by revenue weakness in our liquid chromatography, gas chromatography, liquid chromatography mass spectrometry and spectroscopy products.

Services and other revenue increased 5 percent in 2020 as compared to 2019. Services and other revenue increased 10 percent in 2019 as compared to 2018. Services and other revenue consist of revenue generated from our three business segments: Agilent CrossLab, diagnostics and genomics and our life science and applied markets businesses. Some of the prominent services in the Agilent CrossLab business include repair and maintenance on multi-vendor instruments, compliance services and installation services. Services in the diagnostics and genomics business include consulting services related to the companion diagnostics and nucleic acid businesses. Services in the life science and applied markets business include repair and maintenance and installation services.

For the year ended October 31, 2020, the service revenue from the Agilent CrossLab business increased 4 percent when compared to the same period last year, with a 1 percentage point unfavorable currency impact. This growth for the year ended October 31, 2020 is reflective of the resilience of the contracted service business throughout the year, as well as the recovery of the on-demand and installation service businesses in the latter half of 2020, as customer sites gradually reopened following their COVID-19 related closures earlier in the year. Those site re-openings were fastest in China.

Services and other revenue in the Agilent CrossLab business increased 9 percent in 2019 as compared to 2018, with a 3 percentage point unfavorable currency impact. Nearly all major service offerings from the Agilent CrossLab business contributed to the revenue growth across all geographic regions.
38
Table of Contents            

For the year ended October 31, 2020, the service revenue from the diagnostics and genomics business remained flat when compared to the same period last year. Services in the diagnostics and genomics business in 2019 increased due to growth in service revenue throughout all our businesses when compared to 2018.

For the year ended October 31, 2020, the service revenue from the life sciences and applied markets business increased 28 percent when compared to the same period last year. The increase in life sciences and applied markets service revenue is due to the additional service revenue within the cell analysis business due to the Lionheart Technologies LLC ("BioTek") acquisition. Services and other revenue in the life sciences and applied markets business increased in 2019 as compared to 2018 due to the impact of acquisitions made in 2019.

Net Revenue By Segment

 Years Ended October 31,2020 over 2019
Change		2019 over 2018 Change
 202020192018
 (in millions)  
Net revenue by segment:     
Life sciences and applied markets$2,392 $2,302 $2,270 4%1%
Diagnostics and genomics$1,047 $1,021 $943 2%8%
Agilent CrossLab$1,900 $1,840 $1,701 3%8%
Total net revenue$5,339 $5,163 $4,914 3%5%

Revenue in the life sciences and applied markets business increased 4 percent in 2020 when compared to 2019. Foreign currency movements had no overall impact on revenue in 2020 when compared to 2019. Acquisitions had an overall favorable impact on revenue growth of 7 percentage points and primarily impacted the overall growth in the pharmaceutical and academia and government markets. Revenue growth within the life sciences and applied markets was driven by strong growth in the academia and government, the pharmaceutical and the diagnostics and clinical markets with moderate growth from the food market partially offset by declines in revenue within the environmental and forensics and chemical and energy markets. Revenue in the life sciences and applied markets business increased 1 percent in 2019 when compared to 2018. Foreign currency movements had an overall unfavorable impact of 2 percentage points in 2019 when compared to 2018. Acquisitions had an overall favorable impact on revenue growth of 4 percentage points and primarily impacted the pharmaceutical and academia and government markets when compared to 2018. For the year ended October 31, 2019, revenue growth was favorable within academia and government, moderate within the pharmaceutical and the environmental and forensics markets which was mostly offset by declines in revenue from the food market and to a lesser extent from the chemical and energy market when compared to 2018.

Revenue in the diagnostics and genomics business increased 2 percent in 2020 when compared to 2019. Foreign currency movements had an overall unfavorable impact on revenue of 1 percentage point in 2020 when compared to 2019. Revenue growth within the diagnostics and genomics business was driven by strong growth in our nucleic acid solutions and biomolecular analysis businesses partially offset by declines in our genomics business. Revenue in the diagnostics and genomics business increased 8 percent in 2019 when compared to 2018. Foreign currency movements had an overall unfavorable impact on revenue of 3 percentage points in 2019 when compared to 2018. Revenue growth within the diagnostics and clinical market and the pharmaceutical market continued to be strong led by performance from our nucleic acid solutions and biomolecular analysis businesses.

Revenue in the Agilent CrossLab business increased 3 percent in 2020 when compared to 2019. Foreign currency movements had an overall unfavorable impact on revenue of 1 percentage point in 2020 when compared to 2019. Revenue growth within Agilent CrossLab business was strong within the pharmaceutical and food markets which was partially offset by declines in the academia and government and clinical and diagnostics markets. Revenue generated by Agilent CrossLab increased 8 percent in 2019 when compared to 2018. Foreign currency movements had an overall unfavorable impact of 3 percentage points in 2019 when compared to 2018. Our performance in the Agilent CrossLab business saw continued growth in all key end markets with strong growth in the pharmaceutical, academia and government and food markets compared to 2018.

39
Table of Contents            
Costs and Expenses

 Years Ended October 31,2020 over 2019
Change		2019 over 2018 Change
 202020192018
(in millions, except margin data)
Gross margin on products55.0 %56.7 %57.4 %(2) ppts(1) ppt
Gross margin on services and other47.5 %47.3 %45.3 %— 2 ppts
Total gross margin53.1 %54.3 %54.5 %(1) ppt—
Research and development$495 $404 $387 22%5%
Selling, general and administrative$1,496 $1,460 $1,389 2%5%
Operating margin15.8 %18.2 %18.4 %(2) ppts—

Total gross margin for the year ended October 31, 2020 decreased 1 percentage point when compared to 2019. Gross margin declined due to the impacts of pricing pressure, higher intangible amortization expense, higher wages, net unfavorable currency impact and higher fixed costs related to the new manufacturing facility in Frederick, Colorado, partially offset by lower period and travel costs. Total gross margin for the year ended October 31, 2019 was flat when compared to 2018. Total gross margin reflects the impact of efficiency gains, lower inventory charges and favorable currency impact on costs offset by higher wages and variable pay, product mix, higher expenses related to tariffs and higher amortization expense of intangible assets.

Gross inventory charges were $28 million in 2020, $19 million in 2019 and $26 million in 2018. Sales of previously written down inventory were $7 million in 2020, $6 million in 2019 and $8 million in 2018.

 Research and development expenses increased 22 percent for the year ended October 31, 2020 when compared to 2019. Research and development expenses increased primarily due to intangible and other asset impairments of $97 million related to the shutdown of our sequencer development program. The increase is also due to higher wages and additional expenses related to our acquisition of BioTek partially offset by lower discretionary expenditures including lower travel costs and favorable currency impact. Research and development expenses increased 5 percent for the year ended October 31, 2019 when compared to 2018. Research and development expenses increased due to increased program spending on new products related to all of our businesses in addition to higher wages and variable pay and additional expenses related to acquired businesses partially offset by favorable currency movements when compared to spending in 2018.

Selling, general and administrative expenses increased 2 percent in 2020 when compared to 2019. The increase in selling, general and administrative expenses was due to higher wages, higher intangible amortization expense and higher transformational initiative expenses, which was partially offset by lower discretionary expenditures including lower travel costs and favorable currency impact. Selling, general and administrative expenses increased 5 percent in 2019 compared to 2018. Selling, general and administrative expenses increased due to increased wages and variable pay, higher commissions, higher legal expenses, higher acquisition and integration costs and higher transformation initiatives expenses partially offset by operational efficiencies and savings and favorable currency impact.

Total operating margin decreased 2 percentage points for the year ended October 31, 2020, when compared to 2019. Operating margin declined due to intangible and other asset impairments, higher wages, higher intangible amortization expense and higher transformational initiative expenses partially offset by lower discretionary expenditures including lower travel costs and favorable currency impact. Total operating margin was flat for the year ended October 31, 2019, when compared to 2018. Total operating margin was impacted by higher wages and variable pay, higher acquisition and integration costs, higher expenses related to tariffs and higher transformation initiatives expenses offset by operational efficiencies and savings and favorable currency impact.

Interest income for the year ended October 31, 2020, 2019 and 2018 was $8 million, $36 million and $38 million, respectively. The decrease in interest income in 2020 was primarily due to lower interest rates for our cash and cash equivalents.

Interest expense for the years ended October 31, 2020, 2019 and 2018 was $78 million, $74 million and $75 million, respectively, and relates to the interest charged on our senior notes, credit facilities, commercial paper and the amortization of the deferred loss recorded upon termination of the forward starting interest rate swap contracts partially offset by the amortization of deferred gains recorded upon termination of interest rate swap contracts.
40
Table of Contents            

At October 31, 2020, our headcount was approximately 16,400 compared to 16,300 in 2019.

Other income (expense), net

For the year ended October 31, 2020, other income (expense), net includes income of $12 million related to the provision of site service costs to, and lease income from, Keysight Technologies, Inc. ("Keysight"). The costs associated with these services are reported within income from operations. Other income (expense), net also includes net gains on the fair value of equity investments of approximately $27 million and income of $22 million related to the settlement of our legal claim against Twist Bioscience Corporation.

For the year ended October 31, 2019, other income (expense), net includes income of $12 million related to the provision of site service costs to, and lease income from, Keysight Technologies, Inc. ("Keysight") and $9 million loss on the extinguishment of debt.

For the year ended October 31, 2018, other income (expense), net includes the net gain of $20 million related to the step-up of our initial investment in Lasergen, $15 million of income related to a special one-time settlement with a third-party, a $5 million pension settlement gain related to the substitutional portion of the defined benefit pension plans established under the Japanese Welfare Pension Insurance Law and income of $12 million related to the provision of site service costs to, and lease income from, Keysight.


Income Taxes

 Years Ended October 31,
 202020192018
 (in millions)
Provision (benefit) for income taxes$123 $(152)$630 

For 2020, the company's income tax expense was $123 million with an effective tax rate of 14.6 percent. For the year ended October 31, 2020, our effective tax rate and the resulting provision for income taxes were impacted by foreign income taxed at lower rates.

For 2019, the company's income tax benefit was $152 million with an effective tax rate of (16.5) percent. For the year ended October 31, 2019, our effective tax rate and the resulting provision for income taxes were significantly impacted by the discrete benefit of $299 million related to the extension of the company’s tax incentive in Singapore.

For 2018, the company's income tax expense was $630 million with an effective tax rate of 66.6 percent. For the year ended October 31, 2018, our effective tax rate and the resulting provision for income taxes were significantly impacted by the discrete charge of $552 million related to the enactment of the U.S. Tax Cuts and Jobs Act (the “Tax Act”) consisting of (1) an expense of $499 million of U.S. transition tax and correlative items on deemed repatriated earnings of non-U.S. subsidiaries and (2) an expense of $53 million associated with the impact on deferred taxes resulting from the decreased U.S. corporate tax rate.

The company has negotiated tax holidays in several different jurisdictions, most significantly in Singapore. The tax holidays provide lower rates of taxation on certain classes of income and require various thresholds of investments and employment or specific types of income in those jurisdictions. In December 2018, the tax holiday in Singapore was renegotiated and extended through 2027. As a result of the incentives, the impact of the tax holidays decreased income taxes by $71 million, $368 million, and $87 million in 2020, 2019, and 2018, respectively. The benefit of the tax holidays on net income per share (diluted) was approximately $0.23, $1.16, and $0.27 in 2020, 2019 and 2018, respectively. Of the $1.16 benefit of the tax incentives on net income per share (diluted) in 2019, $0.94 of the benefit relates to one-time items from the extension of the company’s tax incentive in Singapore.

With these jurisdictions and the U.S., it is reasonably possible that there could be significant changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitation or a tax audit settlement which will be partially offset by an anticipated tax liability related to unremitted foreign earnings, where applicable. Given the number of years and numerous matters that remain subject to examination in various tax jurisdictions, management is unable to estimate the range of possible changes to the balance of our unrecognized tax benefits.

41
Table of Contents            
The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax law and regulations in a multitude of jurisdictions. Although the guidance on the accounting for uncertainty in income taxes prescribes the use of a recognition and measurement model, the determination of whether an uncertain tax position has met those thresholds will continue to require significant judgment by management. In accordance with the guidance on the accounting for uncertainty in income taxes, for all U.S. and other tax jurisdictions, we recognize potential liabilities for anticipated tax audit issues based on our estimate of whether, and the extent to which, additional taxes and interest will be due. The ultimate resolution of tax uncertainties may differ from what is currently estimated, which could result in a material impact on income tax expense. If our estimate of income tax liabilities proves to be less than the ultimate assessment, a further charge to expense would be required. If events occur and the payment of these amounts ultimately proves to be unnecessary, the reversal of the liabilities would result in tax benefits being recognized in the period when we determine the liabilities are no longer necessary.

Segment Overview

Through October 31, 2020, we have three business segments comprised of the life sciences and applied markets business, diagnostics and genomics business and the Agilent CrossLab business.


Life Sciences and Applied Markets

Our life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. Key product categories include: liquid chromatography ("LC") systems and components; liquid chromatography mass spectrometry ("LCMS") systems; gas chromatography ("GC") systems and components; gas chromatography mass spectrometry ("GCMS") systems; inductively coupled plasma mass spectrometry ("ICP-MS") instruments; atomic absorption ("AA") instruments; microwave plasma-atomic emission spectrometry (“MP-AES”) instruments; inductively coupled plasma optical emission spectrometry ("ICP-OES") instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software for sample tracking; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps and measurement technologies.

Net Revenue

 Years Ended October 31,2020 over 2019
Change		2019 over 2018 Change
 202020192018
 (in millions)  
Net revenue$2,392 $2,302 $2,270 4%1%

Life science and applied markets business revenue in 2020 increased 4 percent compared to 2019. Foreign currency movements for 2020 had no impact on revenue growth when compared to the same period last year. Acquisitions had an overall favorable impact on revenue growth of 7 percentage points when compared to the same period last year. Geographically, revenue increased 13 percent in the Americas with a 1 percentage point unfavorable currency impact, decreased 2 percent in Europe with no currency impact and increased 1 percent in Asia Pacific with no currency impact. In 2020, revenue increases in our automation, liquid chromatography mass spectrometry and cell analysis products from our acquisitions, primarily in the Americas, were partially offset by declines in other parts of the portfolio when compared to the same period last year.

End market revenue performance in 2020 was mixed with academia and government and diagnostics and clinical markets delivering strong growth and the pharmaceutical and food markets delivering moderate growth which was partially offset by chemical and energy and forensics and environmental markets. In 2020, despite the unfavorable impact from COVID-19, revenue growth in the academia and government and pharmaceutical and diagnostics and clinical markets was primarily driven by strong performance of our cell analysis products from the Lionheart Technologies LLC ("BioTek") acquisition. The growth in the diagnostics and clinical business was also due to the strength in liquid phase mass spectrometry and cell analysis products.

Life science and applied markets business revenue in 2019 increased 1 percent compared to 2018. Foreign currency movements for 2019 had an overall unfavorable currency impact of 2 percentage points on revenue growth when compared to 2018. Acquisitions had an overall favorable impact on revenue growth of 3 percentage points when compared to 2018.
42
Table of Contents            
Geographically, revenue increased 12 percent in the Americas with a 1 percentage point unfavorable currency impact, decreased 4 percent in Europe with a 3 percentage point unfavorable currency impact and decreased 2 percent in Asia Pacific with a 1 percentage point unfavorable currency impact. From a product standpoint, revenue was driven by strength in sales in our gas chromatography mass spectrometry and cell analysis primarily due to contributions from our acquisitions and informatics businesses which was offset by weakness in our liquid chromatography, gas chromatography, liquid chromatography mass spectrometry and spectroscopy products when compared to 2018.

End market performance in 2019 was mixed with the pharmaceutical, academia and government, diagnostics and clinical and forensics markets delivering strong revenue growth, environmental delivering moderate growth while chemical and energy markets decreased modestly, and food delivered weak results compared to 2018.

Looking forward, despite short term uncertainties and the adverse effects of the COVID-19 pandemic, we are optimistic about our long-term growth opportunities in the life sciences and applied markets as our broad portfolio of products and solutions are well suited to address customer needs. We anticipate growth from our new product introductions and acquisitions in the last couple of years as we continue to invest in expanding and improving our applications and solutions portfolio. While we anticipate volatility in our markets, we expect continued growth across most end markets in the long term.

Gross Margin and Operating Margin

The following table shows the life sciences and applied markets business' margins, expenses and income from operations for 2020 versus 2019, and 2019 versus 2018.
 Years Ended October 31,2020 over 2019
Change		2019 over 2018 Change
 202020192018
(in millions, except margin data)
Total gross margin59.2 %61.0 %61.3 %(2) ppts—
Research and development$219 $216 $220 1%(1)%
Selling, general and administrative$650 $646 $630 1%3%
Operating margin22.9 %23.5 %23.9 %(1) ppt—
Income from operations$548 $542 $543 1%—

Gross margin decreased 2 percentage points in 2020 compared to 2019. Gross margin declined due to the increased impact of pricing pressures and a net unfavorable impact from currency movements partially offset by favorable product mix and material cost savings. Gross margin was flat in 2019 compared to 2018. Gross margin was impacted by unfavorable mix and higher expenses related to tariffs which was offset by favorable currency impact.

Research and development expenses increased 1 percent in 2020 when compared to 2019. Research and development expenses increased due to higher wages and additional expenses related to the BioTek acquisition partially offset by lower discretionary spending and favorable impact from foreign currency movements. Research and development expenses decreased 1 percent in 2019 when compared to 2018. Research and development decreased due to lower discretionary spending and a favorable currency offset by additional expenses related to acquisitions as well as higher wages and variable pay.

Selling, general and administrative expenses increased 1 percent in 2020 compared to 2019. Selling, general and administrative expenses increased due to higher wages and additional expenses related to the BioTek acquisition partially offset by favorable impact from foreign currency movements and lower travel costs. Selling, general and administrative expenses increased 3 percent in 2019 compared to 2018. Selling, general and administrative expenses were impacted by higher wages and variable pay and additional expenses related to our recent acquisitions partially offset by operational savings and a favorable currency impact.

Operating margin decreased 1 percentage point in 2020 compared to 2019. Operating margin declined due to additional expenses related to our recent acquisitions and unfavorable gross margin due to pricing pressures partially offset by operational savings and favorable currency impact. Operating margin was relatively flat in 2019 compared to 2018. Operating margin reflects relatively flat revenue growth partially offset by an increase in selling, general and administrative expenses.
43
Table of Contents            

Income from Operations        

Income from operations in 2020 increased by $6 million or increased by 1 percent when compared to 2019 on a revenue increase of $90 million. The increase in income from operations was mainly due to the impact of the BioTek acquisition. Income from operations in 2019 decreased by $1 million or was relatively flat when compared to 2018 on a revenue increase of $32 million. The decrease was due to the impact of acquisitions.

Diagnostics and Genomics

Our diagnostics and genomics business includes the genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership and biomolecular analysis businesses.

Our diagnostics and genomics business is comprised of six areas of activity providing active pharmaceutical ingredients ("APIs") for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our genomics business includes arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as next generation sequencing ("NGS") target enrichment and genetic data management and interpretation support software. This business also includes solutions that enable clinical labs to identify DNA variants associated with genetic disease and help direct cancer therapy. Second, our nucleic acid solutions business provides equipment and expertise focused on production of synthesized oligonucleotides under pharmaceutical good manufacturing practices ("GMP") conditions for use as API in an emerging class of drugs that utilize nucleic acid molecules for disease therapy. Third, our pathology solutions business is focused on product offerings for cancer diagnostics and anatomic pathology workflows. The broad portfolio of offerings includes immunohistochemistry ("IHC"), in situ hybridization ("ISH"), hematoxylin and eosin ("H&E") staining and special staining. Fourth, we also collaborate with a number of major pharmaceutical companies to develop new potential pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. Fifth, the reagent partnership business is a provider of reagents used for turbidimetry and flow cytometry. Finally, our biomolecular analysis business provides complete workflow solutions, including instruments, consumables and software, for quality control analysis of nucleic acid samples.  Samples are analyzed using quantitative and qualitative techniques to ensure accuracy in further genomics analysis techniques utilized in clinical and life science research applications.

Net Revenue

 Years Ended October 31,2020 over 2019
Change		2019 over 2018 Change
 202020192018
 (in millions)  
Net revenue$1,047 $1,021 $943 2%8%

Diagnostics and genomics business revenue in 2020 increased 2 percent compared to 2019. Foreign currency movements for 2020 had an overall unfavorable impact on revenue growth of 1 percentage point when compared to the same period last year. Geographically, revenue increased 2 percent in the Americas with no currency impact, increased 1 percent in Europe with no currency impact and increased 7 percent in Asia Pacific with no currency impact. The increase in the Americas was driven by strong performance in the nucleic acid solutions and reagent partnership businesses. Revenue growth in the Americas was partly offset by a decline in the pathology and genomics business driven by the COVID-19 related reduction in routine and cancer testing, as well as the closure of academic and research laboratories. In Europe, strong revenue from our biomolecular analysis business was partially offset by the COVID-19 related declines from our genomics business. In Asia Pacific, revenue growth was driven by the pathology and biomolecular analysis businesses.

In 2020 revenue performance in the diagnostics and genomics business was led by strong revenue growth in the nucleic acid solutions and biomolecular analyses businesses. This was partly offset by a COVID-19 related reduction in routine and cancer testing, as well as the closure of most academic and research laboratories. The diagnostics and clinical research end markets remain strong long-term and growing driven by an aging population and lifestyle developments such as poor diet and physical inactivity.

Diagnostics and genomics business revenue in 2019 increased 8 percent compared to 2018. Foreign currency movements for 2019 had an overall unfavorable impact on revenue growth of 3 percentage points when compared to 2018. Geographically,
44
Table of Contents            
revenue increased 17 percent in the Americas with a 1 percentage point unfavorable currency impact, was flat in Europe with a 4 percentage point unfavorable currency impact and increased 2 percent in Asia Pacific with a 2 percentage point unfavorable currency impact. The growth in Americas was driven by strong growth in our nucleic acid solutions, companion diagnostics and biomolecular analysis business. In Europe we saw strong growth in the biomolecular analysis business offset by softness in the genomics business. In Asia Pacific the growth was driven by our biomolecular analysis business and negatively impacted by softness in the genomics business.

The revenue growth in 2019 was led by strong revenue performance in our nucleic acid solutions, companion diagnostics and biomolecular analysis business. The diagnostics and clinical research market remains strong and growing driven by an aging population and unhealthy lifestyle developments such as poor diet and physical inactivity.

Looking forward, although we see short-term impacts to routine and cancer testing due to COVID-19 which will affect our revenue growth, we are optimistic about our long-term growth opportunities in our end markets and continue to invest in expanding and improving our applications and solutions portfolio. We remain positive about our growth in our end markets as our product portfolio around OMNIS, PD-L1 assays and SureFISH continue to gain strength with our customers in clinical oncology applications, and our next generation sequencing target enrichment solutions continue to be adopted. Market demand in the nucleic acid solutions business related to therapeutic oligo programs continues, and with our newly opened and planned extension of our nucleic acid solutions production facility in Frederick, Colorado, we are well positioned to serve more of the market demand. We will continue to invest in research and development and seek to expand our position in developing countries and emerging markets.

Gross Margin and Operating Margin

The following table shows the diagnostics and genomics business' margins, expenses and income from operations for 2020 versus 2019, and 2019 versus 2018.

 Years Ended October 31,2020 over 2019
Change		2019 over 2018 Change
 202020192018
(in millions, except margin data)
Total gross margin51.9 %54.7 %56.3 %(3) ppts(2) ppts
Research and development$114 $125 $109 (9)%15%
Selling, general and administrative$238 $248 $249 (4)%—
Operating margin18.3 %18.2 %18.4 %——
Income from operations$192 $185 $173 3%7%

Gross margin decreased 3 percentage points in 2020 when compared to 2019. Gross margin was impacted by unfavorable product mix and higher fixed costs related to the new manufacturing facility in Frederick, Colorado, partially offset by lower period and travel costs. Gross margin decreased 2 percentage points in 2019 when compared to 2018. The decrease in gross margin was driven by an unfavorable product mix and a higher fixed cost structure due to the addition of a second nucleic acid manufacturing facility that offset gains from higher sales volumes.

Research and development expenses decreased 9 percent in 2020 when compared to 2019. Research and development expenses decreased due to the shutdown of our sequencer development program and a reduction in discretionary expenditures including travel costs. Research and development expenses increased 15 percent in 2019 when compared to 2018. The increase was due to additional expenses related to prior year's acquisitions, higher wages and variable pay and increased spending around the development of clinical applications and solutions.

Selling, general and administrative expenses decreased 4 percent in 2020 when compared to 2019. Selling, general and administrative expenses decreased due to a reduction in discretionary expenditures including travel costs partially offset by an increase in wages. Selling, general and administrative expenses were flat in 2019 when compared to 2018. Selling, general and administrative expenses were impacted by efficiency gains offsetting higher wages and variable pay.

Operating margin was relatively flat in 2020 when compared to 2019. Operating margin was aided by savings in operating expenses which were offset by gross margin decline. Operating margin was relatively flat in 2019 when compared to 2018. Operating margin was impacted by higher sales volume, offsetting the gross margin deterioration and the increase in research and development spending.

45
Table of Contents            
Income from Operations

Income from operations in 2020 increased by $7 million or 3 percent when compared to 2019 on a revenue increase of $26 million. The increase was driven by gains from higher volume and lower operating expenses more than offsetting the gross margin percentage decline. Income from operations in 2019 increased by $12 million or 7 percent when compared to 2018 on a revenue increase of $78 million. The increase was due to higher volume partially offset by the gross margin percentage decline and higher research and development expenses.

Agilent CrossLab

The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio, which is designed to improve customer outcomes. Most of the portfolio is vendor neutral, meaning Agilent can serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries and supplies to services and software helping to connect the entire lab. Key product categories in consumables include GC and LC columns, sample preparation products, custom chemistries, and a large selection of laboratory instrument supplies. Services include startup, operational, training and compliance support, software as a service, as well as asset management and consultative services that help increase customer productivity. Custom service and consumable bundles are tailored to meet the specific application needs of various industries and to keep instruments fully operational and compliant with the respective industry requirements.

Net Revenue
 Years Ended October 31,2020 over 2019
Change		2019 over 2018 Change
 202020192018
 (in millions)  
Total net revenue$1,900 $1,840 $1,701 3%8%

Agilent CrossLab business revenue in 2020 increased 3 percent when compared to 2019. Foreign currency movements for 2020 had an overall unfavorable impact of 1 percentage point when compared to 2019. Geographically, revenue was flat in the Americas with a 1 percentage point unfavorable currency impact, increased 2 percent in Europe with a 1 percentage point favorable currency impact and increased 7 percent in Asia Pacific with a 1 percentage point unfavorable currency impact. As a consequence of the COVID-19 related impact on global commerce in 2020, consumable sales growth has been low single digits in comparison to 2019 in most countries excluding China. In addition, the COVID-19 related customer site closures have brought a temporary lull in our delivery of on-demand services and installation services, which has been recovering in the latter half of the year as customer labs reopen. Consumable sales in China and the contracted service business across most regions have seen solid gains throughout 2020. Among our major end markets, the pharmaceutical market and the food market generated the strongest revenue growth when compared to 2019.

Agilent CrossLab business revenue in 2019 increased 8 percent when compared to 2018. Foreign currency movements for 2019 had an overall unfavorable impact of 3 percentage points when compared to 2018. Acquisitions in 2018 added 1 percentage point to the revenue growth reported for 2019. Revenue growth in 2019 was driven broadly by our entire services and consumables portfolio. Geographically, revenue increased 9 percent in the Americas with a 1 percentage point unfavorable currency impact, increased 5 percent in Europe with a 5 percentage point unfavorable currency impact and increased 10 percent in Asia Pacific with a 3 percentage point unfavorable currency impact. Agilent CrossLab business saw strong revenue growth in all key end markets, except in the diagnostics and clinical market, when compared to 2018.

Looking forward, the Agilent CrossLab portfolio of products and services capabilities is well positioned to continue to succeed in our key end markets. With less predictable access to customer sites during the global COVID-19 pandemic, the business is taking advantage of digital and remote capabilities to offer services and consumables to customers. Despite the current COVID-19 environment, we remain confident about the long-term growth opportunities as customer feedback remains very positive on the value Agilent CrossLab brings to customer labs. Geographically, the business is well diversified across all regions to take advantage of local market opportunities as they reopen to commerce.


46

Gross Margin and Operating Margin

The following table shows the Agilent CrossLab business' margins, expenses and income from operations for 2020 versus 2019 and 2019 versus 2018.

 Years Ended October 31,2020 over 2019
Change		2019 over 2018 Change
 202020192018
(in millions, except margin data)
Total gross margin52.2 %51.8 %50.4 %—1 ppt
Research and development$58 $58 $56 —3%
Selling, general and administrative$417 $421 $413 (1)%2%
Operating margin27.2 %25.8 %22.8 %1 ppt3 ppts
Income from operations$516 $475 $388 9%23%

Gross margin for products and services was relatively flat in 2020 when compared to 2019. Gross margin benefited from lower service delivery costs which include travel, parts and labor as well as improved productivity in manufacturing in the consumables business. Those operational gains were offset by a net unfavorable impact from currency movements. Gross margin for products and services increased 1 percentage point in 2019 when compared to 2018. Gross margin was impacted by higher sales volume, combined with efficiency gains in the service delivery operation and in the logistics and manufacturing processes for the consumables business. Some of those gains were offset by higher wages and higher variable costs and increased headcount.

Research and development expenses were relatively flat in 2020 when compared to 2019. The higher wages and variable pay in research and development expenses were offset by lower travel costs and the reduction of other discretionary expenditures. Research and development expenses increased 3 percent in 2019 when compared to 2018. Research and development increased due to higher wages and higher variable pay and additional research and development expenditures from acquisitions made in 2018.

Selling, general and administrative expenses decreased 1 percent in 2020 when compared to 2019. Selling, general and administrative expenses decreased due to favorable currency movements, reduced travel and training by the sales organization, lower sales commissions, and a reduction in discretionary expenditures which were partially offset by higher wages. Selling, general and administrative expenses increased 2 percent in 2019 when compared to 2018. Selling, general and administrative expenses were higher due to additional operating expenses from our acquisitions made in 2018, in addition to higher wages and higher variable pay. Those increases were partially offset by a favorable impact from foreign currency movements.

Operating margin increased 1 percentage point in 2020 when compared to 2019. The increase was primarily due to the growth in revenue while lowering service delivery and selling costs and the reduction of discretionary expenditures, partially offset by higher wages. Operating margin increased 3 percentage points in 2019 when compared to 2018. The increase in operating margin was driven by the higher sales volume, combined with efficiency gains across the service delivery operations, order fulfillment processes and other operations.

Income from Operations

Income from operations in 2020 increased by $41 million or 9 percent when compared to 2019 on a revenue increase of $60 million. The increase was primarily due to the growth in revenue while lowering service delivery and selling costs and the reduction of discretionary expenditures, partially offset by higher wages. Income from operations in 2019 increased by $87 million or 23 percent when compared to 2018 on a revenue increase of $139 million. The increase was driven by the higher sales volume, combined with efficiency gains across the service delivery operations, order fulfillment processes and other operations.

47

Financial Condition

Liquidity and Capital Resources

We believe our cash and cash equivalents, cash generated from operations, and ability to access capital markets and credit lines will satisfy, for at least the next twelve months, our liquidity requirements, both globally and domestically, including the following: working capital needs, capital expenditures, business acquisitions, stock repurchases, cash dividends, contractual obligations, commitments, principal and interest payments on debt, and other liquidity requirements associated with our operations. Our sources and uses of cash were not materially impacted by COVID-19 to date. We have not identified any material liquidity concerns as a result of the COVID-19 pandemic. We will continue to monitor and assess the impact COVID-19 may have on our business and financial results.

Economic stimulus legislation was passed in many countries in response to COVID-19. In March in the U.S., the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was enacted to provide for tax relief and government loans, subsidies and other relief for entities in affected industries. As of October 31, 2020, the CARES Act and other government benefits outside the U.S. did not have a material impact on our consolidated financial statements and related disclosures.

Our financial position as of October 31, 2020 consisted of cash and cash equivalents of $1,441 million as compared to $1,382 million as of October 31, 2019.

As of October 31, 2020, approximately $1,395 million of our cash and cash equivalents is held outside of the U.S. by our foreign subsidiaries and can be repatriated to the U.S. as local working capital and other regulatory conditions permit. We utilize a variety of funding strategies to ensure that our worldwide cash is available in the locations in which it is needed.

We may, from time to time, retire certain outstanding debt of ours through open market cash purchases, privately-negotiated transactions or otherwise. Such transactions, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors.

Net Cash Provided by Operating Activities

Net cash provided by operating activities was $921 million in 2020 as compared to $1,021 million provided in 2019 and $1,087 million provided in 2018. We paid approximately $79 million under our variable and incentive pay programs in 2020, as compared to a total of $118 million in 2019 and $103 million in 2018. The decrease in the amount for variable and incentive pay programs paid in 2020 is primarily due to changes made for certain incentive pay programs which are now paid annually versus semi-annually as was done in 2019 and 2018. Net cash paid for income taxes was approximately $361 million in 2020 which included a one-time payment of $231 million related to the transfer of intellectual property compared to incomes taxes paid of $159 million in 2019 and $102 million in 2018. For the years ended October 31, 2020 and 2019, the net change in tax related assets and liabilities due to the Tax Act was zero compared to $552 million in the same period of 2018. In 2018, $552 million in tax-related assets and liabilities related to the enactment of the U.S. Tax Act, which primarily consisted of an estimated provision of $499 million of U.S. transition tax on deemed repatriated earnings of non-U.S. subsidiaries as well as an estimated $53 million associated with the impact on deferred taxes resulting from the decreased U.S. corporate income tax rate. Deferred tax inflows were $29 million in 2020 compared to cash outflows of $255 million 2019, which included $266 million related to the extension of the company's tax incentive in Singapore, and cash outflows of $16 million in 2018. In 2020, there was a net unrealized gain on fair value of equity investments of $28 million. In 2020, there was an impairment charge of $99 million mainly related to the shutdown of our sequencer development program compared to impairment charges of zero in 2019, and $21 million in 2018. For the years ended October 31, 2020, 2019 and 2018, other assets and liabilities used cash of $181 million, $43 million and $4 million, respectively. The cash outflow in the year ended October 31, 2020 was largely the result of increased income tax payments, interest payments on senior notes and changes in deferred revenue. Cash outflow for the year ended October 31, 2019 and 2018 in other assets and liabilities is primarily due to tax payments and interest on senior notes.

In 2020, the change in accounts receivable used cash of $107 million, $106 million in 2019, and $65 million in 2018. Days' sales outstanding as of October 31, were 63 days in 2020, 61 days in 2019 and 54 days in 2018. The change in accounts payable provided cash of $2 million in 2020, $29 million in 2019 and $40 million in 2018. Cash used in inventory was $68 million in 2020, $36 million in 2019 and $83 million in 2018. Inventory days on-hand decreased to 93 days in 2020 compared to 97 days in 2019 and decreased compared to 98 days in 2018. In the year ended October 31, 2020, we increased our inventory levels to meet our customer needs in response to the COVID-19 pandemic.

48

We made no contributions to our U.S defined benefit plans in 2020, 2019 and 2018. We contributed $31 million in 2020 and $21 million each year in 2019 and 2018 to our non-U.S. defined benefit plans, respectively. We did not contribute to our U.S. post-retirement benefit plans in 2020, 2019 and 2018. Our non-U.S. defined benefit plans are generally funded ratably throughout the year. The increase in 2020 mainly related to $12 million additional contribution in the Netherlands. Our annual contributions are highly dependent on the relative performance of our assets versus our projected liabilities, among other factors. We do not expect to contribute to our U.S. plans and U.S. post-retirement benefit plans during 2021. We expect to contribute $22 million to our non-U.S. defined benefit plans during 2021.
        
Net Cash Used in Investing Activities

Net cash used in investing activities in 2020 was $147 million and in 2019 was $1,590 million as compared to net cash used of $705 million in 2018.

Investments in property, plant and equipment were $119 million in 2020, $155 million in 2019 and $177 million in 2018. In 2020 we made no acquisitions of businesses. In 2019 we invested $1,408 million in acquisitions of businesses and intangible assets, net of cash acquired, for the acquisition of two businesses compared to the acquisition of seven businesses for $516 million in 2018. In 2020 cash used to purchase fair value investments was $20 million compared to $23 million outlay in 2019 and $11 million in 2018.

Net Cash Used in Financing Activities

Net cash used in financing activities in 2020 was $717 million compared to $299 million in 2019 and $797 million in 2018.

Treasury Stock Repurchases

On May 28, 2015 we announced that our board of directors had approved a share repurchase program (the "2015 repurchase program"). The 2015 share repurchase program authorizes the purchase of up to $1.14 billion of our common stock at the company's discretion through and including November 1, 2018. The 2015 repurchase program did not require the company to acquire a specific number of shares and could have been suspended or discontinued at any time. During the year ended October 31, 2018, we repurchased and retired approximately 6.4 million shares for $422 million under this authorization. As of October 31, 2018, we had remaining authorization to repurchase up to $188 million of our common stock under this program which expired on November 1, 2018.

On November 19, 2018 we announced that our board of directors had approved a new share repurchase program (the "2019 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2019 repurchase program authorizes the purchase of up to $1.75 billion of our common stock at the company's discretion and has no fixed termination date. The 2019 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. During the year ended October 31, 2019, we repurchased and retired 10.4 million shares for $723 million under this authorization. During the year ended October 31, 2020, we repurchased and retired approximately 5.2 million shares for $469 million under this authorization. As of October 31, 2020, we had remaining authorization to repurchase up to $558 million of our common stock under this program.

Dividends

For the years ended October 31, 2020, 2019 and 2018 cash dividends of $222 million, $206 million and $191 million were paid on the company's outstanding common stock, respectively. On November 18, 2020 we declared a quarterly dividend of $0.194 per share of common stock, or approximately $59 million which will be paid on January 27, 2021 to shareholders of record as of the close of business on January 5, 2021. The timing and amounts of any future dividends are subject to determination and approval by our board of directors.

49

Credit Facilities

On March 13, 2019, we entered into a credit agreement with a group of financial institutions which provides for a $1 billion five-year unsecured credit facility that will expire on March 13, 2024. For the year ended October 31, 2020, we borrowed $798 million and repaid $913 million under the credit facility. As of October 31, 2020, the company had no borrowings outstanding under the credit facility. On August 7, 2019, we entered into an amendment to the credit agreement, which provides for a $500 million short-term loan facility that was used in full to complete the BioTek acquisition and which was repaid in full as of October 31, 2020. On October 21, 2019, we entered into a second amendment to the credit agreement, which refreshed the amount available for additional incremental term loan facilities under the credit agreement to permit additional incremental facilities of up to $500 million. We had no borrowings under the additional incremental facilities as of October 31, 2020. On April 17, 2020, we entered into a third amendment to the credit agreement which provides the company with the option to request the consent of the applicable class of lenders to extend the maturity date of revolving borrowings and swingline loans for an additional period of one year and of the 2019 incremental term loans for an additional period of up to 364 days. We were in compliance with the covenants for the credit facility during the year ended October 31, 2020.

Commercial Paper

In May 2020, we established a U.S. commercial paper program, under which the company may issue and sell unsecured, short-term promissory notes in the aggregate principal amount not to exceed $1.0 billion with up to 397-day maturities. At any point in time, the company intends to maintain available commitments under its revolving credit facility in an amount at least equal to the amount of the commercial paper notes outstanding. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The proceeds from issuances under the program may be used for general corporate purposes. As of October 31, 2020, borrowings outstanding under our U.S. commercial paper program had a weighted average annual interest rate of 0.17 percent and a weighted average remaining maturity of approximately five days. We had borrowings of $75 million outstanding under the U.S. commercial paper program as of October 31, 2020.

Long-term Debt

2022 Senior Notes

On September 13, 2012, the company issued an aggregate principal amount of $400 million in senior notes ("2022 senior notes"). The 2022 senior notes were issued at 99.80% of their principal amount. The notes will mature on October 1, 2022, and bear interest at a fixed rate of 3.20% per annum. The interest is payable semi-annually on April 1st and October 1st of each year and payments commenced on April 1, 2013.

In July 2012, Agilent executed treasury lock agreements for $400 million in connection with future interest payments to be made on our 2022 senior notes issued on September 13, 2012. The treasury lock contracts were terminated on September 10, 2012 and we recognized a deferred gain in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2022 senior notes. The remaining gain to be amortized related to the treasury lock agreements at October 31, 2020 was less than $1 million.

2023 Senior Notes

On June 21, 2013, the company issued aggregate principal amount of $600 million in senior notes ("2023 senior notes"). The 2023 senior notes were issued at 99.544% of their principal amount. The notes will mature on July 15, 2023 and bear interest at a fixed rate of 3.875% per annum. The interest is payable semi-annually on January 15th and July 15th of each year and payments commenced January 15, 2014.

2026 Senior Notes

On September 22, 2016, the company issued aggregate principal amount of $300 million in senior notes ("2026 senior notes"). The 2026 senior notes were issued at 99.624% of their principal amount. The notes will mature on September 22, 2026 and bear interest at a fixed rate of 3.05% per annum. The interest is payable semi-annually on March 22nd and September 22nd of each year and payments commenced March 22, 2017.

In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. The swap arrangements were terminated on September 15, 2016 with a payment of $10 million, and we recognized this as a deferred loss in accumulated other comprehensive income (loss) which is being amortized to interest expense over the
50

life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at October 31, 2020 was $6 million.

2029 Senior Notes

On September 16, 2019, the company issued an aggregate principal amount of $500 million in senior notes ("2029 senior notes"). The 2029 senior notes were issued at 99.316% of their principal amount. The notes will mature on September 15, 2029, and bear interest at a fixed rate of 2.75% per annum. The interest is payable semi-annually on March 15th and September 15th of each year and payments commenced on March 15, 2020.

In August 2019, Agilent executed treasury lock agreements for $250 million in connection with future interest payments to be made on our 2029 senior notes issued on September 16, 2019. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 6, 2019 and we recognized a deferred loss of $6 million in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2029 senior notes. The remaining loss to be amortized related to the treasury lock agreements at October 31, 2020 was $5 million.

2030 Senior Notes

On June 4, 2020, we issued an aggregate principal amount of $500 million in senior notes ("2030 senior notes"). The 2030 senior notes were issued at 99.812% of their principal amount. The 2030 senior notes will mature on June 4, 2030, and bear interest at a fixed rate of 2.10% per annum. The interest is payable semi-annually on June 4th and December 4th of each year and payments commenced on December 4, 2020.


Off Balance Sheet Arrangements and Other

Our liquidity is affected by many factors, some of which are based on normal ongoing operations of our business and some of which arise from fluctuations related to global economics and markets. Our cash balances are generated and held in many locations throughout the world. Local government regulations may restrict our ability to move cash balances to meet cash needs under certain circumstances. We do not currently expect such regulations and restrictions to impact our ability to pay vendors and conduct operations throughout our global organization.

Contractual Commitments

Our cash flows from operations are dependent on a number of factors, including fluctuations in our operating results, accounts receivable collections, inventory management, and the timing of tax and other payments. As a result, the impact of contractual obligations on our liquidity and capital resources in future periods should be analyzed in conjunction with such factors.

The following table summarizes our total contractual obligations at October 31, 2020 for Agilent operations and excludes amounts recorded in our consolidated balance sheet (in millions):

Less than one
year		One to three yearsThree to five yearsMore than five years
Commitments to contract manufacturers and suppliers$541 $15 $1 $— 
Other purchase commitments85 — — — 
Retirement plans22 — — — 
Transitional pension contributions to our U.S. 401(k) plan6 3 — — 
Total$654 $18 $1 $— 

Commitments to Contract Manufacturers and Suppliers.  We purchase components from a variety of suppliers and use several contract manufacturers to provide manufacturing services for our products. During the normal course of business, we issue purchase orders with estimates of our requirements several months ahead of the delivery dates. The above amounts represent the commitments under the open purchase orders with our suppliers that have not yet been received. However, our agreements with these suppliers usually provide us the option to cancel, reschedule, and adjust our requirements based on our business needs prior to firm orders being placed. We expect to fulfill most of our purchase commitments for inventory within one year.

51

Other Purchase Commitments. We have categorized "other purchase commitments" related to contracts with professional services suppliers. Typically, we can cancel contracts with professional services suppliers without penalties. For those contracts that are not cancelable without penalties, there are termination fees and costs or commitments for continued spending that we are obligated to pay to a supplier under each contact's termination period before such contract can be cancelled. Our contractual obligations with these suppliers under "other purchase commitments" were approximately $85 million within the next year. Approximately $23 million of the contracts relate to penalties that will reduce over the next 13 years.

Retirement Plans.  Commitments under the retirement plans relate to expected contributions to be made to our U.S. and non-U.S. defined benefit plans and to our post-retirement medical plans for the next year only. Contributions after next year are impractical to estimate. Effective May 1, 2016 until April 30, 2022, we will provide an additional transitional company contribution for certain eligible employees equal to 3 percent, 4 percent or 5 percent of an employee's annual eligible compensation due to the U.S. Retirement Plan benefits being frozen.

We had no material off-balance sheet arrangements as of October 31, 2020 or October 31, 2019.

On Balance Sheet Arrangements

The following table summarizes our total contractual obligations on our October 31, 2020 balance sheet (in millions):

Less than one
year		One to three yearsThree to five yearsMore than five years
Senior notes$— $1,000 $— $1,300 
Commercial paper75 — — — 
Interest expense69 126 67 117 
Transition tax— 7 68 49 
Operating leases54 69 25 49 
Total$198 $1,202 $160 $1,515 


Other long-term liabilities as of October 31, 2020 and October 31, 2019 include $323 million and $328 million, respectively, related to long-term income tax liabilities. Of these amounts, $199 million related to uncertain tax positions as of both October 31, 2020 and October 31, 2019, respectively. We are unable to accurately predict when these amounts will be realized or released. However, it is reasonably possible that there could be significant changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitations or a tax audit settlement. The remaining $124 million in other long-term liabilities relates to the one-time transition tax payable.

Item 7A.    Quantitative and Qualitative Disclosures About Market Risk

We are exposed to foreign currency exchange rate risks inherent in our sales commitments, anticipated sales, and assets and liabilities denominated in currencies other than the functional currency of our subsidiaries. We hedge future cash flows denominated in currencies other than the functional currency using sales forecasts up to twelve months in advance. Our exposure to exchange rate risks is mainly managed on an enterprise-wide basis. This strategy utilizes derivative financial instruments, including option and forward contracts, to hedge certain foreign currency exposures with the intent of offsetting gains and losses that occur on the underlying exposures with gains and losses on the derivative contracts hedging them. We may also hedge equity balances denominated in foreign currency on a long-term basis. We do not currently and do not intend to utilize derivative financial instruments for speculative trading purposes. To the extent that we are required to pay for all, or portions, of an acquisition price in foreign currencies, we may enter into foreign exchange contracts to reduce the risk that currency movements will impact the cost of the transaction.

Our operations generate non-functional currency cash flows such as revenues, third party vendor payments and inter-company payments. In anticipation of these foreign currency cash flows and in view of volatility of the currency market, we enter into such foreign exchange contracts as are described above to manage our currency risk. Approximately 52 percent of our revenue in 2020, 51 percent of our revenue in 2019 and 53 percent of our revenue in 2018 were generated in U.S. dollars. The overall unfavorable effect of changes in foreign currency exchange rates, principally as a result of the strength of the U.S. dollar, has decreased revenue by approximately 1 percentage point in the year ended October 31, 2020. We calculate the impact of movements in foreign currency exchange rates by applying the actual foreign currency exchange rates in effect during the last month of each quarter of the current year to both the applicable current and prior year periods.

52

We performed a sensitivity analysis assuming a hypothetical 10 percent adverse movement in foreign exchange rates to the hedging contracts and the underlying exposures described above. As of October 31, 2020 and 2019, the analysis indicated that these hypothetical market movements would not have a material effect on our consolidated financial position, results of operations, statement of comprehensive income or cash flows.

We are also exposed to interest rate risk due to the mismatch between the interest expense we pay on our loans at fixed rates and the variable rates of interest we receive from cash, cash equivalents and other short-term investments. We have issued long-term debt in U.S. dollars or foreign currencies at fixed interest rates based on the market conditions at the time of financing. We believe that the fair value of our fixed rate debt changes when the underlying market rates of interest change, and we may use interest rate swaps to modify such market risk.

We performed a sensitivity analysis assuming a hypothetical 10 percent adverse movement in interest rates relating to the underlying fair value of our fixed rate debt. As of October 31, 2020 and 2019, the sensitivity analyses indicated that a hypothetical 10 percent adverse movement in interest rates would result in an immaterial impact to the fair value of our fixed interest rate debt.

53

Item 8.    Financial Statements and Supplementary Data


54


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


To the Board of Directors and Stockholders of Agilent Technologies, Inc.

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of Agilent Technologies, Inc. and its subsidiaries (the “Company”) as of October 31, 2020 and 2019, and the related consolidated statements of operations, comprehensive income, equity and cash flows for each of the three years in the period ended October 31, 2020, including the related notes and schedule of valuation and qualifying accounts for each of the three years in the period ended October 31, 2020 appearing under Item 15(a)(2) (collectively referred to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of October 31, 2020, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of October 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended October 31, 2020 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of October 31, 2020, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.

Change in Accounting Principle

As discussed in Note 2 to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2020 and the manner in which it accounts for revenue from contracts with customers in 2019.

Basis for Opinions

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit
55

preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Critical Audit Matters

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Uncertain Tax Positions

As described in Note 6 to the consolidated financial statements, the Company has recorded liabilities for uncertain tax positions of $240 million as of October 31, 2020. As disclosed by management, the estimate of the Company’s tax liabilities relating to uncertain tax positions requires management to assess uncertainties and to make judgments about the application of complex tax law and regulations in a multitude of jurisdictions. The Company is subject to taxes in the U.S., Singapore and various other foreign jurisdictions and is subject to examinations of its tax returns by tax authorities in various jurisdictions around the world. The Company has a number of years and matters which remain subject to examination by tax authorities in various jurisdictions that could result in significant changes to unrecognized tax benefits due to either the expiration of a statute of limitation or a tax audit settlement which will be partially offset by an anticipated tax liability related to unremitted foreign earnings, where applicable.

The principal considerations for our determination that performing procedures relating to uncertain tax positions is a critical audit matter are there was significant judgment by management when determining uncertain tax positions, including a high degree of estimation uncertainty relative to the numerous and complex tax laws, tax audits, and potential for significant adjustments as a result of such audits. This in turn led to a high degree of auditor judgment, effort, and subjectivity in performing procedures to evaluate the timely identification and accurate measurement of uncertain tax positions. Also, the evaluation of audit evidence available to support the tax liabilities for uncertain tax positions is complex and required significant auditor judgment as the nature of the evidence is often highly subjective, and the audit effort involved the use of professionals with specialized skill and knowledge.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the identification and recognition of the liability for uncertain tax positions, and controls addressing completeness of the uncertain tax positions, as well as controls over measurement of the liability. These procedures also included, among others, testing the completeness, accuracy, and relevance of information used in the calculation of the liability for uncertain tax positions, including intercompany agreements, international, federal, and state filing positions, and the related final tax returns, testing the calculation of the liability for uncertain tax positions by jurisdiction, including management’s assessment of the technical merits of tax positions and estimates of the amount of tax benefit expected to be sustained, testing the completeness of management’s assessment of both the identification of uncertain tax positions and possible outcomes of each uncertain tax position, and evaluating the status and results of income tax audits with the relevant tax authorities. Professionals with specialized skill and knowledge were used to assist in the evaluation of the Company's uncertain tax positions related to the application of relevant tax laws.

/s/ PricewaterhouseCoopers LLP
San Jose, California
December 17, 2020
We have served as the Company’s auditor since 1999.


56


AGILENT TECHNOLOGIES, INC.
CONSOLIDATED STATEMENT OF OPERATIONS
 Years Ended October 31,
 202020192018
 (in millions, except per
share data)
Net revenue:   
Products$3,993 $3,877 $3,746 
Services and other1,346 1,286 1,168 
Total net revenue5,339 5,163 4,914 
Costs and expenses:   
Cost of products1,796 1,680 1,595 
Cost of services and other706 678 639 
Total costs2,502 2,358 2,234 
Research and development495 404 387 
Selling, general and administrative1,496 1,460 1,389 
Total costs and expenses4,493 4,222 4,010 
Income from operations846 941 904 
Interest income8 36 38 
Interest expense(78)(74)(75)
Other income (expense), net66 16 79 
Income before taxes842 919 946 
Provision (benefit) for income taxes123 (152)630 
Net income$719 $1,071 $316 
Net income per share:   
Basic$2.33 $3.41 $0.98 
Diluted$2.30 $3.37 $0.97 
Weighted average shares used in computing net income per share:   
Basic309 314 321 
Diluted312 318 325 
   
The accompanying notes are an integral part of these consolidated financial statements.
57

AGILENT TECHNOLOGIES, INC.
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(in millions)


Years Ended October 31,
 202020192018
Net income$719 $1,071 $316 
Other comprehensive income (loss):
Gain (loss) on derivative instruments, net of tax expense (benefit) of $(3), $(2) and $1
(9)(4)6 
Amounts reclassified into earnings related to derivative instruments, net of tax expense (benefit) of $0, $(2) and $1
2 (6)3 
Foreign currency translation, net of tax expense (benefit) of $1, $(10) and $7
10 10 (58)
Net defined benefit pension cost and post retirement plan costs:
Change in actuarial net loss, net of tax expense (benefit) of $0, $(25) and $(3)
(5)(93)(7)
Change in net prior service benefit, net of tax benefit of $(1), $(2) and $(2)
(6)(6)(6)
Other comprehensive loss(8)(99)(62)
Total comprehensive income$711 $972 $254 

The accompanying notes are an integral part of these consolidated financial statements.

58

AGILENT TECHNOLOGIES, INC.
CONSOLIDATED BALANCE SHEET
 October 31,
 20202019
 (in millions, except
par value and
share data)
ASSETS  
Current assets:  
Cash and cash equivalents$1,441 $1,382 
Accounts receivable, net1,038 930 
Inventory720 679 
Other current assets216 198 
Total current assets3,415 3,189 
Property, plant and equipment, net845 850 
Goodwill3,602 3,593 
Other intangible assets, net831 1,107 
Long-term investments158 102 
Other assets776 611 
Total assets$9,627 $9,452 
LIABILITIES AND EQUITY  
Current liabilities:  
Accounts payable$354 $354 
Employee compensation and benefits367 334 
Deferred revenue386 336 
Short-term debt75 616 
Other accrued liabilities285 440 
Total current liabilities1,467 2,080 
Long-term debt2,284 1,791 
Retirement and post-retirement benefits389 360 
Other long-term liabilities614 473 
Total liabilities4,754 4,704 
Commitments and contingencies (Note 17)
Total equity:  
Stockholders' equity:  
Preferred stock;$0.01 par value; 125 million shares authorized; none issued and outstanding
— — 
Common stock; $0.01 par value; 2 billion shares authorized; 306 million shares at October 31, 2020 and 309 million shares at October 31, 2019 issued and outstanding
3 3 
Additional paid-in-capital5,311 5,277 
Retained earnings (accumulated deficit)81 (18)
Accumulated other comprehensive loss(522)(514)
Total stockholders' equity4,873 4,748 
Total liabilities and stockholders' equity$9,627 $9,452 
   The accompanying notes are an integral part of these consolidated financial statements.
59

AGILENT TECHNOLOGIES, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
 Years Ended October 31,
 202020192018
 (in millions)
Cash flows from operating activities:   
Net income$719 $1,071 $316 
Adjustments to reconcile net income to net cash provided by operating activities:   
Depreciation and amortization308 238 210 
Share-based compensation83 72 70 
Deferred taxes29 (255)(16)
Excess and obsolete inventory related charges28 19 26 
Gain on step acquisition— — (20)
Asset impairment charges99 — 21 
Unrealized gain on equity securities, net(28)(1)— 
Loss on extinguishment of debt— 9 — 
Other8 7 9 
Changes in assets and liabilities:
Accounts receivable, net(107)(106)(65)
Inventory(68)(36)(83)
Accounts payable2 29 40 
Employee compensation and benefits29 23 31 
Changes in assets and liabilities due to Tax Act— — 552 
Treasury lock agreement payment— (6)— 
Other assets and liabilities(181)(43)(4)
Net cash provided by operating activities921 1,021 1,087 
Cash flows from investing activities:   
Investments in property, plant and equipment(119)(155)(177)
Proceeds from the sale of property, plant and equipment1 — 1 
Payment to acquire fair value investment(20)(23)(11)
Payment in exchange for convertible note(9)(3)(2)
Payment to acquire intangible assets— (1)— 
Acquisitions of businesses and intangible assets, net of cash acquired— (1,408)(516)
Net cash used in investing activities(147)(1,590)(705)
Cash flows from financing activities:   
Issuance of common stock under employee stock plans60 54 56 
Payment of taxes related to net share settlement of equity awards(37)(16)(30)
Treasury stock repurchases(469)(723)(422)
Payment of dividends(222)(206)(191)
Issuance of senior notes499 497 — 
Debt issuance costs(4)(4)— 
Proceeds from commercial paper420 — — 
Repayment of commercial paper(345)— — 
Repayment of finance leases(4)— — 
Purchase of non-controlling interest— (4)— 
Proceeds from credit facility and short-term loan798 805 483 
Repayment of debt and credit facility(1,413)(702)(693)
Net cash used in financing activities(717)(299)(797)
Effect of exchange rate movements2 2 (17)
Net increase (decrease) in cash, cash equivalents and restricted cash59 (866)(432)
Cash, cash equivalents and restricted cash at beginning of year1,388 2,254 2,686 
Cash, cash equivalents and restricted cash at end of year$1,447 $1,388 $2,254 
Supplemental cash flow information:
Income tax payments, net$361 $159 $102 
Interest payments$71 $80 $80 
Net change in property, plant and equipment included in accounts payable and accrued liabilities-increase (decrease)$(1)$(21)$(5)

The accompanying notes are an integral part of these consolidated financial statements.
60

AGILENT TECHNOLOGIES, INC.
CONSOLIDATED STATEMENT OF EQUITY

 Common Stock Accumulated
Other
Comprehensive
Loss		   
 Number
of
Shares		Par
Value		Additional
Paid-in
Capital		Retained
Earnings
(Accumulated Deficit)		Total Stockholders' EquityNon-
Controlling
Interest		Total
Equity
 (in millions, except number of shares in thousands)
Balance as of October 31, 2017321,975 $3 $5,300 $(126)$(346)$4,831 $4 $4,835 
Components of comprehensive income, net of tax:        
Net income— — — 316 — 316 — 316 
Other comprehensive loss— — — — (62)(62)— (62)
Total comprehensive income     254 254 
Cash dividends declared ($0.596 per common share)
— — — (191)— (191)— (191)
Share-based awards issued2,176 — 25 — — 25 — 25 
Repurchase of common stock(6,436)— (87)(335)(422)— (422)
Share-based compensation— — 70 — — 70 — 70 
Balance as of October 31, 2018317,715 $3 $5,308 $(336)$(408)$4,567 $4 $4,571 
Effects of adoption of new accounting standards— — — 33 (7)26 — 26 
Components of comprehensive income, net of tax;        
Net income— — — 1,071 — 1,071 — 1,071 
Other comprehensive loss— — — — (99)(99)— (99)
Total comprehensive income     972 972 
Cash dividends declared ($0.656 per common share)
— — — (206)— (206)— (206)
Purchase of non-controlling interest— — — — — — (4)(4)
Share-based awards issued1,792 — 40 — — 40 — 40 
Repurchase of common stock(10,436)— (143)(580)— (723)— (723)
Share-based compensation— — 72 — — 72 — 72 
Balance as of October 31, 2019309,071 $3 $5,277 $(18)$(514)$4,748 $— $4,748 
Components of comprehensive income, net of tax:
Net income— — — 719 — 719 — 719 
Other comprehensive loss— — — — (8)(8)— (8)
Total comprehensive income     711 711 
Cash dividends declared ($0.720 per common share)             
— — — (222)— (222)— (222)
Share-based awards issued2,354 — 22 — — 22 — 22 
Repurchase of common stock(5,227)— (71)(398)— (469)— (469)
Share-based compensation— — 83 — — 83 — 83 
Balance as of October 31, 2020306,198 $3 $5,311 $81 $(522)$4,873 $— $4,873 

The accompanying notes are an integral part of these consolidated financial statements.
61

AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.     OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Overview.  Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.

Basis of Presentation.  The accompanying consolidated financial statements have been prepared by us pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") and are in conformity with U.S. generally accepted accounting principles ("GAAP"). Our fiscal year end is October 31. Unless otherwise stated, all years and dates refer to our fiscal year.

Principles of Consolidation.  The consolidated financial statements include the accounts of the company and our wholly- and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.

Use of Estimates.  The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, retirement and post-retirement plan assumptions and accounting for income taxes.

Risks and Uncertainties. We are subject to risks common to companies in the analytical instrument industry, such as global economic and financial market conditions, fluctuations in foreign currency exchange rates and fluctuations in customer demand, among others.

Both our domestic and international operations have been and continue to be affected by the ongoing global pandemic of a novel strain of coronavirus (“COVID-19”) and the resulting volatility and uncertainty it has caused in the U.S. and international markets. In March 2020, the World Health Organization declared COVID-19 a pandemic and recommended containment and mitigation measures worldwide. As a result, academic and research laboratories had temporarily closed in our second and third quarters and hospitals and testing laboratories had halted or reduced certain elective medical procedures, which had an adverse effect on our customers' business. The COVID-19 pandemic has caused significant volatility and uncertainty in U.S. and international markets, which could result in a prolonged economic downturn that could disrupt our business.

Revenue Recognition.  We enter into contracts to sell products, services or combinations of products and services. Products may include hardware or software and services may include one-time service events or services performed over time.

We derive revenue primarily from the sale of analytical and diagnostics products and services. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under Accounting Standard Codification Topic 606, Revenue from Contracts with Customers (“ASC 606’’). See also Note 4, "Revenue" for additional information on revenue recognition.

Revenue is recognized when control of the promised products or services is transferred to our customers and the performance obligation is fulfilled in an amount that reflects the consideration that we expect to be entitled in exchange for those products or services, the transaction price. For equipment, consumables, and most software licenses, control transfers to the customer at a point in time. We use present right to payment, legal title, physical possession of the asset, and risks and rewards of ownership as indicators to determine the transfer of control to the customer. Where acceptance is not a formality, the customer must have documented their acceptance of the product or service. For products that include installation, if the installation meets the criteria to be considered a separate performance obligation, product revenue is recognized when control has passed to the customer, and recognition of installation revenue occurs once completed. Product revenue, including sales to
62
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


resellers and distributors is reduced for provisions for warranties, returns, and other adjustments in the period the related sales are recorded.

Service revenue includes extended warranty, customer and software support including: Software as a Service, post contract support, consulting including companion diagnostics, and training and education. Instrument service contracts and software maintenance contracts are typically annual contracts, which are billed at the beginning of the contract or maintenance period. Revenue for these contracts is recognized on a straight-line basis to revenue over the service period, as a time-based measure of progress best reflects our performance in satisfying this obligation. There are no deferred costs associated with the service contract, as the cost of the service is recorded when the service is performed. Service calls not included in a support contract are recognized to revenue at the time a service is performed.

We have sales from standalone software. These arrangements typically include software licenses and maintenance contracts, both of which we have determined are distinct performance obligations. We determine the amount of the transaction price to allocate to the license and maintenance contract based on the relative standalone selling price of each performance obligation. Software license revenue is recognized at the point in time when control has been transferred to the customer. The revenue allocated to the software maintenance contract is recognized on a straight-line basis over the maintenance period, which is the contractual term of the contract, as a time-based measure of progress best reflects our performance in satisfying this obligation. Unspecified rights to software upgrades are typically sold as part of the maintenance contract on a when-and-if-available basis.

Our multiple-element arrangements are generally comprised of a combination of instruments, installation or other start-up services, and/or software, and/or support or services. Hardware and software elements are typically delivered at the same time and revenue is recognized when control passes to the customer. Service revenue is deferred and recognized over the contractual period or as services are rendered and accepted by the customer. Our arrangements generally do not include any provisions for cancellation, termination, or refunds that would significantly impact recognized revenue.

For contracts with multiple performance obligations, we allocate the consideration to which we expect to be entitled to each performance obligation based on relative standalone selling prices and recognize the related revenue when or as control of each individual performance obligation is transferred to customers. We estimate the standalone selling price by calculating the average historical selling price of our products and services per country for each performance obligation. Standalone selling prices are determined for each distinct good or service in the contract, and then we allocate the transaction price in proportion to those standalone selling prices by performance obligations.

A portion of our revenue relates to lease arrangements. Standalone lease arrangements are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 842, Leases for 2020 and ASC 840, Leases for prior periods. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type capital lease using the current lease classification guidance.

Deferred Revenue.  Contract liabilities (deferred revenue) primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements (performance obligations) to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either in current liabilities in deferred revenue or long-term in other long-term liabilities in the consolidated balance sheet based on the timing of when we expect to complete our performance obligation.

Sales Taxes.  Sales taxes collected from customers and remitted to governmental authorities are not included in our revenue.

Shipping and Handling Costs.  Our shipping and handling costs charged to customers are included in net revenue, and the associated expense is recorded in cost of products for all periods presented.

Research and Development.  Costs related to research, design and development of our products are charged to research and development expense as they are incurred.

Advertising.  Advertising costs are generally expensed as incurred and amounted to $48 million in 2020, $36 million in 2019 and $41 million in 2018.

63
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Taxes on Income.  Income tax expense or benefit is based on income or loss before taxes. Deferred tax assets and liabilities are recognized principally for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. See Note 6, "Income Taxes" for more information.

Net Income Per Share.  Basic net income per share is computed by dividing net income - the numerator - by the weighted average number of common shares outstanding - the denominator - during the period excluding the dilutive effect of stock options and other employee stock plans. Diluted net income per share gives effect to all potential common shares outstanding during the period unless the effect is anti-dilutive. The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense are assumed proceeds to be used to repurchase hypothetical shares. See Note 7, "Net Income Per Share".

Cash, Cash Equivalents and Short-Term Investments.  We classify investments as cash equivalents if their original or remaining maturity is three months or less at the date of purchase. Cash equivalents are stated at cost, which approximates fair value.

As of October 31, 2020, approximately $1,395 million of our cash and cash equivalents is held outside of the U.S. by our foreign subsidiaries. Our cash and cash equivalents mainly consist of short-term deposits held at major global financial institutions, institutional money market funds, and similar short duration instruments with original maturities of 90 days or less. We continuously monitor the creditworthiness of the financial institutions and institutional money market funds in which we invest our funds.

We classify investments as short-term investments if their original maturities are greater than three months and their remaining maturities are one year or less. Currently, we have no short-term investments.

Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet follows:
October 31,
202020192018
(in millions)
Cash and cash equivalents$1,441 $1,382 $2,247 
Restricted cash included in other assets6 6 7 
Total cash, cash equivalents and restricted cash$1,447 $1,388 $2,254 

Accounts Receivable, net.  Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Such accounts receivable have been reduced by an allowance for doubtful accounts, which is our best estimate of the amount of probable credit losses in our existing accounts receivable. We determine the allowance based on customer specific experience and the aging of such receivables, among other factors. The allowance for doubtful accounts as of October 31, 2020 and 2019 was not material. We do not have any off-balance-sheet credit exposure related to our customers. Accounts receivable are also recorded net of estimated product returns which are not material.

Concentration of Credit Risk.  Financial instruments that potentially subject Agilent to significant concentration of credit risk include money market fund investments, time deposits and demand deposit balances. These investments are categorized as cash and cash equivalents. In addition, Agilent has credit risk from derivative financial instruments used in hedging activities and accounts receivable. We invest in a variety of financial instruments and limit the amount of credit exposure with any one financial institution. We have a comprehensive credit policy in place and credit exposure is monitored on an ongoing basis.

Credit risk with respect to our accounts receivable is diversified due to the large number of entities comprising our customer base and their dispersion across many different industries and geographies. Credit evaluations are performed on customers requiring credit over a certain amount, and we sell the majority of our products through our direct sales force. Credit risk is mitigated through collateral such as letter of credit, bank guarantees or payment terms like cash in advance. No single customer accounted for more than 10 percent of accounts receivable as of October 31, 2020, or 2019.

64
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Inventory.  Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with manufacturing to maximize recovery of excess inventory.

Property, Plant and Equipment.  Property, plant and equipment are stated at cost less accumulated depreciation. Additions, improvements and major renewals are capitalized; maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation and amortization are removed from our general ledger, and the resulting gain or loss is reflected in the consolidated statement of operations. Buildings and improvements are depreciated over the lesser of their useful lives or the remaining term of the lease and machinery and equipment over 3 years to 10 years. We use the straight-line method to depreciate assets.

Capitalized Software.  We capitalize certain internal and external costs incurred to acquire or create internal use software. Capitalized software is included in property, plant and equipment and is depreciated over 3 years to 5 years once development is complete.

Leases.  We determine whether an arrangement is, or contains, a lease at inception. Prior to November 1, 2019, for leases where we are the lessee, we accounted for operating lease payments by charging them to expense as incurred. At the beginning of fiscal 2020, the company adopted new lease accounting guidance issued by the Financial Accounting Standards Board ("FASB"). The most significant change requires lessees to record the present value of operating lease payments as right-of-use ("ROU") assets and lease liabilities on the consolidated balance sheet. Where we are the lessee, ROU assets represent the company’s right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of operating lease liabilities as either current or non-current is based on the expected timing of payments due under our obligations. As most of our leases do not provide an implicit interest rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rates, we have used a number of factors including the company's credit rating, the lease term and the currency swap rate. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet and lease expense for these leases is recognized on a straight-line basis over the lease term. Lease expense for operating leases with an initial term of more than twelve months is recognized on a straight-line basis over the lease term as an operating expense. We have lease agreements which require payments for lease and non-lease components. We have elected to account for these payments as a single lease component.

A portion of our revenue relates to lease arrangements where Agilent is the lessor. Standalone lease arrangements are outside the scope of Accounting Standard Codification ("ASC") Topic 606, Revenue Contracts with Customers, and are therefore accounted for in accordance with ASC Topic 842, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type finance lease using the current lease classification guidance. In a lease arrangement that is a multiple-element arrangement that contains equipment leases and the supply of consumables, the revenue associated with the instrument rental is treated under the lease accounting standard ASC 842, whereas the revenue associated with the consumables, the non-lease component, is recognized in accordance with the ASC 606 revenue standard.

   See also Note 2, "New Accounting Pronouncements" and Note 10, "Leases" for additional information about the company’s leases.

Acquisitions. Agilent accounts for the acquisition of a business using the acquisition method of accounting, and we allocate the fair value of the purchase price to the tangible assets acquired, liabilities assumed, and intangible assets acquired, including in-process research and development (“IPR&D”), based on their estimated fair values. The excess value of the cost of an acquired business over the fair value of the assets acquired and liabilities assumed is recognized as goodwill. The fair value of IPR&D is initially capitalized as an intangible asset with an indefinite life. When an IPR&D project is completed, the IPR&D is reclassified as an amortizable purchased intangible asset and amortized to costs of revenues over the asset’s estimated useful life.

Our determination of the fair value of the intangible assets acquired involves the use of significant estimates and assumptions. Specifically, our determination of the fair value of the developed product technology and IPR&D acquired
65
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


involve significant estimates and assumptions related to revenue growth rates and discount rates. Our determination of the fair value of customer relationships acquired involved significant estimates and assumptions related to revenue growth rates, discount rates, and customer attrition rates. Our determination of the fair value of the tradename acquired involved the use of significant estimates and assumptions related to revenue growth rates, royalty rates and discount rates. The company believes that the fair value assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that marketplace participants would use. Actual results could differ materially from these estimates.

Goodwill and Purchased Intangible Assets. Under the authoritative guidance we have the option to perform a qualitative assessment to determine whether further impairment testing is necessary. The accounting standard gives an entity the option to first assess qualitative factors to determine whether performing the two-step test is necessary. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not (i.e., greater than 50% chance) that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test will be required. Otherwise, no further testing will be required.

The guidance includes examples of events and circumstances that might indicate that a reporting unit's fair value is less than its carrying amount. These include macro-economic conditions such as deterioration in the entity's operating environment or industry or market considerations; entity-specific events such as increasing costs, declining financial performance, or loss of key personnel; or other events such as an expectation that a reporting unit will be sold or a sustained decrease in the stock price on either an absolute basis or relative to peers.

If it is determined, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, the provisions of authoritative guidance require that we perform a two-step impairment test on goodwill. In the first step, we compare the fair value of each reporting unit to its carrying value. The second step (if necessary) measures the amount of impairment by applying fair-value-based tests to the individual assets and liabilities within each reporting unit. As defined in the authoritative guidance, a reporting unit is an operating segment, or one level below an operating segment. We aggregate components of an operating segment that have similar economic characteristics into our reporting units.

In fiscal year 2020, we assessed goodwill impairment for our three reporting units which consisted of three segments: life sciences and applied markets, diagnostics and genomics and Agilent CrossLab. We performed a qualitative test for goodwill impairment of the three reporting units, as of September 30, 2020, our annual impairment test date. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair value of each reporting unit is greater than its respective carrying value. Each quarter we review the events and circumstances to determine if goodwill impairment is indicated. There was no impairment of goodwill during the years ended October 31, 2020, 2019 and 2018.

Purchased intangible assets consist primarily of acquired developed technologies, proprietary know-how, trademarks, and customer relationships and are amortized using the best estimate of the asset's useful life that reflect the pattern in which the economic benefits are consumed or used up or a straight-line method ranging from 6 months to 15 years. IPR&D is initially capitalized at fair value as an intangible asset with an indefinite life and assessed for impairment thereafter. When the IPR&D project is complete, it is reclassified as an amortizable purchased intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, Agilent will record a charge for the value of the related intangible asset to Agilent's consolidated statement of operations in the period it is abandoned.

Agilent's indefinite-lived intangible assets are IPR&D intangible assets. The accounting guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the issued impairment testing guidance for goodwill and allows the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset to determine whether it is more-likely-than-not (i.e., greater than 50% chance) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value. We performed a qualitative test for impairment of indefinite-lived intangible assets as of September 30, 2020. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair values of these indefinite-lived intangible assets are greater than their respective carrying values. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible asset is indicated. During the year ended October 31, 2020, we recorded an impairment of in-process research and development of $90 million related to the shutdown of our sequencer development program in our diagnostics and genomics segment. During the year ended October 31, 2019 and 2018 there were no impairments of indefinite-lived intangible assets.

66
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Impairment of Long-Lived Assets.  We continually monitor events and changes in circumstances that could indicate carrying amounts of long-lived assets, including intangible assets, may not be recoverable. When such events or changes in circumstances occur, we assess the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the undiscounted future cash flows is less than the carrying amount of those assets, we recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets. During the year ended October 31, 2020 we recorded an impairment charge of long-lived assets including indefinite-lived in-process research and development of $98 million related to the shutdown of our sequencer development program in our diagnostics and genomics segment. During fiscal year 2019, there were no impairments of other assets or intangible assets. During fiscal year 2018, we recorded an impairment charge of $21 million related to purchased intangible assets within the diagnostics and genomics segment that were deemed unrecoverable.

Variable Interest Entities. We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity (“VIE”).  The company evaluates its investments in privately held companies on an ongoing basis. We have determined that as of October 31, 2020 and 2019, there were no VIE's required to be consolidated in the company's consolidated financial statements because we do not have a controlling financial interest in any of the VIE's in which we have invested nor are we the primary beneficiary. We account for these investments under either the equity method or as equity investments without readily determinable fair value, depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs, based on changes in facts and circumstances including changes in contractual arrangements and capital structure.

During the year ended October 31, 2018, we exercised our option and acquired all of the remaining shares of Lasergen, Inc. ("Lasergen") that we did not already own for an additional cash consideration of approximately $107 million. The fair value remeasurement of our previous investment immediately before the acquisition resulted in a net gain of $20 million and was recorded in other income. Lasergen was previously considered a VIE.

As of October 31, 2020 and October 31, 2019, the total carrying value of investments and loans in privately held companies considered as VIEs was $67 million and $29 million respectively. The maximum exposure is equal to the carrying value because we do not have future funding commitments. The investments are included on the long-term investments line and the loans on the other current assets and other assets lines (depending upon tenure of loan) on the consolidated balance sheet.

Investments.  Equity investments without readily determinable fair value consist of non-marketable equity securities (typically investments in privately-held companies). These investments are accounted for using the measurement alternative at cost, and we adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) included in net income as and when it occurs. Equity investments with readily determinable fair value consist of shares we own in a special fund and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. Prior to fiscal year 2019, both equity investments without determinable fair value and with determinable fair value were accounted for using cost method of accounting, measured at historical cost less other-than-temporary investment. Trading securities, which are comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liabilities are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Equity method investments are reported at the amount of the company’s initial investment and adjusted each period for the company’s share of the investee’s income or loss and dividend paid. There are no equity method investments as of October 31, 2020 and 2019. The company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.

Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. The fair value of our senior notes, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy exceeds the carrying value by approximately $162 million as of October 31, 2020 and approximately $62 million as of October 31, 2019. The change in the fair value over carrying value in the year ended October 31, 2020 is primarily due to decreased market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are
67
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 13, "Fair Value Measurements" for additional information on the fair value of financial instruments.

Warranty.  Our standard warranty terms typically extend for one year from the date of delivery. We accrue for standard warranty costs based on historical trends in warranty charges. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost over the period. Estimated warranty charges are recorded within cost of products at the time products are sold. See Note 16, "Guarantees".

Employee Compensation and Benefits.  Amounts owed to employees, such as accrued salary, bonuses and vacation benefits are accounted for within employee compensation and benefits. The total amount of accrued vacation benefit was $111 million and $115 million as of October 31, 2020, and 2019, respectively.

Retirement and Post-Retirement Plans. Substantially all of our employees are covered under various defined benefit and/or defined contribution retirement plans. Additionally, we sponsor post-retirement health care benefits for our eligible U.S. employees. Assumptions used to determine the benefit obligations and the expense for these plans are derived annually. See Note 15, “Retirement plans and post-retirement pension plans” for additional information.

Retirement of Treasury Shares. Upon the formal retirement of treasury shares, we deduct the par value of the retired treasury shares from common stock and allocate the excess of cost over par as a deduction to additional paid-in capital, based on the pro-rata portion of additional paid-in-capital, and the remaining excess as a deduction to retained earnings. All retired treasury shares revert to the status of authorized but unissued shares.

Share-Based Compensation.  For the years ended 2020, 2019 and 2018, we accounted for share-based awards made to our employees and directors including employee stock option awards, restricted stock units, employee stock purchases made under our Employee Stock Purchase Plan ("ESPP") and performance share awards under Agilent Technologies, Inc. Long-Term Performance Program ("LTPP") using the estimated grant date fair value method of accounting. Under the fair value method, we recorded compensation expense for all share-based awards of $84 million in 2020, $72 million in 2019 and $71 million in 2018. See Note 5, "Share-based Compensation" for additional information.

Derivative Instruments.  Agilent is exposed to global foreign currency exchange rate and interest rate risks in the normal course of business. We enter into foreign exchange hedging contracts, primarily forward contracts and purchased options, interest rate swaps and interest rate locks to manage financial exposures resulting from changes in foreign currency exchange rates and interest rates. In the vast majority of cases, these contracts are designated at inception as hedges of the related foreign currency or interest exposures. Foreign currency exposures include committed and anticipated revenue and expense transactions and assets and liabilities that are denominated in currencies other than the functional currency of the subsidiary. Interest rate exposures are associated with the company's fixed-rate debt. For option contracts, we exclude time value from the measurement of effectiveness. To qualify for hedge accounting, contracts must reduce the foreign currency exchange rate and interest rate risk otherwise inherent in the amount and duration of the hedged exposures and comply with established risk management policies. Foreign exchange hedging contracts generally mature within twelve months, interest rate swaps mature at the same time as the maturity of the debt and interest rate locks mature at the same time as the issuance of debt. In order to manage foreign currency exposures in a few limited jurisdictions, we may enter into foreign exchange contracts that do not qualify for hedge accounting. In such circumstances, the local foreign currency exposure is offset by contracts owned by the parent company. We do not use derivative financial instruments for trading or speculative purposes.

All derivatives are recognized on the balance sheet at their fair values. For derivative instruments that are designated and qualify as a cash flow hedge, changes in the value of the effective portion of the derivative instrument are recognized in comprehensive income (loss), a component of stockholders' equity. For derivative instruments that are designated and qualify as a net investment hedge, changes in the value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss). Amounts associated with cash flow hedges are reclassified and recognized in income when either the forecasted transaction occurs or it becomes probable the forecasted transaction will not occur. Derivatives not designated as hedging instruments are recorded on the balance sheet at their fair value and changes in the fair values are recorded in the income statement in the current period. Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet. Changes in the fair value of the ineffective portion of derivative instruments are recognized in earnings in the current period. The impact of the ineffectiveness measurement in 2020, 2019 and 2018 was not material. Cash flows from derivative instruments are classified in the statement of cash flows in the same category as the cash flows from the hedged or economically hedged item, primarily in operating activities.

68
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Foreign Currency Translation.  We translate and remeasure balance sheet and income statement items into U.S. dollars. For those subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using monthly exchange rates which approximate to average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) in stockholders' equity.

For those subsidiaries that operate in a U.S. dollar functional environment, foreign currency assets and liabilities are remeasured into U.S. dollars at current exchange rates except for non-monetary assets and capital accounts which are remeasured at historical exchange rates. Revenue and expenses are generally remeasured at monthly exchange rates which approximate average exchange rates in effect during each period. Gains or losses from foreign currency remeasurement are included in consolidated net income. Net gains or losses resulting from foreign currency transactions, including hedging gains and losses, are reported in other income (expense), net and were $4 million loss for 2020, $7 million loss for 2019 and $3 million loss for 2018.

2.     NEW ACCOUNTING PRONOUNCEMENTS

Recently Adopted Accounting Pronouncements
In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases (Topic 842), which requires lessees to record most leases on the balance sheet as lease liabilities, initially measured at the present value of future lease payments, with a corresponding right-of-use asset. The accounting applied by a lessor is largely unchanged from that applied under the prior accounting standard.

On November 1, 2019, we adopted the new accounting guidance using the modified retrospective method, by applying the transition approach, for all lease arrangements at the beginning of the period of adoption. Results for reporting periods beginning November 1, 2019 are presented under the new accounting standard, while prior period amounts have not been restated. The standard had a significant impact on the opening consolidated balance sheet as of November 1, 2019, but did not have a significant impact on the consolidated statement of operations or consolidated statement of cash flows for the year ended October 31, 2020 when compared to prior periods. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases, while the accounting for finance leases remained substantially unchanged. For leases that commenced before the effective date of the new accounting standard, we elected the permitted practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. We also elected to exclude leases with a term of 12 months or less in the ROU assets and lease liabilities.

Adoption of the new guidance impacted the consolidated balance sheet as follows:

 October 31, 2019Impact of AdoptingNovember 1, 2019
 As ReportedLease GuidanceAs Adopted
(in millions)
Other assets$611 $192 $803 
Other accrued liabilities$440 $48 $488 
Other long-term liabilities$473 $144 $617 

On November 1, 2018, we adopted ASC Topic 606, Revenue from Contracts with Customers, using the modified retrospective approach only to contracts not completed as of this date. Results for reporting periods after November 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and continue to be reported in accordance with ASC Topic 605, Revenue Recognition.

New Accounting Pronouncements Not Yet Adopted

In June 2016, the FASB issued new guidance to require a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. During 2018 and 2019, the FASB issued additional guidance and clarification. The new guidance is effective for us beginning November 1, 2020. We do not expect this guidance to have a material impact on our consolidated financial statements and disclosures.

69
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


In January 2017, the FASB issued an amendment to modify the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. The amendment also simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. The amendments are effective for us beginning November 1, 2020. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We do not expect this guidance to have a material impact on our consolidated financial statements and disclosures.

In August 2018, the FASB issued updates to improve the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement which eliminates certain disclosure requirements and modifies others. These amendments are effective for us beginning November 1, 2020, and for interim periods within that year with early adoption permitted. We currently do not expect this guidance to have a material impact on our consolidated financial statements and disclosures.

In August 2018, the FASB issued updates to improve the effectiveness of disclosures for defined benefit plans under Accounting Standard Codification Topic 715-20. The amendments in this guidance remove disclosures that no longer are considered cost beneficial, clarify the specific requirements of disclosures, and add disclosure requirements identified as relevant. These amendments are effective for us beginning November 1, 2021, with early adoption permitted. We currently do not expect this guidance to have a material impact on our consolidated financial statements and disclosures.

In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. This guidance eliminates certain exceptions to existing guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The guidance also improves consistent application by clarifying and amending existing guidance related to aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step up in the tax basis of goodwill. The new guidance is effective for us beginning November 1, 2021, and for interim periods within that year. Early adoption is permitted. We do not expect that the adoption of this standard will have a material impact on our consolidated financial statements and disclosures.

In January 2020, accounting guidance was issued that clarifies the accounting guidance for equity method investments, joint ventures, and derivatives and hedging. The guidance clarifies the interaction between different sections of the accounting guidance that could be applicable and helps clarify which guidance should be applied in certain situations which should increase relevance and comparability of financial statement information. This guidance is effective for us beginning November 1, 2021, and for interim periods within that year. Early adoption is permitted. We do not expect that the adoption of this standard will have a material impact on our consolidated financial statements and disclosures.

In March 2020, the FASB issued an update for facilitation of the effects of reference rate reform on financial reporting. This update provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments in the guidance provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply to contracts, hedging relationships, and other transactions that reference London Inter-bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. When elected, the optional expedients for contract modifications are applied consistently for all eligible contracts or eligible transactions within the relevant Topic or Industry Subtopic in the FASB's Accounting Standards Codification. The guidance was effective upon issuance and may generally be applied through December 31, 2022 to any new or amended contracts, hedging relationships, and other transactions that reference LIBOR. We are currently evaluating our contracts and we do not expect that the adoption of this guidance will have a material impact on our consolidated financial statements and disclosures.

Other amendments to GAAP in the U.S. that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption.

3.     ACQUISITIONS

Acquisition of BioTek and ACEA

On August 23, 2019 we completed the acquisition of privately-owned Lionheart Technologies LLC ("BioTek"), a leader in the design, manufacture and distribution of innovative life science instrumentation for $1.17 billion, under the merger agreement. As a result of the acquisition, BioTek became a wholly-owned subsidiary of Agilent. Accordingly, the results of
70
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


BioTek are included in Agilent's consolidated financial statements from the acquisition date. The acquisition of BioTek and its portfolio is another step to expand our position in the cell analysis market.

The consideration paid was $1.17 billion. Agilent funded the acquisition using existing cash of $470 million and debt of $700 million.

The BioTek acquisition was accounted for in accordance with the authoritative accounting guidance. The acquired assets and assumed liabilities were recorded by Agilent at their estimated fair values. Agilent determined the estimated fair values with the assistance of appraisals or valuations performed by third party specialists, discounted cash flow analyses, and estimates made by management. We expect to realize revenue synergies, leverage and expand the existing sales channels and product development resources, and utilize the assembled workforce. These factors, among others, contributed to a purchase price in excess of the estimated fair value of BioTek’s net identifiable assets acquired (see summary of net assets below), and, as a result, we have recorded goodwill in connection with this transaction.
 
Goodwill acquired was allocated to our operating segments and reporting units as a part of the purchase price allocation. All goodwill was allocated to the life sciences and applied markets reporting unit.

Agilent’s acquisition of BioTek is treated as an asset purchase for tax purposes. The tax basis of the acquired assets equals the fair market value on acquisition date.

The following table summarizes the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of August 23, 2019 (in millions):
Cash and cash equivalents$10 
Accounts receivable28 
Inventories21 
Other current assets2 
Property, plant and equipment8 
Intangible assets641 
Goodwill483 
Total assets acquired$1,193 
Accounts payable(4)
Deferred revenue(5)
Employee compensation and benefits(7)
Other accrued liabilities(2)
Long-term debt(4)
Net assets acquired$1,171 


The fair value of cash and cash equivalents, accounts receivable, other current assets, accounts payable and other accrued liabilities were generally determined using historical carrying values given the short-term nature of these assets and liabilities.
 
The fair values for acquired intangible assets and deferred revenue were determined with the input from third party valuation specialists.
 
The fair values of certain other assets, inventory, property, plant and equipment, investments, long-term debt, and certain other long-term liabilities were determined internally using historical carrying values and estimates made by management.
 
71
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Valuations of intangible assets acquired
 
The components of intangible assets acquired in connection with the BioTek acquisition were as follows (in millions):

 Fair ValueEstimated
Useful Life
Developed product technology$387 
5-13 years
Customer relationships202 
3-8 years
Backlog5 2 months
Tradenames and trademarks43 10 years
Total intangible assets subject to amortization$637 
In-process research and development4  
Total intangible assets$641  

As noted above, the intangible assets, including in-process research and development, were valued with input from valuation specialists. Agilent used variations of the income approach in determining the fair value of intangible assets acquired in the BioTek acquisition. Specifically, the developed product technology and in-process research and development were valued using the multi-period excess earnings method under the income approach by discounting forecasted cash flows directly related to the products expecting to result from the projects, net of returns on contributory assets. The company utilized the incremental cash flow method for determining the fair value of the customer relationships acquired, and the relief from royalty method to determine the fair value of the tradename. Order backlog was valued on a direct cash flow basis.

The primary in-process research and development project acquired relates to a next version of a product which was subsequently released to customers in 2020. After release, the asset was moved to developed technology.

Acquisition and integration costs directly related to the BioTek acquisition totaled $12 million and $4 million for the year ended October 31, 2020 and 2019, respectively, and were recorded in operating expenses and cost of sales. Such costs are expensed in accordance with the authoritative accounting guidance.

On November 14, 2018, we acquired 100 percent of the stock of ACEA Biosciences (“ACEA”), a developer of cell analysis tools, for $250 million. The financial results of ACEA have been included in our financial results from the acquisition date.
 
The following represents the unaudited proforma operating results as if BioTek and ACEA had been included in the company's consolidated statements of operations as of the beginning of fiscal 2018 (in millions, except per share amounts):

20192018
Net revenue$5,308 $5,112 
Net income$1,012 $210 
Net income per share — basic$3.22 $0.65 
Net income per share — diluted$3.18 $0.65 

The unaudited proforma financial information assumes that the companies were combined as of November 1, 2017 and include business combination accounting effects from the acquisition including amortization charges from acquired intangible assets, the impact on cost of sales due to the respective estimated fair value adjustments to inventory, changes to interest income for cash used in the acquisition, interest expense associated with debt paid in connection with the acquisition and acquisition related transaction costs and tax related effects. The proforma information as presented above is for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of fiscal 2018.
 
The unaudited proforma financial information for the year ended October 31, 2019 combines the historical results of Agilent for the year ended October 31, 2019 (which includes BioTek and ACEA after the acquisition date) and for BioTek for the ten months ended August 23, 2019.
 
The unaudited proforma financial information for the year ended October 31, 2018 combines the historical results of
72
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Agilent and ACEA for the year ended October 31, 2018 and BioTek for the year ended December 31, 2018 (due to differences in reporting periods).

4.     REVENUE

The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:

Life Sciences and Applied MarketsAgilent CrossLabDiagnostics and GenomicsTotal
(in millions)
Year Ended October 31, 2020:
Americas$784 $667 $517 $1,968 
Europe540 532 371 1,443 
Asia Pacific1,068 701 159 1,928 
Total$2,392 $1,900 $1,047 $5,339 
Year Ended October 31, 2019:
Americas$692 $664 $505 $1,861 
Europe551 522 368 1,441 
Asia Pacific1,059 654 148 1,861 
Total$2,302 $1,840 $1,021 $5,163 

The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
Years Ended October 31,
20202019
(in millions)
Revenue by End Markets
Pharmaceutical and Biopharmaceutical$1,754 1,604 
Chemical and Energy1,154 1,199 
Diagnostics and Clinical787 785 
Food517 486 
Academia and Government526 474 
Environmental and Forensics601 615 
Total$5,339 5,163 
Revenue by Type
Instrumentation$2,249 2,150 
Non-instrumentation and other3,090 3,013 
Total$5,339 5,163 

Revenue by region is based on the ship to location of the customer. Revenue by end market is determined by the market indicator of the customer and by customer type. Instrumentation revenue includes sales from instruments, remarketed instruments and third-party products. Non-instrumentation and other revenue include sales from contract and per incident services, our companion diagnostics and our nucleic acid solutions businesses as well as sales from spare parts, consumables, reagents, vacuum pumps, subscriptions, software licenses and associated services.


73
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Contract Balances

Contract Assets

Contract assets (unbilled accounts receivable) primarily relate to the company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are reclassified to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the consolidated balance sheet. The balances of contract assets as of October 31, 2020 and 2019, were $153 million and $110 million, respectively. The increase in unbilled receivables during the year ended October 31, 2020 is a result of recognition of revenue upon the transfer of the control to the customer.

Contract Liabilities

The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the years ended October 31, 2019 and 2020:

Contract
Liabilities
(in millions)
Ending balance as of October 31, 2018$367 
Impact of adoption of new revenue recognition guidance(11)
Net revenue deferred in the period303 
Revenue recognized that was included in the contract liability balance at the beginning of the period(287)
Change in deferrals from customer cash advances, net of revenue recognized5 
Contract liabilities acquired in business combinations9 
Currency translation and other adjustments— 
Ending balance as of October 31, 2019$386 
Net revenue deferred in the period347 
Revenue recognized that was included in the contract liability balance at the beginning of the period(300)
Change in deferrals from customer cash advances, net of revenue recognized9 
Currency translation and other adjustments4 
Ending balance as of October 31,2020$446 

Contract liabilities primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either current in deferred revenue or long-term in other long-term liabilities in the consolidated balance sheet based on the timing of when we expect to complete our performance obligation.

Contract Costs

Incremental costs of obtaining a contract with a customer are recognized as an asset if we expect the benefit of those costs to be longer than one year. We have determined that certain sales incentive programs meet the requirements to be capitalized. The changes in total capitalized costs to obtain a contract were immaterial during the years ended October 31, 2020 and 2019 and are included in other current and long-term assets on the consolidated balance sheet. We have applied the practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the company's internal sales force compensation program, as we have determined that annual compensation is commensurate with annual sales activities.

74
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Transaction Price Allocated to the Remaining Performance Obligations

We have applied the practical expedient in ASC 606-10-50-14 and have not disclosed information about transaction price allocated to remaining performance obligations that have original expected durations of one year or less.
The estimated revenue expected to be recognized for remaining performance obligations that have an original term of more than one year, as of October 31, 2020, was $217 million, the majority of which is expected to be recognized over the next 12 months. Remaining performance obligations primarily include extended warranty, customer manufacturing contracts, and software maintenance contracts and revenue associated with lease arrangements.

5.     SHARE-BASED COMPENSATION

Agilent accounts for share-based awards in accordance with the provisions of the accounting guidance which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including restricted stock units, stock options, employee stock purchases made under our employee stock purchase plan and performance share awards granted to selected members of our senior management under the long-term performance plan ("LTPP") based on estimated fair values.

Description of Share-Based Plans

Employee Stock Purchase Plan.    Effective May 1, 2020, we adopted the 2020 Employee Stock Purchase Plan ("ESPP") which replaced our previous Employee Stock Purchase Plan. The ESPP allows eligible employees to contribute up to 10 percent of their base compensation to purchase shares of our common stock at 85 percent of the closing market price at purchase date. There are 31 million shares authorized for issuance in connection with the ESPP.

Under our ESPP, employees purchased 628,644 shares for $41 million in 2020, 603,488 shares for $37 million in 2019 and 558,116 shares for $32 million in 2018. As of October 31, 2020, the number of shares of common stock authorized and available for issuance under our ESPP was 25,770,573. This excludes the number of shares of common stock to be issued to participants in consideration of the aggregate participant contributions totaling $22 million as of October 31, 2020.

Incentive Compensation Plans. On November 15, 2017 and March 21, 2018, the Board of Directors and the stockholders, respectively, approved the Agilent Technologies, Inc. 2018 Stock Plan (the "2018 Plan") which amends, including renaming and extending the term of, the Agilent Technologies, Inc. 2009 Stock Plan (the "2009 Plan"). The 2009 plan replaced the Agilent Technologies, Inc. Amended and Restated 1999 Stock Plan and 1999 Non-Employee Director Stock Plan. The 2018 Plan provides for the grant of awards in the form of stock options, stock appreciation rights ("SARs"), restricted stock, restricted stock units ("RSUs"), performance shares and performance units with performance-based conditions on vesting or exercisability, and cash awards. The 2018 Plan has a term of ten years. As of October 31, 2020, 25,596,430 shares were available for future awards under the 2018 Plan.

Stock options under the 2018 Plan may be either "incentive stock options", as defined in Section 422 of the Internal Revenue Code, or non-statutory. Options were granted prior to November 1, 2015 and generally vest at a rate of 25 percent per year over a period of four years from the date of grant with a maximum contractual term of ten years. The exercise price for stock options is generally not less than 100 percent of the fair market value of our common stock on the date the stock award is granted. Agilent issues new shares of common stock when employee stock options are exercised.

Effective November 1, 2003, the Compensation Committee of the Board of Directors approved the LTPP, which is a performance stock award program administered under the 2018 Plan, for the company's executive officers and other key employees. Participants in this program are entitled to receive unrestricted shares of the company's stock after the end of a three-year period if specified performance targets are met. Certain LTPP awards are generally designed to meet the criteria of a performance award with the performance metrics and peer group comparison based on the Total Stockholders’ Return (“TSR”) set at the beginning of the performance period. Effective November 1, 2015, the Compensation Committee of the Board of Directors approved another type of performance stock award for the company's executive officers and other key employees. Participants in this program are also entitled to receive unrestricted shares of the company's stock after the end of a three-year period if specified performance targets over the three-year period are met. The performance target for grants made beginning in 2017 and thereafter were based on Earnings Per Share ("EPS"). The performance targets for LTPP-EPS grants for year 2 and year 3 of the performance period are set in the first quarter of year 2 and year 3, respectively. All LTPP awards granted after November 1, 2015, are subject to a one-year post-vest holding period.

75
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Based on the performance metrics, the final LTPP award may vary from zero to 200 percent of the target award. The maximum contractual term for awards under the LTPP program is three years. We consider the dilutive impact of these programs in our diluted net income per share calculation only to the extent that the performance conditions are expected to be met.

We also issue restricted stock units under our share-based plans. The estimated fair value of the restricted stock unit awards granted under the Stock Plans is determined based on the market price of Agilent's common stock on the date of grant adjusted for expected dividend yield. Restricted stock units generally vest, with some exceptions, at a rate of 25 percent per year over a period of four years from the date of grant. All restricted stock units granted to our executives after November 1, 2015, are subject to a one-year post-vest holding period.

Impact of Share-based Compensation Awards

We have recognized compensation expense based on the estimated grant date fair value method under the authoritative guidance. For all share-based awards we have recognized compensation expense using a straight-line amortization method. As the guidance requires that share-based compensation expense be based on awards that are ultimately expected to vest, estimated share-based compensation has been reduced for estimated forfeitures.

The impact on our results for share-based compensation was as follows:

Years Ended October 31,
202020192018
(in millions)
Cost of products and services$21 $18 $16 
Research and development9 7 7 
Selling, general and administrative54 47 48 
Total share-based compensation expense$84 $72 $71 

At October 31, 2020 and 2019, no share-based compensation was capitalized within inventory.

Valuation Assumptions

For all periods presented, shares granted under the LTPP (TSR) were valued using a Monte Carlo simulation. The ESPP allows eligible employees to purchase shares of our common stock at 85 percent of the fair market value at the purchase date.

The estimated fair value of restricted stock unit awards and LTPP (EPS) was determined based on the market price of Agilent's common stock on the date of grant adjusted for expected dividend yield and as appropriate, a discount related to the one-year post vesting. The compensation cost for LTPP (EPS) awards reflects the cost of awards that are probable to vest at the end of the performance period.

The following assumptions were used to estimate the fair value of awards granted.

 Years Ended October 31,
 202020192018
LTPP:   
Volatility of Agilent shares23%22%21%
Volatility of selected peer-company shares
15%-44%
15%-66%
14%-66%
Pair-wise correlation with selected peers29%30%32%
Post-vest restriction discount for all executive awards5.3%5.0%4.8%


Shares granted under the LTPP (TSR) were valued using a Monte Carlo simulation model. The Monte Carlo simulation fair value model requires the use of highly subjective and complex assumptions, including the price volatility of the underlying stock. For LTPP (TSR) grants in 2017 and thereafter, we used our own historical stock price volatility.
76
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)



All LTPP awards granted have a one-year post-vest holding restriction. The estimated discount associated with post-vest holding restrictions is calculated using the Finnerty model. The model calculates the potential lost value if the employee were able to sell the shares during the lack of marketability period instead of being required to hold the shares.


Share-Based Payment Award Activity

Employee Stock Options

The following table summarizes employee stock option award activity of our employees and directors for 2020.

Options
Outstanding 		Weighted
Average
Exercise Price
 (in thousands) 
Outstanding at October 31, 20191,445 $36 
Exercised(575)$34 
Outstanding at October 31, 2020870 $37 

The options outstanding and exercisable for equity share-based payment awards at October 31, 2020 were as follows:

 Options OutstandingOptions Exercisable
Range of
Exercise Prices		Number
Outstanding		Weighted
Average
Remaining
Contractual
Life		Weighted
Average
Exercise
Price		Aggregate
Intrinsic
Value		Number
Exercisable		Weighted
Average
Remaining
Contractual
Life		Weighted
Average
Exercise
Price		Aggregate
Intrinsic
Value
 (in thousands)(in years) (in thousands)(in thousands)(in years) (in thousands)
$25.01 - $30.00
228 1.7$27 $17,192 228 1.7$27 $17,192 
$30.01 - $40.00
121 3.1$39 7,586 121 3.1$39 7,586 
$40.01- over
521 4.0$41 31,883 521 4.0$41 31,883 
870 3.3$37 $56,661 870 3.3$37 $56,661 

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value, based on the company's closing stock price of $102.09 at October 31, 2020, which would have been received by award holders had all award holders exercised their awards that were in-the-money as of that date. The total number of in-the-money awards exercisable at October 31, 2020 was approximately 0.9 million.

The following table summarizes the aggregate intrinsic value of options exercised in 2020, 2019 and 2018:

Aggregate
Intrinsic Value		Weighted
Average
Exercise
Price
 (in thousands) 
Options exercised in fiscal 2018$28,417 $32 
Options exercised in fiscal 2019$24,409 $33 
Options exercised in fiscal 2020$30,481 $34 

As of October 31, 2020, the unrecognized share-based compensation cost for outstanding stock option awards, net of expected forfeitures, was zero. The amount of cash received from the exercise of share-based awards granted was $60 million in 2020, $54 million in 2019 and $56 million in 2018.

77
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Non-Vested Awards

The following table summarizes non-vested award activity in 2020 primarily for our LTPP and restricted stock unit awards.
SharesWeighted
Average
Grant Price
 (in thousands) 
Non-vested at October 31, 20193,173 $60 
Granted1,091 $79 
Vested(1,629)$52 
Forfeited(115)$68 
Change in LTPP shares in the year due to exceeding performance targets298 $47 
Non-vested at October 31, 20202,818 $70 

As of October 31, 2020, the unrecognized share-based compensation cost for non-vested restricted stock awards was approximately $95 million which is expected to be amortized over a weighted average period of 2.1 years. The total fair value of restricted stock awards vested was $85 million for 2020, $69 million for 2019 and $58 million for 2018.

6.     INCOME TAXES

The domestic and foreign components of income before taxes are:

 Years Ended October 31,
 202020192018
 (in millions)
U.S. operations$54 $189 $169 
Non-U.S. operations788 730 777 
Total income before taxes$842 $919 $946 

The provision for income taxes is comprised of:

 Years Ended October 31,
 202020192018
 (in millions)
U.S. federal taxes:   
Current$5 $(191)$520 
Deferred4 — 51 
Non-U.S. taxes:   
Current84 290 95 
Deferred24 (267)(22)
State taxes, net of federal benefit:   
Current5 4 1 
Deferred1 12 (15)
Total provision (benefit)$123 $(152)$630 
78
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)




The differences between the U.S. federal statutory income tax rate and our effective tax rate are:

 Years Ended October 31,
 202020192018
 (in millions)
Profit before tax times statutory rate$177 $193 $221 
Non-U.S. income taxed at different rates(36)(8)(93)
Change in unrecognized tax benefits(9)(13)(17)
Impact of the Tax Act— — 552 
Extension of the tax incentive in Singapore— (299)— 
Excess tax benefits from stock-based compensation(18)(10)(18)
Other, net9 (15)(15)
Provision (benefit) for income taxes$123 $(152)$630 
Effective tax rate14.6 %(16.5)%66.6 %

For 2020, the company's income tax expense was $123 million with an effective tax rate of 14.6 percent. For the year ended October 31, 2020, our effective tax rate and the resulting provision for income taxes were impacted by foreign income taxed at lower rates.

For 2019, the company's income tax benefit was $152 million with an effective tax rate of (16.5) percent. For the year ended October 31, 2019, our effective tax rate and the resulting provision for income taxes were significantly impacted by the discrete benefit of $299 million related to the extension of the company’s tax incentive in Singapore.

As part of the business integration of some of our prior acquisitions, we undertook corporate restructurings in the fourth quarter of fiscal year 2019 that involved on-shoring certain intangible properties held by our foreign subsidiaries to the United States. These restructurings resulted in a cash tax liability of $231 million. These taxes generate tax attributes that will offset our transition tax liability which is included in other long-term liabilities in our consolidated balance sheet. 

For 2018, the company's income tax expense was $630 million with an effective tax rate of 66.6 percent. For the year ended October 31, 2018, our effective tax rate and the resulting provision for income taxes were significantly impacted by the discrete charge of $552 million related to the enactment of the U.S. Tax Cuts and Jobs Act (the “Tax Act”) consisting of (1) an expense of $499 million of U.S. transition tax and correlative items on deemed repatriated earnings of non-U.S. subsidiaries and (2) an expense of $53 million associated with the impact on deferred taxes resulting from the decreased U.S. corporate tax rate.

The company has negotiated tax holidays in several different jurisdictions, most significantly in Singapore. The tax holidays provide lower rates of taxation on certain classes of income and require various thresholds of investments and employment or specific types of income in those jurisdictions. In December 2018, the tax holiday in Singapore was renegotiated and extended through 2027. As a result of the incentives, the impact of the tax holidays decreased income taxes by $71 million, $368 million, and $87 million in 2020, 2019, and 2018, respectively. The benefit of the tax holidays on net income per share (diluted) was approximately $0.23, $1.16, and $0.27 in 2020, 2019 and 2018, respectively. Of the $1.16 benefit of the tax incentives on net income per share (diluted) in 2019, $0.94 of the benefit relates to one-time items from the extension of the company’s tax incentive in Singapore.


79
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


The significant components of deferred tax assets and deferred tax liabilities included on the consolidated balance sheet are:

 Years Ended October 31,
 20202019
 (in millions)
Deferred Tax Assets
Intangibles$153 $131 
Pension benefits and retiree medical benefits65 71 
Employee benefits, other than retirement31 34 
Net operating loss, capital loss, and credit carryforwards182 195 
Share-based compensation27 32 
Deferred revenue22 38 
Lease obligations35 — 
Other41 35 
Deferred tax assets$556 $536 
Tax valuation allowance(132)(134)
Deferred tax assets, net of valuation allowance$424 $402 
Deferred Tax Liabilities
Property, plant and equipment$(19)$(16)
Right-of-use asset(35)— 
Other(14)(7)
Deferred tax liabilities$(68)$(23)
Net deferred tax assets (liabilities)$356 $379 

Valuation allowances require an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction by jurisdiction basis. As of October 31, 2020, we continued to maintain a valuation allowance of $132 million until sufficient positive evidence exists to support reversal. The valuation allowance is primarily related to deferred tax assets for the states of California and Colorado, along with the net operating losses in the Netherlands and capital losses in the U.S. and Australia.

At October 31, 2020, we had federal, state and foreign net operating loss carryforwards of approximately $11 million, $530 million and $411 million, respectively. The federal and state net operating loss carryforwards are subject to various limitations under Section 382 of the Internal Revenue Code and applicable state tax laws. If not utilized, the federal and state net operating loss carryforwards will begin to expire in 2021. If not utilized, $123 million of the foreign net operating loss carryforwards will begin to expire in 2021. The remaining $288 million of the foreign net operating losses carry forward indefinitely. At October 31, 2020, we had federal and foreign capital loss carryforwards of $48 million and $118 million, respectively. If not utilized, the federal capital loss carryforwards will expire in 2022. The foreign capital losses carry forward indefinitely. At October 31, 2020, we had state tax credit carryforwards of approximately $83 million. The state tax credits carry forward indefinitely.

The breakdown between long-term deferred tax assets and deferred tax liabilities was as follows:

 October 31,
 20202019
 (in millions)
Long-term deferred tax assets (included within other assets)$380 $410 
Long-term deferred tax liabilities (included within other long-term liabilities)(24)(31)
Total$356 $379 

80
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)



The breakdown between current and long-term income tax assets and liabilities, excluding deferred tax assets and liabilities, was as follows:
October 31,
20202019
(in millions)
Current income tax assets (included within other current assets)$89 $68 
Long-term income tax assets (included within other assets)6 4 
Current income tax liabilities (included within other accrued liabilities)(63)(292)
Long-term income tax liabilities (included within other long-term liabilities)(323)(328)
Total$(291)$(548)

Uncertain Tax Positions

The aggregate changes in the balances of our gross unrecognized tax benefits including all federal, state and foreign tax jurisdictions are as follows:

202020192018
 (in millions)
Balance, beginning of year$206 $214 $224 
Additions for tax positions related to the current year6 7 27 
Additions for tax positions from prior years— 12 2 
Reductions for tax positions from prior years— (2)(13)
Statute of limitations expirations(17)(25)(26)
Balance, end of year$195 $206 $214 

As of October 31, 2020, we had $240 million of unrecognized tax benefits, including interest and penalties of which $215 million, if recognized, would affect our effective tax rate. However, approximately $25 million of the unrecognized tax benefits were related to state income tax positions that, if recognized, would be in the form of a deferred tax asset that would likely not affect our effective tax rate due to a valuation allowance.

We recognized tax expense of $8 million, $9 million and $11 million for interest and penalties related to unrecognized tax benefits in 2020, 2019 and 2018, respectively. Interest and penalties accrued as of October 31, 2020 and 2019 were $45 million and $36 million, respectively.

In the U.S., tax years remain open back to the year 2017 for federal income tax purposes and for significant states. In other major jurisdictions where the company conducts business, the tax years generally remain open back to the year 2009.

With these jurisdictions and the U.S., it is reasonably possible that there could be significant changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitation or a tax audit settlement which will be partially offset by an anticipated tax liability related to unremitted foreign earnings, where applicable. Given the number of years and numerous matters that remain subject to examination in various tax jurisdictions, management is unable to estimate the range of possible changes to the balance of our unrecognized tax benefits.

81
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


7.     NET INCOME PER SHARE

The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented below.
 Years Ended October 31,
 202020192018
 (in millions)
Numerator:   
Net income$719 $1,071 $316 
Denominators:   
Basic weighted average shares309 314 321 
Potential common shares — stock options and other employee stock plans3 4 4 
Diluted weighted average shares312 318 325 

The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense collectively are assumed proceeds to be used to repurchase hypothetical shares. An increase in the fair market value of the company's common stock can result in a greater dilutive effect from potentially dilutive awards.

We exclude stock options with exercise prices greater than the average market price of our common stock from the calculation of diluted earnings per share because their effect would be anti-dilutive. In addition, we exclude from the calculation of diluted earnings per share, stock options, ESPP, LTPP and restricted stock awards whose combined exercise price and unamortized fair value collectively were greater than the average market price of our common stock because their effect would also be anti-dilutive.

In 2020, 2019 and 2018, we issued share-based awards of approximately 2 million each year.  For the years ended 2020, 2019 and 2018, the impacts of the anti-dilutive potential common shares that were excluded from the calculation of diluted earnings per share were not material.

8.     INVENTORY

Inventory as of October 31, 2020 and 2019 consisted of the following:
 October 31,
 20202019
 (in millions)
Finished goods$417 $416 
Purchased parts and fabricated assemblies303 263 
Inventory$720 $679 

Inventory-related excess and obsolescence charges of $28 million were recorded in cost of products in 2020, $19 million in 2019 and $26 million in 2018. We record excess and obsolete inventory charges for both inventory on our site as well as inventory at our contract manufacturers and suppliers where we have non-cancelable purchase commitments.

82
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


9.     PROPERTY, PLANT AND EQUIPMENT, NET

Property, plant and equipment as of October 31, 2020 and 2019, consisted of the following:
 October 31,
 20202019
 (in millions)
Land$58 $57 
Buildings and leasehold improvements1,055 1,012 
Machinery and equipment579 546 
Software182 160 
Total property, plant and equipment1,874 1,775 
Accumulated depreciation and amortization(1,029)(925)
Property, plant and equipment, net$845 $850 

In 2020 we recorded $6 million in asset impairments related to the shutdown of our sequencer development program. There were no asset impairments in 2019 and less than $1 million in asset impairments in 2018. Depreciation expenses were $119 million in 2020, $111 million in 2019 and $102 million in 2018. In 2020 and 2019 we retired approximately $29 million and $23 million, respectively, of fully depreciated assets that were no longer in use.

10.     LEASES

As a lessee, we have various non-cancelable operating lease agreements for office space, warehouses, distribution centers, research and development facilities, manufacturing and production locations as well as vehicles, personal computers and other equipment. Our real estate leases have remaining lease terms of one to thirty years, which represent the non-cancelable periods of the leases and include extension options that we determined are reasonably certain to be exercised. We exclude options that are not reasonably certain to be exercised from our lease terms, ranging from six months to twenty years. Our lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms. We often receive incentives from our landlords, such as rent abatement periods, which effectively reduce the total lease payments owed for these leases. Vehicle, personal computer and other equipment operating leases have terms between three and five years.

Prior to the adoption of the new lease accounting standard, future minimum lease payments as of October 31, 2019 under non-cancelable leases with initial terms exceeding twelve months were as follows:

Operating Leases
(in millions)
2020$52 
2021$41 
2022$29 
2023$21 
2024$14 
Thereafter$56 

The components of lease cost for operating leases were as follows:
Year Ended October 31, 2020
(in millions)
Operating lease cost$60 
Short-term lease cost1 
Variable lease cost (a)
14 
Sublease income(14)
Total lease cost$61 
(a) Variable lease cost includes cancelable leases, non-fixed maintenance costs and non-recoverable transaction taxes.

Total rent expense was $75 million in 2019 and $64 million in 2018.

Supplemental cash flow information related to leases was as follows:
83
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Year Ended October 31, 2020
(in millions)
Cash paid for amounts included in the amounts included in the measurement of lease liabilities:
Operating cash flow from operating leases$59 
Non-cash right of use assets obtained in exchange for operating lease obligations$37 

Supplemental balance sheet information related to leases was as follows:
Financial Statement Line ItemOctober 31, 2020
(in millions, except lease term and discount rate)
Assets:
Operating lease:
Right of use assetOther assets$175 
Liabilities:
Current
Operating lease liabilitiesOther accrued liabilities$51 
Long-term
Operating lease liabilitiesOther long-term liabilities$127 
Weighted average remaining lease term (in years)
Operating leases7.9 years
Weighted average discount rate
Operating leases2.1 %

Future minimum rents payable as of October 31, 2020 under non-cancelable leases with initial terms exceeding one year reconcile to lease liabilities included in the consolidated balance sheet as follows:
Operating Leases
(in millions)
2021$54 
202241 
202328 
202416 
20259 
Thereafter49 
Total undiscounted future minimum lease payments$197 
Less: amount of lease payments representing interest(19)
Present value of future minimum lease payments$178 
Less: current liabilities(51)
Long-term lease liabilities$127 

As of October 31, 2020, we had no additional significant operating or finance leases that had not yet commenced.

As a lessor, we have contracts for equipment leased to customers in connection with our diagnostics business which include both operating-type lease and sales-type lease arrangements. We account for the non-lease component under the revenue recognition ASC 606 guidance and the lease component under the leasing ASC 842 guidance. Equipment lease revenue for operating lease agreements is recognized as visualization kits and reagents are shipped over the life of the lease, and the cost of customer leased equipment is recorded within property, plant and equipment, net in the consolidated balance sheet and depreciated over the equipment’s estimated useful life. For an arrangement that has been classified as a sales-type lease, revenue is recognized when the transfer of control of the underlying leased asset has occurred and the net investment lease recorded which is calculated at the present value of the remaining lease payments due from the lessee.

84
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Revenue allocated to the lease income for both finance/sales-type lease and operating lease rental arrangements represents less than one percent of total net revenue in the year ended October 31, 2020.

As of October 31, 2020, the original cost and net book value of operating leased assets was $43 million and $12 million, respectively. As of October 31, 2020, lease receivables related to sales-type leases were $44 million. As of October 31, 2019, the original cost and net book value of operating leased assets was $49 million and $17 million, respectively. As of October 31, 2019, lease receivables related to sales-type leases were $37 million.

11.   GOODWILL AND OTHER INTANGIBLE ASSETS

The following table presents goodwill balances and the movements for each of our reportable segments during the years ended October 31, 2019 and 2020:
Life Sciences and Applied MarketsDiagnostics and GenomicsAgilent CrossLabTotal
 (in millions)
Goodwill as of October 31, 2018$803 $1,607 $563 $2,973 
Foreign currency translation impact(1)(2)(2)(5)
Goodwill arising from acquisitions636 (11)— 625 
Goodwill as of October 31, 2019$1,438 $1,594 $561 $3,593 
Foreign currency translation impact3 5 1 9 
Goodwill as of October 31, 2020$1,441 $1,599 $562 $3,602 

As of September 30, 2020, our annual impairment test date, we assessed goodwill for triggering events and circumstances, including impacts due to COVID-19, and determined no impairment of goodwill was indicated for our reporting units.

The component parts of other intangible assets at October 31, 2019 and 2020 are shown in the table below:
 Other Intangible Assets
 Gross
Carrying
Amount		Accumulated
Amortization		Net Book
Value
 (in millions)
As of October 31, 2019:   
Purchased technology$1,413 $763 $650 
Backlog5 5 — 
Trademark/Tradename196 102 94 
Customer relationships329 87 242 
Third-party technology and licenses28 22 6 
Total amortizable intangible assets$1,971 $979 $992 
In-Process R&D115 — 115 
Total$2,086 $979 $1,107 
As of October 31, 2020:   
Purchased technology$1,429 $863 $566 
Trademark/Tradename196 117 79 
Customer relationships330 158 172 
Third-party technology and licenses11 7 4 
Total amortizable intangible assets$1,966 $1,145 $821 
In-Process R&D10 — 10 
Total$1,976 $1,145 $831 


During fiscal year 2020, we recorded no additions to goodwill or to intangible assets. During the year ended October 31, 2020 we moved $15 million of in-process research and development intangible assets to purchased technology on the completion of three projects.

85
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


During fiscal year 2019, we recorded additions to goodwill of $636 million and to other intangible assets of $744 million related to the acquisition of ACEA Biosciences and BioTek. In the second quarter of fiscal year 2019, we recorded a measurement period adjustment to goodwill of $11 million for deferred tax assets related to pre-acquisition net operating losses of Advanced Analytical Technologies, Inc. The increase to other intangible assets due to foreign currency translation was not material in 2019.

In general, for United States federal tax purposes, goodwill from asset purchases is amortizable; however, any goodwill created as part of a stock acquisition is not deductible.

During fiscal year 2020, we recorded an impairment of in-process research and development of $90 million in research and development expenses in the consolidated statement of operations which was related to the shutdown of our sequencer development program in our diagnostics and genomics segment. There were no impairments of indefinite-lived intangible assets during fiscal year 2019 and 2018. During fiscal years 2020 and 2019, there were no impairments of finite-lived intangible assets recorded. During 2018, we recorded an impairment of $21 million related to purchased intangible assets within the diagnostics and genomics segment that were deemed unrecoverable.

During 2020, we also wrote-off the gross carrying amount of $17 million and the related accumulated amortization of fully amortized intangible assets which were no longer being used.

Amortization expense of intangible assets was $186 million in 2020, $128 million in 2019, and $110 million in 2018.

Future amortization expense related to existing finite-lived purchased intangible assets associated with business combinations for the next five fiscal years and thereafter is estimated below:
Estimated future amortization expense:
(in millions)
2021$174 
2022$151 
2023$109 
2024$87 
2025$70 
Thereafter$230 


12.   INVESTMENTS

The following table summarizes the company's equity investments as of October 31, 2020 and 2019 (net book value):

 October 31,
 20202019
 (in millions)
Long-Term  
Equity investments - without readily determinable fair value$103 $47 
Equity investments - with readily determinable fair value25 25 
Trading securities30 30 
Total$158 $102 

Equity investments without readily determinable fair value (RDFV) consist of non-marketable equity securities issued by private companies. These investments are accounted for using the measurement alternative at cost adjusting for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer). The adjustments are included in net income in the period in which they occur. Equity investments with RDFV consist of shares we own in a special fund and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. Prior to fiscal year 2019, both equity investments without RDFV and with RDFV were accounted for using cost method of accounting, measured at historical cost less other-than-temporary impairment. Trading securities are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in earnings.

86
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Our investments without RDFV are subject to periodic impairment review. The impairment analysis requires significant judgment to identify events or circumstances that would likely have a significant adverse effect on the future value of the investment.

We recorded a net unrealized loss on our equity securities with RDFV of $1 million in 2020 and a net unrealized gain of $3 million in 2019. Net unrealized gains on our equity securities without RDFV were $27 million and $1 million in 2020 and 2019, respectively. Upon adoption of new accounting guidance relating to financial instruments beginning fiscal year 2019, the gains and losses on such securities are recognized in other income (expense) and therefore not applicable in prior periods. As of November 1, 2019, total impact of adoption of this accounting guidance to our consolidated balance sheet was an increase of $7 million to equity securities with RDFV (included within long-term investments) and a net increase of $5 million to beginning retained earnings.

Net unrealized gains on our trading securities portfolio were $2 million in 2020, $3 million in 2019 and $1 million in 2018.

13.   FAIR VALUE MEASUREMENTS

The authoritative guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market and assumptions that market participants would use when pricing the asset or liability.

Fair Value Hierarchy

The guidance establishes a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into three levels. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value:

Level 1 — applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2 — applies to assets or liabilities for which there are inputs other than quoted prices included within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less active markets; or other inputs that can be derived principally from, or corroborated by, observable market data.

Level 3 — applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

87
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2020 were as follows:

  Fair Value Measurement at October 31, 2020 Using
 October 31,
2020		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
 (in millions)
Assets:    
Short-term    
Cash equivalents (money market funds)$740 $740 $— $— 
Derivative instruments (foreign exchange contracts)2 — 2 — 
Long-term    
Trading securities30 30 — — 
Other investments25 — 25 — 
Total assets measured at fair value$797 $770 $27 $— 
Liabilities:    
Short-term    
Derivative instruments (foreign exchange contracts)$17 $— $17 $— 
Long-term    
Deferred compensation liability30 — 30 — 
Total liabilities measured at fair value$47 $— $47 $— 

Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2019 were as follows:

  Fair Value Measurement
at October 31, 2019 Using
 October 31,
2019		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
 (in millions)
Assets:    
Short-term    
Cash equivalents (money market funds)$784 $784 $— $— 
Derivative instruments (foreign exchange contracts)12 — 12 — 
Long-term    
Trading securities30 30 — — 
Other investments25 — 25 — 
Total assets measured at fair value$851 $814 $37 $— 
Liabilities:   
Short-term    
Derivative instruments (foreign exchange contracts)$6 $— $6 $— 
Long-term    
Deferred compensation liability30 — 30 — 
Total liabilities measured at fair value$36 $— $36 $— 

Our money market funds and trading securities are generally valued using quoted market prices and therefore are classified within level 1 of the fair value hierarchy. Our derivative financial instruments are classified within level 2, as there is not an active market for each hedge contract, but the inputs used to calculate the value of the instruments are tied to active markets. Our deferred compensation liability is classified as level 2 because, although the values are not directly based on
88
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


quoted market prices, the inputs used in the calculations are observable. Other investments represent shares we own in a special fund that targets underlying investments of approximately 40 percent in debt securities and 60 percent in equity securities. It has been classified as level 2 because, although the shares of the fund are not traded on any active stock exchange, each of the individual underlying securities are or can be derived from and hence we have a readily determinable value for the underlying securities, from which we are able to determine the fair market value for the special fund itself.

Trading securities, which are comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Certain derivative instruments are reported at fair value, with unrealized gains and losses, net of tax, included in accumulated other comprehensive income (loss) within stockholders' equity. Realized gains and losses from the sale of these instruments are recorded in net income.

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

Long-Lived Assets

For assets measured at fair value on a non-recurring basis, the following table summarizes the impairments included in net income for the years ended October 31, 2020, 2019 and 2018:

 Years Ended
October 31,
 202020192018
 (in millions)
Long-lived assets held and used$98 $— $21 
Long-lived assets held for sale$— $— $— 

For the year ended October 31, 2020, long-lived assets held and used, including indefinite lived in-process research and development intangible assets, with a carrying amount of $98 million were written down to their fair value of zero, resulting in an impairment charge of $98 million related to the shutdown of our sequencer development program and other assets in our diagnostics and genomics segment. There were no impairments of long-lived assets held and used in 2019. For 2018, long lived assets held and used with a carrying amount of $21 million were written down to their fair value of zero, resulting in an impairment charge of $21 million, which relates to purchased intangible assets within the diagnostics and genomics segment that were deemed unrecoverable and were included in net income.

There were no impairments of long-lived assets held for sale in 2020, 2019 and 2018.

Fair values for the impaired long-lived assets during 2020 and 2018 were measured using level 3 inputs. To determine the fair value of long-lived assets in 2020 and 2018, we used the income approach based on projected discounted cash flows expected to be generated by the long-lived assets over the remaining useful life.

For the year ended October 31, 2020 and 2019, there were no impairments in non-marketable securities without readily determinable fair value. For the year ended October 31, 2020 and 2019, a net unrealized gain of $27 million and $1 million, respectively, was included in net income as an adjustment to the carrying value of non-marketable equity securities without readily determinable fair value based on an observable market transaction. As of October 31, 2020 and 2019, the carrying amount of non-marketable equity securities without readily determinable fair values was $103 million and $47 million, respectively.

Fair values for the non-marketable securities included in long-term investments on the consolidated balance sheet were measured using Level 3 inputs because they are primarily equity stock issued by private companies without quoted market prices. To estimate the fair value of our non-marketable securities, we use the measurement alternative to record these investments at cost and adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) as and when they occur.

89
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


14.   DERIVATIVES

We are exposed to foreign currency exchange rate fluctuations and interest rate changes in the normal course of our business. As part of our risk management strategy, we use derivative instruments, primarily forward contracts and purchased options to hedge economic and/or accounting exposures resulting from changes in foreign currency exchange rates.

Cash Flow Hedges

We enter into foreign exchange contracts to hedge our forecasted operational cash flow exposures resulting from changes in foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities between one and twelve months. These derivative instruments are designated and qualify as cash flow hedges under the criteria prescribed in the authoritative guidance and are assessed for effectiveness against the underlying exposure every reporting period. For open contracts as of October 31, 2020, changes in the time value of the foreign exchange contract are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the foreign exchange contract. The changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss).  Amounts associated with cash flow hedges are reclassified to cost of sales in the consolidated statement of operations when the forecasted transaction occurs. If it becomes probable that the forecasted transaction will not occur, the hedge relationship will be de-designated and amounts accumulated in other comprehensive income (loss) will be reclassified to other income (expense), net in the current period. Changes in the fair value of the ineffective portion of derivative instruments are recognized in other income (expense), net in the consolidated statement of operations in the current period. We record the premium paid (time value) of an option on the date of purchase as an asset. For options designated as cash flow hedges, changes in the time value are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the option contract. For the years ended October 31, 2020, 2019 and 2018, ineffectiveness and gains and losses recognized in other income (expense), net due to de-designation of cash flow hedge contracts were not significant.

In July 2012, Agilent executed treasury lock agreements for $400 million in connection with future interest payments to be made on our 2022 senior notes issued on September 13, 2012. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 10, 2012, and we recognized a deferred gain in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2022 senior notes. The remaining gain to be amortized related to the treasury lock agreements at October 31, 2020 was less than $1 million.

In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. These derivative instruments were designated and qualified as cash flow hedges under the criteria prescribed in the authoritative guidance. The swap arrangements were terminated on September 15, 2016 with a payment of $10 million, and we recognized this as a deferred loss in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at October 31, 2020 was $6 million.

In August 2019, Agilent executed treasury lock agreements for $250 million in connection with future interest payments to be made on our 2029 senior notes issued on September 16, 2019. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 6, 2019 and we recognized a deferred loss of $6 million in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2029 senior notes. The remaining loss to be amortized related to the treasury lock agreements at October 31, 2020 was $5 million.

Net Investment Hedges

Starting in 2020, we enter into foreign exchange contracts to hedge net investments in foreign operations to mitigate the risk of adverse movements in exchange rates. These foreign exchange contracts are carried at fair value and are designated and qualify as net investment hedges under the criteria prescribed in the authoritative guidance. Changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss) and are assessed for effectiveness against the underlying exposure every reporting period. If the company’s net investment changes during the year, the hedge relationship will be assessed and de-designated if the hedge notional amount is outside of prescribed tolerance with a gain/loss reclassified from other comprehensive income (loss) to other income (expense) in the current period.

As of October 31, 2020, we have 3 open forward contracts to sell euros to buy USD maturing in the first quarter of fiscal year 2021, and these are designated as a net investment hedge of the U.S. parent's interest in foreign subsidiaries denominated in euro functional currency. In the year ended October 31, 2020, the change in fair value of the net investment hedge resulted in
90
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


a net loss of $5 million recognized in accumulated other comprehensive income. For the year ended October 31, 2020, ineffectiveness and the resultant effect of any gains or losses recognized in other income (expense) due to de-designation of the hedge contracts were not significant.

Other Hedges

Additionally, we enter into foreign exchange contracts to hedge monetary assets and liabilities that are denominated in currencies other than the functional currency of our subsidiaries. These foreign exchange contracts are carried at fair value and do not qualify for hedge accounting treatment and are not designated as hedging instruments. Changes in value of the derivative instruments are recognized in other income (expense), net in the consolidated statement of operations, in the current period, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.

Our use of derivative instruments exposes us to credit risk to the extent that the counterparties may be unable to meet the terms of the agreement. We do, however, seek to mitigate such risks by limiting our counterparties to major financial institutions which are selected based on their credit ratings and other factors. We have established policies and procedures for mitigating credit risk that include establishing counterparty credit limits, monitoring credit exposures, and continually assessing the creditworthiness of counterparties.

A number of our derivative agreements contain threshold limits to the net liability position with counterparties and are dependent on our corporate credit rating determined by the major credit rating agencies. The counterparties to the derivative instruments may request collateralization, in accordance with derivative agreements, on derivative instruments in net liability positions.

The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position as of October 31, 2020, was $16 million. The credit-risk-related contingent features underlying these agreements had not been triggered as of October 31, 2020.

There were 270 foreign exchange forward contracts open as of October 31, 2020 and designated as cash flow hedges. There were 183 foreign exchange forward contracts open as of October 31, 2020 not designated as hedging instruments. There were 3 foreign exchange forward contracts open as of October 31, 2020 and designated as a net investment hedge. The aggregated notional amounts by currency and designation as of October 31, 2020 were as follows:
 Derivatives Designated as
Cash Flow Hedges
Derivatives Designated as
Net Investment Hedges		Derivatives
Not
Designated
as Hedging
Instruments
 Forward
Contracts USD		Forward
Contracts USD		Forward
Contracts USD
CurrencyBuy/(Sell)Buy/(Sell)Buy/(Sell)
 (in millions)
Euro$(59)$(94)$17 
British Pound(41)— 7 
Canadian Dollar(33)— (7)
Japanese Yen(83)— (39)
Korean Won(58)— (32)
Singapore Dollar12 — 23 
Chinese Yuan Renminbi(74)— (66)
Swedish Krona— — (10)
Taiwan Dollar— — (14)
India Rupee— — (15)
Other4 — 2 
$(332)$(94)$(134)
91
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)



Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of October 31, 2020 and 2019 were as follows:

Fair Values of Derivative Instruments
Asset DerivativesLiability Derivatives
 Fair Value Fair Value
Balance Sheet LocationOctober 31,
2020		October 31,
2019		Balance Sheet LocationOctober 31,
2020		October 31,
2019
(in millions)
Derivatives designated as hedging instruments:     
Cash flow hedges     
Foreign exchange contracts     
Other current assets$— $3 Other accrued liabilities$12 $2 
Derivatives not designated as hedging instruments:     
Foreign exchange contracts     
Other current assets$2 $9 Other accrued liabilities$5 $4 
Total derivatives$2 $12  $17 $6 

The effects of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows:

Years Ended October 31,
202020192018
 (in millions)
Derivatives designated as hedging instruments:   
Cash flow hedges   
Foreign exchange contracts:
Loss on interest rate swaps recognized in other comprehensive income (loss)$— $(6)$— 
Loss reclassified from accumulated other comprehensive income (loss) into interest expense$(1)$(1)$(1)
Gain (loss) recognized in accumulated other comprehensive income (loss)$(12)$— $7 
Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales$(1)$9 $(3)
Gain (loss) on time value of forward contracts recorded in cost of sales$2 $2 $— 
Net investment hedges
Foreign exchange contracts:
Loss recognized in accumulated other comprehensive income (loss)$(5)$— $— 
Derivatives not designated as hedging instruments:   
Gain (loss) recognized in other income (expense), net $(1)$2 $(2)

At October 31, 2020 the estimated amount of existing net loss that is expected to be reclassified from accumulated other comprehensive income (loss) to cost of sales within the next twelve months is $7 million.

92
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


15.   RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS

General.  Substantially all of our employees are covered under various defined benefit and/or defined contribution retirement plans. Additionally, we sponsor post-retirement health care benefits for our eligible U.S. employees.

Agilent provides defined benefits to U.S. employees who meet eligibility criteria under the Agilent Technologies, Inc. Retirement Plan (the "RP").

For eligible service through October 31, 1993, the benefit payable under the Agilent Retirement Plan is reduced by any amounts due to the eligible employee under the Agilent defined contribution Deferred Profit-Sharing Plan (the "DPSP"), which was closed to new participants as of November 1993.

As of October 31, 2020 and 2019, the fair value of plan assets of the DPSP was $123 million and $132 million, respectively. Note that the projected benefit obligation for the DPSP equals the fair value of plan assets.

Effective November 1, 2014, Agilent’s U.S. defined benefit retirement plan was closed to new entrants including new employees, new transfers to the U.S. payroll and rehires. As of April 30, 2016, benefits under the RP were frozen. Any pension benefit earned in the U.S. Plans through April 30, 2016 remained fully vested, and there are no additional benefit accruals after April 30, 2016.

Agilent also maintains a Supplemental Benefits Retirement Plan ("SBRP") in the U.S., which is a supplemental unfunded non-qualified defined benefit plan to provide benefits that would be provided under the RP but for limitations imposed by the Internal Revenue Code. The RP and the SBRP comprise the "U.S. Plans" in the tables below.

Eligible employees outside the U.S. generally receive retirement benefits under various retirement plans based upon factors such as years of service and/or employee compensation levels. Eligibility is generally determined in accordance with local statutory requirements.

Post-Retirement Medical Benefit Plans.  In addition to receiving retirement benefits, Agilent U.S. employees who meet eligibility requirements as of their termination date may participate in the Agilent Technologies, Inc. Health Plan for Retirees.
–Eligible retirees who were less than age 50 as of January 1, 2005 and who retire after age 55 with 15 or more years of service are eligible for a fixed amount which can be utilized to pay for either sponsored plans and/or individual Medicare plans.
–Effective January 1, 2012, employees who were at least age 50 as of January 1, 2005 and who retire after age 55 with 15 or more years of service are eligible for fixed dollar subsidies and stipends. Grandfathered retirees receive a fixed monthly subsidy toward pre-65 premium costs (subsidy capped at 2011 levels) and a fixed monthly stipend post-65. The subsidy amounts will not increase.
–Any new employee hired on or after November 1, 2014, will not be eligible to participate in the retiree medical plans upon retiring.
–As of April 30, 2016, benefits under this plan were changed for Active employees who have not met the eligibility requirement - 55 years old with at least 15 years of Agilent service, as of April 30, 2016 - for the Retiree Medical Account (RMA) under the U.S. Post Retirement Benefit Plan. These employees will only be eligible for 50 percent of the current RMA reimbursement amount upon retirement.

401(k) Defined Contribution Plan.  Eligible Agilent U.S. employees may participate in the Agilent Technologies, Inc. 401(k) Plan. We match contributions to employees up to a maximum of 6 percent of an employee's annual eligible compensation. Effective May 1, 2016 until April 30, 2022, we will provide an additional transitional company contribution for certain eligible employees equal to 3 percent, 4 percent or 5 percent of an employee's annual eligible compensation due to the RP benefits being frozen. The maximum contribution to the 401(k) Plan is 50 percent of an employee's annual eligible compensation, subject to regulatory limitations. The 401(k) Plan employer expense included in income from operations was $41 million in 2020, $39 million in 2019 and $37 million in 2018.

93
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Components of Net periodic cost.  The service cost component is recorded in cost of sales and operating expenses in the consolidated statement of operations. All other cost components are recorded in other income (expense), net in the consolidated statement of operations. The company uses alternate methods of amortization as allowed by the authoritative guidance which amortizes the actuarial gains and losses on a consistent basis for the years presented. For U.S. Plans, gains and losses are amortized over the average future lifetime of participants using the corridor method. For most Non-U.S. Plans and U.S. Post-Retirement Benefit Plans, gains and losses are amortized using a separate layer for each year's gains and losses.

For the years ended October 31, 2020, 2019 and 2018, components of net periodic benefit cost and other amounts recognized in other comprehensive income were comprised of:
 PensionsU.S. Post-Retirement Benefit Plans
 U.S. PlansNon-U.S. Plans
 202020192018202020192018202020192018
 (in millions)
Net periodic benefit cost (benefit)         
Service cost — benefits earned during the period$— $— $— $24 $20 $20 $1 $— $1 
Interest cost on benefit obligation15 18 16 8 14 13 3 4 3 
Expected return on plan assets(28)(27)(28)(47)(43)(46)(7)(7)(7)
Amortization of net actuarial loss3 1 1 49 34 29 4 4 8 
Amortization of prior service benefit— — — — — — (7)(8)(8)
Total periodic benefit cost (benefit)$(10)$(8)$(11)$34 $25 $16 $(6)$(7)$(3)
Settlement (gain) loss$4 $— $— $— $— $(5)$— $— $— 
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss         
Net actuarial (gain) loss$26 $51 $2 $20 $104 $49 $5 $5 $(2)
Amortization of net actuarial loss(3)(1)(1)(49)(34)(29)(4)(4)(8)
Amortization of prior service benefit— — — — — — 7 8 8 
Loss due to settlement(4)— — — — — — — — 
Foreign currency— — — 10 (3)1 — — — 
Total recognized in other comprehensive (income) loss$19 $50 $1 $(19)$67 $21 $8 $9 $(2)
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss$13 $42 $(10)$15 $92 $32 $2 $2 $(5)


94
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)



Funded Status.    As of October 31, 2020 and 2019, the funded status of the defined benefit and post-retirement benefit plans was:

 U.S. Defined
Benefit Plans		Non-U.S. Defined
Benefit Plans		U.S.
Post-Retirement
Benefit Plans
 202020192020201920202019
 (in millions)
Change in fair value of plan assets:      
Fair value — beginning of year$432 $401 $911 $825 $95 $90 
Actual return on plan assets30 50 (2)85 6 11 
Employer contributions— — 32 21 — — 
Participants' contributions— — 1 1 — — 
Benefits paid(8)(19)(31)(29)(8)(6)
Settlements(15)— — — — — 
Currency impact— — 34 8 — — 
Fair value — end of year$439 $432 $945 $911 $93 $95 
Change in benefit obligation:      
Benefit obligation — beginning of year$491 $420 $1,067 $913 $94 $87 
Service cost— — 24 20 1 — 
Interest cost15 18 8 14 3 4 
Participants' contributions— — 1 1 — — 
Actuarial (gain) loss28 74 (19)143 4 9 
Benefits paid(9)(21)(31)(29)(8)(6)
Settlements(15)— — — — — 
Currency impact— — 44 5 — — 
Benefit obligation — end of year$510 $491 $1,094 $1,067 $94 $94 
Overfunded (underfunded) status of PBO$(71)$(59)$(149)$(156)$(1)$1 
Amounts recognized in the consolidated balance sheet consist of:      
Other assets$— $— $123 $106 $— $1 
Employee compensation and benefits(1)(1)— — — — 
Retirement and post-retirement benefits(70)(58)(272)(262)(1)— 
Total net asset (liability)$(71)$(59)$(149)$(156)$(1)$1 
Amounts Recognized in Accumulated Other Comprehensive Income (Loss):
Actuarial (gains) losses$134 $115 $311 $330 $11 $10 
Prior service costs (benefits)— — — — (5)(12)
Total$134 $115 $311 $330 $6 $(2)

The amounts in accumulated other comprehensive income (loss) expected to be recognized by Agilent as components of net expense during 2021 are as follows:
U.S. Defined
Benefit Plans		Non-U.S. Defined
Benefit Plans		U.S. Post-Retirement
Benefit Plans
 (in millions)
Amortization of net prior service cost (benefit)$— $— $(1)
Amortization of actuarial net loss$4 $52 $4 

95
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)



Investment Policies and Strategies as of October 31, 2020 and 2019. In the U.S., target asset allocations for our retirement and post-retirement benefit plans are approximately 80 percent to equities and approximately 20 percent to fixed income investments. Our DPSP target asset allocation is approximately 60 percent to equities and approximately 40 percent to fixed income investments. Approximately 1 percent of the retirement and post-retirement plans consist of limited partnerships. The general investment objective for all our plan assets is to obtain the optimum rate of investment return on the total investment portfolio consistent with the assumption of a reasonable level of risk. Specific investment objectives for the plans' portfolios are to: maintain and enhance the purchasing power of the plans' assets; achieve investment returns consistent with the level of risk being taken; and earn performance rates of return in accordance with the benchmarks adopted for each asset class. Outside the U.S., our target asset allocation ranges from 24 percent to 60 percent to equities, from 38 percent to 65 percent to fixed income investments, and from zero to 25 percent to real estate, depending on the plan. All plans' assets are broadly diversified. Due to fluctuations in equity markets, our actual allocations of plan assets at October 31, 2020 and 2019 differ from the target allocation. Our policy is to bring the actual allocation in line with the target allocation.

Equity securities include exchange-traded common stock and preferred stock of companies from broadly diversified industries. Fixed income securities include a global portfolio of corporate bonds of companies from diversified industries, government securities, mortgage-backed securities, asset-backed securities, derivative instruments and other. Other investments include a group trust consisting primarily of private equity partnerships. Portions of the cash and cash equivalent, equity, and fixed income investments are held in commingled funds that are valued using Net Asset Value (“NAV”) as the practical expedient. In addition, some of the investments valued using NAV as the practical expedient may have limits on their redemption to weekly or monthly and/or may require prior written notice specified by each fund.

Fair Value. The measurement of the fair value of pension and post-retirement plan assets uses the valuation methodologies and the inputs as described in Note 13, "Fair Value Measurements".

Cash and Cash Equivalents - Cash and cash equivalents consist of short-term investment funds. The funds also invest in short-term domestic fixed income securities and other securities with debt-like characteristics emphasizing short-term maturities and quality. Some of our cash and cash equivalents are held in commingled funds. Other cash and cash equivalents are classified as Level 1 investments.

Equity - Some equity securities consisting of common and preferred stock that are not traded on an active market are valued at quoted prices reported by investment dealers based on the underlying terms of the security and comparison to similar securities traded on an active market; these are classified as Level 2 investments. Securities which have quoted prices in active markets are classified as Level 1 investments.

Fixed Income - Some of the fixed income securities are not actively traded and are valued at quoted prices based on the terms of the security and comparison to similar securities traded on an active market; these are classified as Level 2 investments. Securities which have quoted prices in active markets are classified as Level 1 investments.

Other Investments - Other investments also include partnership investments where, due to their private nature, pricing inputs are not readily observable. Asset valuations are developed by the general partners that manage the partnerships. These valuations are based on proprietary appraisals, application of public market multiples to private company cash flows, utilization of market transactions that provide valuation information for comparable companies and other methods. Holdings of limited partnerships are classified as Level 3.

Agilent has adopted the accounting guidance related to the presentation of certain investments using the NAV practical expedient. The accounting guidance exempts investments using this practical expedient from categorization within the fair value hierarchy.










96
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)



The following tables present the fair value of U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2020 and 2019.
  Fair Value Measurement
at October 31, 2020 Using
 October 31,
2020		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$1 $— $— $— $1 
Equity357 77 — — 280 
Fixed Income79 39 — — 40 
Other Investments2 — — 2 — 
Total assets measured at fair value$439 $116 $— $2 $321 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
  Fair Value Measurement
at October 31, 2019 Using
 October 31,
2019		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$1 $— $— $— $1 
Equity336 78 — — 258 
Fixed Income91 46 — — 45 
Other Investments4 — — 4 — 
Total assets measured at fair value$432 $124 $— $4 $304 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

For U.S. Defined Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2020 and 2019:
 Years Ended
October 31.
 20202019
Balance, beginning of year$4 $6 
Realized gains/(losses)(3)(1)
Unrealized gains/(losses)2 1 
Purchases, sales, issuances, and settlements(1)(2)
Transfers in (out)— — 
Balance, end of year$2 $4 












97
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)





The following tables present the fair value of U.S. Post-Retirement Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2020 and 2019.
  Fair Value Measurement
at October 31, 2020 Using
 October 31,
2020		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$4 $— $— $— $4 
Equity70 17 — — 53 
Fixed Income18 9 — — 9 
Other Investments1 — — 1 — 
Total assets measured at fair value$93 $26 $— $1 $66 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

  Fair Value Measurement
at October 31, 2019 Using
 October 31,
2019		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$3 $— $— $— $3 
Equity69 18 — — 51 
Fixed Income21 11 — — 10 
Other Investments2 — — 2 — 
Total assets measured at fair value$95 $29 $— $2 $64 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.


For U.S. Post-Retirement Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2020 and 2019:
 Years Ended
October 31,
 20202019
Balance, beginning of year$2 $4 
Realized gains/(losses)(1)(1)
Unrealized gains/(losses)1 — 
Purchases, sales, issuances, and settlements(1)(1)
Transfers in (out)— — 
Balance, end of year$1 $2 
98
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)




The following tables present the fair value of non-U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2020 and 2019:

  Fair Value Measurement
at October 31, 2020 Using
 October 31,
2020		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$7 $— $6 $— $1 
Equity504 315 48 — 141 
Fixed Income434 102 238 — 94 
Other Investments— — — — — 
Total assets measured at fair value$945 $417 $292 $— $236 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

  Fair Value Measurement
at October 31, 2019 Using
 October 31,
2019		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$1 $— $1 $— $— 
Equity512 318 61 — 133 
Fixed Income398 98 213 — 87 
Other Investments— — — — — 
Total assets measured at fair value$911 $416 $275 $— $220 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.




99
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


The table below presents the combined projected benefit obligation ("PBO"), accumulated benefit obligation ("ABO") and fair value of plan assets, grouping plans using comparisons of the PBO and ABO relative to the plan assets as of October 31, 2020 or 2019.
 20202019
 Benefit
Obligation		 Benefit
Obligation		 
 Fair Value of
Plan Assets		Fair Value of
Plan Assets
 PBOPBO
 (in millions)
U.S. defined benefit plans where PBO exceeds the fair value of plan assets $510 $439 $491 $432 
U.S. defined benefit plans where fair value of plan assets exceeds PBO — — — — 
Total$510 $439 $491 $432 
Non-U.S. defined benefit plans where PBO exceeds or is equal to the fair value of plan assets $697 $425 $752 $490 
Non-U.S. defined benefit plans where fair value of plan assets exceeds PBO 397 520 315 421 
Total$1,094 $945 $1,067 $911 
 ABO ABO 
U.S. defined benefit plans where ABO exceeds the fair value of plan assets$510 $439 $491 $432 
U.S. defined benefit plans where the fair value of plan assets exceeds ABO— — — — 
Total$510 $439 $491 $432 
Non-U.S. defined benefit plans where ABO exceeds or is equal to the fair value of plan assets $675 $425 $651 $418 
Non-U.S. defined benefit plans where fair value of plan assets exceeds ABO387 520 381 493 
Total$1,062 $945 $1,032 $911 

Contributions and Estimated Future Benefit Payments.  During fiscal year 2021, we expect to make no contributions to the U.S. defined benefit plans and the Post-Retirement Medical Plans. We expect to contribute $22 million to plans outside the U.S. The following table presents expected future benefit payments for the next 10 years:

U.S. Defined
Benefit Plans		Non-U.S. Defined
Benefit Plans		U.S. Post-Retirement
Benefit Plans
 (in millions)
2021$33 $33 $8 
2022$31 $34 $8 
2023$33 $36 $7 
2024$34 $36 $7 
2025$33 $37 $7 
2026 - 2030$152 $192 $35 

Assumptions.  The assumptions used to determine the benefit obligations and expense for our defined benefit and post-retirement benefit plans are presented in the tables below. The expected long-term return on assets below represents an estimate of long-term returns on investment portfolios consisting of a mixture of equities, fixed income and alternative investments in proportion to the asset allocations of each of our plans. We consider long-term rates of return, which are weighted based on the asset classes (both historical and forecasted) in which we expect our pension and post-retirement funds to be invested. Discount rates reflect the current rate at which pension and post-retirement obligations could be settled based on the measurement dates of the plans - October 31. The U.S. discount rates at October 31, 2020 and 2019, were determined based on the results of
100
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


matching expected plan benefit payments with cash flows from a hypothetically constructed bond portfolio. The non-U.S. rates were generally based on published rates for high-quality corporate bonds. The range of assumptions that were used for the non-U.S. defined benefit plans reflects the different economic environments within various countries.

Assumptions used to calculate the net periodic cost in each year were as follows:

 For years ended October 31,
 202020192018
U.S. defined benefit plans:   
Discount rate3.25%4.50%3.75%
Expected long-term return on assets7.00%7.00%7.00%
Non-U.S. defined benefit plans:   
Discount rate
0.22-1.81%
0.83-2.68%
0.67-2.52%
Average increase in compensation levels
2.25-3.00%
2.25-3.25%
2.00-3.25%
Expected long-term return on assets
4.00-5.75%
4.00-5.75%
4.00-6.00%
U.S. post-retirement benefits plans:   
Discount rate3.00%4.25%3.50%
Expected long-term return on assets7.00%7.00%7.00%
Current medical cost trend rate6.25%6.00%6.00%
Ultimate medical cost trend rate4.50%3.50%3.50%
Medical cost trend rate decreases to ultimate rate in year202920292029

Assumptions used to calculate the benefit obligation were as follows:

 As of the Years Ending October 31,
 20202019
U.S. defined benefit plans:  
Discount rate2.75%3.25%
Non-U.S. defined benefit plans:  
Discount rate
0.07-1.54%
0.22-1.81%
Average increase in compensation levels
2.00-3.00%
2.25-3.00%
U.S. post-retirement benefits plans:  
Discount rate2.50%3.00%
Current medical cost trend rate6.25%6.25%
Ultimate medical cost trend rate4.50%4.50%
Medical cost trend rate decreases to ultimate rate in year20292029

Health care trend rates do not have a significant effect on the total service and interest cost components or on the post-retirement benefit obligation amounts reported for the U.S. Post-Retirement Benefit Plan for the year ended October 31, 2020.

16.   GUARANTEES

Standard Warranty

We accrue for standard warranty costs based on historical trends in actual warranty charges over the past 12 months. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost over the period. The standard warranty accrual balances are held in other accrued and other long-term liabilities on our consolidated balance sheet. Our standard warranty terms typically extend to one year from the date of delivery, depending on the product.
101
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)



A summary of the standard warranty accrual activity is shown in the table below.

 October 31,
 20202019
 (in millions)
Standard warranty accrual, beginning balance$32 $35 
Accruals for warranties including change in estimates49 54 
Settlements made during the period(49)(57)
Standard warranty accrual, ending balance$32 $32 
Accruals for warranties due within one year$30 $32 
Accruals for warranties due after one year2 — 
Standard warranty accrual, ending balance$32 $32 

Bank Guarantees

Guarantees consist primarily of outstanding standby letters of credit and bank guarantees and were approximately $43 million and $40 million as of October 31, 2020 and 2019, respectively. A standby letter of credit is a guarantee of payment issued by a bank on behalf of us that is used as payment of last resort should we fail to fulfill a contractual commitment with a third party. A bank guarantee is a promise from a bank or other lending institution that if we default on a loan, the bank will cover the loss.

Indemnifications in Connection with Transactions

In connection with various divestitures, acquisitions, spin-offs and other transactions, we have agreed to indemnify certain parties, their affiliates and/or other related parties against certain damages and expenses that might occur in the future. These indemnifications may cover a variety of liabilities, including, but not limited to, employee, tax, environmental, intellectual property, litigation and other liabilities related to the business conducted prior to the date of the transaction. In our opinion, the fair value of these indemnification obligations was not material as of October 31, 2020.

Indemnifications to Officers and Directors

Our corporate bylaws require that we indemnify our officers and directors, as well as those who act as directors and officers of other entities at our request, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceedings arising out of their services to Agilent and such other entities, including service with respect to employee benefit plans. In addition, we have entered into separate indemnification agreements with each director and each board-appointed officer of Agilent which provide for indemnification of these directors and officers under similar circumstances and under additional circumstances. The indemnification obligations are more fully described in the bylaws and the indemnification agreements. We purchase standard insurance to cover claims or a portion of the claims made against our directors and officers. Since a maximum obligation is not explicitly stated in our bylaws or in our indemnification agreements and will depend on the facts and circumstances that arise out of any future claims, the overall maximum amount of the obligations cannot be reasonably estimated. Historically, we have not made payments related to these obligations, and the fair value for these indemnification obligations was not material as of October 31, 2020.

Other Indemnifications

As is customary in our industry and as provided for in local law in the U.S. and other jurisdictions, many of our standard contracts provide remedies to our customers and others with whom we enter into contracts, such as defense, settlement, or payment of judgment for intellectual property claims related to the use of our products. From time to time, we indemnify customers, as well as our suppliers, contractors, lessors, lessees, companies that purchase our businesses or assets and others with whom we enter into contracts, against combinations of loss, expense, or liability arising from various triggering events related to the sale and the use of our products and services, the use of their goods and services, the use of facilities and state of our owned facilities, the state of the assets and businesses that we sell and other matters covered by such contracts, usually up to a specified maximum amount. In addition, from time to time we also provide protection to these parties against claims related to
102
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


undiscovered liabilities, additional product liability or environmental obligations. In our experience, claims made under such indemnifications are rare and the associated estimated fair value of the liability was not material as of October 31, 2020.

In connection with the sale of several of our businesses, we have agreed to indemnify the buyers of such business, their respective affiliates and other related parties against certain damages that they might incur in the future. The continuing indemnifications primarily cover damages relating to liabilities of the businesses that Agilent retained and did not transfer to the buyers, as well as other specified items. In our opinion, the fair value of these indemnification obligations was not material as of October 31, 2020.

17.   COMMITMENTS AND CONTINGENCIES

Other Purchase Commitments.  Typically, we can cancel contracts with professional services suppliers without penalties. For those contracts that are not cancelable without penalties, there are termination fees and costs or commitments for continued spending that we are obligated to pay to a supplier under each contact's termination period before such contract can be cancelled. Our contractual obligations with these suppliers under "other purchase commitments" were approximately $85 million. Approximately $23 million of the penalties for the new contracts will reduce over the next 13 years.

Contingencies: We are involved in lawsuits, claims, investigations and proceedings, including, but not limited to, intellectual property, commercial, real estate, environmental and employment matters, which arise in the ordinary course of business. There are no matters pending that we currently believe are reasonably possible of having a material impact to our business, consolidated financial condition, results of operations or cash flows.

18.   SHORT-TERM DEBT

Credit Facilities

On March 13, 2019, we entered into a credit agreement with a group of financial institutions which provides for a $1 billion five-year unsecured credit facility that will expire on March 13, 2024. For the year ended October 31, 2020, we borrowed $798 million and repaid $913 million under the credit facility. As of October 31, 2020, the company had no borrowings outstanding under the credit facility. On August 7, 2019, we entered into an amendment to the credit agreement, which provides for a $500 million short-term loan facility that was used in full to complete the BioTek acquisition and which was repaid in full as of October 31, 2020. On October 21, 2019, we entered into a second amendment to the credit agreement, which refreshed the amount available for additional incremental term loan facilities under the credit agreement to permit additional incremental facilities of up to $500 million. We had no borrowings under the additional incremental facilities as of October 31, 2020. On April 17, 2020, we entered into a third amendment to the credit agreement which provides the company with the option to request the consent of the applicable class of lenders to extend the maturity date of revolving borrowings and swingline loans for an additional period of one year and of the 2019 incremental term loans for an additional period of up to 364 days. We were in compliance with the covenants for the credit facility during the year ended October 31, 2020.

Commercial Paper

In May 2020, we established a U.S. commercial paper program, under which the company may issue and sell unsecured, short-term promissory notes in the aggregate principal amount not to exceed $1.0 billion with up to 397-day maturities. At any point in time, the company intends to maintain available commitments under its revolving credit facility in an amount at least equal to the amount of the commercial paper notes outstanding. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The proceeds from issuances under the program may be used for general corporate purposes. As of October 31, 2020, borrowings outstanding under our U.S. commercial paper program had a weighted average annual interest rate of 0.17 percent and a weighted average remaining maturity of approximately five days. We had borrowings of $75 million outstanding under the U.S. commercial paper program as of October 31, 2020.

2020 Senior Notes

On July 13, 2010, the company issued an aggregate principal amount of $500 million in senior notes ("2020 senior notes"). The 2020 senior notes were issued at 99.54% of their principal amount. The notes were scheduled to mature on July 15, 2020, and bear interest at a fixed rate of 5.00% per annum.

On August 9, 2011, we terminated our interest rate swap contracts related to our 2020 senior notes that represented the notional amount of $500 million. The asset value, including interest receivable, upon termination for these contracts was
103
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


approximately $34 million. The gain was deferred and amortized to interest expense over the remaining life of the 2020 senior notes.

On September 17, 2019, we repaid the $500 million outstanding aggregate principal amount of our 2020 senior notes due July 15, 2020 that were called for redemption on August 16, 2019. The redemption price of approximately $512 million included a $12 million prepayment penalty. The redemption price was computed in accordance with the terms of the 2020 senior notes as the present value of the remaining scheduled payments of principal and unpaid interest related to the redemption.  The prepayment penalty plus amortization of the previously deferred interest swap gain of $4 million and amortization of previously deferred debt issuance costs and discount of $1 million were recorded in other income (expense), net in the consolidated statement of operations. We also paid accrued and unpaid interest of $4 million on the 2020 senior notes up to but not including the redemption date.
19.   LONG-TERM DEBT

Senior Notes

The following table summarizes the company's long-term senior notes:

 October 31, 2020October 31, 2019
 Amortized
Principal		Amortized
Principal
 (in millions)
2022 Senior Notes$400 $399 
2023 Senior Notes598 597 
2026 Senior Notes298 298 
2029 Senior Notes493 492 
2030 Senior Notes495 — 
Total$2,284 $1,786 


2022 Senior Notes

On September 13, 2012, the company issued an aggregate principal amount of $400 million in senior notes ("2022 senior notes"). The 2022 senior notes were issued at 99.80% of their principal amount. The notes will mature on October 1, 2022, and bear interest at a fixed rate of 3.20% per annum. The interest is payable semi-annually on April 1st and October 1st of each year and payments commenced on April 1, 2013.

In July 2012, Agilent executed treasury lock agreements for $400 million in connection with future interest payments to be made on our 2022 senior notes issued on September 13, 2012. The treasury lock contracts were terminated on September 10, 2012 and we recognized a deferred gain in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2022 senior notes. The remaining gain to be amortized related to the treasury lock agreements at October 31, 2020 was less than $1 million.

2023 Senior Notes

On June 21, 2013, the company issued aggregate principal amount of $600 million in senior notes ("2023 senior notes"). The 2023 senior notes were issued at 99.544% of their principal amount. The notes will mature on July 15, 2023 and bear interest at a fixed rate of 3.875% per annum. The interest is payable semi-annually on January 15th and July 15th of each year and payments commenced January 15, 2014.

2026 Senior Notes

On September 22, 2016, the company issued aggregate principal amount of $300 million in senior notes ("2026 senior notes"). The 2026 senior notes were issued at 99.624% of their principal amount. The notes will mature on September 22, 2026 and bear interest at a fixed rate of 3.05% per annum. The interest is payable semi-annually on March 22nd and September 22nd of each year and payments commenced March 22, 2017.

104
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. The swap arrangements were terminated on September 15, 2016 with a payment of $10 million, and we recognized this as a deferred loss in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at October 31, 2020 was $6 million.

2029 Senior Notes

On September 16, 2019, the company issued an aggregate principal amount of $500 million in senior notes ("2029 senior notes"). The 2029 senior notes were issued at 99.316% of their principal amount. The notes will mature on September 15, 2029, and bear interest at a fixed rate of 2.75% per annum. The interest is payable semi-annually on March 15th and September 15th of each year and payments commenced on March 15, 2020.

In August 2019, Agilent executed treasury lock agreements for $250 million in connection with future interest payments to be made on our 2029 senior notes issued on September 16, 2019. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 6, 2019 and we recognized a deferred loss of $6 million in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2029 senior notes. The remaining loss to be amortized related to the treasury lock agreements at October 31, 2020 was $5 million.

2030 Senior Notes

On June 4, 2020, we issued an aggregate principal amount of $500 million in senior notes ("2030 senior notes"). The 2030 senior notes were issued at 99.812% of their principal amount. The 2030 senior notes will mature on June 4, 2030, and bear interest at a fixed rate of 2.10% per annum. The interest is payable semi-annually on June 4th and December 4th of each year and payments commenced on December 4, 2020.

All outstanding notes listed above are unsecured and rank equally in right of payment with all of Agilent's other senior unsecured indebtedness.

20.   STOCKHOLDERS' EQUITY

Stock Repurchase Program

On May 28, 2015 we announced that our board of directors had approved a share repurchase program (the "2015 repurchase program"). The 2015 repurchase program authorizes the purchase of up to $1.14 billion of our common stock at the company's discretion through and including November 1, 2018. The 2015 repurchase program did not require the company to acquire a specific number of shares and could have been suspended or discontinued at any time. During the year ended October 31, 2018, we repurchased and retired approximately 6.4 million shares for $422 million under this authorization. As of October 31, 2018, we had remaining authorization to repurchase up to $188 million of our common stock under this program which expired on November 1, 2018.

On November 19, 2018 we announced that our board of directors had approved a new share repurchase program (the "2019 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2019 share repurchase program authorizes the purchase of up to $1.75 billion of our common stock at the company's discretion and has no fixed termination date. The 2019 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. During the year ended October 31, 2019, we repurchased and retired 10.4 million shares for $723 million under this authorization. During the year ended October 31, 2020, we repurchased and retired approximately 5.2 million shares for $469 million under this authorization. As of October 31, 2020, we had remaining authorization to repurchase up to $558 million of our common stock under this program.

Cash Dividends on Shares of Common Stock

During the year ended October 31, 2020, cash dividends of 0.720 per share, or $222 million were declared and paid on the company's outstanding common stock. During the year ended October 31, 2019, cash dividends of 0.656 per share, or $206 million were declared and paid on the company's outstanding common stock. During the year ended October 31, 2018, cash dividends of 0.596 per share, or $191 million were declared and paid on the company's outstanding common stock.
105
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


On November 18, 2020 we declared a quarterly dividend of $0.194 per share of common stock, or approximately $59 million which will be paid on January 27, 2021 to shareholders of record as of the close of business on January 5, 2021. The timing and amounts of any future dividends are subject to determination and approval by our board of directors.

Accumulated Other Comprehensive Income (Loss)

The following table summarizes the components of our accumulated other comprehensive income (loss) as of October 31, 2020 and 2019, net of tax effect:

 October 31,
 20202019
 (in millions)
Foreign currency translation, net of tax expense of $(6) and $(5) for 2020 and 2019, respectively
$(194)(204)
Unrealized losses (including prior service benefit) on defined benefit plans, net of tax benefit of $154 and $153 for 2020 and 2019, respectively
(317)(306)
Unrealized gains (losses) on derivative instruments, net of tax benefit of $6 and $3 for 2020 and 2019, respectively
(11)(4)
Total accumulated other comprehensive loss$(522)$(514)

106
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Changes in accumulated other comprehensive income (loss) by component and related tax effects for the years ended October 31, 2020 and 2019 were as follows:

Net defined benefit pension cost and post retirement plan costs
Foreign currency translationPrior service creditsActuarial LossesUnrealized gains (losses) on derivativesTotal
(in millions)
As of October 31, 2018$(214)$134 $(335)$7 $(408)
Impact of adoption of new guidance on tax effects in accumulated other comprehensive income (loss)— 3 (9)(1)(7)
As of November 1, 2018(214)137 (344)6 (415)
Other comprehensive loss before reclassifications— — (157)(6)(163)
Amounts reclassified out of accumulated other comprehensive income (loss)— (8)39 (8)23 
Tax benefit10 2 25 4 41 
Other comprehensive income (loss)10 (6)(93)(10)(99)
As of October 31, 2019$(204)$131 $(437)$(4)$(514)
Other comprehensive income (loss) before reclassifications11 — (66)(12)(67)
Amounts reclassified out of accumulated other comprehensive income (loss)— (7)61 2 56 
Tax (expense) benefit(1)1 — 3 3 
Other comprehensive income (loss)10 (6)(5)(7)(8)
As of October 31, 2020$(194)$125 $(442)$(11)$(522)
107
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)



Reclassifications out of accumulated other comprehensive income (loss) for the years ended October 31, 2020 and 2019 were as follows (in millions):
Details about Accumulated Other
Comprehensive Income components		Amounts Reclassified
from Other Comprehensive Income		Affected line item in
statement of operations
20202019
Unrealized gains and (losses) on derivatives$(2)$8 Cost of products and interest expense
(2)8 Total before income tax
— (2)(Provision)/benefit for income tax
(2)6 Total net of income tax
Net defined benefit pension cost and post retirement plan costs:
Actuarial net loss(61)(39)Other (income) expense
Prior service benefit7 8 Other (income) expense
(54)(31)Total before income tax
16 12 Benefit for income tax
(38)(19)Total net of income tax
Total reclassifications for the period$(40)$(13)

Amounts in parentheses indicate reductions to income and increases to other comprehensive income.

Reclassifications of prior service benefit and actuarial net loss in respect of retirement plans and post retirement pension plans are included in the computation of net periodic cost (see Note 15, "Retirement Plans and Post Retirement Pension Plans").

21.   SEGMENT INFORMATION

Description of Segments. We are a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.
Agilent has three business segments comprised of the life sciences and applied markets business, diagnostics and genomics business and the Agilent CrossLab business each of which comprises a reportable segment. The three operating segments were determined based primarily on how the chief operating decision maker views and evaluates our operations. Operating results are regularly reviewed by the chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance. Other factors, including market separation and customer specific applications, go-to-market channels, products and services and manufacturing are considered in determining the formation of these operating segments.
A description of our three reportable segments is as follows:

Our life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. Key product categories include: liquid chromatography ("LC") systems and components; liquid chromatography mass spectrometry ("LCMS") systems; gas chromatography ("GC") systems and components; gas chromatography mass spectrometry ("GCMS") systems; inductively coupled plasma mass spectrometry ("ICP-MS") instruments; atomic absorption ("AA") instruments; microwave plasma-atomic emission spectrometry ("MP-AES") instruments; inductively coupled plasma optical emission spectrometry ("ICP-OES") instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software for sample tracking; information
108
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps and measurement technologies.

Our diagnostics and genomics business is comprised of six areas of activity providing active pharmaceutical ingredients ("APIs") for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our genomics business includes arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as next generation sequencing ("NGS") target enrichment and genetic data management and interpretation support software. This business also includes solutions that enable clinical labs to identify DNA variants associated with genetic disease and help direct cancer therapy. Second, our nucleic acid solutions business provides equipment and expertise focused on production of synthesized oligonucleotides under pharmaceutical good manufacturing practices ("GMP") conditions for use as API in an emerging class of drugs that utilize nucleic acid molecules for disease therapy. Third, our pathology solutions business is focused on product offerings for cancer diagnostics and anatomic pathology workflows. The broad portfolio of offerings includes immunohistochemistry ("IHC"), in situ hybridization ("ISH"), hematoxylin and eosin ("H&E") staining and special staining. Fourth, we also collaborate with a number of major pharmaceutical companies to develop new potential pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. Fifth, the reagent partnership business is a provider of reagents used for turbidimetry and flow cytometry. Finally, our biomolecular analysis business provides complete workflow solutions, including instruments, consumables and software, for quality control analysis of nucleic acid samples.  Samples are analyzed using quantitative and qualitative techniques to ensure accuracy in further genomics analysis techniques utilized in clinical and life science research applications.

The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio, which is designed to improve customer outcomes. Most of the portfolio is vendor neutral, meaning Agilent can serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries and supplies to services and software helping to connect the entire lab. Key product categories in consumables include GC and LC columns, sample preparation products, custom chemistries, and a large selection of laboratory instrument supplies. Services include startup, operational, training and compliance support, software as a service, as well as asset management and consultative services that help increase customer productivity. Custom service and consumable bundles are tailored to meet the specific application needs of various industries and to keep instruments fully operational and compliant with the respective industry requirements.

A significant portion of the segments' expenses arise from shared services and infrastructure that we have historically provided to the segments in order to realize economies of scale and to efficiently use resources. These expenses, collectively called corporate charges, include legal, accounting, tax, real estate, insurance services, information technology services, treasury, order administration, other corporate infrastructure expenses and costs of centralized research and development. Charges are allocated to the segments, and the allocations have been determined on a basis that we consider to be a reasonable reflection of the utilization of services provided to or benefits received by the segments. In addition, we do not allocate amortization and impairment of acquisition-related intangible assets, pension curtailment or settlement gains, restructuring and transformational initiatives expenses, acquisition and integration costs, business exit and divestiture costs, special compliance costs, some nucleic acid solutions division ("NASD") site costs and certain other charges to the operating margin for each segment because management does not include this information in its measurement of the performance of the operating segments. Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers, site consolidations, legal entity and other business reorganizations, in-sourcing or outsourcing of activities.

The following tables reflect the results of our reportable segments under our management reporting system. The performance of each segment is measured based on several metrics, including segment income from operations. These results are used, in part, by the chief operating decision maker in evaluating the performance of, and in allocating resources to, each of the segments.








109
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


The profitability of each of the segments is measured after excluding items such as asset impairment charges, transformational initiatives, acquisition and integration costs, non-cash amortization of intangible assets related to business combinations, interest income, interest expense, and other items as noted in the reconciliations below.
Life Sciences and Applied MarketsDiagnostics and GenomicsAgilent CrossLabTotal
Segments
 (in millions)
Year Ended October 31, 2020:    
Total net revenue$2,392 $1,047 $1,900 $5,339 
Income from operations$548 $192 $516 $1,256 
Depreciation expense$43 $39 $37 $119 
Share-based compensation expense (1)
$35 $17 $29 $81 
Year Ended October 31, 2019:   
Total net revenue$2,302 $1,021 $1,840 $5,163 
Income from operations$542 $185 $475 $1,202 
Depreciation expense$41 $35 $35 $111 
Share-based compensation expense$33 $14 $25 $72 
Year Ended October 31, 2018:   
Total net revenue$2,270 $943 $1,701 $4,914 
Income from operations$543 $173 $388 $1,104 
Depreciation expense$38 $33 $31 $102 
Share-based compensation expense$33 $14 $24 $71 

(1) Share-based compensation expense in 2020 excludes amounts not allocated to the segments related to accelerated share-based compensation expense from workforce reduction and from our acquisition of BioTek.

The following table reconciles reportable segments' income from operations to Agilent's total enterprise income before taxes:

 Years Ended October 31,
 202020192018
 (in millions)
Total reportable segments' income from operations$1,256 $1,202 $1,104 
Amortization of intangible assets related to business combinations(184)(125)(105)
Acquisition and integration costs(41)(48)(23)
Transformational initiatives(53)(44)(25)
Acceleration of share-based compensation expense related to workforce reduction(2)— — 
Asset impairments(99)— (21)
Business exit and divestiture costs (2)— (9)
NASD site costs— (12)(8)
Special compliance costs— (2)(4)
Other (1)
(29)(30)(5)
Interest Income8 36 38 
Interest Expense(78)(74)(75)
Other income (expense), net (2)
66 16 79 
Income before taxes, as reported$842 $919 $946 

(1) For the years ended October 31, 2020 and 2019, the other category primarily includes legal costs related to a claim we pursued against Twist Bioscience Corporation in addition to other miscellaneous adjustments.
(2) For the year ended October 31, 2020, other income (expense), net includes the settlement of a legal claim against Twist Bioscience Corporation.
110
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Major Customers.    No customer represented 10 percent or more of our total net revenue in 2020, 2019 or 2018.

The following table reflects segment assets and capital expenditures under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets.
Life Sciences and Applied MarketsDiagnostics and GenomicsAgilent CrossLabTotal
Segments
 (in millions)
As of and for the Year Ended October 31, 2020:    
Assets$3,143 $2,515 $1,375 $7,033 
Capital expenditures$44 $34 $41 $119 
As of and for the Year Ended October 31, 2019:    
Assets$3,202 $2,620 $1,331 $7,153 
Capital expenditures$59 $48 $48 $155 


The following table reconciles segment assets to Agilent's total assets:
 October 31,
 20202019
 (in millions)
Total reportable segments' assets$7,033 $7,153 
Cash and cash equivalents1,441 1,382 
Prepaid expenses106 94 
Investments158 102 
Long-term and other receivables114 100 
Deferred tax assets380 410 
Right of use assets175 — 
Other220 211 
Total assets$9,627 $9,452 

The other category primarily includes overfunded pension assets which are not allocated to the segments.

The following table presents summarized information for net revenue by geographic region. Revenues from external customers are generally attributed to countries based upon the customers' location.

United
States
China(1)
Rest of the
World		Total
 (in millions)
Net revenue:    
Year Ended October 31, 2020$1,752 $1,087 $2,500 $5,339 
Year Ended October 31, 2019$1,619 $1,019 $2,525 $5,163 
Year Ended October 31, 2018$1,414 $1,015 $2,485 $4,914 
1.China also includes Hong Kong net revenue.



The following table presents summarized information for long-lived assets by geographic region. Long lived assets consist of property, plant, and equipment, right-of-use assets, long-term receivables and other long-term assets excluding intangible assets. The rest of the world primarily consists of Asia and the rest of Europe.
111
AGILENT TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


United
States		GermanyRest of the
World		Total
 (in millions)
Long-lived assets:   
October 31, 2020$727 $126 $538 $1,391 
October 31, 2019$621 $122 $404 $1,147 

112

QUARTERLY SUMMARY
(Unaudited)

 Three Months Ended
 January 31,April 30,July 31,October 31,
 (in millions, except per share data)
2020   
Net revenue$1,357 $1,238 $1,261 $1,483 
Gross profit723 657 669 788 
Income from operations215 102 230 299 
Net income197 101 199 222 
Net income per share — Basic$0.64 $0.33 $0.64 $0.72 
Net income per share — Diluted$0.63 $0.32 $0.64 $0.71 
Weighted average shares used in computing net income per share:    
Basic310 309 309 308 
Diluted313 312 312 311 
Cash dividends per common share$0.180 $0.180 $0.180 $0.180 
2019   
Net revenue$1,284 $1,238 $1,274 $1,367 
Gross profit707 669 692 737 
Income from operations250 216 225 250 
Net income504 182 191 194 
Net income per share — Basic$1.58 $0.57 $0.61 $0.63 
Net income per share — Diluted$1.57 $0.57 $0.60 $0.62 
Weighted average shares used in computing net income per share:    
Basic318 317 312 309 
Diluted322 321 316 313 
Cash dividends per common share$0.164 $0.164 $0.164 $0.164 

113

Item 9.    Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A.    Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management has evaluated, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as of October 31, 2020, pursuant to and as required by Rule 13a-15(b) under the Securities Exchange Act of 1934 (“Exchange Act”). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of October 31, 2020, the company's disclosure controls and procedures, as defined by Rule 13a-15(e) under the Exchange Act, were effective and designed to ensure that (i) information required to be disclosed in the company's reports filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and (ii) information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.

Management's Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we assessed the effectiveness of our internal control over financial reporting based on the framework in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO"). As a result of that assessment, management concluded that our internal control over financial reporting was effective as of October 31, 2020 based on criteria in Internal Control - Integrated Framework (2013) issued by the COSO.

The effectiveness of our internal control over financial reporting as of October 31, 2020 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears in Item 8 of this Annual Report on Form 10-K.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during Agilent's last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 9B.    Other Information

None.

PART III


Item 10. Directors, Executive Officers and Corporate Governance
Information regarding our directors appears under “Proposal No. 1 - Election of Directors” in our Proxy Statement for the Annual Meeting of Stockholders (“Proxy Statement”), to be held March 17, 2021. That portion of the Proxy Statement is incorporated by reference into this report. Information regarding our executive officers appears in Item 1 of this report under “Executive Officers of the Registrant.” Information regarding our Audit and Finance Committee and our Audit and Finance Committee's financial expert appears under “Audit and Finance Committee Report” and “Corporate Governance” in our Proxy Statement. That portion of the Proxy Statement is incorporated by reference into this report.
There were no material changes to the procedures by which security holders may recommend nominees to our Board of Directors in fiscal year 2020. Information regarding our code of ethics (the company's Standards of Business Conduct) applicable to our principal executive officer, our principal financial officer, our controller and other senior financial officers appears in Item 1 of this report under “Investor Information.” We will post amendments to or waivers from a provision of the Standards of Business Conduct with respect to those persons on our website at www.investor.agilent.com.

114

Compliance with Section 16(a) of the Exchange Act
Information about compliance with Section 16(a) of the Exchange Act appears under “Section 16(a) Beneficial Ownership Reporting Compliance” in the Proxy Statement. That portion of the Proxy Statement is incorporated by reference into this report.

Item 11.    Executive Compensation

Information about compensation of our named executive officers appears under “Executive Compensation” in the Proxy Statement. Information about compensation of our directors appears under “Compensation of Non-Employee Directors” and “Compensation Committee Report” in the Proxy Statement. Those portions of the Proxy Statement are incorporated by reference into this report.

Item 12.    Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Information about security ownership of certain beneficial owners and management appears under "Beneficial Ownership" in the Proxy Statement. That portion of the Proxy Statement is incorporated by reference into this report.

EQUITY COMPENSATION PLAN INFORMATION

The following table summarizes information about our equity compensation plans as of October 31, 2020. All outstanding awards relate to our common stock.

Plan CategoryNumber of Securities
to be Issued upon
Exercise of
Outstanding Options,
Warrants and Rights		Weighted-average
Exercise Price of
Outstanding
Options,
Warrants and
Rights		Number of Securities
Remaining Available for
Future Issuance under
Equity Compensation Plans
(Excluding Securities
Reflected in Column
(a))
 (a)(b)(c)
Equity compensation plans approved by security holders (1)(2)(3)
3,687,752 $37 51,367,003 
Equity compensation plans not approved by security holders
— — — 
Total3,687,752 $37 51,367,003 

(1)The number of securities remaining available for future issuance in column (c) includes 25,770,573 shares of common stock authorized and available for issuance under our current Employee Stock Purchase Plan ("ESPP"). The number of shares authorized for issuance under the ESPP is subject to an automatic annual increase of the lesser of one percent of the outstanding common stock of Agilent or an amount determined by the Compensation Committee of our Board of Directors. Under the terms of the ESPP, in no event shall the aggregate number of shares issued under the ESPP exceed 31 million shares.

(2)We issue securities under our equity compensation plans in forms other than options, warrants or rights. On November 15, 2017 and March 21, 2018, the Board and the stockholders, respectively, approved the Agilent Technologies, Inc. 2018 Stock Plan (the “2018 Plan”), which was an amendment and restatement of the company’s 2009 Stock Plan, approved by the Board and the stockholders, respectively, on November 19, 2008 and March 11, 2009. The 2018 Plan provides for awards of stock-based incentive compensation to our employees (including officers), directors and consultants. The 2018 Plan provides for the grant of awards in the form of stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares and performance units with performance-based conditions to vesting or exercisability, and cash awards. The 2018 Plan has a term of ten years.

(3)We issue securities under our equity compensation plans in forms which do not require a payment by the recipient to us at the time of exercise or vesting, including restricted stock, restricted stock units and performance units. Accordingly, the weighted-average exercise price in column (b) does not take these awards into account.

115

Item 13.    Certain Relationships and Related Transactions, and Director Independence

Information about certain relationships and related transactions appears under "Related Person Transactions Policy and Procedures" in the Proxy Statement. Information about director independence appears under the heading "Corporate Governance — Director Independence" in the Proxy Statement. Each of those portions of the Proxy Statement is incorporated by reference into this report.

Item 14.    Principal Accounting Fees and Services

Information about principal accountant fees and services as well as related pre-approval policies appear under "Fees Paid to PricewaterhouseCoopers LLP" and "Policy on Preapproval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm" in the Proxy Statement. Those portions of the Proxy Statement are incorporated by reference into this report.

PART IV

Item 15.    Exhibits and Financial Statement Schedules

(a)    The following documents are filed as part of this report:
1.    Financial Statements.
See Index to Consolidated Financial Statements under Item 8 on Page 54 of this report.
2.    Financial Statement Schedule.
The following additional financial statement schedule should be considered in conjunction with our consolidated financial statements. All other schedules have been omitted because the required information is either not applicable or not sufficiently material to require submission of the schedule:

SCHEDULE II

SCHEDULE II
VALUATION AND QUALIFYING ACCOUNTS

Column AColumn BColumn CColumn DColumn E
DescriptionBalance at
Beginning
of Period		Additions Charged to
Expenses or
Other Accounts*		Deductions Credited to Expenses or Other Accounts**Balance at
End of
Period
 (in millions)
2020    
Tax valuation allowance$134 $6 $(8)$132 
2019    
Tax valuation allowance$135 $9 $(10)$134 
2018    
Tax valuation allowance$138 $4 $(7)$135 

* Additions include current year additions charged to expenses and current year build due to increases in net deferred tax assets, return to provision true-ups, other adjustments and other comprehensive income impact to deferred taxes.

** Deductions include current year releases credited to expenses and current year reductions due to decreases in net deferred tax assets, return to provision true-ups, other adjustments and other comprehensive income impact to deferred taxes.

3.    Exhibits.
Exhibits are incorporated herein by reference or are filed with this report as indicated below (numbered in accordance with Item 601 of Regulation S-K):
116


Incorporation by Reference
Exhibit
Number		DescriptionFormDateExhibit
Number		Filed
Herewith
2.1 8-K8/5/20142.1
3.1 S-18/16/19993.1
3.2 10-K12/19/20193.2
4.18-K11/27/200199.3
4.2S-3ASR10/24/20074.01
4.3 8-K9/13/20124.01
4.4 8-K6/21/20134.01
4.5 8-K9/22/20164.01
4.6 8-K9/16/20194.1
4.7 8-K9/16/20194.2
4.8 8-K6/4/20204.1
4.9 10-K12/19/20194.8
10.110-K12/22/200610.8
10.28-K11/12/200410.1
10.38-K11/12/200410.2
10.410-Q6/1/202010.1
10.5DEF14A1/27/2009Appendix A
10.6 10‑K12/20/201010.17

117

Incorporation by Reference
Exhibit
Number		DescriptionFormDateExhibit
Number		Filed
Herewith
10.7 10-K12/21/200910.31
10.8 10‑K12/20/201010.19
10.9 10-K12/21/200910.32
10.10 10‑K12/20/201010.21
10.11 10-K12/21/201510.26
10.12 10-K12/21/201510.28
10.13 10-K12/21/201510.29
10.14 DEF14A2/7/2019Appendix B
10.15 10-Q5/31/201810.1
10.16 10-Q5/31/201810.2
10.17 

10-K12/20/201810.17
10.18 

10-K12/20/201810.18
10.19 10-K12/21/201710.17
10.20 10-Q3/9/200610.63
10.21 10-K12/21/200910.39
10.22 10-K12/21/201710.20
10.23 DEF14A2/6/2015Annex A
10.24 8-K4/10/200810.1
118

Incorporation by Reference
Exhibit
Number		DescriptionFormDateExhibit
Number		Filed
Herewith
10.25 10-K12/22/201410.35
10.26 8-K4/10/200810.3
10.27 10-K12/22/201410.37
10.28 10-K12/21/200910.5
10.29 10-K12/22/201410.39
10.30 8-K8/5/201410.1
10.31 8-K8/5/201410.2
10.32 8-K8/5/201410.3
10.33 8-K8/5/201410.4
10.34 8-K8/5/201410.5
10.35 8-K3/13/201910.1
10.36 8-K8/8/201910.1
10.37 

8-K10/22/201910.1
10.38 8-K4/20/202010.1
10.39 10-K12/22/201410.62
10.40 10-K12/21/201510.70
119

Incorporation by Reference
Exhibit
Number		DescriptionFormDateExhibit
Number		Filed
Herewith
10.41 10-Q3/8/201610.1
10.42 10-K12/20/201810.41
10.43 10-Q6/1/202010.2
10.44 10-K12/21/201710.40
21.1X
23.1X
24.1X
31.1X
31.2X
32.1X
32.2 X
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.X
101.SCHXBRL Taxonomy Extension Schema Document.X
101.CALXBRL Taxonomy Extension Calculation Linkbase Document.X
101.LABXBRL Taxonomy Extension Label Linkbase Document.X
101.PREXBRL Taxonomy Extension Presentation Linkbase Document.X
101.DEFXBRL Taxonomy Extension Definition Linkbase Document.X

*    Indicates management contract or compensatory plan, contract or arrangement.


120

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  AGILENT TECHNOLOGIES, INC.
  BY /s/ MICHAEL TANG
Michael Tang
Senior Vice President,
General Counsel and Secretary

Date: December 17, 2020


121

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael Tang and P. Diana Chiu, or either of them, his or her attorneys-in-fact, for such person in any and all capacities, to sign any amendments to this report and to file the same, with exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that any of said attorneys-in-fact, or substitute or substitutes, may do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ MICHAEL R. MCMULLENDirector, President and Chief Executive OfficerDecember 17, 2020
Michael R. McMullen(Principal Executive Officer)
/s/ ROBERT W. MCMAHONSenior Vice President and Chief Financial OfficerDecember 17, 2020
Robert W. McMahon(Principal Financial Officer)
/s/ RODNEY GONSALVESVice President, Corporate ControllershipDecember 17, 2020
Rodney Gonsalves(Principal Accounting Officer)
/s/ KOH BOON HWEEChairman of the Board of DirectorsDecember 17, 2020
Koh Boon Hwee
/s/ MALA ANANDDirectorDecember 17, 2020
Mala Anand
/s/ HANS E. BISHOPDirectorDecember 17, 2020
Hans E. Bishop
/s/ PAUL N. CLARKDirectorDecember 17, 2020
Paul N. Clark
/s/ HEIDI KUNZDirectorDecember 17, 2020
Heidi Kunz
/s/ DANIEL K. PODOLSKY, M.D.DirectorDecember 17, 2020
Daniel K. Podolsky, M.D.
/s/ SUE H. RATAJDirectorDecember 17, 2020
Sue H. Rataj
/s/ GEORGE A. SCANGOS, Ph.D.DirectorDecember 17, 2020
George A. Scangos, Ph.D.
/s/ DOW R. WILSONDirectorDecember 17, 2020
Dow R. Wilson
/s/ TADATAKA YAMADA, M.D.DirectorDecember 17, 2020
Tadataka Yamada, M.D.


122
 EX-21.1 2 a-10312020xexx211.htm EX-21.1 Document

Exhibit 21.1
SIGNIFICANT SUBSIDIARIES


Organized Under the Laws of
Agilent Technologies World Trade, Inc.Delaware
Agilent Technologies Luxembourg Holding S.à.r.l.Luxembourg
Agilent Technologies Luxco S.à.r.l.Luxembourg
Agilent Technologies Singapore (Holding) Pte. Ltd.Singapore
Agilent Technologies Singapore (International) Pte. Ltd.Singapore
Agilent Technologies Singapore (Global) Pte Ltd.Singapore
AT Rhone Pte. Ltd.Singapore
BioTek Instruments LLCVermont
Dako Denmark ApSDenmark
Lionheart Technologies LLCNevada



 EX-23.1 3 a-10312020xexx231.htm EX-23.1 Document

Exhibit 23.1 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 
       
 We hereby consent to the incorporation by reference in the Registration Statements on Forms S-3 (No. 333-233593) and S-8 (No’s. 333-249212, 333-230454, 333-189051, 333-158096, 333-157002, 333-150873, 333-116400, 333-88864, 333-47024, 333-38194, 333-38080, 333-35016, and 333-91121) of Agilent Technologies, Inc. of our report dated December 17, 2020 relating to the consolidated financial statements, financial statement schedule and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.

/s/ PricewaterhouseCoopers LLP

San Jose, California
December 17, 2020





EX-31.1 4 a-10312020xexx311.htm EX-31.1 Document

Exhibit 31.1 
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 

I, Michael R. McMullen, certify that:

1.I have reviewed this Form 10-K of Agilent Technologies, Inc. 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 

4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; 
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 

5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and 
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:December 17, 2020/s/ Michael R. McMullen
Michael R. McMullen
Director, President and Chief Executive Officer


 EX-31.2 5 a-10312020xexx312.htm EX-31.2 Document

Exhibit 31.2

CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 

I, Robert W. McMahon, certify that:

1.I have reviewed this Form 10-K of Agilent Technologies, Inc. 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 

4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; 
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 

5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and 
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:December 17, 2020/s/ Robert W. McMahon
Robert W. McMahon


Senior Vice President and Chief Financial Officer


 EX-32.1 6 a-10312020xexx321.htm EX-32.1 Document

Exhibit 32.1 

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

       
 In connection with the Annual Report of Agilent Technologies, Inc. (the "Company"), on Form 10-K for the period ended October 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Michael R. McMullen, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

        A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Date:December 17, 2020/s/ Michael R. McMullen
Michael R. McMullen
Director, President and Chief Executive Officer

 EX-32.2 7 a-10312020xexx322.htm EX-32.2 Document

Exhibit 32.2 

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

       
 In connection with the Annual Report of Agilent Technologies, Inc. (the "Company"), on Form 10-K for the period ended October 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Robert W. McMahon, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

        A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Date:December 17, 2020/s/ Robert W. McMahon
Robert W. McMahon


Senior Vice President and Chief Financial Officer


 EX-101.SCH 8 a-20201031.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000010001 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 100010002 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 100020003 - Statement - CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 100030004 - Statement - CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100040005 - Statement - CONSOLIDATED BALANCE SHEET link:presentationLink link:calculationLink link:definitionLink 100050006 - Statement - CONSOLIDATED BALANCE SHEET (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100060007 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 100070008 - Statement - CONSOLIDATED STATEMENT OF EQUITY link:presentationLink link:calculationLink link:definitionLink 100080009 - Statement - CONSOLIDATED STATEMENT OF EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 210011001 - Disclosure - OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 220022001 - Disclosure - OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 230033001 - Disclosure - OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 240044001 - Disclosure - OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 210051002 - Disclosure - NEW ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 230063002 - Disclosure - NEW ACCOUNTING PRONOUNCEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 240074002 - Disclosure - NEW ACCOUNTING PRONOUNCEMENTS - (Details) link:presentationLink link:calculationLink link:definitionLink 210081003 - Disclosure - ACQUISITIONS (Notes) link:presentationLink link:calculationLink link:definitionLink 230093003 - Disclosure - ACQUISITIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 240104003 - Disclosure - ACQUISITIONS - Text (Details) link:presentationLink link:calculationLink link:definitionLink 240114004 - Disclosure - ACQUISITIONS - Assets and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 240124005 - Disclosure - ACQUISITIONS ACQUISITIONS - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 240134006 - Disclosure - ACQUISITIONS ACQUISITIONS - Proforma Operating Results (Details) link:presentationLink link:calculationLink link:definitionLink 210141004 - Disclosure - REVENUE (Notes) link:presentationLink link:calculationLink link:definitionLink 230153004 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 240164007 - Disclosure - REVENUE - Revenue by Region (Details) link:presentationLink link:calculationLink link:definitionLink 240174008 - Disclosure - REVENUE - Revenue by End Markets (Details) link:presentationLink link:calculationLink link:definitionLink 240184009 - Disclosure - REVENUE - Revenue by Type (Details) link:presentationLink link:calculationLink link:definitionLink 240194010 - Disclosure - REVENUE - Contract Balances (Details) link:presentationLink link:calculationLink link:definitionLink 210201005 - Disclosure - SHARE-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 230213005 - Disclosure - SHARE-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 240224011 - Disclosure - SHARE-BASED COMPENSATION General Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 240234012 - Disclosure - SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 240244013 - Disclosure - SHARE-BASED COMPENSATION-Fair Value Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 240254014 - Disclosure - SHARE-BASED COMPENSATION Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 240264015 - Disclosure - SHARE-BASED COMPENSATION Shares Authorized by Exercise Price Range (Details) link:presentationLink link:calculationLink link:definitionLink 240274016 - Disclosure - SHARE-BASED COMPENSATION Non-vested award activity disclosure (Details) link:presentationLink link:calculationLink link:definitionLink 210281006 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 230293006 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 240304017 - Disclosure - INCOME TAXES INCOME TAXES- Provision (Details) link:presentationLink link:calculationLink link:definitionLink 240314018 - Disclosure - INCOME TAXES INCOME TAXES Effective tax rate and tax holidays (Details) link:presentationLink link:calculationLink link:definitionLink 240324019 - Disclosure - INCOME TAXES INCOME TAXES - Deferred Taxes and other (Details) link:presentationLink link:calculationLink link:definitionLink 240334020 - Disclosure - INCOME TAXES - Carryforwards (Details) link:presentationLink link:calculationLink link:definitionLink 240344021 - Disclosure - INCOME TAXES - Current and long-term income tax assets and liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 240354022 - Disclosure - INCOME TAXES INCOME TAXES - Uncertain Tax Positions (Details) link:presentationLink link:calculationLink link:definitionLink 210361007 - Disclosure - NET INCOME (LOSS) PER SHARE link:presentationLink link:calculationLink link:definitionLink 230373007 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 240384023 - Disclosure - NET INCOME (LOSS) PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 210391008 - Disclosure - INVENTORY link:presentationLink link:calculationLink link:definitionLink 230403008 - Disclosure - INVENTORY (Tables) link:presentationLink link:calculationLink link:definitionLink 240414024 - Disclosure - INVENTORY (Details) link:presentationLink link:calculationLink link:definitionLink 210421009 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET link:presentationLink link:calculationLink link:definitionLink 230433009 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 240444025 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Details) link:presentationLink link:calculationLink link:definitionLink 210451010 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 230463010 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 240474026 - Disclosure - LEASES - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 240484027 - Disclosure - LEASES - Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 240494028 - Disclosure - LEASES - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 240504029 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 240514030 - Disclosure - LEASES - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 240524031 - Disclosure - LEASES - Textual (Details) link:presentationLink link:calculationLink link:definitionLink 210531011 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 230543011 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 240554032 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Roll forward (Details) link:presentationLink link:calculationLink link:definitionLink 240564033 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Other Intangibles (Details) link:presentationLink link:calculationLink link:definitionLink 240574034 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Text (Details) link:presentationLink link:calculationLink link:definitionLink 240584035 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Amortization Expense and Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 210591012 - Disclosure - INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 230603012 - Disclosure - INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 240614036 - Disclosure - INVESTMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 210621013 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 230633013 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 240644037 - Disclosure - FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) link:presentationLink link:calculationLink link:definitionLink 240654038 - Disclosure - FAIR VALUE MEASUREMENTS FAIR VALUE MEASURMENTS - Fair value of assets and liabilities measured on non recurring (Details) link:presentationLink link:calculationLink link:definitionLink 210661014 - Disclosure - DERIVATIVES link:presentationLink link:calculationLink link:definitionLink 230673014 - Disclosure - DERIVATIVES (Tables) link:presentationLink link:calculationLink link:definitionLink 240684039 - Disclosure - DERIVATIVES (Details) link:presentationLink link:calculationLink link:definitionLink 240694040 - Disclosure - DERIVATIVES, Disclosures and derivative instrument aggregated notional amounts by currency and designations (Details) link:presentationLink link:calculationLink link:definitionLink 240704041 - Disclosure - DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details) link:presentationLink link:calculationLink link:definitionLink 240714042 - Disclosure - DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 210721015 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS link:presentationLink link:calculationLink link:definitionLink 230733015 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables) link:presentationLink link:calculationLink link:definitionLink 240744043 - Disclosure - RETIREMENT PLANS AND POST RETIEMENT PENSION PLANS - Deferred Profit Sharing Plan (Details) link:presentationLink link:calculationLink link:definitionLink 240754044 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS Defined Contribution (Details) link:presentationLink link:calculationLink link:definitionLink 240764045 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Components of Net Periodic Costs (Details) link:presentationLink link:calculationLink link:definitionLink 240774046 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Funded Status (Details) link:presentationLink link:calculationLink link:definitionLink 240784047 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Financial Statement Location (Details) link:presentationLink link:calculationLink link:definitionLink 240794048 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS , Target Allocations (Details) link:presentationLink link:calculationLink link:definitionLink 240804049 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Fair Value of Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 240814050 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Expected Benefit Payments (Details) link:presentationLink link:calculationLink link:definitionLink 240824051 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 210831016 - Disclosure - GUARANTEES link:presentationLink link:calculationLink link:definitionLink 230843016 - Disclosure - GUARANTEES (Tables) link:presentationLink link:calculationLink link:definitionLink 240854052 - Disclosure - GUARANTEES (Details) link:presentationLink link:calculationLink link:definitionLink 210861017 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 230873017 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 240884053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 210891018 - Disclosure - SHORT-TERM DEBT link:presentationLink link:calculationLink link:definitionLink 240904054 - Disclosure - SHORT-TERM DEBT - Credit Facility and Commercial Paper (Details) link:presentationLink link:calculationLink link:definitionLink 240914055 - Disclosure - SHORT-TERM DEBT - Senior Notes (Details) link:presentationLink link:calculationLink link:definitionLink 210921019 - Disclosure - LONG-TERM DEBT link:presentationLink link:calculationLink link:definitionLink 230933018 - Disclosure - LONG-TERM DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 240944056 - Disclosure - LONG-TERM DEBT - Carrying Value (Details) link:presentationLink link:calculationLink link:definitionLink 240954057 - Disclosure - LONG-TERM DEBT - Senior Notes (Details) link:presentationLink link:calculationLink link:definitionLink 210961020 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 230973019 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 240984058 - Disclosure - STOCKHOLDERS' EQUITY Stock Repurchases (Details) link:presentationLink link:calculationLink link:definitionLink 240994059 - Disclosure - STOCKHOLDERS' EQUITY STOCKHOLDERS EQUITY DIvidends (Details) link:presentationLink link:calculationLink link:definitionLink 241004060 - Disclosure - STOCKHOLDERS' EQUITY -Accumulated other comprehensive income (Details) link:presentationLink link:calculationLink link:definitionLink 241014061 - Disclosure - STOCKHOLDERS' EQUITY - Changes in accumulated other comprehensive income (Details) link:presentationLink link:calculationLink link:definitionLink 241024062 - Disclosure - STOCKHOLDERS' EQUITY - Reclassifications out of accumulated other comprehensive income (Details) link:presentationLink link:calculationLink link:definitionLink 211031021 - Disclosure - SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 231043020 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 241054063 - Disclosure - SEGMENT INFORMATION Profitability (Details) link:presentationLink link:calculationLink link:definitionLink 241064064 - Disclosure - SEGMENT INFORMATION Reconciliation of Reportable Results (Details) link:presentationLink link:calculationLink link:definitionLink 241074065 - Disclosure - SEGMENT INFORMATION Segment Assets (Details) link:presentationLink link:calculationLink link:definitionLink 241084066 - Disclosure - SEGMENT INFORMATION - Entity-Wide Disclosures Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 241094067 - Disclosure - SEGMENT INFORMATION - Entity-Wide Disclosure Long-Lived Assets (Details) link:presentationLink link:calculationLink link:definitionLink 211101022 - Disclosure - Schedule II Valuation and Qualifying Accounts link:presentationLink link:calculationLink link:definitionLink 241114068 - Disclosure - Schedule II Valuation and Qualifying Accounts (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 a-20201031_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 a-20201031_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 a-20201031_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Other Comprehensive Income (Loss) Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Deferred Revenue, Period Increase (Decrease) Deferred Revenue, Period Increase (Decrease) Revision of Prior Period [Axis] Revision of Prior Period [Axis] Target Allocation Percentage of Plan Assets Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Components of comprehensive income, net of tax: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year Change in benefit obligation: [Roll Forward] Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] GERMANY GERMANY Change in fair value of plan assets: [Roll Forward] Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward] Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Number Of Foreign Exchange Forward Contracts Designated As Cash Flow Hedge Number Of Foreign Exchange Forward Contracts Designated As Cash Flow Hedge Number of foreign currency exchange forward contract derivatives held by the entity at the reporting date and designated as cash flow hedges. CHINA CHINA Fair value of plan assets [Abstract] Fair value of plan assets [Abstract] Fair value of plan assets [Abstract] Senior Notes 2022 Senior Notes 2022 [Member] Bond that takes priority over other debt securities by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured ( general) creditors. Beginning Balance Ending Balance Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax GUARANTEES Product Warranty Disclosure [Text Block] Research and Development Research, Development, and Computer Software, Policy [Policy Text Block] Early repayment of senior notes prepayment penalty Early repayment of senior notes prepayment penalty Early repayment of senior notes prepayment penalty Statistical Measurement [Domain] Statistical Measurement [Domain] LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Gain (loss) on derivative instruments, tax expense (benefit) Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax Unrealized gains (losses) on derivative instruments, net of tax benefit of $6 and $3 for 2020 and 2019, respectively Beginning Balance Ending Balance Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax Risk and Uncertainties Risk and Uncertainties [Policy Text Block] Risk and Uncertainties Security Exchange Name Security Exchange Name Fair Value of Plan Assets Fair Value Balance, beginning of year Fair Value Balance, end of year Defined Benefit Plan, Plan Assets, Amount Interest Rate Swap Interest Rate Swap Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period recorded in debt. Total current liabilities Liabilities, Current Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract] Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax [Abstract] Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax [Abstract] Proforma net income per share - diluted Business Acquisition, Pro Forma Earnings Per Share, Diluted Settlements Defined Benefit Plan, Plan Assets, Payment for Settlement Non-vested at October 31, 2019 -Weighted Average Grant Price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Variable Rate [Domain] Variable Rate [Domain] 2025 Defined Benefit Plan, Expected Future Benefit Payment, Year Five Numerator: Numerator [Abstract] Numerator [Abstract] ASSETS Assets [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] Danish Krone Denmark, Kroner Cash, Cash Equivalents and Short-Term Investments and Restricted Cash and Restricted Cash Equivalents Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Share-based awards issued Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Foreign currency translation, net of tax expense (benefit) of $1, $(10) and $7 Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax ACEA Biosciences, Inc. ACEA Biosciences, Inc. [Member] ACEA Biosciences, Inc. [Member] Fully depreciated assets no longer in use retired Fully depreciated assets no longer in use Fully depreciated assets no longer in use retired in the period Amortization of net actuarial loss Other Comprehensive Income Defined Benefit Plan Amortization Of Net Actuarial Loss Other Comprehensive Income Defined Benefit Plan Amortization Of Net Actuarial Loss The change in other comprehensive income due to the amortization of the net actuarial gains (losses) into net periodic pension costs. Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Terminated Interest Rate Swaps Interest Rate Derivatives [Abstract] 2021 Lessee, Operating Lease, Liability, to be Paid, Year One Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 2024 Lessee, Operating Lease, Liability, to be Paid, Year Four Fair Value Assets And Liabilities Measured On Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Carrying value of long-lived asset Impaired Assets to be Disposed of by Method Other than Sale, Carrying Value of Asset Share Repurchase Program [Table] Share Repurchase Program [Table] Share Repurchase Program [Table] State taxes, net of federal benefit - current Current State and Local Tax Expense (Benefit) Tax credit carryforwards Tax Credit Carryforward, Amount Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding Preferred Stock, Value, Issued Minimum price of options outstanding in the period (in dollars per share) Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Hedging contracts general maturity Description Of Types And Terms Of Fair Value Hedging Instruments Used Description of the types and terms of derivatives designated as fair value hedging instruments. For example, interest rate swaps, forward contracts, and so forth. Adjustments for New Accounting Pronouncement Adjustments for New Accounting Pronouncement [Member] Asset impairment charges Tangible Asset Impairment Charges Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Common stock par value (in dollars per share) Common Stock, Par or Stated Value Per Share Percentage Of Face Amount Of Senior Note Instrument Issued Issue rate percentage of principal amount Percentage Of Face Amount Of Senior Note Instrument Issued Proceeds obtained expressed as a percentage of debt instrument face value. 2023 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Denominator: Denominators [Abstract] Denominators [Abstract] Other long-term liabilities Other Liabilities, Noncurrent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Weighted-average exercise price per share, cancelled, expired and forfeited (in dollars per shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Agilent CrossLab Agilent CrossLab [Member] Agilent CrossLab [Member] Repayments of finance leases Finance Lease, Principal Payments Operating Activities [Axis] Operating Activities [Axis] Other investments Alternative Investment Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax [Abstract] Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax [Abstract] SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] Inventory Inventory, Net Tax (expense) benefit Other Comprehensive Income (loss) pension and other post retirement benefit plans, amortization of net loss, tax Other Comprehensive Income (loss) pension and other post retirement benefit plans, amortization of net loss, tax Settlement Defined Benefit Plan, Benefit Obligation, Payment for Settlement Measurement Frequency [Domain] Measurement Frequency [Domain] Employee compensation and benefits [Member] Employee compensation and benefits [Member] Employee compensation and benefits [Member] Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range 02 Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range 02 [Member] Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices. Schedule of Investments [Abstract] Schedule of Investments [Abstract] Accumulated benefit obligation in excess of accumulated benefit obligation - aggregate fair value of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets Foreign currency translation net gain (Ioss) Foreign Currency Transaction Gain (Loss), Realized SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Singapore, Dollars Singapore, Dollars Percentage market value of the common stock option exercise price is generally not less than (in hundredths) Share Based Compensation Arrangement By Share Based Payment Award Incentive Compensation Plan Percent Of Market Price An entity may opt to disclose the percent of market value on offering date that participants pay for options granted. Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year Inventory [Axis] Inventory [Axis] Statement [Line Items] Statement [Line Items] Class of Stock [Domain] Class of Stock [Domain] Tax Period [Axis] Tax Period [Axis] Buy Long [Member] Statement [Table] Statement [Table] Assets and capital expenditures directly managed by each segment Assets And Capital Expenditures Directly Managed By Each Segment [Table Text Block] Tabular disclosure of the total assets and capital expenditures for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. Warranty Standard Product Warranty, Policy [Policy Text Block] Interest cost on benefit obligation Interest cost Defined Benefit Plan, Interest Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year [Abstract] Defined Benefit Plan, Expected Amortization, Next Fiscal Year [Abstract] Non-vested award activity disclosure Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Roll Forward [Text Block] Disclosure of components of non-vested stock option or other award plan under which share-based compensation is awarded to employees, typically comprised of the amount of unearned compensation, compensation expense, and changes in the quantity and fair value of the shares granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Sweden, Kronor Sweden, Kronor Outstanding balance Line of Credit Facility, Fair Value of Amount Outstanding Entity Small Business Entity Small Business Principles of Consolidation Consolidation, Policy [Policy Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Derivative instruments (foreign exchange contracts) Fair Value Assets Measured On Recurring Basis Derivative Instruments Foreign Exhange Contracts This element represents a certain statement of financial position asset which includes foreign exchange contracts derivative instruments, measured at fair value on a recurring basis. Share Repurchase Program [Domain] Share Repurchase Program [Domain] Amendment Flag Amendment Flag Revenue by geography Geographic Areas, Revenues from External Customers [Abstract] Summary of stock option award activity Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Interest and penalties accrued related to unrecognized tax benefits accrued and reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Maximum number of shares authorized for issuance under the ESPP (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized End Markets [Axis] End Markets [Axis] End Markets [Axis] Unrecognized tax benefits that would not impact the effective tax rate Unrecognized tax benefits that would not impact the effective tax rate The total amount of unrecognized tax benefits that, if recognized, would not affect the effective tax rate. Common stock available for future awards under the 2018 Stock Plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Measurement Frequency [Axis] Measurement Frequency [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Employee Compensation and Benefits Compensation Related Costs, Policy [Policy Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Gain (loss) recognized in other income (expense), net within continuing operations Derivative, Gain (Loss) on Derivative, Net Actuarial (gains) losses Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Net Actuarial Gain Loss Before Tax Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Net Actuarial Gain Loss Before Tax The net increase or decrease of changes in the value of either the benefit obligation or the plan assets resulting from experience different from that assumed or from a change in an actuarial assumption, or the consequence of a decision to temporarily deviate from the substantive plan, recognized in other comprehensive income. Tax Interest and Penalties Tax Interest and Penalties [Member] Tax Interest and Penalties [Member] Derivative Instruments Derivatives, Policy [Policy Text Block] Total number of share-based awards issued (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Collective-Bargaining Arrangement [Axis] Collective-Bargaining Arrangement [Axis] Early Repayment of Senior Debt Early Repayment of Senior Debt Long-term income tax liabilities (included within other long-term liabilities) Accrued Income Taxes, Noncurrent Entity Wide Disclosure Entity Wide Disclosure On Geographic Areas Attributed To Individual Foreign Countries [Line Items] Entity Wide Disclosure On Geographic Areas Attributed To Individual Foreign Countries [Line Items] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Employee Stock Purchase Plan Employee Stock [Member] Balance at Beginning of Period Balance at End of Period SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Short-term Loan Facility Short-term Loan Facility [Member] Short-term Loan Facility Income Statement Location [Domain] Income Statement Location [Domain] Segment Reporting Reconciliation Item Assets Segment Reporting Reconciliation Item Assets Amounts of assets held by an entity, and used in a reconciliation of assets by segment to the entity consolidated balance sheet. 2022 Lessee, Operating Lease, Liability, to be Paid, Year Two Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain] Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Selling, general and administrative Selling, General and Administrative Expense Amounts Reclassified out of Accumulated Other Comprehensive Income Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis] Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis] Foreign Exchange Contracts Foreign Exchange Contract [Member] Deferred revenue Deferred Tax Assets, Deferred Income Treasury lock agreement payment interest rate swap payments interest rate swap payments interest rate swap payments Lease, Cost Lease, Cost [Table Text Block] Treasury Lock Treasury Lock [Member] 2023 Lessee, Operating Lease, Liability, to be Paid, Year Three Other assets Other Assets, Noncurrent Cash equivalents (money market funds) Cash and Cash Equivalents, Fair Value Disclosure Total assets Assets Total assets Assets Impairment of indefinite-lived intangible assets Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Exercise Price Range [Domain] Exercise Price Range [Domain] Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range 03 Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range 03 [Member] Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices. Non-vested beginning (in shares) Non-vested ending (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Cumulative Effect of New Accounting Principle in Period of Adoption, Increase (Decrease) to AOCI. Cumulative Effect of New Accounting Principle in Period of Adoption, Increase (Decrease) to AOCI. Cumulative Effect of New Accounting Principle in Period of Adoption, Increase (Decrease) to AOCI. Foreign currency translation, tax Foreign currency translation, tax Tax effect on the change in the balance sheet adjustment that results from the adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into reporting currency as of the balance sheet date. Backlog Order or Production Backlog [Member] Amortization of prior service benefit Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Future benefit payments [Abstract] Defined Benefit Plan, Expected Future Benefit Payment [Abstract] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Cost of Product and Services Cost of Sales [Member] Cost of Sales [Member] Japanese Yen Japan, Yen Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Acquisitions Disclosure Mergers, Acquisitions and Dispositions Disclosures [Text Block] Weighted Average Exercise Price (in dollars per share) Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Unrealized gain on equity securities, net Net unrealized gains on our equity securities with RDFV Equity Securities, FV-NI, Unrealized Gain (Loss) Total liabilities Liabilities Issuance date of debt Debt Instrument, Issuance Date Amounts recognized in accumulated other comprehensive income (loss) Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Volatility of Agilent shares (in hundreths) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Less: amount of lease payments representing interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Current medical cost trend rate Current medical cost trend rate Weighted average rate of current medical cost trend rate used to determine net periodic benefit cost of defined benefit plan. Share Repurchase Program [Line Items] Share Repurchase Program [Line Items] Share Repurchase Program [Line Items] Volatility of peer-company shares -Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionspeercompaniesVolatilityRateMinimum The measure of the percentage amount by which a share price fluctuates during a period for peer companies - minimum range. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense Inventory Increase (Decrease) in Inventories Term of the 2018 Stock Plan (in years) Share Based Compensation Arrangement By Share Based Payment Stock Plan Award Terms Of Award Description of pertinent provisions of share based compensation awards that have actual or potential impact upon the company's financial statements. Additional Incremental Term Loan Facility Additional Incremental Term Loan Facility [Member] Additional Incremental Term Loan Facility Employee stock purchase plan [Abstract] Employee stock purchase plan [Abstract] Employee stock purchase plan [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Other assets and liabilities Increase (Decrease) in Other Operating Assets and Liabilities, Net Deferred compensation liability Fair Value Liabilities Measured On Recurring Basis Deferred Compensation Liability This element represents a certain statement of financial position liability which deferred compensation liability, measured at fair value on a recurring basis. Additional Paid-in Capital Additional Paid-in Capital [Member] Short-term debt terms (years) Short-term Debt, Terms Intangibles Deferred Tax Assets, Goodwill and Intangible Assets JAPAN JAPAN Impaired Long-Lived Assets Held and Used by Type [Axis] Impaired Long-Lived Assets Held and Used by Type [Axis] Lasergen Lasergen [Member] Lasergen [Member] Balance (in shares) Balance (in shares) Shares, Issued Machinery and Equipment Machinery and Equipment [Member] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Purchase of non-controlling interests Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Unrecognized tax benefit including interest and penalties Unrecognized tax benefit including interest and penalties Unrecognized tax benefit including interest and penalties. Equity Method Investments Equity Method Investments Common stock outstanding Common Stock, Shares, Outstanding Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Capital loss carryforwards Deferred Tax Assets, Capital Loss Carryforwards Schedule of Goodwill [Table] Schedule of Goodwill [Table] Short-term Debt [Line Items] Short-term Debt [Line Items] Purchases, sales, issuances, and settlements Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Acquisitions of businesses and intangible assets, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Common stock shares authorized (in shares) Common Stock, Shares Authorized Total property, plant and equipment Property, Plant and Equipment, Gross Potential common shares - stock options and other employeee stock plans Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements U.S. federal taxes - deferred Deferred Federal Income Tax Expense (Benefit) 2022 Defined Benefit Plan, Expected Future Benefit Payment, Year Two Beginning balance Ending balance Standard Product Warranty Accrual Proceeds from commercial paper Proceeds from Issuance of Commercial Paper Segment profitability Schedule of Segment Reporting Information, by Segment [Table Text Block] Funded status of plan Defined Benefit Plan, Funded (Unfunded) Status of Plan Defined Benefit Plan, Funded (Unfunded) Status of Plan Net defined benefit pension cost and post retirement plan costs: Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax [Abstract] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Employee compensation and benefits Increase (Decrease) in Employee Related Liabilities Income Statement [Abstract] Income Statement [Abstract] Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Senior Notes 2023 [Member] Senior Notes 2023 [Member] Senior Notes 2023 [Member] Other accrued and long-term liabilities [Member] Other accrued and long-term liabilities [Member] Other accrued and long-term liabilities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] State net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, State and Local Use of Estimates Use of Estimates, Policy [Policy Text Block] Income Tax Authority [Domain] Income Tax Authority [Domain] Equity Securities without Readily Determinable Fair Value Equity Securities without Readily Determinable Fair Value [Member] Equity Securities without Readily Determinable Fair Value Assumptions used to calculate the net periodic cost and benefit obligation Defined Benefit Plan, Assumptions [Table Text Block] Additions and adjustments to other intangibles Finite-Lived Intangible Assets, Period Increase (Decrease) Consolidated Entities [Axis] Consolidated Entities [Axis] Senior Notes 2026 Senior Notes 2026 [Member] Senior Notes 2026 Future Amortization Expense Schedule Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] Scenario [Domain] Scenario [Domain] Investments in property, plant and equipment Capital expenditures Payments to Acquire Property, Plant, and Equipment Consolidation Items [Domain] Consolidation Items [Domain] LONG-TERM DEBT Long-term Debt [Text Block] GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Tax Cuts and Jobs Act, Income Tax Expense (Benefit) Tax Cuts and Jobs Act, Income Tax Expense (Benefit) Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Senior Notes 2030 [Member] Senior Notes 2030 [Member] Senior Notes 2030 Prior service costs (benefits) Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax Lessee Assets and Liabilities Lessee Assets and Liabilities [Table Text Block] Lease Assets and Liabilities balances and classification. Income before taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Hedging Designation [Axis] Hedging Designation [Axis] Employee benefits, other than retirement Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Issuance of senior notes Proceeds from Issuance of Senior Long-term Debt 2026 - 2030 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Inventory Schedule of Inventory, Current [Table Text Block] Federal net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Domestic Product Warranties Disclosures [Abstract] Product Warranties Disclosures [Abstract] Other income (expense) [Member] Other Income [Member] SHORT-TERM DEBT Short-term Debt [Text Block] Equity investments - with readily determinable fair value Equity Securities, FV-NI Entity [Domain] Entity [Domain] Payment of taxes related to net share settlement of equity awards Payment, Tax Withholding, Share-based Payment Arrangement Derivatives Designated as Hedging Instrument Designated as Hedging Instrument Designated as Hedging Instrument [Member] Goodwill Additions Goodwill arising from acquisitions Goodwill, Acquired During Period Revisions [Abstract] Revisions [Abstract] Revisions [Abstract] Retirement of Treasury Shares Retirement of Treasury Shares accounting policy [Policy Text Block] Disclosure of the accounting policy for the retirement of the company's treasury shares. [Policy Text Block] Benefit of income tax holidays on net income per share Income Tax Holiday, Income Tax Benefits Per Share Share Repurchases Authorization Program Date [Domain] Share Repurchases Authorization Program Date [Domain] Date upon which the share repurchase authorization agreement was approved. Unrealized gain on non-marketable equity securities Equity Securities, FV-NI, Unrealized Gain Amortization Expense Other Expenses [Abstract] Property, Plant and Equipment, Useful Life Property, Plant and Equipment, Useful Life Inventories Inventories [Member] Goodwill [Line Items] Goodwill [Line Items] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Employee compensation and benefits Employee compensation and benefits assumed Total obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer) assumed at the acquisition date. Fair Value Disclosures Fair Value Disclosures [Abstract] 2020 Operating Leases, Future Minimum Payments Due, Next Twelve Months Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-based Payment Arrangement, Option, Exercise Price Range [Table] Subsegments Consolidation Items [Axis] Subsegments Consolidation Items [Axis] Deferred tax Assets, net Deferred Tax Assets, Net Deferred Tax Assets, Net Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] operating leased assets - original cost operating leased assets - original cost Original costs for operating leased assets. Accounts receivables Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Share-based compensation disclosures Share-based Payment Arrangement [Abstract] Consolidated Entities [Domain] Consolidated Entities [Domain] Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Operating lease liabilities - Current Less: Current liabilities Operating Lease, Liability, Current Short-term Debt, Weighted Average Interest Rate, at Point in Time Short-term Debt, Weighted Average Interest Rate, at Point in Time Defined Benefit Plan, Ultimate Health Care Cost Trend Rate Defined Benefit Plan, Ultimate Health Care Cost Trend Rate Defined Benefit Plan Us Portfolio Equity Securities Percentage Of Alternative Investments Defined Benefit Plan Us Portfolio Equity Securities Percentage Of Alternative Investments Actual percentage of alternative investments that the US equity portfolio consist. Weighted Averge Shares Used In Computing Net Income Per Share Weighted Averge Shares Used In Computing Net Income Loss Per Share [Abstract] Weighted Averge Shares Used In Computing Net Income Loss Per Share [Abstract] Schedule of Short-term Debt [Table] Schedule of Short-term Debt [Table] Impaired Long-Lived Assets Held and Used, Asset Name [Domain] Impaired Long-Lived Assets Held and Used, Asset Name [Domain] Effect of derivative instruments for foreign exchange contracts in the consolidated statement of operations Derivative Instruments, Gain (Loss) [Table Text Block] Foreited- Weighted Average Grant Price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Maximum employer matching contribution in the 401(k) plan (in hundredths) Defined Contribution Plan, Employer Matching Contribution, Percent of Match Gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Accounts Receivable Accounts Receivable [Member] Interest Rate Swap [Member] Interest Rate Swap [Member] British Pounds United Kingdom, Pounds Aggregate instrinsic value of options [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Total accumulated benefit obligation - aggregate benefit obligation Defined Benefit Plan Accumulated Benefit Obligation Total Aggregate Benefit Obligation If aggregate disclosures are presented for the accumulated benefit obligation, the aggregate fair value of assets. Entity Registrant Name Entity Registrant Name Foreign currency translation, net of tax expense of $(6) and $(5) for 2020 and 2019, respectively Beginning Balance Ending Balance Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Subsequent Event Type [Domain] Subsequent Event Type [Domain] Long-Term [Abstract] Marketable Securities [Abstract] Variable Interest Entity Variable Interest Entity, Not Primary Beneficiary, Disclosures [Abstract] Business Acquisition [Line Items] Business Acquisition [Line Items] Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Share-based compensation arrangement by share-based payment award fair value assumptions and methodology schedule Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Text Block] Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, and long-term performance plan grants. Reconciliation of segment results to total enterprise results Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Diagnostics and Genomics Diagnostics and Genomics [Member] Diagnostics and Genomics segment includes; DNA mutation detection; genotyping; gene copy number determination; identification of gene rearrangements; DNA methylation profiling; gene expression profiling; and automated gel electrophoresis-based sample analysis systems. Provision (benefit) for income taxes Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Debt Instrument, Redemption Period, End Date Debt Instrument, Redemption Period, End Date Payment of dividends Aggregate cash dividends paid Payments of Ordinary Dividends, Common Stock Other Comprehensive Income (Loss), before Reclassifications Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax Equity Securities Equity Securities [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Net Operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract] Dividends date of record Dividends Payable, Date of Record Accounting Standards Update [Axis] Accounting Standards Update [Axis] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Accounting Standards Update 2016-02- Leases Accounting Standards Update 2016-02 [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Deferred Tax Assets, Net of Valuation Allowance Long-term deferred tax assets ( included within other assets) Deferred Tax Assets, Net of Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance ESPP eligible employee common stock purchase price ratio Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Other Comprehensive Income (Loss) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Goodwill Beginning Balance Ending Balance Goodwill Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Acquisition transaction costs Business Acquisition, Transaction Costs Net operating loss, capital loss and credit carryforwards Deferred Tax Assets, Operating Loss Carryforwards Stock Repurchased and Retired During Period, Value Stock Repurchased and Retired During Period, Value Stock Repurchased and Retired During Period, Value Cash Dividends Declared (per common share) Common Stock, Dividends, Per Share, Declared Debt Instrument, Face Amount Aggregate face amount of debt Debt Instrument, Face Amount Other current assets Other Assets, Current Goodwill balances and movements for each reportable segments during the period Schedule of Goodwill [Table Text Block] Equity [Abstract] Equity [Abstract] Fair value of assets, nonrecurring Assets, Fair Value Disclosure Entities [Table] Entities [Table] Repayments Repayments of Short-term Debt Derivative Contract Type [Domain] Derivative Contract [Domain] Derivative Contract [Domain] Future Amortization expense for the next five years and thereafter Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Long -Lived Assets Long -Lived Assets [Abstract] Long -Lived Assets [Abstract] Diluted (in shares) Diluted weighted average shares Weighted Average Number of Shares Outstanding, Diluted Defined Contribution Plan [Table] Defined Contribution Plan [Table] Other accrued liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Number of operating segments Number of Operating Segments Transformational initiatives Transformational Programs The charge against earnings in the period, comprised of costs associated with restructuring activities not otherwise specified in the taxonomy that are not part of a specific plan as required by GAAP. Change in LTPP shares vested in the year- Weighted Average Grant Date Fair Value Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options LTPP Incremental Issuance Nonvested Weighted Average Grant Date Fair Value The weighted average fair value of incremental issuance associated with LTPP nonvested awards on share-based plans excluding option plans (for example, phantom stock plan, stock appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee. Debt Disclosure [Abstract] Debt Disclosure [Abstract] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Goodwill and Intangible Asset Impairment [Abstract] Goodwill and Intangible Asset Impairment [Abstract] Inventory, Current [Table] Inventory, Current [Table] Amortization of Debt Issuance Costs and Discounts Amortization of Debt Issuance Costs and Discounts Restructuring Plan [Axis] Restructuring Plan [Axis] Operating leased assets net book value Operatingleasedassetsnetbookvalue Operating leased assets net book value. Other Segment Reporting Other reconciling items for operating profit loss segment to consolidated Amount of an item in the reconciliation of total profit or loss from reportable segments to the entity's consolidated income before income taxes, extraordinary items, discontinued operations. Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Short-term Debt, Type [Axis] Short-term Debt, Type [Axis] Schedule of share-based compensation, shares authorized under stock option plans, by exercise price range Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Employee Compensation and Benefits Employee-related Liabilities [Abstract] Revenue, Remaining Performance Obligation, Amount Revenue, Remaining Performance Obligation, Amount Accounting Standards Update and Change in Accounting Principle [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Balance, beginning of year Balance, end of year Unrecognized Tax Benefits Common stock; $0.01 par value; 2 billion shares authorized; 306 million shares at October 31, 2020 and 309 million shares at October 31, 2019 issued and outstanding Common Stock, Value, Issued Long-term investments Long-term investments Long-term Investments 2024 Defined Benefit Plan, Expected Future Benefit Payment, Year Four Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Document Fiscal Year Focus Document Fiscal Year Focus 2022 Finite-Lived Intangible Asset, Expected Amortization, Year Two Assets, Long-term [Abstract] Assets, Noncurrent [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] Benefit Obligation Balance, Beginning of year Benefit Obligation Balance, end of year Benefit Obligation Defined Benefit Plan, Benefit Obligation Settlements with taxing authorities Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Entity Current Reporting Status Entity Current Reporting Status Net Income (Loss) Per Share Earnings Per Share, Policy [Policy Text Block] Total comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Realized gains/(losses) Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Sold Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Percentage which rate options generally vest per year (in hundredths) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Common stock issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Investments Segment Reporting Reconciliation Item Investments Amount of investments held by an entity, and used in a reconciliation of assets by segment to the entity consolidated balance sheet. Number Outstanding (in shares) Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding Present value of future minimum lease payments Operating Lease, Liability Long-term deferred tax liabilities ( included within other long-term liabilities) Deferred Tax Liabilities, Net Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net Long-term debt Long-term Debt, Excluding Current Maturities Segment Reporting [Abstract] Segment Reporting [Abstract] Share Repurchase Program [Axis] Share Repurchase Program [Axis] OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss Other Comprehensive Income (Loss), Defined Benefit Plan, Transition Asset (Obligation), Reclassification Adjustment from AOCI, before Tax Total stockholders' equity Stockholders' Equity Attributable to Parent Non-U.S. income taxed at different rates Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Purchase price for acquisition Business Combination, Consideration Transferred 5 yr unsecured credit facility 5 yr Unsecured Credit Facility [Member] 5 yr Unsecured Credit Facility Entity Address, City or Town Entity Address, City or Town Employee compensation and benefits Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Payment to acquire intangible assets Payments to Acquire Intangible Assets Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year Total Stockholders Equity Parent [Member] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Five Compensation percentage maximum eligible contribution to purchase shares of common stock Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate Other Assets Other Assets [Member] Financial Instrument [Axis] Financial Instrument [Axis] Accounting Standards Update [Domain] Accounting Standards Update [Domain] 2023 Operating Leases, Future Minimum Payments, Due in Four Years Change in net prior service benefit, tax (benefit) Tax (expense) benefit Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Tax Products Product [Member] Short-term Lease, Cost Short-term Lease, Cost Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease) Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease) Change in actuarial net loss, tax expense (benefit) Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax Write-off of fully amortized intangible assets Write-off of fully amortized intangible assets Write-off of gross carrying amount and related accumulated amortization of fully amortized intangible assets that are no longer in use. Deferred Tax Liabilities, Leasing Arrangements Deferred Tax Liabilities, Leasing Arrangements Tax valuation allowance Deferred Tax Assets, Valuation Allowance Pair-wise correlation with selected peers (in hundredths) Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Peer Company Shares Price Wise Correlationy Rate The measure of the percentage amount of share price correlation during the period with a selected group of peer companies. Pair-wise correlations with selected peers is calculated as the correlation between each pair and the sum of correlations divided by the number of pairs to produce the average correlation between each pair. Currency impact Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Three Accounting Guidance [Domain] Accounting Guidance [Domain] Other accrued liabilities Other Liabilities, Current AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member] Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Nature of Uncertainty [Domain] Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Nature of Uncertainty [Domain] Other comprehensive loss Other comprehensive income (loss) Other Comprehensive Income (Loss) Other Comprehensive Income (Loss), Net of Tax Leases [Abstract] Leases [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Net income per share: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Significant components of deferred tax assets and deferred tax liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Sales-type Lease, Lease Receivable Sales-type Lease, Lease Receivable Amortization of prior service benefit Amortization of prior service benefit Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax Derivative, Fair Value, Net [Abstract] Derivative, Fair Value, Net [Abstract] Non-Instrumentation and Other Non-Instrumentation and Other [Member] Non-Instrumentation and Other[Member] Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Retirement and post-retirement benefits Retirement and post-retirement benefits [Member] Retirement and post-retirement benefits [Member] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Fiscal Period Focus Document Fiscal Period Focus Total Total income tax payable, net of income tax receivable Total amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes. Software Development Software Development [Member] Equity Securities with Readily Determinable Fair Value Equity Securities with Readily Determinable Fair Value [Member] Equity Securities with Readily Determinable Fair Value Incentive compensation plans [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Non-controlling interest Noncontrolling Interest, Period Increase (Decrease) Employer contributions Defined Benefit Plan, Plan Assets, Contributions by Employer Collective-Bargaining Arrangement [Domain] Collective-Bargaining Arrangement [Domain] Third-Party Technology and Licenses [Member] Third-Party Technology and Licenses [Member] Third-Party Technology and Licenses [Member] Debt Instrument, Redemption Price, Percentage Debt Instrument, Redemption Price, Percentage Entity Filer Category Entity Filer Category Allocated Share-based compensation expense disclosure Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Common Stock Common Stock [Member] Accumulated Foreign Currency Adjustment Attributable to Parent Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Product and Service [Domain] Product and Service [Domain] Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Maximum final share award percentage of the target award based on performance metrics (in hundredths) Share Based Compensation Arrangement Maximum Payout Range The maximum payout range for participants of the original target grant based upon the company's attainments of pre-established operating ratio targets. 401(k) Plan employer expense Defined Contribution Plan, Cost Fair value of plan assets for defined benefit pension plan where the fair value of plan assets exceeds ABO. Fair value of plan assets for defined benefit pension plan where the fair value of plan assets exceeds ABO. Fair value of plan assets for defined benefit pension plan where the fair value of plan assets exceeds accumulated benefit obligation. Other Commitments [Axis] Other Commitments [Axis] Prospective Adoption of New Accounting Pronouncements [Axis] Prospective Adoption of New Accounting Pronouncements [Axis] Schedule of Product Warranty Liability classification Schedule of Product Warranty Liability classification [Table Text Block] Schedule of Product Warranty Liability classification [Table Text Block] Payments to Noncontrolling Interests Proceeds from (Payments to) Noncontrolling Interests Amounts recognized in the consolidated balance sheet Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract] Revision of Prior Period [Domain] Revision of Prior Period [Domain] Fixed interest rate per annum (in hundredths) Debt Instrument, Interest Rate, Stated Percentage Projected benefit obligation and fair value of plan assets [Abstract] Defined Benefit Plan Analysis Of Benefit Obligations In Relation To Fair Value Of Plan Assets [Abstract] Defined Benefit Plan Analysis Of Benefit Obligations In Relation To Fair Value Of Plan Assets [Abstract] Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Share-based Payment Arrangement, Option Stock Options Share-based Payment Arrangement, Option [Member] Subsegments Consolidation Items [Domain] Subsegments Consolidation Items [Domain] Interest Rate Swap On Senior Notes [Axis] Interest Rate Swap On Senior Notes [Axis] Pertinent information about each long-term debt arrangement including the carrying amount as of the balance sheet date, by type of long-term debt. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer. Volatility of peer-company shares -Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionspeercompaniesVolatilityRateMaximum The measure of the percentage amount by which a share price fluctuates during a period for peer companies - maximum range. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. State taxes, net of federal benefit - deferred Deferred State and Local Income Tax Expense (Benefit) Expected long-term return on assets (in hundredths) Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets U.S. operations Income (Loss) from Continuing Operations before Income Taxes, Domestic Interest payments Interest Paid, Excluding Capitalized Interest, Operating Activities Tax Period [Domain] Tax Period [Domain] Net operating loss carryforwards, not subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration Equity investments - without readily determinable fair value Carrying amount of non-marketable equity securities without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Balance Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Unrecognized Tax Benefits Rollforward Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued [Abstract] Additional paid-in-capital Additional Paid in Capital 2021 Finite-Lived Intangible Asset, Expected Amortization, Year One State California Franchise Tax Board [Member] 2022 Operating Leases, Future Minimum Payments, Due in Three Years Class of Stock [Axis] Class of Stock [Axis] Curtaliment and settlement Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment Aggregated notional amounts by currency and designation Schedule of Derivative Instruments [Table Text Block] Asset impairment charges Impairment of Intangible Assets (Excluding Goodwill) Maturity date Debt Instrument, Maturity Date Long Term Deferred Tax Assets And Liabilities [Abstract] Current And Long Term Deferred Tax Assets And Liabilities [Abstract] Current And Long Term Deferred Tax Assets And Liabilities [Abstract] Remaining gain loss to be amortized on derivative Remaining gain loss to be amortized on derivative Remaining gain loss to be amortized on derivative Net income per share - diluted Earnings Per Share, Diluted Revenue and assets by geographic areas Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] 2021 Operating Leases, Future Minimum Payments, Due in Two Years Net operating loss carryforwards, subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Guarantees [Abstract] Guarantees [Abstract] Tax (expense) benefit Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Goodwill and Purchased Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Weighted Average Remaining Contractual Life (in years) Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term Long-term debt - Senior Notes Schedule of Long-term Debt Instruments [Table Text Block] Depreciation expense Depreciation Entity Address, Address Line One Entity Address, Address Line One Entity Emerging Growth Company Entity Emerging Growth Company In-Process R&D Indefinite-lived Intangible Assets (Excluding Goodwill) Environmental and Forensics Market Environmental and Forensics Market [Member] Environmental and Forensics Market [Member] Proforma net revenue Business Acquisition, Pro Forma Revenue Deferred taxes Deferred Income Tax Expense (Benefit) Derivative Liability, Fair Value Derivative Liability, Fair Value, Gross Liability Long lived assets held for sale Impairment Impairment of Long-Lived Assets to be Disposed of Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Maximum 5 Percent Maximum [Member] Preferred stock shares authorized (in shares) Preferred Stock, Shares Authorized Non-controlling Interest Noncontrolling Interest [Member] Share-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Cash dividends declared Cash dividends declared Dividends, Common Stock, Cash Aggregate participants contributions to ESPP Aggregate participants contributions to ESPP Aggregate participant contributions to employee stock purchase plan for the purchase of shares of the company's common stock not yet issued to participants at the end of the period. Shares are excluded from the available for issuance balance at the end of the period. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Effective tax rate (in hundredths) Effective Income Tax Rate Reconciliation, Percent Accounts Receivable Accounts Receivable Additional Disclosures [Abstract] Amortization of net prior service cost (benefit) Defined Benefit Plan, Expected Amortization of Prior Service Cost (Credit), Next Fiscal Year Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Total projected benefit obligation - aggregate benefit obligation Defined Benefit Plan Projected Benefit Obligation Total Aggregate Benefit Obligation If aggregate disclosures are presented for the projected benefit obligation, the aggregate benefit obligation value. Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit) Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit) Other Postretirement Benefits Plan [Member] Other Postretirement Benefits Plan [Member] Trading Symbol Trading Symbol Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Issuance of common stock under employee stock plans Amount of cash received from the exercise of share-based awards granted Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised Settlements made during the period Standard Product Warranty Accrual, Decrease for Payments Contract with Customer, Asset, after Allowance for Credit Loss Contract with Customer, Asset, after Allowance for Credit Loss Penalty reduce over period of time Penalty reduce over period of time [Member] Penalty reduce over period of time [Member] Debt Instrument, Redemption Period, Start Date Debt Instrument, Redemption Period, Start Date Debt Instrument, Increase, Accrued Interest Debt Instrument, Increase, Accrued Interest Non-U.S. operations Income (Loss) from Continuing Operations before Income Taxes, Foreign Entity Shell Company Entity Shell Company Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Fair Value, Recurring Fair Value, Recurring [Member] Extension of the tax incentive in Singapore Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount Entity Public Float Entity Public Float Entity Wide Disclosure On Geographic Areas Attributed To Individual Foreign Countries [Table] Entity Wide Disclosure On Geographic Areas Attributed To Individual Foreign Countries [Table] Entity Wide Disclosure On Geographic Areas Attributed To Individual Foreign Countries [Table] Acquisitions Business Combinations Policy [Policy Text Block] Document Type Document Type ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Other income (expense), net Other Nonoperating Income (Expense) Standard Warranty Schedule of Product Warranty Liability [Table Text Block] Deferred Profit Sharing Deferred Profit Sharing [Member] Total liabilities measured at fair value Fair Value Liabilities Measured On Recurring Basis Total Liabilities This element represents total liabilities, measured at fair value on a recurring basis. Components of intangible assets acquired Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Segments [Axis] Business Segments [Axis] Segments [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS Retirement Benefits [Text Block] Accumulated other comprehensive income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] In Process Research and Development In Process Research and Development [Member] Vested- Weighted Average Grant Price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Gain (loss) on derivative instruments, net of tax expense (benefit) of $(3), $(2) and $1 Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Excess and obsolete inventory related charges Inventory-related excess and obsolescence charges Inventory Write-down Change in unrecognized tax benefits Income tax reconciliation change in US deferred tax reserves Income tax reconciliation change in US deferred tax reserves Leases Lessee, Leases [Policy Text Block] Other Current Assets [Member] Other Current Assets [Member] Change in LTPP shares vested in the year due to performance conditions Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Incremental Issuance In Period The issuance in the number of non-vested shares under a share-based award plan made during the period on other than stock option plans (for example, phantom stock plan, stock appreciation rights plan, performance target plan). Change in actuarial net loss, net of tax expense (benefit) of $0, $(25) and $(3) Other comprehensive income (loss) Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax Benefits paid Defined Benefit Plan, Plan Assets, Benefits Paid Prepaid expenses Segment Reporting Reconciliation Item Prepaids Amount of prepaid expense balance held by an entity, and used in a reconciliation of assets by segment to the entity consolidated balance sheet. Indefinite-lived Intangible Assets, Purchase Accounting Adjustments Indefinite-lived Intangible Assets, Purchase Accounting Adjustments Line of Credit Line of Credit [Member] Retirement and Post-Retirement Plans Pension and Other Postretirement Plans, Policy [Policy Text Block] DERIVATIVES Derivative Instruments and Hedging Activities Disclosure [Text Block] Interest Rate Swap On Senior Notes [Domain] Interest Rate Swap On Senior Notes [Domain] Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer. Advertising Expense Marketing and Advertising Expense [Abstract] Other intangible assets, net Other intangible assets, net Intangible Assets, Net (Excluding Goodwill) Accruals for warranties due within one year Standard Product Warranty Accrual, Current Post-vest restriction discount for all executive awards Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions Tradenames and trademarks Trademarks and Trade Names [Member] Deferred revenue Deferred Revenue, Current Income from operations Income from operations Operating Income (Loss) Debt issuance costs Payments of Debt Issuance Costs Weighted Average Exercise Price (in dollars per share) Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price Defined Contribution Plan Disclosure [Line Items] Defined Contribution Plan Disclosure [Line Items] Unrealized losses on defined benefit plans, tax Unrealized losses on defined benefit plans, tax The tax effect of the total net gains (losses) and changes in benefit cost which haven't yet been recognized as components of periodic benefit costs, as of the balance sheet date. Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Contract with Customer, Asset and Liability Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Variable Rate [Axis] Variable Rate [Axis] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Gain on step acquisition Remeasurement Gain on step acquisition Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain Commitments and contingencies (Note 17) Commitments and Contingencies Maximum employee contribution to 401(k) Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Treasury stock repurchases Payments for Repurchase of Common Stock Number of years from the date of grant generally vest (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Entity Address, State or Province Entity Address, State or Province Schedule of Defined Benefit Plans Disclosures Schedule of Defined Benefit Plans Disclosures [Table Text Block] Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Other Comprehensive Income (Loss), before Reclassifications Other Comprehensive Income (Loss), before Tax Profit before tax times statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Accounts payable Accounts Payable, Current Foreign currency translation impact Goodwill, Foreign Currency Translation Gain (Loss) Sublease Income Sublease Income Capitalized Software Internal Use Software, Policy [Policy Text Block] Retained earnings (accumulated deficit) Retained Earnings (Accumulated Deficit) 2019 Repurchase Program [Member] 2019 Repurchase Program [Member] 2019 Repurchase Program [Member] Right-of-use asset Operating Lease, Right-of-Use Asset Repayments of debt and credit facility Repayments Repayments of Lines of Credit Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Accounting Standards Update 2016-01 Accounting Standards Update 2016-01 [Member] Property, plant and equipment Deferred Tax Liabilities, Property, Plant and Equipment Defined benefit plans assets measured at fair value using significant unobservable inputs (level 3) Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block] Income tax payments, net Income Taxes Paid Swiss Franc Switzerland, Francs Property, plant, and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Total equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Weighted-average period non-vested restricted stock awards are expected to be amortized over (in years) Employee Service Share Based Compensation Unrecognized Compensation Costs On Nonvested Equity Other Than Stock Option Awards Weighted Average Period Of Recognition The weighted average period over which unrecognized share-based compensation costs on equity other than stock options are expected to be reported Foreign exchange translation impact to other intangible assets Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss) Taxes on Income Income Tax, Policy [Policy Text Block] Hedging Designation [Domain] Hedging Designation [Domain] Lease, Cost Lease, Cost Machinery and equipment Machinery and Equipment, Gross Impairment of Long-lived assets included in net income Impairment of Long-lived assets included in net income [Text Block] For long-lived assets of an entity, disclosures may include a description of the impaired long-lived asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired long-lived asset is reported. Share-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Senior Notes 2029 Senior Notes 2029 [Member] Senior Notes 2029 [Member] Difference between Revenue Guidance in Effect before and after Topic 606 Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Options Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Net revenue Revenue from Contract with Customer, Excluding Assessed Tax Advertising costs expensed as incurred Advertising Expense Inventory [Line Items] Inventory [Line Items] Lender Name [Axis] Lender Name [Axis] Investments Investment, Policy [Policy Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Geographical [Domain] Geographical [Domain] Gain due to settlement Pension settlement gain Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Number Of Foreign Exchange Forward Contracts Not Designated As Hedges Number Of Foreign Exchange Forward Contracts Not Designated As Hedges Number of foreign currency exchange forward contract derivatives held by the entity at the reporting date and not designated as hedges. Deferred revenue Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Non-U.S. taxes - deferred Deferred Foreign Income Tax Expense (Benefit) Share Repurchases Program Authorization Date [Axis] Share Repurchases Program Authorization Date [Axis] Share repurchases programs by authorization date. Payment in exchange for convertible note Payments to Acquire Notes Receivable Entity Voluntary Filers Entity Voluntary Filers Acquisition and integration costs Business Combination, Acquisition Related Costs Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Credit Facility [Axis] Credit Facility [Axis] Preferred Stock, Shares Issued (in shares) Preferred Stock, Shares Issued Sharebased Compensation Arrangement By Exercise Price Range [Abstract] Sharebased Compensation Arrangement By Sharebased Payment Award Stock Option Plan By Exercise Price Range [Abstract] Sharebased Compensation Arrangement By Sharebased Payment Award Stock Option Plan By Exercise Price Range [Abstract] Assumptions used to calculate the benefit obligation Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] Land Land Foreign Foreign Tax Authority [Member] Business Combinations [Abstract] Business Combinations [Abstract] Standard Product Warranty Accrual, Balance Sheet Classification [Abstract] Standard Product Warranty Accrual, Balance Sheet Classification [Abstract] Retirement Plan Name [Domain] Retirement Plan Name [Domain] Interest Rate Derivatives Terminated Date Interest Rate Derivatives Terminated Date Interest Rate Swap Terminated Date Future Minimum Lease Payment Due Lessee, Operating Lease, Liability, Payment, Due [Abstract] Purchased parts and fabricated assemblies Inventory, Work in Process and Raw Materials Malaysian Ringgit Malaysia, Ringgits Selling, General and Administrative Selling, General and Administrative Expenses [Member] Terminated Interest Rate Fair Value Hedge Derivative Assets At Fair Value Terminated Interest Rate Fair Value Hedge Derivative Assets At Fair Value The asset value of interest rate swap contracts upon termination. Goodwill - Rollforward Goodwill [Roll Forward] Reconciliation of the numerators and denominators of the basic and diluted net income per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Line of credit facility expiration date Line of Credit Facility, Expiration Date Fair value of long term debt in excess of carrying value Fair value of long term debt in excess of carrying value Amount of fair value of long term debt in excess of carrying value. Schedule of the fair value of assets and liabilities assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Real Estate Real Estate [Member] Foreign Currency Translation Foreign Currency Translation [Abstract] Operating cash flow from operating leases Operating Lease, Payments, Use Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Funded status of plan [Abstract] Defined Benefit Plan, Funded (Unfunded) Status of Plan [Abstract] Deferred tax assets - lease obligations Deferred tax assets - lease obligations Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease arrangements. Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Entity Central Index Key Entity Central Index Key Derivative Instrument Risk [Axis] Derivative Instrument [Axis] Derivative Instrument [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Current income tax assets (included within other current assets) Income Taxes Receivable, Current Geographical [Axis] Geographical [Axis] Valuation allowances Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Segments [Domain] Segments [Domain] Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax [Abstract] Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax [Abstract] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Line of Credit Facility [Abstract] Line of Credit Facility [Abstract] Transitional company contribution to employee 401(k) Transitional company contribution to employee 401(k) Additional transitional company contribution to employee 401(k) plans for certain employees. Proforma net income Business Acquisition, Pro Forma Net Income (Loss) Effect of exchange rate movements Effect of Exchange Rate on Cash and Cash Equivalents Income Statement Location [Axis] Income Statement Location [Axis] Weighted Average Remaining Contractual Life (in years) Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Accruals for warranties due after one year Standard Product Warranty Accrual, Noncurrent Total Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax Accounts Receivable, net Receivable [Policy Text Block] U.S. federal taxes - current Current Federal Tax Expense (Benefit) Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Derivative, Notional Amount Derivative, Notional Amount Amortization of intangible assets during the period Amortization of Intangible Assets Line of Credit Facility [Table] Line of Credit Facility [Table] Prior service cost (benefit) Other Comprehensive (Income) Loss, before Reclassifications Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Statement, Scenario [Axis] Scenario [Axis] Scenario [Axis] Combined projected benefit obligation, accumulated benefit obligations and fair value of plan assets Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block] Notional Amount Of Terminated Interest Rate Fair Value Hedge Derivatives Notional Amount Of Terminated Interest Rate Fair Value Hedge Derivatives Aggregate notional amount of all interest rate derivatives designated as hedging instruments in fair value hedges that were terminated. Notional amount refers to the monetary amount specified in the interest rate derivative contract. Amounts Recognized in Accumulated Other Comprehensive Income (loss): [Abstract] Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract] Title of 12(b) Security Title of 12(b) Security Total amortizable intangible assets Finite-Lived Intangible Assets, Net Long-Lived Assets Long-Lived Assets Business exit and divestiture costs Business Exit Costs Assets for Plan Benefits, Defined Benefit Plan Assets for Plan Benefits, Defined Benefit Plan Current income tax liabilities (included within other accrued liabilities) Accrued Income Taxes, Current Korean Won Korea (South), Won Business Description and Basis of Presentation Business Description and Basis of Presentation [Text Block] Dividends [Abstract] Dividends [Abstract] Interest expense Interest Expense Interest Expense India, Rupees India, Rupees Closing stock price basis for aggregate intrinsic value (in dollars per share) Entity Closing Stock Price Fair market closing stock price for entity share at end of fiscal year as reflected on national stock exchange. Depreciation and amortization Depreciation, Depletion and Amortization Provision for income taxes from operations Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Accounting Standards Update and Change in Accounting Principle -Leases Accounting Standards Update and Change in Accounting Principle [Table Text Block] Product and Service [Axis] Product and Service [Axis] Canadian Dollars Canada, Dollars Date payments commenced Debt Instrument, Date of First Required Payment Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member] Balance, end of year Balance, end of year Assets, usually stocks, bonds, and other investments, that have been segregated and restricted (usually in a trust) to provide benefits, at their fair value as of the measurement date. Plan assets include amounts contributed by the employer (and by employees for a contributory plan) and amounts earned from investing the contributions, less benefits paid. If a plan has liabilities other than for benefits, those non-benefit obligations may be considered as reductions of plan assets. Other Noncurrent Assets [Member] Other Noncurrent Assets [Member] Non-US Non-US [Member] Diagnostics and Clinical Market Diagnostics and Clinical Market [Member] Diagnostics and Clinical Market [Member] Senior Notes 2020 Senior Notes 2020 [Member] Notes Payable with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), including current and non-current portion. Senior note holders are paid off in full before any payments are made to junior note holders. Position [Domain] Position [Domain] Amounts Reclassified Amounts Reclassified out of Accumulated Other Comprehensive Income Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax Contract with Customer, Liability, Revenue Recognized Contract with Customer, Liability, Revenue Recognized Unrealized gains (losses) on derivative instruments, tax Unrealized gains (losses) on derivative instruments, tax Tax effect on the change in the balance sheet adjustment that results from the unrealized gains (losses) on derivative instruments as of the balance sheet date. Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accounts payable Increase (Decrease) in Accounts Payable Food Market Food Market [Member] Food Market [Member] Aggregate cash dividends paid (per common share) Common Stock, Dividends, Per Share, Cash Paid Interest payment frequency Debt Instrument, Frequency of Periodic Payment Schedule of intrinsic value of options exercised and the fair value of options granted Share Based Compensation Arrangement By Share Based Payment Award Fair Value Intrinsic Value Options Exercised [Text Block] Disclosure of grant date fair value of stock options granted and the intrinsic value of a stock option exercised during the period under share-based compensation plan. Debt Instrument [Axis] Debt Instrument [Axis] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Class of Stock [Line Items] Class of Stock [Line Items] Amounts reclassified into earnings related to derivative instruments, net of tax expense (benefit) of $0, $(2). and $1 Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax Derivative instruments (foreign exchange contracts) Derivative Liability Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Change in assets and liabilities due to Tax Act Change in assets and liabilities due to Tax Act Change in assets and liabilities due to Tax Act Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Other Investments Other Plan Assets [Member] Assets held in a defined plan not otherwise previously defined. Operating Activities [Domain] Operating Activities [Domain] Entity Information [Line Items] Entity Information [Line Items] Variable Lease, Cost Variable Lease, Cost State income taxes, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Non-vested at October 31, 2020 -Weighted Average Grant Price (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Period End Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Period End Number Exercisable (in shares) Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Loss Contingencies by Nature of Contingency [Axis] Loss Contingency Nature [Axis] Research and development Research and Development Expense Projected Benefit Obligation Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation Variable Interest Entity, Not Primary Beneficiary Variable Interest Entity, Not Primary Beneficiary [Member] Subsequent Event Subsequent Event [Member] Domestic Domestic Tax Authority [Member] Bank Guarantees Letters of Credit Outstanding, Amount LTPP & RSU LTPP & RSU [Member] LTPP & RSU [Member] Restructuring Plan [Domain] Restructuring Plan [Domain] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Revenue Recognition Revenue [Policy Text Block] Impairment of Long-Lived Assets Long-lived assets held for use impairment Impairment of Long-Lived Assets Held-for-use Liability incurred to pay for acquisition Business Combination, Consideration Transferred, Liabilities Incurred Pharmaceutical and Biopharmaceutical Market Pharmaceutical and Biopharmaceutical Market [Member] Pharmaceutical and Biopharmaceutical Market [Member] Number of customers representing 10 percent or more of accounts receivable. Number of customers representing 10 percent or more of total net revenue Number of Significant Customers Number of Customers representing 10 percent or more of the balance. Operating lease liabilities - Long-term Long-term lease liabilities Operating Lease, Liability, Noncurrent 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Four Accruals for warranties including change in estimates Standard Product Warranty Accrual, Increase for Warranties Issued Total rent expense Operating Leases, Rent Expense Income Tax Holiday [Table] Income Tax Holiday [Table] Beginning Balance Ending Balance Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax Loss on interest rate swaps recognized in other comprehensive income (loss) Gain (loss) recognized in accumulated other comprehensive income(loss) Loss on interest rate swap Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax Income before income tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract] Current assets: Assets, Short-term [Abstract] Assets, Current [Abstract] Aggregate Intrinsic Value of Stock options Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Aggregate Intrinsic Value As of the balance sheet date, the total dollar difference between fair values of the underlying shares reserved for issuance and exercise prices of the options exercised in period. Interest income Interest income Investment Income, Interest Credit facility initiation date Line of Credit Facility, Initiation Date Amortization Amortization Excess tax benefits from stock-based compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount Remaining authorized repurchase amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Early repayment of senior notes including prepayment penalty Early repayment of senior notes including prepayment penalty The cash outflow for the extinguishment of long-term borrowing (including prepayment penalty), with the highest claim on the assets of the entity in case of bankruptcy or liquidation, before its maturity. Subsegments [Domain] Subsegments [Domain] Total comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Foreign currency Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax Preferred stock par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Documents Incorporated by Reference [Text Block] Documents Incorporated by Reference [Text Block] Tax rate reconciliation, U.S. federal statutory rate to effective tax rate from operations Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Deductions Credited to Expenses or Other Accounts SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Asia Pacific Asia Pacific [Member] City Area Code City Area Code Legal Entity [Axis] Legal Entity [Axis] Income Tax Authority [Axis] Income Tax Authority [Axis] Document Period End Date Document Period End Date Net Investment Hedging Net Investment Hedging [Member] Net asset value excluded from fair value by input Net asset value excluded from fair value by input Represents investments for which fair value is measured using net asset value (NAV) per share practical expedient, and excluded from the fair value schedule by input. Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Authorized Amount Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Summary of standard warranty accrual activity Movement in Standard Product Warranty Accrual [Roll Forward] Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, Tax Trading securities Debt Securities, Trading, and Equity Securities, FV-NI Share-based compensation expense Share-based Payment Arrangement, Amount Capitalized Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Share-based compensation Share-based Payment Arrangement, Noncash Expense Amounts in accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year Schedule of Amounts in Accumulated Other Comprehensive Income (Loss) to be Recognized over Next Fiscal Year [Table Text Block] Intangible Assets, Including Goodwill) Intangible Assets, Net (Including Goodwill) [Abstract] Cover [Abstract] Ultimate medical cost trend rate Ultimate medical cost trend rate Weighted average rate of ultimate medical cost trend rate used to determine net periodic benefit cost of defined benefit plan. Stock Repurchased and Retired During Period, Shares Stock Repurchased and Retired During Period, Shares Stock Repurchased and Retired During Period, Shares Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Change in net prior service benefit, net of tax benefit of $(1), $(2) and $(2) Other Comprehensive (Income) Loss Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax Income before income taxes domestic and foreign Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Fixed Income Securities Fixed Income Securities [Member] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] Increase (Decrease) in Contract with Customer, Liability Increase (Decrease) in Contract with Customer, Liability Lessee, Operating Leases Lessee, Operating Leases [Text Block] Participant's contributions Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant Employee compensation and benefits accrued Accrued Employee Benefits Retirement Plan Name [Axis] Retirement Plan Name [Axis] Service cost - benefits earned during the period Service cost Defined Benefit Plan, Service Cost Customer relationships Customer Relationships Customer Relationships [Member] Cost of revenue Cost of Goods and Services Sold Tax Holidays [Abstract] Tax Holidays [Abstract] Tax Holidays [Abstract] Total costs and expenses Costs and Expenses Equity Components [Axis] Equity Components [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Subtotal Deferred Tax Assets, Gross Minimum 3 Percent Minimum [Member] Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Balance Sheet Location [Domain] Balance Sheet Location [Domain] Long-term income tax assets (included within other assets) Income Taxes Receivable, Noncurrent Long-term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Accumulated benefit obligation in excess of fair value of plan assets - aggregate benefit obligation Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation Europe Europe [Member] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Equity Securities Defined Benefit Plan, Equity Securities [Member] Amortization of net actuarial loss Defined Benefit Plan, Amortization of Gain (Loss) Amounts recognized in the consolidated balance sheet Schedule of Amounts Recognized in Balance Sheet [Table Text Block] Entity Interactive Data Current Entity Interactive Data Current Total periodic benefit cost (benefit) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) U.S. Plan UNITED STATES UNITED STATES Schedule of Allocation of Plan Assets Schedule of Allocation of Plan Assets [Table Text Block] Weighted-average exercise price per share, exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Restricted Cash and Cash Equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Net revenue: Revenues [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Segment Total Segment Total [Member] Reportable amounts associated with all reporting segments included in a reconciliation from segment reporting to consolidated income from operations, before taxes. STOCKHOLDERS EQUITY Stockholders' Equity Note Disclosure [Text Block] Capital Loss Carryforward Deferred Tax Assets, Operating Loss Carryforwards, Alternative [Abstract] Share-Based Compensation Share-based Payment Arrangement [Policy Text Block] Movement in valuation and qualifying accounts [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Non-U.S. taxes - current Current Foreign Tax Expense (Benefit) Fair value of plan assets for defined benefit plan with benefit obligation in excess of plan assets. Fair value of plan assets for defined benefit plan with benefit obligation in excess of plan assets. Fair value of plan assets for defined benefit plan with benefit obligation in excess of plan assets. Chemical and Energy Market Chemical and Energy Market [Member] Chemical and Energy Market [Member] Derivative [Table] Derivative [Table] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Schedule of Acquired Finite-Lived Intangible Assets by Major Class Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] 2021 Defined Benefit Plan, Expected Future Benefit Payment, Year One Subtotal Deferred Tax Liabilities, Gross Advertising Advertising Cost [Policy Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Nonvested Additional Disclosures [Abstract] Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Nonvested Additional Disclosures [Abstract] Proceeds from the sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Total intangible assets acquired - excluding goodwill Gross Book Value Intangible Assets, Gross (Excluding Goodwill) Retirement Plan Type [Domain] Retirement Plan Type [Domain] End Markets [Domain] End Markets [Domain] [Domain] for End Markets [Axis] Exercise Price Range [Axis] Exercise Price Range [Axis] Additions Charged to Expenses or Other Accounts SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months Consolidation Items [Axis] Consolidation Items [Axis] Research and Development Research and Development Expense [Member] Forward Contracts Buy/(Sell) Forward Contracts [Member] Net actuarial (gain) loss Other Comprehensive Income (Loss), before Reclassifications Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax Payments to acquire fair value investments Payments to Acquire Other Investments Derivatives Not Designated as Hedging Instruments Not Designated as Hedging Instrument [Member] Accrued Liabilities [Member] Accrued Liabilities [Member] Goodwill impairment Goodwill, Impairment Loss Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Unrealized losses (including prior service benefit) on defined benefit plans, net of tax benefit of $154 and $153 for 2020 and 2019, respectively Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Finished goods Inventory, Finished Goods, Gross Total undiscounted future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Other Deferred Tax Assets, Other Non-U.S. Plans Foreign Plan [Member] Components of Deferred Tax Liabilities Components of Deferred Tax Liabilities [Abstract] Income Tax Holiday [Line Items] Income Tax Holiday [Line Items] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Trademark/Tradename Trademarks [Member] Dividends payment date Dividends Payable, Date to be Paid Dividends Payable, Date Declared Dividends Payable, Date Declared Net change in property, plant and equipment increase (decrease) Non-cash changes in investments in property, plant and equipment increase (decrease) Changes to the cost of fixed assets that are not the result of cash capital expenditures. Other Comprehensive Income (Loss) [Member] Other Comprehensive Income (Loss) [Member] Proforma net income per share - basic Business Acquisition, Pro Forma Earnings Per Share, Basic Gain(loss reclassified from accumulated other comprehensive income (loss) into cost of sales Unrealized gains (losses) on derivatives reclassification out of AOCI to cost of sales Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net Australian Dollars Australia, Dollars Document Transition Report Document Transition Report Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Unrealized gains/(losses) Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held Derivative Asset, Fair Value Derivative Asset, Fair Value, Gross Asset Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Sell Short [Member] Tax Credit Carryforwards Deferred Tax Assets, Tax Credit Carryforwards [Abstract] Net periodic benefit cost (benefit) [Abstract] Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] BioTek BioTek [Member] BioTek [Member] Post-Retirement Benefit Plan Postretirement Health Coverage [Member] Minimum final share award percentage of the target award based on performance metrics (in hundredths) Share Based Compensation Arrangement Minimum Payout Range The minimum payout range for participants of the original target grant based upon the company's attainments of pre-established operating ratio targets. Revision of Prior Period, Accounting Standards Update, Adjustment Revision of Prior Period, Accounting Standards Update, Adjustment [Member] Credit Faciity [Domain] Credit Facility [Domain] NEW ACCOUNTING PRONOUNCEMENTS Accounting Standards Update and Change in Accounting Principle [Text Block] Senior Notes Amortized principal Debt Instrument, Unamortized Discount (Premium), Net Components of Deferred Tax Assets Components of Deferred Tax Assets [Abstract] Net income per share - basic Earnings Per Share, Basic Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Entity File Number Entity File Number Other Current Liabilities Other Current Liabilities [Member] Retirement and post-retirement benefits Liability, Defined Benefit Plan, Noncurrent Average increase in compensation levels (in hundredths) Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract] Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract] Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] Share-based compensation expense Share-based Payment Arrangement, Expense Aggregate Value stock issued under Employee Stock Purchase Plan Stock Issued During Period, Value, Employee Stock Purchase Plan Balance Sheet Location [Axis] Balance Sheet Location [Axis] Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Abstract] Current and Long Term Tax Assets and Liabilities [Table Text Block] Current and Long Term Tax Assets and Liabilities [Table Text Block] Tabular disclosure of the breakdown between current and long term income tax payable and receivable and their location in the consolidated balance sheet. Impairment of finite-lived intangible assets Impairment of Intangible Assets, Finite-lived Document Annual Report Document Annual Report Accumulated Benefit Obligation where Fair Value of plan Assets exceeds ABO Accumulated Benefit Obligation where Fair Value of plan Assets exceeds ABO Amount of accumulated benefit obligation for defined benefit pension plan where the fair value of plan assets exceeds accumulated benefit obligation. Amounts included in other income (expense), net [Abstract] Gain (Loss) on Investments, Marketable Securities [Abstract] Gain (Loss) on Investments, Marketable Securities [Abstract] Commercial Paper Commercial Paper [Member] Short-term Debt [Abstract] Short-term Debt [Abstract] Aggregate Intrinsic Value - Options Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Taiwan, New Dollars Taiwan, New Dollars Business Acquisition Business Acquisition, Date of Acquisition [Abstract] NASD Site costs Property, Plant and Equipment, Additions Defined Benefit obligation where Fair Value exceeds Pension benefit obligation Defined Benefit obligation where Fair Value exceeds Pension benefit obligation Amount of benefit obligation for defined benefit plan where fair value of plan assets exceeds pension benefit obligation Position [Axis] Position [Axis] All Currencies [Domain] All Currencies [Domain] Accumulated benefit obligation and fair value of plan assets Retirement Benefits [Abstract] Share-based awards issued (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Income tax contingencies rollforward Summary of Income Tax Contingencies [Table Text Block] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] weighted average maturity date at a point in time Weighted average maturity date at a point in time Weighted average maturity date at a point in time Granted - Weighted Average Grant Price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Short-term debt Short-term Debt Total assets measured at fair value Fair Value Assets Measured On Recurring Basis Total Assets This element represents total assets, measured at fair value on a recurring basis. Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Range of Exercise Prices - $25.01 - $30 Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range 01 [Member] Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices. Derivative Contracts [Abstract] Derivative Contracts [Abstract] Derivative Contracts [Abstract] Instrumentation Instrumentation [Member] Instrumentation [Member] Other Deferred Tax Liabilities, Other Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Net unrealized gains on trading securities Trading Securities, Change in Unrealized Holding Gain (Loss) Extinguishment of Debt, Amount Extinguishment of Debt, Amount Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax Accounts receivable, net Increase (Decrease) in Accounts Receivable Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Cash and cash equivalents Segment Reporting Reconciliation Item Cash And Cash Equivalents Amounts of cash, cash equivalents and short term investments held by an entity, and used in a reconciliation of assets by segment to the entity consolidated balance sheet. Total liabilities and equity Liabilities and Equity INVESTMENTS Investment [Text Block] Buildings and leasehold improvements Buildings and Improvements, Gross Loss Contingencies [Line Items] Loss Contingencies [Line Items] Number of Businesses Acquired Number of Businesses Acquired Accumulated other comprehensive loss Beginning Balance Ending Balance Accumulated Other Comprehensive Income (Loss), Net of Tax INCOME TAXES Income Tax Disclosure [Text Block] Operating Lease, Cost Operating Lease, Cost Statute of limitations expirations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Hedging Relationship [Axis] Hedging Relationship [Axis] Antidilutive shares excluded from EPS computation (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Equity Investments Marketable Securities [Table Text Block] Other Other Noncash Income (Expense) Additions for tax positions from prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Additions for tax positions related to the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Finite Lived Intangible Assets Useful Life Finite-Lived Intangible Asset, Useful Life Equity Component [Domain] Equity Component [Domain] Pension benefits and retiree medical benefits Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Postretirement Benefits Schedule of expected benefit payments Schedule of Expected Benefit Payments [Table Text Block] Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net In-the-money awards exercisable (in shares) Share Based Compensation Arrangement By Share Based Payment Award Options In The Money Exercisable Number The number of Stocks options eligible for exercise and at an exercise price below the closing market price of the underlying stock on the last trading day of the fiscal year as reflected on the national stock exchange. Entity Tax Identification Number Entity Tax Identification Number Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Currency impact Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) SHARE-BASED COMPENSATION Share-based Payment Arrangement [Text Block] Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] INVENTORY Inventory Disclosure [Text Block] Long term and other receivables Segment Reporting Reconciliation Item Long Term And Other Receivables Amount of long-term and other receivables held by an entity, and used in a reconciliation of assets by segment to the entity consolidated balance sheet. Fair Value of plan assets where fair value exceeds pension benefit obligation Fair Value of plan assets where fair value exceeds pension benefit obligation Fair value of plan assets for defined benefit plan where fair value of plan assets exceeds pension benefit obligation. Time period after which participants of the performance stock award plan are entitled to receive unrestricted share of the company's stock, if specified performance targets are met Share Based Compensation Arrangement Performance Stock Award Vesting Period Description of the period of time over which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, which may be expressed in a variety of ways (for example, in years, month and year). Current Fiscal Year End Date Current Fiscal Year End Date accelerated amortization of interest rate swap gain accelerated amortization of interest rate swap gain accelerated amortization of interest rate swap gain Costs and expenses: Operating Expenses [Abstract] Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Rest Of World Rest Of World [Member] A specified country or group of countries about which segment information is provided by the entity. This element is used for a group of countries not specifically disclosed. Amounts reclassified into earnings related to derivative instruments, tax expense (benefit) Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax BioTek and ACEA BioTek and ACEA [Member] BioTek and ACEA Biosciences [Member] Software Capitalized Computer Software, Gross Maximum contractual term (in years) Share Based Compensation Arrangement By Share Based Payment Award Award Maximum Contractual Term Reflects the duration as to when the share-based award expires as specified in the award agreement, which may be presented in a variety of ways (for example, in years, months, quarter of a year). Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Cash and Cash Equivalents Cash and Cash Equivalents [Abstract] Purchased technology Developed product technology Developed Technology Rights [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Euro Euro Member Countries, Euro Nature of Uncertainty [Axis] Nature of Uncertainty [Axis] Supplemental Cash Flow Information [Abstract] Supplemental Cash Flow Information [Abstract] Other Segment Reporting Reconciliation Item Other Assets Amount of other assets and assets not otherwise identified in other reconciliation balances, and used in a reconciliation of assets by segment to the entity consolidated balance sheet. Share-based awards issued Shares Granted or Issued, Share-based Payment Arrangement [Abstract] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Life Sciences and Applied Markets Life Sciences and Applied Markets [Member] Life Sciences and Applied Markets [Member] Number of shares purchased under ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Total recognized in other comprehensive (income) loss Other Comprehensive Income Defined Benefit Plans Period Increase Decrease Amounts recognized in other comprehensive income (but not yet recognized in net periodic benefit cost), including the net gain (loss) and net prior service cost (credit) arising during the period. Benefits paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Inventory [Domain] Inventory [Domain] Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Other Commitments [Domain] Other Commitments [Domain] Tax (expense) benefit Other Comprehensive Income (Loss), Tax Fair value lower than carrying value Fair value lower than carrying value Amount of fair value of long term debt is lower than of carrying value. Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets Finite-lived intangible assets acquired Gross Carrying Amount Finite-Lived Intangible Assets, Gross Advanced Analytical Technologies, Inc (AATI) Advanced Analytical Technologies, Inc (AATI) [Member] Advanced Analytical Technologies, Inc (AATI) Schedule of Other Intangible Assets By Major Class [Abstract] Finite-Lived Intangible Assets, Net [Abstract] Foreign currency translation, tax expense (benefit) Tax (expense) benefit Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Aggregate Intrinsic Value - Options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Currency [Axis] Currency [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Long-term deferred tax assets and deferred tax liabilities Current And Long Term Tax Assets And Current And Long Term Tax Liabilities Disclosure [Text Block] Description containing the entire income tax comparison of temporary differences on current and long term deferred tax assets and liabilities disclosure. This element may be used as a single block of text to encapsulate the entire disclosure including data and tables. Schedule of Future Minimum Rent Payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Effective Income Tax Rate Reconciliation Effective Income Tax Rate Reconciliation, Amount [Abstract] Adjustments to earnings of foreign subsidiaries Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Basic (in shares) Basic weighted average shares Weighted Average Number of Shares Outstanding, Basic Special compliance costs Special compliance costs Special compliance costs Reconcilitation between statement results and enterprise results [Abstract] Segment Reporting Information, Operating Income (Loss) [Abstract] Cash and Cash Equivalents Cash and Cash Equivalents [Member] Variable Interest Entity Consolidation, Variable Interest Entity, Policy [Policy Text Block] Other Currency No currency Cash Flow Hedges Cash Flow Hedging [Member] Loss Contingencies [Table] Loss Contingencies [Table] Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Revenue from Contract with Customer Revenue from Contract with Customer [Text Block] Contract with Customer, Refund Liability Change in deferrals from customer cash advances net of revenue recognized The increase (decrease) during the reporting period in the amount of prepayments by customers for goods and services to be provided at a later date net of revenue recognized. Foreign net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Foreign Amounts reclassified out of accumulated other comprehensive income Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax Non-cash right of use assets obtained in exchange for operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Actuarial (gain) loss Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Inventory Inventory, Policy [Policy Text Block] Provision (benefit) for income taxes Income tax expense (benefit) Income tax expense (benefit) Income Tax Expense (Benefit) Medical cost trend rate decreases to ultimate rate in year Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate 2024 Operating Leases, Future Minimum Payments, Due in Five Years Impact of the income tax holidays Income Tax Holiday, Aggregate Dollar Amount Cash, cash equivalents and restricted cash at beginning of year Cash, cash equivalents and restricted cash at end of year Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Deferred Tax Liability, Intra-entity Transfer, Asset Other than Inventory Deferred Tax Liability, Intra-entity Transfer, Asset Other than Inventory Local Phone Number Local Phone Number Amounts Reclassified out of Accumulated Other Comprehensive Income Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Cash payment to acquire business Payments to Acquire Businesses, Gross Proforma operating results Business Acquisition, Pro Forma Information [Table Text Block] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Americas Americas [Member] Amount borrowed Line of Credit Facility, Average Outstanding Amount Derivative Instruments Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instrument Detail [Abstract] Share-based Payment Arrangement, Accelerated Cost Share-based Payment Arrangement, Accelerated Cost Derivative [Line Items] Derivative [Line Items] Maximum price of options outstanding, end of the period (in dollars per share) Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Impairments in non-marketable securities without readily determinable fair value Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount Reductions for tax positions from prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Contract Liability ending balance Contract Liability ending balance Contract with Customer, Liability Schedule II - Valuation and Qualifying Accounts SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] China, Yuan Renminbi China, Yuan Renminbi Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Assumptions used to calculate the net periodic cost Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] Award Type [Axis] Award Type [Axis] Academia and Government Market Academia and Government Market [Member] Academia and Government Market [Member] Discount rate (in hundredths) Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Total fair value of restricted stock awards vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Select income statement components Segment Reporting Information, Profit (Loss) [Abstract] Restricted Cash Restricted Cash Retained Earnings (Accumulated Deficit) Retained Earnings Retained Earnings [Member] Preferred Stock, Shares Outstanding (in shares) Preferred Stock, Shares Outstanding Repayments of commercial paper Repayments of Commercial Paper Short-term Debt, Type [Domain] Short-term Debt, Type [Domain] Schedule of Net Benefit Costs Schedule of Net Benefit Costs [Table Text Block] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Services and Other Service, Other [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Schedule of Funded status of Defined Benefit and Post-Retirement Benefit plans Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block] Total reportable segment income from operations Segment income (loss) from operations The net result for the period of deducting segment operating expenses from segment operating revenues. Share-based Payment Arrangement, Noncash Expense [Abstract] Share-based Payment Arrangement, Noncash Expense [Abstract] 2015 Repurchase Program [Member] 2015 Repurchase Program [Member] 2015 Repurchase Program - On May 28, 2015 we announced that our board of directors had approved a new share repurchase program. The new share repurchase program authorizes the purchase of up to $1.14 billion of our common stock through and including November 1, 2018. The new program will commence, at the option of the company, on either November 1, 2015, or the date on which we complete the purchase of $365 million of common stock under the existing stock repurchase program in fiscal 2015. Upon commencement, the new program replaces our existing stock repurchase program, which authorized the repurchase of shares to reduce or eliminate share dilution from equity programs. Award Type [Domain] Award Type [Domain] Liabilities, Long-term [Abstract] Liabilities, Noncurrent [Abstract] Long-term Debt, Unclassified [Abstract] Long-term Debt, Unclassified [Abstract] Aggregate fair value , net liability position Derivative, Net Liability Position, Aggregate Fair Value Balance, beginning of year Balance, beginning of year Assets, usually stocks, bonds, and other investments, that have been segregated and restricted (usually in a trust) to provide benefits, at their fair value as of the measurement date. Plan assets include amounts contributed by the employer (and by employees for a contributory plan) and amounts earned from investing the contributions, less benefits paid. If a plan has liabilities other than for benefits, those non-benefit obligations may be considered as reductions of plan assets. Other Purchase Commitments Other Commitment PROPERTY, PLANT AND EQUIPMENT, NET Property, Plant and Equipment Disclosure [Text Block] 401(k) Additional company contribution Pension Plan Pension Plan [Member] NET INCOME (LOSS) PER SHARE Earnings Per Share [Text Block] Discount rate (in hundredths) Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Current liabilities: Liabilities, Short-term [Abstract] Liabilities, Current [Abstract] Transfers in (out) Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3 Proceeds from credit facility and short-term loan Short-term Debt Proceeds from Lines of Credit LTPP LTPP [Member] Long Term Performance Plan. Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Subsegments [Axis] Subsegments [Axis] EX-101.PRE 12 a-20201031_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 a-20201031_g1.jpg begin 644 a-20201031_g1.jpg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end XML 14 a-20201031_htm.xml IDEA: XBRL DOCUMENT 0001090872 2019-11-01 2020-10-31 0001090872 2020-04-30 0001090872 2020-12-10 0001090872 us-gaap:ProductMember 2019-11-01 2020-10-31 0001090872 us-gaap:ProductMember 2018-11-01 2019-10-31 0001090872 us-gaap:ProductMember 2017-11-01 2018-10-31 0001090872 us-gaap:ServiceOtherMember 2019-11-01 2020-10-31 0001090872 us-gaap:ServiceOtherMember 2018-11-01 2019-10-31 0001090872 us-gaap:ServiceOtherMember 2017-11-01 2018-10-31 0001090872 2018-11-01 2019-10-31 0001090872 2017-11-01 2018-10-31 0001090872 2020-10-31 0001090872 2019-10-31 0001090872 2018-10-31 0001090872 2017-10-31 0001090872 us-gaap:CommonStockMember 2017-10-31 0001090872 us-gaap:AdditionalPaidInCapitalMember 2017-10-31 0001090872 us-gaap:RetainedEarningsMember 2017-10-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-10-31 0001090872 us-gaap:ParentMember 2017-10-31 0001090872 us-gaap:NoncontrollingInterestMember 2017-10-31 0001090872 us-gaap:RetainedEarningsMember 2017-11-01 2018-10-31 0001090872 us-gaap:ParentMember 2017-11-01 2018-10-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-11-01 2018-10-31 0001090872 us-gaap:CommonStockMember 2017-11-01 2018-10-31 0001090872 us-gaap:AdditionalPaidInCapitalMember 2017-11-01 2018-10-31 0001090872 us-gaap:CommonStockMember 2018-10-31 0001090872 us-gaap:AdditionalPaidInCapitalMember 2018-10-31 0001090872 us-gaap:RetainedEarningsMember 2018-10-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-10-31 0001090872 us-gaap:ParentMember 2018-10-31 0001090872 us-gaap:NoncontrollingInterestMember 2018-10-31 0001090872 srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember us-gaap:RetainedEarningsMember 2018-10-31 0001090872 srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-10-31 0001090872 srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember us-gaap:ParentMember 2018-10-31 0001090872 srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember 2018-10-31 0001090872 us-gaap:RetainedEarningsMember 2018-11-01 2019-10-31 0001090872 us-gaap:ParentMember 2018-11-01 2019-10-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-11-01 2019-10-31 0001090872 us-gaap:NoncontrollingInterestMember 2018-11-01 2019-10-31 0001090872 us-gaap:CommonStockMember 2018-11-01 2019-10-31 0001090872 us-gaap:AdditionalPaidInCapitalMember 2018-11-01 2019-10-31 0001090872 us-gaap:CommonStockMember 2019-10-31 0001090872 us-gaap:AdditionalPaidInCapitalMember 2019-10-31 0001090872 us-gaap:RetainedEarningsMember 2019-10-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-10-31 0001090872 us-gaap:ParentMember 2019-10-31 0001090872 us-gaap:NoncontrollingInterestMember 2019-10-31 0001090872 us-gaap:RetainedEarningsMember 2019-11-01 2020-10-31 0001090872 us-gaap:ParentMember 2019-11-01 2020-10-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-11-01 2020-10-31 0001090872 us-gaap:CommonStockMember 2019-11-01 2020-10-31 0001090872 us-gaap:AdditionalPaidInCapitalMember 2019-11-01 2020-10-31 0001090872 us-gaap:CommonStockMember 2020-10-31 0001090872 us-gaap:AdditionalPaidInCapitalMember 2020-10-31 0001090872 us-gaap:RetainedEarningsMember 2020-10-31 0001090872 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-10-31 0001090872 us-gaap:ParentMember 2020-10-31 0001090872 us-gaap:NoncontrollingInterestMember 2020-10-31 0001090872 us-gaap:NonUsMember 2020-10-31 0001090872 us-gaap:AccountsReceivableMember 2020-10-31 0001090872 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2019-11-01 2020-10-31 0001090872 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2019-11-01 2020-10-31 0001090872 srt:MinimumMember us-gaap:SoftwareDevelopmentMember 2019-11-01 2020-10-31 0001090872 srt:MaximumMember us-gaap:SoftwareDevelopmentMember 2019-11-01 2020-10-31 0001090872 srt:MinimumMember 2019-11-01 2020-10-31 0001090872 srt:MaximumMember 2019-11-01 2020-10-31 0001090872 a:LasergenMember 2018-11-01 2019-10-31 0001090872 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2020-10-31 0001090872 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2019-10-31 0001090872 us-gaap:AccountingStandardsUpdate201602Member 2019-11-01 0001090872 2019-11-01 0001090872 a:BioTekMember 2019-08-23 2019-08-23 0001090872 a:BioTekMember 2019-08-23 0001090872 a:BioTekMember us-gaap:DevelopedTechnologyRightsMember 2019-08-23 0001090872 srt:MinimumMember a:BioTekMember us-gaap:DevelopedTechnologyRightsMember 2019-08-23 2019-08-23 0001090872 srt:MaximumMember a:BioTekMember us-gaap:DevelopedTechnologyRightsMember 2019-08-23 2019-08-23 0001090872 a:BioTekMember us-gaap:CustomerRelationshipsMember 2019-08-23 0001090872 srt:MinimumMember a:BioTekMember us-gaap:CustomerRelationshipsMember 2019-08-23 2019-08-23 0001090872 srt:MaximumMember a:BioTekMember us-gaap:CustomerRelationshipsMember 2019-08-23 2019-08-23 0001090872 a:BioTekMember us-gaap:OrderOrProductionBacklogMember 2019-08-23 0001090872 a:BioTekMember us-gaap:OrderOrProductionBacklogMember 2019-08-23 2019-08-23 0001090872 a:BioTekMember us-gaap:TrademarksAndTradeNamesMember 2019-08-23 0001090872 a:BioTekMember us-gaap:TrademarksAndTradeNamesMember 2019-08-23 2019-08-23 0001090872 a:BioTekMember 2020-10-31 0001090872 a:BioTekMember 2019-10-31 0001090872 a:ACEABiosciencesInc.Member 2018-11-14 2018-11-14 0001090872 srt:AmericasMember a:LifeSciencesandAppliedMarketsMember 2019-11-01 2020-10-31 0001090872 srt:AmericasMember a:AgilentCrossLabMember 2019-11-01 2020-10-31 0001090872 srt:AmericasMember a:DiagnosticsAndGenomicsMember 2019-11-01 2020-10-31 0001090872 srt:AmericasMember 2019-11-01 2020-10-31 0001090872 srt:EuropeMember a:LifeSciencesandAppliedMarketsMember 2019-11-01 2020-10-31 0001090872 srt:EuropeMember a:AgilentCrossLabMember 2019-11-01 2020-10-31 0001090872 srt:EuropeMember a:DiagnosticsAndGenomicsMember 2019-11-01 2020-10-31 0001090872 srt:EuropeMember 2019-11-01 2020-10-31 0001090872 srt:AsiaPacificMember a:LifeSciencesandAppliedMarketsMember 2019-11-01 2020-10-31 0001090872 srt:AsiaPacificMember a:AgilentCrossLabMember 2019-11-01 2020-10-31 0001090872 srt:AsiaPacificMember a:DiagnosticsAndGenomicsMember 2019-11-01 2020-10-31 0001090872 srt:AsiaPacificMember 2019-11-01 2020-10-31 0001090872 a:LifeSciencesandAppliedMarketsMember 2019-11-01 2020-10-31 0001090872 a:AgilentCrossLabMember 2019-11-01 2020-10-31 0001090872 a:DiagnosticsAndGenomicsMember 2019-11-01 2020-10-31 0001090872 srt:AmericasMember a:LifeSciencesandAppliedMarketsMember 2018-11-01 2019-10-31 0001090872 srt:AmericasMember a:AgilentCrossLabMember 2018-11-01 2019-10-31 0001090872 srt:AmericasMember a:DiagnosticsAndGenomicsMember 2018-11-01 2019-10-31 0001090872 srt:AmericasMember 2018-11-01 2019-10-31 0001090872 srt:EuropeMember a:LifeSciencesandAppliedMarketsMember 2018-11-01 2019-10-31 0001090872 srt:EuropeMember a:AgilentCrossLabMember 2018-11-01 2019-10-31 0001090872 srt:EuropeMember a:DiagnosticsAndGenomicsMember 2018-11-01 2019-10-31 0001090872 srt:EuropeMember 2018-11-01 2019-10-31 0001090872 srt:AsiaPacificMember a:LifeSciencesandAppliedMarketsMember 2018-11-01 2019-10-31 0001090872 srt:AsiaPacificMember a:AgilentCrossLabMember 2018-11-01 2019-10-31 0001090872 srt:AsiaPacificMember a:DiagnosticsAndGenomicsMember 2018-11-01 2019-10-31 0001090872 srt:AsiaPacificMember 2018-11-01 2019-10-31 0001090872 a:LifeSciencesandAppliedMarketsMember 2018-11-01 2019-10-31 0001090872 a:AgilentCrossLabMember 2018-11-01 2019-10-31 0001090872 a:DiagnosticsAndGenomicsMember 2018-11-01 2019-10-31 0001090872 a:PharmaceuticalandBiopharmaceuticalMarketMember 2019-11-01 2020-10-31 0001090872 a:PharmaceuticalandBiopharmaceuticalMarketMember 2018-11-01 2019-10-31 0001090872 a:ChemicalandEnergyMarketMember 2019-11-01 2020-10-31 0001090872 a:ChemicalandEnergyMarketMember 2018-11-01 2019-10-31 0001090872 a:DiagnosticsandClinicalMarketMember 2019-11-01 2020-10-31 0001090872 a:DiagnosticsandClinicalMarketMember 2018-11-01 2019-10-31 0001090872 a:FoodMarketMember 2019-11-01 2020-10-31 0001090872 a:FoodMarketMember 2018-11-01 2019-10-31 0001090872 a:AcademiaandGovernmentMarketMember 2019-11-01 2020-10-31 0001090872 a:AcademiaandGovernmentMarketMember 2018-11-01 2019-10-31 0001090872 a:EnvironmentalandForensicsMarketMember 2019-11-01 2020-10-31 0001090872 a:EnvironmentalandForensicsMarketMember 2018-11-01 2019-10-31 0001090872 a:InstrumentationMember 2019-11-01 2020-10-31 0001090872 a:InstrumentationMember 2018-11-01 2019-10-31 0001090872 a:NonInstrumentationandOtherMember 2019-11-01 2020-10-31 0001090872 a:NonInstrumentationandOtherMember 2018-11-01 2019-10-31 0001090872 us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-11-01 2018-11-01 0001090872 us-gaap:EmployeeStockMember 2020-10-31 0001090872 us-gaap:EmployeeStockOptionMember 2019-11-01 2020-10-31 0001090872 us-gaap:RestrictedStockUnitsRSUMember 2019-11-01 2020-10-31 0001090872 us-gaap:CostOfSalesMember 2019-11-01 2020-10-31 0001090872 us-gaap:CostOfSalesMember 2018-11-01 2019-10-31 0001090872 us-gaap:CostOfSalesMember 2017-11-01 2018-10-31 0001090872 us-gaap:ResearchAndDevelopmentExpenseMember 2019-11-01 2020-10-31 0001090872 us-gaap:ResearchAndDevelopmentExpenseMember 2018-11-01 2019-10-31 0001090872 us-gaap:ResearchAndDevelopmentExpenseMember 2017-11-01 2018-10-31 0001090872 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-11-01 2020-10-31 0001090872 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-11-01 2019-10-31 0001090872 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-11-01 2018-10-31 0001090872 us-gaap:InventoriesMember 2019-11-01 2020-10-31 0001090872 us-gaap:InventoriesMember 2018-11-01 2019-10-31 0001090872 a:LtppMember 2019-11-01 2020-10-31 0001090872 a:LtppMember 2018-11-01 2019-10-31 0001090872 a:LtppMember 2017-11-01 2018-10-31 0001090872 a:LTPPRSUMember 2019-11-01 2020-10-31 0001090872 a:LTPPRSUMember 2018-11-01 2019-10-31 0001090872 a:LTPPRSUMember 2017-11-01 2018-10-31 0001090872 a:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange01Member 2019-11-01 2020-10-31 0001090872 a:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange01Member 2020-10-31 0001090872 a:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange02Member 2019-11-01 2020-10-31 0001090872 a:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange02Member 2020-10-31 0001090872 a:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange03Member 2020-10-31 0001090872 a:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange03Member 2019-11-01 2020-10-31 0001090872 us-gaap:EmployeeStockOptionMember 2020-10-31 0001090872 us-gaap:ForeignCountryMember 2019-11-01 2020-10-31 0001090872 us-gaap:ForeignCountryMember 2020-10-31 0001090872 us-gaap:DomesticCountryMember 2020-10-31 0001090872 us-gaap:CaliforniaFranchiseTaxBoardMember 2020-10-31 0001090872 us-gaap:OtherNoncurrentAssetsMember 2020-10-31 0001090872 us-gaap:OtherNoncurrentAssetsMember 2019-10-31 0001090872 us-gaap:OtherNoncurrentLiabilitiesMember 2020-10-31 0001090872 us-gaap:OtherNoncurrentLiabilitiesMember 2019-10-31 0001090872 a:TaxInterestandPenaltiesMember 2019-11-01 2020-10-31 0001090872 a:TaxInterestandPenaltiesMember 2018-11-01 2019-10-31 0001090872 a:TaxInterestandPenaltiesMember 2017-11-01 2018-10-31 0001090872 us-gaap:OtherAssetsMember 2020-10-31 0001090872 us-gaap:OtherCurrentLiabilitiesMember 2020-10-31 0001090872 a:OtherAccruedAndLongTermLiabilitiesMember 2020-10-31 0001090872 a:LifeSciencesandAppliedMarketsMember 2018-10-31 0001090872 a:DiagnosticsAndGenomicsMember 2018-10-31 0001090872 a:AgilentCrossLabMember 2018-10-31 0001090872 a:LifeSciencesandAppliedMarketsMember 2019-10-31 0001090872 a:DiagnosticsAndGenomicsMember 2019-10-31 0001090872 a:AgilentCrossLabMember 2019-10-31 0001090872 a:LifeSciencesandAppliedMarketsMember 2020-10-31 0001090872 a:DiagnosticsAndGenomicsMember 2020-10-31 0001090872 a:AgilentCrossLabMember 2020-10-31 0001090872 us-gaap:DevelopedTechnologyRightsMember 2019-10-31 0001090872 us-gaap:OrderOrProductionBacklogMember 2019-10-31 0001090872 us-gaap:TrademarksMember 2019-10-31 0001090872 us-gaap:CustomerRelationshipsMember 2019-10-31 0001090872 a:ThirdPartyTechnologyandLicensesMember 2019-10-31 0001090872 us-gaap:DevelopedTechnologyRightsMember 2020-10-31 0001090872 us-gaap:TrademarksMember 2020-10-31 0001090872 us-gaap:CustomerRelationshipsMember 2020-10-31 0001090872 a:ThirdPartyTechnologyandLicensesMember 2020-10-31 0001090872 a:BioTekandACEAMember a:LifeSciencesandAppliedMarketsMember 2018-11-01 2019-10-31 0001090872 a:AdvancedAnalyticalTechnologiesIncAATIMember a:DiagnosticsAndGenomicsMember 2018-11-01 2019-10-31 0001090872 a:EquitySecuritiesWithReadilyDeterminableFairValueMember 2019-11-01 2020-10-31 0001090872 a:EquitySecuritiesWithReadilyDeterminableFairValueMember 2018-11-01 2019-10-31 0001090872 a:EquitySecuritiesWithoutReadilyDeterminableFairValueMember 2019-11-01 2020-10-31 0001090872 a:EquitySecuritiesWithoutReadilyDeterminableFairValueMember 2018-11-01 2019-10-31 0001090872 us-gaap:AccountingStandardsUpdate201601Member 2018-11-01 0001090872 us-gaap:FairValueMeasurementsRecurringMember 2020-10-31 0001090872 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-10-31 0001090872 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-10-31 0001090872 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-10-31 0001090872 us-gaap:FairValueMeasurementsRecurringMember 2019-10-31 0001090872 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-10-31 0001090872 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-10-31 0001090872 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-10-31 0001090872 us-gaap:TreasuryLockMember a:SeniorNotes2022Member 2012-07-01 0001090872 us-gaap:TreasuryLockMember a:SeniorNotes2022Member 2020-10-31 0001090872 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember a:SeniorNotes2026Member 2016-02-01 0001090872 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember a:SeniorNotes2026Member 2016-09-14 2016-09-15 0001090872 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember a:SeniorNotes2026Member 2020-10-31 0001090872 us-gaap:TreasuryLockMember a:SeniorNotes2029Member 2019-08-01 0001090872 us-gaap:TreasuryLockMember a:SeniorNotes2029Member 2019-09-06 2019-09-06 0001090872 us-gaap:TreasuryLockMember a:SeniorNotes2029Member 2020-10-31 0001090872 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-11-01 2020-10-31 0001090872 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-10-31 0001090872 us-gaap:NondesignatedMember 2020-10-31 0001090872 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-10-31 0001090872 currency:EUR us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-10-31 0001090872 currency:EUR us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-10-31 0001090872 currency:EUR us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:LongMember 2020-10-31 0001090872 currency:GBP us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-10-31 0001090872 currency:GBP us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:LongMember 2020-10-31 0001090872 currency:CAD us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-10-31 0001090872 currency:CAD us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-10-31 0001090872 currency:JPY us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-10-31 0001090872 currency:JPY us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-10-31 0001090872 currency:KRW us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-10-31 0001090872 currency:KRW us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-10-31 0001090872 currency:SGD us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-10-31 0001090872 currency:SGD us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:LongMember 2020-10-31 0001090872 currency:CNY us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-10-31 0001090872 currency:CNY us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-10-31 0001090872 currency:SEK us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-10-31 0001090872 currency:SEK us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-10-31 0001090872 currency:TWD us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-10-31 0001090872 currency:TWD us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-10-31 0001090872 currency:INR us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-10-31 0001090872 currency:INR us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-10-31 0001090872 currency:XXX us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-10-31 0001090872 currency:XXX us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:LongMember 2020-10-31 0001090872 us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-10-31 0001090872 us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-10-31 0001090872 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-10-31 0001090872 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-10-31 0001090872 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-10-31 0001090872 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-10-31 0001090872 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-10-31 0001090872 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-10-31 0001090872 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-10-31 0001090872 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-10-31 0001090872 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-10-31 0001090872 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherComprehensiveIncomeMember 2019-11-01 2020-10-31 0001090872 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherComprehensiveIncomeMember 2018-11-01 2019-10-31 0001090872 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherComprehensiveIncomeMember 2017-11-01 2018-10-31 0001090872 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-11-01 2020-10-31 0001090872 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-11-01 2019-10-31 0001090872 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-11-01 2018-10-31 0001090872 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2019-11-01 2020-10-31 0001090872 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2018-11-01 2019-10-31 0001090872 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2017-11-01 2018-10-31 0001090872 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-11-01 2019-10-31 0001090872 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-11-01 2018-10-31 0001090872 us-gaap:NondesignatedMember us-gaap:OtherIncomeMember 2019-11-01 2020-10-31 0001090872 us-gaap:NondesignatedMember us-gaap:OtherIncomeMember 2018-11-01 2019-10-31 0001090872 us-gaap:NondesignatedMember us-gaap:OtherIncomeMember 2017-11-01 2018-10-31 0001090872 2018-11-01 2019-01-31 0001090872 us-gaap:DeferredProfitSharingMember 2020-10-31 0001090872 us-gaap:DeferredProfitSharingMember 2019-10-31 0001090872 srt:MinimumMember us-gaap:PensionPlansDefinedBenefitMember 2019-11-01 2020-10-31 0001090872 us-gaap:PensionPlansDefinedBenefitMember 2019-11-01 2020-10-31 0001090872 srt:MaximumMember us-gaap:PensionPlansDefinedBenefitMember 2019-11-01 2020-10-31 0001090872 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-11-01 2020-10-31 0001090872 country:US us-gaap:PensionPlansDefinedBenefitMember 2018-11-01 2019-10-31 0001090872 country:US us-gaap:PensionPlansDefinedBenefitMember 2017-11-01 2018-10-31 0001090872 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-11-01 2020-10-31 0001090872 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2018-11-01 2019-10-31 0001090872 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2017-11-01 2018-10-31 0001090872 country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-11-01 2020-10-31 0001090872 country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-11-01 2019-10-31 0001090872 country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-11-01 2018-10-31 0001090872 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 country:US us-gaap:PensionPlansDefinedBenefitMember 2018-10-31 0001090872 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2018-10-31 0001090872 country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-10-31 0001090872 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 us-gaap:OtherAssetsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:OtherAssetsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:OtherAssetsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:OtherAssetsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:OtherAssetsMember country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 us-gaap:OtherAssetsMember country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 a:EmployeecompensationandbenefitsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 a:EmployeecompensationandbenefitsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 a:EmployeecompensationandbenefitsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 a:EmployeecompensationandbenefitsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 a:EmployeecompensationandbenefitsMember country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 a:EmployeecompensationandbenefitsMember country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 a:RetirementandpostretirementbenefitsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 a:RetirementandpostretirementbenefitsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 a:RetirementandpostretirementbenefitsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 a:RetirementandpostretirementbenefitsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 a:RetirementandpostretirementbenefitsMember country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 a:RetirementandpostretirementbenefitsMember country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 us-gaap:EquitySecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:EquitySecuritiesMember country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:EquitySecuritiesMember country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:EquitySecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:DeferredProfitSharingMember us-gaap:EquitySecuritiesMember country:US 2020-10-31 0001090872 us-gaap:DeferredProfitSharingMember us-gaap:EquitySecuritiesMember country:US 2019-10-31 0001090872 us-gaap:DeferredProfitSharingMember us-gaap:FixedIncomeSecuritiesMember country:US 2020-10-31 0001090872 us-gaap:DeferredProfitSharingMember us-gaap:FixedIncomeSecuritiesMember country:US 2019-10-31 0001090872 a:OtherPlanAssetsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 a:OtherPlanAssetsMember country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-10-31 0001090872 a:OtherPlanAssetsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 a:OtherPlanAssetsMember country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-10-31 0001090872 srt:MinimumMember us-gaap:EquitySecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 srt:MaximumMember us-gaap:EquitySecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 srt:MinimumMember us-gaap:FixedIncomeSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 srt:MaximumMember us-gaap:FixedIncomeSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 srt:MinimumMember us-gaap:RealEstateMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 srt:MaximumMember us-gaap:RealEstateMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:DefinedBenefitPlanEquitySecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 a:OtherPlanAssetsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 a:OtherPlanAssetsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 a:OtherPlanAssetsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:DefinedBenefitPlanEquitySecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 a:OtherPlanAssetsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 a:OtherPlanAssetsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 a:OtherPlanAssetsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2018-10-31 0001090872 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2019-11-01 2020-10-31 0001090872 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2018-11-01 2019-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 us-gaap:EquitySecuritiesMember country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 a:OtherPlanAssetsMember country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 a:OtherPlanAssetsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 a:OtherPlanAssetsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 a:OtherPlanAssetsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 us-gaap:FairValueInputsLevel1Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 us-gaap:FairValueInputsLevel2Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 us-gaap:FairValueInputsLevel3Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 us-gaap:EquitySecuritiesMember country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 a:OtherPlanAssetsMember country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 a:OtherPlanAssetsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 a:OtherPlanAssetsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 a:OtherPlanAssetsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 us-gaap:FairValueInputsLevel1Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 us-gaap:FairValueInputsLevel2Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 us-gaap:FairValueInputsLevel3Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-10-31 0001090872 us-gaap:FairValueInputsLevel3Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-10-31 0001090872 us-gaap:FairValueInputsLevel3Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-11-01 2020-10-31 0001090872 us-gaap:FairValueInputsLevel3Member country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-11-01 2019-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 a:OtherPlanAssetsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 a:OtherPlanAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 a:OtherPlanAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 a:OtherPlanAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 a:OtherPlanAssetsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 a:OtherPlanAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 a:OtherPlanAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 a:OtherPlanAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-10-31 0001090872 srt:MinimumMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-11-01 2020-10-31 0001090872 srt:MaximumMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-11-01 2020-10-31 0001090872 srt:MinimumMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2018-11-01 2019-10-31 0001090872 srt:MaximumMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2018-11-01 2019-10-31 0001090872 srt:MinimumMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2017-11-01 2018-10-31 0001090872 srt:MaximumMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2017-11-01 2018-10-31 0001090872 srt:MinimumMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 srt:MaximumMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-10-31 0001090872 srt:MinimumMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 srt:MaximumMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-10-31 0001090872 a:PenaltyreduceoverperiodoftimeMember 2020-10-31 0001090872 us-gaap:LineOfCreditMember a:A5YrUnsecuredCreditFacilityMember 2019-03-13 2019-03-13 0001090872 us-gaap:LineOfCreditMember a:A5YrUnsecuredCreditFacilityMember 2020-10-31 0001090872 us-gaap:LineOfCreditMember a:A5YrUnsecuredCreditFacilityMember 2019-11-01 2020-10-31 0001090872 us-gaap:LineOfCreditMember a:ShortTermLoanFacilityMember 2019-08-23 2019-08-23 0001090872 us-gaap:LineOfCreditMember a:ShortTermLoanFacilityMember 2019-08-07 0001090872 us-gaap:LineOfCreditMember a:ShortTermLoanFacilityMember 2019-11-01 2020-10-31 0001090872 us-gaap:LineOfCreditMember a:AdditionalIncrementalTermLoanFacilityMember 2019-10-21 0001090872 us-gaap:LineOfCreditMember a:AdditionalIncrementalTermLoanFacilityMember 2020-10-31 0001090872 us-gaap:LineOfCreditMember us-gaap:CommercialPaperMember 2020-05-26 0001090872 us-gaap:LineOfCreditMember us-gaap:CommercialPaperMember 2020-10-31 0001090872 us-gaap:LineOfCreditMember us-gaap:CommercialPaperMember 2019-11-01 2020-10-31 0001090872 a:SeniorNotes2020Member 2010-07-12 2010-07-13 0001090872 a:SeniorNotes2020Member 2010-07-13 0001090872 a:SeniorNotes2020Member 2011-08-08 2011-08-09 0001090872 a:SeniorNotes2020Member 2011-08-09 0001090872 a:SeniorNotes2020Member 2019-09-17 2019-09-17 0001090872 a:SeniorNotes2022Member 2020-10-31 0001090872 a:SeniorNotes2022Member 2019-10-31 0001090872 a:SeniorNotes2023Member 2020-10-31 0001090872 a:SeniorNotes2023Member 2019-10-31 0001090872 a:SeniorNotes2026Member 2020-10-31 0001090872 a:SeniorNotes2026Member 2019-10-31 0001090872 a:SeniorNotes2029Member 2020-10-31 0001090872 a:SeniorNotes2029Member 2019-10-31 0001090872 a:SeniorNotes2030Member 2020-10-31 0001090872 a:SeniorNotes2030Member 2019-10-31 0001090872 a:SeniorNotes2022Member 2012-09-13 2012-09-13 0001090872 a:SeniorNotes2022Member 2012-09-13 0001090872 a:SeniorNotes2023Member 2013-06-21 2013-06-21 0001090872 a:SeniorNotes2023Member 2013-06-21 0001090872 a:SeniorNotes2026Member 2016-09-22 2016-09-22 0001090872 a:SeniorNotes2026Member 2016-09-22 0001090872 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember a:SeniorNotes2026Member 2016-09-15 0001090872 a:SeniorNotes2029Member 2019-09-16 2019-09-16 0001090872 a:SeniorNotes2029Member 2019-09-16 0001090872 a:SeniorNotes2030Member 2020-06-04 2020-06-04 0001090872 a:SeniorNotes2030Member 2020-06-04 0001090872 a:A2015RepurchaseProgramMember 2015-05-28 0001090872 a:A2015RepurchaseProgramMember 2017-11-01 2018-10-31 0001090872 a:A2015RepurchaseProgramMember 2019-10-31 0001090872 a:A2019RepurchaseProgramMember 2018-11-19 0001090872 a:A2019RepurchaseProgramMember 2018-11-01 2019-10-31 0001090872 a:A2019RepurchaseProgramMember 2019-11-01 2020-10-31 0001090872 a:A2019RepurchaseProgramMember 2020-10-31 0001090872 us-gaap:SubsequentEventMember 2020-11-18 2020-11-18 0001090872 srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember us-gaap:AccumulatedTranslationAdjustmentMember 2018-11-01 0001090872 srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2018-11-01 2018-11-01 0001090872 srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2018-11-01 2018-11-01 0001090872 srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2018-11-01 2018-11-01 0001090872 srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember 2018-11-01 2018-11-01 0001090872 2018-11-01 0001090872 a:SegmentTotalMember 2019-11-01 2020-10-31 0001090872 a:SegmentTotalMember 2018-11-01 2019-10-31 0001090872 a:LifeSciencesandAppliedMarketsMember 2017-11-01 2018-10-31 0001090872 a:DiagnosticsAndGenomicsMember 2017-11-01 2018-10-31 0001090872 a:AgilentCrossLabMember 2017-11-01 2018-10-31 0001090872 a:SegmentTotalMember 2017-11-01 2018-10-31 0001090872 a:SegmentTotalMember 2020-10-31 0001090872 a:SegmentTotalMember 2019-10-31 0001090872 country:US 2019-11-01 2020-10-31 0001090872 country:CN 2019-11-01 2020-10-31 0001090872 a:RestOfWorldMember 2019-11-01 2020-10-31 0001090872 country:US 2018-11-01 2019-10-31 0001090872 country:CN 2018-11-01 2019-10-31 0001090872 a:RestOfWorldMember 2018-11-01 2019-10-31 0001090872 country:US 2017-11-01 2018-10-31 0001090872 country:CN 2017-11-01 2018-10-31 0001090872 a:RestOfWorldMember 2017-11-01 2018-10-31 0001090872 country:US 2020-10-31 0001090872 country:DE 2020-10-31 0001090872 a:RestOfWorldMember 2020-10-31 0001090872 country:US 2019-10-31 0001090872 country:DE 2019-10-31 0001090872 a:RestOfWorldMember 2019-10-31 0001090872 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-10-31 0001090872 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-11-01 2020-10-31 0001090872 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2020-10-31 0001090872 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-10-31 0001090872 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-11-01 2019-10-31 0001090872 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-10-31 0001090872 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-11-01 2018-10-31 iso4217:USD shares iso4217:USD shares a:numberOfCustomers pure utr:Y a:contracts a:segment 0001090872 false 2020 FY 10-K true 2020-10-31 --10-31 false 001-15405 Agilent Technologies, Inc. DE 77-0518772 5301 Stevens Creek Blvd. Santa Clara, CA 95051 (800) 227-9770 Common Stock, $0.01 par value A NYSE Yes No Yes Yes Large Accelerated Filer false false true false 18000000000.0 306849526 Portions of the Proxy Statement for the Annual Meeting of Stockholders (the "Proxy Statement") to be held on March 17, 2021, and to be filed pursuant to Regulation 14A within 120 days after registrant's fiscal year ended October 31, 2020 are incorporated by reference into Part III of this Report 3993000000 3877000000 3746000000 1346000000 1286000000 1168000000 5339000000 5163000000 4914000000 1796000000 1680000000 1595000000 706000000 678000000 639000000 2502000000 2358000000 2234000000 495000000 404000000 387000000 1496000000 1460000000 1389000000 4493000000 4222000000 4010000000 846000000 941000000 904000000 8000000 36000000 38000000 78000000 74000000 75000000 66000000 16000000 79000000 842000000 919000000 946000000 123000000 -152000000 630000000 719000000 1071000000 316000000 2.33 3.41 0.98 2.30 3.37 0.97 309000000 314000000 321000000 312000000 318000000 325000000 719000000 1071000000 316000000 -3000000 -2000000 1000000 -9000000 -4000000 6000000 0 -2000000 1000000 -2000000 6000000 -3000000 1000000 -10000000 7000000 10000000 10000000 -58000000 0 -25000000 -3000000 -5000000 -93000000 -7000000 -1000000 -2000000 -2000000 6000000 6000000 6000000 -8000000 -99000000 -62000000 711000000 972000000 254000000 1441000000 1382000000 1038000000 930000000 720000000 679000000 216000000 198000000 3415000000 3189000000 845000000 850000000 3602000000 3593000000 831000000 1107000000 158000000 102000000 776000000 611000000 9627000000 9452000000 354000000 354000000 367000000 334000000 386000000 336000000 75000000 616000000 285000000 440000000 1467000000 2080000000 2284000000 1791000000 389000000 360000000 614000000 473000000 4754000000 4704000000 0.01 0.01 125000000 125000000 0 0 0 0 0 0 0.01 0.01 2000000000 2000000000 306000000 306000000 309000000 309000000 3000000 3000000 5311000000 5277000000 81000000 -18000000 -522000000 -514000000 4873000000 4748000000 9627000000 9452000000 719000000 1071000000 316000000 308000000 238000000 210000000 83000000 72000000 70000000 29000000 -255000000 -16000000 28000000 28000000 19000000 19000000 26000000 26000000 0 0 20000000 99000000 0 21000000 28000000 1000000 0 0 -9000000 0 -8000000 -7000000 -9000000 107000000 106000000 65000000 68000000 36000000 83000000 2000000 29000000 40000000 29000000 23000000 31000000 0 0 552000000 0 6000000 0 181000000 43000000 4000000 921000000 1021000000 1087000000 119000000 155000000 177000000 1000000 0 1000000 20000000 23000000 11000000 9000000 3000000 2000000 0 1000000 0 0 1408000000 516000000 -147000000 -1590000000 -705000000 60000000 54000000 56000000 37000000 16000000 30000000 469000000 723000000 422000000 222000000 206000000 191000000 499000000 497000000 0 4000000 4000000 0 420000000 0 0 345000000 0 0 4000000 0 0 0 -4000000 0 798000000 805000000 483000000 1413000000 702000000 693000000 -717000000 -299000000 -797000000 2000000 2000000 -17000000 59000000 -866000000 -432000000 1388000000 2254000000 2686000000 1447000000 1388000000 2254000000 361000000 159000000 102000000 71000000 80000000 80000000 -1000000 -21000000 -5000000 321975000 3000000 5300000000 -126000000 -346000000 4831000000 4000000 4835000000 316000000 316000000 316000000 -62000000 -62000000 -62000000 254000000 254000000 0.596 191000000 191000000 191000000 2176000 25000000 25000000 25000000 6436000 0 87000000 335000000 422000000 422000000 70000000 70000000 70000000 317715000 3000000 5308000000 -336000000 -408000000 4567000000 4000000 4571000000 33000000 -7000000 26000000 26000000 1071000000 1071000000 1071000000 -99000000 -99000000 -99000000 972000000 972000000 0.656 206000000 206000000 206000000 -4000000 -4000000 1792000 40000000 40000000 40000000 10436000 0 143000000 580000000 723000000 723000000 72000000 72000000 72000000 309071000 3000000 5277000000 -18000000 -514000000 4748000000 0 4748000000 719000000 719000000 719000000 -8000000 -8000000 -8000000 711000000 711000000 0.720 222000000 222000000 222000000 2354000 22000000 22000000 22000000 5227000 0 71000000 398000000 469000000 469000000 83000000 83000000 83000000 306198000 3000000 5311000000 81000000 -522000000 4873000000 0 4873000000 OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The accompanying consolidated financial statements have been prepared by us pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") and are in conformity with U.S. generally accepted accounting principles ("GAAP"). Our fiscal year end is October 31. Unless otherwise stated, all years and dates refer to our fiscal year.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The consolidated financial statements include the accounts of the company and our wholly- and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, retirement and post-retirement plan assumptions and accounting for income taxes.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks common to companies in the analytical instrument industry, such as global economic and financial market conditions, fluctuations in foreign currency exchange rates and fluctuations in customer demand, among others.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Both our domestic and international operations have been and continue to be affected by the ongoing global pandemic of a novel strain of coronavirus (“COVID-19”) and the resulting volatility and uncertainty it has caused in the U.S. and international markets. In March 2020, the World Health Organization declared COVID-19 a pandemic and recommended containment and mitigation measures worldwide.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result, academic and research laboratories had temporarily closed in our second and third quarters and hospitals and testing laboratories had halted or reduced certain elective medical procedures, which had an adverse effect on our customers' business. The COVID-19 pandemic has caused significant volatility and uncertainty in U.S. and international markets, which could result in a prolonged economic downturn that could disrupt our business.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We enter into contracts to sell products, services or combinations of products and services. Products may include hardware or software and services may include one-time service events or services performed over time.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from the sale of analytical and diagnostics products and services. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under Accounting Standard Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 606’’). See also Note 4, "Revenue" for additional information on revenue recognition.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control of the promised products or services is transferred to our customers and the performance obligation is fulfilled in an amount that reflects the consideration that we expect to be entitled in exchange for those products or services, the transaction price. For equipment, consumables, and most software licenses, control transfers to the customer at a point in time. We use present right to payment, legal title, physical possession of the asset, and risks and rewards of ownership as indicators to determine the transfer of control to the customer. Where acceptance is not a formality, the customer must have documented their acceptance of the product or service. For products that include installation, if the installation meets the criteria to be considered a separate performance obligation, product revenue is recognized when control has passed to the customer, and recognition of installation revenue occurs once completed. Product revenue, including sales to </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resellers and distributors is reduced for provisions for warranties, returns, and other adjustments in the period the related sales are recorded.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue includes extended warranty, customer and software support including: Software as a Service, post contract support, consulting including companion diagnostics, and training and education. Instrument service contracts and software maintenance contracts are typically annual contracts, which are billed at the beginning of the contract or maintenance period. Revenue for these contracts is recognized on a straight-line basis to revenue over the service period, as a time-based measure of progress best reflects our performance in satisfying this obligation. There are no deferred costs associated with the service contract, as the cost of the service is recorded when the service is performed. Service calls not included in a support contract are recognized to revenue at the time a service is performed. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have sales from standalone software. These arrangements typically include software licenses and maintenance contracts, both of which we have determined are distinct performance obligations. We determine the amount of the transaction price to allocate to the license and maintenance contract based on the relative standalone selling price of each performance obligation. Software license revenue is recognized at the point in time when control has been transferred to the customer. The revenue allocated to the software maintenance contract is recognized on a straight-line basis over the maintenance period, which is the contractual term of the contract, as a time-based measure of progress best reflects our performance in satisfying this obligation. Unspecified rights to software upgrades are typically sold as part of the maintenance contract on a when-and-if-available basis.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our multiple-element arrangements are generally comprised of a combination of instruments, installation or other start-up services, and/or software, and/or support or services. Hardware and software elements are typically delivered at the same time and revenue is recognized when control passes to the customer. Service revenue is deferred and recognized over the contractual period or as services are rendered and accepted by the customer. Our arrangements generally do not include any provisions for cancellation, termination, or refunds that would significantly impact recognized revenue.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with multiple performance obligations, we allocate the consideration to which we expect to be entitled to each performance obligation based on relative standalone selling prices and recognize the related revenue when or as control of each individual performance obligation is transferred to customers. We estimate the standalone selling price by calculating the average historical selling price of our products and services per country for each performance obligation. Standalone selling prices are determined for each distinct good or service in the contract, and then we allocate the transaction price in proportion to those standalone selling prices by performance obligations.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of our revenue relates to lease arrangements. Standalone lease arrangements are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for 2020 and ASC 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for prior periods. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type capital lease using the current lease classification guidance.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Contract liabilities (deferred revenue) primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements (performance obligations) to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either in current liabilities in deferred revenue or long-term in other long-term liabilities in the consolidated balance sheet based on the timing of when we expect to complete our performance obligation. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Sales taxes collected from customers and remitted to governmental authorities are not included in our revenue.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shipping and Handling Costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Our shipping and handling costs charged to customers are included in net revenue, and the associated expense is recorded in cost of products for all periods presented.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Costs related to research, design and development of our products are charged to research and development expense as they are incurred.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advertising.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Advertising costs are generally expensed as incurred and amounted to $48 million in 2020, $36 million in 2019 and $41 million in 2018.</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Income tax expense or benefit is based on income or loss before taxes. Deferred tax assets and liabilities are recognized principally for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. See Note 6, "Income Taxes" for more information.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Income Per Share.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Basic net income per share is computed by dividing net income - the numerator - by the weighted average number of common shares outstanding - the denominator - during the period excluding the dilutive effect of stock options and other employee stock plans. Diluted net income per share gives effect to all potential common shares outstanding during the period unless the effect is anti-dilutive. The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense are assumed proceeds to be used to repurchase hypothetical shares. See Note 7, "Net Income Per Share".</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We classify investments as cash equivalents if their original or remaining maturity is three months or less at the date of purchase. Cash equivalents are stated at cost, which approximates fair value.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 31, 2020, approximately $1,395 million of our cash and cash equivalents is held outside of the U.S. by our foreign subsidiaries. Our cash and cash equivalents mainly consist of short-term deposits held at major global financial institutions, institutional money market funds, and similar short duration instruments with original maturities of 90 days or less. We continuously monitor the creditworthiness of the financial institutions and institutional money market funds in which we invest our funds.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify investments as short-term investments if their original maturities are greater than three months and their remaining maturities are one year or less. Currently, we have no short-term investments.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash and Restricted Cash Equivalents. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,447 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,254 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable, net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Such accounts receivable have been reduced by an allowance for doubtful accounts, which is our best estimate of the amount of probable credit losses in our existing accounts receivable. We determine the allowance based on customer specific experience and the aging of such receivables, among other factors. The allowance for doubtful accounts as of October 31, 2020 and 2019 was not material. We do not have any off-balance-sheet credit exposure related to our customers. Accounts receivable are also recorded net of estimated product returns which are not material.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Financial instruments that potentially subject Agilent to significant concentration of credit risk include money market fund investments, time deposits and demand deposit balances. These investments are categorized as cash and cash equivalents. In addition, Agilent has credit risk from derivative financial instruments used in hedging activities and accounts receivable. We invest in a variety of financial instruments and limit the amount of credit exposure with any one financial institution. We have a comprehensive credit policy in place and credit exposure is monitored on an ongoing basis. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Credit risk with respect to our accounts receivable is diversified due to the large number of entities comprising our customer base and their dispersion across many different industries and geographies. Credit evaluations are performed on customers requiring credit over a certain amount, and we sell the majority of our products through our direct sales force. Credit risk is mitigated through collateral such as letter of credit, bank guarantees or payment terms like cash in advance. No single customer accounted for more than 10 percent of accounts receivable as of October 31, 2020, or 2019.</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with manufacturing to maximize recovery of excess inventory.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Property, plant and equipment are stated at cost less accumulated depreciation. Additions, improvements and major renewals are capitalized; maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation and amortization are removed from our general ledger, and the resulting gain or loss is reflected in the consolidated statement of operations. Buildings and improvements are depreciated over the lesser of their useful lives or the remaining term of the lease and machinery and equipment over 3 years to 10 years. We use the straight-line method to depreciate assets.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitalized Software.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We capitalize certain internal and external costs incurred to acquire or create internal use software. Capitalized software is included in property, plant and equipment and is depreciated over 3 years to 5 years once development is complete.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We determine whether an arrangement is, or contains, a lease at inception. Prior to November 1, 2019, for leases where we are the lessee, we accounted for operating lease payments by charging them to expense as incurred. At the beginning of fiscal 2020, the company adopted new lease accounting guidance issued by the Financial Accounting Standards Board ("FASB"). The most significant change requires lessees to record the present value of operating lease payments as right-of-use ("ROU") assets and lease liabilities on the consolidated balance sheet. Where we are the lessee, ROU assets represent the company’s right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of operating lease liabilities as either current or non-current is based on the expected timing of payments due under our obligations. As most of our leases do not provide an implicit interest rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rates, we have used a number of factors including the company's credit rating, the lease term and the currency swap rate. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet and lease expense for these leases is recognized on a straight-line basis over the lease term. Lease expense for operating leases with an initial term of more than twelve months is recognized on a straight-line basis over the lease term as an operating expense. We have lease agreements which require payments for lease and non-lease components. We have elected to account for these payments as a single lease component.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of our revenue relates to lease arrangements where Agilent is the lessor. Standalone lease arrangements are outside the scope of Accounting Standard Codification ("ASC") Topic 606, Revenue Contracts with Customers, and are therefore accounted for in accordance with ASC Topic 842, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type finance lease using the current lease classification guidance. In a lease arrangement that is a multiple-element arrangement that contains equipment leases and the supply of consumables, the revenue associated with the instrument rental is treated under the lease accounting standard ASC 842, whereas the revenue associated with the consumables, the non-lease component, is recognized in accordance with the ASC 606 revenue standard.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   See also Note 2, "New Accounting Pronouncements" and Note 10, "Leases" for additional information about the company’s leases. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agilent accounts for the acquisition of a business using the acquisition method of accounting, and we allocate the fair value of the purchase price to the tangible assets acquired, liabilities assumed, and intangible assets acquired, including in-process research and development (“IPR&amp;D”), based on their estimated fair values. The excess value of the cost of an acquired business over the fair value of the assets acquired and liabilities assumed is recognized as goodwill. The fair value of IPR&amp;D is initially capitalized as an intangible asset with an indefinite life. When an IPR&amp;D project is completed, the IPR&amp;D is reclassified as an amortizable purchased intangible asset and amortized to costs of revenues over the asset’s estimated useful life.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determination of the fair value of the intangible assets acquired involves the use of significant estimates and assumptions. Specifically, our determination of the fair value of the developed product technology and IPR&amp;D acquired </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">involve significant estimates and assumptions related to revenue growth rates and discount rates. Our determination of the fair value of customer relationships acquired involved significant estimates and assumptions related to revenue growth rates, discount rates, and customer attrition rates. Our determination of the fair value of the tradename acquired involved the use of significant estimates and assumptions related to revenue growth rates, royalty rates and discount rates. The company believes that the fair value assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that marketplace participants would use. Actual results could differ materially from these estimates. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Purchased Intangible Assets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the authoritative guidance we have the option to perform a qualitative assessment to determine whether further impairment testing is necessary. The accounting standard gives an entity the option to first assess qualitative factors to determine whether performing the two-step test is necessary. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not (i.e., greater than 50% chance) that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test will be required. Otherwise, no further testing will be required.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance includes examples of events and circumstances that might indicate that a reporting unit's fair value is less than its carrying amount. These include macro-economic conditions such as deterioration in the entity's operating environment or industry or market considerations; entity-specific events such as increasing costs, declining financial performance, or loss of key personnel; or other events such as an expectation that a reporting unit will be sold or a sustained decrease in the stock price on either an absolute basis or relative to peers. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If it is determined, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, the provisions of authoritative guidance require that we perform a two-step impairment test on goodwill. In the first step, we compare the fair value of each reporting unit to its carrying value. The second step (if necessary) measures the amount of impairment by applying fair-value-based tests to the individual assets and liabilities within each reporting unit. As defined in the authoritative guidance, a reporting unit is an operating segment, or one level below an operating segment. We aggregate components of an operating segment that have similar economic characteristics into our reporting units. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In fiscal year 2020, we assessed goodwill impairment for our three reporting units which consisted of three segments: life sciences and applied markets, diagnostics and genomics and Agilent CrossLab. We performed a qualitative test for goodwill impairment of the three reporting units, as of September 30, 2020, our annual impairment test date. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair value of each reporting unit is greater than its respective carrying value. Each quarter we review the events and circumstances to determine if goodwill impairment is indicated. There was no impairment of goodwill during the years ended October 31, 2020, 2019 and 2018. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased intangible assets consist primarily of acquired developed technologies, proprietary know-how, trademarks, and customer relationships and are amortized using the best estimate of the asset's useful life that reflect the pattern in which the economic benefits are consumed or used up or a straight-line method ranging from 6 months to 15 years. IPR&amp;D is initially capitalized at fair value as an intangible asset with an indefinite life and assessed for impairment thereafter. When the IPR&amp;D project is complete, it is reclassified as an amortizable purchased intangible asset and is amortized over its estimated useful life. If an IPR&amp;D project is abandoned, Agilent will record a charge for the value of the related intangible asset to Agilent's consolidated statement of operations in the period it is abandoned.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agilent's indefinite-lived intangible assets are IPR&amp;D intangible assets. The accounting guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the issued impairment testing guidance for goodwill and allows the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset to determine whether it is more-likely-than-not (i.e., greater than 50% chance) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value. We performed a qualitative test for impairment of indefinite-lived intangible assets as of September 30, 2020. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair values of these indefinite-lived intangible assets are greater than their respective carrying values. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible asset is indicated. During the year ended October 31, 2020, we recorded an impairment of in-process research and development of $90 million related to the shutdown of our sequencer development program in our diagnostics and genomics segment. During the year ended October 31, 2019 and 2018 there were no impairments of indefinite-lived intangible assets. </span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Long-Lived Assets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We continually monitor events and changes in circumstances that could indicate carrying amounts of long-lived assets, including intangible assets, may not be recoverable. When such events or changes in circumstances occur, we assess the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the undiscounted future cash flows is less than the carrying amount of those assets, we recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets. During the year ended October 31, 2020 we recorded an impairment charge of long-lived assets including indefinite-lived in-process research and development of $98 million related to the shutdown of our sequencer development program in our diagnostics and genomics segment. During fiscal year 2019, there were no impairments of other assets or intangible assets. During fiscal year 2018, we recorded an impairment charge of $21 million related to purchased intangible assets within the diagnostics and genomics segment that were deemed unrecoverable. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity (“VIE”).  The company evaluates its investments in privately held companies on an ongoing basis. We have determined that as of October 31, 2020 and 2019, there were no VIE's required to be consolidated in the company's consolidated financial statements because we do not have a controlling financial interest in any of the VIE's in which we have invested nor are we the primary beneficiary. We account for these investments under either the equity method or as equity investments without readily determinable fair value, depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs, based on changes in facts and circumstances including changes in contractual arrangements and capital structure. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the year ended October 31, 2018, we exercised our option and acquired all of the remaining shares of Lasergen, Inc. ("Lasergen") that we did not already own for an additional cash consideration of approximately $107 million. The fair value remeasurement of our previous investment immediately before the acquisition resulted in a net gain of $20 million and was recorded in other income. Lasergen was previously considered a VIE. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 31, 2020 and October 31, 2019, the total carrying value of investments and loans in privately held companies considered as VIEs was $67 million and $29 million respectively. The maximum exposure is equal to the carrying value because we do not have future funding commitments. The investments are included on the long-term investments line and the loans on the other current assets and other assets lines (depending upon tenure of loan) on the consolidated balance sheet.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Equity investments without readily determinable fair value consist of non-marketable equity securities (typically investments in privately-held companies). These investments are accounted for using the measurement alternative at cost, and we adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) included in net income as and when it occurs. Equity investments with readily determinable fair value consist of shares we own in a special fund and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. Prior to fiscal year 2019, both equity investments without determinable fair value and with determinable fair value were accounted for using cost method of accounting, measured at historical cost less other-than-temporary investment. Trading securities, which are comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liabilities are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Equity method investments are reported at the amount of the company’s initial investment and adjusted each period for the company’s share of the investee’s income or loss and dividend paid. There are no equity method investments as of October 31, 2020 and 2019. The company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. The fair value of our senior notes, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy exceeds the carrying value by approximately $162 million as of October 31, 2020 and approximately $62 million as of October 31, 2019. The change in the fair value over carrying value in the year ended October 31, 2020 is primarily due to decreased market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 13, "Fair Value Measurements" for additional information on the fair value of financial instruments.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warranty.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Our standard warranty terms typically extend for one year from the date of delivery. We accrue for standard warranty costs based on historical trends in warranty charges. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost over the period. Estimated warranty charges are recorded within cost of products at the time products are sold. See Note 16, "Guarantees".</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Compensation and Benefits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Amounts owed to employees, such as accrued salary, bonuses and vacation benefits are accounted for within employee compensation and benefits. The total amount of accrued vacation benefit was $111 million and $115 million as of October 31, 2020, and 2019, respectively.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retirement and Post-Retirement Plans. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our employees are covered under various defined benefit and/or defined contribution retirement plans. Additionally, we sponsor post-retirement health care benefits for our eligible U.S. employees. Assumptions used to determine the benefit obligations and the expense for these plans are derived annually. See Note 15, “Retirement plans and post-retirement pension plans” for additional information.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retirement of Treasury Shares. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the formal retirement of treasury shares, we deduct the par value of the retired treasury shares from common stock and allocate the excess of cost over par as a deduction to additional paid-in capital, based on the pro-rata portion of additional paid-in-capital, and the remaining excess as a deduction to retained earnings. All retired treasury shares revert to the status of authorized but unissued shares.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  For the years ended 2020, 2019 and 2018, we accounted for share-based awards made to our employees and directors including employee stock option awards, restricted stock units, employee stock purchases made under our Employee Stock Purchase Plan ("ESPP") and performance share awards under Agilent Technologies, Inc. Long-Term Performance Program ("LTPP") using the estimated grant date fair value method of accounting. Under the fair value method, we recorded compensation expense for all share-based awards of $84 million in 2020, $72 million in 2019 and $71 million in 2018. See Note 5, "Share-based Compensation" for additional information.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Agilent is exposed to global foreign currency exchange rate and interest rate risks in the normal course of business. We enter into foreign exchange hedging contracts, primarily forward contracts and purchased options, interest rate swaps and interest rate locks to manage financial exposures resulting from changes in foreign currency exchange rates and interest rates. In the vast majority of cases, these contracts are designated at inception as hedges of the related foreign currency or interest exposures. Foreign currency exposures include committed and anticipated revenue and expense transactions and assets and liabilities that are denominated in currencies other than the functional currency of the subsidiary. Interest rate exposures are associated with the company's fixed-rate debt. For option contracts, we exclude time value from the measurement of effectiveness. To qualify for hedge accounting, contracts must reduce the foreign currency exchange rate and interest rate risk otherwise inherent in the amount and duration of the hedged exposures and comply with established risk management policies. Foreign exchange hedging contracts generally mature within twelve months, interest rate swaps mature at the same time as the maturity of the debt and interest rate locks mature at the same time as the issuance of debt. In order to manage foreign currency exposures in a few limited jurisdictions, we may enter into foreign exchange contracts that do not qualify for hedge accounting. In such circumstances, the local foreign currency exposure is offset by contracts owned by the parent company. We do not use derivative financial instruments for trading or speculative purposes.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivatives are recognized on the balance sheet at their fair values. For derivative instruments that are designated and qualify as a cash flow hedge, changes in the value of the effective portion of the derivative instrument are recognized in comprehensive income (loss), a component of stockholders' equity. For derivative instruments that are designated and qualify as a net investment hedge, changes in the value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss). Amounts associated with cash flow hedges are reclassified and recognized in income when either the forecasted transaction occurs or it becomes probable the forecasted transaction will not occur. Derivatives not designated as hedging instruments are recorded on the balance sheet at their fair value and changes in the fair values are recorded in the income statement in the current period. Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet. Changes in the fair value of the ineffective portion of derivative instruments are recognized in earnings in the current period. The impact of the ineffectiveness measurement in 2020, 2019 and 2018 was not material. Cash flows from derivative instruments are classified in the statement of cash flows in the same category as the cash flows from the hedged or economically hedged item, primarily in operating activities.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We translate and remeasure balance sheet and income statement items into U.S. dollars. For those subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using monthly exchange rates which approximate to average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) in stockholders' equity.</span>For those subsidiaries that operate in a U.S. dollar functional environment, foreign currency assets and liabilities are remeasured into U.S. dollars at current exchange rates except for non-monetary assets and capital accounts which are remeasured at historical exchange rates. Revenue and expenses are generally remeasured at monthly exchange rates which approximate average exchange rates in effect during each period. Gains or losses from foreign currency remeasurement are included in consolidated net income. Net gains or losses resulting from foreign currency transactions, including hedging gains and losses, are reported in other income (expense), net and were $4 million loss for 2020, $7 million loss for 2019 and $3 million loss for 2018. <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The accompanying consolidated financial statements have been prepared by us pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") and are in conformity with U.S. generally accepted accounting principles ("GAAP"). Our fiscal year end is October 31. Unless otherwise stated, all years and dates refer to our fiscal year.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The consolidated financial statements include the accounts of the company and our wholly- and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, retirement and post-retirement plan assumptions and accounting for income taxes.</span> <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks common to companies in the analytical instrument industry, such as global economic and financial market conditions, fluctuations in foreign currency exchange rates and fluctuations in customer demand, among others.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Both our domestic and international operations have been and continue to be affected by the ongoing global pandemic of a novel strain of coronavirus (“COVID-19”) and the resulting volatility and uncertainty it has caused in the U.S. and international markets. In March 2020, the World Health Organization declared COVID-19 a pandemic and recommended containment and mitigation measures worldwide.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result, academic and research laboratories had temporarily closed in our second and third quarters and hospitals and testing laboratories had halted or reduced certain elective medical procedures, which had an adverse effect on our customers' business. The COVID-19 pandemic has caused significant volatility and uncertainty in U.S. and international markets, which could result in a prolonged economic downturn that could disrupt our business.</span></div> <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We enter into contracts to sell products, services or combinations of products and services. Products may include hardware or software and services may include one-time service events or services performed over time.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from the sale of analytical and diagnostics products and services. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under Accounting Standard Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 606’’). See also Note 4, "Revenue" for additional information on revenue recognition.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control of the promised products or services is transferred to our customers and the performance obligation is fulfilled in an amount that reflects the consideration that we expect to be entitled in exchange for those products or services, the transaction price. For equipment, consumables, and most software licenses, control transfers to the customer at a point in time. We use present right to payment, legal title, physical possession of the asset, and risks and rewards of ownership as indicators to determine the transfer of control to the customer. Where acceptance is not a formality, the customer must have documented their acceptance of the product or service. For products that include installation, if the installation meets the criteria to be considered a separate performance obligation, product revenue is recognized when control has passed to the customer, and recognition of installation revenue occurs once completed. Product revenue, including sales to </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resellers and distributors is reduced for provisions for warranties, returns, and other adjustments in the period the related sales are recorded.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue includes extended warranty, customer and software support including: Software as a Service, post contract support, consulting including companion diagnostics, and training and education. Instrument service contracts and software maintenance contracts are typically annual contracts, which are billed at the beginning of the contract or maintenance period. Revenue for these contracts is recognized on a straight-line basis to revenue over the service period, as a time-based measure of progress best reflects our performance in satisfying this obligation. There are no deferred costs associated with the service contract, as the cost of the service is recorded when the service is performed. Service calls not included in a support contract are recognized to revenue at the time a service is performed. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have sales from standalone software. These arrangements typically include software licenses and maintenance contracts, both of which we have determined are distinct performance obligations. We determine the amount of the transaction price to allocate to the license and maintenance contract based on the relative standalone selling price of each performance obligation. Software license revenue is recognized at the point in time when control has been transferred to the customer. The revenue allocated to the software maintenance contract is recognized on a straight-line basis over the maintenance period, which is the contractual term of the contract, as a time-based measure of progress best reflects our performance in satisfying this obligation. Unspecified rights to software upgrades are typically sold as part of the maintenance contract on a when-and-if-available basis.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our multiple-element arrangements are generally comprised of a combination of instruments, installation or other start-up services, and/or software, and/or support or services. Hardware and software elements are typically delivered at the same time and revenue is recognized when control passes to the customer. Service revenue is deferred and recognized over the contractual period or as services are rendered and accepted by the customer. Our arrangements generally do not include any provisions for cancellation, termination, or refunds that would significantly impact recognized revenue.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with multiple performance obligations, we allocate the consideration to which we expect to be entitled to each performance obligation based on relative standalone selling prices and recognize the related revenue when or as control of each individual performance obligation is transferred to customers. We estimate the standalone selling price by calculating the average historical selling price of our products and services per country for each performance obligation. Standalone selling prices are determined for each distinct good or service in the contract, and then we allocate the transaction price in proportion to those standalone selling prices by performance obligations.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of our revenue relates to lease arrangements. Standalone lease arrangements are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for 2020 and ASC 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for prior periods. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type capital lease using the current lease classification guidance.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Contract liabilities (deferred revenue) primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements (performance obligations) to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either in current liabilities in deferred revenue or long-term in other long-term liabilities in the consolidated balance sheet based on the timing of when we expect to complete our performance obligation. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Sales taxes collected from customers and remitted to governmental authorities are not included in our revenue.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shipping and Handling Costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Our shipping and handling costs charged to customers are included in net revenue, and the associated expense is recorded in cost of products for all periods presented.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Costs related to research, design and development of our products are charged to research and development expense as they are incurred.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advertising.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Advertising costs are generally expensed as incurred and amounted to $48 million in 2020, $36 million in 2019 and $41 million in 2018.</span> 48000000 36000000 41000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Income tax expense or benefit is based on income or loss before taxes. Deferred tax assets and liabilities are recognized principally for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. See Note 6, "Income Taxes" for more information.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Income Per Share.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Basic net income per share is computed by dividing net income - the numerator - by the weighted average number of common shares outstanding - the denominator - during the period excluding the dilutive effect of stock options and other employee stock plans. Diluted net income per share gives effect to all potential common shares outstanding during the period unless the effect is anti-dilutive. The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense are assumed proceeds to be used to repurchase hypothetical shares. See Note 7, "Net Income Per Share".</span> <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We classify investments as cash equivalents if their original or remaining maturity is three months or less at the date of purchase. Cash equivalents are stated at cost, which approximates fair value.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 31, 2020, approximately $1,395 million of our cash and cash equivalents is held outside of the U.S. by our foreign subsidiaries. Our cash and cash equivalents mainly consist of short-term deposits held at major global financial institutions, institutional money market funds, and similar short duration instruments with original maturities of 90 days or less. We continuously monitor the creditworthiness of the financial institutions and institutional money market funds in which we invest our funds.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify investments as short-term investments if their original maturities are greater than three months and their remaining maturities are one year or less. Currently, we have no short-term investments.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash and Restricted Cash Equivalents. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,447 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,254 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1395000000 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash and Restricted Cash Equivalents. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,447 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,254 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1441000000 1382000000 2247000000 6000000 6000000 7000000 1447000000 1388000000 2254000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable, net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Such accounts receivable have been reduced by an allowance for doubtful accounts, which is our best estimate of the amount of probable credit losses in our existing accounts receivable. We determine the allowance based on customer specific experience and the aging of such receivables, among other factors. The allowance for doubtful accounts as of October 31, 2020 and 2019 was not material. We do not have any off-balance-sheet credit exposure related to our customers. Accounts receivable are also recorded net of estimated product returns which are not material.</span> <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Financial instruments that potentially subject Agilent to significant concentration of credit risk include money market fund investments, time deposits and demand deposit balances. These investments are categorized as cash and cash equivalents. In addition, Agilent has credit risk from derivative financial instruments used in hedging activities and accounts receivable. We invest in a variety of financial instruments and limit the amount of credit exposure with any one financial institution. We have a comprehensive credit policy in place and credit exposure is monitored on an ongoing basis. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Credit risk with respect to our accounts receivable is diversified due to the large number of entities comprising our customer base and their dispersion across many different industries and geographies. Credit evaluations are performed on customers requiring credit over a certain amount, and we sell the majority of our products through our direct sales force. Credit risk is mitigated through collateral such as letter of credit, bank guarantees or payment terms like cash in advance. No single customer accounted for more than 10 percent of accounts receivable as of October 31, 2020, or 2019.</span></div> 0 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with manufacturing to maximize recovery of excess inventory.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Property, plant and equipment are stated at cost less accumulated depreciation. Additions, improvements and major renewals are capitalized; maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation and amortization are removed from our general ledger, and the resulting gain or loss is reflected in the consolidated statement of operations. Buildings and improvements are depreciated over the lesser of their useful lives or the remaining term of the lease and machinery and equipment over 3 years to 10 years. We use the straight-line method to depreciate assets.</span> P3Y P10Y <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitalized Software.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We capitalize certain internal and external costs incurred to acquire or create internal use software. Capitalized software is included in property, plant and equipment and is depreciated over 3 years to 5 years once development is complete.</span> P3Y P5Y <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We determine whether an arrangement is, or contains, a lease at inception. Prior to November 1, 2019, for leases where we are the lessee, we accounted for operating lease payments by charging them to expense as incurred. At the beginning of fiscal 2020, the company adopted new lease accounting guidance issued by the Financial Accounting Standards Board ("FASB"). The most significant change requires lessees to record the present value of operating lease payments as right-of-use ("ROU") assets and lease liabilities on the consolidated balance sheet. Where we are the lessee, ROU assets represent the company’s right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of operating lease liabilities as either current or non-current is based on the expected timing of payments due under our obligations. As most of our leases do not provide an implicit interest rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rates, we have used a number of factors including the company's credit rating, the lease term and the currency swap rate. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet and lease expense for these leases is recognized on a straight-line basis over the lease term. Lease expense for operating leases with an initial term of more than twelve months is recognized on a straight-line basis over the lease term as an operating expense. We have lease agreements which require payments for lease and non-lease components. We have elected to account for these payments as a single lease component.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of our revenue relates to lease arrangements where Agilent is the lessor. Standalone lease arrangements are outside the scope of Accounting Standard Codification ("ASC") Topic 606, Revenue Contracts with Customers, and are therefore accounted for in accordance with ASC Topic 842, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type finance lease using the current lease classification guidance. In a lease arrangement that is a multiple-element arrangement that contains equipment leases and the supply of consumables, the revenue associated with the instrument rental is treated under the lease accounting standard ASC 842, whereas the revenue associated with the consumables, the non-lease component, is recognized in accordance with the ASC 606 revenue standard.</span></div>   See also Note 2, "New Accounting Pronouncements" and Note 10, "Leases" for additional information about the company’s leases. <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agilent accounts for the acquisition of a business using the acquisition method of accounting, and we allocate the fair value of the purchase price to the tangible assets acquired, liabilities assumed, and intangible assets acquired, including in-process research and development (“IPR&amp;D”), based on their estimated fair values. The excess value of the cost of an acquired business over the fair value of the assets acquired and liabilities assumed is recognized as goodwill. The fair value of IPR&amp;D is initially capitalized as an intangible asset with an indefinite life. When an IPR&amp;D project is completed, the IPR&amp;D is reclassified as an amortizable purchased intangible asset and amortized to costs of revenues over the asset’s estimated useful life.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determination of the fair value of the intangible assets acquired involves the use of significant estimates and assumptions. Specifically, our determination of the fair value of the developed product technology and IPR&amp;D acquired </span></div>involve significant estimates and assumptions related to revenue growth rates and discount rates. Our determination of the fair value of customer relationships acquired involved significant estimates and assumptions related to revenue growth rates, discount rates, and customer attrition rates. Our determination of the fair value of the tradename acquired involved the use of significant estimates and assumptions related to revenue growth rates, royalty rates and discount rates. The company believes that the fair value assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that marketplace participants would use. Actual results could differ materially from these estimates. <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Purchased Intangible Assets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the authoritative guidance we have the option to perform a qualitative assessment to determine whether further impairment testing is necessary. The accounting standard gives an entity the option to first assess qualitative factors to determine whether performing the two-step test is necessary. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not (i.e., greater than 50% chance) that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test will be required. Otherwise, no further testing will be required.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance includes examples of events and circumstances that might indicate that a reporting unit's fair value is less than its carrying amount. These include macro-economic conditions such as deterioration in the entity's operating environment or industry or market considerations; entity-specific events such as increasing costs, declining financial performance, or loss of key personnel; or other events such as an expectation that a reporting unit will be sold or a sustained decrease in the stock price on either an absolute basis or relative to peers. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If it is determined, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, the provisions of authoritative guidance require that we perform a two-step impairment test on goodwill. In the first step, we compare the fair value of each reporting unit to its carrying value. The second step (if necessary) measures the amount of impairment by applying fair-value-based tests to the individual assets and liabilities within each reporting unit. As defined in the authoritative guidance, a reporting unit is an operating segment, or one level below an operating segment. We aggregate components of an operating segment that have similar economic characteristics into our reporting units. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In fiscal year 2020, we assessed goodwill impairment for our three reporting units which consisted of three segments: life sciences and applied markets, diagnostics and genomics and Agilent CrossLab. We performed a qualitative test for goodwill impairment of the three reporting units, as of September 30, 2020, our annual impairment test date. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair value of each reporting unit is greater than its respective carrying value. Each quarter we review the events and circumstances to determine if goodwill impairment is indicated. There was no impairment of goodwill during the years ended October 31, 2020, 2019 and 2018. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased intangible assets consist primarily of acquired developed technologies, proprietary know-how, trademarks, and customer relationships and are amortized using the best estimate of the asset's useful life that reflect the pattern in which the economic benefits are consumed or used up or a straight-line method ranging from 6 months to 15 years. IPR&amp;D is initially capitalized at fair value as an intangible asset with an indefinite life and assessed for impairment thereafter. When the IPR&amp;D project is complete, it is reclassified as an amortizable purchased intangible asset and is amortized over its estimated useful life. If an IPR&amp;D project is abandoned, Agilent will record a charge for the value of the related intangible asset to Agilent's consolidated statement of operations in the period it is abandoned.</span></div>Agilent's indefinite-lived intangible assets are IPR&amp;D intangible assets. The accounting guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the issued impairment testing guidance for goodwill and allows the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset to determine whether it is more-likely-than-not (i.e., greater than 50% chance) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value. We performed a qualitative test for impairment of indefinite-lived intangible assets as of September 30, 2020. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair values of these indefinite-lived intangible assets are greater than their respective carrying values. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible asset is indicated. During the year ended October 31, 2020, we recorded an impairment of in-process research and development of $90 million related to the shutdown of our sequencer development program in our diagnostics and genomics segment. During the year ended October 31, 2019 and 2018 there were no impairments of indefinite-lived intangible assets. 0 0 0 P6M P15Y 90000000 0 0 Impairment of Long-Lived Assets.  We continually monitor events and changes in circumstances that could indicate carrying amounts of long-lived assets, including intangible assets, may not be recoverable. When such events or changes in circumstances occur, we assess the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the undiscounted future cash flows is less than the carrying amount of those assets, we recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets. During the year ended October 31, 2020 we recorded an impairment charge of long-lived assets including indefinite-lived in-process research and development of $98 million related to the shutdown of our sequencer development program in our diagnostics and genomics segment. During fiscal year 2019, there were no impairments of other assets or intangible assets. During fiscal year 2018, we recorded an impairment charge of $21 million related to purchased intangible assets within the diagnostics and genomics segment that were deemed unrecoverable. 98000000 0 21000000 21000000 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity (“VIE”).  The company evaluates its investments in privately held companies on an ongoing basis. We have determined that as of October 31, 2020 and 2019, there were no VIE's required to be consolidated in the company's consolidated financial statements because we do not have a controlling financial interest in any of the VIE's in which we have invested nor are we the primary beneficiary. We account for these investments under either the equity method or as equity investments without readily determinable fair value, depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs, based on changes in facts and circumstances including changes in contractual arrangements and capital structure. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the year ended October 31, 2018, we exercised our option and acquired all of the remaining shares of Lasergen, Inc. ("Lasergen") that we did not already own for an additional cash consideration of approximately $107 million. The fair value remeasurement of our previous investment immediately before the acquisition resulted in a net gain of $20 million and was recorded in other income. Lasergen was previously considered a VIE. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 31, 2020 and October 31, 2019, the total carrying value of investments and loans in privately held companies considered as VIEs was $67 million and $29 million respectively. The maximum exposure is equal to the carrying value because we do not have future funding commitments. The investments are included on the long-term investments line and the loans on the other current assets and other assets lines (depending upon tenure of loan) on the consolidated balance sheet.</span></div> 107000000 20000000 67000000 29000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Equity investments without readily determinable fair value consist of non-marketable equity securities (typically investments in privately-held companies). These investments are accounted for using the measurement alternative at cost, and we adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) included in net income as and when it occurs. Equity investments with readily determinable fair value consist of shares we own in a special fund and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. Prior to fiscal year 2019, both equity investments without determinable fair value and with determinable fair value were accounted for using cost method of accounting, measured at historical cost less other-than-temporary investment. Trading securities, which are comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liabilities are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Equity method investments are reported at the amount of the company’s initial investment and adjusted each period for the company’s share of the investee’s income or loss and dividend paid. There are no equity method investments as of October 31, 2020 and 2019. The company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. The fair value of our senior notes, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy exceeds the carrying value by approximately $162 million as of October 31, 2020 and approximately $62 million as of October 31, 2019. The change in the fair value over carrying value in the year ended October 31, 2020 is primarily due to decreased market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are </span>observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 13, "Fair Value Measurements" for additional information on the fair value of financial instruments. 162000000 62000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warranty.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Our standard warranty terms typically extend for one year from the date of delivery. We accrue for standard warranty costs based on historical trends in warranty charges. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost over the period. Estimated warranty charges are recorded within cost of products at the time products are sold. See Note 16, "Guarantees".</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Compensation and Benefits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Amounts owed to employees, such as accrued salary, bonuses and vacation benefits are accounted for within employee compensation and benefits. The total amount of accrued vacation benefit was $111 million and $115 million as of October 31, 2020, and 2019, respectively.</span> 111000000 115000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retirement and Post-Retirement Plans. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our employees are covered under various defined benefit and/or defined contribution retirement plans. Additionally, we sponsor post-retirement health care benefits for our eligible U.S. employees. Assumptions used to determine the benefit obligations and the expense for these plans are derived annually. See Note 15, “Retirement plans and post-retirement pension plans” for additional information.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retirement of Treasury Shares. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the formal retirement of treasury shares, we deduct the par value of the retired treasury shares from common stock and allocate the excess of cost over par as a deduction to additional paid-in capital, based on the pro-rata portion of additional paid-in-capital, and the remaining excess as a deduction to retained earnings. All retired treasury shares revert to the status of authorized but unissued shares.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  For the years ended 2020, 2019 and 2018, we accounted for share-based awards made to our employees and directors including employee stock option awards, restricted stock units, employee stock purchases made under our Employee Stock Purchase Plan ("ESPP") and performance share awards under Agilent Technologies, Inc. Long-Term Performance Program ("LTPP") using the estimated grant date fair value method of accounting. Under the fair value method, we recorded compensation expense for all share-based awards of $84 million in 2020, $72 million in 2019 and $71 million in 2018. See Note 5, "Share-based Compensation" for additional information.</span> 84000000 72000000 71000000 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Agilent is exposed to global foreign currency exchange rate and interest rate risks in the normal course of business. We enter into foreign exchange hedging contracts, primarily forward contracts and purchased options, interest rate swaps and interest rate locks to manage financial exposures resulting from changes in foreign currency exchange rates and interest rates. In the vast majority of cases, these contracts are designated at inception as hedges of the related foreign currency or interest exposures. Foreign currency exposures include committed and anticipated revenue and expense transactions and assets and liabilities that are denominated in currencies other than the functional currency of the subsidiary. Interest rate exposures are associated with the company's fixed-rate debt. For option contracts, we exclude time value from the measurement of effectiveness. To qualify for hedge accounting, contracts must reduce the foreign currency exchange rate and interest rate risk otherwise inherent in the amount and duration of the hedged exposures and comply with established risk management policies. Foreign exchange hedging contracts generally mature within twelve months, interest rate swaps mature at the same time as the maturity of the debt and interest rate locks mature at the same time as the issuance of debt. In order to manage foreign currency exposures in a few limited jurisdictions, we may enter into foreign exchange contracts that do not qualify for hedge accounting. In such circumstances, the local foreign currency exposure is offset by contracts owned by the parent company. We do not use derivative financial instruments for trading or speculative purposes.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivatives are recognized on the balance sheet at their fair values. For derivative instruments that are designated and qualify as a cash flow hedge, changes in the value of the effective portion of the derivative instrument are recognized in comprehensive income (loss), a component of stockholders' equity. For derivative instruments that are designated and qualify as a net investment hedge, changes in the value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss). Amounts associated with cash flow hedges are reclassified and recognized in income when either the forecasted transaction occurs or it becomes probable the forecasted transaction will not occur. Derivatives not designated as hedging instruments are recorded on the balance sheet at their fair value and changes in the fair values are recorded in the income statement in the current period. Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet. Changes in the fair value of the ineffective portion of derivative instruments are recognized in earnings in the current period. The impact of the ineffectiveness measurement in 2020, 2019 and 2018 was not material. Cash flows from derivative instruments are classified in the statement of cash flows in the same category as the cash flows from the hedged or economically hedged item, primarily in operating activities.</span></div> P12M <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We translate and remeasure balance sheet and income statement items into U.S. dollars. For those subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using monthly exchange rates which approximate to average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) in stockholders' equity.</span>For those subsidiaries that operate in a U.S. dollar functional environment, foreign currency assets and liabilities are remeasured into U.S. dollars at current exchange rates except for non-monetary assets and capital accounts which are remeasured at historical exchange rates. Revenue and expenses are generally remeasured at monthly exchange rates which approximate average exchange rates in effect during each period. Gains or losses from foreign currency remeasurement are included in consolidated net income. Net gains or losses resulting from foreign currency transactions, including hedging gains and losses, are reported in other income (expense), net and were $4 million loss for 2020, $7 million loss for 2019 and $3 million loss for 2018. -4000000 -7000000 -3000000 NEW ACCOUNTING PRONOUNCEMENTS<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases (Topic 842), which requires lessees to record most leases on the balance sheet as lease liabilities, initially measured at the present value of future lease payments, with a corresponding right-of-use asset. The accounting applied by a lessor is largely unchanged from that applied under the prior accounting standard. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2019, we adopted the new accounting guidance using the modified retrospective method, by applying the transition approach, for all lease arrangements at the beginning of the period of adoption. Results for reporting periods beginning November 1, 2019 are presented under the new accounting standard, while prior period amounts have not been restated. The standard had a significant impact on the opening consolidated balance sheet as of November 1, 2019, but did not have a significant impact on the consolidated statement of operations or consolidated statement of cash flows for the year ended October 31, 2020 when compared to prior periods. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases, while the accounting for finance leases remained substantially unchanged. For leases that commenced before the effective date of the new accounting standard, we elected the permitted practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. We also elected to exclude leases with a term of 12 months or less in the ROU assets and lease liabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of the new guidance impacted the consolidated balance sheet as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:43.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impact of Adopting</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">November 1, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Reported</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Guidance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Adopted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:29.25pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2018, we adopted ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, using the modified retrospective approach only to contracts not completed as of this date. Results for reporting periods after November 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and continue to be reported in accordance with ASC Topic 605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements Not Yet Adopted</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2016, the FASB issued new guidance to require a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. During 2018 and 2019, the FASB issued additional guidance and clarification. The new guidance is effective for us beginning November 1, 2020. We do not expect this guidance to have a material impact on our consolidated financial statements and disclosures.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2017, the FASB issued an amendment to modify the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. The amendment also simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. The amendments are effective for us beginning November 1, 2020. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We do not expect this guidance to have a material impact on our consolidated financial statements and disclosures.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued updates to improve the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement which eliminates certain disclosure requirements and modifies others. These amendments are effective for us beginning November 1, 2020, and for interim periods within that year with early adoption permitted. We currently do not expect this guidance to have a material impact on our consolidated financial statements and disclosures.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued updates to improve the effectiveness of disclosures for defined benefit plans under Accounting Standard Codification Topic 715-20. The amendments in this guidance remove disclosures that no longer are considered cost beneficial, clarify the specific requirements of disclosures, and add disclosure requirements identified as relevant. These amendments are effective for us beginning November 1, 2021, with early adoption permitted. We currently do not expect this guidance to have a material impact on our consolidated financial statements and disclosures.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. This guidance eliminates certain exceptions to existing guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The guidance also improves consistent application by clarifying and amending existing guidance related to aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step up in the tax basis of goodwill. The new guidance is effective for us beginning November 1, 2021, and for interim periods within that year. Early adoption is permitted. We do not expect that the adoption of this standard will have a material impact on our consolidated financial statements and disclosures.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, accounting guidance was issued that clarifies the accounting guidance for equity method investments, joint ventures, and derivatives and hedging. The guidance clarifies the interaction between different sections of the accounting guidance that could be applicable and helps clarify which guidance should be applied in certain situations which should increase relevance and comparability of financial statement information. This guidance is effective for us beginning November 1, 2021, and for interim periods within that year. Early adoption is permitted. We do not expect that the adoption of this standard will have a material impact on our consolidated financial statements and disclosures.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued an update for facilitation of the effects of reference rate reform on financial reporting. This update provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments in the guidance provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply to contracts, hedging relationships, and other transactions that reference London Inter-bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. When elected, the optional expedients for contract modifications are applied consistently for all eligible contracts or eligible transactions within the relevant Topic or Industry Subtopic in the FASB's Accounting Standards Codification. The guidance was effective upon issuance and may generally be applied through December 31, 2022 to any new or amended contracts, hedging relationships, and other transactions that reference LIBOR. We are currently evaluating our contracts and we do not expect that the adoption of this guidance will have a material impact on our consolidated financial statements and disclosures.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other amendments to GAAP in the U.S. that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of the new guidance impacted the consolidated balance sheet as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:43.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impact of Adopting</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">November 1, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Reported</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Guidance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Adopted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 611000000 192000000 803000000 440000000 48000000 488000000 473000000 144000000 617000000 ACQUISITIONS<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition of BioTek</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and ACEA</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 23, 2019 we completed the acquisition of privately-owned Lionheart Technologies LLC ("BioTek"), a leader in the design, manufacture and distribution of innovative life science instrumentation for $1.17 billion, under the merger agreement. As a result of the acquisition, BioTek became a wholly-owned subsidiary of Agilent. Accordingly, the results of </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioTek are included in Agilent's consolidated financial statements from the acquisition date. The acquisition of BioTek and its portfolio is another step to expand our position in the cell analysis market.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration paid was $1.17 billion. Agilent funded the acquisition using existing cash of $470 million and debt of $700 million. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BioTek acquisition was accounted for in accordance with the authoritative accounting guidance. The acquired assets and assumed liabilities were recorded by Agilent at their estimated fair values. Agilent determined the estimated fair values with the assistance of appraisals or valuations performed by third party specialists, discounted cash flow analyses, and estimates made by management. We expect to realize revenue synergies, leverage and expand the existing sales channels and product development resources, and utilize the assembled workforce. These factors, among others, contributed to a purchase price in excess of the estimated fair value of BioTek’s net identifiable assets acquired (see summary of net assets below), and, as a result, we have recorded goodwill in connection with this transaction.</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill acquired was allocated to our operating segments and reporting units as a part of the purchase price allocation. All goodwill was allocated to the life sciences and applied markets reporting unit. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agilent’s acquisition of BioTek is treated as an asset purchase for tax purposes. The tax basis of the acquired assets equals the fair market value on acquisition date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of August 23, 2019 (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="4" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of cash and cash equivalents, accounts receivable, other current assets, accounts payable and other accrued liabilities were generally determined using historical carrying values given the short-term nature of these assets and liabilities.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values for acquired intangible assets and deferred revenue were determined with the input from third party valuation specialists.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of certain other assets, inventory, property, plant and equipment, investments, long-term debt, and certain other long-term liabilities were determined internally using historical carrying values and estimates made by management.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuations of intangible assets acquired</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of intangible assets acquired in connection with the BioTek acquisition were as follows (in millions):</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:77.230%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.883%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed product technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-13 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-8 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Backlog</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tradenames and trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets subject to amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the intangible assets, including in-process research and development, were valued with input from valuation specialists. Agilent used variations of the income approach in determining the fair value of intangible assets acquired in the BioTek acquisition. Specifically, the developed product technology and in-process research and development were valued using the multi-period excess earnings method under the income approach by discounting forecasted cash flows directly related to the products expecting to result from the projects, net of returns on contributory assets. The company utilized the incremental cash flow method for determining the fair value of the customer relationships acquired, and the relief from royalty method to determine the fair value of the tradename. Order backlog was valued on a direct cash flow basis. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary in-process research and development project acquired relates to a next version of a product which was subsequently released to customers in 2020. After release, the asset was moved to developed technology.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition and integration costs directly related to the BioTek acquisition totaled $12 million and $4 million for the year ended October 31, 2020 and 2019, respectively, and were recorded in operating expenses and cost of sales. Such costs are expensed in accordance with the authoritative accounting guidance.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 14, 2018, we acquired 100 percent of the stock of ACEA Biosciences (“ACEA”), a developer of cell analysis tools, for $250 million. The financial results of ACEA have been included in our financial results from the acquisition date.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents the unaudited proforma operating results as if BioTek and ACEA had been included in the company's consolidated statements of operations as of the beginning of fiscal 2018 (in millions, except per share amounts): </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,308 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share — basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share — diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited proforma financial information assumes that the companies were combined as of November 1, 2017 and include business combination accounting effects from the acquisition including amortization charges from acquired intangible assets, the impact on cost of sales due to the respective estimated fair value adjustments to inventory, changes to interest income for cash used in the acquisition, interest expense associated with debt paid in connection with the acquisition and acquisition related transaction costs and tax related effects. The proforma information as presented above is for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of fiscal 2018.</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited proforma financial information for the year ended October 31, 2019 combines the historical results of Agilent for the year ended October 31, 2019 (which includes BioTek and ACEA after the acquisition date) and for BioTek for the ten months ended August 23, 2019.</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited proforma financial information for the year ended October 31, 2018 combines the historical results of </span></div>Agilent and ACEA for the year ended October 31, 2018 and BioTek for the year ended December 31, 2018 (due to differences in reporting periods). 1170000000 1170000000 470000000 700000000 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of August 23, 2019 (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="4" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div> 10000000 28000000 21000000 2000000 8000000 641000000 483000000 1193000000 4000000 5000000 7000000 2000000 4000000 1171000000 <div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of intangible assets acquired in connection with the BioTek acquisition were as follows (in millions):</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:77.230%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.883%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed product technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-13 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-8 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Backlog</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tradenames and trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets subject to amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr></table></div> 387000000 P5Y P13Y 202000000 P3Y P8Y 5000000 P2M 43000000 P10Y 637000000 4000000 641000000 12000000 4000000 250000000 <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents the unaudited proforma operating results as if BioTek and ACEA had been included in the company's consolidated statements of operations as of the beginning of fiscal 2018 (in millions, except per share amounts): </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,308 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share — basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share — diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5308000000 5112000000 1012000000 210000000 3.22 0.65 3.18 0.65 REVENUE<div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the company’s total revenue and segment revenue disaggregated by geographical region: </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life Sciences and Applied Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Agilent CrossLab</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diagnostics and Genomics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended October 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,339 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended October 31, 2019:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,861 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,861 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,163 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the company’s total revenue disaggregated by end markets and by revenue type:</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.148%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Revenue by End Markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical and Biopharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,754 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chemical and Energy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics and Clinical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Food</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Academia and Government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Environmental and Forensics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,339 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,163 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Revenue by Type</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instrumentation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-instrumentation and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,090 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,339 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,163 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by region is based on the ship to location of the customer. Revenue by end market is determined by the market indicator of the customer and by customer type. Instrumentation revenue includes sales from instruments, remarketed instruments and third-party products. Non-instrumentation and other revenue include sales from contract and per incident services, our companion diagnostics and our nucleic acid solutions businesses as well as sales from spare parts, consumables, reagents, vacuum pumps, subscriptions, software licenses and associated services.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Balances</span></div><div><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets (unbilled accounts receivable) primarily relate to the company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are reclassified to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the consolidated balance sheet. The balances of contract assets as of October 31, 2020 and 2019, were $153 million and $110 million, respectively. The increase in unbilled receivables during the year ended October 31, 2020 is a result of recognition of revenue upon the transfer of the control to the customer. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Liabilities</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the years ended October 31, 2019 and 2020: </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:78.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract <br/>Liabilities</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance as of October 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of adoption of new revenue recognition guidance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue deferred in the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized that was included in the contract liability balance at the beginning of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferrals from customer cash advances, net of revenue recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities acquired in business combinations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation and other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance as of October 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue deferred in the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized that was included in the contract liability balance at the beginning of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferrals from customer cash advances, net of revenue recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation and other adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance as of October 31,2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either current in deferred revenue or long-term in other long-term liabilities in the consolidated balance sheet based on the timing of when we expect to complete our performance obligation.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incremental costs of obtaining a contract with a customer are recognized as an asset if we expect the benefit of those costs to be longer than one year. We have determined that certain sales incentive programs meet the requirements to be capitalized. The changes in total capitalized costs to obtain a contract were immaterial during the years ended October 31, 2020 and 2019 and are included in other current and long-term assets on the consolidated balance sheet. We have applied the practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the company's internal sales force compensation program, as we have determined that annual compensation is commensurate with annual sales activities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transaction Price Allocated to the Remaining Performance Obligations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have applied the practical expedient in ASC 606-10-50-14 and have not disclosed information about transaction price allocated to remaining performance obligations that have original expected durations of one year or less.</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>The estimated revenue expected to be recognized for remaining performance obligations that have an original term of more than one year, as of October 31, 2020, was $217 million, the majority of which is expected to be recognized over the next 12 months. Remaining performance obligations primarily include extended warranty, customer manufacturing contracts, and software maintenance contracts and revenue associated with lease arrangements. <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the company’s total revenue and segment revenue disaggregated by geographical region: </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life Sciences and Applied Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Agilent CrossLab</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diagnostics and Genomics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended October 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,339 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended October 31, 2019:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,861 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,861 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,163 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the company’s total revenue disaggregated by end markets and by revenue type:</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.148%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Revenue by End Markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical and Biopharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,754 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chemical and Energy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics and Clinical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Food</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Academia and Government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Environmental and Forensics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,339 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,163 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Revenue by Type</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instrumentation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-instrumentation and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,090 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,339 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,163 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 784000000 667000000 517000000 1968000000 540000000 532000000 371000000 1443000000 1068000000 701000000 159000000 1928000000 2392000000 1900000000 1047000000 5339000000 692000000 664000000 505000000 1861000000 551000000 522000000 368000000 1441000000 1059000000 654000000 148000000 1861000000 2302000000 1840000000 1021000000 5163000000 1754000000 1604000000 1154000000 1199000000 787000000 785000000 517000000 486000000 526000000 474000000 601000000 615000000 5339000000 5163000000 2249000000 2150000000 3090000000 3013000000 5339000000 5163000000 153000000 110000000 <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the years ended October 31, 2019 and 2020: </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:78.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract <br/>Liabilities</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance as of October 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of adoption of new revenue recognition guidance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue deferred in the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized that was included in the contract liability balance at the beginning of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferrals from customer cash advances, net of revenue recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities acquired in business combinations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation and other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance as of October 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue deferred in the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized that was included in the contract liability balance at the beginning of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferrals from customer cash advances, net of revenue recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation and other adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance as of October 31,2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 367000000 -11000000 303000000 -287000000 5000000 9000000 0 386000000 347000000 -300000000 9000000 4000000 446000000 217000000 SHARE-BASED COMPENSATION<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agilent accounts for share-based awards in accordance with the provisions of the accounting guidance which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including restricted stock units, stock options, employee stock purchases made under our employee stock purchase plan and performance share awards granted to selected members of our senior management under the long-term performance plan ("LTPP") based on estimated fair values. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Share-Based Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Effective May 1, 2020, we adopted the 2020 Employee Stock Purchase Plan ("ESPP") which replaced our previous Employee Stock Purchase Plan. The ESPP allows eligible employees to contribute up to 10 percent of their base compensation to purchase shares of our common stock at 85 percent of the closing market price at purchase date. There are 31 million shares authorized for issuance in connection with the ESPP.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our ESPP, employees purchased 628,644 shares for $41 million in 2020, 603,488 shares for $37 million in 2019 and 558,116 shares for $32 million in 2018. As of October 31, 2020, the number of shares of common stock authorized and available for issuance under our ESPP was 25,770,573. This excludes the number of shares of common stock to be issued to participants in consideration of the aggregate participant contributions totaling $22 million as of October 31, 2020.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incentive Compensation Plans.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On November 15, 2017 and March 21, 2018, the Board of Directors and the stockholders, respectively, approved the Agilent Technologies, Inc. 2018 Stock Plan (the "2018 Plan") which amends, including renaming and extending the term of, the Agilent Technologies, Inc. 2009 Stock Plan (the "2009 Plan"). The 2009 plan replaced the Agilent Technologies, Inc. Amended and Restated 1999 Stock Plan and 1999 Non-Employee Director Stock Plan. The 2018 Plan provides for the grant of awards in the form of stock options, stock appreciation rights ("SARs"), restricted stock, restricted stock units ("RSUs"), performance shares and performance units with performance-based conditions on vesting or exercisability, and cash awards. The 2018 Plan has a term of ten years. As of October 31, 2020, 25,596,430 shares were available for future awards under the 2018 Plan.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options under the 2018 Plan may be either "incentive stock options", as defined in Section 422 of the Internal Revenue Code, or non-statutory. Options were granted prior to November 1, 2015 and generally vest at a rate of 25 percent per year over a period of four years from the date of grant with a maximum contractual term of ten years. The exercise price for stock options is generally not less than 100 percent of the fair market value of our common stock on the date the stock award is granted. Agilent issues new shares of common stock when employee stock options are exercised. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective November 1, 2003, the Compensation Committee of the Board of Directors approved the LTPP, which is a performance stock award program administered under the 2018 Plan, for the company's executive officers and other key employees. Participants in this program are entitled to receive unrestricted shares of the company's stock after the end of a three-year period if specified performance targets are met. Certain LTPP awards are generally designed to meet the criteria of a performance award with the performance metrics and peer group comparison based on the Total Stockholders’ Return (“TSR”) set at the beginning of the performance period. Effective November 1, 2015, the Compensation Committee of the Board of Directors approved another type of performance stock award for the company's executive officers and other key employees. Participants in this program are also entitled to receive unrestricted shares of the company's stock after the end of a three-year period if specified performance targets over the three-year period are met. The performance target for grants made beginning in 2017 and thereafter were based on Earnings Per Share ("EPS"). The performance targets for LTPP-EPS grants for year 2 and year 3 of the performance period are set in the first quarter of year 2 and year 3, respectively. All LTPP awards granted after November 1, 2015, are subject to a one-year post-vest holding period.</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the performance metrics, the final LTPP award may vary from zero to 200 percent of the target award. The maximum contractual term for awards under the LTPP program is three years. We consider the dilutive impact of these programs in our diluted net income per share calculation only to the extent that the performance conditions are expected to be met.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also issue restricted stock units under our share-based plans. The estimated fair value of the restricted stock unit awards granted under the Stock Plans is determined based on the market price of Agilent's common stock on the date of grant adjusted for expected dividend yield. Restricted stock units generally vest, with some exceptions, at a rate of 25 percent per year over a period of four years from the date of grant. All restricted stock units granted to our executives after November 1, 2015, are subject to a one-year post-vest holding period.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of Share-based Compensation Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recognized compensation expense based on the estimated grant date fair value method under the authoritative guidance. For all share-based awards we have recognized compensation expense using a straight-line amortization method. As the guidance requires that share-based compensation expense be based on awards that are ultimately expected to vest, estimated share-based compensation has been reduced for estimated forfeitures.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact on our results for share-based compensation was as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products and services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At October 31, 2020 and 2019, no share-based compensation was capitalized within inventory. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all periods presented, shares granted under the LTPP (TSR) were valued using a Monte Carlo simulation. The ESPP allows eligible employees to purchase shares of our common stock at 85 percent of the fair market value at the purchase date.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of restricted stock unit awards and LTPP (EPS) was determined based on the market price of Agilent's common stock on the date of grant adjusted for expected dividend yield and as appropriate, a discount related to the one-year post vesting. The compensation cost for LTPP (EPS) awards reflects the cost of awards that are probable to vest at the end of the performance period.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to estimate the fair value of awards granted.</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:52.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LTPP:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of Agilent shares</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of selected peer-company shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%-44%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%-66%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%-66%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pair-wise correlation with selected peers</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Post-vest restriction discount for all executive awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8%</span></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares granted under the LTPP (TSR) were valued using a Monte Carlo simulation model. The Monte Carlo simulation fair value model requires the use of highly subjective and complex assumptions, including the price volatility of the underlying stock. For LTPP (TSR) grants in 2017 and thereafter, we used our own historical stock price volatility.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> All LTPP awards granted have a one-year post-vest holding restriction. The estimated discount associated with post-vest holding restrictions is calculated using the Finnerty model. The model calculates the potential lost value if the employee were able to sell the shares during the lack of marketability period instead of being required to hold the shares. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Payment Award Activity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes employee stock option award activity of our employees and directors for 2020. </span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>Outstanding </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at October 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at October 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options outstanding and exercisable for equity share-based payment awards at October 31, 2020 were as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:13.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of<br/>Exercise Prices</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$25.01 - $30.00</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$30.01 - $40.00</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$40.01- over</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,883 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,883 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,661 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,661 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value, based on the company's closing stock price of $102.09 at October 31, 2020, which would have been received by award holders had all award holders exercised their awards that were in-the-money as of that date. The total number of in-the-money awards exercisable at October 31, 2020 was approximately 0.9 million.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate intrinsic value of options exercised in 2020, 2019 and 2018:</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised in fiscal 2018</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised in fiscal 2019</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised in fiscal 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,481 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 31, 2020, the unrecognized share-based compensation cost for outstanding stock option awards, net of expected forfeitures, was zero. The amount of cash received from the exercise of share-based awards granted was $60 million in 2020, $54 million in 2019 and $56 million in 2018. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Vested Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested award activity in 2020 primarily for our LTPP and restricted stock unit awards. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at October 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,629)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in LTPP shares in the year due to exceeding performance targets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at October 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,818 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 31, 2020, the unrecognized share-based compensation cost for non-vested restricted stock awards was approximately $95 million which is expected to be amortized over a weighted average period of 2.1 years. The total fair value of restricted stock awards vested was $85 million for 2020, $69 million for 2019 and $58 million for 2018.</span></div> 0.10 0.85 31000000 628644 41000000 603488 37000000 558116 32000000 25770573 22000000 ten years 25596430 0.25 P4Y ten years 1 0 2 three years 0.25 P4Y <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact on our results for share-based compensation was as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products and services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 21000000 18000000 16000000 9000000 7000000 7000000 54000000 47000000 48000000 84000000 72000000 71000000 0 0 0.85 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to estimate the fair value of awards granted.</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:52.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LTPP:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of Agilent shares</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of selected peer-company shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%-44%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%-66%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%-66%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pair-wise correlation with selected peers</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Post-vest restriction discount for all executive awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8%</span></td></tr></table></div> <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to estimate the fair value of awards granted.</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:52.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LTPP:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of Agilent shares</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of selected peer-company shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%-44%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%-66%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%-66%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pair-wise correlation with selected peers</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Post-vest restriction discount for all executive awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8%</span></td></tr></table></div> 0.23 0.22 0.21 0.15 0.44 0.15 0.66 0.14 0.66 0.29 0.30 0.32 0.053 0.050 0.048 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes employee stock option award activity of our employees and directors for 2020. </span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>Outstanding </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at October 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at October 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1445000 36 575000 34 870000 37 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options outstanding and exercisable for equity share-based payment awards at October 31, 2020 were as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:13.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of<br/>Exercise Prices</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$25.01 - $30.00</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$30.01 - $40.00</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$40.01- over</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,883 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,883 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,661 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,661 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 25010000.00 30000.00 228000 P1Y8M12D 27 17192000 228000 P1Y8M12D 27 17192000 30010000.00 40000.00 121000 P3Y1M6D 39 7586000 121000 P3Y1M6D 39 7586000 40.01 521000 P4Y 41 31883000 521000 P4Y 41 31883000 870000 P3Y3M18D 37 56661000 870000 P3Y3M18D 37 56661000 102.09 900000 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate intrinsic value of options exercised in 2020, 2019 and 2018:</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised in fiscal 2018</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised in fiscal 2019</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised in fiscal 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,481 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 28417000 32 24409000 33 30481000 34 0 60000000 54000000 56000000 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested award activity in 2020 primarily for our LTPP and restricted stock unit awards. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at October 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,629)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in LTPP shares in the year due to exceeding performance targets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at October 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,818 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3173000 60 1091000 79 1629000 52 115000 68 298000 47 2818000 70 95000000 2.1 85000000 69000000 58000000 INCOME TAXES <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The domestic and foreign components of income before taxes are:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. operations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income before taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is comprised of:</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. taxes:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(267)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision (benefit)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between the U.S. federal statutory income tax rate and our effective tax rate are:</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:59.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profit before tax times statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. income taxed at different rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of the Tax Act</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Extension of the tax incentive in Singapore</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefits from stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (benefit) for income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020, the company's income tax expense was $123 million with an effective tax rate of 14.6 percent. For the year ended October 31, 2020, our effective tax rate and the resulting provision for income taxes were impacted by foreign income taxed at lower rates.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2019, the company's income tax benefit was $152 million with an effective tax rate of (16.5) percent. For the year ended October 31, 2019, our effective tax rate and the resulting provision for income taxes were significantly impacted by the discrete benefit of $299 million related to the extension of the company’s tax incentive in Singapore.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the business integration of some of our prior acquisitions, we undertook corporate restructurings in the fourth quarter of fiscal year 2019 that involved on-shoring certain intangible properties held by our foreign subsidiaries to the United States. These restructurings resulted in a cash tax liability of $231 million. These taxes generate tax attributes that will offset our transition tax liability which is included in other long-term liabilities in our consolidated balance sheet. </span><span style="color:#4472c4;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2018, the company's income tax expense was $630 million with an effective tax rate of 66.6 percent. For the year ended October 31, 2018, our effective tax rate and the resulting provision for income taxes were significantly impacted by the discrete charge of $552 million related to the enactment of the U.S. Tax Cuts and Jobs Act (the “Tax Act”) consisting of (1) an expense of $499 million of U.S. transition tax and correlative items on deemed repatriated earnings of non-U.S. subsidiaries and (2) an expense of $53 million associated with the impact on deferred taxes resulting from the decreased U.S. corporate tax rate.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has negotiated tax holidays in several different jurisdictions, most significantly in Singapore. The tax holidays provide lower rates of taxation on certain classes of income and require various thresholds of investments and employment or specific types of income in those jurisdictions. In December 2018, the tax holiday in Singapore was renegotiated and extended through 2027. As a result of the incentives, the impact of the tax holidays decreased income taxes by $71 million, $368 million, and $87 million in 2020, 2019, and 2018, respectively. The benefit of the tax holidays on net income per share (diluted) was approximately $0.23, $1.16, and $0.27 in 2020, 2019 and 2018, respectively. Of the $1.16 benefit of the tax incentives on net income per share (diluted) in 2019, $0.94 of the benefit relates to one-time items from the extension of the company’s tax incentive in Singapore.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of deferred tax assets and deferred tax liabilities included on the consolidated balance sheet are:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:69.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.228%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits and retiree medical benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefits, other than retirement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss, capital loss, and credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances require an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction by jurisdiction basis. As of October 31, 2020, we continued to maintain a valuation allowance of $132 million until sufficient positive evidence exists to support reversal. The valuation allowance is primarily related to deferred tax assets for the states of California and Colorado, along with the net operating losses in the Netherlands and capital losses in the U.S. and Australia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At October 31, 2020, we had federal, state and foreign net operating loss carryforwards of approximately $11 million, $530 million and $411 million, respectively. The federal and state net operating loss carryforwards are subject to various limitations under Section 382 of the Internal Revenue Code and applicable state tax laws. If not utilized, the federal and state net operating loss carryforwards will begin to expire in 2021. If not utilized, $123 million of the foreign net operating loss carryforwards will begin to expire in 2021. The remaining $288 million of the foreign net operating losses carry forward indefinitely. At October 31, 2020, we had federal and foreign capital loss carryforwards of $48 million and $118 million, respectively. If not utilized, the federal capital loss carryforwards will expire in 2022. The foreign capital losses carry forward indefinitely. At October 31, 2020, we had state tax credit carryforwards of approximately $83 million. The state tax credits carry forward indefinitely. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The breakdown between long-term deferred tax assets and deferred tax liabilities was as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred tax assets (included within other assets)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred tax liabilities (included within other long-term liabilities)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The breakdown between current and long-term income tax assets and liabilities, excluding deferred tax assets and liabilities, was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:76.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax assets (included within other current assets)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term income tax assets (included within other assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax liabilities (included within other accrued liabilities)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term income tax liabilities (included within other long-term liabilities)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(548)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertain Tax Positions</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate changes in the balances of our gross unrecognized tax benefits including all federal, state and foreign tax jurisdictions are as follows:</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions from prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions from prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statute of limitations expirations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 31, 2020, we had $240 million of unrecognized tax benefits, including interest and penalties of which $215 million, if recognized, would affect our effective tax rate. However, approximately $25 million of the unrecognized tax benefits were related to state income tax positions that, if recognized, would be in the form of a deferred tax asset that would likely not affect our effective tax rate due to a valuation allowance.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized tax expense of $8 million, $9 million and $11 million for interest and penalties related to unrecognized tax benefits in 2020, 2019 and 2018, respectively. Interest and penalties accrued as of October 31, 2020 and 2019 were $45 million and $36 million, respectively.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., tax years remain open back to the year 2017 for federal income tax purposes and for significant states. In other major jurisdictions where the company conducts business, the tax years generally remain open back to the year 2009. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With these jurisdictions and the U.S., it is reasonably possible that there could be significant changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitation or a tax audit settlement which will be partially offset by an anticipated tax liability related to unremitted foreign earnings, where applicable. Given the number of years and numerous matters that remain subject to examination in various tax jurisdictions, management is unable to estimate the range of possible changes to the balance of our unrecognized tax benefits.</span></div> INCOME TAXES <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The domestic and foreign components of income before taxes are:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. operations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income before taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is comprised of:</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. taxes:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(267)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision (benefit)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between the U.S. federal statutory income tax rate and our effective tax rate are:</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:59.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profit before tax times statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. income taxed at different rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of the Tax Act</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Extension of the tax incentive in Singapore</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefits from stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (benefit) for income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020, the company's income tax expense was $123 million with an effective tax rate of 14.6 percent. For the year ended October 31, 2020, our effective tax rate and the resulting provision for income taxes were impacted by foreign income taxed at lower rates.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2019, the company's income tax benefit was $152 million with an effective tax rate of (16.5) percent. For the year ended October 31, 2019, our effective tax rate and the resulting provision for income taxes were significantly impacted by the discrete benefit of $299 million related to the extension of the company’s tax incentive in Singapore.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the business integration of some of our prior acquisitions, we undertook corporate restructurings in the fourth quarter of fiscal year 2019 that involved on-shoring certain intangible properties held by our foreign subsidiaries to the United States. These restructurings resulted in a cash tax liability of $231 million. These taxes generate tax attributes that will offset our transition tax liability which is included in other long-term liabilities in our consolidated balance sheet. </span><span style="color:#4472c4;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2018, the company's income tax expense was $630 million with an effective tax rate of 66.6 percent. For the year ended October 31, 2018, our effective tax rate and the resulting provision for income taxes were significantly impacted by the discrete charge of $552 million related to the enactment of the U.S. Tax Cuts and Jobs Act (the “Tax Act”) consisting of (1) an expense of $499 million of U.S. transition tax and correlative items on deemed repatriated earnings of non-U.S. subsidiaries and (2) an expense of $53 million associated with the impact on deferred taxes resulting from the decreased U.S. corporate tax rate.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has negotiated tax holidays in several different jurisdictions, most significantly in Singapore. The tax holidays provide lower rates of taxation on certain classes of income and require various thresholds of investments and employment or specific types of income in those jurisdictions. In December 2018, the tax holiday in Singapore was renegotiated and extended through 2027. As a result of the incentives, the impact of the tax holidays decreased income taxes by $71 million, $368 million, and $87 million in 2020, 2019, and 2018, respectively. The benefit of the tax holidays on net income per share (diluted) was approximately $0.23, $1.16, and $0.27 in 2020, 2019 and 2018, respectively. Of the $1.16 benefit of the tax incentives on net income per share (diluted) in 2019, $0.94 of the benefit relates to one-time items from the extension of the company’s tax incentive in Singapore.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of deferred tax assets and deferred tax liabilities included on the consolidated balance sheet are:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:69.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.228%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits and retiree medical benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefits, other than retirement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss, capital loss, and credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances require an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction by jurisdiction basis. As of October 31, 2020, we continued to maintain a valuation allowance of $132 million until sufficient positive evidence exists to support reversal. The valuation allowance is primarily related to deferred tax assets for the states of California and Colorado, along with the net operating losses in the Netherlands and capital losses in the U.S. and Australia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At October 31, 2020, we had federal, state and foreign net operating loss carryforwards of approximately $11 million, $530 million and $411 million, respectively. The federal and state net operating loss carryforwards are subject to various limitations under Section 382 of the Internal Revenue Code and applicable state tax laws. If not utilized, the federal and state net operating loss carryforwards will begin to expire in 2021. If not utilized, $123 million of the foreign net operating loss carryforwards will begin to expire in 2021. The remaining $288 million of the foreign net operating losses carry forward indefinitely. At October 31, 2020, we had federal and foreign capital loss carryforwards of $48 million and $118 million, respectively. If not utilized, the federal capital loss carryforwards will expire in 2022. The foreign capital losses carry forward indefinitely. At October 31, 2020, we had state tax credit carryforwards of approximately $83 million. The state tax credits carry forward indefinitely. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The breakdown between long-term deferred tax assets and deferred tax liabilities was as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred tax assets (included within other assets)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred tax liabilities (included within other long-term liabilities)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The breakdown between current and long-term income tax assets and liabilities, excluding deferred tax assets and liabilities, was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:76.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax assets (included within other current assets)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term income tax assets (included within other assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax liabilities (included within other accrued liabilities)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term income tax liabilities (included within other long-term liabilities)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(548)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertain Tax Positions</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate changes in the balances of our gross unrecognized tax benefits including all federal, state and foreign tax jurisdictions are as follows:</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions from prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions from prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statute of limitations expirations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 31, 2020, we had $240 million of unrecognized tax benefits, including interest and penalties of which $215 million, if recognized, would affect our effective tax rate. However, approximately $25 million of the unrecognized tax benefits were related to state income tax positions that, if recognized, would be in the form of a deferred tax asset that would likely not affect our effective tax rate due to a valuation allowance.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized tax expense of $8 million, $9 million and $11 million for interest and penalties related to unrecognized tax benefits in 2020, 2019 and 2018, respectively. Interest and penalties accrued as of October 31, 2020 and 2019 were $45 million and $36 million, respectively.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., tax years remain open back to the year 2017 for federal income tax purposes and for significant states. In other major jurisdictions where the company conducts business, the tax years generally remain open back to the year 2009. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With these jurisdictions and the U.S., it is reasonably possible that there could be significant changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitation or a tax audit settlement which will be partially offset by an anticipated tax liability related to unremitted foreign earnings, where applicable. Given the number of years and numerous matters that remain subject to examination in various tax jurisdictions, management is unable to estimate the range of possible changes to the balance of our unrecognized tax benefits.</span></div> <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The domestic and foreign components of income before taxes are:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. operations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income before taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 54000000 189000000 169000000 788000000 730000000 777000000 842000000 919000000 946000000 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is comprised of:</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. taxes:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(267)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision (benefit)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5000000 -191000000 520000000 4000000 0 51000000 84000000 290000000 95000000 24000000 -267000000 -22000000 5000000 4000000 1000000 1000000 12000000 -15000000 123000000 -152000000 630000000 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between the U.S. federal statutory income tax rate and our effective tax rate are:</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:59.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profit before tax times statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. income taxed at different rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of the Tax Act</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Extension of the tax incentive in Singapore</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefits from stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (benefit) for income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 177000000 193000000 221000000 -36000000 -8000000 -93000000 -9000000 -13000000 -17000000 0 0 552000000 0 -299000000 0 18000000 10000000 18000000 9000000 -15000000 -15000000 123000000 -152000000 630000000 0.146 -0.165 0.666 123000000 0.146 -152000000 -0.165 -299000000 231000000 630000000 0.666 552000000 499000000 53000000 71000000 368000000 87000000 0.23 1.16 0.27 1.16 0.94 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of deferred tax assets and deferred tax liabilities included on the consolidated balance sheet are:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:69.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.228%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits and retiree medical benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefits, other than retirement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss, capital loss, and credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 153000000 131000000 65000000 71000000 31000000 34000000 182000000 195000000 27000000 32000000 22000000 38000000 35000000 0 41000000 35000000 556000000 536000000 132000000 134000000 424000000 402000000 19000000 16000000 35000000 0 14000000 7000000 68000000 23000000 356000000 379000000 132000000 11000000 530000000 411000000 123000000 288000000 48000000 118000000 83000000 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The breakdown between long-term deferred tax assets and deferred tax liabilities was as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred tax assets (included within other assets)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred tax liabilities (included within other long-term liabilities)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 380000000 410000000 24000000 31000000 356000000 379000000 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The breakdown between current and long-term income tax assets and liabilities, excluding deferred tax assets and liabilities, was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:76.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax assets (included within other current assets)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term income tax assets (included within other assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax liabilities (included within other accrued liabilities)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term income tax liabilities (included within other long-term liabilities)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(548)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 89000000 68000000 6000000 4000000 63000000 292000000 323000000 328000000 291000000 548000000 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate changes in the balances of our gross unrecognized tax benefits including all federal, state and foreign tax jurisdictions are as follows:</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions from prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions from prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statute of limitations expirations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 206000000 214000000 224000000 6000000 7000000 27000000 0 12000000 2000000 0 2000000 13000000 17000000 25000000 26000000 195000000 206000000 214000000 240000000 215000000 25000000 8000000 9000000 11000000 45000000 36000000 NET INCOME PER SHARE<div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented below. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominators:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential common shares — stock options and other employee stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense collectively are assumed proceeds to be used to repurchase hypothetical shares. An increase in the fair market value of the company's common stock can result in a greater dilutive effect from potentially dilutive awards. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclude stock options with exercise prices greater than the average market price of our common stock from the calculation of diluted earnings per share because their effect would be anti-dilutive. In addition, we exclude from the calculation of diluted earnings per share, stock options, ESPP, LTPP and restricted stock awards whose combined exercise price and unamortized fair value collectively were greater than the average market price of our common stock because their effect would also be anti-dilutive.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, 2019 and 2018, we issued share-based awards of approximately 2 million each year.  For the years ended 2020, 2019 and 2018, the impacts of the anti-dilutive potential common shares that were excluded from the calculation of diluted earnings per share were not material.</span></div> <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented below. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominators:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential common shares — stock options and other employee stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 719000000 1071000000 316000000 309000000 314000000 321000000 3000000 4000000 4000000 312000000 318000000 325000000 2000000 2000000 2000000 INVENTORY<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory as of October 31, 2020 and 2019 consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased parts and fabricated assemblies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory-related excess and obsolescence charges of $28 million were recorded in cost of products in 2020, $19 million in 2019 and $26 million in 2018. We record excess and obsolete inventory charges for both inventory on our site as well as inventory at our contract manufacturers and suppliers where we have non-cancelable purchase commitments.</span></div> INVENTORY<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory as of October 31, 2020 and 2019 consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased parts and fabricated assemblies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory-related excess and obsolescence charges of $28 million were recorded in cost of products in 2020, $19 million in 2019 and $26 million in 2018. We record excess and obsolete inventory charges for both inventory on our site as well as inventory at our contract manufacturers and suppliers where we have non-cancelable purchase commitments.</span></div> <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory as of October 31, 2020 and 2019 consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased parts and fabricated assemblies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 417000000 416000000 303000000 263000000 720000000 679000000 28000000 28000000 19000000 19000000 26000000 26000000 PROPERTY, PLANT AND EQUIPMENT, NET<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment as of October 31, 2020 and 2019, consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,055 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,029)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(925)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020 we recorded $6 million in asset impairments related to the shutdown of our sequencer development program. There were no asset impairments in 2019 and less than $1 million in asset impairments in 2018. Depreciation expenses were $119 million in 2020, $111 million in 2019 and $102 million in 2018. In 2020 and 2019 we retired approximately $29 million and $23 million, respectively, of fully depreciated assets that were no longer in use.</span></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment as of October 31, 2020 and 2019, consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,055 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,029)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(925)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 58000000 57000000 1055000000 1012000000 579000000 546000000 182000000 160000000 1874000000 1775000000 1029000000 925000000 845000000 850000000 6000000 0 1000000 119000000 111000000 102000000 29000000 23000000 LEASES<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a lessee, we have various non-cancelable operating lease agreements for office space, warehouses, distribution centers, research and development facilities, manufacturing and production locations as well as vehicles, personal computers and other equipment. Our real estate leases have remaining lease terms of one to thirty years, which represent the non-cancelable periods of the leases and include extension options that we determined are reasonably certain to be exercised. We exclude options that are not reasonably certain to be exercised from our lease terms, ranging from six months to twenty years. Our lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms. We often receive incentives from our landlords, such as rent abatement periods, which effectively reduce the total lease payments owed for these leases. Vehicle, personal computer and other equipment operating leases have terms between three and five years. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the adoption of the new lease accounting standard, future minimum lease payments as of October 31, 2019 under non-cancelable leases with initial terms exceeding twelve months were as follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.461%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for operating leases were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.461%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended October 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Variable lease cost includes cancelable leases, non-fixed maintenance costs and non-recoverable transaction taxes.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Total rent expense was $75 million in 2019 and $64 million in 2018.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended October 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flow from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash right of use assets obtained in exchange for operating lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.089%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Statement Line Item</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except lease term and discount rate)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rents payable as of October 31, 2020 under non-cancelable leases with initial terms exceeding one year reconcile to lease liabilities included in the consolidated balance sheet as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.461%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 31, 2020, we had no additional significant operating or finance leases that had not yet commenced.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a lessor, we have contracts for equipment leased to customers in connection with our diagnostics business which include both operating-type lease and sales-type lease arrangements. We account for the non-lease component under the revenue recognition ASC 606 guidance and the lease component under the leasing ASC 842 guidance. Equipment lease revenue for operating lease agreements is recognized as visualization kits and reagents are shipped over the life of the lease, and the cost of customer leased equipment is recorded within property, plant and equipment, net in the consolidated balance sheet and depreciated over the equipment’s estimated useful life. For an arrangement that has been classified as a sales-type lease, revenue is recognized when the transfer of control of the underlying leased asset has occurred and the net investment lease recorded which is calculated at the present value of the remaining lease payments due from the lessee. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue allocated to the lease income for both finance/sales-type lease and operating lease rental arrangements represents less than one percent of total net revenue in the year ended October 31, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 31, 2020, the original cost and net book value of operating leased assets was $43 million and $12 million, respectively. As of October 31, 2020, lease receivables related to sales-type leases were $44 million. As of October 31, 2019, the original cost and net book value of operating leased assets was $49 million and $17 million, respectively. As of October 31, 2019, lease receivables related to sales-type leases were $37 million.</span></div> <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the adoption of the new lease accounting standard, future minimum lease payments as of October 31, 2019 under non-cancelable leases with initial terms exceeding twelve months were as follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.461%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 52000000 41000000 29000000 21000000 14000000 56000000 <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for operating leases were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.461%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended October 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Variable lease cost includes cancelable leases, non-fixed maintenance costs and non-recoverable transaction taxes.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Total rent expense was $75 million in 2019 and $64 million in 2018.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended October 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flow from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash right of use assets obtained in exchange for operating lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 60000000 1000000 14000000 14000000 61000000 75000000 64000000 59000000 37000000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.089%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Statement Line Item</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except lease term and discount rate)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 175000000 51000000 127000000 P7Y10M24D 0.021 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rents payable as of October 31, 2020 under non-cancelable leases with initial terms exceeding one year reconcile to lease liabilities included in the consolidated balance sheet as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.461%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 54000000 41000000 28000000 16000000 9000000 49000000 197000000 19000000 178000000 51000000 127000000 43000000 12000000 44000000 49000000 17000000 37000000 GOODWILL AND OTHER INTANGIBLE ASSETS<div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents goodwill balances and the movements for each of our reportable segments during the years ended October 31, 2019 and 2020:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:55.287%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life Sciences and Applied Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diagnostics and Genomics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Agilent CrossLab</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of October 31, 2018</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,973 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill arising from acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of October 31, 2019</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,594 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,593 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of October 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,602 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, our annual impairment test date, we assessed goodwill for triggering events and circumstances, including impacts due to COVID-19, and determined no impairment of goodwill was indicated for our reporting units.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The component parts of other intangible assets at October 31, 2019 and 2020 are shown in the table below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Intangible Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of October 31, 2019:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Backlog</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark/Tradename</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third-party technology and licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortizable intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,971 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-Process R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,086 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of October 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,429 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark/Tradename</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third-party technology and licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortizable intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-Process R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2020, we recorded no additions to goodwill or to intangible assets. During the year ended October 31, 2020 we moved $15 million of in-process research and development intangible assets to purchased technology on the completion of three projects.</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2019, </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e recorded additions to goodwill of $636 million and to other intangible assets of $744 million related to the acquisition of ACEA Biosciences and BioTek. In the second quarter of fiscal year 2019, we recorded a measurement period adjustment to goodwill of $11 million for deferred tax assets related to pre-acquisition net operating losses of Advanced Analytical Technologies, Inc. The increase to other intangible assets due to foreign currency translation was not material in 2019.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In general, for United States federal tax purposes, goodwill from asset purchases is amortizable; however, any goodwill created as part of a stock acquisition is not deductible.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2020, we recorded an impairment of in-process research and development of $90 million in research and development expenses in the consolidated statement of operations which was related to the shutdown of our sequencer development program in our diagnostics and genomics segment. There were no impairments of indefinite-lived intangible assets during fiscal year 2019 and 2018. During fiscal years 2020 and 2019, there were no impairments of finite-lived intangible assets recorded. During 2018, we recorded an impairment of $21 million related to purchased intangible assets within the diagnostics and genomics segment that were deemed unrecoverable. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we also wrote-off the gross carrying amount of $17 million and the related accumulated amortization of fully amortized intangible assets which were no longer being used. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense of intangible assets was $186 million in 2020, $128 million in 2019, and $110 million in 2018. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense related to existing finite-lived purchased intangible assets associated with business combinations for the next five fiscal years and thereafter is estimated below:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated future amortization expense:</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents goodwill balances and the movements for each of our reportable segments during the years ended October 31, 2019 and 2020:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:55.287%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life Sciences and Applied Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diagnostics and Genomics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Agilent CrossLab</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of October 31, 2018</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,973 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill arising from acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of October 31, 2019</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,594 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,593 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of October 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,602 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div> 803000000 1607000000 563000000 2973000000 -1000000 -2000000 -2000000 -5000000 636000000 -11000000 0 625000000 1438000000 1594000000 561000000 3593000000 3000000 5000000 1000000 9000000 1441000000 1599000000 562000000 3602000000 0 <div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The component parts of other intangible assets at October 31, 2019 and 2020 are shown in the table below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Intangible Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of October 31, 2019:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Backlog</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark/Tradename</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third-party technology and licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortizable intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,971 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-Process R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,086 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of October 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,429 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark/Tradename</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third-party technology and licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortizable intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-Process R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div> 1413000000 763000000 650000000 5000000 5000000 0 196000000 102000000 94000000 329000000 87000000 242000000 28000000 22000000 6000000 1971000000 979000000 992000000 115000000 115000000 2086000000 979000000 1107000000 1429000000 863000000 566000000 196000000 117000000 79000000 330000000 158000000 172000000 11000000 7000000 4000000 1966000000 1145000000 821000000 10000000 10000000 1976000000 1145000000 831000000 0 0 636000000 744000000 -11000000 90000000 0 0 0 0 21000000 21000000 17000000 186000000 128000000 110000000 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense related to existing finite-lived purchased intangible assets associated with business combinations for the next five fiscal years and thereafter is estimated below:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated future amortization expense:</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 174000000 151000000 109000000 87000000 70000000 230000000 INVESTMENTS<div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the company's equity investments as of October 31, 2020 and 2019 (net book value):</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-Term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments - without readily determinable fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments - with readily determinable fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments without readily determinable fair value (RDFV) consist of non-marketable equity securities issued by private companies. These investments are accounted for using the measurement alternative at cost adjusting for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer). The adjustments are included in net income in the period in which they occur. Equity investments with RDFV consist of shares we own in a special fund and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. Prior to fiscal year 2019, both equity investments without RDFV and with RDFV were accounted for using cost method of accounting, measured at historical cost less other-than-temporary impairment. Trading securities are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in earnings.</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments without RDFV are subject to periodic impairment review. The impairment analysis requires significant judgment to identify events or circumstances that would likely have a significant adverse effect on the future value of the investment.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded a net unrealized loss on our equity securities with RDFV of $1 million in 2020 and a net unrealized gain of $3 million in 2019. Net unrealized gains on our equity securities without RDFV were $27 million and $1 million in 2020 and 2019, respectively. Upon adoption of new accounting guidance relating to financial instruments beginning fiscal year 2019, the gains and losses on such securities are recognized in other income (expense) and therefore not applicable in prior periods. As of November 1, 2019, total impact of adoption of this accounting guidance to our consolidated balance sheet was an increase of $7 million to equity securities with RDFV (included within long-term investments) and a net increase of $5 million to beginning retained earnings.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net unrealized gains on our trading securities portfolio were $2 million in 2020, $3 million in 2019 and $1 million in 2018.</span></div> <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the company's equity investments as of October 31, 2020 and 2019 (net book value):</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-Term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments - without readily determinable fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments - with readily determinable fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 103000000 47000000 25000000 25000000 30000000 30000000 158000000 102000000 -1000000 3000000 27000000 1000000 7000000 5000000 2000000 3000000 1000000 FAIR VALUE MEASUREMENTS<div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market and assumptions that market participants would use when pricing the asset or liability.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Hierarchy</span></div><div style="text-align:justify;text-indent:20.25pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance establishes a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into three levels. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value:</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — applies to assets or liabilities for which there are inputs other than quoted prices included within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less active markets; or other inputs that can be derived principally from, or corroborated by, observable market data.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.</span></div><div style="text-align:justify;text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="text-align:justify;text-indent:20.25pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2020 were as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at October 31, 2020 Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents (money market funds)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (foreign exchange contracts)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (foreign exchange contracts)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2019 were as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement <br/>at October 31, 2019 Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents (money market funds)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (foreign exchange contracts)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (foreign exchange contracts)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our money market funds and trading securities are generally valued using quoted market prices and therefore are classified within level 1 of the fair value hierarchy. Our derivative financial instruments are classified within level 2, as there is not an active market for each hedge contract, but the inputs used to calculate the value of the instruments are tied to active markets. Our deferred compensation liability is classified as level 2 because, although the values are not directly based on </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quoted market prices, the inputs used in the calculations are observable. Other investments represent shares we own in a special fund that targets underlying investments of approximately 40 percent in debt securities and 60 percent in equity securities. It has been classified as level 2 because, although the shares of the fund are not traded on any active stock exchange, each of the individual underlying securities are or can be derived from and hence we have a readily determinable value for the underlying securities, from which we are able to determine the fair market value for the special fund itself.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trading securities, which are comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Certain derivative instruments are reported at fair value, with unrealized gains and losses, net of tax, included in accumulated other comprehensive income (loss) within stockholders' equity. Realized gains and losses from the sale of these instruments are recorded in net income.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For assets measured at fair value on a non-recurring basis, the following table summarizes the impairments included in net income for the years ended October 31, 2020, 2019 and 2018:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:65.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended<br/>October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets held and used</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets held for sale</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended October 31, 2020, long-lived assets held and used, including indefinite lived in-process research and development intangible assets, with a carrying amount of $98 million were written down to their fair value of zero, resulting in an impairment charge of $98 million related to the shutdown of our sequencer development program and other assets in our diagnostics and genomics segment. There were no impairments of long-lived assets held and used in 2019. For 2018, long lived assets held and used with a carrying amount of $21 million were written down to their fair value of zero, resulting in an impairment charge of $21 million, which relates to purchased intangible assets within the diagnostics and genomics segment that were deemed unrecoverable and were included in net income. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no impairments of long-lived assets held for sale in 2020, 2019 and 2018.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair values for the impaired long-lived assets during 2020 and 2018 were measured using level 3 inputs. To determine the fair value of long-lived assets in 2020 and 2018, we used the income approach based on projected discounted cash flows expected to be generated by the long-lived assets over the remaining useful life.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended October 31, 2020 and 2019, there were no impairments in non-marketable securities without readily determinable fair value. For the year ended October 31, 2020 and 2019, a net unrealized gain of $27 million and $1 million, respectively, was included in net income as an adjustment to the carrying value of non-marketable equity securities without readily determinable fair value based on an observable market transaction. As of October 31, 2020 and 2019, the carrying amount of non-marketable equity securities without readily determinable fair values was $103 million and $47 million, respectively.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair values for the non-marketable securities included in long-term investments on the consolidated balance sheet were measured using Level 3 inputs because they are primarily equity stock issued by private companies without quoted market prices. To estimate the fair value of our non-marketable securities, we use the measurement alternative to record these investments at cost and adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) as and when they occur.</span></div> <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2020 were as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at October 31, 2020 Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents (money market funds)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (foreign exchange contracts)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (foreign exchange contracts)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2019 were as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement <br/>at October 31, 2019 Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents (money market funds)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (foreign exchange contracts)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (foreign exchange contracts)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 740000000 740000000 0 0 2000000 0 2000000 0 30000000 30000000 0 0 25000000 0 25000000 0 797000000 770000000 27000000 0 17000000 0 17000000 0 30000000 0 30000000 0 47000000 0 47000000 0 784000000 784000000 0 0 12000000 0 12000000 0 30000000 30000000 0 0 25000000 0 25000000 0 851000000 814000000 37000000 0 6000000 0 6000000 0 30000000 0 30000000 0 36000000 0 36000000 0 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For assets measured at fair value on a non-recurring basis, the following table summarizes the impairments included in net income for the years ended October 31, 2020, 2019 and 2018:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:65.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended<br/>October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets held and used</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets held for sale</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 98000000 0 21000000 0 0 0 98000000 0 98000000 0 21000000 0 21000000 0 0 0 0 0 27000000 1000000 103000000 47000000 DERIVATIVES<div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to foreign currency exchange rate fluctuations and interest rate changes in the normal course of our business. As part of our risk management strategy, we use derivative instruments, primarily forward contracts and purchased options to hedge economic and/or accounting exposures resulting from changes in foreign currency exchange rates.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="text-align:justify;text-indent:20.25pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign exchange contracts to hedge our forecasted operational cash flow exposures resulting from changes in foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities between one and twelve months. These derivative instruments are designated and qualify as cash flow hedges under the criteria prescribed in the authoritative guidance and are assessed for effectiveness against the underlying exposure every reporting period. For open contracts as of October 31, 2020, changes in the time value of the foreign exchange contract are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the foreign exchange contract. The changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss).  Amounts associated with cash flow hedges are reclassified to cost of sales in the consolidated statement of operations when the forecasted transaction occurs. If it becomes probable that the forecasted transaction will not occur, the hedge relationship will be de-designated and amounts accumulated in other comprehensive income (loss) will be reclassified to other income (expense), net in the current period. Changes in the fair value of the ineffective portion of derivative instruments are recognized in other income (expense), net in the consolidated statement of operations in the current period. We record the premium paid (time value) of an option on the date of purchase as an asset. For options designated as cash flow hedges, changes in the time value are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the option contract. For the years ended October 31, 2020, 2019 and 2018, ineffectiveness and gains and losses recognized in other income (expense), net due to de-designation of cash flow hedge contracts were not significant. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2012, Agilent executed treasury lock agreements for $400 million in connection with future interest payments to be made on our 2022 senior notes issued on September 13, 2012. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 10, 2012, and we recognized a deferred gain in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2022 senior notes. The remaining gain to be amortized related to the treasury lock agreements at October 31, 2020 was less than $1 million. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. These derivative instruments were designated and qualified as cash flow hedges under the criteria prescribed in the authoritative guidance. The swap arrangements were terminated on September 15, 2016 with a payment of $10 million, and we recognized this as a deferred loss in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at October 31, 2020 was $6 million. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, Agilent executed treasury lock agreements for $250 million in connection with future interest payments to be made on our 2029 senior notes issued on September 16, 2019. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 6, 2019 and we recognized a deferred loss of $6 million in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2029 senior notes. The remaining loss to be amortized related to the treasury lock agreements at October 31, 2020 was $5 million. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in 2020, we enter into foreign exchange contracts to hedge net investments in foreign operations to mitigate the risk of adverse movements in exchange rates. These foreign exchange contracts are carried at fair value and are designated and qualify as net investment hedges under the criteria prescribed in the authoritative guidance. Changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss) and are assessed for effectiveness against the underlying exposure every reporting period. If the company’s net investment changes during the year, the hedge relationship will be assessed and de-designated if the hedge notional amount is outside of prescribed tolerance with a gain/loss reclassified from other comprehensive income (loss) to other income (expense) in the current period.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 31, 2020, we have 3 open forward contracts to sell euros to buy USD maturing in the first quarter of fiscal year 2021, and these are designated as a net investment hedge of the U.S. parent's interest in foreign subsidiaries denominated in euro functional currency. In the year ended October 31, 2020, the change in fair value of the net investment hedge resulted in </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a net loss of $5 million recognized in accumulated other comprehensive income. For the year ended October 31, 2020, ineffectiveness and the resultant effect of any gains or losses recognized in other income (expense) due to de-designation of the hedge contracts were not significant.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Hedges</span></div><div style="text-align:justify;text-indent:20.25pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we enter into foreign exchange contracts to hedge monetary assets and liabilities that are denominated in currencies other than the functional currency of our subsidiaries. These foreign exchange contracts are carried at fair value and do not qualify for hedge accounting treatment and are not designated as hedging instruments. Changes in value of the derivative instruments are recognized in other income (expense), net in the consolidated statement of operations, in the current period, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our use of derivative instruments exposes us to credit risk to the extent that the counterparties may be unable to meet the terms of the agreement. We do, however, seek to mitigate such risks by limiting our counterparties to major financial institutions which are selected based on their credit ratings and other factors. We have established policies and procedures for mitigating credit risk that include establishing counterparty credit limits, monitoring credit exposures, and continually assessing the creditworthiness of counterparties.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of our derivative agreements contain threshold limits to the net liability position with counterparties and are dependent on our corporate credit rating determined by the major credit rating agencies. The counterparties to the derivative instruments may request collateralization, in accordance with derivative agreements, on derivative instruments in net liability positions.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position as of October 31, 2020, was $16 million. The credit-risk-related contingent features underlying these agreements had not been triggered as of October 31, 2020.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were 270 foreign exchange forward contracts open as of October 31, 2020 and designated as cash flow hedges. There were 183 foreign exchange forward contracts open as of October 31, 2020 not designated as hedging instruments. There were 3 foreign exchange forward contracts open as of October 31, 2020 and designated as a net investment hedge. The aggregated notional amounts by currency and designation as of October 31, 2020 were as follows:</span></div><div style="text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:48.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.103%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.103%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Designated as <br/>Cash Flow Hedges<br/></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Designated as <br/>Net Investment Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives<br/>Not<br/>Designated<br/>as Hedging<br/>Instruments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward<br/>Contracts USD</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward<br/>Contracts USD</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward<br/>Contracts USD</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Buy/(Sell)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Buy/(Sell)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Buy/(Sell)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British Pound</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian Dollar</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japanese Yen</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korean Won</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore Dollar</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chinese Yuan Renminbi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swedish Krona</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan Dollar</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India Rupee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of October 31, 2020 and 2019 were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:30.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.639%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Values of Derivative Instruments</span></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2019</span></td></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:67.035%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.033%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on interest rate swaps recognized in other comprehensive income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss reclassified from accumulated other comprehensive income (loss) into interest expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in accumulated other comprehensive income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on time value of forward contracts recorded in cost of sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss recognized in accumulated other comprehensive income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in other income (expense), net </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At October 31, 2020 the estimated amount of existing net loss that is expected to be reclassified from accumulated other comprehensive income (loss) to cost of sales within the next twelve months is $7 million.</span></div> 400000000 1000000 300000000 10000000 6000000 250000000 6000000 5000000 -5000000 16000000 270 183 3 The aggregated notional amounts by currency and designation as of October 31, 2020 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:48.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.103%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.103%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Designated as <br/>Cash Flow Hedges<br/></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Designated as <br/>Net Investment Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives<br/>Not<br/>Designated<br/>as Hedging<br/>Instruments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward<br/>Contracts USD</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward<br/>Contracts USD</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward<br/>Contracts USD</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Buy/(Sell)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Buy/(Sell)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Buy/(Sell)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British Pound</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian Dollar</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japanese Yen</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korean Won</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore Dollar</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chinese Yuan Renminbi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swedish Krona</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan Dollar</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India Rupee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 59000000 94000000 17000000 41000000 7000000 33000000 7000000 83000000 39000000 58000000 32000000 12000000 23000000 74000000 66000000 0 10000000 0 14000000 0 15000000 4000000 2000000 332000000 94000000 134000000 The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of October 31, 2020 and 2019 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:30.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.639%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Values of Derivative Instruments</span></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2019</span></td></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 3000000 12000000 2000000 2000000 9000000 5000000 4000000 2000000 12000000 17000000 6000000 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:67.035%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.033%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on interest rate swaps recognized in other comprehensive income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss reclassified from accumulated other comprehensive income (loss) into interest expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in accumulated other comprehensive income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on time value of forward contracts recorded in cost of sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss recognized in accumulated other comprehensive income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in other income (expense), net </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 6000000 0 -1000000 -1000000 -1000000 -12000000 0 7000000 -1000000 9000000 -3000000 2000000 2000000 0 -5000000 0 0 -1000000 2000000 -2000000 7000000 RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS<div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Substantially all of our employees are covered under various defined benefit and/or defined contribution retirement plans. Additionally, we sponsor post-retirement health care benefits for our eligible U.S. employees.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agilent provides defined benefits to U.S. employees who meet eligibility criteria under the Agilent Technologies, Inc. Retirement Plan (the "RP"). </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For eligible service through October 31, 1993, the benefit payable under the Agilent Retirement Plan is reduced by any amounts due to the eligible employee under the Agilent defined contribution Deferred Profit-Sharing Plan (the "DPSP"), which was closed to new participants as of November 1993. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 31, 2020 and 2019, the fair value of plan assets of the DPSP was $123 million and $132 million, respectively. Note that the projected benefit obligation for the DPSP equals the fair value of plan assets.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective November 1, 2014, Agilent’s U.S. defined benefit retirement plan was closed to new entrants including new employees, new transfers to the U.S. payroll and rehires. As of April 30, 2016, benefits under the RP were frozen. Any pension benefit earned in the U.S. Plans through April 30, 2016 remained fully vested, and there are no additional benefit accruals after April 30, 2016.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agilent also maintains a Supplemental Benefits Retirement Plan ("SBRP") in the U.S., which is a supplemental unfunded non-qualified defined benefit plan to provide benefits that would be provided under the RP but for limitations imposed by the Internal Revenue Code. The RP and the SBRP comprise the "U.S. Plans" in the tables below.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eligible employees outside the U.S. generally receive retirement benefits under various retirement plans based upon factors such as years of service and/or employee compensation levels. Eligibility is generally determined in accordance with local statutory requirements.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Retirement Medical Benefit Plans.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In addition to receiving retirement benefits, Agilent U.S. employees who meet eligibility requirements as of their termination date may participate in the Agilent Technologies, Inc. Health Plan for Retirees. </span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Eligible retirees who were less than age 50 as of January 1, 2005 and who retire after age 55 with 15 or more years of service are eligible for a fixed amount which can be utilized to pay for either sponsored plans and/or individual Medicare plans. </span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Effective January 1, 2012, employees who were at least age 50 as of January 1, 2005 and who retire after age 55 with 15 or more years of service are eligible for fixed dollar subsidies and stipends. Grandfathered retirees receive a fixed monthly subsidy toward pre-65 premium costs (subsidy capped at 2011 levels) and a fixed monthly stipend post-65. The subsidy amounts will not increase. </span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Any new employee hired on or after November 1, 2014, will not be eligible to participate in the retiree medical plans upon retiring. </span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">As of April 30, 2016, benefits under this plan were changed for Active employees who have not met the eligibility requirement - 55 years old with at least 15 years of Agilent service, as of April 30, 2016 - for the Retiree Medical Account (RMA) under the U.S. Post Retirement Benefit Plan. These employees will only be eligible for 50 percent of the current RMA reimbursement amount upon retirement.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">401(k) Defined Contribution Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Eligible Agilent U.S. employees may participate in the Agilent Technologies, Inc. 401(k) Plan. We match contributions to employees up to a maximum of 6 percent of an employee's annual eligible compensation. Effective May 1, 2016 until April 30, 2022, we will provide an additional transitional company contribution for certain eligible employees equal to 3 percent, 4 percent or 5 percent of an employee's annual eligible compensation due to the RP benefits being frozen. The maximum contribution to the 401(k) Plan is 50 percent of an employee's annual eligible compensation, subject to regulatory limitations. The 401(k) Plan employer expense included in income from operations was $41 million in 2020, $39 million in 2019 and $37 million in 2018.</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Components of Net periodic cost.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The service cost component is recorded in cost of sales and operating expenses in the consolidated statement of operations. All other cost components are recorded in other income (expense), net in the consolidated statement of operations. The company uses alternate methods of amortization as allowed by the authoritative guidance which amortizes the actuarial gains and losses on a consistent basis for the years presented. For U.S. Plans, gains and losses are amortized over the average future lifetime of participants using the corridor method. For most Non-U.S. Plans and U.S. Post-Retirement Benefit Plans, gains and losses are amortized using a separate layer for each year's gains and losses.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended October 31, 2020, 2019 and 2018, components of net periodic benefit cost and other amounts recognized in other comprehensive income were comprised of: </span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:34.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.525%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pensions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Post-Retirement Benefit Plans</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="51" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net periodic benefit cost (benefit)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost — benefits earned during the period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost on benefit obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total periodic benefit cost (benefit)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement (gain) loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial (gain) loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss due to settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in other comprehensive (income) loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Funded Status.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of October 31, 2020 and 2019, the funded status of the defined benefit and post-retirement benefit plans was:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:48.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Defined<br/>Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Defined<br/>Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.<br/>Post-Retirement<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value — beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participants' contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value — end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation — beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participants' contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation — end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Overfunded (underfunded) status of PBO</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:48.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in the consolidated balance sheet consist of:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement and post-retirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net asset (liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:48.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts Recognized in Accumulated Other Comprehensive Income (Loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains) losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service costs (benefits)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts in accumulated other comprehensive income (loss) expected to be recognized by Agilent as components of net expense during 2021 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Defined<br/>Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Defined<br/>Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Post-Retirement<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net prior service cost (benefit)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment Policies and Strategies as of October 31, 2020 and 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the U.S., target asset allocations for our retirement and post-retirement benefit plans are approximately 80 percent to equities and approximately 20 percent to fixed income investments. Our DPSP target asset allocation is approximately 60 percent to equities and approximately 40 percent to fixed income investments. Approximately 1 percent of the retirement and post-retirement plans consist of limited partnerships. The general investment objective for all our plan assets is to obtain the optimum rate of investment return on the total investment portfolio consistent with the assumption of a reasonable level of risk. Specific investment objectives for the plans' portfolios are to: maintain and enhance the purchasing power of the plans' assets; achieve investment returns consistent with the level of risk being taken; and earn performance rates of return in accordance with the benchmarks adopted for each asset class. Outside the U.S., our target asset allocation ranges from 24 percent to 60 percent to equities, from 38 percent to 65 percent to fixed income investments, and from zero to 25 percent to real estate, depending on the plan. All plans' assets are broadly diversified. Due to fluctuations in equity markets, our actual allocations of plan assets at October 31, 2020 and 2019 differ from the target allocation. Our policy is to bring the actual allocation in line with the target allocation.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities include exchange-traded common stock and preferred stock of companies from broadly diversified industries. Fixed income securities include a global portfolio of corporate bonds of companies from diversified industries, government securities, mortgage-backed securities, asset-backed securities, derivative instruments and other. Other investments include a group trust consisting primarily of private equity partnerships. Portions of the cash and cash equivalent, equity, and fixed income investments are held in commingled funds that are valued using Net Asset Value (“NAV”) as the practical expedient. In addition, some of the investments valued using NAV as the practical expedient may have limits on their redemption to weekly or monthly and/or may require prior written notice specified by each fund.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The measurement of the fair value of pension and post-retirement plan assets uses the valuation methodologies and the inputs as described in Note 13, "Fair Value Measurements".</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and Cash Equivalents - Cash and cash equivalents consist of short-term investment funds. The funds also invest in short-term domestic fixed income securities and other securities with debt-like characteristics emphasizing short-term maturities and quality. Some of our cash and cash equivalents are held in commingled funds. Other cash and cash equivalents are classified as Level 1 investments.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity - Some equity securities consisting of common and preferred stock that are not traded on an active market are valued at quoted prices reported by investment dealers based on the underlying terms of the security and comparison to similar securities traded on an active market; these are classified as Level 2 investments. Securities which have quoted prices in active markets are classified as Level 1 investments.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed Income - Some of the fixed income securities are not actively traded and are valued at quoted prices based on the terms of the security and comparison to similar securities traded on an active market; these are classified as Level 2 investments. Securities which have quoted prices in active markets are classified as Level 1 investments.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Investments - Other investments also include partnership investments where, due to their private nature, pricing inputs are not readily observable. Asset valuations are developed by the general partners that manage the partnerships. These valuations are based on proprietary appraisals, application of public market multiples to private company cash flows, utilization of market transactions that provide valuation information for comparable companies and other methods. Holdings of limited partnerships are classified as Level 3.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agilent has adopted the accounting guidance related to the presentation of certain investments using the NAV practical expedient. The accounting guidance exempts investments using this practical expedient from categorization within the fair value hierarchy. </span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair value of U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2020 and 2019.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:39.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement<br/> at October 31, 2020 Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Not Subject to Leveling</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:39.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement <br/>at October 31, 2019 Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Not Subject to Leveling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For U.S. Defined Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2020 and 2019:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended<br/>October 31.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gains/(losses)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains/(losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, sales, issuances, and settlements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers in (out)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair value of U.S. Post-Retirement Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2020 and 2019.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:39.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement <br/>at October 31, 2020 Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Not Subject to Leveling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:39.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement <br/>at October 31, 2019 Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Not Subject to Leveling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For U.S. Post-Retirement Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2020 and 2019:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended<br/>October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gains/(losses)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains/(losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, sales, issuances, and settlements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers in (out)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair value of non-U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2020 and 2019:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:39.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement <br/>at October 31, 2020 Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Not Subject to Leveling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:39.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement <br/>at October 31, 2019 Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Not Subject to Leveling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the combined projected benefit obligation ("PBO"), accumulated benefit obligation ("ABO") and fair value of plan assets, grouping plans using comparisons of the PBO and ABO relative to the plan assets as of October 31, 2020 or 2019.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Benefit<br/>Obligation</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Benefit<br/>Obligation</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of<br/>Plan Assets</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of<br/>Plan Assets</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PBO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PBO</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. defined benefit plans where PBO exceeds the fair value of plan assets </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. defined benefit plans where fair value of plan assets exceeds PBO </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. defined benefit plans where PBO exceeds or is equal to the fair value of plan assets </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. defined benefit plans where fair value of plan assets exceeds PBO </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ABO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ABO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. defined benefit plans where ABO exceeds the fair value of plan assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. defined benefit plans where the fair value of plan assets exceeds ABO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. defined benefit plans where ABO exceeds or is equal to the fair value of plan assets </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. defined benefit plans where fair value of plan assets exceeds ABO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contributions and Estimated Future Benefit Payments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  During fiscal year 2021, we expect to make no contributions to the U.S. defined benefit plans and the Post-Retirement Medical Plans. We expect to contribute $22 million to plans outside the U.S. The following table presents expected future benefit payments for the next 10 years:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Defined<br/>Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Defined<br/>Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Post-Retirement<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 - 2030</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assumptions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The assumptions used to determine the benefit obligations and expense for our defined benefit and post-retirement benefit plans are presented in the tables below. The expected long-term return on assets below represents an estimate of long-term returns on investment portfolios consisting of a mixture of equities, fixed income and alternative investments in proportion to the asset allocations of each of our plans. We consider long-term rates of return, which are weighted based on the asset classes (both historical and forecasted) in which we expect our pension and post-retirement funds to be invested. Discount rates reflect the current rate at which pension and post-retirement obligations could be settled based on the measurement dates of the plans - October 31. The U.S. discount rates at October 31, 2020 and 2019, were determined based on the results of </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">matching expected plan benefit payments with cash flows from a hypothetically constructed bond portfolio. The non-U.S. rates were generally based on published rates for high-quality corporate bonds. The range of assumptions that were used for the non-U.S. defined benefit plans reflects the different economic environments within various countries.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions used to calculate the net periodic cost in each year were as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For years ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. defined benefit plans:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term return on assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. defined benefit plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22-1.81%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.83-2.68%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.67-2.52%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average increase in compensation levels</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25-3.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25-3.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00-3.25%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term return on assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00-5.75%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00-5.75%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00-6.00%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. post-retirement benefits plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term return on assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current medical cost trend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ultimate medical cost trend rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical cost trend rate decreases to ultimate rate in year</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions used to calculate the benefit obligation were as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of the Years Ending October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. defined benefit plans:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. defined benefit plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.07-1.54%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22-1.81%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average increase in compensation levels</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00-3.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25-3.00%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. post-retirement benefits plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current medical cost trend rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ultimate medical cost trend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical cost trend rate decreases to ultimate rate in year</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr></table></div>Health care trend rates do not have a significant effect on the total service and interest cost components or on the post-retirement benefit obligation amounts reported for the U.S. Post-Retirement Benefit Plan for the year ended October 31, 2020 123000000 123000000 132000000 132000000 0.06 0.03 0.04 0.05 0.50 41000000 39000000 37000000 For the years ended October 31, 2020, 2019 and 2018, components of net periodic benefit cost and other amounts recognized in other comprehensive income were comprised of: <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:34.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.525%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pensions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Post-Retirement Benefit Plans</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="51" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net periodic benefit cost (benefit)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost — benefits earned during the period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost on benefit obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total periodic benefit cost (benefit)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement (gain) loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial (gain) loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss due to settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in other comprehensive (income) loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 0 0 24000000 20000000 20000000 1000000 0 1000000 15000000 18000000 16000000 8000000 14000000 13000000 3000000 4000000 3000000 28000000 27000000 28000000 47000000 43000000 46000000 7000000 7000000 7000000 -3000000 -1000000 -1000000 -49000000 -34000000 -29000000 -4000000 -4000000 -8000000 0 0 0 0 0 0 -7000000 -8000000 -8000000 -10000000 -8000000 -11000000 34000000 25000000 16000000 -6000000 -7000000 -3000000 -4000000 0 0 0 0 5000000 0 0 0 -26000000 -51000000 -2000000 -20000000 -104000000 -49000000 -5000000 -5000000 2000000 -3000000 -1000000 -1000000 -49000000 -34000000 -29000000 -4000000 -4000000 -8000000 0 0 0 0 0 0 -7000000 -8000000 -8000000 4000000 0 0 0 0 0 0 0 0 0 0 0 -10000000 3000000 -1000000 0 0 0 19000000 50000000 1000000 -19000000 67000000 21000000 8000000 9000000 -2000000 13000000 42000000 -10000000 15000000 92000000 32000000 2000000 2000000 -5000000 <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Funded Status.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of October 31, 2020 and 2019, the funded status of the defined benefit and post-retirement benefit plans was:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:48.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Defined<br/>Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Defined<br/>Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.<br/>Post-Retirement<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value — beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participants' contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value — end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation — beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participants' contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation — end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Overfunded (underfunded) status of PBO</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 432000000 401000000 911000000 825000000 95000000 90000000 30000000 50000000 -2000000 85000000 6000000 11000000 0 0 32000000 21000000 0 0 0 0 1000000 1000000 0 0 8000000 19000000 31000000 29000000 8000000 6000000 15000000 0 0 0 0 0 0 0 34000000 8000000 0 0 439000000 432000000 945000000 911000000 93000000 95000000 491000000 420000000 1067000000 913000000 94000000 87000000 0 0 24000000 20000000 1000000 0 15000000 18000000 8000000 14000000 3000000 4000000 0 0 1000000 1000000 0 0 28000000 74000000 -19000000 143000000 4000000 9000000 9000000 21000000 31000000 29000000 8000000 6000000 -15000000 0 0 0 0 0 0 0 44000000 5000000 0 0 510000000 491000000 1094000000 1067000000 94000000 94000000 -71000000 -59000000 -149000000 -156000000 -1000000 1000000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:48.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in the consolidated balance sheet consist of:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement and post-retirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net asset (liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table> 0 0 123000000 106000000 0 1000000 1000000 1000000 0 0 0 0 70000000 58000000 272000000 262000000 1000000 0 -71000000 -59000000 -149000000 -156000000 -1000000 1000000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:48.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts Recognized in Accumulated Other Comprehensive Income (Loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains) losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service costs (benefits)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:48.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts Recognized in Accumulated Other Comprehensive Income (Loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains) losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service costs (benefits)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table> -134000000 -115000000 -311000000 -330000000 -11000000 -10000000 0 0 0 0 -5000000 -12000000 134000000 115000000 311000000 330000000 6000000 -2000000 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts in accumulated other comprehensive income (loss) expected to be recognized by Agilent as components of net expense during 2021 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Defined<br/>Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Defined<br/>Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Post-Retirement<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net prior service cost (benefit)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 -1000000 4000000 52000000 4000000 0.80 0.80 0.80 0.80 0.20 0.20 0.20 0.20 0.60 0.60 0.40 0.40 0.01 0.01 0.01 0.01 0.24 0.60 0.38 0.65 0 0.25 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair value of U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2020 and 2019.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:39.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement<br/> at October 31, 2020 Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Not Subject to Leveling</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:39.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement <br/>at October 31, 2019 Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Not Subject to Leveling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair value of U.S. Post-Retirement Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2020 and 2019.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:39.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement <br/>at October 31, 2020 Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Not Subject to Leveling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:39.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement <br/>at October 31, 2019 Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Not Subject to Leveling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair value of non-U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2020 and 2019:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:39.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement <br/>at October 31, 2020 Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Not Subject to Leveling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:39.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement <br/>at October 31, 2019 Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Not Subject to Leveling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.</span></div> 1000000 0 0 0 1000000 357000000 77000000 0 0 280000000 79000000 39000000 0 0 40000000 2000000 0 0 2000000 0 439000000 116000000 0 2000000 321000000 1000000 0 0 0 1000000 336000000 78000000 0 0 258000000 91000000 46000000 0 0 45000000 4000000 0 0 4000000 0 432000000 124000000 0 4000000 304000000 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For U.S. Defined Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2020 and 2019:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended<br/>October 31.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gains/(losses)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains/(losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, sales, issuances, and settlements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers in (out)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For U.S. Post-Retirement Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2020 and 2019:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended<br/>October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gains/(losses)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains/(losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, sales, issuances, and settlements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers in (out)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div> 4000000 6000000 3000000 -1000000 2000000 -1000000 -1000000 -2000000 0 0 2000000 4000000 4000000 0 0 0 4000000 70000000 17000000 0 0 53000000 18000000 9000000 0 0 9000000 1000000 0 0 1000000 0 93000000 26000000 0 1000000 66000000 3000000 0 0 0 3000000 69000000 18000000 0 0 51000000 21000000 11000000 0 0 10000000 2000000 0 0 2000000 0 95000000 29000000 0 2000000 64000000 2000000 4000000 1000000 -1000000 1000000 0 -1000000 -1000000 0 0 1000000 2000000 7000000 0 6000000 0 1000000 504000000 315000000 48000000 0 141000000 434000000 102000000 238000000 0 94000000 0 0 0 0 0 945000000 417000000 292000000 0 236000000 1000000 0 1000000 0 0 512000000 318000000 61000000 0 133000000 398000000 98000000 213000000 0 87000000 0 0 0 0 0 911000000 416000000 275000000 0 220000000 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the combined projected benefit obligation ("PBO"), accumulated benefit obligation ("ABO") and fair value of plan assets, grouping plans using comparisons of the PBO and ABO relative to the plan assets as of October 31, 2020 or 2019.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Benefit<br/>Obligation</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Benefit<br/>Obligation</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of<br/>Plan Assets</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of<br/>Plan Assets</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PBO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PBO</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. defined benefit plans where PBO exceeds the fair value of plan assets </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. defined benefit plans where fair value of plan assets exceeds PBO </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. defined benefit plans where PBO exceeds or is equal to the fair value of plan assets </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. defined benefit plans where fair value of plan assets exceeds PBO </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ABO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ABO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. defined benefit plans where ABO exceeds the fair value of plan assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. defined benefit plans where the fair value of plan assets exceeds ABO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. defined benefit plans where ABO exceeds or is equal to the fair value of plan assets </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. defined benefit plans where fair value of plan assets exceeds ABO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 510000000 439000000 491000000 432000000 0 0 0 0 510000000 439000000 491000000 432000000 697000000 425000000 752000000 490000000 397000000 520000000 315000000 421000000 1094000000 945000000 1067000000 911000000 510000000 439000000 491000000 432000000 0 0 0 0 510000000 439000000 491000000 432000000 675000000 425000000 651000000 418000000 387000000 520000000 381000000 493000000 1062000000 945000000 1032000000 911000000 0 0 22000000 The following table presents expected future benefit payments for the next 10 years:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Defined<br/>Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Defined<br/>Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Post-Retirement<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 - 2030</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table> 33000000 33000000 8000000 31000000 34000000 8000000 33000000 36000000 7000000 34000000 36000000 7000000 33000000 37000000 7000000 152000000 192000000 35000000 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions used to calculate the net periodic cost in each year were as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For years ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. defined benefit plans:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term return on assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. defined benefit plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22-1.81%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.83-2.68%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.67-2.52%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average increase in compensation levels</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25-3.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25-3.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00-3.25%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term return on assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00-5.75%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00-5.75%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00-6.00%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. post-retirement benefits plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term return on assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current medical cost trend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ultimate medical cost trend rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical cost trend rate decreases to ultimate rate in year</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions used to calculate the benefit obligation were as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of the Years Ending October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. defined benefit plans:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. defined benefit plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.07-1.54%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22-1.81%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average increase in compensation levels</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00-3.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25-3.00%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. post-retirement benefits plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current medical cost trend rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ultimate medical cost trend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical cost trend rate decreases to ultimate rate in year</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr></table></div> 0.0325 0.0450 0.0375 0.0700 0.0700 0.0700 0.0022 0.0181 0.0083 0.0268 0.0067 0.0252 0.0225 0.0300 0.0225 0.0325 0.0200 0.0325 0.0400 0.0575 0.0400 0.0575 0.0400 0.0600 0.0300 0.0425 0.0350 0.0700 0.0700 0.0700 0.0625 0.0600 0.0600 0.0450 0.0350 0.0350 2029 2029 2029 0.0275 0.0325 0.0007 0.0154 0.0022 0.0181 0.0200 0.0300 0.0225 0.0300 0.0250 0.0300 0.0625 0.0625 0.0450 0.0450 2029 2029 GUARANTEES<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standard Warranty</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for standard warranty costs based on historical trends in actual warranty charges over the past 12 months. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost over the period. The standard warranty accrual balances are held in other accrued and other long-term liabilities on our consolidated balance sheet. Our standard warranty terms typically extend to one year from the date of delivery, depending on the product.</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the standard warranty accrual activity is shown in the table below. </span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard warranty accrual, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals for warranties including change in estimates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements made during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard warranty accrual, ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals for warranties due within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals for warranties due after one year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard warranty accrual, ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bank Guarantees</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Guarantees consist primarily of outstanding standby letters of credit and bank guarantees and were approximately $43 million and $40 million as of October 31, 2020 and 2019, respectively. A standby letter of credit is a guarantee of payment issued by a bank on behalf of us that is used as payment of last resort should we fail to fulfill a contractual commitment with a third party. A bank guarantee is a promise from a bank or other lending institution that if we default on a loan, the bank will cover the loss. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications in Connection with Transactions</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with various divestitures, acquisitions, spin-offs and other transactions, we have agreed to indemnify certain parties, their affiliates and/or other related parties against certain damages and expenses that might occur in the future. These indemnifications may cover a variety of liabilities, including, but not limited to, employee, tax, environmental, intellectual property, litigation and other liabilities related to the business conducted prior to the date of the transaction. In our opinion, the fair value of these indemnification obligations was not material as of October 31, 2020. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications to Officers and Directors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate bylaws require that we indemnify our officers and directors, as well as those who act as directors and officers of other entities at our request, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceedings arising out of their services to Agilent and such other entities, including service with respect to employee benefit plans. In addition, we have entered into separate indemnification agreements with each director and each board-appointed officer of Agilent which provide for indemnification of these directors and officers under similar circumstances and under additional circumstances. The indemnification obligations are more fully described in the bylaws and the indemnification agreements. We purchase standard insurance to cover claims or a portion of the claims made against our directors and officers. Since a maximum obligation is not explicitly stated in our bylaws or in our indemnification agreements and will depend on the facts and circumstances that arise out of any future claims, the overall maximum amount of the obligations cannot be reasonably estimated. Historically, we have not made payments related to these obligations, and the fair value for these indemnification obligations was not material as of October 31, 2020.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in our industry and as provided for in local law in the U.S. and other jurisdictions, many of our standard contracts provide remedies to our customers and others with whom we enter into contracts, such as defense, settlement, or payment of judgment for intellectual property claims related to the use of our products. From time to time, we indemnify customers, as well as our suppliers, contractors, lessors, lessees, companies that purchase our businesses or assets and others with whom we enter into contracts, against combinations of loss, expense, or liability arising from various triggering events related to the sale and the use of our products and services, the use of their goods and services, the use of facilities and state of our owned facilities, the state of the assets and businesses that we sell and other matters covered by such contracts, usually up to a specified maximum amount. In addition, from time to time we also provide protection to these parties against claims related to </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">undiscovered liabilities, additional product liability or environmental obligations. In our experience, claims made under such indemnifications are rare and the associated estimated fair value of the liability was not material as of October 31, 2020.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of several of our businesses, we have agreed to indemnify the buyers of such business, their respective affiliates and other related parties against certain damages that they might incur in the future. The continuing indemnifications primarily cover damages relating to liabilities of the businesses that Agilent retained and did not transfer to the buyers, as well as other specified items. In our opinion, the fair value of these indemnification obligations was not material as of October 31, 2020.</span></div> <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the standard warranty accrual activity is shown in the table below. </span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard warranty accrual, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals for warranties including change in estimates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements made during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard warranty accrual, ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 32000000 35000000 49000000 54000000 49000000 57000000 32000000 32000000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals for warranties due within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals for warranties due after one year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard warranty accrual, ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 30000000 32000000 2000000 0 32000000 32000000 43000000 40000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.   COMMITMENTS AND CONTINGENCIES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Purchase Commitments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Typically, we can cancel contracts with professional services suppliers without penalties. For those contracts that are not cancelable without penalties, there are termination fees and costs or commitments for continued spending that we are obligated to pay to a supplier under each contact's termination period before such contract can be cancelled. Our contractual obligations with these suppliers under "other purchase commitments" were approximately $85 million. Approximately $23 million of the penalties for the new contracts will reduce over the next 13 years.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in lawsuits, claims, investigations and proceedings, including, but not limited to, intellectual property, commercial, real estate, environmental and employment matters, which arise in the ordinary course of business. There are no matters pending that we currently believe are reasonably possible of having a material impact to our business, consolidated financial condition, results of operations or cash flows.</span></div> 85000000 23000000 SHORT-TERM DEBT<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 13, 2019, we entered into a credit agreement with a group of financial institutions which provides for a $1 billion five-year unsecured credit facility that will expire on March 13, 2024. For the year ended October 31, 2020, we borrowed $798 million and repaid $913 million under the credit facility. As of October 31, 2020, the company had no borrowings outstanding under the credit facility. On August 7, 2019, we entered into an amendment to the credit agreement, which provides for a $500 million short-term loan facility that was used in full to complete the BioTek acquisition and which was repaid in full as of October 31, 2020. On October 21, 2019, we entered into a second amendment to the credit agreement, which refreshed the amount available for additional incremental term loan facilities under the credit agreement to permit additional incremental facilities of up to $500 million. We had no borrowings under the additional incremental facilities as of October 31, 2020. On April 17, 2020, we entered into a third amendment to the credit agreement which provides the company with the option to request the consent of the applicable class of lenders to extend the maturity date of revolving borrowings and swingline loans for an additional period of one year and of the 2019 incremental term loans for an additional period of up to 364 days. We were in compliance with the covenants for the credit facility during the year ended October 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial Paper</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2020, we established a U.S. commercial paper program, under which the company may issue and sell unsecured, short-term promissory notes in the aggregate principal amount not to exceed $1.0 billion with up to 397-day maturities. At any point in time, the company intends to maintain available commitments under its revolving credit facility in an amount at least equal to the amount of the commercial paper notes outstanding. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The proceeds from issuances under the program may be used for general corporate purposes. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 31, 2020</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, borrowings outstanding under our U.S. commercial paper program had a weighted average annual interest rate of 0.17 percent and a weighted average remaining maturity of approximately five days. We had borrowings of $75 million outstanding under the U.S. commercial paper program as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 31, 2020.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Senior Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 13, 2010, the company issued an aggregate principal amount of $500 million in senior notes ("2020 senior notes"). The 2020 senior notes were issued at 99.54% of their principal amount. The notes were scheduled to mature on July 15, 2020, and bear interest at a fixed rate of 5.00% per annum. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2011, we terminated our interest rate swap contracts related to our 2020 senior notes that represented the notional amount of $500 million. The asset value, including interest receivable, upon termination for these contracts was </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $34 million. The gain was deferred and amortized to interest expense over the remaining life of the 2020 senior notes.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2019, we repaid the $500 million outstanding aggregate principal amount of our 2020 senior notes due July 15, 2020 that were called for redemption on August 16, 2019. The redemption price of approximately $512 million included a $12 million prepayment penalty. The redemption price was computed in accordance with the terms of the 2020 senior notes as the present value of the remaining scheduled payments of principal and unpaid interest related to the redemption.  The prepayment penalty plus amortization of the previously deferred interest swap gain of $4 million and amortization of previously deferred debt issuance costs and discount of $1 million were recorded in other income (expense), net in the consolidated statement of operations. We also paid accrued and unpaid interest of $4 million on the 2020 senior notes up to but not including the redemption date.</span></div> 2019-03-13 1000000000 five 2024-03-13 798000000 913000000 0 500000000 500000000 500000000 500000000 0 1000000000.0 0.0017 P5D 75000000 2010-07-13 500000000 0.9954 2020-07-15 0.0500 August 9, 2011 500000000 34000000 2019-09-17 500000000 512000000 12000000 4000000 1000000 4000000 LONG-TERM DEBT<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the company's long-term senior notes:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:2.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.860%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Principal</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Principal</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Senior Notes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Senior Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 Senior Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,284 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,786 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Senior Notes</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 13, 2012, the company issued an aggregate principal amount of $400 million in senior notes ("2022 senior notes"). The 2022 senior notes were issued at 99.80% of their principal amount. The notes will mature on October 1, 2022, and bear interest at a fixed rate of 3.20% per annum. The interest is payable semi-annually on April 1st and October 1st of each year and payments commenced on April 1, 2013.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2012, Agilent executed treasury lock agreements for $400 million in connection with future interest payments to be made on our 2022 senior notes issued on September 13, 2012. The treasury lock contracts were terminated on September 10, 2012 and we recognized a deferred gain in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2022 senior notes. The remaining gain to be amortized related to the treasury lock agreements at October 31, 2020 was less than $1 million. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 Senior Notes</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2013, the company issued aggregate principal amount of $600 million in senior notes ("2023 senior notes"). The 2023 senior notes were issued at 99.544% of their principal amount. The notes will mature on July 15, 2023 and bear interest at a fixed rate of 3.875% per annum. The interest is payable semi-annually on January 15th and July 15th of each year and payments commenced January 15, 2014. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2026 Senior Notes</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2016, the company issued aggregate principal amount of $300 million in senior notes ("2026 senior notes"). The 2026 senior notes were issued at 99.624% of their principal amount. The notes will mature on September 22, 2026 and bear interest at a fixed rate of 3.05% per annum. The interest is payable semi-annually on March 22nd and September 22nd of each year and payments commenced March 22, 2017. </span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. The swap arrangements were terminated on September 15, 2016 with a payment of $10 million, and we recognized this as a deferred loss in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at October 31, 2020 was $6 million. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2029 Senior Notes</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 16, 2019, the company issued an aggregate principal amount of $500 million in senior notes ("2029 senior notes"). The 2029 senior notes were issued at 99.316% of their principal amount. The notes will mature on September 15, 2029, and bear interest at a fixed rate of 2.75% per annum. The interest is payable semi-annually on March 15th and September 15th of each year and payments commenced on March 15, 2020.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, Agilent executed treasury lock agreements for $250 million in connection with future interest payments to be made on our 2029 senior notes issued on September 16, 2019. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 6, 2019 and we recognized a deferred loss of $6 million in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2029 senior notes. The remaining loss to be amortized related to the treasury lock agreements at October 31, 2020 was $5 million. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2030 Senior Notes</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2020, we issued an aggregate principal amount of $500 million in senior notes ("2030 senior notes"). The 2030 senior notes were issued at 99.812% of their principal amount. The 2030 senior notes will mature on June 4, 2030, and bear interest at a fixed rate of 2.10% per annum. The interest is payable semi-annually on June 4th and December 4th of each year and payments commenced on December 4, 2020.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All outstanding notes listed above are unsecured and rank equally in right of payment with all of Agilent's other senior unsecured indebtedness.</span></div> <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the company's long-term senior notes:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:2.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.860%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Principal</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Principal</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Senior Notes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Senior Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 Senior Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,284 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,786 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 400000000 399000000 598000000 597000000 298000000 298000000 493000000 492000000 495000000 0 2284000000 1786000000 2012-09-13 400000000 0.9980 2022-10-01 0.0320 semi-annually 2013-04-01 400000000 1000000 2013-06-21 600000000 0.99544 2023-07-15 0.03875 semi-annually 2014-01-15 2016-09-22 300000000 0.99624 2026-09-22 0.0305 semi-annually 2017-03-22 300000000 10000000 6000000 2019-09-16 500000000 0.99316 2029-09-15 0.0275 semi-annually 2020-03-15 2020-03-15 250000000 250000000 6000000 5000000 5000000 2020-06-04 500000000 0.99812 2030-06-04 0.0210 semi-annually 2020-12-04 STOCKHOLDERS' EQUITY<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Program</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On May 28, 2015 we announced that our board of directors had approved a share repurchase program (the "2015 repurchase program"). The 2015 repurchase program authorizes the purchase of up to $1.14 billion of our common stock at the company's discretion through and including November 1, 2018. The 2015 repurchase program did not require the company to acquire a specific number of shares and could have been suspended or discontinued at any time. During the year ended October 31, 2018, we repurchased and retired approximately 6.4 million shares for $422 million under this authorization. As of October 31, 2018, we had remaining authorization to repurchase up to $188 million of our common stock under this program which expired on November 1, 2018.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2018 we announced that our board of directors had approved a new share repurchase program (the "2019 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2019 share repurchase program authorizes the purchase of up to $1.75 billion of our common stock at the company's discretion and has no fixed termination date. The 2019 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. During the year ended October 31, 2019, we repurchased and retired 10.4 million shares for $723 million under this authorization. During the year ended October 31, 2020, we repurchased and retired approximately 5.2 million shares for $469 million under this authorization. As of October 31, 2020, we had remaining authorization to repurchase up to $558 million of our common stock under this program.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Dividends on Shares of Common Stock</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the year ended October 31, 2020, cash dividends of 0.720 per share, or $222 million were declared and paid on the company's outstanding common stock. During the year ended October 31, 2019, cash dividends of 0.656 per share, or $206 million were declared and paid on the company's outstanding common stock. During the year ended October 31, 2018, cash dividends of 0.596 per share, or $191 million were declared and paid on the company's outstanding common stock. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2020 we declared a quarterly dividend of $0.194 per share of common stock, or approximately $59 million which will be paid on January 27, 2021 to shareholders of record as of the close of business on January 5, 2021. The timing and amounts of any future dividends are subject to determination and approval by our board of directors.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our accumulated other comprehensive income (loss) as of October 31, 2020 and 2019, net of tax effect:</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation, net of tax expense of $(6) and $(5) for 2020 and 2019, respectively</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses (including prior service benefit) on defined benefit plans, net of tax benefit of $154 and $153 for 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses) on derivative instruments, net of tax benefit of $6 and $3 for 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accumulated other comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(522)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in accumulated other comprehensive income (loss) by component and related tax effects for the years ended October 31, 2020 and 2019 were as follows:</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.113%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.857%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net defined benefit pension cost and post retirement plan costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prior service credits</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Actuarial Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of October 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of adoption of new guidance on tax effects in accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of November 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(344)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out of accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of October 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(437)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out of accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax (expense) benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of October 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(442)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(522)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive income (loss) for the years ended October 31, 2020 and 2019 were as follows (in millions): </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other<br/>Comprehensive Income components</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified<br/>from Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected line item in<br/>statement of operations</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains and (losses) on derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products and interest expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before income tax</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Provision)/benefit for income tax</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net of income tax</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net defined benefit pension cost and post retirement plan costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before income tax</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit for income tax</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net of income tax</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in parentheses indicate reductions to income and increases to other comprehensive income.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications of prior service benefit and actuarial net loss in respect of retirement plans and post retirement pension plans are included in the computation of net periodic cost (see Note 15, "Retirement Plans and Post Retirement Pension Plans").</span></div> 1140000000 6400000 422000000 188000000 1750000000 10400000 723000000 5200000 469000000 558000000 0.720 222000000 222000000 0.656 206000000 206000000 0.596 191000000 191000000 2020-11-18 0.194 59000000 2021-01-27 2021-01-05 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our accumulated other comprehensive income (loss) as of October 31, 2020 and 2019, net of tax effect:</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation, net of tax expense of $(6) and $(5) for 2020 and 2019, respectively</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses (including prior service benefit) on defined benefit plans, net of tax benefit of $154 and $153 for 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses) on derivative instruments, net of tax benefit of $6 and $3 for 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accumulated other comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(522)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in accumulated other comprehensive income (loss) by component and related tax effects for the years ended October 31, 2020 and 2019 were as follows:</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.113%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.857%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net defined benefit pension cost and post retirement plan costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prior service credits</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Actuarial Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of October 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of adoption of new guidance on tax effects in accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of November 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(344)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out of accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of October 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(437)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out of accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax (expense) benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of October 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(442)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(522)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div> 6000000 5000000 -194000000 -204000000 154000000 153000000 -317000000 -306000000 6000000 3000000 -11000000 -4000000 -522000000 -514000000 -214000000 -134000000 -335000000 7000000 -408000000 0 -3000000 -9000000 -1000000 -7000000 -214000000 -137000000 -344000000 6000000 -415000000 0 0 -157000000 -6000000 -163000000 0 -8000000 39000000 -8000000 23000000 -10000000 -2000000 -25000000 4000000 41000000 10000000 6000000 -93000000 -10000000 -99000000 -204000000 -131000000 -437000000 -4000000 -514000000 11000000 0 -66000000 -12000000 -67000000 0 7000000 61000000 2000000 56000000 1000000 -1000000 0 3000000 3000000 10000000 6000000 -5000000 -7000000 -8000000 -194000000 -125000000 -442000000 -11000000 -522000000 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive income (loss) for the years ended October 31, 2020 and 2019 were as follows (in millions): </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other<br/>Comprehensive Income components</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified<br/>from Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected line item in<br/>statement of operations</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains and (losses) on derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products and interest expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before income tax</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Provision)/benefit for income tax</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net of income tax</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net defined benefit pension cost and post retirement plan costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before income tax</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit for income tax</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net of income tax</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div> 2000000 -8000000 2000000 -8000000 0 -2000000 -2000000 6000000 -61000000 -39000000 7000000 -8000000 -54000000 -31000000 16000000 12000000 -38000000 -19000000 -40000000 -13000000 SEGMENT INFORMATION<div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of Segments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agilent has three business segments comprised of the life sciences and applied markets business, diagnostics and genomics business and the Agilent CrossLab business each of which comprises a reportable segment. The three operating segments were determined based primarily on how the chief operating decision maker views and evaluates our operations. Operating results are regularly reviewed by the chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance. Other factors, including market separation and customer specific applications, go-to-market channels, products and services and manufacturing are considered in determining the formation of these operating segments.</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A description of our three reportable segments is as follows:</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. Key product categories include: liquid chromatography ("LC") systems and components; liquid chromatography mass spectrometry ("LCMS") systems; gas chromatography ("GC") systems and components; gas chromatography mass spectrometry ("GCMS") systems; inductively coupled plasma mass spectrometry ("ICP-MS") instruments; atomic absorption ("AA") instruments; microwave plasma-atomic emission spectrometry ("MP-AES") instruments; inductively coupled plasma optical emission spectrometry ("ICP-OES") instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software for sample tracking; information </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps and measurement technologies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our diagnostics and genomics business is comprised of six areas of activity providing active pharmaceutical ingredients ("APIs") for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our genomics business includes arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as next generation sequencing ("NGS") target enrichment and genetic data management and interpretation support software. This business also includes solutions that enable clinical labs to identify DNA variants associated with genetic disease and help direct cancer therapy. Second, our nucleic acid solutions business provides equipment and expertise focused on production of synthesized oligonucleotides under pharmaceutical good manufacturing practices ("GMP") conditions for use as API in an emerging class of drugs that utilize nucleic acid molecules for disease therapy. Third, our pathology solutions business is focused on product offerings for cancer diagnostics and anatomic pathology workflows. The broad portfolio of offerings includes immunohistochemistry ("IHC"), in situ hybridization ("ISH"), hematoxylin and eosin ("H&amp;E") staining and special staining. Fourth, we also collaborate with a number of major pharmaceutical companies to develop new potential pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. Fifth, the reagent partnership business is a provider of reagents used for turbidimetry and flow cytometry. Finally, our biomolecular analysis business provides complete workflow solutions, including instruments, consumables and software, for quality control analysis of nucleic acid samples.  Samples are analyzed using quantitative and qualitative techniques to ensure accuracy in further genomics analysis techniques utilized in clinical and life science research applications.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio, which is designed to improve customer outcomes. Most of the portfolio is vendor neutral, meaning Agilent can serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries and supplies to services and software helping to connect the entire lab. Key product categories in consumables include GC and LC columns, sample preparation products, custom chemistries, and a large selection of laboratory instrument supplies. Services include startup, operational, training and compliance support, software as a service, as well as asset management and consultative services that help increase customer productivity. Custom service and consumable bundles are tailored to meet the specific application needs of various industries and to keep instruments fully operational and compliant with the respective industry requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the segments' expenses arise from shared services and infrastructure that we have historically provided to the segments in order to realize economies of scale and to efficiently use resources. These expenses, collectively called corporate charges, include legal, accounting, tax, real estate, insurance services, information technology services, treasury, order administration, other corporate infrastructure expenses and costs of centralized research and development. Charges are allocated to the segments, and the allocations have been determined on a basis that we consider to be a reasonable reflection of the utilization of services provided to or benefits received by the segments. In addition, we do not allocate amortization and impairment of acquisition-related intangible assets, pension curtailment or settlement gains, restructuring and transformational initiatives expenses, acquisition and integration costs, business exit and divestiture costs, special compliance costs, some nucleic acid solutions division ("NASD") site costs and certain other charges to the operating margin for each segment because management does not include this information in its measurement of the performance of the operating segments. Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers, site consolidations, legal entity and other business reorganizations, in-sourcing or outsourcing of activities.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables reflect the results of our reportable segments under our management reporting system. The performance of each segment is measured based on several metrics, including segment income from operations. These results are used, in part, by the chief operating decision maker in evaluating the performance of, and in allocating resources to, each of the segments.</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The profitability of each of the segments is measured after excluding items such as asset impairment charges, transformational initiatives, acquisition and integration costs, non-cash amortization of intangible assets related to business combinations, interest income, interest expense, and other items as noted in the reconciliations below.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:55.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life Sciences and Applied Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diagnostics and Genomics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Agilent CrossLab</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Segments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended October 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,339 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended October 31, 2019:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended October 31, 2018:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,270 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,701 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,914 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Share-based compensation expense in 2020 excludes amounts not allocated to the segments related to accelerated share-based compensation expense from workforce reduction and from our acquisition of BioTek.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles reportable segments' income from operations to Agilent's total enterprise income before taxes:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segments' income from operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets related to business combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformational initiatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acceleration of share-based compensation expense related to workforce reduction</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business exit and divestiture costs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NASD site costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Special compliance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before taxes, as reported</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) For the years ended October 31, 2020 and 2019, the other category primarily includes legal costs related to a claim we pursued against Twist Bioscience Corporation in addition to other miscellaneous adjustments.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) For the year ended October 31, 2020, other income (expense), net includes the settlement of a legal claim against Twist Bioscience Corporation.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Major Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    No customer represented 10 percent or more of our total net revenue in 2020, 2019 or 2018.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects segment assets and capital expenditures under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:55.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life Sciences and Applied Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diagnostics and Genomics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Agilent CrossLab</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Segments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of and for the Year Ended October 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,143 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,515 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,033 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of and for the Year Ended October 31, 2019:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,620 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles segment assets to Agilent's total assets:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segments' assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,033 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term and other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,627 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,452 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other category primarily includes overfunded pension assets which are not allocated to the segments.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents summarized information for net revenue by geographic region. Revenues from external customers are generally attributed to countries based upon the customers' location. </span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:61.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">China</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of the<br/>World</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended October 31, 2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,752 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,339 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended October 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,619 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended October 31, 2018</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,914 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">China also includes Hong Kong net revenue. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents summarized information for long-lived assets by geographic region. Long lived assets consist of property, plant, and equipment, right-of-use assets, long-term receivables and other long-term assets excluding intangible assets. The rest of the world primarily consists of Asia and the rest of Europe.</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:61.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of the<br/>World</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 31, 2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,391 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 3 3 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The profitability of each of the segments is measured after excluding items such as asset impairment charges, transformational initiatives, acquisition and integration costs, non-cash amortization of intangible assets related to business combinations, interest income, interest expense, and other items as noted in the reconciliations below.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:55.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life Sciences and Applied Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diagnostics and Genomics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Agilent CrossLab</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Segments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended October 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,339 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended October 31, 2019:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended October 31, 2018:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,270 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,701 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,914 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Share-based compensation expense in 2020 excludes amounts not allocated to the segments related to accelerated share-based compensation expense from workforce reduction and from our acquisition of BioTek.</span></div> 2392000000 1047000000 1900000000 5339000000 548000000 192000000 516000000 1256000000 43000000 39000000 37000000 119000000 35000000 17000000 29000000 81000000 2302000000 1021000000 1840000000 5163000000 542000000 185000000 475000000 1202000000 41000000 35000000 35000000 111000000 33000000 14000000 25000000 72000000 2270000000 943000000 1701000000 4914000000 543000000 173000000 388000000 1104000000 38000000 33000000 31000000 102000000 33000000 14000000 24000000 71000000 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles reportable segments' income from operations to Agilent's total enterprise income before taxes:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segments' income from operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets related to business combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformational initiatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acceleration of share-based compensation expense related to workforce reduction</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business exit and divestiture costs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NASD site costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Special compliance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before taxes, as reported</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) For the years ended October 31, 2020 and 2019, the other category primarily includes legal costs related to a claim we pursued against Twist Bioscience Corporation in addition to other miscellaneous adjustments.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) For the year ended October 31, 2020, other income (expense), net includes the settlement of a legal claim against Twist Bioscience Corporation.</span></div> 1256000000 1202000000 1104000000 184000000 125000000 105000000 41000000 48000000 23000000 53000000 44000000 25000000 2000000 0 0 99000000 0 21000000 2000000 0 9000000 0 12000000 8000000 0 2000000 4000000 29000000 30000000 5000000 8000000 36000000 38000000 78000000 74000000 75000000 66000000 16000000 79000000 842000000 919000000 946000000 0 0 0 <div style="margin-bottom:7pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects segment assets and capital expenditures under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:55.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life Sciences and Applied Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diagnostics and Genomics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Agilent CrossLab</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Segments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of and for the Year Ended October 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,143 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,515 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,033 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of and for the Year Ended October 31, 2019:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,620 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles segment assets to Agilent's total assets:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segments' assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,033 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term and other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,627 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,452 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other category primarily includes overfunded pension assets which are not allocated to the segments.</span></div> 3143000000 2515000000 1375000000 7033000000 44000000 34000000 41000000 119000000 3202000000 2620000000 1331000000 7153000000 59000000 48000000 48000000 155000000 7033000000 7153000000 1441000000 1382000000 106000000 94000000 158000000 102000000 114000000 100000000 380000000 410000000 175000000 0 220000000 211000000 9627000000 9452000000 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents summarized information for net revenue by geographic region. Revenues from external customers are generally attributed to countries based upon the customers' location. </span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:61.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">China</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of the<br/>World</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended October 31, 2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,752 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,339 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended October 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,619 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended October 31, 2018</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,914 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">China also includes Hong Kong net revenue. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents summarized information for long-lived assets by geographic region. Long lived assets consist of property, plant, and equipment, right-of-use assets, long-term receivables and other long-term assets excluding intangible assets. The rest of the world primarily consists of Asia and the rest of Europe.</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:61.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of the<br/>World</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 31, 2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,391 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1752000000 1087000000 2500000000 5339000000 1619000000 1019000000 2525000000 5163000000 1414000000 1015000000 2485000000 4914000000 727000000 126000000 538000000 1391000000 621000000 122000000 404000000 1147000000 <div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VALUATION AND QUALIFYING ACCOUNTS</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:32.967%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.385%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Column A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Column B</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Column C</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Column D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Column E</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning<br/>of Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions Charged to<br/>Expenses or<br/>Other Accounts*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions Credited to Expenses or Other Accounts**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>End of<br/>Period</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax valuation allowance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax valuation allowance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax valuation allowance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Additions include current year additions charged to expenses and current year build due to increases in net deferred tax assets, return to provision true-ups, other adjustments and other comprehensive income impact to deferred taxes. </span></div>** Deductions include current year releases credited to expenses and current year reductions due to decreases in net deferred tax assets, return to provision true-ups, other adjustments and other comprehensive income impact to deferred taxes. 134000000 6000000 8000000 132000000 135000000 9000000 10000000 134000000 138000000 4000000 7000000 135000000 XML 15 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document And Entity Information - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Dec. 10, 2020
Apr. 30, 2020
Entity Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Oct. 31, 2020    
Document Fiscal Period Focus FY    
Current Fiscal Year End Date --10-31    
Document Fiscal Year Focus 2020    
Document Transition Report false    
Entity File Number 001-15405    
Entity Registrant Name Agilent Technologies, Inc.    
Entity Central Index Key 0001090872    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 77-0518772    
Entity Address, Address Line One 5301 Stevens Creek Blvd.    
Entity Address, City or Town Santa Clara,    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 95051    
City Area Code (800)    
Local Phone Number 227-9770    
Title of 12(b) Security Common Stock, $0.01 par value    
Trading Symbol A    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 18,000
Entity Common Stock, Shares Outstanding   306,849,526  
Amendment Flag false    
Documents Incorporated by Reference [Text Block] Portions of the Proxy Statement for the Annual Meeting of Stockholders (the "Proxy Statement") to be held on March 17, 2021, and to be filed pursuant to Regulation 14A within 120 days after registrant's fiscal year ended October 31, 2020 are incorporated by reference into Part III of this Report    

XML 16 R2.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Net revenue:      
Net revenue $ 5,339 $ 5,163 $ 4,914
Costs and expenses:      
Cost of revenue 2,502 2,358 2,234
Research and development 495 404 387
Selling, general and administrative 1,496 1,460 1,389
Total costs and expenses 4,493 4,222 4,010
Income from operations 846 941 904
Interest income 8 36 38
Interest expense (78) (74) (75)
Other income (expense), net 66 16 79
Income before taxes 842 919 946
Provision (benefit) for income taxes 123 (152) 630
Net income $ 719 $ 1,071 $ 316
Net income per share:      
Net income per share - basic $ 2.33 $ 3.41 $ 0.98
Net income per share - diluted $ 2.30 $ 3.37 $ 0.97
Weighted Averge Shares Used In Computing Net Income Per Share      
Basic (in shares) 309 314 321
Diluted (in shares) 312 318 325
Products      
Net revenue:      
Net revenue $ 3,993 $ 3,877 $ 3,746
Costs and expenses:      
Cost of revenue 1,796 1,680 1,595
Services and Other      
Net revenue:      
Net revenue 1,346 1,286 1,168
Costs and expenses:      
Cost of revenue $ 706 $ 678 $ 639
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Statement of Comprehensive Income [Abstract]      
Net income $ 719 $ 1,071 $ 316
Other comprehensive income (loss):      
Gain (loss) on derivative instruments, net of tax expense (benefit) of $(3), $(2) and $1 (9) (4) 6
Amounts reclassified into earnings related to derivative instruments, net of tax expense (benefit) of $0, $(2). and $1 2 (6) 3
Foreign currency translation, net of tax expense (benefit) of $1, $(10) and $7 10 10 (58)
Net defined benefit pension cost and post retirement plan costs:      
Change in actuarial net loss, net of tax expense (benefit) of $0, $(25) and $(3) (5) (93) (7)
Change in net prior service benefit, net of tax benefit of $(1), $(2) and $(2) (6) (6) (6)
Other comprehensive loss (8) (99) (62)
Total comprehensive income $ 711 $ 972 $ 254
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Parenthetical) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]      
Gain (loss) on derivative instruments, tax expense (benefit) $ (3) $ (2) $ 1
Amounts reclassified into earnings related to derivative instruments, tax expense (benefit) 0 (2) 1
Foreign currency translation, tax expense (benefit) 1 (10) 7
Change in actuarial net loss, tax expense (benefit) 0 (25) (3)
Change in net prior service benefit, tax (benefit) $ (1) $ (2) $ (2)
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED BALANCE SHEET - USD ($)
$ in Millions
Oct. 31, 2020
Oct. 31, 2019
Current assets:    
Cash and cash equivalents $ 1,441 $ 1,382
Accounts receivable, net 1,038 930
Inventory 720 679
Other current assets 216 198
Total current assets 3,415 3,189
Property, plant and equipment, net 845 850
Goodwill 3,602 3,593
Other intangible assets, net 831 1,107
Long-term investments 158 102
Other assets 776 611
Total assets 9,627 9,452
Current liabilities:    
Accounts payable 354 354
Employee compensation and benefits 367 334
Deferred revenue 386 336
Short-term debt 75 616
Other accrued liabilities 285 440
Total current liabilities 1,467 2,080
Long-term debt 2,284 1,791
Retirement and post-retirement benefits 389 360
Other long-term liabilities 614 473
Total liabilities 4,754 4,704
Commitments and contingencies (Note 17)
Stockholders' equity:    
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding 0 0
Common stock; $0.01 par value; 2 billion shares authorized; 306 million shares at October 31, 2020 and 309 million shares at October 31, 2019 issued and outstanding 3 3
Additional paid-in-capital 5,311 5,277
Retained earnings (accumulated deficit) 81 (18)
Accumulated other comprehensive loss (522) (514)
Total stockholders' equity 4,873 4,748
Total liabilities and equity $ 9,627 $ 9,452
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares
shares in Thousands
Oct. 31, 2020
Oct. 31, 2019
Stockholders' equity:    
Preferred stock par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock shares authorized (in shares) 125,000 125,000
Preferred Stock, Shares Issued (in shares) 0 0
Preferred Stock, Shares Outstanding (in shares) 0 0
Common stock par value (in dollars per share) $ 0.01 $ 0.01
Common stock shares authorized (in shares) 2,000,000 2,000,000
Common stock issued (in shares) 306,000 309,000
Common stock outstanding 306,000 309,000
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Cash flows from operating activities:      
Net income $ 719 $ 1,071 $ 316
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 308 238 210
Share-based compensation 83 72 70
Deferred taxes 29 (255) (16)
Excess and obsolete inventory related charges 28 19 26
Gain on step acquisition 0 0 (20)
Asset impairment charges 99 0 21
Unrealized gain on equity securities, net 28 1 0
Loss on extinguishment of debt 0 9 0
Other 8 7 9
Changes in assets and liabilities:      
Accounts receivable, net (107) (106) (65)
Inventory (68) (36) (83)
Accounts payable 2 29 40
Employee compensation and benefits 29 23 31
Change in assets and liabilities due to Tax Act 0 0 552
Treasury lock agreement payment 0 (6) 0
Other assets and liabilities (181) (43) (4)
Net cash provided by operating activities 921 1,021 1,087
Cash flows from investing activities:      
Investments in property, plant and equipment (119) (155) (177)
Proceeds from the sale of property, plant and equipment 1 0 1
Payments to acquire fair value investments (20) (23) (11)
Payment in exchange for convertible note (9) (3) (2)
Payment to acquire intangible assets 0 (1) 0
Acquisitions of businesses and intangible assets, net of cash acquired 0 (1,408) (516)
Net cash used in investing activities (147) (1,590) (705)
Cash flows from financing activities:      
Issuance of common stock under employee stock plans 60 54 56
Payment of taxes related to net share settlement of equity awards (37) (16) (30)
Treasury stock repurchases (469) (723) (422)
Payment of dividends (222) (206) (191)
Issuance of senior notes 499 497 0
Debt issuance costs (4) (4) 0
Proceeds from commercial paper 420 0 0
Repayments of commercial paper (345) 0 0
Repayments of finance leases (4) 0 0
Payments to Noncontrolling Interests 0 (4) 0
Proceeds from credit facility and short-term loan 798 805 483
Repayments of debt and credit facility (1,413) (702) (693)
Net cash used in financing activities (717) (299) (797)
Effect of exchange rate movements 2 2 (17)
Net increase (decrease) in cash, cash equivalents and restricted cash 59 (866) (432)
Cash, cash equivalents and restricted cash at beginning of year 1,388 2,254 2,686
Cash, cash equivalents and restricted cash at end of year 1,447 1,388 2,254
Supplemental Cash Flow Information [Abstract]      
Income tax payments, net 361 159 102
Interest payments 71 80 80
Net change in property, plant and equipment increase (decrease) $ (1) $ (21) $ (5)
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENT OF EQUITY - USD ($)
shares in Thousands, $ in Millions
Total
Revision of Prior Period, Accounting Standards Update, Adjustment
Common Stock
Additional Paid-in Capital
Retained Earnings (Accumulated Deficit)
Retained Earnings (Accumulated Deficit)
Revision of Prior Period, Accounting Standards Update, Adjustment
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Loss
Revision of Prior Period, Accounting Standards Update, Adjustment
Total Stockholders Equity
Total Stockholders Equity
Revision of Prior Period, Accounting Standards Update, Adjustment
Non-controlling Interest
Balance (in shares) at Oct. 31, 2017     321,975                
Balance at Oct. 31, 2017 $ 4,835   $ 3 $ 5,300 $ (126)   $ (346)   $ 4,831   $ 4
Components of comprehensive income, net of tax:                      
Net income 316       316       316    
Other comprehensive income (loss) (62)           (62)   (62)    
Total comprehensive income 254               254    
Cash dividends declared (191)       (191)       (191)    
Share-based awards issued (in shares)     2,176                
Share-based awards issued 25     25         25    
Stock Repurchased and Retired During Period, Value (422)   $ 0 (87) (335)       (422)    
Stock Repurchased and Retired During Period, Shares     (6,436)                
Share-based compensation 70     70         70    
Balance at Oct. 31, 2018 4,571 $ 26 $ 3 5,308 (336) $ 33 (408) $ (7) 4,567 $ 26 4
Balance (in shares) at Oct. 31, 2018     317,715                
Components of comprehensive income, net of tax:                      
Net income 1,071       1,071       1,071    
Other comprehensive income (loss) (99)           (99)   (99)    
Total comprehensive income 972               972    
Cash dividends declared (206)       (206)       (206)    
Purchase of non-controlling interests (4)                   (4)
Share-based awards issued (in shares)     1,792                
Share-based awards issued 40     40         40    
Stock Repurchased and Retired During Period, Value (723)   $ 0 (143) (580)       (723)    
Stock Repurchased and Retired During Period, Shares     (10,436)                
Share-based compensation 72     72         72    
Balance at Oct. 31, 2019 4,748   $ 3 5,277 (18)   (514)   4,748   0
Balance (in shares) at Oct. 31, 2019     309,071                
Components of comprehensive income, net of tax:                      
Net income 719       719       719    
Other comprehensive income (loss) (8)           (8)   (8)    
Total comprehensive income 711               711    
Cash dividends declared (222)       (222)       (222)    
Share-based awards issued (in shares)     2,354                
Share-based awards issued 22     22         22    
Stock Repurchased and Retired During Period, Value (469)   $ 0 (71) (398)       (469)    
Stock Repurchased and Retired During Period, Shares     (5,227)                
Share-based compensation 83     83         83    
Balance at Oct. 31, 2020 $ 4,873   $ 3 $ 5,311 $ 81   $ (522)   $ 4,873   $ 0
Balance (in shares) at Oct. 31, 2020     306,198                
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENT OF EQUITY (Parenthetical) - $ / shares
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Statement of Stockholders' Equity [Abstract]      
Cash Dividends Declared (per common share) $ 0.720 $ 0.656 $ 0.596
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.20.4
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Oct. 31, 2020
Accounting Policies [Abstract]  
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Overview.  Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.

Basis of Presentation.  The accompanying consolidated financial statements have been prepared by us pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") and are in conformity with U.S. generally accepted accounting principles ("GAAP"). Our fiscal year end is October 31. Unless otherwise stated, all years and dates refer to our fiscal year.

Principles of Consolidation.  The consolidated financial statements include the accounts of the company and our wholly- and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.

Use of Estimates.  The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, retirement and post-retirement plan assumptions and accounting for income taxes.

Risks and Uncertainties. We are subject to risks common to companies in the analytical instrument industry, such as global economic and financial market conditions, fluctuations in foreign currency exchange rates and fluctuations in customer demand, among others.

Both our domestic and international operations have been and continue to be affected by the ongoing global pandemic of a novel strain of coronavirus (“COVID-19”) and the resulting volatility and uncertainty it has caused in the U.S. and international markets. In March 2020, the World Health Organization declared COVID-19 a pandemic and recommended containment and mitigation measures worldwide. As a result, academic and research laboratories had temporarily closed in our second and third quarters and hospitals and testing laboratories had halted or reduced certain elective medical procedures, which had an adverse effect on our customers' business. The COVID-19 pandemic has caused significant volatility and uncertainty in U.S. and international markets, which could result in a prolonged economic downturn that could disrupt our business.

Revenue Recognition.  We enter into contracts to sell products, services or combinations of products and services. Products may include hardware or software and services may include one-time service events or services performed over time.

We derive revenue primarily from the sale of analytical and diagnostics products and services. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under Accounting Standard Codification Topic 606, Revenue from Contracts with Customers (“ASC 606’’). See also Note 4, "Revenue" for additional information on revenue recognition.

Revenue is recognized when control of the promised products or services is transferred to our customers and the performance obligation is fulfilled in an amount that reflects the consideration that we expect to be entitled in exchange for those products or services, the transaction price. For equipment, consumables, and most software licenses, control transfers to the customer at a point in time. We use present right to payment, legal title, physical possession of the asset, and risks and rewards of ownership as indicators to determine the transfer of control to the customer. Where acceptance is not a formality, the customer must have documented their acceptance of the product or service. For products that include installation, if the installation meets the criteria to be considered a separate performance obligation, product revenue is recognized when control has passed to the customer, and recognition of installation revenue occurs once completed. Product revenue, including sales to
resellers and distributors is reduced for provisions for warranties, returns, and other adjustments in the period the related sales are recorded.

Service revenue includes extended warranty, customer and software support including: Software as a Service, post contract support, consulting including companion diagnostics, and training and education. Instrument service contracts and software maintenance contracts are typically annual contracts, which are billed at the beginning of the contract or maintenance period. Revenue for these contracts is recognized on a straight-line basis to revenue over the service period, as a time-based measure of progress best reflects our performance in satisfying this obligation. There are no deferred costs associated with the service contract, as the cost of the service is recorded when the service is performed. Service calls not included in a support contract are recognized to revenue at the time a service is performed.

We have sales from standalone software. These arrangements typically include software licenses and maintenance contracts, both of which we have determined are distinct performance obligations. We determine the amount of the transaction price to allocate to the license and maintenance contract based on the relative standalone selling price of each performance obligation. Software license revenue is recognized at the point in time when control has been transferred to the customer. The revenue allocated to the software maintenance contract is recognized on a straight-line basis over the maintenance period, which is the contractual term of the contract, as a time-based measure of progress best reflects our performance in satisfying this obligation. Unspecified rights to software upgrades are typically sold as part of the maintenance contract on a when-and-if-available basis.

Our multiple-element arrangements are generally comprised of a combination of instruments, installation or other start-up services, and/or software, and/or support or services. Hardware and software elements are typically delivered at the same time and revenue is recognized when control passes to the customer. Service revenue is deferred and recognized over the contractual period or as services are rendered and accepted by the customer. Our arrangements generally do not include any provisions for cancellation, termination, or refunds that would significantly impact recognized revenue.

For contracts with multiple performance obligations, we allocate the consideration to which we expect to be entitled to each performance obligation based on relative standalone selling prices and recognize the related revenue when or as control of each individual performance obligation is transferred to customers. We estimate the standalone selling price by calculating the average historical selling price of our products and services per country for each performance obligation. Standalone selling prices are determined for each distinct good or service in the contract, and then we allocate the transaction price in proportion to those standalone selling prices by performance obligations.

A portion of our revenue relates to lease arrangements. Standalone lease arrangements are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 842, Leases for 2020 and ASC 840, Leases for prior periods. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type capital lease using the current lease classification guidance.

Deferred Revenue.  Contract liabilities (deferred revenue) primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements (performance obligations) to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either in current liabilities in deferred revenue or long-term in other long-term liabilities in the consolidated balance sheet based on the timing of when we expect to complete our performance obligation.

Sales Taxes.  Sales taxes collected from customers and remitted to governmental authorities are not included in our revenue.

Shipping and Handling Costs.  Our shipping and handling costs charged to customers are included in net revenue, and the associated expense is recorded in cost of products for all periods presented.

Research and Development.  Costs related to research, design and development of our products are charged to research and development expense as they are incurred.

Advertising.  Advertising costs are generally expensed as incurred and amounted to $48 million in 2020, $36 million in 2019 and $41 million in 2018.
Taxes on Income.  Income tax expense or benefit is based on income or loss before taxes. Deferred tax assets and liabilities are recognized principally for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. See Note 6, "Income Taxes" for more information.

Net Income Per Share.  Basic net income per share is computed by dividing net income - the numerator - by the weighted average number of common shares outstanding - the denominator - during the period excluding the dilutive effect of stock options and other employee stock plans. Diluted net income per share gives effect to all potential common shares outstanding during the period unless the effect is anti-dilutive. The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense are assumed proceeds to be used to repurchase hypothetical shares. See Note 7, "Net Income Per Share".

Cash, Cash Equivalents and Short-Term Investments.  We classify investments as cash equivalents if their original or remaining maturity is three months or less at the date of purchase. Cash equivalents are stated at cost, which approximates fair value.

As of October 31, 2020, approximately $1,395 million of our cash and cash equivalents is held outside of the U.S. by our foreign subsidiaries. Our cash and cash equivalents mainly consist of short-term deposits held at major global financial institutions, institutional money market funds, and similar short duration instruments with original maturities of 90 days or less. We continuously monitor the creditworthiness of the financial institutions and institutional money market funds in which we invest our funds.

We classify investments as short-term investments if their original maturities are greater than three months and their remaining maturities are one year or less. Currently, we have no short-term investments.

Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet follows:
October 31,
202020192018
(in millions)
Cash and cash equivalents$1,441 $1,382 $2,247 
Restricted cash included in other assets6 6 7 
Total cash, cash equivalents and restricted cash$1,447 $1,388 $2,254 

Accounts Receivable, net.  Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Such accounts receivable have been reduced by an allowance for doubtful accounts, which is our best estimate of the amount of probable credit losses in our existing accounts receivable. We determine the allowance based on customer specific experience and the aging of such receivables, among other factors. The allowance for doubtful accounts as of October 31, 2020 and 2019 was not material. We do not have any off-balance-sheet credit exposure related to our customers. Accounts receivable are also recorded net of estimated product returns which are not material.

Concentration of Credit Risk.  Financial instruments that potentially subject Agilent to significant concentration of credit risk include money market fund investments, time deposits and demand deposit balances. These investments are categorized as cash and cash equivalents. In addition, Agilent has credit risk from derivative financial instruments used in hedging activities and accounts receivable. We invest in a variety of financial instruments and limit the amount of credit exposure with any one financial institution. We have a comprehensive credit policy in place and credit exposure is monitored on an ongoing basis.

Credit risk with respect to our accounts receivable is diversified due to the large number of entities comprising our customer base and their dispersion across many different industries and geographies. Credit evaluations are performed on customers requiring credit over a certain amount, and we sell the majority of our products through our direct sales force. Credit risk is mitigated through collateral such as letter of credit, bank guarantees or payment terms like cash in advance. No single customer accounted for more than 10 percent of accounts receivable as of October 31, 2020, or 2019.
Inventory.  Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with manufacturing to maximize recovery of excess inventory.

Property, Plant and Equipment.  Property, plant and equipment are stated at cost less accumulated depreciation. Additions, improvements and major renewals are capitalized; maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation and amortization are removed from our general ledger, and the resulting gain or loss is reflected in the consolidated statement of operations. Buildings and improvements are depreciated over the lesser of their useful lives or the remaining term of the lease and machinery and equipment over 3 years to 10 years. We use the straight-line method to depreciate assets.

Capitalized Software.  We capitalize certain internal and external costs incurred to acquire or create internal use software. Capitalized software is included in property, plant and equipment and is depreciated over 3 years to 5 years once development is complete.

Leases.  We determine whether an arrangement is, or contains, a lease at inception. Prior to November 1, 2019, for leases where we are the lessee, we accounted for operating lease payments by charging them to expense as incurred. At the beginning of fiscal 2020, the company adopted new lease accounting guidance issued by the Financial Accounting Standards Board ("FASB"). The most significant change requires lessees to record the present value of operating lease payments as right-of-use ("ROU") assets and lease liabilities on the consolidated balance sheet. Where we are the lessee, ROU assets represent the company’s right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of operating lease liabilities as either current or non-current is based on the expected timing of payments due under our obligations. As most of our leases do not provide an implicit interest rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rates, we have used a number of factors including the company's credit rating, the lease term and the currency swap rate. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet and lease expense for these leases is recognized on a straight-line basis over the lease term. Lease expense for operating leases with an initial term of more than twelve months is recognized on a straight-line basis over the lease term as an operating expense. We have lease agreements which require payments for lease and non-lease components. We have elected to account for these payments as a single lease component.

A portion of our revenue relates to lease arrangements where Agilent is the lessor. Standalone lease arrangements are outside the scope of Accounting Standard Codification ("ASC") Topic 606, Revenue Contracts with Customers, and are therefore accounted for in accordance with ASC Topic 842, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type finance lease using the current lease classification guidance. In a lease arrangement that is a multiple-element arrangement that contains equipment leases and the supply of consumables, the revenue associated with the instrument rental is treated under the lease accounting standard ASC 842, whereas the revenue associated with the consumables, the non-lease component, is recognized in accordance with the ASC 606 revenue standard.

   See also Note 2, "New Accounting Pronouncements" and Note 10, "Leases" for additional information about the company’s leases.

Acquisitions. Agilent accounts for the acquisition of a business using the acquisition method of accounting, and we allocate the fair value of the purchase price to the tangible assets acquired, liabilities assumed, and intangible assets acquired, including in-process research and development (“IPR&D”), based on their estimated fair values. The excess value of the cost of an acquired business over the fair value of the assets acquired and liabilities assumed is recognized as goodwill. The fair value of IPR&D is initially capitalized as an intangible asset with an indefinite life. When an IPR&D project is completed, the IPR&D is reclassified as an amortizable purchased intangible asset and amortized to costs of revenues over the asset’s estimated useful life.

Our determination of the fair value of the intangible assets acquired involves the use of significant estimates and assumptions. Specifically, our determination of the fair value of the developed product technology and IPR&D acquired
involve significant estimates and assumptions related to revenue growth rates and discount rates. Our determination of the fair value of customer relationships acquired involved significant estimates and assumptions related to revenue growth rates, discount rates, and customer attrition rates. Our determination of the fair value of the tradename acquired involved the use of significant estimates and assumptions related to revenue growth rates, royalty rates and discount rates. The company believes that the fair value assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that marketplace participants would use. Actual results could differ materially from these estimates.

Goodwill and Purchased Intangible Assets. Under the authoritative guidance we have the option to perform a qualitative assessment to determine whether further impairment testing is necessary. The accounting standard gives an entity the option to first assess qualitative factors to determine whether performing the two-step test is necessary. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not (i.e., greater than 50% chance) that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test will be required. Otherwise, no further testing will be required.

The guidance includes examples of events and circumstances that might indicate that a reporting unit's fair value is less than its carrying amount. These include macro-economic conditions such as deterioration in the entity's operating environment or industry or market considerations; entity-specific events such as increasing costs, declining financial performance, or loss of key personnel; or other events such as an expectation that a reporting unit will be sold or a sustained decrease in the stock price on either an absolute basis or relative to peers.

If it is determined, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, the provisions of authoritative guidance require that we perform a two-step impairment test on goodwill. In the first step, we compare the fair value of each reporting unit to its carrying value. The second step (if necessary) measures the amount of impairment by applying fair-value-based tests to the individual assets and liabilities within each reporting unit. As defined in the authoritative guidance, a reporting unit is an operating segment, or one level below an operating segment. We aggregate components of an operating segment that have similar economic characteristics into our reporting units.

In fiscal year 2020, we assessed goodwill impairment for our three reporting units which consisted of three segments: life sciences and applied markets, diagnostics and genomics and Agilent CrossLab. We performed a qualitative test for goodwill impairment of the three reporting units, as of September 30, 2020, our annual impairment test date. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair value of each reporting unit is greater than its respective carrying value. Each quarter we review the events and circumstances to determine if goodwill impairment is indicated. There was no impairment of goodwill during the years ended October 31, 2020, 2019 and 2018.

Purchased intangible assets consist primarily of acquired developed technologies, proprietary know-how, trademarks, and customer relationships and are amortized using the best estimate of the asset's useful life that reflect the pattern in which the economic benefits are consumed or used up or a straight-line method ranging from 6 months to 15 years. IPR&D is initially capitalized at fair value as an intangible asset with an indefinite life and assessed for impairment thereafter. When the IPR&D project is complete, it is reclassified as an amortizable purchased intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, Agilent will record a charge for the value of the related intangible asset to Agilent's consolidated statement of operations in the period it is abandoned.

Agilent's indefinite-lived intangible assets are IPR&D intangible assets. The accounting guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the issued impairment testing guidance for goodwill and allows the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset to determine whether it is more-likely-than-not (i.e., greater than 50% chance) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value. We performed a qualitative test for impairment of indefinite-lived intangible assets as of September 30, 2020. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair values of these indefinite-lived intangible assets are greater than their respective carrying values. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible asset is indicated. During the year ended October 31, 2020, we recorded an impairment of in-process research and development of $90 million related to the shutdown of our sequencer development program in our diagnostics and genomics segment. During the year ended October 31, 2019 and 2018 there were no impairments of indefinite-lived intangible assets.
Impairment of Long-Lived Assets.  We continually monitor events and changes in circumstances that could indicate carrying amounts of long-lived assets, including intangible assets, may not be recoverable. When such events or changes in circumstances occur, we assess the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the undiscounted future cash flows is less than the carrying amount of those assets, we recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets. During the year ended October 31, 2020 we recorded an impairment charge of long-lived assets including indefinite-lived in-process research and development of $98 million related to the shutdown of our sequencer development program in our diagnostics and genomics segment. During fiscal year 2019, there were no impairments of other assets or intangible assets. During fiscal year 2018, we recorded an impairment charge of $21 million related to purchased intangible assets within the diagnostics and genomics segment that were deemed unrecoverable.

Variable Interest Entities. We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity (“VIE”).  The company evaluates its investments in privately held companies on an ongoing basis. We have determined that as of October 31, 2020 and 2019, there were no VIE's required to be consolidated in the company's consolidated financial statements because we do not have a controlling financial interest in any of the VIE's in which we have invested nor are we the primary beneficiary. We account for these investments under either the equity method or as equity investments without readily determinable fair value, depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs, based on changes in facts and circumstances including changes in contractual arrangements and capital structure.

During the year ended October 31, 2018, we exercised our option and acquired all of the remaining shares of Lasergen, Inc. ("Lasergen") that we did not already own for an additional cash consideration of approximately $107 million. The fair value remeasurement of our previous investment immediately before the acquisition resulted in a net gain of $20 million and was recorded in other income. Lasergen was previously considered a VIE.

As of October 31, 2020 and October 31, 2019, the total carrying value of investments and loans in privately held companies considered as VIEs was $67 million and $29 million respectively. The maximum exposure is equal to the carrying value because we do not have future funding commitments. The investments are included on the long-term investments line and the loans on the other current assets and other assets lines (depending upon tenure of loan) on the consolidated balance sheet.

Investments.  Equity investments without readily determinable fair value consist of non-marketable equity securities (typically investments in privately-held companies). These investments are accounted for using the measurement alternative at cost, and we adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) included in net income as and when it occurs. Equity investments with readily determinable fair value consist of shares we own in a special fund and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. Prior to fiscal year 2019, both equity investments without determinable fair value and with determinable fair value were accounted for using cost method of accounting, measured at historical cost less other-than-temporary investment. Trading securities, which are comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liabilities are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Equity method investments are reported at the amount of the company’s initial investment and adjusted each period for the company’s share of the investee’s income or loss and dividend paid. There are no equity method investments as of October 31, 2020 and 2019. The company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.

Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. The fair value of our senior notes, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy exceeds the carrying value by approximately $162 million as of October 31, 2020 and approximately $62 million as of October 31, 2019. The change in the fair value over carrying value in the year ended October 31, 2020 is primarily due to decreased market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are
observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 13, "Fair Value Measurements" for additional information on the fair value of financial instruments.

Warranty.  Our standard warranty terms typically extend for one year from the date of delivery. We accrue for standard warranty costs based on historical trends in warranty charges. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost over the period. Estimated warranty charges are recorded within cost of products at the time products are sold. See Note 16, "Guarantees".

Employee Compensation and Benefits.  Amounts owed to employees, such as accrued salary, bonuses and vacation benefits are accounted for within employee compensation and benefits. The total amount of accrued vacation benefit was $111 million and $115 million as of October 31, 2020, and 2019, respectively.

Retirement and Post-Retirement Plans. Substantially all of our employees are covered under various defined benefit and/or defined contribution retirement plans. Additionally, we sponsor post-retirement health care benefits for our eligible U.S. employees. Assumptions used to determine the benefit obligations and the expense for these plans are derived annually. See Note 15, “Retirement plans and post-retirement pension plans” for additional information.

Retirement of Treasury Shares. Upon the formal retirement of treasury shares, we deduct the par value of the retired treasury shares from common stock and allocate the excess of cost over par as a deduction to additional paid-in capital, based on the pro-rata portion of additional paid-in-capital, and the remaining excess as a deduction to retained earnings. All retired treasury shares revert to the status of authorized but unissued shares.

Share-Based Compensation.  For the years ended 2020, 2019 and 2018, we accounted for share-based awards made to our employees and directors including employee stock option awards, restricted stock units, employee stock purchases made under our Employee Stock Purchase Plan ("ESPP") and performance share awards under Agilent Technologies, Inc. Long-Term Performance Program ("LTPP") using the estimated grant date fair value method of accounting. Under the fair value method, we recorded compensation expense for all share-based awards of $84 million in 2020, $72 million in 2019 and $71 million in 2018. See Note 5, "Share-based Compensation" for additional information.

Derivative Instruments.  Agilent is exposed to global foreign currency exchange rate and interest rate risks in the normal course of business. We enter into foreign exchange hedging contracts, primarily forward contracts and purchased options, interest rate swaps and interest rate locks to manage financial exposures resulting from changes in foreign currency exchange rates and interest rates. In the vast majority of cases, these contracts are designated at inception as hedges of the related foreign currency or interest exposures. Foreign currency exposures include committed and anticipated revenue and expense transactions and assets and liabilities that are denominated in currencies other than the functional currency of the subsidiary. Interest rate exposures are associated with the company's fixed-rate debt. For option contracts, we exclude time value from the measurement of effectiveness. To qualify for hedge accounting, contracts must reduce the foreign currency exchange rate and interest rate risk otherwise inherent in the amount and duration of the hedged exposures and comply with established risk management policies. Foreign exchange hedging contracts generally mature within twelve months, interest rate swaps mature at the same time as the maturity of the debt and interest rate locks mature at the same time as the issuance of debt. In order to manage foreign currency exposures in a few limited jurisdictions, we may enter into foreign exchange contracts that do not qualify for hedge accounting. In such circumstances, the local foreign currency exposure is offset by contracts owned by the parent company. We do not use derivative financial instruments for trading or speculative purposes.

All derivatives are recognized on the balance sheet at their fair values. For derivative instruments that are designated and qualify as a cash flow hedge, changes in the value of the effective portion of the derivative instrument are recognized in comprehensive income (loss), a component of stockholders' equity. For derivative instruments that are designated and qualify as a net investment hedge, changes in the value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss). Amounts associated with cash flow hedges are reclassified and recognized in income when either the forecasted transaction occurs or it becomes probable the forecasted transaction will not occur. Derivatives not designated as hedging instruments are recorded on the balance sheet at their fair value and changes in the fair values are recorded in the income statement in the current period. Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet. Changes in the fair value of the ineffective portion of derivative instruments are recognized in earnings in the current period. The impact of the ineffectiveness measurement in 2020, 2019 and 2018 was not material. Cash flows from derivative instruments are classified in the statement of cash flows in the same category as the cash flows from the hedged or economically hedged item, primarily in operating activities.
Foreign Currency Translation.  We translate and remeasure balance sheet and income statement items into U.S. dollars. For those subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using monthly exchange rates which approximate to average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) in stockholders' equity.For those subsidiaries that operate in a U.S. dollar functional environment, foreign currency assets and liabilities are remeasured into U.S. dollars at current exchange rates except for non-monetary assets and capital accounts which are remeasured at historical exchange rates. Revenue and expenses are generally remeasured at monthly exchange rates which approximate average exchange rates in effect during each period. Gains or losses from foreign currency remeasurement are included in consolidated net income. Net gains or losses resulting from foreign currency transactions, including hedging gains and losses, are reported in other income (expense), net and were $4 million loss for 2020, $7 million loss for 2019 and $3 million loss for 2018.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.20.4
NEW ACCOUNTING PRONOUNCEMENTS
 12 Months Ended
Oct. 31, 2020
Accounting Standards Update and Change in Accounting Principle [Abstract]  
NEW ACCOUNTING PRONOUNCEMENTS NEW ACCOUNTING PRONOUNCEMENTS
Recently Adopted Accounting Pronouncements
In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases (Topic 842), which requires lessees to record most leases on the balance sheet as lease liabilities, initially measured at the present value of future lease payments, with a corresponding right-of-use asset. The accounting applied by a lessor is largely unchanged from that applied under the prior accounting standard.

On November 1, 2019, we adopted the new accounting guidance using the modified retrospective method, by applying the transition approach, for all lease arrangements at the beginning of the period of adoption. Results for reporting periods beginning November 1, 2019 are presented under the new accounting standard, while prior period amounts have not been restated. The standard had a significant impact on the opening consolidated balance sheet as of November 1, 2019, but did not have a significant impact on the consolidated statement of operations or consolidated statement of cash flows for the year ended October 31, 2020 when compared to prior periods. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases, while the accounting for finance leases remained substantially unchanged. For leases that commenced before the effective date of the new accounting standard, we elected the permitted practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. We also elected to exclude leases with a term of 12 months or less in the ROU assets and lease liabilities.

Adoption of the new guidance impacted the consolidated balance sheet as follows:

 October 31, 2019Impact of AdoptingNovember 1, 2019
 As ReportedLease GuidanceAs Adopted
(in millions)
Other assets$611 $192 $803 
Other accrued liabilities$440 $48 $488 
Other long-term liabilities$473 $144 $617 

On November 1, 2018, we adopted ASC Topic 606, Revenue from Contracts with Customers, using the modified retrospective approach only to contracts not completed as of this date. Results for reporting periods after November 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and continue to be reported in accordance with ASC Topic 605, Revenue Recognition.

New Accounting Pronouncements Not Yet Adopted

In June 2016, the FASB issued new guidance to require a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. During 2018 and 2019, the FASB issued additional guidance and clarification. The new guidance is effective for us beginning November 1, 2020. We do not expect this guidance to have a material impact on our consolidated financial statements and disclosures.
In January 2017, the FASB issued an amendment to modify the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. The amendment also simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. The amendments are effective for us beginning November 1, 2020. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We do not expect this guidance to have a material impact on our consolidated financial statements and disclosures.

In August 2018, the FASB issued updates to improve the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement which eliminates certain disclosure requirements and modifies others. These amendments are effective for us beginning November 1, 2020, and for interim periods within that year with early adoption permitted. We currently do not expect this guidance to have a material impact on our consolidated financial statements and disclosures.

In August 2018, the FASB issued updates to improve the effectiveness of disclosures for defined benefit plans under Accounting Standard Codification Topic 715-20. The amendments in this guidance remove disclosures that no longer are considered cost beneficial, clarify the specific requirements of disclosures, and add disclosure requirements identified as relevant. These amendments are effective for us beginning November 1, 2021, with early adoption permitted. We currently do not expect this guidance to have a material impact on our consolidated financial statements and disclosures.

In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. This guidance eliminates certain exceptions to existing guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The guidance also improves consistent application by clarifying and amending existing guidance related to aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step up in the tax basis of goodwill. The new guidance is effective for us beginning November 1, 2021, and for interim periods within that year. Early adoption is permitted. We do not expect that the adoption of this standard will have a material impact on our consolidated financial statements and disclosures.

In January 2020, accounting guidance was issued that clarifies the accounting guidance for equity method investments, joint ventures, and derivatives and hedging. The guidance clarifies the interaction between different sections of the accounting guidance that could be applicable and helps clarify which guidance should be applied in certain situations which should increase relevance and comparability of financial statement information. This guidance is effective for us beginning November 1, 2021, and for interim periods within that year. Early adoption is permitted. We do not expect that the adoption of this standard will have a material impact on our consolidated financial statements and disclosures.

In March 2020, the FASB issued an update for facilitation of the effects of reference rate reform on financial reporting. This update provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments in the guidance provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply to contracts, hedging relationships, and other transactions that reference London Inter-bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. When elected, the optional expedients for contract modifications are applied consistently for all eligible contracts or eligible transactions within the relevant Topic or Industry Subtopic in the FASB's Accounting Standards Codification. The guidance was effective upon issuance and may generally be applied through December 31, 2022 to any new or amended contracts, hedging relationships, and other transactions that reference LIBOR. We are currently evaluating our contracts and we do not expect that the adoption of this guidance will have a material impact on our consolidated financial statements and disclosures.

Other amendments to GAAP in the U.S. that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.20.4
ACQUISITIONS (Notes)
 12 Months Ended
Oct. 31, 2020
Business Combinations [Abstract]  
Acquisitions Disclosure ACQUISITIONS
Acquisition of BioTek and ACEA

On August 23, 2019 we completed the acquisition of privately-owned Lionheart Technologies LLC ("BioTek"), a leader in the design, manufacture and distribution of innovative life science instrumentation for $1.17 billion, under the merger agreement. As a result of the acquisition, BioTek became a wholly-owned subsidiary of Agilent. Accordingly, the results of
BioTek are included in Agilent's consolidated financial statements from the acquisition date. The acquisition of BioTek and its portfolio is another step to expand our position in the cell analysis market.

The consideration paid was $1.17 billion. Agilent funded the acquisition using existing cash of $470 million and debt of $700 million.

The BioTek acquisition was accounted for in accordance with the authoritative accounting guidance. The acquired assets and assumed liabilities were recorded by Agilent at their estimated fair values. Agilent determined the estimated fair values with the assistance of appraisals or valuations performed by third party specialists, discounted cash flow analyses, and estimates made by management. We expect to realize revenue synergies, leverage and expand the existing sales channels and product development resources, and utilize the assembled workforce. These factors, among others, contributed to a purchase price in excess of the estimated fair value of BioTek’s net identifiable assets acquired (see summary of net assets below), and, as a result, we have recorded goodwill in connection with this transaction.
 
Goodwill acquired was allocated to our operating segments and reporting units as a part of the purchase price allocation. All goodwill was allocated to the life sciences and applied markets reporting unit.

Agilent’s acquisition of BioTek is treated as an asset purchase for tax purposes. The tax basis of the acquired assets equals the fair market value on acquisition date.

The following table summarizes the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of August 23, 2019 (in millions):
Cash and cash equivalents$10 
Accounts receivable28 
Inventories21 
Other current assets2 
Property, plant and equipment8 
Intangible assets641 
Goodwill483 
Total assets acquired$1,193 
Accounts payable(4)
Deferred revenue(5)
Employee compensation and benefits(7)
Other accrued liabilities(2)
Long-term debt(4)
Net assets acquired$1,171 


The fair value of cash and cash equivalents, accounts receivable, other current assets, accounts payable and other accrued liabilities were generally determined using historical carrying values given the short-term nature of these assets and liabilities.
 
The fair values for acquired intangible assets and deferred revenue were determined with the input from third party valuation specialists.
 
The fair values of certain other assets, inventory, property, plant and equipment, investments, long-term debt, and certain other long-term liabilities were determined internally using historical carrying values and estimates made by management.
 
Valuations of intangible assets acquired
 
The components of intangible assets acquired in connection with the BioTek acquisition were as follows (in millions):

 Fair ValueEstimated
Useful Life
Developed product technology$387 
5-13 years
Customer relationships202 
3-8 years
Backlog5 2 months
Tradenames and trademarks43 10 years
Total intangible assets subject to amortization$637 
In-process research and development4  
Total intangible assets$641  

As noted above, the intangible assets, including in-process research and development, were valued with input from valuation specialists. Agilent used variations of the income approach in determining the fair value of intangible assets acquired in the BioTek acquisition. Specifically, the developed product technology and in-process research and development were valued using the multi-period excess earnings method under the income approach by discounting forecasted cash flows directly related to the products expecting to result from the projects, net of returns on contributory assets. The company utilized the incremental cash flow method for determining the fair value of the customer relationships acquired, and the relief from royalty method to determine the fair value of the tradename. Order backlog was valued on a direct cash flow basis.

The primary in-process research and development project acquired relates to a next version of a product which was subsequently released to customers in 2020. After release, the asset was moved to developed technology.

Acquisition and integration costs directly related to the BioTek acquisition totaled $12 million and $4 million for the year ended October 31, 2020 and 2019, respectively, and were recorded in operating expenses and cost of sales. Such costs are expensed in accordance with the authoritative accounting guidance.

On November 14, 2018, we acquired 100 percent of the stock of ACEA Biosciences (“ACEA”), a developer of cell analysis tools, for $250 million. The financial results of ACEA have been included in our financial results from the acquisition date.
 
The following represents the unaudited proforma operating results as if BioTek and ACEA had been included in the company's consolidated statements of operations as of the beginning of fiscal 2018 (in millions, except per share amounts):

20192018
Net revenue$5,308 $5,112 
Net income$1,012 $210 
Net income per share — basic$3.22 $0.65 
Net income per share — diluted$3.18 $0.65 

The unaudited proforma financial information assumes that the companies were combined as of November 1, 2017 and include business combination accounting effects from the acquisition including amortization charges from acquired intangible assets, the impact on cost of sales due to the respective estimated fair value adjustments to inventory, changes to interest income for cash used in the acquisition, interest expense associated with debt paid in connection with the acquisition and acquisition related transaction costs and tax related effects. The proforma information as presented above is for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of fiscal 2018.
 
The unaudited proforma financial information for the year ended October 31, 2019 combines the historical results of Agilent for the year ended October 31, 2019 (which includes BioTek and ACEA after the acquisition date) and for BioTek for the ten months ended August 23, 2019.
 
The unaudited proforma financial information for the year ended October 31, 2018 combines the historical results of
Agilent and ACEA for the year ended October 31, 2018 and BioTek for the year ended December 31, 2018 (due to differences in reporting periods).
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE (Notes)
 12 Months Ended
Oct. 31, 2020
Revenue from Contract with Customer [Abstract]  
Revenue from Contract with Customer REVENUE
The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:

Life Sciences and Applied MarketsAgilent CrossLabDiagnostics and GenomicsTotal
(in millions)
Year Ended October 31, 2020:
Americas$784 $667 $517 $1,968 
Europe540 532 371 1,443 
Asia Pacific1,068 701 159 1,928 
Total$2,392 $1,900 $1,047 $5,339 
Year Ended October 31, 2019:
Americas$692 $664 $505 $1,861 
Europe551 522 368 1,441 
Asia Pacific1,059 654 148 1,861 
Total$2,302 $1,840 $1,021 $5,163 

The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
Years Ended October 31,
20202019
(in millions)
Revenue by End Markets
Pharmaceutical and Biopharmaceutical$1,754 1,604 
Chemical and Energy1,154 1,199 
Diagnostics and Clinical787 785 
Food517 486 
Academia and Government526 474 
Environmental and Forensics601 615 
Total$5,339 5,163 
Revenue by Type
Instrumentation$2,249 2,150 
Non-instrumentation and other3,090 3,013 
Total$5,339 5,163 

Revenue by region is based on the ship to location of the customer. Revenue by end market is determined by the market indicator of the customer and by customer type. Instrumentation revenue includes sales from instruments, remarketed instruments and third-party products. Non-instrumentation and other revenue include sales from contract and per incident services, our companion diagnostics and our nucleic acid solutions businesses as well as sales from spare parts, consumables, reagents, vacuum pumps, subscriptions, software licenses and associated services.
Contract Balances

Contract Assets

Contract assets (unbilled accounts receivable) primarily relate to the company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are reclassified to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the consolidated balance sheet. The balances of contract assets as of October 31, 2020 and 2019, were $153 million and $110 million, respectively. The increase in unbilled receivables during the year ended October 31, 2020 is a result of recognition of revenue upon the transfer of the control to the customer.

Contract Liabilities

The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the years ended October 31, 2019 and 2020:

Contract
Liabilities
(in millions)
Ending balance as of October 31, 2018$367 
Impact of adoption of new revenue recognition guidance(11)
Net revenue deferred in the period303 
Revenue recognized that was included in the contract liability balance at the beginning of the period(287)
Change in deferrals from customer cash advances, net of revenue recognized5 
Contract liabilities acquired in business combinations9 
Currency translation and other adjustments— 
Ending balance as of October 31, 2019$386 
Net revenue deferred in the period347 
Revenue recognized that was included in the contract liability balance at the beginning of the period(300)
Change in deferrals from customer cash advances, net of revenue recognized9 
Currency translation and other adjustments4 
Ending balance as of October 31,2020$446 

Contract liabilities primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either current in deferred revenue or long-term in other long-term liabilities in the consolidated balance sheet based on the timing of when we expect to complete our performance obligation.

Contract Costs

Incremental costs of obtaining a contract with a customer are recognized as an asset if we expect the benefit of those costs to be longer than one year. We have determined that certain sales incentive programs meet the requirements to be capitalized. The changes in total capitalized costs to obtain a contract were immaterial during the years ended October 31, 2020 and 2019 and are included in other current and long-term assets on the consolidated balance sheet. We have applied the practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the company's internal sales force compensation program, as we have determined that annual compensation is commensurate with annual sales activities.
Transaction Price Allocated to the Remaining Performance Obligations

We have applied the practical expedient in ASC 606-10-50-14 and have not disclosed information about transaction price allocated to remaining performance obligations that have original expected durations of one year or less.
The estimated revenue expected to be recognized for remaining performance obligations that have an original term of more than one year, as of October 31, 2020, was $217 million, the majority of which is expected to be recognized over the next 12 months. Remaining performance obligations primarily include extended warranty, customer manufacturing contracts, and software maintenance contracts and revenue associated with lease arrangements.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.20.4
SHARE-BASED COMPENSATION
 12 Months Ended
Oct. 31, 2020
Share-based Payment Arrangement, Noncash Expense [Abstract]  
SHARE-BASED COMPENSATION SHARE-BASED COMPENSATION
Agilent accounts for share-based awards in accordance with the provisions of the accounting guidance which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including restricted stock units, stock options, employee stock purchases made under our employee stock purchase plan and performance share awards granted to selected members of our senior management under the long-term performance plan ("LTPP") based on estimated fair values.

Description of Share-Based Plans

Employee Stock Purchase Plan.    Effective May 1, 2020, we adopted the 2020 Employee Stock Purchase Plan ("ESPP") which replaced our previous Employee Stock Purchase Plan. The ESPP allows eligible employees to contribute up to 10 percent of their base compensation to purchase shares of our common stock at 85 percent of the closing market price at purchase date. There are 31 million shares authorized for issuance in connection with the ESPP.

Under our ESPP, employees purchased 628,644 shares for $41 million in 2020, 603,488 shares for $37 million in 2019 and 558,116 shares for $32 million in 2018. As of October 31, 2020, the number of shares of common stock authorized and available for issuance under our ESPP was 25,770,573. This excludes the number of shares of common stock to be issued to participants in consideration of the aggregate participant contributions totaling $22 million as of October 31, 2020.

Incentive Compensation Plans. On November 15, 2017 and March 21, 2018, the Board of Directors and the stockholders, respectively, approved the Agilent Technologies, Inc. 2018 Stock Plan (the "2018 Plan") which amends, including renaming and extending the term of, the Agilent Technologies, Inc. 2009 Stock Plan (the "2009 Plan"). The 2009 plan replaced the Agilent Technologies, Inc. Amended and Restated 1999 Stock Plan and 1999 Non-Employee Director Stock Plan. The 2018 Plan provides for the grant of awards in the form of stock options, stock appreciation rights ("SARs"), restricted stock, restricted stock units ("RSUs"), performance shares and performance units with performance-based conditions on vesting or exercisability, and cash awards. The 2018 Plan has a term of ten years. As of October 31, 2020, 25,596,430 shares were available for future awards under the 2018 Plan.

Stock options under the 2018 Plan may be either "incentive stock options", as defined in Section 422 of the Internal Revenue Code, or non-statutory. Options were granted prior to November 1, 2015 and generally vest at a rate of 25 percent per year over a period of four years from the date of grant with a maximum contractual term of ten years. The exercise price for stock options is generally not less than 100 percent of the fair market value of our common stock on the date the stock award is granted. Agilent issues new shares of common stock when employee stock options are exercised.

Effective November 1, 2003, the Compensation Committee of the Board of Directors approved the LTPP, which is a performance stock award program administered under the 2018 Plan, for the company's executive officers and other key employees. Participants in this program are entitled to receive unrestricted shares of the company's stock after the end of a three-year period if specified performance targets are met. Certain LTPP awards are generally designed to meet the criteria of a performance award with the performance metrics and peer group comparison based on the Total Stockholders’ Return (“TSR”) set at the beginning of the performance period. Effective November 1, 2015, the Compensation Committee of the Board of Directors approved another type of performance stock award for the company's executive officers and other key employees. Participants in this program are also entitled to receive unrestricted shares of the company's stock after the end of a three-year period if specified performance targets over the three-year period are met. The performance target for grants made beginning in 2017 and thereafter were based on Earnings Per Share ("EPS"). The performance targets for LTPP-EPS grants for year 2 and year 3 of the performance period are set in the first quarter of year 2 and year 3, respectively. All LTPP awards granted after November 1, 2015, are subject to a one-year post-vest holding period.
Based on the performance metrics, the final LTPP award may vary from zero to 200 percent of the target award. The maximum contractual term for awards under the LTPP program is three years. We consider the dilutive impact of these programs in our diluted net income per share calculation only to the extent that the performance conditions are expected to be met.

We also issue restricted stock units under our share-based plans. The estimated fair value of the restricted stock unit awards granted under the Stock Plans is determined based on the market price of Agilent's common stock on the date of grant adjusted for expected dividend yield. Restricted stock units generally vest, with some exceptions, at a rate of 25 percent per year over a period of four years from the date of grant. All restricted stock units granted to our executives after November 1, 2015, are subject to a one-year post-vest holding period.

Impact of Share-based Compensation Awards

We have recognized compensation expense based on the estimated grant date fair value method under the authoritative guidance. For all share-based awards we have recognized compensation expense using a straight-line amortization method. As the guidance requires that share-based compensation expense be based on awards that are ultimately expected to vest, estimated share-based compensation has been reduced for estimated forfeitures.

The impact on our results for share-based compensation was as follows:

Years Ended October 31,
202020192018
(in millions)
Cost of products and services$21 $18 $16 
Research and development9 7 7 
Selling, general and administrative54 47 48 
Total share-based compensation expense$84 $72 $71 

At October 31, 2020 and 2019, no share-based compensation was capitalized within inventory.

Valuation Assumptions

For all periods presented, shares granted under the LTPP (TSR) were valued using a Monte Carlo simulation. The ESPP allows eligible employees to purchase shares of our common stock at 85 percent of the fair market value at the purchase date.

The estimated fair value of restricted stock unit awards and LTPP (EPS) was determined based on the market price of Agilent's common stock on the date of grant adjusted for expected dividend yield and as appropriate, a discount related to the one-year post vesting. The compensation cost for LTPP (EPS) awards reflects the cost of awards that are probable to vest at the end of the performance period.

The following assumptions were used to estimate the fair value of awards granted.

 Years Ended October 31,
 202020192018
LTPP:   
Volatility of Agilent shares23%22%21%
Volatility of selected peer-company shares
15%-44%
15%-66%
14%-66%
Pair-wise correlation with selected peers29%30%32%
Post-vest restriction discount for all executive awards5.3%5.0%4.8%


Shares granted under the LTPP (TSR) were valued using a Monte Carlo simulation model. The Monte Carlo simulation fair value model requires the use of highly subjective and complex assumptions, including the price volatility of the underlying stock. For LTPP (TSR) grants in 2017 and thereafter, we used our own historical stock price volatility.
All LTPP awards granted have a one-year post-vest holding restriction. The estimated discount associated with post-vest holding restrictions is calculated using the Finnerty model. The model calculates the potential lost value if the employee were able to sell the shares during the lack of marketability period instead of being required to hold the shares.


Share-Based Payment Award Activity

Employee Stock Options

The following table summarizes employee stock option award activity of our employees and directors for 2020.

Options
Outstanding 		Weighted
Average
Exercise Price
 (in thousands) 
Outstanding at October 31, 20191,445 $36 
Exercised(575)$34 
Outstanding at October 31, 2020870 $37 

The options outstanding and exercisable for equity share-based payment awards at October 31, 2020 were as follows:

 Options OutstandingOptions Exercisable
Range of
Exercise Prices		Number
Outstanding		Weighted
Average
Remaining
Contractual
Life		Weighted
Average
Exercise
Price		Aggregate
Intrinsic
Value		Number
Exercisable		Weighted
Average
Remaining
Contractual
Life		Weighted
Average
Exercise
Price		Aggregate
Intrinsic
Value
 (in thousands)(in years) (in thousands)(in thousands)(in years) (in thousands)
$25.01 - $30.00
228 1.7$27 $17,192 228 1.7$27 $17,192 
$30.01 - $40.00
121 3.1$39 7,586 121 3.1$39 7,586 
$40.01- over
521 4.0$41 31,883 521 4.0$41 31,883 
870 3.3$37 $56,661 870 3.3$37 $56,661 

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value, based on the company's closing stock price of $102.09 at October 31, 2020, which would have been received by award holders had all award holders exercised their awards that were in-the-money as of that date. The total number of in-the-money awards exercisable at October 31, 2020 was approximately 0.9 million.

The following table summarizes the aggregate intrinsic value of options exercised in 2020, 2019 and 2018:

Aggregate
Intrinsic Value		Weighted
Average
Exercise
Price
 (in thousands) 
Options exercised in fiscal 2018$28,417 $32 
Options exercised in fiscal 2019$24,409 $33 
Options exercised in fiscal 2020$30,481 $34 

As of October 31, 2020, the unrecognized share-based compensation cost for outstanding stock option awards, net of expected forfeitures, was zero. The amount of cash received from the exercise of share-based awards granted was $60 million in 2020, $54 million in 2019 and $56 million in 2018.
Non-Vested Awards

The following table summarizes non-vested award activity in 2020 primarily for our LTPP and restricted stock unit awards.
SharesWeighted
Average
Grant Price
 (in thousands) 
Non-vested at October 31, 20193,173 $60 
Granted1,091 $79 
Vested(1,629)$52 
Forfeited(115)$68 
Change in LTPP shares in the year due to exceeding performance targets298 $47 
Non-vested at October 31, 20202,818 $70 

As of October 31, 2020, the unrecognized share-based compensation cost for non-vested restricted stock awards was approximately $95 million which is expected to be amortized over a weighted average period of 2.1 years. The total fair value of restricted stock awards vested was $85 million for 2020, $69 million for 2019 and $58 million for 2018.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES
 12 Months Ended
Oct. 31, 2020
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The domestic and foreign components of income before taxes are:

 Years Ended October 31,
 202020192018
 (in millions)
U.S. operations$54 $189 $169 
Non-U.S. operations788 730 777 
Total income before taxes$842 $919 $946 

The provision for income taxes is comprised of:

 Years Ended October 31,
 202020192018
 (in millions)
U.S. federal taxes:   
Current$5 $(191)$520 
Deferred4 — 51 
Non-U.S. taxes:   
Current84 290 95 
Deferred24 (267)(22)
State taxes, net of federal benefit:   
Current5 4 1 
Deferred1 12 (15)
Total provision (benefit)$123 $(152)$630 
The differences between the U.S. federal statutory income tax rate and our effective tax rate are:

 Years Ended October 31,
 202020192018
 (in millions)
Profit before tax times statutory rate$177 $193 $221 
Non-U.S. income taxed at different rates(36)(8)(93)
Change in unrecognized tax benefits(9)(13)(17)
Impact of the Tax Act— — 552 
Extension of the tax incentive in Singapore— (299)— 
Excess tax benefits from stock-based compensation(18)(10)(18)
Other, net9 (15)(15)
Provision (benefit) for income taxes$123 $(152)$630 
Effective tax rate14.6 %(16.5)%66.6 %

For 2020, the company's income tax expense was $123 million with an effective tax rate of 14.6 percent. For the year ended October 31, 2020, our effective tax rate and the resulting provision for income taxes were impacted by foreign income taxed at lower rates.

For 2019, the company's income tax benefit was $152 million with an effective tax rate of (16.5) percent. For the year ended October 31, 2019, our effective tax rate and the resulting provision for income taxes were significantly impacted by the discrete benefit of $299 million related to the extension of the company’s tax incentive in Singapore.

As part of the business integration of some of our prior acquisitions, we undertook corporate restructurings in the fourth quarter of fiscal year 2019 that involved on-shoring certain intangible properties held by our foreign subsidiaries to the United States. These restructurings resulted in a cash tax liability of $231 million. These taxes generate tax attributes that will offset our transition tax liability which is included in other long-term liabilities in our consolidated balance sheet. 

For 2018, the company's income tax expense was $630 million with an effective tax rate of 66.6 percent. For the year ended October 31, 2018, our effective tax rate and the resulting provision for income taxes were significantly impacted by the discrete charge of $552 million related to the enactment of the U.S. Tax Cuts and Jobs Act (the “Tax Act”) consisting of (1) an expense of $499 million of U.S. transition tax and correlative items on deemed repatriated earnings of non-U.S. subsidiaries and (2) an expense of $53 million associated with the impact on deferred taxes resulting from the decreased U.S. corporate tax rate.

The company has negotiated tax holidays in several different jurisdictions, most significantly in Singapore. The tax holidays provide lower rates of taxation on certain classes of income and require various thresholds of investments and employment or specific types of income in those jurisdictions. In December 2018, the tax holiday in Singapore was renegotiated and extended through 2027. As a result of the incentives, the impact of the tax holidays decreased income taxes by $71 million, $368 million, and $87 million in 2020, 2019, and 2018, respectively. The benefit of the tax holidays on net income per share (diluted) was approximately $0.23, $1.16, and $0.27 in 2020, 2019 and 2018, respectively. Of the $1.16 benefit of the tax incentives on net income per share (diluted) in 2019, $0.94 of the benefit relates to one-time items from the extension of the company’s tax incentive in Singapore.
The significant components of deferred tax assets and deferred tax liabilities included on the consolidated balance sheet are:

 Years Ended October 31,
 20202019
 (in millions)
Deferred Tax Assets
Intangibles$153 $131 
Pension benefits and retiree medical benefits65 71 
Employee benefits, other than retirement31 34 
Net operating loss, capital loss, and credit carryforwards182 195 
Share-based compensation27 32 
Deferred revenue22 38 
Lease obligations35 — 
Other41 35 
Deferred tax assets$556 $536 
Tax valuation allowance(132)(134)
Deferred tax assets, net of valuation allowance$424 $402 
Deferred Tax Liabilities
Property, plant and equipment$(19)$(16)
Right-of-use asset(35)— 
Other(14)(7)
Deferred tax liabilities$(68)$(23)
Net deferred tax assets (liabilities)$356 $379 

Valuation allowances require an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction by jurisdiction basis. As of October 31, 2020, we continued to maintain a valuation allowance of $132 million until sufficient positive evidence exists to support reversal. The valuation allowance is primarily related to deferred tax assets for the states of California and Colorado, along with the net operating losses in the Netherlands and capital losses in the U.S. and Australia.

At October 31, 2020, we had federal, state and foreign net operating loss carryforwards of approximately $11 million, $530 million and $411 million, respectively. The federal and state net operating loss carryforwards are subject to various limitations under Section 382 of the Internal Revenue Code and applicable state tax laws. If not utilized, the federal and state net operating loss carryforwards will begin to expire in 2021. If not utilized, $123 million of the foreign net operating loss carryforwards will begin to expire in 2021. The remaining $288 million of the foreign net operating losses carry forward indefinitely. At October 31, 2020, we had federal and foreign capital loss carryforwards of $48 million and $118 million, respectively. If not utilized, the federal capital loss carryforwards will expire in 2022. The foreign capital losses carry forward indefinitely. At October 31, 2020, we had state tax credit carryforwards of approximately $83 million. The state tax credits carry forward indefinitely.

The breakdown between long-term deferred tax assets and deferred tax liabilities was as follows:

 October 31,
 20202019
 (in millions)
Long-term deferred tax assets (included within other assets)$380 $410 
Long-term deferred tax liabilities (included within other long-term liabilities)(24)(31)
Total$356 $379 
The breakdown between current and long-term income tax assets and liabilities, excluding deferred tax assets and liabilities, was as follows:
October 31,
20202019
(in millions)
Current income tax assets (included within other current assets)$89 $68 
Long-term income tax assets (included within other assets)6 4 
Current income tax liabilities (included within other accrued liabilities)(63)(292)
Long-term income tax liabilities (included within other long-term liabilities)(323)(328)
Total$(291)$(548)

Uncertain Tax Positions

The aggregate changes in the balances of our gross unrecognized tax benefits including all federal, state and foreign tax jurisdictions are as follows:

202020192018
 (in millions)
Balance, beginning of year$206 $214 $224 
Additions for tax positions related to the current year6 7 27 
Additions for tax positions from prior years— 12 2 
Reductions for tax positions from prior years— (2)(13)
Statute of limitations expirations(17)(25)(26)
Balance, end of year$195 $206 $214 

As of October 31, 2020, we had $240 million of unrecognized tax benefits, including interest and penalties of which $215 million, if recognized, would affect our effective tax rate. However, approximately $25 million of the unrecognized tax benefits were related to state income tax positions that, if recognized, would be in the form of a deferred tax asset that would likely not affect our effective tax rate due to a valuation allowance.

We recognized tax expense of $8 million, $9 million and $11 million for interest and penalties related to unrecognized tax benefits in 2020, 2019 and 2018, respectively. Interest and penalties accrued as of October 31, 2020 and 2019 were $45 million and $36 million, respectively.

In the U.S., tax years remain open back to the year 2017 for federal income tax purposes and for significant states. In other major jurisdictions where the company conducts business, the tax years generally remain open back to the year 2009.

With these jurisdictions and the U.S., it is reasonably possible that there could be significant changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitation or a tax audit settlement which will be partially offset by an anticipated tax liability related to unremitted foreign earnings, where applicable. Given the number of years and numerous matters that remain subject to examination in various tax jurisdictions, management is unable to estimate the range of possible changes to the balance of our unrecognized tax benefits.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.20.4
NET INCOME (LOSS) PER SHARE
 12 Months Ended
Oct. 31, 2020
Earnings Per Share [Abstract]  
NET INCOME (LOSS) PER SHARE NET INCOME PER SHARE
The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented below.
 Years Ended October 31,
 202020192018
 (in millions)
Numerator:   
Net income$719 $1,071 $316 
Denominators:   
Basic weighted average shares309 314 321 
Potential common shares — stock options and other employee stock plans3 4 4 
Diluted weighted average shares312 318 325 

The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense collectively are assumed proceeds to be used to repurchase hypothetical shares. An increase in the fair market value of the company's common stock can result in a greater dilutive effect from potentially dilutive awards.

We exclude stock options with exercise prices greater than the average market price of our common stock from the calculation of diluted earnings per share because their effect would be anti-dilutive. In addition, we exclude from the calculation of diluted earnings per share, stock options, ESPP, LTPP and restricted stock awards whose combined exercise price and unamortized fair value collectively were greater than the average market price of our common stock because their effect would also be anti-dilutive.

In 2020, 2019 and 2018, we issued share-based awards of approximately 2 million each year.  For the years ended 2020, 2019 and 2018, the impacts of the anti-dilutive potential common shares that were excluded from the calculation of diluted earnings per share were not material.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.20.4
INVENTORY
 12 Months Ended
Oct. 31, 2020
Inventory Disclosure [Abstract]  
INVENTORY INVENTORY
Inventory as of October 31, 2020 and 2019 consisted of the following:
 October 31,
 20202019
 (in millions)
Finished goods$417 $416 
Purchased parts and fabricated assemblies303 263 
Inventory$720 $679 

Inventory-related excess and obsolescence charges of $28 million were recorded in cost of products in 2020, $19 million in 2019 and $26 million in 2018. We record excess and obsolete inventory charges for both inventory on our site as well as inventory at our contract manufacturers and suppliers where we have non-cancelable purchase commitments.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.20.4
PROPERTY, PLANT AND EQUIPMENT, NET
 12 Months Ended
Oct. 31, 2020
Property, Plant and Equipment [Abstract]  
PROPERTY, PLANT AND EQUIPMENT, NET PROPERTY, PLANT AND EQUIPMENT, NET
Property, plant and equipment as of October 31, 2020 and 2019, consisted of the following:
 October 31,
 20202019
 (in millions)
Land$58 $57 
Buildings and leasehold improvements1,055 1,012 
Machinery and equipment579 546 
Software182 160 
Total property, plant and equipment1,874 1,775 
Accumulated depreciation and amortization(1,029)(925)
Property, plant and equipment, net$845 $850 

In 2020 we recorded $6 million in asset impairments related to the shutdown of our sequencer development program. There were no asset impairments in 2019 and less than $1 million in asset impairments in 2018. Depreciation expenses were $119 million in 2020, $111 million in 2019 and $102 million in 2018. In 2020 and 2019 we retired approximately $29 million and $23 million, respectively, of fully depreciated assets that were no longer in use.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES
 12 Months Ended
Oct. 31, 2020
Leases [Abstract]  
Lessee, Operating Leases LEASES
As a lessee, we have various non-cancelable operating lease agreements for office space, warehouses, distribution centers, research and development facilities, manufacturing and production locations as well as vehicles, personal computers and other equipment. Our real estate leases have remaining lease terms of one to thirty years, which represent the non-cancelable periods of the leases and include extension options that we determined are reasonably certain to be exercised. We exclude options that are not reasonably certain to be exercised from our lease terms, ranging from six months to twenty years. Our lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms. We often receive incentives from our landlords, such as rent abatement periods, which effectively reduce the total lease payments owed for these leases. Vehicle, personal computer and other equipment operating leases have terms between three and five years.

Prior to the adoption of the new lease accounting standard, future minimum lease payments as of October 31, 2019 under non-cancelable leases with initial terms exceeding twelve months were as follows:

Operating Leases
(in millions)
2020$52 
2021$41 
2022$29 
2023$21 
2024$14 
Thereafter$56 

The components of lease cost for operating leases were as follows:
Year Ended October 31, 2020
(in millions)
Operating lease cost$60 
Short-term lease cost1 
Variable lease cost (a)
14 
Sublease income(14)
Total lease cost$61 
(a) Variable lease cost includes cancelable leases, non-fixed maintenance costs and non-recoverable transaction taxes.

Total rent expense was $75 million in 2019 and $64 million in 2018.

Supplemental cash flow information related to leases was as follows:
Year Ended October 31, 2020
(in millions)
Cash paid for amounts included in the amounts included in the measurement of lease liabilities:
Operating cash flow from operating leases$59 
Non-cash right of use assets obtained in exchange for operating lease obligations$37 

Supplemental balance sheet information related to leases was as follows:
Financial Statement Line ItemOctober 31, 2020
(in millions, except lease term and discount rate)
Assets:
Operating lease:
Right of use assetOther assets$175 
Liabilities:
Current
Operating lease liabilitiesOther accrued liabilities$51 
Long-term
Operating lease liabilitiesOther long-term liabilities$127 
Weighted average remaining lease term (in years)
Operating leases7.9 years
Weighted average discount rate
Operating leases2.1 %

Future minimum rents payable as of October 31, 2020 under non-cancelable leases with initial terms exceeding one year reconcile to lease liabilities included in the consolidated balance sheet as follows:
Operating Leases
(in millions)
2021$54 
202241 
202328 
202416 
20259 
Thereafter49 
Total undiscounted future minimum lease payments$197 
Less: amount of lease payments representing interest(19)
Present value of future minimum lease payments$178 
Less: current liabilities(51)
Long-term lease liabilities$127 

As of October 31, 2020, we had no additional significant operating or finance leases that had not yet commenced.

As a lessor, we have contracts for equipment leased to customers in connection with our diagnostics business which include both operating-type lease and sales-type lease arrangements. We account for the non-lease component under the revenue recognition ASC 606 guidance and the lease component under the leasing ASC 842 guidance. Equipment lease revenue for operating lease agreements is recognized as visualization kits and reagents are shipped over the life of the lease, and the cost of customer leased equipment is recorded within property, plant and equipment, net in the consolidated balance sheet and depreciated over the equipment’s estimated useful life. For an arrangement that has been classified as a sales-type lease, revenue is recognized when the transfer of control of the underlying leased asset has occurred and the net investment lease recorded which is calculated at the present value of the remaining lease payments due from the lessee.
Revenue allocated to the lease income for both finance/sales-type lease and operating lease rental arrangements represents less than one percent of total net revenue in the year ended October 31, 2020.

As of October 31, 2020, the original cost and net book value of operating leased assets was $43 million and $12 million, respectively. As of October 31, 2020, lease receivables related to sales-type leases were $44 million. As of October 31, 2019, the original cost and net book value of operating leased assets was $49 million and $17 million, respectively. As of October 31, 2019, lease receivables related to sales-type leases were $37 million.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.20.4
GOODWILL AND OTHER INTANGIBLE ASSETS
 12 Months Ended
Oct. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS
The following table presents goodwill balances and the movements for each of our reportable segments during the years ended October 31, 2019 and 2020:
Life Sciences and Applied MarketsDiagnostics and GenomicsAgilent CrossLabTotal
 (in millions)
Goodwill as of October 31, 2018$803 $1,607 $563 $2,973 
Foreign currency translation impact(1)(2)(2)(5)
Goodwill arising from acquisitions636 (11)— 625 
Goodwill as of October 31, 2019$1,438 $1,594 $561 $3,593 
Foreign currency translation impact3 5 1 9 
Goodwill as of October 31, 2020$1,441 $1,599 $562 $3,602 

As of September 30, 2020, our annual impairment test date, we assessed goodwill for triggering events and circumstances, including impacts due to COVID-19, and determined no impairment of goodwill was indicated for our reporting units.

The component parts of other intangible assets at October 31, 2019 and 2020 are shown in the table below:
 Other Intangible Assets
 Gross
Carrying
Amount		Accumulated
Amortization		Net Book
Value
 (in millions)
As of October 31, 2019:   
Purchased technology$1,413 $763 $650 
Backlog5 5 — 
Trademark/Tradename196 102 94 
Customer relationships329 87 242 
Third-party technology and licenses28 22 6 
Total amortizable intangible assets$1,971 $979 $992 
In-Process R&D115 — 115 
Total$2,086 $979 $1,107 
As of October 31, 2020:   
Purchased technology$1,429 $863 $566 
Trademark/Tradename196 117 79 
Customer relationships330 158 172 
Third-party technology and licenses11 7 4 
Total amortizable intangible assets$1,966 $1,145 $821 
In-Process R&D10 — 10 
Total$1,976 $1,145 $831 


During fiscal year 2020, we recorded no additions to goodwill or to intangible assets. During the year ended October 31, 2020 we moved $15 million of in-process research and development intangible assets to purchased technology on the completion of three projects.
During fiscal year 2019, we recorded additions to goodwill of $636 million and to other intangible assets of $744 million related to the acquisition of ACEA Biosciences and BioTek. In the second quarter of fiscal year 2019, we recorded a measurement period adjustment to goodwill of $11 million for deferred tax assets related to pre-acquisition net operating losses of Advanced Analytical Technologies, Inc. The increase to other intangible assets due to foreign currency translation was not material in 2019.

In general, for United States federal tax purposes, goodwill from asset purchases is amortizable; however, any goodwill created as part of a stock acquisition is not deductible.

During fiscal year 2020, we recorded an impairment of in-process research and development of $90 million in research and development expenses in the consolidated statement of operations which was related to the shutdown of our sequencer development program in our diagnostics and genomics segment. There were no impairments of indefinite-lived intangible assets during fiscal year 2019 and 2018. During fiscal years 2020 and 2019, there were no impairments of finite-lived intangible assets recorded. During 2018, we recorded an impairment of $21 million related to purchased intangible assets within the diagnostics and genomics segment that were deemed unrecoverable.

During 2020, we also wrote-off the gross carrying amount of $17 million and the related accumulated amortization of fully amortized intangible assets which were no longer being used.

Amortization expense of intangible assets was $186 million in 2020, $128 million in 2019, and $110 million in 2018.

Future amortization expense related to existing finite-lived purchased intangible assets associated with business combinations for the next five fiscal years and thereafter is estimated below:
Estimated future amortization expense:
(in millions)
2021$174 
2022$151 
2023$109 
2024$87 
2025$70 
Thereafter$230 
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.20.4
INVESTMENTS
 12 Months Ended
Oct. 31, 2020
Schedule of Investments [Abstract]  
INVESTMENTS INVESTMENTS
The following table summarizes the company's equity investments as of October 31, 2020 and 2019 (net book value):

 October 31,
 20202019
 (in millions)
Long-Term  
Equity investments - without readily determinable fair value$103 $47 
Equity investments - with readily determinable fair value25 25 
Trading securities30 30 
Total$158 $102 

Equity investments without readily determinable fair value (RDFV) consist of non-marketable equity securities issued by private companies. These investments are accounted for using the measurement alternative at cost adjusting for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer). The adjustments are included in net income in the period in which they occur. Equity investments with RDFV consist of shares we own in a special fund and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. Prior to fiscal year 2019, both equity investments without RDFV and with RDFV were accounted for using cost method of accounting, measured at historical cost less other-than-temporary impairment. Trading securities are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in earnings.
Our investments without RDFV are subject to periodic impairment review. The impairment analysis requires significant judgment to identify events or circumstances that would likely have a significant adverse effect on the future value of the investment.

We recorded a net unrealized loss on our equity securities with RDFV of $1 million in 2020 and a net unrealized gain of $3 million in 2019. Net unrealized gains on our equity securities without RDFV were $27 million and $1 million in 2020 and 2019, respectively. Upon adoption of new accounting guidance relating to financial instruments beginning fiscal year 2019, the gains and losses on such securities are recognized in other income (expense) and therefore not applicable in prior periods. As of November 1, 2019, total impact of adoption of this accounting guidance to our consolidated balance sheet was an increase of $7 million to equity securities with RDFV (included within long-term investments) and a net increase of $5 million to beginning retained earnings.

Net unrealized gains on our trading securities portfolio were $2 million in 2020, $3 million in 2019 and $1 million in 2018.
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE MEASUREMENTS
 12 Months Ended
Oct. 31, 2020
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
The authoritative guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market and assumptions that market participants would use when pricing the asset or liability.

Fair Value Hierarchy

The guidance establishes a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into three levels. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value:

Level 1 — applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2 — applies to assets or liabilities for which there are inputs other than quoted prices included within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less active markets; or other inputs that can be derived principally from, or corroborated by, observable market data.

Level 3 — applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2020 were as follows:

  Fair Value Measurement at October 31, 2020 Using
 October 31,
2020		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
 (in millions)
Assets:    
Short-term    
Cash equivalents (money market funds)$740 $740 $— $— 
Derivative instruments (foreign exchange contracts)2 — 2 — 
Long-term    
Trading securities30 30 — — 
Other investments25 — 25 — 
Total assets measured at fair value$797 $770 $27 $— 
Liabilities:    
Short-term    
Derivative instruments (foreign exchange contracts)$17 $— $17 $— 
Long-term    
Deferred compensation liability30 — 30 — 
Total liabilities measured at fair value$47 $— $47 $— 

Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2019 were as follows:

  Fair Value Measurement
at October 31, 2019 Using
 October 31,
2019		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
 (in millions)
Assets:    
Short-term    
Cash equivalents (money market funds)$784 $784 $— $— 
Derivative instruments (foreign exchange contracts)12 — 12 — 
Long-term    
Trading securities30 30 — — 
Other investments25 — 25 — 
Total assets measured at fair value$851 $814 $37 $— 
Liabilities:   
Short-term    
Derivative instruments (foreign exchange contracts)$6 $— $6 $— 
Long-term    
Deferred compensation liability30 — 30 — 
Total liabilities measured at fair value$36 $— $36 $— 

Our money market funds and trading securities are generally valued using quoted market prices and therefore are classified within level 1 of the fair value hierarchy. Our derivative financial instruments are classified within level 2, as there is not an active market for each hedge contract, but the inputs used to calculate the value of the instruments are tied to active markets. Our deferred compensation liability is classified as level 2 because, although the values are not directly based on
quoted market prices, the inputs used in the calculations are observable. Other investments represent shares we own in a special fund that targets underlying investments of approximately 40 percent in debt securities and 60 percent in equity securities. It has been classified as level 2 because, although the shares of the fund are not traded on any active stock exchange, each of the individual underlying securities are or can be derived from and hence we have a readily determinable value for the underlying securities, from which we are able to determine the fair market value for the special fund itself.

Trading securities, which are comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Certain derivative instruments are reported at fair value, with unrealized gains and losses, net of tax, included in accumulated other comprehensive income (loss) within stockholders' equity. Realized gains and losses from the sale of these instruments are recorded in net income.

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

Long-Lived Assets

For assets measured at fair value on a non-recurring basis, the following table summarizes the impairments included in net income for the years ended October 31, 2020, 2019 and 2018:

 Years Ended
October 31,
 202020192018
 (in millions)
Long-lived assets held and used$98 $— $21 
Long-lived assets held for sale$— $— $— 

For the year ended October 31, 2020, long-lived assets held and used, including indefinite lived in-process research and development intangible assets, with a carrying amount of $98 million were written down to their fair value of zero, resulting in an impairment charge of $98 million related to the shutdown of our sequencer development program and other assets in our diagnostics and genomics segment. There were no impairments of long-lived assets held and used in 2019. For 2018, long lived assets held and used with a carrying amount of $21 million were written down to their fair value of zero, resulting in an impairment charge of $21 million, which relates to purchased intangible assets within the diagnostics and genomics segment that were deemed unrecoverable and were included in net income.

There were no impairments of long-lived assets held for sale in 2020, 2019 and 2018.

Fair values for the impaired long-lived assets during 2020 and 2018 were measured using level 3 inputs. To determine the fair value of long-lived assets in 2020 and 2018, we used the income approach based on projected discounted cash flows expected to be generated by the long-lived assets over the remaining useful life.

For the year ended October 31, 2020 and 2019, there were no impairments in non-marketable securities without readily determinable fair value. For the year ended October 31, 2020 and 2019, a net unrealized gain of $27 million and $1 million, respectively, was included in net income as an adjustment to the carrying value of non-marketable equity securities without readily determinable fair value based on an observable market transaction. As of October 31, 2020 and 2019, the carrying amount of non-marketable equity securities without readily determinable fair values was $103 million and $47 million, respectively.

Fair values for the non-marketable securities included in long-term investments on the consolidated balance sheet were measured using Level 3 inputs because they are primarily equity stock issued by private companies without quoted market prices. To estimate the fair value of our non-marketable securities, we use the measurement alternative to record these investments at cost and adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) as and when they occur.
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.20.4
DERIVATIVES
 12 Months Ended
Oct. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVES DERIVATIVES
We are exposed to foreign currency exchange rate fluctuations and interest rate changes in the normal course of our business. As part of our risk management strategy, we use derivative instruments, primarily forward contracts and purchased options to hedge economic and/or accounting exposures resulting from changes in foreign currency exchange rates.

Cash Flow Hedges

We enter into foreign exchange contracts to hedge our forecasted operational cash flow exposures resulting from changes in foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities between one and twelve months. These derivative instruments are designated and qualify as cash flow hedges under the criteria prescribed in the authoritative guidance and are assessed for effectiveness against the underlying exposure every reporting period. For open contracts as of October 31, 2020, changes in the time value of the foreign exchange contract are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the foreign exchange contract. The changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss).  Amounts associated with cash flow hedges are reclassified to cost of sales in the consolidated statement of operations when the forecasted transaction occurs. If it becomes probable that the forecasted transaction will not occur, the hedge relationship will be de-designated and amounts accumulated in other comprehensive income (loss) will be reclassified to other income (expense), net in the current period. Changes in the fair value of the ineffective portion of derivative instruments are recognized in other income (expense), net in the consolidated statement of operations in the current period. We record the premium paid (time value) of an option on the date of purchase as an asset. For options designated as cash flow hedges, changes in the time value are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the option contract. For the years ended October 31, 2020, 2019 and 2018, ineffectiveness and gains and losses recognized in other income (expense), net due to de-designation of cash flow hedge contracts were not significant.

In July 2012, Agilent executed treasury lock agreements for $400 million in connection with future interest payments to be made on our 2022 senior notes issued on September 13, 2012. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 10, 2012, and we recognized a deferred gain in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2022 senior notes. The remaining gain to be amortized related to the treasury lock agreements at October 31, 2020 was less than $1 million.

In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. These derivative instruments were designated and qualified as cash flow hedges under the criteria prescribed in the authoritative guidance. The swap arrangements were terminated on September 15, 2016 with a payment of $10 million, and we recognized this as a deferred loss in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at October 31, 2020 was $6 million.

In August 2019, Agilent executed treasury lock agreements for $250 million in connection with future interest payments to be made on our 2029 senior notes issued on September 16, 2019. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 6, 2019 and we recognized a deferred loss of $6 million in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2029 senior notes. The remaining loss to be amortized related to the treasury lock agreements at October 31, 2020 was $5 million.

Net Investment Hedges

Starting in 2020, we enter into foreign exchange contracts to hedge net investments in foreign operations to mitigate the risk of adverse movements in exchange rates. These foreign exchange contracts are carried at fair value and are designated and qualify as net investment hedges under the criteria prescribed in the authoritative guidance. Changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss) and are assessed for effectiveness against the underlying exposure every reporting period. If the company’s net investment changes during the year, the hedge relationship will be assessed and de-designated if the hedge notional amount is outside of prescribed tolerance with a gain/loss reclassified from other comprehensive income (loss) to other income (expense) in the current period.

As of October 31, 2020, we have 3 open forward contracts to sell euros to buy USD maturing in the first quarter of fiscal year 2021, and these are designated as a net investment hedge of the U.S. parent's interest in foreign subsidiaries denominated in euro functional currency. In the year ended October 31, 2020, the change in fair value of the net investment hedge resulted in
a net loss of $5 million recognized in accumulated other comprehensive income. For the year ended October 31, 2020, ineffectiveness and the resultant effect of any gains or losses recognized in other income (expense) due to de-designation of the hedge contracts were not significant.

Other Hedges

Additionally, we enter into foreign exchange contracts to hedge monetary assets and liabilities that are denominated in currencies other than the functional currency of our subsidiaries. These foreign exchange contracts are carried at fair value and do not qualify for hedge accounting treatment and are not designated as hedging instruments. Changes in value of the derivative instruments are recognized in other income (expense), net in the consolidated statement of operations, in the current period, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.

Our use of derivative instruments exposes us to credit risk to the extent that the counterparties may be unable to meet the terms of the agreement. We do, however, seek to mitigate such risks by limiting our counterparties to major financial institutions which are selected based on their credit ratings and other factors. We have established policies and procedures for mitigating credit risk that include establishing counterparty credit limits, monitoring credit exposures, and continually assessing the creditworthiness of counterparties.

A number of our derivative agreements contain threshold limits to the net liability position with counterparties and are dependent on our corporate credit rating determined by the major credit rating agencies. The counterparties to the derivative instruments may request collateralization, in accordance with derivative agreements, on derivative instruments in net liability positions.

The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position as of October 31, 2020, was $16 million. The credit-risk-related contingent features underlying these agreements had not been triggered as of October 31, 2020.

There were 270 foreign exchange forward contracts open as of October 31, 2020 and designated as cash flow hedges. There were 183 foreign exchange forward contracts open as of October 31, 2020 not designated as hedging instruments. There were 3 foreign exchange forward contracts open as of October 31, 2020 and designated as a net investment hedge. The aggregated notional amounts by currency and designation as of October 31, 2020 were as follows:
 Derivatives Designated as
Cash Flow Hedges
Derivatives Designated as
Net Investment Hedges		Derivatives
Not
Designated
as Hedging
Instruments
 Forward
Contracts USD		Forward
Contracts USD		Forward
Contracts USD
CurrencyBuy/(Sell)Buy/(Sell)Buy/(Sell)
 (in millions)
Euro$(59)$(94)$17 
British Pound(41)— 7 
Canadian Dollar(33)— (7)
Japanese Yen(83)— (39)
Korean Won(58)— (32)
Singapore Dollar12 — 23 
Chinese Yuan Renminbi(74)— (66)
Swedish Krona— — (10)
Taiwan Dollar— — (14)
India Rupee— — (15)
Other4 — 2 
$(332)$(94)$(134)
Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of October 31, 2020 and 2019 were as follows:

Fair Values of Derivative Instruments
Asset DerivativesLiability Derivatives
 Fair Value Fair Value
Balance Sheet LocationOctober 31,
2020		October 31,
2019		Balance Sheet LocationOctober 31,
2020		October 31,
2019
(in millions)
Derivatives designated as hedging instruments:     
Cash flow hedges     
Foreign exchange contracts     
Other current assets$— $3 Other accrued liabilities$12 $2 
Derivatives not designated as hedging instruments:     
Foreign exchange contracts     
Other current assets$2 $9 Other accrued liabilities$5 $4 
Total derivatives$2 $12  $17 $6 

The effects of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows:

Years Ended October 31,
202020192018
 (in millions)
Derivatives designated as hedging instruments:   
Cash flow hedges   
Foreign exchange contracts:
Loss on interest rate swaps recognized in other comprehensive income (loss)$— $(6)$— 
Loss reclassified from accumulated other comprehensive income (loss) into interest expense$(1)$(1)$(1)
Gain (loss) recognized in accumulated other comprehensive income (loss)$(12)$— $7 
Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales$(1)$9 $(3)
Gain (loss) on time value of forward contracts recorded in cost of sales$2 $2 $— 
Net investment hedges
Foreign exchange contracts:
Loss recognized in accumulated other comprehensive income (loss)$(5)$— $— 
Derivatives not designated as hedging instruments:   
Gain (loss) recognized in other income (expense), net $(1)$2 $(2)

At October 31, 2020 the estimated amount of existing net loss that is expected to be reclassified from accumulated other comprehensive income (loss) to cost of sales within the next twelve months is $7 million.
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.20.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS
 12 Months Ended
Oct. 31, 2020
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]  
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS
General.  Substantially all of our employees are covered under various defined benefit and/or defined contribution retirement plans. Additionally, we sponsor post-retirement health care benefits for our eligible U.S. employees.

Agilent provides defined benefits to U.S. employees who meet eligibility criteria under the Agilent Technologies, Inc. Retirement Plan (the "RP").

For eligible service through October 31, 1993, the benefit payable under the Agilent Retirement Plan is reduced by any amounts due to the eligible employee under the Agilent defined contribution Deferred Profit-Sharing Plan (the "DPSP"), which was closed to new participants as of November 1993.

As of October 31, 2020 and 2019, the fair value of plan assets of the DPSP was $123 million and $132 million, respectively. Note that the projected benefit obligation for the DPSP equals the fair value of plan assets.

Effective November 1, 2014, Agilent’s U.S. defined benefit retirement plan was closed to new entrants including new employees, new transfers to the U.S. payroll and rehires. As of April 30, 2016, benefits under the RP were frozen. Any pension benefit earned in the U.S. Plans through April 30, 2016 remained fully vested, and there are no additional benefit accruals after April 30, 2016.

Agilent also maintains a Supplemental Benefits Retirement Plan ("SBRP") in the U.S., which is a supplemental unfunded non-qualified defined benefit plan to provide benefits that would be provided under the RP but for limitations imposed by the Internal Revenue Code. The RP and the SBRP comprise the "U.S. Plans" in the tables below.

Eligible employees outside the U.S. generally receive retirement benefits under various retirement plans based upon factors such as years of service and/or employee compensation levels. Eligibility is generally determined in accordance with local statutory requirements.

Post-Retirement Medical Benefit Plans.  In addition to receiving retirement benefits, Agilent U.S. employees who meet eligibility requirements as of their termination date may participate in the Agilent Technologies, Inc. Health Plan for Retirees.
–Eligible retirees who were less than age 50 as of January 1, 2005 and who retire after age 55 with 15 or more years of service are eligible for a fixed amount which can be utilized to pay for either sponsored plans and/or individual Medicare plans.
–Effective January 1, 2012, employees who were at least age 50 as of January 1, 2005 and who retire after age 55 with 15 or more years of service are eligible for fixed dollar subsidies and stipends. Grandfathered retirees receive a fixed monthly subsidy toward pre-65 premium costs (subsidy capped at 2011 levels) and a fixed monthly stipend post-65. The subsidy amounts will not increase.
–Any new employee hired on or after November 1, 2014, will not be eligible to participate in the retiree medical plans upon retiring.
–As of April 30, 2016, benefits under this plan were changed for Active employees who have not met the eligibility requirement - 55 years old with at least 15 years of Agilent service, as of April 30, 2016 - for the Retiree Medical Account (RMA) under the U.S. Post Retirement Benefit Plan. These employees will only be eligible for 50 percent of the current RMA reimbursement amount upon retirement.

401(k) Defined Contribution Plan.  Eligible Agilent U.S. employees may participate in the Agilent Technologies, Inc. 401(k) Plan. We match contributions to employees up to a maximum of 6 percent of an employee's annual eligible compensation. Effective May 1, 2016 until April 30, 2022, we will provide an additional transitional company contribution for certain eligible employees equal to 3 percent, 4 percent or 5 percent of an employee's annual eligible compensation due to the RP benefits being frozen. The maximum contribution to the 401(k) Plan is 50 percent of an employee's annual eligible compensation, subject to regulatory limitations. The 401(k) Plan employer expense included in income from operations was $41 million in 2020, $39 million in 2019 and $37 million in 2018.
Components of Net periodic cost.  The service cost component is recorded in cost of sales and operating expenses in the consolidated statement of operations. All other cost components are recorded in other income (expense), net in the consolidated statement of operations. The company uses alternate methods of amortization as allowed by the authoritative guidance which amortizes the actuarial gains and losses on a consistent basis for the years presented. For U.S. Plans, gains and losses are amortized over the average future lifetime of participants using the corridor method. For most Non-U.S. Plans and U.S. Post-Retirement Benefit Plans, gains and losses are amortized using a separate layer for each year's gains and losses.

For the years ended October 31, 2020, 2019 and 2018, components of net periodic benefit cost and other amounts recognized in other comprehensive income were comprised of:
 PensionsU.S. Post-Retirement Benefit Plans
 U.S. PlansNon-U.S. Plans
 202020192018202020192018202020192018
 (in millions)
Net periodic benefit cost (benefit)         
Service cost — benefits earned during the period$— $— $— $24 $20 $20 $1 $— $1 
Interest cost on benefit obligation15 18 16 8 14 13 3 4 3 
Expected return on plan assets(28)(27)(28)(47)(43)(46)(7)(7)(7)
Amortization of net actuarial loss3 1 1 49 34 29 4 4 8 
Amortization of prior service benefit— — — — — — (7)(8)(8)
Total periodic benefit cost (benefit)$(10)$(8)$(11)$34 $25 $16 $(6)$(7)$(3)
Settlement (gain) loss$4 $— $— $— $— $(5)$— $— $— 
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss         
Net actuarial (gain) loss$26 $51 $2 $20 $104 $49 $5 $5 $(2)
Amortization of net actuarial loss(3)(1)(1)(49)(34)(29)(4)(4)(8)
Amortization of prior service benefit— — — — — — 7 8 8 
Loss due to settlement(4)— — — — — — — — 
Foreign currency— — — 10 (3)1 — — — 
Total recognized in other comprehensive (income) loss$19 $50 $1 $(19)$67 $21 $8 $9 $(2)
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss$13 $42 $(10)$15 $92 $32 $2 $2 $(5)
Funded Status.    As of October 31, 2020 and 2019, the funded status of the defined benefit and post-retirement benefit plans was:

 U.S. Defined
Benefit Plans		Non-U.S. Defined
Benefit Plans		U.S.
Post-Retirement
Benefit Plans
 202020192020201920202019
 (in millions)
Change in fair value of plan assets:      
Fair value — beginning of year$432 $401 $911 $825 $95 $90 
Actual return on plan assets30 50 (2)85 6 11 
Employer contributions— — 32 21 — — 
Participants' contributions— — 1 1 — — 
Benefits paid(8)(19)(31)(29)(8)(6)
Settlements(15)— — — — — 
Currency impact— — 34 8 — — 
Fair value — end of year$439 $432 $945 $911 $93 $95 
Change in benefit obligation:      
Benefit obligation — beginning of year$491 $420 $1,067 $913 $94 $87 
Service cost— — 24 20 1 — 
Interest cost15 18 8 14 3 4 
Participants' contributions— — 1 1 — — 
Actuarial (gain) loss28 74 (19)143 4 9 
Benefits paid(9)(21)(31)(29)(8)(6)
Settlements(15)— — — — — 
Currency impact— — 44 5 — — 
Benefit obligation — end of year$510 $491 $1,094 $1,067 $94 $94 
Overfunded (underfunded) status of PBO$(71)$(59)$(149)$(156)$(1)$1 
Amounts recognized in the consolidated balance sheet consist of:      
Other assets$— $— $123 $106 $— $1 
Employee compensation and benefits(1)(1)— — — — 
Retirement and post-retirement benefits(70)(58)(272)(262)(1)— 
Total net asset (liability)$(71)$(59)$(149)$(156)$(1)$1 
Amounts Recognized in Accumulated Other Comprehensive Income (Loss):
Actuarial (gains) losses$134 $115 $311 $330 $11 $10 
Prior service costs (benefits)— — — — (5)(12)
Total$134 $115 $311 $330 $6 $(2)

The amounts in accumulated other comprehensive income (loss) expected to be recognized by Agilent as components of net expense during 2021 are as follows:
U.S. Defined
Benefit Plans		Non-U.S. Defined
Benefit Plans		U.S. Post-Retirement
Benefit Plans
 (in millions)
Amortization of net prior service cost (benefit)$— $— $(1)
Amortization of actuarial net loss$4 $52 $4 
Investment Policies and Strategies as of October 31, 2020 and 2019. In the U.S., target asset allocations for our retirement and post-retirement benefit plans are approximately 80 percent to equities and approximately 20 percent to fixed income investments. Our DPSP target asset allocation is approximately 60 percent to equities and approximately 40 percent to fixed income investments. Approximately 1 percent of the retirement and post-retirement plans consist of limited partnerships. The general investment objective for all our plan assets is to obtain the optimum rate of investment return on the total investment portfolio consistent with the assumption of a reasonable level of risk. Specific investment objectives for the plans' portfolios are to: maintain and enhance the purchasing power of the plans' assets; achieve investment returns consistent with the level of risk being taken; and earn performance rates of return in accordance with the benchmarks adopted for each asset class. Outside the U.S., our target asset allocation ranges from 24 percent to 60 percent to equities, from 38 percent to 65 percent to fixed income investments, and from zero to 25 percent to real estate, depending on the plan. All plans' assets are broadly diversified. Due to fluctuations in equity markets, our actual allocations of plan assets at October 31, 2020 and 2019 differ from the target allocation. Our policy is to bring the actual allocation in line with the target allocation.

Equity securities include exchange-traded common stock and preferred stock of companies from broadly diversified industries. Fixed income securities include a global portfolio of corporate bonds of companies from diversified industries, government securities, mortgage-backed securities, asset-backed securities, derivative instruments and other. Other investments include a group trust consisting primarily of private equity partnerships. Portions of the cash and cash equivalent, equity, and fixed income investments are held in commingled funds that are valued using Net Asset Value (“NAV”) as the practical expedient. In addition, some of the investments valued using NAV as the practical expedient may have limits on their redemption to weekly or monthly and/or may require prior written notice specified by each fund.

Fair Value. The measurement of the fair value of pension and post-retirement plan assets uses the valuation methodologies and the inputs as described in Note 13, "Fair Value Measurements".

Cash and Cash Equivalents - Cash and cash equivalents consist of short-term investment funds. The funds also invest in short-term domestic fixed income securities and other securities with debt-like characteristics emphasizing short-term maturities and quality. Some of our cash and cash equivalents are held in commingled funds. Other cash and cash equivalents are classified as Level 1 investments.

Equity - Some equity securities consisting of common and preferred stock that are not traded on an active market are valued at quoted prices reported by investment dealers based on the underlying terms of the security and comparison to similar securities traded on an active market; these are classified as Level 2 investments. Securities which have quoted prices in active markets are classified as Level 1 investments.

Fixed Income - Some of the fixed income securities are not actively traded and are valued at quoted prices based on the terms of the security and comparison to similar securities traded on an active market; these are classified as Level 2 investments. Securities which have quoted prices in active markets are classified as Level 1 investments.

Other Investments - Other investments also include partnership investments where, due to their private nature, pricing inputs are not readily observable. Asset valuations are developed by the general partners that manage the partnerships. These valuations are based on proprietary appraisals, application of public market multiples to private company cash flows, utilization of market transactions that provide valuation information for comparable companies and other methods. Holdings of limited partnerships are classified as Level 3.

Agilent has adopted the accounting guidance related to the presentation of certain investments using the NAV practical expedient. The accounting guidance exempts investments using this practical expedient from categorization within the fair value hierarchy.
The following tables present the fair value of U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2020 and 2019.
  Fair Value Measurement
at October 31, 2020 Using
 October 31,
2020		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$1 $— $— $— $1 
Equity357 77 — — 280 
Fixed Income79 39 — — 40 
Other Investments2 — — 2 — 
Total assets measured at fair value$439 $116 $— $2 $321 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
  Fair Value Measurement
at October 31, 2019 Using
 October 31,
2019		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$1 $— $— $— $1 
Equity336 78 — — 258 
Fixed Income91 46 — — 45 
Other Investments4 — — 4 — 
Total assets measured at fair value$432 $124 $— $4 $304 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

For U.S. Defined Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2020 and 2019:
 Years Ended
October 31.
 20202019
Balance, beginning of year$4 $6 
Realized gains/(losses)(3)(1)
Unrealized gains/(losses)2 1 
Purchases, sales, issuances, and settlements(1)(2)
Transfers in (out)— — 
Balance, end of year$2 $4 
The following tables present the fair value of U.S. Post-Retirement Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2020 and 2019.
  Fair Value Measurement
at October 31, 2020 Using
 October 31,
2020		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$4 $— $— $— $4 
Equity70 17 — — 53 
Fixed Income18 9 — — 9 
Other Investments1 — — 1 — 
Total assets measured at fair value$93 $26 $— $1 $66 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

  Fair Value Measurement
at October 31, 2019 Using
 October 31,
2019		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$3 $— $— $— $3 
Equity69 18 — — 51 
Fixed Income21 11 — — 10 
Other Investments2 — — 2 — 
Total assets measured at fair value$95 $29 $— $2 $64 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.


For U.S. Post-Retirement Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2020 and 2019:
 Years Ended
October 31,
 20202019
Balance, beginning of year$2 $4 
Realized gains/(losses)(1)(1)
Unrealized gains/(losses)1 — 
Purchases, sales, issuances, and settlements(1)(1)
Transfers in (out)— — 
Balance, end of year$1 $2 
The following tables present the fair value of non-U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2020 and 2019:

  Fair Value Measurement
at October 31, 2020 Using
 October 31,
2020		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$7 $— $6 $— $1 
Equity504 315 48 — 141 
Fixed Income434 102 238 — 94 
Other Investments— — — — — 
Total assets measured at fair value$945 $417 $292 $— $236 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

  Fair Value Measurement
at October 31, 2019 Using
 October 31,
2019		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$1 $— $1 $— $— 
Equity512 318 61 — 133 
Fixed Income398 98 213 — 87 
Other Investments— — — — — 
Total assets measured at fair value$911 $416 $275 $— $220 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
The table below presents the combined projected benefit obligation ("PBO"), accumulated benefit obligation ("ABO") and fair value of plan assets, grouping plans using comparisons of the PBO and ABO relative to the plan assets as of October 31, 2020 or 2019.
 20202019
 Benefit
Obligation		 Benefit
Obligation		 
 Fair Value of
Plan Assets		Fair Value of
Plan Assets
 PBOPBO
 (in millions)
U.S. defined benefit plans where PBO exceeds the fair value of plan assets $510 $439 $491 $432 
U.S. defined benefit plans where fair value of plan assets exceeds PBO — — — — 
Total$510 $439 $491 $432 
Non-U.S. defined benefit plans where PBO exceeds or is equal to the fair value of plan assets $697 $425 $752 $490 
Non-U.S. defined benefit plans where fair value of plan assets exceeds PBO 397 520 315 421 
Total$1,094 $945 $1,067 $911 
 ABO ABO 
U.S. defined benefit plans where ABO exceeds the fair value of plan assets$510 $439 $491 $432 
U.S. defined benefit plans where the fair value of plan assets exceeds ABO— — — — 
Total$510 $439 $491 $432 
Non-U.S. defined benefit plans where ABO exceeds or is equal to the fair value of plan assets $675 $425 $651 $418 
Non-U.S. defined benefit plans where fair value of plan assets exceeds ABO387 520 381 493 
Total$1,062 $945 $1,032 $911 

Contributions and Estimated Future Benefit Payments.  During fiscal year 2021, we expect to make no contributions to the U.S. defined benefit plans and the Post-Retirement Medical Plans. We expect to contribute $22 million to plans outside the U.S. The following table presents expected future benefit payments for the next 10 years:

U.S. Defined
Benefit Plans		Non-U.S. Defined
Benefit Plans		U.S. Post-Retirement
Benefit Plans
 (in millions)
2021$33 $33 $8 
2022$31 $34 $8 
2023$33 $36 $7 
2024$34 $36 $7 
2025$33 $37 $7 
2026 - 2030$152 $192 $35 

Assumptions.  The assumptions used to determine the benefit obligations and expense for our defined benefit and post-retirement benefit plans are presented in the tables below. The expected long-term return on assets below represents an estimate of long-term returns on investment portfolios consisting of a mixture of equities, fixed income and alternative investments in proportion to the asset allocations of each of our plans. We consider long-term rates of return, which are weighted based on the asset classes (both historical and forecasted) in which we expect our pension and post-retirement funds to be invested. Discount rates reflect the current rate at which pension and post-retirement obligations could be settled based on the measurement dates of the plans - October 31. The U.S. discount rates at October 31, 2020 and 2019, were determined based on the results of
matching expected plan benefit payments with cash flows from a hypothetically constructed bond portfolio. The non-U.S. rates were generally based on published rates for high-quality corporate bonds. The range of assumptions that were used for the non-U.S. defined benefit plans reflects the different economic environments within various countries.

Assumptions used to calculate the net periodic cost in each year were as follows:

 For years ended October 31,
 202020192018
U.S. defined benefit plans:   
Discount rate3.25%4.50%3.75%
Expected long-term return on assets7.00%7.00%7.00%
Non-U.S. defined benefit plans:   
Discount rate
0.22-1.81%
0.83-2.68%
0.67-2.52%
Average increase in compensation levels
2.25-3.00%
2.25-3.25%
2.00-3.25%
Expected long-term return on assets
4.00-5.75%
4.00-5.75%
4.00-6.00%
U.S. post-retirement benefits plans:   
Discount rate3.00%4.25%3.50%
Expected long-term return on assets7.00%7.00%7.00%
Current medical cost trend rate6.25%6.00%6.00%
Ultimate medical cost trend rate4.50%3.50%3.50%
Medical cost trend rate decreases to ultimate rate in year202920292029

Assumptions used to calculate the benefit obligation were as follows:

 As of the Years Ending October 31,
 20202019
U.S. defined benefit plans:  
Discount rate2.75%3.25%
Non-U.S. defined benefit plans:  
Discount rate
0.07-1.54%
0.22-1.81%
Average increase in compensation levels
2.00-3.00%
2.25-3.00%
U.S. post-retirement benefits plans:  
Discount rate2.50%3.00%
Current medical cost trend rate6.25%6.25%
Ultimate medical cost trend rate4.50%4.50%
Medical cost trend rate decreases to ultimate rate in year20292029
Health care trend rates do not have a significant effect on the total service and interest cost components or on the post-retirement benefit obligation amounts reported for the U.S. Post-Retirement Benefit Plan for the year ended October 31, 2020
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.20.4
GUARANTEES
 12 Months Ended
Oct. 31, 2020
Guarantees [Abstract]  
GUARANTEES GUARANTEES
Standard Warranty

We accrue for standard warranty costs based on historical trends in actual warranty charges over the past 12 months. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost over the period. The standard warranty accrual balances are held in other accrued and other long-term liabilities on our consolidated balance sheet. Our standard warranty terms typically extend to one year from the date of delivery, depending on the product.
A summary of the standard warranty accrual activity is shown in the table below.

 October 31,
 20202019
 (in millions)
Standard warranty accrual, beginning balance$32 $35 
Accruals for warranties including change in estimates49 54 
Settlements made during the period(49)(57)
Standard warranty accrual, ending balance$32 $32 
Accruals for warranties due within one year$30 $32 
Accruals for warranties due after one year2 — 
Standard warranty accrual, ending balance$32 $32 

Bank Guarantees

Guarantees consist primarily of outstanding standby letters of credit and bank guarantees and were approximately $43 million and $40 million as of October 31, 2020 and 2019, respectively. A standby letter of credit is a guarantee of payment issued by a bank on behalf of us that is used as payment of last resort should we fail to fulfill a contractual commitment with a third party. A bank guarantee is a promise from a bank or other lending institution that if we default on a loan, the bank will cover the loss.

Indemnifications in Connection with Transactions

In connection with various divestitures, acquisitions, spin-offs and other transactions, we have agreed to indemnify certain parties, their affiliates and/or other related parties against certain damages and expenses that might occur in the future. These indemnifications may cover a variety of liabilities, including, but not limited to, employee, tax, environmental, intellectual property, litigation and other liabilities related to the business conducted prior to the date of the transaction. In our opinion, the fair value of these indemnification obligations was not material as of October 31, 2020.

Indemnifications to Officers and Directors

Our corporate bylaws require that we indemnify our officers and directors, as well as those who act as directors and officers of other entities at our request, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceedings arising out of their services to Agilent and such other entities, including service with respect to employee benefit plans. In addition, we have entered into separate indemnification agreements with each director and each board-appointed officer of Agilent which provide for indemnification of these directors and officers under similar circumstances and under additional circumstances. The indemnification obligations are more fully described in the bylaws and the indemnification agreements. We purchase standard insurance to cover claims or a portion of the claims made against our directors and officers. Since a maximum obligation is not explicitly stated in our bylaws or in our indemnification agreements and will depend on the facts and circumstances that arise out of any future claims, the overall maximum amount of the obligations cannot be reasonably estimated. Historically, we have not made payments related to these obligations, and the fair value for these indemnification obligations was not material as of October 31, 2020.

Other Indemnifications

As is customary in our industry and as provided for in local law in the U.S. and other jurisdictions, many of our standard contracts provide remedies to our customers and others with whom we enter into contracts, such as defense, settlement, or payment of judgment for intellectual property claims related to the use of our products. From time to time, we indemnify customers, as well as our suppliers, contractors, lessors, lessees, companies that purchase our businesses or assets and others with whom we enter into contracts, against combinations of loss, expense, or liability arising from various triggering events related to the sale and the use of our products and services, the use of their goods and services, the use of facilities and state of our owned facilities, the state of the assets and businesses that we sell and other matters covered by such contracts, usually up to a specified maximum amount. In addition, from time to time we also provide protection to these parties against claims related to
undiscovered liabilities, additional product liability or environmental obligations. In our experience, claims made under such indemnifications are rare and the associated estimated fair value of the liability was not material as of October 31, 2020.

In connection with the sale of several of our businesses, we have agreed to indemnify the buyers of such business, their respective affiliates and other related parties against certain damages that they might incur in the future. The continuing indemnifications primarily cover damages relating to liabilities of the businesses that Agilent retained and did not transfer to the buyers, as well as other specified items. In our opinion, the fair value of these indemnification obligations was not material as of October 31, 2020.
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.20.4
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Oct. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES
17.   COMMITMENTS AND CONTINGENCIES

Other Purchase Commitments.  Typically, we can cancel contracts with professional services suppliers without penalties. For those contracts that are not cancelable without penalties, there are termination fees and costs or commitments for continued spending that we are obligated to pay to a supplier under each contact's termination period before such contract can be cancelled. Our contractual obligations with these suppliers under "other purchase commitments" were approximately $85 million. Approximately $23 million of the penalties for the new contracts will reduce over the next 13 years.

Contingencies: We are involved in lawsuits, claims, investigations and proceedings, including, but not limited to, intellectual property, commercial, real estate, environmental and employment matters, which arise in the ordinary course of business. There are no matters pending that we currently believe are reasonably possible of having a material impact to our business, consolidated financial condition, results of operations or cash flows.
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.20.4
SHORT-TERM DEBT
 12 Months Ended
Oct. 31, 2020
Short-term Debt [Abstract]  
SHORT-TERM DEBT SHORT-TERM DEBT
Credit Facilities

On March 13, 2019, we entered into a credit agreement with a group of financial institutions which provides for a $1 billion five-year unsecured credit facility that will expire on March 13, 2024. For the year ended October 31, 2020, we borrowed $798 million and repaid $913 million under the credit facility. As of October 31, 2020, the company had no borrowings outstanding under the credit facility. On August 7, 2019, we entered into an amendment to the credit agreement, which provides for a $500 million short-term loan facility that was used in full to complete the BioTek acquisition and which was repaid in full as of October 31, 2020. On October 21, 2019, we entered into a second amendment to the credit agreement, which refreshed the amount available for additional incremental term loan facilities under the credit agreement to permit additional incremental facilities of up to $500 million. We had no borrowings under the additional incremental facilities as of October 31, 2020. On April 17, 2020, we entered into a third amendment to the credit agreement which provides the company with the option to request the consent of the applicable class of lenders to extend the maturity date of revolving borrowings and swingline loans for an additional period of one year and of the 2019 incremental term loans for an additional period of up to 364 days. We were in compliance with the covenants for the credit facility during the year ended October 31, 2020.

Commercial Paper

In May 2020, we established a U.S. commercial paper program, under which the company may issue and sell unsecured, short-term promissory notes in the aggregate principal amount not to exceed $1.0 billion with up to 397-day maturities. At any point in time, the company intends to maintain available commitments under its revolving credit facility in an amount at least equal to the amount of the commercial paper notes outstanding. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The proceeds from issuances under the program may be used for general corporate purposes. As of October 31, 2020, borrowings outstanding under our U.S. commercial paper program had a weighted average annual interest rate of 0.17 percent and a weighted average remaining maturity of approximately five days. We had borrowings of $75 million outstanding under the U.S. commercial paper program as of October 31, 2020.

2020 Senior Notes

On July 13, 2010, the company issued an aggregate principal amount of $500 million in senior notes ("2020 senior notes"). The 2020 senior notes were issued at 99.54% of their principal amount. The notes were scheduled to mature on July 15, 2020, and bear interest at a fixed rate of 5.00% per annum.

On August 9, 2011, we terminated our interest rate swap contracts related to our 2020 senior notes that represented the notional amount of $500 million. The asset value, including interest receivable, upon termination for these contracts was
approximately $34 million. The gain was deferred and amortized to interest expense over the remaining life of the 2020 senior notes.

On September 17, 2019, we repaid the $500 million outstanding aggregate principal amount of our 2020 senior notes due July 15, 2020 that were called for redemption on August 16, 2019. The redemption price of approximately $512 million included a $12 million prepayment penalty. The redemption price was computed in accordance with the terms of the 2020 senior notes as the present value of the remaining scheduled payments of principal and unpaid interest related to the redemption.  The prepayment penalty plus amortization of the previously deferred interest swap gain of $4 million and amortization of previously deferred debt issuance costs and discount of $1 million were recorded in other income (expense), net in the consolidated statement of operations. We also paid accrued and unpaid interest of $4 million on the 2020 senior notes up to but not including the redemption date.
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.20.4
LONG-TERM DEBT
 12 Months Ended
Oct. 31, 2020
Debt Disclosure [Abstract]  
LONG-TERM DEBT LONG-TERM DEBT
Senior Notes

The following table summarizes the company's long-term senior notes:

 October 31, 2020October 31, 2019
 Amortized
Principal		Amortized
Principal
 (in millions)
2022 Senior Notes$400 $399 
2023 Senior Notes598 597 
2026 Senior Notes298 298 
2029 Senior Notes493 492 
2030 Senior Notes495 — 
Total$2,284 $1,786 


2022 Senior Notes

On September 13, 2012, the company issued an aggregate principal amount of $400 million in senior notes ("2022 senior notes"). The 2022 senior notes were issued at 99.80% of their principal amount. The notes will mature on October 1, 2022, and bear interest at a fixed rate of 3.20% per annum. The interest is payable semi-annually on April 1st and October 1st of each year and payments commenced on April 1, 2013.

In July 2012, Agilent executed treasury lock agreements for $400 million in connection with future interest payments to be made on our 2022 senior notes issued on September 13, 2012. The treasury lock contracts were terminated on September 10, 2012 and we recognized a deferred gain in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2022 senior notes. The remaining gain to be amortized related to the treasury lock agreements at October 31, 2020 was less than $1 million.

2023 Senior Notes

On June 21, 2013, the company issued aggregate principal amount of $600 million in senior notes ("2023 senior notes"). The 2023 senior notes were issued at 99.544% of their principal amount. The notes will mature on July 15, 2023 and bear interest at a fixed rate of 3.875% per annum. The interest is payable semi-annually on January 15th and July 15th of each year and payments commenced January 15, 2014.

2026 Senior Notes

On September 22, 2016, the company issued aggregate principal amount of $300 million in senior notes ("2026 senior notes"). The 2026 senior notes were issued at 99.624% of their principal amount. The notes will mature on September 22, 2026 and bear interest at a fixed rate of 3.05% per annum. The interest is payable semi-annually on March 22nd and September 22nd of each year and payments commenced March 22, 2017.
In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. The swap arrangements were terminated on September 15, 2016 with a payment of $10 million, and we recognized this as a deferred loss in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at October 31, 2020 was $6 million.

2029 Senior Notes

On September 16, 2019, the company issued an aggregate principal amount of $500 million in senior notes ("2029 senior notes"). The 2029 senior notes were issued at 99.316% of their principal amount. The notes will mature on September 15, 2029, and bear interest at a fixed rate of 2.75% per annum. The interest is payable semi-annually on March 15th and September 15th of each year and payments commenced on March 15, 2020.

In August 2019, Agilent executed treasury lock agreements for $250 million in connection with future interest payments to be made on our 2029 senior notes issued on September 16, 2019. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 6, 2019 and we recognized a deferred loss of $6 million in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2029 senior notes. The remaining loss to be amortized related to the treasury lock agreements at October 31, 2020 was $5 million.

2030 Senior Notes

On June 4, 2020, we issued an aggregate principal amount of $500 million in senior notes ("2030 senior notes"). The 2030 senior notes were issued at 99.812% of their principal amount. The 2030 senior notes will mature on June 4, 2030, and bear interest at a fixed rate of 2.10% per annum. The interest is payable semi-annually on June 4th and December 4th of each year and payments commenced on December 4, 2020.

All outstanding notes listed above are unsecured and rank equally in right of payment with all of Agilent's other senior unsecured indebtedness.
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.20.4
STOCKHOLDERS' EQUITY
 12 Months Ended
Oct. 31, 2020
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS EQUITY STOCKHOLDERS' EQUITY
Stock Repurchase Program

On May 28, 2015 we announced that our board of directors had approved a share repurchase program (the "2015 repurchase program"). The 2015 repurchase program authorizes the purchase of up to $1.14 billion of our common stock at the company's discretion through and including November 1, 2018. The 2015 repurchase program did not require the company to acquire a specific number of shares and could have been suspended or discontinued at any time. During the year ended October 31, 2018, we repurchased and retired approximately 6.4 million shares for $422 million under this authorization. As of October 31, 2018, we had remaining authorization to repurchase up to $188 million of our common stock under this program which expired on November 1, 2018.

On November 19, 2018 we announced that our board of directors had approved a new share repurchase program (the "2019 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2019 share repurchase program authorizes the purchase of up to $1.75 billion of our common stock at the company's discretion and has no fixed termination date. The 2019 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. During the year ended October 31, 2019, we repurchased and retired 10.4 million shares for $723 million under this authorization. During the year ended October 31, 2020, we repurchased and retired approximately 5.2 million shares for $469 million under this authorization. As of October 31, 2020, we had remaining authorization to repurchase up to $558 million of our common stock under this program.

Cash Dividends on Shares of Common Stock

During the year ended October 31, 2020, cash dividends of 0.720 per share, or $222 million were declared and paid on the company's outstanding common stock. During the year ended October 31, 2019, cash dividends of 0.656 per share, or $206 million were declared and paid on the company's outstanding common stock. During the year ended October 31, 2018, cash dividends of 0.596 per share, or $191 million were declared and paid on the company's outstanding common stock.
On November 18, 2020 we declared a quarterly dividend of $0.194 per share of common stock, or approximately $59 million which will be paid on January 27, 2021 to shareholders of record as of the close of business on January 5, 2021. The timing and amounts of any future dividends are subject to determination and approval by our board of directors.

Accumulated Other Comprehensive Income (Loss)

The following table summarizes the components of our accumulated other comprehensive income (loss) as of October 31, 2020 and 2019, net of tax effect:

 October 31,
 20202019
 (in millions)
Foreign currency translation, net of tax expense of $(6) and $(5) for 2020 and 2019, respectively
$(194)(204)
Unrealized losses (including prior service benefit) on defined benefit plans, net of tax benefit of $154 and $153 for 2020 and 2019, respectively
(317)(306)
Unrealized gains (losses) on derivative instruments, net of tax benefit of $6 and $3 for 2020 and 2019, respectively
(11)(4)
Total accumulated other comprehensive loss$(522)$(514)
Changes in accumulated other comprehensive income (loss) by component and related tax effects for the years ended October 31, 2020 and 2019 were as follows:

Net defined benefit pension cost and post retirement plan costs
Foreign currency translationPrior service creditsActuarial LossesUnrealized gains (losses) on derivativesTotal
(in millions)
As of October 31, 2018$(214)$134 $(335)$7 $(408)
Impact of adoption of new guidance on tax effects in accumulated other comprehensive income (loss)— 3 (9)(1)(7)
As of November 1, 2018(214)137 (344)6 (415)
Other comprehensive loss before reclassifications— — (157)(6)(163)
Amounts reclassified out of accumulated other comprehensive income (loss)— (8)39 (8)23 
Tax benefit10 2 25 4 41 
Other comprehensive income (loss)10 (6)(93)(10)(99)
As of October 31, 2019$(204)$131 $(437)$(4)$(514)
Other comprehensive income (loss) before reclassifications11 — (66)(12)(67)
Amounts reclassified out of accumulated other comprehensive income (loss)— (7)61 2 56 
Tax (expense) benefit(1)1 — 3 3 
Other comprehensive income (loss)10 (6)(5)(7)(8)
As of October 31, 2020$(194)$125 $(442)$(11)$(522)
Reclassifications out of accumulated other comprehensive income (loss) for the years ended October 31, 2020 and 2019 were as follows (in millions):
Details about Accumulated Other
Comprehensive Income components		Amounts Reclassified
from Other Comprehensive Income		Affected line item in
statement of operations
20202019
Unrealized gains and (losses) on derivatives$(2)$8 Cost of products and interest expense
(2)8 Total before income tax
— (2)(Provision)/benefit for income tax
(2)6 Total net of income tax
Net defined benefit pension cost and post retirement plan costs:
Actuarial net loss(61)(39)Other (income) expense
Prior service benefit7 8 Other (income) expense
(54)(31)Total before income tax
16 12 Benefit for income tax
(38)(19)Total net of income tax
Total reclassifications for the period$(40)$(13)

Amounts in parentheses indicate reductions to income and increases to other comprehensive income.

Reclassifications of prior service benefit and actuarial net loss in respect of retirement plans and post retirement pension plans are included in the computation of net periodic cost (see Note 15, "Retirement Plans and Post Retirement Pension Plans").
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.20.4
SEGMENT INFORMATION
 12 Months Ended
Oct. 31, 2020
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
Description of Segments. We are a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.
Agilent has three business segments comprised of the life sciences and applied markets business, diagnostics and genomics business and the Agilent CrossLab business each of which comprises a reportable segment. The three operating segments were determined based primarily on how the chief operating decision maker views and evaluates our operations. Operating results are regularly reviewed by the chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance. Other factors, including market separation and customer specific applications, go-to-market channels, products and services and manufacturing are considered in determining the formation of these operating segments.
A description of our three reportable segments is as follows:

Our life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. Key product categories include: liquid chromatography ("LC") systems and components; liquid chromatography mass spectrometry ("LCMS") systems; gas chromatography ("GC") systems and components; gas chromatography mass spectrometry ("GCMS") systems; inductively coupled plasma mass spectrometry ("ICP-MS") instruments; atomic absorption ("AA") instruments; microwave plasma-atomic emission spectrometry ("MP-AES") instruments; inductively coupled plasma optical emission spectrometry ("ICP-OES") instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software for sample tracking; information
management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps and measurement technologies.

Our diagnostics and genomics business is comprised of six areas of activity providing active pharmaceutical ingredients ("APIs") for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our genomics business includes arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as next generation sequencing ("NGS") target enrichment and genetic data management and interpretation support software. This business also includes solutions that enable clinical labs to identify DNA variants associated with genetic disease and help direct cancer therapy. Second, our nucleic acid solutions business provides equipment and expertise focused on production of synthesized oligonucleotides under pharmaceutical good manufacturing practices ("GMP") conditions for use as API in an emerging class of drugs that utilize nucleic acid molecules for disease therapy. Third, our pathology solutions business is focused on product offerings for cancer diagnostics and anatomic pathology workflows. The broad portfolio of offerings includes immunohistochemistry ("IHC"), in situ hybridization ("ISH"), hematoxylin and eosin ("H&E") staining and special staining. Fourth, we also collaborate with a number of major pharmaceutical companies to develop new potential pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. Fifth, the reagent partnership business is a provider of reagents used for turbidimetry and flow cytometry. Finally, our biomolecular analysis business provides complete workflow solutions, including instruments, consumables and software, for quality control analysis of nucleic acid samples.  Samples are analyzed using quantitative and qualitative techniques to ensure accuracy in further genomics analysis techniques utilized in clinical and life science research applications.

The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio, which is designed to improve customer outcomes. Most of the portfolio is vendor neutral, meaning Agilent can serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries and supplies to services and software helping to connect the entire lab. Key product categories in consumables include GC and LC columns, sample preparation products, custom chemistries, and a large selection of laboratory instrument supplies. Services include startup, operational, training and compliance support, software as a service, as well as asset management and consultative services that help increase customer productivity. Custom service and consumable bundles are tailored to meet the specific application needs of various industries and to keep instruments fully operational and compliant with the respective industry requirements.

A significant portion of the segments' expenses arise from shared services and infrastructure that we have historically provided to the segments in order to realize economies of scale and to efficiently use resources. These expenses, collectively called corporate charges, include legal, accounting, tax, real estate, insurance services, information technology services, treasury, order administration, other corporate infrastructure expenses and costs of centralized research and development. Charges are allocated to the segments, and the allocations have been determined on a basis that we consider to be a reasonable reflection of the utilization of services provided to or benefits received by the segments. In addition, we do not allocate amortization and impairment of acquisition-related intangible assets, pension curtailment or settlement gains, restructuring and transformational initiatives expenses, acquisition and integration costs, business exit and divestiture costs, special compliance costs, some nucleic acid solutions division ("NASD") site costs and certain other charges to the operating margin for each segment because management does not include this information in its measurement of the performance of the operating segments. Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers, site consolidations, legal entity and other business reorganizations, in-sourcing or outsourcing of activities.

The following tables reflect the results of our reportable segments under our management reporting system. The performance of each segment is measured based on several metrics, including segment income from operations. These results are used, in part, by the chief operating decision maker in evaluating the performance of, and in allocating resources to, each of the segments.
The profitability of each of the segments is measured after excluding items such as asset impairment charges, transformational initiatives, acquisition and integration costs, non-cash amortization of intangible assets related to business combinations, interest income, interest expense, and other items as noted in the reconciliations below.
Life Sciences and Applied MarketsDiagnostics and GenomicsAgilent CrossLabTotal
Segments
 (in millions)
Year Ended October 31, 2020:    
Total net revenue$2,392 $1,047 $1,900 $5,339 
Income from operations$548 $192 $516 $1,256 
Depreciation expense$43 $39 $37 $119 
Share-based compensation expense (1)
$35 $17 $29 $81 
Year Ended October 31, 2019:   
Total net revenue$2,302 $1,021 $1,840 $5,163 
Income from operations$542 $185 $475 $1,202 
Depreciation expense$41 $35 $35 $111 
Share-based compensation expense$33 $14 $25 $72 
Year Ended October 31, 2018:   
Total net revenue$2,270 $943 $1,701 $4,914 
Income from operations$543 $173 $388 $1,104 
Depreciation expense$38 $33 $31 $102 
Share-based compensation expense$33 $14 $24 $71 

(1) Share-based compensation expense in 2020 excludes amounts not allocated to the segments related to accelerated share-based compensation expense from workforce reduction and from our acquisition of BioTek.

The following table reconciles reportable segments' income from operations to Agilent's total enterprise income before taxes:

 Years Ended October 31,
 202020192018
 (in millions)
Total reportable segments' income from operations$1,256 $1,202 $1,104 
Amortization of intangible assets related to business combinations(184)(125)(105)
Acquisition and integration costs(41)(48)(23)
Transformational initiatives(53)(44)(25)
Acceleration of share-based compensation expense related to workforce reduction(2)— — 
Asset impairments(99)— (21)
Business exit and divestiture costs (2)— (9)
NASD site costs— (12)(8)
Special compliance costs— (2)(4)
Other (1)
(29)(30)(5)
Interest Income8 36 38 
Interest Expense(78)(74)(75)
Other income (expense), net (2)
66 16 79 
Income before taxes, as reported$842 $919 $946 

(1) For the years ended October 31, 2020 and 2019, the other category primarily includes legal costs related to a claim we pursued against Twist Bioscience Corporation in addition to other miscellaneous adjustments.
(2) For the year ended October 31, 2020, other income (expense), net includes the settlement of a legal claim against Twist Bioscience Corporation.
Major Customers.    No customer represented 10 percent or more of our total net revenue in 2020, 2019 or 2018.

The following table reflects segment assets and capital expenditures under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets.
Life Sciences and Applied MarketsDiagnostics and GenomicsAgilent CrossLabTotal
Segments
 (in millions)
As of and for the Year Ended October 31, 2020:    
Assets$3,143 $2,515 $1,375 $7,033 
Capital expenditures$44 $34 $41 $119 
As of and for the Year Ended October 31, 2019:    
Assets$3,202 $2,620 $1,331 $7,153 
Capital expenditures$59 $48 $48 $155 


The following table reconciles segment assets to Agilent's total assets:
 October 31,
 20202019
 (in millions)
Total reportable segments' assets$7,033 $7,153 
Cash and cash equivalents1,441 1,382 
Prepaid expenses106 94 
Investments158 102 
Long-term and other receivables114 100 
Deferred tax assets380 410 
Right of use assets175 — 
Other220 211 
Total assets$9,627 $9,452 

The other category primarily includes overfunded pension assets which are not allocated to the segments.

The following table presents summarized information for net revenue by geographic region. Revenues from external customers are generally attributed to countries based upon the customers' location.

United
States
China(1)
Rest of the
World		Total
 (in millions)
Net revenue:    
Year Ended October 31, 2020$1,752 $1,087 $2,500 $5,339 
Year Ended October 31, 2019$1,619 $1,019 $2,525 $5,163 
Year Ended October 31, 2018$1,414 $1,015 $2,485 $4,914 
1.China also includes Hong Kong net revenue.



The following table presents summarized information for long-lived assets by geographic region. Long lived assets consist of property, plant, and equipment, right-of-use assets, long-term receivables and other long-term assets excluding intangible assets. The rest of the world primarily consists of Asia and the rest of Europe.
United
States		GermanyRest of the
World		Total
 (in millions)
Long-lived assets:   
October 31, 2020$727 $126 $538 $1,391 
October 31, 2019$621 $122 $404 $1,147 
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.20.4
Schedule II Valuation and Qualifying Accounts
 12 Months Ended
Oct. 31, 2020
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
Schedule II - Valuation and Qualifying Accounts
SCHEDULE II
VALUATION AND QUALIFYING ACCOUNTS

Column AColumn BColumn CColumn DColumn E
DescriptionBalance at
Beginning
of Period		Additions Charged to
Expenses or
Other Accounts*		Deductions Credited to Expenses or Other Accounts**Balance at
End of
Period
 (in millions)
2020    
Tax valuation allowance$134 $6 $(8)$132 
2019    
Tax valuation allowance$135 $9 $(10)$134 
2018    
Tax valuation allowance$138 $4 $(7)$135 

* Additions include current year additions charged to expenses and current year build due to increases in net deferred tax assets, return to provision true-ups, other adjustments and other comprehensive income impact to deferred taxes.
** Deductions include current year releases credited to expenses and current year reductions due to decreases in net deferred tax assets, return to provision true-ups, other adjustments and other comprehensive income impact to deferred taxes.
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.20.4
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Oct. 31, 2020
Accounting Policies [Abstract]  
Business Description and Basis of Presentation
Overview.  Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.

Basis of Presentation.  The accompanying consolidated financial statements have been prepared by us pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") and are in conformity with U.S. generally accepted accounting principles ("GAAP"). Our fiscal year end is October 31. Unless otherwise stated, all years and dates refer to our fiscal year.
Principles of Consolidation Principles of Consolidation.  The consolidated financial statements include the accounts of the company and our wholly- and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Use of Estimates Use of Estimates.  The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, retirement and post-retirement plan assumptions and accounting for income taxes.
Risk and Uncertainties
Risks and Uncertainties. We are subject to risks common to companies in the analytical instrument industry, such as global economic and financial market conditions, fluctuations in foreign currency exchange rates and fluctuations in customer demand, among others.

Both our domestic and international operations have been and continue to be affected by the ongoing global pandemic of a novel strain of coronavirus (“COVID-19”) and the resulting volatility and uncertainty it has caused in the U.S. and international markets. In March 2020, the World Health Organization declared COVID-19 a pandemic and recommended containment and mitigation measures worldwide. As a result, academic and research laboratories had temporarily closed in our second and third quarters and hospitals and testing laboratories had halted or reduced certain elective medical procedures, which had an adverse effect on our customers' business. The COVID-19 pandemic has caused significant volatility and uncertainty in U.S. and international markets, which could result in a prolonged economic downturn that could disrupt our business.
Revenue Recognition
Revenue Recognition.  We enter into contracts to sell products, services or combinations of products and services. Products may include hardware or software and services may include one-time service events or services performed over time.

We derive revenue primarily from the sale of analytical and diagnostics products and services. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under Accounting Standard Codification Topic 606, Revenue from Contracts with Customers (“ASC 606’’). See also Note 4, "Revenue" for additional information on revenue recognition.

Revenue is recognized when control of the promised products or services is transferred to our customers and the performance obligation is fulfilled in an amount that reflects the consideration that we expect to be entitled in exchange for those products or services, the transaction price. For equipment, consumables, and most software licenses, control transfers to the customer at a point in time. We use present right to payment, legal title, physical possession of the asset, and risks and rewards of ownership as indicators to determine the transfer of control to the customer. Where acceptance is not a formality, the customer must have documented their acceptance of the product or service. For products that include installation, if the installation meets the criteria to be considered a separate performance obligation, product revenue is recognized when control has passed to the customer, and recognition of installation revenue occurs once completed. Product revenue, including sales to
resellers and distributors is reduced for provisions for warranties, returns, and other adjustments in the period the related sales are recorded.

Service revenue includes extended warranty, customer and software support including: Software as a Service, post contract support, consulting including companion diagnostics, and training and education. Instrument service contracts and software maintenance contracts are typically annual contracts, which are billed at the beginning of the contract or maintenance period. Revenue for these contracts is recognized on a straight-line basis to revenue over the service period, as a time-based measure of progress best reflects our performance in satisfying this obligation. There are no deferred costs associated with the service contract, as the cost of the service is recorded when the service is performed. Service calls not included in a support contract are recognized to revenue at the time a service is performed.

We have sales from standalone software. These arrangements typically include software licenses and maintenance contracts, both of which we have determined are distinct performance obligations. We determine the amount of the transaction price to allocate to the license and maintenance contract based on the relative standalone selling price of each performance obligation. Software license revenue is recognized at the point in time when control has been transferred to the customer. The revenue allocated to the software maintenance contract is recognized on a straight-line basis over the maintenance period, which is the contractual term of the contract, as a time-based measure of progress best reflects our performance in satisfying this obligation. Unspecified rights to software upgrades are typically sold as part of the maintenance contract on a when-and-if-available basis.

Our multiple-element arrangements are generally comprised of a combination of instruments, installation or other start-up services, and/or software, and/or support or services. Hardware and software elements are typically delivered at the same time and revenue is recognized when control passes to the customer. Service revenue is deferred and recognized over the contractual period or as services are rendered and accepted by the customer. Our arrangements generally do not include any provisions for cancellation, termination, or refunds that would significantly impact recognized revenue.

For contracts with multiple performance obligations, we allocate the consideration to which we expect to be entitled to each performance obligation based on relative standalone selling prices and recognize the related revenue when or as control of each individual performance obligation is transferred to customers. We estimate the standalone selling price by calculating the average historical selling price of our products and services per country for each performance obligation. Standalone selling prices are determined for each distinct good or service in the contract, and then we allocate the transaction price in proportion to those standalone selling prices by performance obligations.

A portion of our revenue relates to lease arrangements. Standalone lease arrangements are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 842, Leases for 2020 and ASC 840, Leases for prior periods. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type capital lease using the current lease classification guidance.

Deferred Revenue.  Contract liabilities (deferred revenue) primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements (performance obligations) to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either in current liabilities in deferred revenue or long-term in other long-term liabilities in the consolidated balance sheet based on the timing of when we expect to complete our performance obligation.

Sales Taxes.  Sales taxes collected from customers and remitted to governmental authorities are not included in our revenue.

Shipping and Handling Costs.  Our shipping and handling costs charged to customers are included in net revenue, and the associated expense is recorded in cost of products for all periods presented.
Research and Development Research and Development.  Costs related to research, design and development of our products are charged to research and development expense as they are incurred.
Advertising Advertising.  Advertising costs are generally expensed as incurred and amounted to $48 million in 2020, $36 million in 2019 and $41 million in 2018.
Taxes on Income Taxes on Income.  Income tax expense or benefit is based on income or loss before taxes. Deferred tax assets and liabilities are recognized principally for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. See Note 6, "Income Taxes" for more information.
Net Income (Loss) Per Share Net Income Per Share.  Basic net income per share is computed by dividing net income - the numerator - by the weighted average number of common shares outstanding - the denominator - during the period excluding the dilutive effect of stock options and other employee stock plans. Diluted net income per share gives effect to all potential common shares outstanding during the period unless the effect is anti-dilutive. The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense are assumed proceeds to be used to repurchase hypothetical shares. See Note 7, "Net Income Per Share".
Cash, Cash Equivalents and Short-Term Investments and Restricted Cash and Restricted Cash Equivalents
Cash, Cash Equivalents and Short-Term Investments.  We classify investments as cash equivalents if their original or remaining maturity is three months or less at the date of purchase. Cash equivalents are stated at cost, which approximates fair value.

As of October 31, 2020, approximately $1,395 million of our cash and cash equivalents is held outside of the U.S. by our foreign subsidiaries. Our cash and cash equivalents mainly consist of short-term deposits held at major global financial institutions, institutional money market funds, and similar short duration instruments with original maturities of 90 days or less. We continuously monitor the creditworthiness of the financial institutions and institutional money market funds in which we invest our funds.

We classify investments as short-term investments if their original maturities are greater than three months and their remaining maturities are one year or less. Currently, we have no short-term investments.

Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet follows:
October 31,
202020192018
(in millions)
Cash and cash equivalents$1,441 $1,382 $2,247 
Restricted cash included in other assets6 6 7 
Total cash, cash equivalents and restricted cash$1,447 $1,388 $2,254 
Accounts Receivable, net Accounts Receivable, net.  Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Such accounts receivable have been reduced by an allowance for doubtful accounts, which is our best estimate of the amount of probable credit losses in our existing accounts receivable. We determine the allowance based on customer specific experience and the aging of such receivables, among other factors. The allowance for doubtful accounts as of October 31, 2020 and 2019 was not material. We do not have any off-balance-sheet credit exposure related to our customers. Accounts receivable are also recorded net of estimated product returns which are not material.
Concentration of Credit Risk
Concentration of Credit Risk.  Financial instruments that potentially subject Agilent to significant concentration of credit risk include money market fund investments, time deposits and demand deposit balances. These investments are categorized as cash and cash equivalents. In addition, Agilent has credit risk from derivative financial instruments used in hedging activities and accounts receivable. We invest in a variety of financial instruments and limit the amount of credit exposure with any one financial institution. We have a comprehensive credit policy in place and credit exposure is monitored on an ongoing basis.

Credit risk with respect to our accounts receivable is diversified due to the large number of entities comprising our customer base and their dispersion across many different industries and geographies. Credit evaluations are performed on customers requiring credit over a certain amount, and we sell the majority of our products through our direct sales force. Credit risk is mitigated through collateral such as letter of credit, bank guarantees or payment terms like cash in advance. No single customer accounted for more than 10 percent of accounts receivable as of October 31, 2020, or 2019.
Inventory Inventory.  Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with manufacturing to maximize recovery of excess inventory.
Property, Plant and Equipment Property, Plant and Equipment.  Property, plant and equipment are stated at cost less accumulated depreciation. Additions, improvements and major renewals are capitalized; maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation and amortization are removed from our general ledger, and the resulting gain or loss is reflected in the consolidated statement of operations. Buildings and improvements are depreciated over the lesser of their useful lives or the remaining term of the lease and machinery and equipment over 3 years to 10 years. We use the straight-line method to depreciate assets.
Capitalized Software Capitalized Software.  We capitalize certain internal and external costs incurred to acquire or create internal use software. Capitalized software is included in property, plant and equipment and is depreciated over 3 years to 5 years once development is complete.
Leases
Leases.  We determine whether an arrangement is, or contains, a lease at inception. Prior to November 1, 2019, for leases where we are the lessee, we accounted for operating lease payments by charging them to expense as incurred. At the beginning of fiscal 2020, the company adopted new lease accounting guidance issued by the Financial Accounting Standards Board ("FASB"). The most significant change requires lessees to record the present value of operating lease payments as right-of-use ("ROU") assets and lease liabilities on the consolidated balance sheet. Where we are the lessee, ROU assets represent the company’s right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of operating lease liabilities as either current or non-current is based on the expected timing of payments due under our obligations. As most of our leases do not provide an implicit interest rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rates, we have used a number of factors including the company's credit rating, the lease term and the currency swap rate. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet and lease expense for these leases is recognized on a straight-line basis over the lease term. Lease expense for operating leases with an initial term of more than twelve months is recognized on a straight-line basis over the lease term as an operating expense. We have lease agreements which require payments for lease and non-lease components. We have elected to account for these payments as a single lease component.

A portion of our revenue relates to lease arrangements where Agilent is the lessor. Standalone lease arrangements are outside the scope of Accounting Standard Codification ("ASC") Topic 606, Revenue Contracts with Customers, and are therefore accounted for in accordance with ASC Topic 842, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type finance lease using the current lease classification guidance. In a lease arrangement that is a multiple-element arrangement that contains equipment leases and the supply of consumables, the revenue associated with the instrument rental is treated under the lease accounting standard ASC 842, whereas the revenue associated with the consumables, the non-lease component, is recognized in accordance with the ASC 606 revenue standard.
   See also Note 2, "New Accounting Pronouncements" and Note 10, "Leases" for additional information about the company’s leases.
Acquisitions
Acquisitions. Agilent accounts for the acquisition of a business using the acquisition method of accounting, and we allocate the fair value of the purchase price to the tangible assets acquired, liabilities assumed, and intangible assets acquired, including in-process research and development (“IPR&D”), based on their estimated fair values. The excess value of the cost of an acquired business over the fair value of the assets acquired and liabilities assumed is recognized as goodwill. The fair value of IPR&D is initially capitalized as an intangible asset with an indefinite life. When an IPR&D project is completed, the IPR&D is reclassified as an amortizable purchased intangible asset and amortized to costs of revenues over the asset’s estimated useful life.

Our determination of the fair value of the intangible assets acquired involves the use of significant estimates and assumptions. Specifically, our determination of the fair value of the developed product technology and IPR&D acquired
involve significant estimates and assumptions related to revenue growth rates and discount rates. Our determination of the fair value of customer relationships acquired involved significant estimates and assumptions related to revenue growth rates, discount rates, and customer attrition rates. Our determination of the fair value of the tradename acquired involved the use of significant estimates and assumptions related to revenue growth rates, royalty rates and discount rates. The company believes that the fair value assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that marketplace participants would use. Actual results could differ materially from these estimates.
Goodwill and Purchased Intangible Assets
Goodwill and Purchased Intangible Assets. Under the authoritative guidance we have the option to perform a qualitative assessment to determine whether further impairment testing is necessary. The accounting standard gives an entity the option to first assess qualitative factors to determine whether performing the two-step test is necessary. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not (i.e., greater than 50% chance) that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test will be required. Otherwise, no further testing will be required.

The guidance includes examples of events and circumstances that might indicate that a reporting unit's fair value is less than its carrying amount. These include macro-economic conditions such as deterioration in the entity's operating environment or industry or market considerations; entity-specific events such as increasing costs, declining financial performance, or loss of key personnel; or other events such as an expectation that a reporting unit will be sold or a sustained decrease in the stock price on either an absolute basis or relative to peers.

If it is determined, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, the provisions of authoritative guidance require that we perform a two-step impairment test on goodwill. In the first step, we compare the fair value of each reporting unit to its carrying value. The second step (if necessary) measures the amount of impairment by applying fair-value-based tests to the individual assets and liabilities within each reporting unit. As defined in the authoritative guidance, a reporting unit is an operating segment, or one level below an operating segment. We aggregate components of an operating segment that have similar economic characteristics into our reporting units.

In fiscal year 2020, we assessed goodwill impairment for our three reporting units which consisted of three segments: life sciences and applied markets, diagnostics and genomics and Agilent CrossLab. We performed a qualitative test for goodwill impairment of the three reporting units, as of September 30, 2020, our annual impairment test date. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair value of each reporting unit is greater than its respective carrying value. Each quarter we review the events and circumstances to determine if goodwill impairment is indicated. There was no impairment of goodwill during the years ended October 31, 2020, 2019 and 2018.

Purchased intangible assets consist primarily of acquired developed technologies, proprietary know-how, trademarks, and customer relationships and are amortized using the best estimate of the asset's useful life that reflect the pattern in which the economic benefits are consumed or used up or a straight-line method ranging from 6 months to 15 years. IPR&D is initially capitalized at fair value as an intangible asset with an indefinite life and assessed for impairment thereafter. When the IPR&D project is complete, it is reclassified as an amortizable purchased intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, Agilent will record a charge for the value of the related intangible asset to Agilent's consolidated statement of operations in the period it is abandoned.
Agilent's indefinite-lived intangible assets are IPR&D intangible assets. The accounting guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the issued impairment testing guidance for goodwill and allows the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset to determine whether it is more-likely-than-not (i.e., greater than 50% chance) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value. We performed a qualitative test for impairment of indefinite-lived intangible assets as of September 30, 2020. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair values of these indefinite-lived intangible assets are greater than their respective carrying values. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible asset is indicated. During the year ended October 31, 2020, we recorded an impairment of in-process research and development of $90 million related to the shutdown of our sequencer development program in our diagnostics and genomics segment. During the year ended October 31, 2019 and 2018 there were no impairments of indefinite-lived intangible assets.
Impairment of Long-Lived Assets Impairment of Long-Lived Assets.  We continually monitor events and changes in circumstances that could indicate carrying amounts of long-lived assets, including intangible assets, may not be recoverable. When such events or changes in circumstances occur, we assess the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the undiscounted future cash flows is less than the carrying amount of those assets, we recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets. During the year ended October 31, 2020 we recorded an impairment charge of long-lived assets including indefinite-lived in-process research and development of $98 million related to the shutdown of our sequencer development program in our diagnostics and genomics segment. During fiscal year 2019, there were no impairments of other assets or intangible assets. During fiscal year 2018, we recorded an impairment charge of $21 million related to purchased intangible assets within the diagnostics and genomics segment that were deemed unrecoverable.
Variable Interest Entity
Variable Interest Entities. We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity (“VIE”).  The company evaluates its investments in privately held companies on an ongoing basis. We have determined that as of October 31, 2020 and 2019, there were no VIE's required to be consolidated in the company's consolidated financial statements because we do not have a controlling financial interest in any of the VIE's in which we have invested nor are we the primary beneficiary. We account for these investments under either the equity method or as equity investments without readily determinable fair value, depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs, based on changes in facts and circumstances including changes in contractual arrangements and capital structure.

During the year ended October 31, 2018, we exercised our option and acquired all of the remaining shares of Lasergen, Inc. ("Lasergen") that we did not already own for an additional cash consideration of approximately $107 million. The fair value remeasurement of our previous investment immediately before the acquisition resulted in a net gain of $20 million and was recorded in other income. Lasergen was previously considered a VIE.

As of October 31, 2020 and October 31, 2019, the total carrying value of investments and loans in privately held companies considered as VIEs was $67 million and $29 million respectively. The maximum exposure is equal to the carrying value because we do not have future funding commitments. The investments are included on the long-term investments line and the loans on the other current assets and other assets lines (depending upon tenure of loan) on the consolidated balance sheet.
Investments Investments.  Equity investments without readily determinable fair value consist of non-marketable equity securities (typically investments in privately-held companies). These investments are accounted for using the measurement alternative at cost, and we adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) included in net income as and when it occurs. Equity investments with readily determinable fair value consist of shares we own in a special fund and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. Prior to fiscal year 2019, both equity investments without determinable fair value and with determinable fair value were accounted for using cost method of accounting, measured at historical cost less other-than-temporary investment. Trading securities, which are comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liabilities are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Equity method investments are reported at the amount of the company’s initial investment and adjusted each period for the company’s share of the investee’s income or loss and dividend paid. There are no equity method investments as of October 31, 2020 and 2019. The company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.
Fair Value of Financial Instruments Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. The fair value of our senior notes, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy exceeds the carrying value by approximately $162 million as of October 31, 2020 and approximately $62 million as of October 31, 2019. The change in the fair value over carrying value in the year ended October 31, 2020 is primarily due to decreased market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 13, "Fair Value Measurements" for additional information on the fair value of financial instruments.
Warranty Warranty.  Our standard warranty terms typically extend for one year from the date of delivery. We accrue for standard warranty costs based on historical trends in warranty charges. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost over the period. Estimated warranty charges are recorded within cost of products at the time products are sold. See Note 16, "Guarantees".
Employee Compensation and Benefits Employee Compensation and Benefits.  Amounts owed to employees, such as accrued salary, bonuses and vacation benefits are accounted for within employee compensation and benefits. The total amount of accrued vacation benefit was $111 million and $115 million as of October 31, 2020, and 2019, respectively.
Retirement and Post-Retirement Plans Retirement and Post-Retirement Plans. Substantially all of our employees are covered under various defined benefit and/or defined contribution retirement plans. Additionally, we sponsor post-retirement health care benefits for our eligible U.S. employees. Assumptions used to determine the benefit obligations and the expense for these plans are derived annually. See Note 15, “Retirement plans and post-retirement pension plans” for additional information.
Retirement of Treasury Shares Retirement of Treasury Shares. Upon the formal retirement of treasury shares, we deduct the par value of the retired treasury shares from common stock and allocate the excess of cost over par as a deduction to additional paid-in capital, based on the pro-rata portion of additional paid-in-capital, and the remaining excess as a deduction to retained earnings. All retired treasury shares revert to the status of authorized but unissued shares.
Share-Based Compensation Share-Based Compensation.  For the years ended 2020, 2019 and 2018, we accounted for share-based awards made to our employees and directors including employee stock option awards, restricted stock units, employee stock purchases made under our Employee Stock Purchase Plan ("ESPP") and performance share awards under Agilent Technologies, Inc. Long-Term Performance Program ("LTPP") using the estimated grant date fair value method of accounting. Under the fair value method, we recorded compensation expense for all share-based awards of $84 million in 2020, $72 million in 2019 and $71 million in 2018. See Note 5, "Share-based Compensation" for additional information.
Derivative Instruments
Derivative Instruments.  Agilent is exposed to global foreign currency exchange rate and interest rate risks in the normal course of business. We enter into foreign exchange hedging contracts, primarily forward contracts and purchased options, interest rate swaps and interest rate locks to manage financial exposures resulting from changes in foreign currency exchange rates and interest rates. In the vast majority of cases, these contracts are designated at inception as hedges of the related foreign currency or interest exposures. Foreign currency exposures include committed and anticipated revenue and expense transactions and assets and liabilities that are denominated in currencies other than the functional currency of the subsidiary. Interest rate exposures are associated with the company's fixed-rate debt. For option contracts, we exclude time value from the measurement of effectiveness. To qualify for hedge accounting, contracts must reduce the foreign currency exchange rate and interest rate risk otherwise inherent in the amount and duration of the hedged exposures and comply with established risk management policies. Foreign exchange hedging contracts generally mature within twelve months, interest rate swaps mature at the same time as the maturity of the debt and interest rate locks mature at the same time as the issuance of debt. In order to manage foreign currency exposures in a few limited jurisdictions, we may enter into foreign exchange contracts that do not qualify for hedge accounting. In such circumstances, the local foreign currency exposure is offset by contracts owned by the parent company. We do not use derivative financial instruments for trading or speculative purposes.

All derivatives are recognized on the balance sheet at their fair values. For derivative instruments that are designated and qualify as a cash flow hedge, changes in the value of the effective portion of the derivative instrument are recognized in comprehensive income (loss), a component of stockholders' equity. For derivative instruments that are designated and qualify as a net investment hedge, changes in the value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss). Amounts associated with cash flow hedges are reclassified and recognized in income when either the forecasted transaction occurs or it becomes probable the forecasted transaction will not occur. Derivatives not designated as hedging instruments are recorded on the balance sheet at their fair value and changes in the fair values are recorded in the income statement in the current period. Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet. Changes in the fair value of the ineffective portion of derivative instruments are recognized in earnings in the current period. The impact of the ineffectiveness measurement in 2020, 2019 and 2018 was not material. Cash flows from derivative instruments are classified in the statement of cash flows in the same category as the cash flows from the hedged or economically hedged item, primarily in operating activities.
Foreign Currency Translation Foreign Currency Translation.  We translate and remeasure balance sheet and income statement items into U.S. dollars. For those subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using monthly exchange rates which approximate to average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) in stockholders' equity.For those subsidiaries that operate in a U.S. dollar functional environment, foreign currency assets and liabilities are remeasured into U.S. dollars at current exchange rates except for non-monetary assets and capital accounts which are remeasured at historical exchange rates. Revenue and expenses are generally remeasured at monthly exchange rates which approximate average exchange rates in effect during each period. Gains or losses from foreign currency remeasurement are included in consolidated net income. Net gains or losses resulting from foreign currency transactions, including hedging gains and losses, are reported in other income (expense), net and were $4 million loss for 2020, $7 million loss for 2019 and $3 million loss for 2018.
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.20.4
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Oct. 31, 2020
Accounting Policies [Abstract]  
Restricted Cash and Cash Equivalents
Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet follows:
October 31,
202020192018
(in millions)
Cash and cash equivalents$1,441 $1,382 $2,247 
Restricted cash included in other assets6 6 7 
Total cash, cash equivalents and restricted cash$1,447 $1,388 $2,254 
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.20.4
NEW ACCOUNTING PRONOUNCEMENTS (Tables)
 12 Months Ended
Oct. 31, 2020
Accounting Standards Update and Change in Accounting Principle [Abstract]  
Accounting Standards Update and Change in Accounting Principle -Leases
Adoption of the new guidance impacted the consolidated balance sheet as follows:

 October 31, 2019Impact of AdoptingNovember 1, 2019
 As ReportedLease GuidanceAs Adopted
(in millions)
Other assets$611 $192 $803 
Other accrued liabilities$440 $48 $488 
Other long-term liabilities$473 $144 $617 
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.20.4
ACQUISITIONS (Tables)
 12 Months Ended
Oct. 31, 2020
Business Combinations [Abstract]  
Schedule of the fair value of assets and liabilities assumed
The following table summarizes the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of August 23, 2019 (in millions):
Cash and cash equivalents$10 
Accounts receivable28 
Inventories21 
Other current assets2 
Property, plant and equipment8 
Intangible assets641 
Goodwill483 
Total assets acquired$1,193 
Accounts payable(4)
Deferred revenue(5)
Employee compensation and benefits(7)
Other accrued liabilities(2)
Long-term debt(4)
Net assets acquired$1,171 
Components of intangible assets acquired
The components of intangible assets acquired in connection with the BioTek acquisition were as follows (in millions):

 Fair ValueEstimated
Useful Life
Developed product technology$387 
5-13 years
Customer relationships202 
3-8 years
Backlog5 2 months
Tradenames and trademarks43 10 years
Total intangible assets subject to amortization$637 
In-process research and development4  
Total intangible assets$641  
Proforma operating results
The following represents the unaudited proforma operating results as if BioTek and ACEA had been included in the company's consolidated statements of operations as of the beginning of fiscal 2018 (in millions, except per share amounts):

20192018
Net revenue$5,308 $5,112 
Net income$1,012 $210 
Net income per share — basic$3.22 $0.65 
Net income per share — diluted$3.18 $0.65 
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE (Tables)
 12 Months Ended
Oct. 31, 2020
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:

Life Sciences and Applied MarketsAgilent CrossLabDiagnostics and GenomicsTotal
(in millions)
Year Ended October 31, 2020:
Americas$784 $667 $517 $1,968 
Europe540 532 371 1,443 
Asia Pacific1,068 701 159 1,928 
Total$2,392 $1,900 $1,047 $5,339 
Year Ended October 31, 2019:
Americas$692 $664 $505 $1,861 
Europe551 522 368 1,441 
Asia Pacific1,059 654 148 1,861 
Total$2,302 $1,840 $1,021 $5,163 

The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
Years Ended October 31,
20202019
(in millions)
Revenue by End Markets
Pharmaceutical and Biopharmaceutical$1,754 1,604 
Chemical and Energy1,154 1,199 
Diagnostics and Clinical787 785 
Food517 486 
Academia and Government526 474 
Environmental and Forensics601 615 
Total$5,339 5,163 
Revenue by Type
Instrumentation$2,249 2,150 
Non-instrumentation and other3,090 3,013 
Total$5,339 5,163 
Contract with Customer, Asset and Liability
The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the years ended October 31, 2019 and 2020:

Contract
Liabilities
(in millions)
Ending balance as of October 31, 2018$367 
Impact of adoption of new revenue recognition guidance(11)
Net revenue deferred in the period303 
Revenue recognized that was included in the contract liability balance at the beginning of the period(287)
Change in deferrals from customer cash advances, net of revenue recognized5 
Contract liabilities acquired in business combinations9 
Currency translation and other adjustments— 
Ending balance as of October 31, 2019$386 
Net revenue deferred in the period347 
Revenue recognized that was included in the contract liability balance at the beginning of the period(300)
Change in deferrals from customer cash advances, net of revenue recognized9 
Currency translation and other adjustments4 
Ending balance as of October 31,2020$446 
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.20.4
SHARE-BASED COMPENSATION (Tables)
 12 Months Ended
Oct. 31, 2020
Share-based Payment Arrangement, Noncash Expense [Abstract]  
Allocated Share-based compensation expense disclosure
The impact on our results for share-based compensation was as follows:

Years Ended October 31,
202020192018
(in millions)
Cost of products and services$21 $18 $16 
Research and development9 7 7 
Selling, general and administrative54 47 48 
Total share-based compensation expense$84 $72 $71 
Share-based compensation arrangement by share-based payment award fair value assumptions and methodology schedule
The following assumptions were used to estimate the fair value of awards granted.

 Years Ended October 31,
 202020192018
LTPP:   
Volatility of Agilent shares23%22%21%
Volatility of selected peer-company shares
15%-44%
15%-66%
14%-66%
Pair-wise correlation with selected peers29%30%32%
Post-vest restriction discount for all executive awards5.3%5.0%4.8%
Summary of stock option award activity
The following table summarizes employee stock option award activity of our employees and directors for 2020.

Options
Outstanding 		Weighted
Average
Exercise Price
 (in thousands) 
Outstanding at October 31, 20191,445 $36 
Exercised(575)$34 
Outstanding at October 31, 2020870 $37 
Schedule of share-based compensation, shares authorized under stock option plans, by exercise price range
The options outstanding and exercisable for equity share-based payment awards at October 31, 2020 were as follows:

 Options OutstandingOptions Exercisable
Range of
Exercise Prices		Number
Outstanding		Weighted
Average
Remaining
Contractual
Life		Weighted
Average
Exercise
Price		Aggregate
Intrinsic
Value		Number
Exercisable		Weighted
Average
Remaining
Contractual
Life		Weighted
Average
Exercise
Price		Aggregate
Intrinsic
Value
 (in thousands)(in years) (in thousands)(in thousands)(in years) (in thousands)
$25.01 - $30.00
228 1.7$27 $17,192 228 1.7$27 $17,192 
$30.01 - $40.00
121 3.1$39 7,586 121 3.1$39 7,586 
$40.01- over
521 4.0$41 31,883 521 4.0$41 31,883 
870 3.3$37 $56,661 870 3.3$37 $56,661 
Schedule of intrinsic value of options exercised and the fair value of options granted
The following table summarizes the aggregate intrinsic value of options exercised in 2020, 2019 and 2018:

Aggregate
Intrinsic Value		Weighted
Average
Exercise
Price
 (in thousands) 
Options exercised in fiscal 2018$28,417 $32 
Options exercised in fiscal 2019$24,409 $33 
Options exercised in fiscal 2020$30,481 $34 
Non-vested award activity disclosure
The following table summarizes non-vested award activity in 2020 primarily for our LTPP and restricted stock unit awards.
SharesWeighted
Average
Grant Price
 (in thousands) 
Non-vested at October 31, 20193,173 $60 
Granted1,091 $79 
Vested(1,629)$52 
Forfeited(115)$68 
Change in LTPP shares in the year due to exceeding performance targets298 $47 
Non-vested at October 31, 20202,818 $70 
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES (Tables)
 12 Months Ended
Oct. 31, 2020
Income Tax Disclosure [Abstract]  
Income before income taxes domestic and foreign
The domestic and foreign components of income before taxes are:

 Years Ended October 31,
 202020192018
 (in millions)
U.S. operations$54 $189 $169 
Non-U.S. operations788 730 777 
Total income before taxes$842 $919 $946 
Provision for income taxes from operations
The provision for income taxes is comprised of:

 Years Ended October 31,
 202020192018
 (in millions)
U.S. federal taxes:   
Current$5 $(191)$520 
Deferred4 — 51 
Non-U.S. taxes:   
Current84 290 95 
Deferred24 (267)(22)
State taxes, net of federal benefit:   
Current5 4 1 
Deferred1 12 (15)
Total provision (benefit)$123 $(152)$630 
Tax rate reconciliation, U.S. federal statutory rate to effective tax rate from operations
The differences between the U.S. federal statutory income tax rate and our effective tax rate are:

 Years Ended October 31,
 202020192018
 (in millions)
Profit before tax times statutory rate$177 $193 $221 
Non-U.S. income taxed at different rates(36)(8)(93)
Change in unrecognized tax benefits(9)(13)(17)
Impact of the Tax Act— — 552 
Extension of the tax incentive in Singapore— (299)— 
Excess tax benefits from stock-based compensation(18)(10)(18)
Other, net9 (15)(15)
Provision (benefit) for income taxes$123 $(152)$630 
Effective tax rate14.6 %(16.5)%66.6 %
Significant components of deferred tax assets and deferred tax liabilities
The significant components of deferred tax assets and deferred tax liabilities included on the consolidated balance sheet are:

 Years Ended October 31,
 20202019
 (in millions)
Deferred Tax Assets
Intangibles$153 $131 
Pension benefits and retiree medical benefits65 71 
Employee benefits, other than retirement31 34 
Net operating loss, capital loss, and credit carryforwards182 195 
Share-based compensation27 32 
Deferred revenue22 38 
Lease obligations35 — 
Other41 35 
Deferred tax assets$556 $536 
Tax valuation allowance(132)(134)
Deferred tax assets, net of valuation allowance$424 $402 
Deferred Tax Liabilities
Property, plant and equipment$(19)$(16)
Right-of-use asset(35)— 
Other(14)(7)
Deferred tax liabilities$(68)$(23)
Net deferred tax assets (liabilities)$356 $379 
Long-term deferred tax assets and deferred tax liabilities
The breakdown between long-term deferred tax assets and deferred tax liabilities was as follows:

 October 31,
 20202019
 (in millions)
Long-term deferred tax assets (included within other assets)$380 $410 
Long-term deferred tax liabilities (included within other long-term liabilities)(24)(31)
Total$356 $379 
Current and Long Term Tax Assets and Liabilities [Table Text Block]
The breakdown between current and long-term income tax assets and liabilities, excluding deferred tax assets and liabilities, was as follows:
October 31,
20202019
(in millions)
Current income tax assets (included within other current assets)$89 $68 
Long-term income tax assets (included within other assets)6 4 
Current income tax liabilities (included within other accrued liabilities)(63)(292)
Long-term income tax liabilities (included within other long-term liabilities)(323)(328)
Total$(291)$(548)
Income tax contingencies rollforward
The aggregate changes in the balances of our gross unrecognized tax benefits including all federal, state and foreign tax jurisdictions are as follows:

202020192018
 (in millions)
Balance, beginning of year$206 $214 $224 
Additions for tax positions related to the current year6 7 27 
Additions for tax positions from prior years— 12 2 
Reductions for tax positions from prior years— (2)(13)
Statute of limitations expirations(17)(25)(26)
Balance, end of year$195 $206 $214 
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.20.4
NET INCOME (LOSS) PER SHARE (Tables)
 12 Months Ended
Oct. 31, 2020
Earnings Per Share [Abstract]  
Reconciliation of the numerators and denominators of the basic and diluted net income per share
The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented below.
 Years Ended October 31,
 202020192018
 (in millions)
Numerator:   
Net income$719 $1,071 $316 
Denominators:   
Basic weighted average shares309 314 321 
Potential common shares — stock options and other employee stock plans3 4 4 
Diluted weighted average shares312 318 325 
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.20.4
INVENTORY (Tables)
 12 Months Ended
Oct. 31, 2020
Inventory Disclosure [Abstract]  
Inventory
Inventory as of October 31, 2020 and 2019 consisted of the following:
 October 31,
 20202019
 (in millions)
Finished goods$417 $416 
Purchased parts and fabricated assemblies303 263 
Inventory$720 $679 
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.20.4
PROPERTY, PLANT AND EQUIPMENT, NET (Tables)
 12 Months Ended
Oct. 31, 2020
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment
Property, plant and equipment as of October 31, 2020 and 2019, consisted of the following:
 October 31,
 20202019
 (in millions)
Land$58 $57 
Buildings and leasehold improvements1,055 1,012 
Machinery and equipment579 546 
Software182 160 
Total property, plant and equipment1,874 1,775 
Accumulated depreciation and amortization(1,029)(925)
Property, plant and equipment, net$845 $850 
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES (Tables)
 12 Months Ended
Oct. 31, 2020
Leases [Abstract]  
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
Prior to the adoption of the new lease accounting standard, future minimum lease payments as of October 31, 2019 under non-cancelable leases with initial terms exceeding twelve months were as follows:

Operating Leases
(in millions)
2020$52 
2021$41 
2022$29 
2023$21 
2024$14 
Thereafter$56 
Lease, Cost
The components of lease cost for operating leases were as follows:
Year Ended October 31, 2020
(in millions)
Operating lease cost$60 
Short-term lease cost1 
Variable lease cost (a)
14 
Sublease income(14)
Total lease cost$61 
(a) Variable lease cost includes cancelable leases, non-fixed maintenance costs and non-recoverable transaction taxes.

Total rent expense was $75 million in 2019 and $64 million in 2018.

Supplemental cash flow information related to leases was as follows:
Year Ended October 31, 2020
(in millions)
Cash paid for amounts included in the amounts included in the measurement of lease liabilities:
Operating cash flow from operating leases$59 
Non-cash right of use assets obtained in exchange for operating lease obligations$37 
Lessee Assets and Liabilities
Supplemental balance sheet information related to leases was as follows:
Financial Statement Line ItemOctober 31, 2020
(in millions, except lease term and discount rate)
Assets:
Operating lease:
Right of use assetOther assets$175 
Liabilities:
Current
Operating lease liabilitiesOther accrued liabilities$51 
Long-term
Operating lease liabilitiesOther long-term liabilities$127 
Weighted average remaining lease term (in years)
Operating leases7.9 years
Weighted average discount rate
Operating leases2.1 %
Schedule of Future Minimum Rent Payments
Future minimum rents payable as of October 31, 2020 under non-cancelable leases with initial terms exceeding one year reconcile to lease liabilities included in the consolidated balance sheet as follows:
Operating Leases
(in millions)
2021$54 
202241 
202328 
202416 
20259 
Thereafter49 
Total undiscounted future minimum lease payments$197 
Less: amount of lease payments representing interest(19)
Present value of future minimum lease payments$178 
Less: current liabilities(51)
Long-term lease liabilities$127 
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.20.4
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
 12 Months Ended
Oct. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill balances and movements for each reportable segments during the period
The following table presents goodwill balances and the movements for each of our reportable segments during the years ended October 31, 2019 and 2020:
Life Sciences and Applied MarketsDiagnostics and GenomicsAgilent CrossLabTotal
 (in millions)
Goodwill as of October 31, 2018$803 $1,607 $563 $2,973 
Foreign currency translation impact(1)(2)(2)(5)
Goodwill arising from acquisitions636 (11)— 625 
Goodwill as of October 31, 2019$1,438 $1,594 $561 $3,593 
Foreign currency translation impact3 5 1 9 
Goodwill as of October 31, 2020$1,441 $1,599 $562 $3,602 
Schedule of Acquired Finite-Lived Intangible Assets by Major Class
The component parts of other intangible assets at October 31, 2019 and 2020 are shown in the table below:
 Other Intangible Assets
 Gross
Carrying
Amount		Accumulated
Amortization		Net Book
Value
 (in millions)
As of October 31, 2019:   
Purchased technology$1,413 $763 $650 
Backlog5 5 — 
Trademark/Tradename196 102 94 
Customer relationships329 87 242 
Third-party technology and licenses28 22 6 
Total amortizable intangible assets$1,971 $979 $992 
In-Process R&D115 — 115 
Total$2,086 $979 $1,107 
As of October 31, 2020:   
Purchased technology$1,429 $863 $566 
Trademark/Tradename196 117 79 
Customer relationships330 158 172 
Third-party technology and licenses11 7 4 
Total amortizable intangible assets$1,966 $1,145 $821 
In-Process R&D10 — 10 
Total$1,976 $1,145 $831 
Future Amortization expense for the next five years and thereafter
Future amortization expense related to existing finite-lived purchased intangible assets associated with business combinations for the next five fiscal years and thereafter is estimated below:
Estimated future amortization expense:
(in millions)
2021$174 
2022$151 
2023$109 
2024$87 
2025$70 
Thereafter$230 
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.20.4
INVESTMENTS (Tables)
 12 Months Ended
Oct. 31, 2020
Schedule of Investments [Abstract]  
Equity Investments
The following table summarizes the company's equity investments as of October 31, 2020 and 2019 (net book value):

 October 31,
 20202019
 (in millions)
Long-Term  
Equity investments - without readily determinable fair value$103 $47 
Equity investments - with readily determinable fair value25 25 
Trading securities30 30 
Total$158 $102 
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE MEASUREMENTS (Tables)
 12 Months Ended
Oct. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value Assets And Liabilities Measured On Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2020 were as follows:

  Fair Value Measurement at October 31, 2020 Using
 October 31,
2020		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
 (in millions)
Assets:    
Short-term    
Cash equivalents (money market funds)$740 $740 $— $— 
Derivative instruments (foreign exchange contracts)2 — 2 — 
Long-term    
Trading securities30 30 — — 
Other investments25 — 25 — 
Total assets measured at fair value$797 $770 $27 $— 
Liabilities:    
Short-term    
Derivative instruments (foreign exchange contracts)$17 $— $17 $— 
Long-term    
Deferred compensation liability30 — 30 — 
Total liabilities measured at fair value$47 $— $47 $— 

Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2019 were as follows:

  Fair Value Measurement
at October 31, 2019 Using
 October 31,
2019		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
 (in millions)
Assets:    
Short-term    
Cash equivalents (money market funds)$784 $784 $— $— 
Derivative instruments (foreign exchange contracts)12 — 12 — 
Long-term    
Trading securities30 30 — — 
Other investments25 — 25 — 
Total assets measured at fair value$851 $814 $37 $— 
Liabilities:   
Short-term    
Derivative instruments (foreign exchange contracts)$6 $— $6 $— 
Long-term    
Deferred compensation liability30 — 30 — 
Total liabilities measured at fair value$36 $— $36 $— 
Impairment of Long-lived assets included in net income
For assets measured at fair value on a non-recurring basis, the following table summarizes the impairments included in net income for the years ended October 31, 2020, 2019 and 2018:

 Years Ended
October 31,
 202020192018
 (in millions)
Long-lived assets held and used$98 $— $21 
Long-lived assets held for sale$— $— $— 
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.20.4
DERIVATIVES (Tables)
 12 Months Ended
Oct. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Aggregated notional amounts by currency and designation The aggregated notional amounts by currency and designation as of October 31, 2020 were as follows:
 Derivatives Designated as
Cash Flow Hedges
Derivatives Designated as
Net Investment Hedges		Derivatives
Not
Designated
as Hedging
Instruments
 Forward
Contracts USD		Forward
Contracts USD		Forward
Contracts USD
CurrencyBuy/(Sell)Buy/(Sell)Buy/(Sell)
 (in millions)
Euro$(59)$(94)$17 
British Pound(41)— 7 
Canadian Dollar(33)— (7)
Japanese Yen(83)— (39)
Korean Won(58)— (32)
Singapore Dollar12 — 23 
Chinese Yuan Renminbi(74)— (66)
Swedish Krona— — (10)
Taiwan Dollar— — (14)
India Rupee— — (15)
Other4 — 2 
$(332)$(94)$(134)
Gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of October 31, 2020 and 2019 were as follows:
Fair Values of Derivative Instruments
Asset DerivativesLiability Derivatives
 Fair Value Fair Value
Balance Sheet LocationOctober 31,
2020		October 31,
2019		Balance Sheet LocationOctober 31,
2020		October 31,
2019
(in millions)
Derivatives designated as hedging instruments:     
Cash flow hedges     
Foreign exchange contracts     
Other current assets$— $3 Other accrued liabilities$12 $2 
Derivatives not designated as hedging instruments:     
Foreign exchange contracts     
Other current assets$2 $9 Other accrued liabilities$5 $4 
Total derivatives$2 $12  $17 $6 
Effect of derivative instruments for foreign exchange contracts in the consolidated statement of operations
The effects of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows:

Years Ended October 31,
202020192018
 (in millions)
Derivatives designated as hedging instruments:   
Cash flow hedges   
Foreign exchange contracts:
Loss on interest rate swaps recognized in other comprehensive income (loss)$— $(6)$— 
Loss reclassified from accumulated other comprehensive income (loss) into interest expense$(1)$(1)$(1)
Gain (loss) recognized in accumulated other comprehensive income (loss)$(12)$— $7 
Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales$(1)$9 $(3)
Gain (loss) on time value of forward contracts recorded in cost of sales$2 $2 $— 
Net investment hedges
Foreign exchange contracts:
Loss recognized in accumulated other comprehensive income (loss)$(5)$— $— 
Derivatives not designated as hedging instruments:   
Gain (loss) recognized in other income (expense), net $(1)$2 $(2)
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.20.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables)
 12 Months Ended
Oct. 31, 2020
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]  
Schedule of Net Benefit Costs For the years ended October 31, 2020, 2019 and 2018, components of net periodic benefit cost and other amounts recognized in other comprehensive income were comprised of:
 PensionsU.S. Post-Retirement Benefit Plans
 U.S. PlansNon-U.S. Plans
 202020192018202020192018202020192018
 (in millions)
Net periodic benefit cost (benefit)         
Service cost — benefits earned during the period$— $— $— $24 $20 $20 $1 $— $1 
Interest cost on benefit obligation15 18 16 8 14 13 3 4 3 
Expected return on plan assets(28)(27)(28)(47)(43)(46)(7)(7)(7)
Amortization of net actuarial loss3 1 1 49 34 29 4 4 8 
Amortization of prior service benefit— — — — — — (7)(8)(8)
Total periodic benefit cost (benefit)$(10)$(8)$(11)$34 $25 $16 $(6)$(7)$(3)
Settlement (gain) loss$4 $— $— $— $— $(5)$— $— $— 
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss         
Net actuarial (gain) loss$26 $51 $2 $20 $104 $49 $5 $5 $(2)
Amortization of net actuarial loss(3)(1)(1)(49)(34)(29)(4)(4)(8)
Amortization of prior service benefit— — — — — — 7 8 8 
Loss due to settlement(4)— — — — — — — — 
Foreign currency— — — 10 (3)1 — — — 
Total recognized in other comprehensive (income) loss$19 $50 $1 $(19)$67 $21 $8 $9 $(2)
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss$13 $42 $(10)$15 $92 $32 $2 $2 $(5)
Schedule of Funded status of Defined Benefit and Post-Retirement Benefit plans
Funded Status.    As of October 31, 2020 and 2019, the funded status of the defined benefit and post-retirement benefit plans was:

 U.S. Defined
Benefit Plans		Non-U.S. Defined
Benefit Plans		U.S.
Post-Retirement
Benefit Plans
 202020192020201920202019
 (in millions)
Change in fair value of plan assets:      
Fair value — beginning of year$432 $401 $911 $825 $95 $90 
Actual return on plan assets30 50 (2)85 6 11 
Employer contributions— — 32 21 — — 
Participants' contributions— — 1 1 — — 
Benefits paid(8)(19)(31)(29)(8)(6)
Settlements(15)— — — — — 
Currency impact— — 34 8 — — 
Fair value — end of year$439 $432 $945 $911 $93 $95 
Change in benefit obligation:      
Benefit obligation — beginning of year$491 $420 $1,067 $913 $94 $87 
Service cost— — 24 20 1 — 
Interest cost15 18 8 14 3 4 
Participants' contributions— — 1 1 — — 
Actuarial (gain) loss28 74 (19)143 4 9 
Benefits paid(9)(21)(31)(29)(8)(6)
Settlements(15)— — — — — 
Currency impact— — 44 5 — — 
Benefit obligation — end of year$510 $491 $1,094 $1,067 $94 $94 
Overfunded (underfunded) status of PBO$(71)$(59)$(149)$(156)$(1)$1 
Amounts recognized in the consolidated balance sheet
Amounts recognized in the consolidated balance sheet consist of:      
Other assets$— $— $123 $106 $— $1 
Employee compensation and benefits(1)(1)— — — — 
Retirement and post-retirement benefits(70)(58)(272)(262)(1)— 
Total net asset (liability)$(71)$(59)$(149)$(156)$(1)$1 
Amounts recognized in accumulated other comprehensive income (loss)
Amounts Recognized in Accumulated Other Comprehensive Income (Loss):
Actuarial (gains) losses$134 $115 $311 $330 $11 $10 
Prior service costs (benefits)— — — — (5)(12)
Total$134 $115 $311 $330 $6 $(2)
Amounts in accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year
The amounts in accumulated other comprehensive income (loss) expected to be recognized by Agilent as components of net expense during 2021 are as follows:
U.S. Defined
Benefit Plans		Non-U.S. Defined
Benefit Plans		U.S. Post-Retirement
Benefit Plans
 (in millions)
Amortization of net prior service cost (benefit)$— $— $(1)
Amortization of actuarial net loss$4 $52 $4 
Schedule of Allocation of Plan Assets
The following tables present the fair value of U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2020 and 2019.
  Fair Value Measurement
at October 31, 2020 Using
 October 31,
2020		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$1 $— $— $— $1 
Equity357 77 — — 280 
Fixed Income79 39 — — 40 
Other Investments2 — — 2 — 
Total assets measured at fair value$439 $116 $— $2 $321 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
  Fair Value Measurement
at October 31, 2019 Using
 October 31,
2019		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$1 $— $— $— $1 
Equity336 78 — — 258 
Fixed Income91 46 — — 45 
Other Investments4 — — 4 — 
Total assets measured at fair value$432 $124 $— $4 $304 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
The following tables present the fair value of U.S. Post-Retirement Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2020 and 2019.
  Fair Value Measurement
at October 31, 2020 Using
 October 31,
2020		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$4 $— $— $— $4 
Equity70 17 — — 53 
Fixed Income18 9 — — 9 
Other Investments1 — — 1 — 
Total assets measured at fair value$93 $26 $— $1 $66 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

  Fair Value Measurement
at October 31, 2019 Using
 October 31,
2019		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$3 $— $— $— $3 
Equity69 18 — — 51 
Fixed Income21 11 — — 10 
Other Investments2 — — 2 — 
Total assets measured at fair value$95 $29 $— $2 $64 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
The following tables present the fair value of non-U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2020 and 2019:

  Fair Value Measurement
at October 31, 2020 Using
 October 31,
2020		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$7 $— $6 $— $1 
Equity504 315 48 — 141 
Fixed Income434 102 238 — 94 
Other Investments— — — — — 
Total assets measured at fair value$945 $417 $292 $— $236 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

  Fair Value Measurement
at October 31, 2019 Using
 October 31,
2019		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$1 $— $1 $— $— 
Equity512 318 61 — 133 
Fixed Income398 98 213 — 87 
Other Investments— — — — — 
Total assets measured at fair value$911 $416 $275 $— $220 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
Defined benefit plans assets measured at fair value using significant unobservable inputs (level 3)
For U.S. Defined Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2020 and 2019:
 Years Ended
October 31.
 20202019
Balance, beginning of year$4 $6 
Realized gains/(losses)(3)(1)
Unrealized gains/(losses)2 1 
Purchases, sales, issuances, and settlements(1)(2)
Transfers in (out)— — 
Balance, end of year$2 $4 
For U.S. Post-Retirement Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2020 and 2019:
 Years Ended
October 31,
 20202019
Balance, beginning of year$2 $4 
Realized gains/(losses)(1)(1)
Unrealized gains/(losses)1 — 
Purchases, sales, issuances, and settlements(1)(1)
Transfers in (out)— — 
Balance, end of year$1 $2 
Combined projected benefit obligation, accumulated benefit obligations and fair value of plan assets
The table below presents the combined projected benefit obligation ("PBO"), accumulated benefit obligation ("ABO") and fair value of plan assets, grouping plans using comparisons of the PBO and ABO relative to the plan assets as of October 31, 2020 or 2019.
 20202019
 Benefit
Obligation		 Benefit
Obligation		 
 Fair Value of
Plan Assets		Fair Value of
Plan Assets
 PBOPBO
 (in millions)
U.S. defined benefit plans where PBO exceeds the fair value of plan assets $510 $439 $491 $432 
U.S. defined benefit plans where fair value of plan assets exceeds PBO — — — — 
Total$510 $439 $491 $432 
Non-U.S. defined benefit plans where PBO exceeds or is equal to the fair value of plan assets $697 $425 $752 $490 
Non-U.S. defined benefit plans where fair value of plan assets exceeds PBO 397 520 315 421 
Total$1,094 $945 $1,067 $911 
 ABO ABO 
U.S. defined benefit plans where ABO exceeds the fair value of plan assets$510 $439 $491 $432 
U.S. defined benefit plans where the fair value of plan assets exceeds ABO— — — — 
Total$510 $439 $491 $432 
Non-U.S. defined benefit plans where ABO exceeds or is equal to the fair value of plan assets $675 $425 $651 $418 
Non-U.S. defined benefit plans where fair value of plan assets exceeds ABO387 520 381 493 
Total$1,062 $945 $1,032 $911 
Schedule of expected benefit payments The following table presents expected future benefit payments for the next 10 years:
U.S. Defined
Benefit Plans		Non-U.S. Defined
Benefit Plans		U.S. Post-Retirement
Benefit Plans
 (in millions)
2021$33 $33 $8 
2022$31 $34 $8 
2023$33 $36 $7 
2024$34 $36 $7 
2025$33 $37 $7 
2026 - 2030$152 $192 $35 
Assumptions used to calculate the net periodic cost and benefit obligation
Assumptions used to calculate the net periodic cost in each year were as follows:

 For years ended October 31,
 202020192018
U.S. defined benefit plans:   
Discount rate3.25%4.50%3.75%
Expected long-term return on assets7.00%7.00%7.00%
Non-U.S. defined benefit plans:   
Discount rate
0.22-1.81%
0.83-2.68%
0.67-2.52%
Average increase in compensation levels
2.25-3.00%
2.25-3.25%
2.00-3.25%
Expected long-term return on assets
4.00-5.75%
4.00-5.75%
4.00-6.00%
U.S. post-retirement benefits plans:   
Discount rate3.00%4.25%3.50%
Expected long-term return on assets7.00%7.00%7.00%
Current medical cost trend rate6.25%6.00%6.00%
Ultimate medical cost trend rate4.50%3.50%3.50%
Medical cost trend rate decreases to ultimate rate in year202920292029

Assumptions used to calculate the benefit obligation were as follows:

 As of the Years Ending October 31,
 20202019
U.S. defined benefit plans:  
Discount rate2.75%3.25%
Non-U.S. defined benefit plans:  
Discount rate
0.07-1.54%
0.22-1.81%
Average increase in compensation levels
2.00-3.00%
2.25-3.00%
U.S. post-retirement benefits plans:  
Discount rate2.50%3.00%
Current medical cost trend rate6.25%6.25%
Ultimate medical cost trend rate4.50%4.50%
Medical cost trend rate decreases to ultimate rate in year20292029
Schedule of Defined Benefit Plans Disclosures
Amounts Recognized in Accumulated Other Comprehensive Income (Loss):
Actuarial (gains) losses$134 $115 $311 $330 $11 $10 
Prior service costs (benefits)— — — — (5)(12)
Total$134 $115 $311 $330 $6 $(2)
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.20.4
GUARANTEES (Tables)
 12 Months Ended
Oct. 31, 2020
Guarantees [Abstract]  
Standard Warranty
A summary of the standard warranty accrual activity is shown in the table below.

 October 31,
 20202019
 (in millions)
Standard warranty accrual, beginning balance$32 $35 
Accruals for warranties including change in estimates49 54 
Settlements made during the period(49)(57)
Standard warranty accrual, ending balance$32 $32 
Schedule of Product Warranty Liability classification
Accruals for warranties due within one year$30 $32 
Accruals for warranties due after one year2 — 
Standard warranty accrual, ending balance$32 $32 
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.20.4
LONG-TERM DEBT (Tables)
 12 Months Ended
Oct. 31, 2020
Debt Disclosure [Abstract]  
Long-term debt - Senior Notes
The following table summarizes the company's long-term senior notes:

 October 31, 2020October 31, 2019
 Amortized
Principal		Amortized
Principal
 (in millions)
2022 Senior Notes$400 $399 
2023 Senior Notes598 597 
2026 Senior Notes298 298 
2029 Senior Notes493 492 
2030 Senior Notes495 — 
Total$2,284 $1,786 
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.20.4
STOCKHOLDERS' EQUITY (Tables)
 12 Months Ended
Oct. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Accumulated other comprehensive income
The following table summarizes the components of our accumulated other comprehensive income (loss) as of October 31, 2020 and 2019, net of tax effect:

 October 31,
 20202019
 (in millions)
Foreign currency translation, net of tax expense of $(6) and $(5) for 2020 and 2019, respectively
$(194)(204)
Unrealized losses (including prior service benefit) on defined benefit plans, net of tax benefit of $154 and $153 for 2020 and 2019, respectively
(317)(306)
Unrealized gains (losses) on derivative instruments, net of tax benefit of $6 and $3 for 2020 and 2019, respectively
(11)(4)
Total accumulated other comprehensive loss$(522)$(514)
Changes in accumulated other comprehensive income (loss) by component and related tax effects for the years ended October 31, 2020 and 2019 were as follows:

Net defined benefit pension cost and post retirement plan costs
Foreign currency translationPrior service creditsActuarial LossesUnrealized gains (losses) on derivativesTotal
(in millions)
As of October 31, 2018$(214)$134 $(335)$7 $(408)
Impact of adoption of new guidance on tax effects in accumulated other comprehensive income (loss)— 3 (9)(1)(7)
As of November 1, 2018(214)137 (344)6 (415)
Other comprehensive loss before reclassifications— — (157)(6)(163)
Amounts reclassified out of accumulated other comprehensive income (loss)— (8)39 (8)23 
Tax benefit10 2 25 4 41 
Other comprehensive income (loss)10 (6)(93)(10)(99)
As of October 31, 2019$(204)$131 $(437)$(4)$(514)
Other comprehensive income (loss) before reclassifications11 — (66)(12)(67)
Amounts reclassified out of accumulated other comprehensive income (loss)— (7)61 2 56 
Tax (expense) benefit(1)1 — 3 3 
Other comprehensive income (loss)10 (6)(5)(7)(8)
As of October 31, 2020$(194)$125 $(442)$(11)$(522)
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]
Reclassifications out of accumulated other comprehensive income (loss) for the years ended October 31, 2020 and 2019 were as follows (in millions):
Details about Accumulated Other
Comprehensive Income components		Amounts Reclassified
from Other Comprehensive Income		Affected line item in
statement of operations
20202019
Unrealized gains and (losses) on derivatives$(2)$8 Cost of products and interest expense
(2)8 Total before income tax
— (2)(Provision)/benefit for income tax
(2)6 Total net of income tax
Net defined benefit pension cost and post retirement plan costs:
Actuarial net loss(61)(39)Other (income) expense
Prior service benefit7 8 Other (income) expense
(54)(31)Total before income tax
16 12 Benefit for income tax
(38)(19)Total net of income tax
Total reclassifications for the period$(40)$(13)
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.20.4
SEGMENT INFORMATION (Tables)
 12 Months Ended
Oct. 31, 2020
Revenue from External Customer [Line Items]  
Segment profitability
The profitability of each of the segments is measured after excluding items such as asset impairment charges, transformational initiatives, acquisition and integration costs, non-cash amortization of intangible assets related to business combinations, interest income, interest expense, and other items as noted in the reconciliations below.
Life Sciences and Applied MarketsDiagnostics and GenomicsAgilent CrossLabTotal
Segments
 (in millions)
Year Ended October 31, 2020:    
Total net revenue$2,392 $1,047 $1,900 $5,339 
Income from operations$548 $192 $516 $1,256 
Depreciation expense$43 $39 $37 $119 
Share-based compensation expense (1)
$35 $17 $29 $81 
Year Ended October 31, 2019:   
Total net revenue$2,302 $1,021 $1,840 $5,163 
Income from operations$542 $185 $475 $1,202 
Depreciation expense$41 $35 $35 $111 
Share-based compensation expense$33 $14 $25 $72 
Year Ended October 31, 2018:   
Total net revenue$2,270 $943 $1,701 $4,914 
Income from operations$543 $173 $388 $1,104 
Depreciation expense$38 $33 $31 $102 
Share-based compensation expense$33 $14 $24 $71 

(1) Share-based compensation expense in 2020 excludes amounts not allocated to the segments related to accelerated share-based compensation expense from workforce reduction and from our acquisition of BioTek.
Reconciliation of segment results to total enterprise results
The following table reconciles reportable segments' income from operations to Agilent's total enterprise income before taxes:

 Years Ended October 31,
 202020192018
 (in millions)
Total reportable segments' income from operations$1,256 $1,202 $1,104 
Amortization of intangible assets related to business combinations(184)(125)(105)
Acquisition and integration costs(41)(48)(23)
Transformational initiatives(53)(44)(25)
Acceleration of share-based compensation expense related to workforce reduction(2)— — 
Asset impairments(99)— (21)
Business exit and divestiture costs (2)— (9)
NASD site costs— (12)(8)
Special compliance costs— (2)(4)
Other (1)
(29)(30)(5)
Interest Income8 36 38 
Interest Expense(78)(74)(75)
Other income (expense), net (2)
66 16 79 
Income before taxes, as reported$842 $919 $946 

(1) For the years ended October 31, 2020 and 2019, the other category primarily includes legal costs related to a claim we pursued against Twist Bioscience Corporation in addition to other miscellaneous adjustments.
(2) For the year ended October 31, 2020, other income (expense), net includes the settlement of a legal claim against Twist Bioscience Corporation.
Assets and capital expenditures directly managed by each segment
The following table reflects segment assets and capital expenditures under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets.
Life Sciences and Applied MarketsDiagnostics and GenomicsAgilent CrossLabTotal
Segments
 (in millions)
As of and for the Year Ended October 31, 2020:    
Assets$3,143 $2,515 $1,375 $7,033 
Capital expenditures$44 $34 $41 $119 
As of and for the Year Ended October 31, 2019:    
Assets$3,202 $2,620 $1,331 $7,153 
Capital expenditures$59 $48 $48 $155 


The following table reconciles segment assets to Agilent's total assets:
 October 31,
 20202019
 (in millions)
Total reportable segments' assets$7,033 $7,153 
Cash and cash equivalents1,441 1,382 
Prepaid expenses106 94 
Investments158 102 
Long-term and other receivables114 100 
Deferred tax assets380 410 
Right of use assets175 — 
Other220 211 
Total assets$9,627 $9,452 

The other category primarily includes overfunded pension assets which are not allocated to the segments.
Revenue and assets by geographic areas
The following table presents summarized information for net revenue by geographic region. Revenues from external customers are generally attributed to countries based upon the customers' location.

United
States
China(1)
Rest of the
World		Total
 (in millions)
Net revenue:    
Year Ended October 31, 2020$1,752 $1,087 $2,500 $5,339 
Year Ended October 31, 2019$1,619 $1,019 $2,525 $5,163 
Year Ended October 31, 2018$1,414 $1,015 $2,485 $4,914 
1.China also includes Hong Kong net revenue.



The following table presents summarized information for long-lived assets by geographic region. Long lived assets consist of property, plant, and equipment, right-of-use assets, long-term receivables and other long-term assets excluding intangible assets. The rest of the world primarily consists of Asia and the rest of Europe.
United
States		GermanyRest of the
World		Total
 (in millions)
Long-lived assets:   
October 31, 2020$727 $126 $538 $1,391 
October 31, 2019$621 $122 $404 $1,147 
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.20.4
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)
$ in Millions
 12 Months Ended
Oct. 31, 2020
USD ($)
numberOfCustomers
Oct. 31, 2019
USD ($)
numberOfCustomers
Oct. 31, 2018
USD ($)
numberOfCustomers
Oct. 31, 2017
USD ($)
Advertising Expense        
Advertising costs expensed as incurred $ 48 $ 36 $ 41  
Cash and Cash Equivalents        
Cash and cash equivalents 1,441 1,382 2,247  
Restricted Cash 6 6 7  
Cash, cash equivalents and restricted cash $ 1,447 $ 1,388 $ 2,254 $ 2,686
Accounts Receivable        
Number of customers representing 10 percent or more of accounts receivable. | numberOfCustomers 0 0 0  
Goodwill and Intangible Assets        
Goodwill impairment $ 0 $ 0 $ 0  
Impairment of indefinite-lived intangible assets 90 0 0  
Impairment of finite-lived intangible assets 0 0 21  
Long -Lived Assets        
Impairment of Long-Lived Assets 98 0 21  
Variable Interest Entity        
Remeasurement Gain on step acquisition 0 0 20  
Assets 9,627 9,452    
Fair Value Disclosures        
Fair value of long term debt in excess of carrying value 162 62    
Employee Compensation and Benefits        
Employee compensation and benefits accrued 111 115    
Share-based Payment Arrangement, Noncash Expense [Abstract]        
Share-based compensation expense $ 84 72 71  
Derivative Instruments        
Hedging contracts general maturity 12 months      
Foreign Currency Translation        
Foreign currency translation net gain (Ioss) $ (4) (7) $ (3)  
Accounts Receivable        
Accounts Receivable        
Number of customers representing 10 percent or more of accounts receivable. | numberOfCustomers 0      
Variable Interest Entity, Not Primary Beneficiary        
Variable Interest Entity        
Assets $ 67 29    
Non-US        
Cash and Cash Equivalents        
Cash and cash equivalents $ 1,395      
Lasergen        
Variable Interest Entity        
Purchase price for acquisition   107    
Remeasurement Gain on step acquisition   $ 20    
Minimum        
Goodwill and Intangible Assets        
Finite Lived Intangible Assets Useful Life 6 months      
Minimum | Machinery and Equipment        
Property, Plant and Equipment [Abstract]        
Property, Plant and Equipment, Useful Life 3 years      
Minimum | Software Development        
Property, Plant and Equipment [Abstract]        
Property, Plant and Equipment, Useful Life 3 years      
Maximum        
Goodwill and Intangible Assets        
Finite Lived Intangible Assets Useful Life 15 years      
Maximum | Machinery and Equipment        
Property, Plant and Equipment [Abstract]        
Property, Plant and Equipment, Useful Life 10 years      
Maximum | Software Development        
Property, Plant and Equipment [Abstract]        
Property, Plant and Equipment, Useful Life 5 years      
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.20.4
NEW ACCOUNTING PRONOUNCEMENTS - (Details) - USD ($)
$ in Millions
Oct. 31, 2020
Nov. 01, 2019
Oct. 31, 2019
Other assets $ 776 $ 803 $ 611
Other accrued liabilities 285 488 440
Other long-term liabilities $ 614 617 $ 473
Accounting Standards Update 2016-02- Leases      
Other assets   192  
Other accrued liabilities   48  
Other long-term liabilities   $ 144  
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.20.4
ACQUISITIONS - Text (Details) - USD ($)
$ in Millions
Aug. 23, 2019
Nov. 14, 2018
Oct. 31, 2020
Oct. 31, 2019
ACEA Biosciences, Inc.        
Business Acquisition [Line Items]        
Purchase price for acquisition   $ 250    
BioTek        
Business Acquisition [Line Items]        
Purchase price for acquisition $ 1,170      
Cash payment to acquire business 470      
Liability incurred to pay for acquisition $ 700      
Acquisition transaction costs     $ 12 $ 4
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.20.4
ACQUISITIONS - Assets and Liabilities Assumed (Details) - USD ($)
$ in Millions
 12 Months Ended
Aug. 23, 2019
Oct. 31, 2020
Oct. 31, 2019
Business Acquisition [Line Items]      
Goodwill Additions   $ 0 $ 625
BioTek      
Business Acquisition [Line Items]      
Cash and cash equivalents $ 10    
Accounts receivables 28    
Inventories 21    
Other current assets 2    
Property, plant, and equipment 8    
Intangible assets 641    
Goodwill Additions 483    
Total assets acquired 1,193    
Accounts payable 4    
Deferred revenue 5    
Employee compensation and benefits 7    
Other accrued liabilities 2    
Long-term debt 4    
Net assets acquired $ 1,171    
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.20.4
ACQUISITIONS ACQUISITIONS - Intangible Assets (Details) - USD ($)
$ in Millions
Aug. 23, 2019
Oct. 31, 2020
Oct. 31, 2019
Business Acquisition [Line Items]      
Finite-lived intangible assets acquired   $ 1,966 $ 1,971
In-Process R&D   10 115
Total intangible assets acquired - excluding goodwill   1,976 2,086
BioTek      
Business Acquisition [Line Items]      
Finite-lived intangible assets acquired $ 637    
In-Process R&D 4    
Total intangible assets acquired - excluding goodwill 641    
Developed product technology      
Business Acquisition [Line Items]      
Finite-lived intangible assets acquired   1,429 1,413
Developed product technology | BioTek      
Business Acquisition [Line Items]      
Finite-lived intangible assets acquired 387    
Customer relationships      
Business Acquisition [Line Items]      
Finite-lived intangible assets acquired   $ 330 329
Customer relationships | BioTek      
Business Acquisition [Line Items]      
Finite-lived intangible assets acquired 202    
Backlog      
Business Acquisition [Line Items]      
Finite-lived intangible assets acquired     $ 5
Backlog | BioTek      
Business Acquisition [Line Items]      
Finite-lived intangible assets acquired $ 5    
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 2 months    
Tradenames and trademarks | BioTek      
Business Acquisition [Line Items]      
Finite-lived intangible assets acquired $ 43    
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 10 years    
Minimum | Developed product technology | BioTek      
Business Acquisition [Line Items]      
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 5 years    
Minimum | Customer relationships | BioTek      
Business Acquisition [Line Items]      
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 3 years    
Maximum | Developed product technology | BioTek      
Business Acquisition [Line Items]      
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 13 years    
Maximum | Customer relationships | BioTek      
Business Acquisition [Line Items]      
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 8 years    
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.20.4
ACQUISITIONS ACQUISITIONS - Proforma Operating Results (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Oct. 31, 2019
Oct. 31, 2018
Business Acquisition [Line Items]    
Proforma net revenue $ 5,308 $ 5,112
Proforma net income $ 1,012 $ 210
Proforma net income per share - basic $ 3.22 $ 0.65
Proforma net income per share - diluted $ 3.18 $ 0.65
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE - Revenue by Region (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Disaggregation of Revenue [Line Items]      
Net revenue $ 5,339 $ 5,163 $ 4,914
Americas      
Disaggregation of Revenue [Line Items]      
Net revenue 1,968 1,861  
Europe      
Disaggregation of Revenue [Line Items]      
Net revenue 1,443 1,441  
Asia Pacific      
Disaggregation of Revenue [Line Items]      
Net revenue 1,928 1,861  
Life Sciences and Applied Markets      
Disaggregation of Revenue [Line Items]      
Net revenue 2,392 2,302 2,270
Life Sciences and Applied Markets | Americas      
Disaggregation of Revenue [Line Items]      
Net revenue 784 692  
Life Sciences and Applied Markets | Europe      
Disaggregation of Revenue [Line Items]      
Net revenue 540 551  
Life Sciences and Applied Markets | Asia Pacific      
Disaggregation of Revenue [Line Items]      
Net revenue 1,068 1,059  
Diagnostics and Genomics      
Disaggregation of Revenue [Line Items]      
Net revenue 1,047 1,021 943
Diagnostics and Genomics | Americas      
Disaggregation of Revenue [Line Items]      
Net revenue 517 505  
Diagnostics and Genomics | Europe      
Disaggregation of Revenue [Line Items]      
Net revenue 371 368  
Diagnostics and Genomics | Asia Pacific      
Disaggregation of Revenue [Line Items]      
Net revenue 159 148  
Agilent CrossLab      
Disaggregation of Revenue [Line Items]      
Net revenue 1,900 1,840 $ 1,701
Agilent CrossLab | Americas      
Disaggregation of Revenue [Line Items]      
Net revenue 667 664  
Agilent CrossLab | Europe      
Disaggregation of Revenue [Line Items]      
Net revenue 532 522  
Agilent CrossLab | Asia Pacific      
Disaggregation of Revenue [Line Items]      
Net revenue $ 701 $ 654  
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE - Revenue by End Markets (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Disaggregation of Revenue [Line Items]      
Net revenue $ 5,339 $ 5,163 $ 4,914
Pharmaceutical and Biopharmaceutical Market      
Disaggregation of Revenue [Line Items]      
Net revenue 1,754 1,604  
Chemical and Energy Market      
Disaggregation of Revenue [Line Items]      
Net revenue 1,154 1,199  
Diagnostics and Clinical Market      
Disaggregation of Revenue [Line Items]      
Net revenue 787 785  
Food Market      
Disaggregation of Revenue [Line Items]      
Net revenue 517 486  
Academia and Government Market      
Disaggregation of Revenue [Line Items]      
Net revenue 526 474  
Environmental and Forensics Market      
Disaggregation of Revenue [Line Items]      
Net revenue $ 601 $ 615  
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE - Revenue by Type (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Disaggregation of Revenue [Line Items]      
Net revenue $ 5,339 $ 5,163 $ 4,914
Instrumentation      
Disaggregation of Revenue [Line Items]      
Net revenue 2,249 2,150  
Non-Instrumentation and Other      
Disaggregation of Revenue [Line Items]      
Net revenue $ 3,090 $ 3,013  
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE - Contract Balances (Details) - USD ($)
$ in Millions
 12 Months Ended
Nov. 01, 2018
Oct. 31, 2020
Oct. 31, 2019
Contract with Customer, Asset, after Allowance for Credit Loss   $ 153 $ 110
Contract Liability ending balance $ 367 386 367
Increase (Decrease) in Contract with Customer, Liability   347 303
Contract with Customer, Liability, Revenue Recognized   (300) (287)
Contract with Customer, Refund Liability   9 5
Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination     9
Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease)   4 0
Contract Liability ending balance   446 $ 386
Revenue, Remaining Performance Obligation, Amount   $ 217  
Difference between Revenue Guidance in Effect before and after Topic 606      
Deferred Revenue, Period Increase (Decrease) $ (11)    
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.20.4
SHARE-BASED COMPENSATION General Disclosures (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Employee stock purchase plan [Abstract]      
Compensation percentage maximum eligible contribution to purchase shares of common stock 10.00%    
ESPP eligible employee common stock purchase price ratio 85.00%    
Maximum number of shares authorized for issuance under the ESPP (in shares) 31,000,000    
Number of shares purchased under ESPP (in shares) 628,644 603,488 558,116
Aggregate Value stock issued under Employee Stock Purchase Plan $ 41 $ 37 $ 32
Aggregate participants contributions to ESPP $ 22    
Incentive compensation plans [Abstract]      
Term of the 2018 Stock Plan (in years) ten years    
Common stock available for future awards under the 2018 Stock Plan (in shares) 25,596,430    
Maximum contractual term (in years) ten years    
Percentage market value of the common stock option exercise price is generally not less than (in hundredths) 100.00%    
Minimum final share award percentage of the target award based on performance metrics (in hundredths) 0.00%    
Maximum final share award percentage of the target award based on performance metrics (in hundredths) 200.00%    
Time period after which participants of the performance stock award plan are entitled to receive unrestricted share of the company's stock, if specified performance targets are met three years    
Employee Stock Purchase Plan      
Incentive compensation plans [Abstract]      
Common stock available for future awards under the 2018 Stock Plan (in shares) 25,770,573    
Share-based Payment Arrangement, Option      
Incentive compensation plans [Abstract]      
Percentage which rate options generally vest per year (in hundredths) 25.00%    
Number of years from the date of grant generally vest (in years) 4 years    
Restricted Stock Units (RSUs)      
Incentive compensation plans [Abstract]      
Percentage which rate options generally vest per year (in hundredths) 25.00%    
Number of years from the date of grant generally vest (in years) 4 years    
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.20.4
SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Share-based compensation disclosures      
Share-based compensation expense $ 84 $ 72 $ 71
Cost of Product and Services      
Share-based compensation disclosures      
Share-based compensation expense 21 18 16
Research and Development      
Share-based compensation disclosures      
Share-based compensation expense 9 7 7
Selling, General and Administrative      
Share-based compensation disclosures      
Share-based compensation expense 54 47 $ 48
Inventories      
Share-based Payment Arrangement, Expensed and Capitalized, Amount      
Share-based compensation expense $ 0 $ 0  
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.20.4
SHARE-BASED COMPENSATION-Fair Value Assumptions (Details)
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
LTPP      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Volatility of Agilent shares (in hundreths) 23.00% 22.00% 21.00%
Volatility of peer-company shares -Minimum 15.00% 15.00% 14.00%
Volatility of peer-company shares -Maximum 44.00% 66.00% 66.00%
Pair-wise correlation with selected peers (in hundredths) 29.00% 30.00% 32.00%
LTPP & RSU      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Post-vest restriction discount for all executive awards 5.30% 5.00% 4.80%
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.20.4
SHARE-BASED COMPENSATION Stock Option Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]      
Outstanding, beginning balance (in shares) 1,445    
Exercised (in shares) (575)    
Outstanding, ending balance (in shares) 870 1,445  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $ 37 $ 36  
Aggregate Intrinsic Value of Stock options $ 30,481 $ 24,409 $ 28,417
Weighted-average exercise price per share, exercised (in dollars per share) $ 34 $ 33 $ 32
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.20.4
SHARE-BASED COMPENSATION Shares Authorized by Exercise Price Range (Details) - USD ($)
$ / shares in Units, shares in Thousands
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]      
Minimum price of options outstanding in the period (in dollars per share) $ 40.01    
Number Outstanding (in shares) 870    
Weighted Average Remaining Contractual Life (in years) 3 years 3 months 18 days    
Weighted Average Exercise Price (in dollars per share) $ 37    
Aggregate Intrinsic Value - Options outstanding $ 56,661,000    
Number Exercisable (in shares) 870    
Weighted Average Remaining Contractual Life (in years) 3 years 3 months 18 days    
Weighted Average Exercise Price (in dollars per share) $ 37    
Aggregate Intrinsic Value - Options Exercisable $ 56,661,000    
Incentive compensation plans [Abstract]      
Closing stock price basis for aggregate intrinsic value (in dollars per share) $ 102.09    
In-the-money awards exercisable (in shares) 900    
Aggregate instrinsic value of options [Abstract]      
Amount of cash received from the exercise of share-based awards granted $ 60,000,000 $ 54,000,000 $ 56,000,000
Range of Exercise Prices - $25.01 - $30      
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]      
Minimum price of options outstanding in the period (in dollars per share) $ 25,010,000.00    
Maximum price of options outstanding, end of the period (in dollars per share) $ 30,000.00    
Number Outstanding (in shares) 228    
Weighted Average Remaining Contractual Life (in years) 1 year 8 months 12 days    
Weighted Average Exercise Price (in dollars per share) $ 27    
Aggregate Intrinsic Value - Options outstanding $ 17,192,000    
Number Exercisable (in shares) 228    
Weighted Average Remaining Contractual Life (in years) 1 year 8 months 12 days    
Weighted Average Exercise Price (in dollars per share) $ 27    
Aggregate Intrinsic Value - Options Exercisable $ 17,192,000    
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range 02      
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]      
Minimum price of options outstanding in the period (in dollars per share) $ 30,010,000.00    
Maximum price of options outstanding, end of the period (in dollars per share) $ 40,000.00    
Number Outstanding (in shares) 121    
Weighted Average Remaining Contractual Life (in years) 3 years 1 month 6 days    
Weighted Average Exercise Price (in dollars per share) $ 39    
Aggregate Intrinsic Value - Options outstanding $ 7,586,000    
Number Exercisable (in shares) 121    
Weighted Average Remaining Contractual Life (in years) 3 years 1 month 6 days    
Weighted Average Exercise Price (in dollars per share) $ 39    
Aggregate Intrinsic Value - Options Exercisable $ 7,586,000    
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range 03      
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]      
Number Outstanding (in shares) 521    
Weighted Average Remaining Contractual Life (in years) 4 years    
Weighted Average Exercise Price (in dollars per share) $ 41    
Aggregate Intrinsic Value - Options outstanding $ 31,883,000    
Number Exercisable (in shares) 521    
Weighted Average Remaining Contractual Life (in years) 4 years    
Weighted Average Exercise Price (in dollars per share) $ 41    
Aggregate Intrinsic Value - Options Exercisable $ 31,883,000    
Share-based Payment Arrangement, Option      
Aggregate instrinsic value of options [Abstract]      
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 0    
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.20.4
SHARE-BASED COMPENSATION Non-vested award activity disclosure (Details)
$ / shares in Units, shares in Thousands, $ in Millions
 12 Months Ended
Oct. 31, 2020
USD ($)
yr
$ / shares
shares
Oct. 31, 2019
USD ($)
shares
Oct. 31, 2018
USD ($)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Non-vested beginning (in shares) | shares 3,173    
Granted (in shares) | shares 1,091    
Vested (in shares) | shares (1,629)    
Forfeited (in shares) | shares (115)    
Change in LTPP shares vested in the year due to performance conditions | shares 298    
Non-vested ending (in shares) | shares 2,818 3,173  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]      
Non-vested at October 31, 2019 -Weighted Average Grant Price (in dollars per share) | $ / shares $ 60    
Granted - Weighted Average Grant Price (in dollars per share) | $ / shares 79    
Vested- Weighted Average Grant Price (in dollars per share) | $ / shares 52    
Foreited- Weighted Average Grant Price (in dollars per share) | $ / shares 68    
Change in LTPP shares vested in the year- Weighted Average Grant Date Fair Value | $ / shares 47    
Non-vested at October 31, 2020 -Weighted Average Grant Price (in dollars per share) | $ / shares $ 70    
Unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures | $ $ 95    
Weighted-average period non-vested restricted stock awards are expected to be amortized over (in years) | yr 2.1    
Total fair value of restricted stock awards vested | $ $ 85 $ 69 $ 58
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES INCOME TAXES- Provision (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Income before income tax      
U.S. operations $ 54 $ 189 $ 169
Non-U.S. operations 788 730 777
Income before taxes 842 919 946
Provision (benefit) for income taxes      
U.S. federal taxes - current 5 (191) 520
U.S. federal taxes - deferred 4 0 51
Non-U.S. taxes - current 84 290 95
Non-U.S. taxes - deferred 24 (267) (22)
State taxes, net of federal benefit - current 5 4 1
State taxes, net of federal benefit - deferred 1 12 (15)
Income tax expense (benefit) $ 123 $ (152) $ 630
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES INCOME TAXES Effective tax rate and tax holidays (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Effective Income Tax Rate Reconciliation      
Profit before tax times statutory rate $ 177 $ 193 $ 221
Non-U.S. income taxed at different rates (36) (8) (93)
Change in unrecognized tax benefits (9) (13) (17)
Tax Cuts and Jobs Act, Income Tax Expense (Benefit) 0 0 552
Extension of the tax incentive in Singapore 0 (299) 0
Excess tax benefits from stock-based compensation (18) (10) (18)
Adjustments to earnings of foreign subsidiaries 9 (15) (15)
Income tax expense (benefit) $ 123 $ (152) $ 630
Effective tax rate (in hundredths) 14.60% (16.50%) 66.60%
Deferred Tax Liability, Intra-entity Transfer, Asset Other than Inventory   $ 231  
Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense     $ 499
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)     53
Tax Holidays [Abstract]      
Impact of the income tax holidays $ 71 $ 368 $ 87
Benefit of income tax holidays on net income per share $ 0.23 $ 1.16 $ 0.27
Foreign      
Tax Holidays [Abstract]      
Benefit of income tax holidays on net income per share $ 0.94    
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES INCOME TAXES - Deferred Taxes and other (Details) - USD ($)
$ in Millions
Oct. 31, 2020
Oct. 31, 2019
Components of Deferred Tax Assets    
Intangibles $ 153 $ 131
Pension benefits and retiree medical benefits 65 71
Employee benefits, other than retirement 31 34
Net operating loss, capital loss and credit carryforwards 182 195
Share-based compensation 27 32
Deferred revenue 22 38
Deferred tax assets - lease obligations 35 0
Other 41 35
Subtotal 556 536
Tax valuation allowance (132) (134)
Deferred Tax Assets, Net of Valuation Allowance 424 402
Components of Deferred Tax Liabilities    
Property, plant and equipment (19) (16)
Deferred Tax Liabilities, Leasing Arrangements (35) 0
Other (14) (7)
Subtotal (68) (23)
Deferred tax Assets, net 356 379
Long Term Deferred Tax Assets And Liabilities [Abstract]    
Long-term deferred tax assets ( included within other assets) 424 402
Deferred Tax Assets, Net 356 379
Other Noncurrent Assets [Member]    
Components of Deferred Tax Assets    
Deferred Tax Assets, Net of Valuation Allowance 380 410
Long Term Deferred Tax Assets And Liabilities [Abstract]    
Long-term deferred tax assets ( included within other assets) 380 410
Other Noncurrent Liabilities    
Long Term Deferred Tax Assets And Liabilities [Abstract]    
Long-term deferred tax liabilities ( included within other long-term liabilities) $ 24 $ 31
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES - Carryforwards (Details)
$ in Millions
Oct. 31, 2020
USD ($)
Net Operating loss carryforwards  
Federal net operating loss carryforwards $ 11
State net operating loss carryforwards 530
Foreign net operating loss carryforwards 411
Foreign  
Net Operating loss carryforwards  
Net operating loss carryforwards, subject to expiration 123
Net operating loss carryforwards, not subject to expiration 288
Capital Loss Carryforward  
Capital loss carryforwards 118
Domestic  
Capital Loss Carryforward  
Capital loss carryforwards 48
State  
Tax Credit Carryforwards  
Tax credit carryforwards $ 83
XML 86 R72.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES - Current and long-term income tax assets and liabilities (Details) - USD ($)
$ in Millions
Oct. 31, 2020
Oct. 31, 2019
Income Tax Disclosure [Abstract]    
Current income tax assets (included within other current assets) $ 89 $ 68
Long-term income tax assets (included within other assets) 6 4
Current income tax liabilities (included within other accrued liabilities) 63 292
Long-term income tax liabilities (included within other long-term liabilities) 323 328
Total $ 291 $ 548
XML 87 R73.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES INCOME TAXES - Uncertain Tax Positions (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Unrecognized Tax Benefits Rollforward      
Balance, beginning of year $ 206 $ 214 $ 224
Additions for tax positions related to the current year 6 7 27
Additions for tax positions from prior years 0 12 2
Reductions for tax positions from prior years 0 2 13
Statute of limitations expirations 17 25 26
Balance, end of year 195 206 214
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]      
Unrecognized tax benefit including interest and penalties 240    
Unrecognized Tax Benefits that Would Impact Effective Tax Rate 215    
Unrecognized tax benefits that would not impact the effective tax rate 25    
Interest and penalties accrued related to unrecognized tax benefits accrued and reported 45 36  
Tax Interest and Penalties      
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]      
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense $ 8 $ 9 $ 11
XML 88 R74.htm IDEA: XBRL DOCUMENT v3.20.4
NET INCOME (LOSS) PER SHARE (Details) - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Numerator:      
Net income $ 719 $ 1,071 $ 316
Denominator:      
Basic weighted average shares 309 314 321
Potential common shares - stock options and other employeee stock plans 3 4 4
Diluted weighted average shares 312 318 325
Share-based awards issued      
Total number of share-based awards issued (in shares) 2 2 2
XML 89 R75.htm IDEA: XBRL DOCUMENT v3.20.4
INVENTORY (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Inventory [Line Items]      
Finished goods $ 417 $ 416  
Purchased parts and fabricated assemblies 303 263  
Inventory 720 679  
Inventory-related excess and obsolescence charges $ 28 $ 19 $ 26
XML 90 R76.htm IDEA: XBRL DOCUMENT v3.20.4
PROPERTY, PLANT AND EQUIPMENT, NET (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Property, Plant and Equipment [Line Items]      
Land $ 58 $ 57  
Buildings and leasehold improvements 1,055 1,012  
Machinery and equipment 579 546  
Software 182 160  
Total property, plant and equipment 1,874 1,775  
Accumulated depreciation and amortization (1,029) (925)  
Property, plant and equipment, net 845 850  
Asset impairment charges 6 0 $ 1
Depreciation expense 119 111 $ 102
Fully depreciated assets no longer in use retired $ 29 $ 23  
XML 91 R77.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES - Future Minimum Lease Payments (Details)
$ in Millions
Oct. 31, 2019
USD ($)
Future Minimum Lease Payment Due  
2020 $ 52
2021 41
2022 29
2023 21
2024 14
Thereafter $ 56
XML 92 R78.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES - Lease Costs (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Leases [Abstract]      
Operating Lease, Cost $ 60    
Short-term Lease, Cost 1    
Variable Lease, Cost 14    
Sublease Income (14)    
Lease, Cost $ 61    
Total rent expense   $ 75 $ 64
XML 93 R79.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES - Supplemental Cash Flow Information (Details)
$ in Millions
 12 Months Ended
Oct. 31, 2020
USD ($)
Leases [Abstract]  
Operating cash flow from operating leases $ 59
Non-cash right of use assets obtained in exchange for operating lease obligations $ 37
XML 94 R80.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES - Supplemental Balance Sheet Information (Details) - USD ($)
$ in Millions
Oct. 31, 2020
Oct. 31, 2019
Lessee, Lease, Description [Line Items]    
Right-of-use asset $ 175 $ 0
Operating Lease, Weighted Average Remaining Lease Term 7 years 10 months 24 days  
Operating Lease, Weighted Average Discount Rate, Percent 2.10%  
Other Assets    
Lessee, Lease, Description [Line Items]    
Right-of-use asset $ 175  
Other Current Liabilities    
Lessee, Lease, Description [Line Items]    
Operating lease liabilities - Current 51  
Other Noncurrent Liabilities    
Lessee, Lease, Description [Line Items]    
Operating lease liabilities - Long-term $ 127  
XML 95 R81.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES - Maturities of Lease Liabilities (Details)
$ in Millions
Oct. 31, 2020
USD ($)
Future Minimum Lease Payment Due  
2021 $ 54
2022 41
2023 28
2024 16
2025 9
Thereafter 49
Total undiscounted future minimum lease payments 197
Less: amount of lease payments representing interest (19)
Other accrued and long-term liabilities [Member]  
Future Minimum Lease Payment Due  
Present value of future minimum lease payments $ 178
XML 96 R82.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES - Textual (Details) - USD ($)
$ in Millions
Oct. 31, 2020
Oct. 31, 2019
Leases [Abstract]    
operating leased assets - original cost $ 43 $ 49
Operating leased assets net book value 12 17
Sales-type Lease, Lease Receivable $ 44 $ 37
XML 97 R83.htm IDEA: XBRL DOCUMENT v3.20.4
GOODWILL AND OTHER INTANGIBLE ASSETS Roll forward (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Goodwill - Rollforward    
Beginning Balance $ 3,593 $ 2,973
Foreign currency translation impact 9 (5)
Goodwill arising from acquisitions 0 625
Ending Balance 3,602 3,593
Life Sciences and Applied Markets    
Goodwill - Rollforward    
Beginning Balance 1,438 803
Foreign currency translation impact 3 (1)
Goodwill arising from acquisitions   636
Ending Balance 1,441 1,438
Diagnostics and Genomics    
Goodwill - Rollforward    
Beginning Balance 1,594 1,607
Foreign currency translation impact 5 (2)
Indefinite-lived Intangible Assets, Purchase Accounting Adjustments   (11)
Ending Balance 1,599 1,594
Agilent CrossLab    
Goodwill - Rollforward    
Beginning Balance 561 563
Foreign currency translation impact 1 (2)
Goodwill arising from acquisitions   0
Ending Balance $ 562 $ 561
XML 98 R84.htm IDEA: XBRL DOCUMENT v3.20.4
GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Other Intangibles (Details) - USD ($)
$ in Millions
Oct. 31, 2020
Oct. 31, 2019
Schedule of Other Intangible Assets By Major Class [Abstract]    
Gross Carrying Amount $ 1,966 $ 1,971
Accumulated Amortization 1,145 979
Other intangible assets, net 831 1,107
Total amortizable intangible assets 821 992
Gross Book Value 1,976 2,086
In-Process R&D 10 115
Purchased technology    
Schedule of Other Intangible Assets By Major Class [Abstract]    
Gross Carrying Amount 1,429 1,413
Accumulated Amortization 863 763
Other intangible assets, net 566 650
Backlog    
Schedule of Other Intangible Assets By Major Class [Abstract]    
Gross Carrying Amount   5
Accumulated Amortization   5
Other intangible assets, net   0
Trademark/Tradename    
Schedule of Other Intangible Assets By Major Class [Abstract]    
Gross Carrying Amount 196 196
Accumulated Amortization 117 102
Other intangible assets, net 79 94
Customer Relationships    
Schedule of Other Intangible Assets By Major Class [Abstract]    
Gross Carrying Amount 330 329
Accumulated Amortization 158 87
Other intangible assets, net 172 242
Third-Party Technology and Licenses [Member]    
Schedule of Other Intangible Assets By Major Class [Abstract]    
Gross Carrying Amount 11 28
Accumulated Amortization 7 22
Other intangible assets, net $ 4 $ 6
XML 99 R85.htm IDEA: XBRL DOCUMENT v3.20.4
GOODWILL AND OTHER INTANGIBLE ASSETS Text (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Intangible Assets, Including Goodwill)      
Goodwill Additions $ 0 $ 625  
Additions and adjustments to other intangibles 0    
Goodwill and Intangible Asset Impairment [Abstract]      
Goodwill impairment 0 0 $ 0
Impairment of finite-lived intangible assets 0 0 21
Impairment of indefinite-lived intangible assets 90 0 $ 0
Business Acquisition      
Write-off of fully amortized intangible assets $ 17    
Diagnostics and Genomics      
Intangible Assets, Including Goodwill)      
Indefinite-lived Intangible Assets, Purchase Accounting Adjustments   (11)  
Life Sciences and Applied Markets      
Intangible Assets, Including Goodwill)      
Goodwill Additions   636  
Advanced Analytical Technologies, Inc (AATI) | Diagnostics and Genomics      
Intangible Assets, Including Goodwill)      
Indefinite-lived Intangible Assets, Purchase Accounting Adjustments   (11)  
BioTek and ACEA | Life Sciences and Applied Markets      
Intangible Assets, Including Goodwill)      
Goodwill Additions   636  
Additions and adjustments to other intangibles   $ 744  
XML 100 R86.htm IDEA: XBRL DOCUMENT v3.20.4
GOODWILL AND OTHER INTANGIBLE ASSETS Amortization Expense and Future Amortization Expense (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Future Amortization Expense Schedule      
2021 $ 174    
2022 151    
2023 109    
2024 87    
2025 70    
Thereafter 230    
Amortization Expense      
Amortization of intangible assets during the period $ 186 $ 128 $ 110
XML 101 R87.htm IDEA: XBRL DOCUMENT v3.20.4
INVESTMENTS (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Nov. 01, 2018
Long-Term [Abstract]        
Equity investments - without readily determinable fair value $ 103 $ 47    
Equity investments - with readily determinable fair value 25 25    
Trading securities 30 30    
Long-term investments 158 102    
Amounts included in other income (expense), net [Abstract]        
Net unrealized gains on our equity securities with RDFV 28 1 $ 0  
Retained earnings (accumulated deficit) 81 (18)    
Net unrealized gains on trading securities 2 3 $ 1  
Equity Securities without Readily Determinable Fair Value        
Amounts included in other income (expense), net [Abstract]        
Unrealized gain on non-marketable equity securities 27 1    
Equity Securities with Readily Determinable Fair Value        
Amounts included in other income (expense), net [Abstract]        
Net unrealized gains on our equity securities with RDFV $ (1) $ 3    
Accounting Standards Update 2016-01        
Long-Term [Abstract]        
Long-term investments       $ 7
Amounts included in other income (expense), net [Abstract]        
Retained earnings (accumulated deficit)       $ 5
XML 102 R88.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) - USD ($)
$ in Millions
Oct. 31, 2020
Oct. 31, 2019
Assets, Long-term [Abstract]    
Trading securities $ 30 $ 30
Fair Value, Recurring    
Assets, Short-term [Abstract]    
Cash equivalents (money market funds) 740 784
Derivative instruments (foreign exchange contracts) 2 12
Assets, Long-term [Abstract]    
Trading securities 30 30
Other investments 25 25
Total assets measured at fair value 797 851
Liabilities, Short-term [Abstract]    
Derivative instruments (foreign exchange contracts) 17 6
Liabilities, Long-term [Abstract]    
Deferred compensation liability 30 30
Total liabilities measured at fair value 47 36
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Assets, Short-term [Abstract]    
Cash equivalents (money market funds) 740 784
Derivative instruments (foreign exchange contracts) 0 0
Assets, Long-term [Abstract]    
Trading securities 30 30
Other investments 0 0
Total assets measured at fair value 770 814
Liabilities, Short-term [Abstract]    
Derivative instruments (foreign exchange contracts) 0 0
Liabilities, Long-term [Abstract]    
Deferred compensation liability 0 0
Total liabilities measured at fair value 0 0
Fair Value, Recurring | Significant Other Observable Inputs (Level 2)    
Assets, Short-term [Abstract]    
Cash equivalents (money market funds) 0 0
Derivative instruments (foreign exchange contracts) 2 12
Assets, Long-term [Abstract]    
Trading securities 0 0
Other investments 25 25
Total assets measured at fair value 27 37
Liabilities, Short-term [Abstract]    
Derivative instruments (foreign exchange contracts) 17 6
Liabilities, Long-term [Abstract]    
Deferred compensation liability 30 30
Total liabilities measured at fair value 47 36
Fair Value, Recurring | Significant Unobservable Inputs (Level 3)    
Assets, Short-term [Abstract]    
Cash equivalents (money market funds) 0 0
Derivative instruments (foreign exchange contracts) 0 0
Assets, Long-term [Abstract]    
Trading securities 0 0
Other investments 0 0
Total assets measured at fair value 0 0
Liabilities, Short-term [Abstract]    
Derivative instruments (foreign exchange contracts) 0 0
Liabilities, Long-term [Abstract]    
Deferred compensation liability 0 0
Total liabilities measured at fair value $ 0 $ 0
XML 103 R89.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE MEASUREMENTS FAIR VALUE MEASURMENTS - Fair value of assets and liabilities measured on non recurring (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Carrying value of long-lived asset $ 98   $ 21
Long-lived assets held for use impairment 98 $ 0 21
Fair value of assets, nonrecurring 0   0
Long lived assets held for sale Impairment 0 0 $ 0
Impairments in non-marketable securities without readily determinable fair value 0 0  
Carrying amount of non-marketable equity securities without readily determinable fair values 103 47  
Equity Securities without Readily Determinable Fair Value      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Unrealized gain on non-marketable equity securities $ 27 $ 1  
XML 104 R90.htm IDEA: XBRL DOCUMENT v3.20.4
DERIVATIVES (Details) - USD ($)
$ in Millions
 12 Months Ended
Sep. 06, 2019
Sep. 15, 2016
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Aug. 01, 2019
Feb. 01, 2016
Jul. 01, 2012
Derivative Contracts [Abstract]                
interest rate swap payments     $ 0 $ 6 $ 0      
Aggregate fair value , net liability position     16          
Senior Notes 2022 | Treasury Lock                
Derivative Contracts [Abstract]                
Derivative, Notional Amount               $ 400
Remaining gain loss to be amortized on derivative     1          
Senior Notes 2026 | Treasury Lock | Cash Flow Hedges                
Derivative Contracts [Abstract]                
Derivative, Notional Amount             $ 300  
interest rate swap payments   $ 10            
Remaining gain loss to be amortized on derivative     6          
Senior Notes 2029 | Treasury Lock                
Derivative Contracts [Abstract]                
Derivative, Notional Amount           $ 250    
interest rate swap payments $ 6              
Remaining gain loss to be amortized on derivative     $ 5          
XML 105 R91.htm IDEA: XBRL DOCUMENT v3.20.4
DERIVATIVES, Disclosures and derivative instrument aggregated notional amounts by currency and designations (Details)
$ in Millions
Oct. 31, 2020
USD ($)
contracts
Designated as Hedging Instrument | Cash Flow Hedges  
Derivative [Line Items]  
Number Of Foreign Exchange Forward Contracts Designated As Cash Flow Hedge | contracts 270
Designated as Hedging Instrument | Cash Flow Hedges | Forward Contracts Buy/(Sell) | Buy | Singapore, Dollars  
Derivative [Line Items]  
Derivative, Notional Amount $ 12
Designated as Hedging Instrument | Cash Flow Hedges | Forward Contracts Buy/(Sell) | Buy | Other Currency  
Derivative [Line Items]  
Derivative, Notional Amount 4
Designated as Hedging Instrument | Cash Flow Hedges | Forward Contracts Buy/(Sell) | Sell  
Derivative [Line Items]  
Derivative, Notional Amount 332
Designated as Hedging Instrument | Cash Flow Hedges | Forward Contracts Buy/(Sell) | Sell | Euro  
Derivative [Line Items]  
Derivative, Notional Amount 59
Designated as Hedging Instrument | Cash Flow Hedges | Forward Contracts Buy/(Sell) | Sell | British Pounds  
Derivative [Line Items]  
Derivative, Notional Amount 41
Designated as Hedging Instrument | Cash Flow Hedges | Forward Contracts Buy/(Sell) | Sell | Canadian Dollars  
Derivative [Line Items]  
Derivative, Notional Amount 33
Designated as Hedging Instrument | Cash Flow Hedges | Forward Contracts Buy/(Sell) | Sell | Japanese Yen  
Derivative [Line Items]  
Derivative, Notional Amount 83
Designated as Hedging Instrument | Cash Flow Hedges | Forward Contracts Buy/(Sell) | Sell | Korean Won  
Derivative [Line Items]  
Derivative, Notional Amount 58
Designated as Hedging Instrument | Cash Flow Hedges | Forward Contracts Buy/(Sell) | Sell | China, Yuan Renminbi  
Derivative [Line Items]  
Derivative, Notional Amount 74
Designated as Hedging Instrument | Cash Flow Hedges | Forward Contracts Buy/(Sell) | Sell | Sweden, Kronor  
Derivative [Line Items]  
Derivative, Notional Amount 0
Designated as Hedging Instrument | Cash Flow Hedges | Forward Contracts Buy/(Sell) | Sell | Taiwan, New Dollars  
Derivative [Line Items]  
Derivative, Notional Amount 0
Designated as Hedging Instrument | Cash Flow Hedges | Forward Contracts Buy/(Sell) | Sell | India, Rupees  
Derivative [Line Items]  
Derivative, Notional Amount $ 0
Designated as Hedging Instrument | Net Investment Hedging  
Derivative [Line Items]  
Number Of Foreign Exchange Forward Contracts Designated As Cash Flow Hedge | contracts 3
Designated as Hedging Instrument | Net Investment Hedging | Forward Contracts Buy/(Sell) | Sell  
Derivative [Line Items]  
Derivative, Notional Amount $ 94
Designated as Hedging Instrument | Net Investment Hedging | Forward Contracts Buy/(Sell) | Sell | Euro  
Derivative [Line Items]  
Derivative, Notional Amount $ 94
Derivatives Not Designated as Hedging Instruments  
Derivative [Line Items]  
Number Of Foreign Exchange Forward Contracts Not Designated As Hedges | contracts 183
Derivatives Not Designated as Hedging Instruments | Forward Contracts Buy/(Sell) | Buy | Euro  
Derivative [Line Items]  
Derivative, Notional Amount $ 17
Derivatives Not Designated as Hedging Instruments | Forward Contracts Buy/(Sell) | Buy | British Pounds  
Derivative [Line Items]  
Derivative, Notional Amount 7
Derivatives Not Designated as Hedging Instruments | Forward Contracts Buy/(Sell) | Buy | Singapore, Dollars  
Derivative [Line Items]  
Derivative, Notional Amount 23
Derivatives Not Designated as Hedging Instruments | Forward Contracts Buy/(Sell) | Buy | Other Currency  
Derivative [Line Items]  
Derivative, Notional Amount 2
Derivatives Not Designated as Hedging Instruments | Forward Contracts Buy/(Sell) | Sell  
Derivative [Line Items]  
Derivative, Notional Amount 134
Derivatives Not Designated as Hedging Instruments | Forward Contracts Buy/(Sell) | Sell | Canadian Dollars  
Derivative [Line Items]  
Derivative, Notional Amount 7
Derivatives Not Designated as Hedging Instruments | Forward Contracts Buy/(Sell) | Sell | Japanese Yen  
Derivative [Line Items]  
Derivative, Notional Amount 39
Derivatives Not Designated as Hedging Instruments | Forward Contracts Buy/(Sell) | Sell | Korean Won  
Derivative [Line Items]  
Derivative, Notional Amount 32
Derivatives Not Designated as Hedging Instruments | Forward Contracts Buy/(Sell) | Sell | China, Yuan Renminbi  
Derivative [Line Items]  
Derivative, Notional Amount 66
Derivatives Not Designated as Hedging Instruments | Forward Contracts Buy/(Sell) | Sell | Sweden, Kronor  
Derivative [Line Items]  
Derivative, Notional Amount 10
Derivatives Not Designated as Hedging Instruments | Forward Contracts Buy/(Sell) | Sell | Taiwan, New Dollars  
Derivative [Line Items]  
Derivative, Notional Amount 14
Derivatives Not Designated as Hedging Instruments | Forward Contracts Buy/(Sell) | Sell | India, Rupees  
Derivative [Line Items]  
Derivative, Notional Amount $ 15
XML 106 R92.htm IDEA: XBRL DOCUMENT v3.20.4
DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details) - USD ($)
$ in Millions
Oct. 31, 2020
Oct. 31, 2019
Derivative, Fair Value, Net [Abstract]    
Derivative Asset, Fair Value $ 2 $ 12
Derivative Liability, Fair Value 17 6
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contracts | Other Current Assets [Member]    
Derivative, Fair Value, Net [Abstract]    
Derivative Asset, Fair Value 2 9
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contracts | Accrued Liabilities [Member]    
Derivative, Fair Value, Net [Abstract]    
Derivative Liability, Fair Value 5 4
Cash Flow Hedges | Derivatives Designated as Hedging Instrument | Foreign Exchange Contracts | Other Current Assets [Member]    
Derivative, Fair Value, Net [Abstract]    
Derivative Asset, Fair Value 0 3
Cash Flow Hedges | Derivatives Designated as Hedging Instrument | Foreign Exchange Contracts | Accrued Liabilities [Member]    
Derivative, Fair Value, Net [Abstract]    
Derivative Liability, Fair Value $ 12 $ 2
XML 107 R93.htm IDEA: XBRL DOCUMENT v3.20.4
DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Jan. 31, 2019
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Derivative [Line Items]        
Loss on interest rate swaps recognized in other comprehensive income (loss)   $ 12 $ 6  
Gain (loss) recognized in accumulated other comprehensive income(loss)   (12) (6)  
Gain(loss reclassified from accumulated other comprehensive income (loss) into cost of sales   2 (8)  
Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months $ 7      
Derivatives Not Designated as Hedging Instruments | Other income (expense) [Member]        
Derivative [Line Items]        
Gain (loss) recognized in other income (expense), net within continuing operations   (1) 2 $ (2)
Cash Flow Hedges | Derivatives Designated as Hedging Instrument | Interest Rate Swap [Member] | Other Comprehensive Income (Loss) [Member]        
Derivative [Line Items]        
Loss on interest rate swaps recognized in other comprehensive income (loss)   0 (6) 0
Gain (loss) recognized in accumulated other comprehensive income(loss)   0 6 0
Cash Flow Hedges | Derivatives Designated as Hedging Instrument | Foreign Exchange Contracts | Accumulated Other Comprehensive Loss        
Derivative [Line Items]        
Loss on interest rate swaps recognized in other comprehensive income (loss)   12 0 (7)
Gain (loss) recognized in accumulated other comprehensive income(loss)   (12) 0 7
Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net   (1) (1) (1)
Cash Flow Hedges | Derivatives Designated as Hedging Instrument | Foreign Exchange Contracts | Cost of Sales [Member]        
Derivative [Line Items]        
Gain(loss reclassified from accumulated other comprehensive income (loss) into cost of sales   (1) 9 (3)
Gain (loss) recognized in other income (expense), net within continuing operations   2 2 0
Net Investment Hedging | Derivatives Designated as Hedging Instrument | Foreign Exchange Contracts | Accumulated Other Comprehensive Loss        
Derivative [Line Items]        
Loss on interest rate swaps recognized in other comprehensive income (loss)   5 0 0
Gain (loss) recognized in accumulated other comprehensive income(loss)   $ (5) $ 0 $ 0
XML 108 R94.htm IDEA: XBRL DOCUMENT v3.20.4
RETIREMENT PLANS AND POST RETIEMENT PENSION PLANS - Deferred Profit Sharing Plan (Details) - Deferred Profit Sharing - USD ($)
$ in Millions
Oct. 31, 2020
Oct. 31, 2019
Defined Benefit Plan Disclosure [Line Items]    
Fair Value of Plan Assets $ 123 $ 132
Projected Benefit Obligation $ 123 $ 132
XML 109 R95.htm IDEA: XBRL DOCUMENT v3.20.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS Defined Contribution (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Defined Contribution Plan Disclosure [Line Items]      
Maximum employer matching contribution in the 401(k) plan (in hundredths) 6.00%    
Maximum employee contribution to 401(k) 50.00%    
401(k) Plan employer expense $ 41 $ 39 $ 37
401(k) Additional company contribution      
Defined Contribution Plan Disclosure [Line Items]      
Transitional company contribution to employee 401(k) 4.00%    
401(k) Additional company contribution | 3 Percent      
Defined Contribution Plan Disclosure [Line Items]      
Transitional company contribution to employee 401(k) 3.00%    
401(k) Additional company contribution | 5 Percent      
Defined Contribution Plan Disclosure [Line Items]      
Transitional company contribution to employee 401(k) 5.00%    
XML 110 R96.htm IDEA: XBRL DOCUMENT v3.20.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Components of Net Periodic Costs (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]      
Net actuarial (gain) loss $ 66 $ 157  
Amortization of net actuarial loss (61) (39)  
Prior service cost (benefit) 0 0  
Amortization of prior service benefit 7 (8)  
Pension Plan | U.S. Plan      
Net periodic benefit cost (benefit) [Abstract]      
Service cost - benefits earned during the period 0 0 $ 0
Interest cost on benefit obligation 15 18 16
Expected return on plan assets (28) (27) (28)
Amortization of net actuarial loss 3 1 1
Amortization of prior service benefit 0 0 0
Total periodic benefit cost (benefit) (10) (8) (11)
Curtaliment and settlement (4) 0 0
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]      
Net actuarial (gain) loss 26 51 2
Amortization of net actuarial loss (3) (1) (1)
Amortization of prior service benefit 0 0 0
Gain due to settlement 4 0 0
Foreign currency 0 0 0
Total recognized in other comprehensive (income) loss 19 50 1
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss 13 42 (10)
Pension Plan | Non-U.S. Plans      
Net periodic benefit cost (benefit) [Abstract]      
Service cost - benefits earned during the period 24 20 20
Interest cost on benefit obligation 8 14 13
Expected return on plan assets (47) (43) (46)
Amortization of net actuarial loss 49 34 29
Amortization of prior service benefit 0 0 0
Total periodic benefit cost (benefit) 34 25 16
Curtaliment and settlement 0 0 5
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]      
Net actuarial (gain) loss 20 104 49
Amortization of net actuarial loss (49) (34) (29)
Amortization of prior service benefit 0 0 0
Gain due to settlement 0 0 0
Foreign currency 10 (3) 1
Total recognized in other comprehensive (income) loss (19) 67 21
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss 15 92 32
Post-Retirement Benefit Plan | U.S. Plan      
Net periodic benefit cost (benefit) [Abstract]      
Service cost - benefits earned during the period 1 0 1
Interest cost on benefit obligation 3 4 3
Expected return on plan assets (7) (7) (7)
Amortization of net actuarial loss 4 4 8
Amortization of prior service benefit (7) (8) (8)
Total periodic benefit cost (benefit) (6) (7) (3)
Curtaliment and settlement 0 0 0
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]      
Net actuarial (gain) loss 5 5 (2)
Amortization of net actuarial loss (4) (4) (8)
Amortization of prior service benefit (7) (8) (8)
Gain due to settlement 0 0 0
Foreign currency 0 0 0
Total recognized in other comprehensive (income) loss 8 9 (2)
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss $ 2 $ 2 $ (5)
XML 111 R97.htm IDEA: XBRL DOCUMENT v3.20.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Funded Status (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Non-U.S. Plans | Pension Plan      
Change in fair value of plan assets: [Roll Forward]      
Fair Value Balance, beginning of year $ 911 $ 825  
Actual return on plan assets (2) 85  
Employer contributions 32 21  
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant 1 1  
Benefits paid 31 29  
Settlements 0 0  
Currency impact 34 8  
Fair Value Balance, end of year 945 911 $ 825
Change in benefit obligation: [Roll Forward]      
Benefit Obligation Balance, Beginning of year 1,067 913  
Service cost 24 20 20
Interest cost 8 14 13
Participant's contributions 1 1  
Actuarial (gain) loss (19) 143  
Benefits paid 31 29  
Settlement 0 0  
Currency impact 44 5  
Benefit Obligation Balance, end of year 1,094 1,067 913
Funded status of plan [Abstract]      
Funded status of plan (149) (156)  
Actuarial (gains) losses (311) (330)  
Prior service costs (benefits) 0 0  
Total 311 330  
U.S. Plan | Pension Plan      
Change in fair value of plan assets: [Roll Forward]      
Fair Value Balance, beginning of year 432 401  
Actual return on plan assets 30 50  
Employer contributions 0 0  
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant 0 0  
Benefits paid 8 19  
Settlements 15 0  
Currency impact 0 0  
Fair Value Balance, end of year 439 432 401
Change in benefit obligation: [Roll Forward]      
Benefit Obligation Balance, Beginning of year 491 420  
Service cost 0 0 0
Interest cost 15 18 16
Participant's contributions 0 0  
Actuarial (gain) loss 28 74  
Benefits paid 9 21  
Settlement (15) 0  
Currency impact 0 0  
Benefit Obligation Balance, end of year 510 491 420
Funded status of plan [Abstract]      
Funded status of plan (71) (59)  
Actuarial (gains) losses (134) (115)  
Prior service costs (benefits) 0 0  
Total 134 115  
U.S. Plan | Post-Retirement Benefit Plan      
Change in fair value of plan assets: [Roll Forward]      
Fair Value Balance, beginning of year 95 90  
Actual return on plan assets 6 11  
Employer contributions 0 0  
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant 0 0  
Benefits paid 8 6  
Settlements 0 0  
Currency impact 0 0  
Fair Value Balance, end of year 93 95 90
Change in benefit obligation: [Roll Forward]      
Benefit Obligation Balance, Beginning of year 94 87  
Service cost 1 0 1
Interest cost 3 4 3
Participant's contributions 0 0  
Actuarial (gain) loss 4 9  
Benefits paid 8 6  
Settlement 0 0  
Currency impact 0 0  
Benefit Obligation Balance, end of year 94 94 $ 87
Funded status of plan [Abstract]      
Funded status of plan (1) 1  
Actuarial (gains) losses (11) (10)  
Prior service costs (benefits) (5) (12)  
Total 6 (2)  
Other Assets | Non-U.S. Plans | Pension Plan      
Funded status of plan [Abstract]      
Funded status of plan 123 106  
Other Assets | U.S. Plan | Pension Plan      
Funded status of plan [Abstract]      
Funded status of plan 0 0  
Other Assets | U.S. Plan | Post-Retirement Benefit Plan      
Funded status of plan [Abstract]      
Funded status of plan 0 1  
Employee compensation and benefits [Member] | Non-U.S. Plans | Pension Plan      
Funded status of plan [Abstract]      
Funded status of plan 0 0  
Employee compensation and benefits [Member] | U.S. Plan | Pension Plan      
Funded status of plan [Abstract]      
Funded status of plan 1 1  
Employee compensation and benefits [Member] | U.S. Plan | Post-Retirement Benefit Plan      
Funded status of plan [Abstract]      
Funded status of plan 0 0  
Retirement and post-retirement benefits | Non-U.S. Plans | Pension Plan      
Funded status of plan [Abstract]      
Funded status of plan 272 262  
Retirement and post-retirement benefits | U.S. Plan | Pension Plan      
Funded status of plan [Abstract]      
Funded status of plan 70 58  
Retirement and post-retirement benefits | U.S. Plan | Post-Retirement Benefit Plan      
Funded status of plan [Abstract]      
Funded status of plan $ 1 $ 0  
XML 112 R98.htm IDEA: XBRL DOCUMENT v3.20.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Financial Statement Location (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Pension Plan | Non-U.S. Plans    
Accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year [Abstract]    
Amortization of net prior service cost (benefit) $ 0  
Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year 52  
Defined Benefit Plan, Funded (Unfunded) Status of Plan 149 $ 156
Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Net Actuarial Gain Loss Before Tax 311 330
Prior service costs (benefits) 0 0
Total 311 330
Pension Plan | Non-U.S. Plans | Other Assets    
Accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year [Abstract]    
Defined Benefit Plan, Funded (Unfunded) Status of Plan (123) (106)
Pension Plan | Non-U.S. Plans | Employee compensation and benefits [Member]    
Accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year [Abstract]    
Defined Benefit Plan, Funded (Unfunded) Status of Plan 0 0
Pension Plan | Non-U.S. Plans | Retirement and post-retirement benefits    
Accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year [Abstract]    
Defined Benefit Plan, Funded (Unfunded) Status of Plan (272) (262)
Pension Plan | U.S. Plan    
Accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year [Abstract]    
Amortization of net prior service cost (benefit) 0  
Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year 4  
Defined Benefit Plan, Funded (Unfunded) Status of Plan 71 59
Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Net Actuarial Gain Loss Before Tax 134 115
Prior service costs (benefits) 0 0
Total 134 115
Pension Plan | U.S. Plan | Other Assets    
Accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year [Abstract]    
Defined Benefit Plan, Funded (Unfunded) Status of Plan 0 0
Pension Plan | U.S. Plan | Employee compensation and benefits [Member]    
Accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year [Abstract]    
Defined Benefit Plan, Funded (Unfunded) Status of Plan (1) (1)
Pension Plan | U.S. Plan | Retirement and post-retirement benefits    
Accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year [Abstract]    
Defined Benefit Plan, Funded (Unfunded) Status of Plan (70) (58)
Post-Retirement Benefit Plan | U.S. Plan    
Accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year [Abstract]    
Amortization of net prior service cost (benefit) (1)  
Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year 4  
Defined Benefit Plan, Funded (Unfunded) Status of Plan 1 (1)
Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Net Actuarial Gain Loss Before Tax 11 10
Prior service costs (benefits) (5) (12)
Total 6 (2)
Post-Retirement Benefit Plan | U.S. Plan | Other Assets    
Accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year [Abstract]    
Defined Benefit Plan, Funded (Unfunded) Status of Plan 0 (1)
Post-Retirement Benefit Plan | U.S. Plan | Employee compensation and benefits [Member]    
Accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year [Abstract]    
Defined Benefit Plan, Funded (Unfunded) Status of Plan 0 0
Post-Retirement Benefit Plan | U.S. Plan | Retirement and post-retirement benefits    
Accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year [Abstract]    
Defined Benefit Plan, Funded (Unfunded) Status of Plan $ (1) $ 0
XML 113 R99.htm IDEA: XBRL DOCUMENT v3.20.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS , Target Allocations (Details)
Oct. 31, 2020
Oct. 31, 2019
U.S. Plan | Deferred Profit Sharing | Equity Securities    
Defined Benefit Plan Disclosure [Line Items]    
Target Allocation Percentage of Plan Assets 60.00% 60.00%
U.S. Plan | Deferred Profit Sharing | Fixed Income Securities    
Defined Benefit Plan Disclosure [Line Items]    
Target Allocation Percentage of Plan Assets 40.00% 40.00%
U.S. Plan | Pension Plan | Equity Securities    
Defined Benefit Plan Disclosure [Line Items]    
Target Allocation Percentage of Plan Assets 80.00% 80.00%
U.S. Plan | Pension Plan | Fixed Income Securities    
Defined Benefit Plan Disclosure [Line Items]    
Target Allocation Percentage of Plan Assets 20.00% 20.00%
U.S. Plan | Pension Plan | Other Investments    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit Plan Us Portfolio Equity Securities Percentage Of Alternative Investments 1.00% 1.00%
U.S. Plan | Other Postretirement Benefits Plan [Member] | Equity Securities    
Defined Benefit Plan Disclosure [Line Items]    
Target Allocation Percentage of Plan Assets 80.00% 80.00%
U.S. Plan | Other Postretirement Benefits Plan [Member] | Fixed Income Securities    
Defined Benefit Plan Disclosure [Line Items]    
Target Allocation Percentage of Plan Assets 20.00% 20.00%
U.S. Plan | Other Postretirement Benefits Plan [Member] | Other Investments    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit Plan Us Portfolio Equity Securities Percentage Of Alternative Investments 1.00% 1.00%
Non-U.S. Plans | Pension Plan | Minimum | Equity Securities    
Defined Benefit Plan Disclosure [Line Items]    
Target Allocation Percentage of Plan Assets 24.00%  
Non-U.S. Plans | Pension Plan | Minimum | Fixed Income Securities    
Defined Benefit Plan Disclosure [Line Items]    
Target Allocation Percentage of Plan Assets 38.00%  
Non-U.S. Plans | Pension Plan | Minimum | Real Estate    
Defined Benefit Plan Disclosure [Line Items]    
Target Allocation Percentage of Plan Assets 0.00%  
Non-U.S. Plans | Pension Plan | Maximum | Equity Securities    
Defined Benefit Plan Disclosure [Line Items]    
Target Allocation Percentage of Plan Assets 60.00%  
Non-U.S. Plans | Pension Plan | Maximum | Fixed Income Securities    
Defined Benefit Plan Disclosure [Line Items]    
Target Allocation Percentage of Plan Assets 65.00%  
Non-U.S. Plans | Pension Plan | Maximum | Real Estate    
Defined Benefit Plan Disclosure [Line Items]    
Target Allocation Percentage of Plan Assets 25.00%  
XML 114 R100.htm IDEA: XBRL DOCUMENT v3.20.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Fair Value of Plan Assets (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Pension Plan | U.S. Plan      
Fair value of plan assets [Abstract]      
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets $ 510 $ 491  
Fair value of plan assets for defined benefit plan with benefit obligation in excess of plan assets. 439 432  
Projected benefit obligation and fair value of plan assets [Abstract]      
Defined Benefit obligation where Fair Value exceeds Pension benefit obligation 0 0  
Fair Value of plan assets where fair value exceeds pension benefit obligation 0 0  
Benefit Obligation 510 491 $ 420
Accumulated benefit obligation and fair value of plan assets      
Accumulated benefit obligation in excess of fair value of plan assets - aggregate benefit obligation 510 491  
Accumulated benefit obligation in excess of accumulated benefit obligation - aggregate fair value of plan assets 439 432  
Accumulated Benefit Obligation where Fair Value of plan Assets exceeds ABO 0 0  
Fair value of plan assets for defined benefit pension plan where the fair value of plan assets exceeds ABO. 0 0  
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year 0    
Fair Value of Plan Assets 439 432 401
Net asset value excluded from fair value by input 321 304  
Assets for Plan Benefits, Defined Benefit Plan 439    
Pension Plan | U.S. Plan | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 1 1  
Net asset value excluded from fair value by input 1 1  
Pension Plan | U.S. Plan | Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Net asset value excluded from fair value by input   258  
Pension Plan | U.S. Plan | Defined Benefit Plan, Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 357 336  
Net asset value excluded from fair value by input 280    
Pension Plan | U.S. Plan | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 79 91  
Net asset value excluded from fair value by input 40 45  
Pension Plan | U.S. Plan | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 2 4  
Net asset value excluded from fair value by input 0 0  
Pension Plan | U.S. Plan | Quoted Prices in Active Markets for Identical Assets (Level 1)      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets   124  
Assets for Plan Benefits, Defined Benefit Plan 116    
Pension Plan | U.S. Plan | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | U.S. Plan | Quoted Prices in Active Markets for Identical Assets (Level 1) | Defined Benefit Plan, Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 77 78  
Pension Plan | U.S. Plan | Quoted Prices in Active Markets for Identical Assets (Level 1) | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 39 46  
Pension Plan | U.S. Plan | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | U.S. Plan | Significant Unobservable Inputs (Level 3)      
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]      
Balance, beginning of year 4 6  
Realized gains/(losses) (3) 1  
Unrealized gains/(losses) (2) 1  
Purchases, sales, issuances, and settlements (1) (2)  
Transfers in (out) 0 0  
Balance, end of year 2 4  
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets   4  
Assets for Plan Benefits, Defined Benefit Plan 2    
Pension Plan | U.S. Plan | Significant Unobservable Inputs (Level 3) | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | U.S. Plan | Significant Unobservable Inputs (Level 3) | Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets   0  
Pension Plan | U.S. Plan | Significant Unobservable Inputs (Level 3) | Defined Benefit Plan, Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0    
Pension Plan | U.S. Plan | Significant Unobservable Inputs (Level 3) | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | U.S. Plan | Significant Unobservable Inputs (Level 3) | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 2 4  
Pension Plan | U.S. Plan | Significant Other Observable Inputs (Level 2)      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets   0  
Assets for Plan Benefits, Defined Benefit Plan 0    
Pension Plan | U.S. Plan | Significant Other Observable Inputs (Level 2) | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | U.S. Plan | Significant Other Observable Inputs (Level 2) | Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets   0  
Pension Plan | U.S. Plan | Significant Other Observable Inputs (Level 2) | Defined Benefit Plan, Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0    
Pension Plan | U.S. Plan | Significant Other Observable Inputs (Level 2) | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | U.S. Plan | Significant Other Observable Inputs (Level 2) | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | Non-U.S. Plans      
Fair value of plan assets [Abstract]      
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets 697 752  
Fair value of plan assets for defined benefit plan with benefit obligation in excess of plan assets. 425 490  
Projected benefit obligation and fair value of plan assets [Abstract]      
Total projected benefit obligation - aggregate benefit obligation 1,094 1,067  
Defined Benefit obligation where Fair Value exceeds Pension benefit obligation 397 315  
Fair Value of plan assets where fair value exceeds pension benefit obligation 520 421  
Benefit Obligation 1,094 1,067 913
Accumulated benefit obligation and fair value of plan assets      
Accumulated benefit obligation in excess of fair value of plan assets - aggregate benefit obligation 675 651  
Total accumulated benefit obligation - aggregate benefit obligation 1,062 1,032  
Accumulated benefit obligation in excess of accumulated benefit obligation - aggregate fair value of plan assets 425 418  
Accumulated Benefit Obligation where Fair Value of plan Assets exceeds ABO 387 381  
Fair value of plan assets for defined benefit pension plan where the fair value of plan assets exceeds ABO. 520 493  
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year 22    
Fair Value of Plan Assets 945 911 825
Net asset value excluded from fair value by input 236 220  
Pension Plan | Non-U.S. Plans | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 7 1  
Net asset value excluded from fair value by input 1 0  
Pension Plan | Non-U.S. Plans | Defined Benefit Plan, Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 504 512  
Net asset value excluded from fair value by input 141 133  
Pension Plan | Non-U.S. Plans | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 434 398  
Net asset value excluded from fair value by input 94 87  
Pension Plan | Non-U.S. Plans | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Net asset value excluded from fair value by input 0 0  
Pension Plan | Non-U.S. Plans | Quoted Prices in Active Markets for Identical Assets (Level 1)      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 417 416  
Pension Plan | Non-U.S. Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | Non-U.S. Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Defined Benefit Plan, Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 315 318  
Pension Plan | Non-U.S. Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 102 98  
Pension Plan | Non-U.S. Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | Non-U.S. Plans | Significant Unobservable Inputs (Level 3)      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | Non-U.S. Plans | Significant Unobservable Inputs (Level 3) | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | Non-U.S. Plans | Significant Unobservable Inputs (Level 3) | Defined Benefit Plan, Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | Non-U.S. Plans | Significant Unobservable Inputs (Level 3) | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | Non-U.S. Plans | Significant Unobservable Inputs (Level 3) | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | Non-U.S. Plans | Significant Other Observable Inputs (Level 2)      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 292 275  
Pension Plan | Non-U.S. Plans | Significant Other Observable Inputs (Level 2) | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 6 1  
Pension Plan | Non-U.S. Plans | Significant Other Observable Inputs (Level 2) | Defined Benefit Plan, Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 48 61  
Pension Plan | Non-U.S. Plans | Significant Other Observable Inputs (Level 2) | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 238 213  
Pension Plan | Non-U.S. Plans | Significant Other Observable Inputs (Level 2) | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | U.S. Plan      
Projected benefit obligation and fair value of plan assets [Abstract]      
Benefit Obligation 94 94 87
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 93 95 $ 90
Net asset value excluded from fair value by input 66 64  
Post-Retirement Benefit Plan | U.S. Plan | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 4 3  
Net asset value excluded from fair value by input 4 3  
Post-Retirement Benefit Plan | U.S. Plan | Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 70 69  
Net asset value excluded from fair value by input 53 51  
Post-Retirement Benefit Plan | U.S. Plan | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 18 21  
Net asset value excluded from fair value by input 9 10  
Post-Retirement Benefit Plan | U.S. Plan | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 1 2  
Net asset value excluded from fair value by input 0 0  
Post-Retirement Benefit Plan | U.S. Plan | Quoted Prices in Active Markets for Identical Assets (Level 1)      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 26 29  
Post-Retirement Benefit Plan | U.S. Plan | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | U.S. Plan | Quoted Prices in Active Markets for Identical Assets (Level 1) | Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 17 18  
Post-Retirement Benefit Plan | U.S. Plan | Quoted Prices in Active Markets for Identical Assets (Level 1) | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 9 11  
Post-Retirement Benefit Plan | U.S. Plan | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | U.S. Plan | Significant Unobservable Inputs (Level 3)      
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]      
Balance, beginning of year 2 4  
Realized gains/(losses) (1) 1  
Unrealized gains/(losses) (1) 0  
Purchases, sales, issuances, and settlements (1) (1)  
Transfers in (out) 0 0  
Balance, end of year 1 2  
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 1 2  
Post-Retirement Benefit Plan | U.S. Plan | Significant Unobservable Inputs (Level 3) | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | U.S. Plan | Significant Unobservable Inputs (Level 3) | Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | U.S. Plan | Significant Unobservable Inputs (Level 3) | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | U.S. Plan | Significant Unobservable Inputs (Level 3) | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 1 2  
Post-Retirement Benefit Plan | U.S. Plan | Significant Other Observable Inputs (Level 2)      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | U.S. Plan | Significant Other Observable Inputs (Level 2) | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | U.S. Plan | Significant Other Observable Inputs (Level 2) | Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | U.S. Plan | Significant Other Observable Inputs (Level 2) | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | U.S. Plan | Significant Other Observable Inputs (Level 2) | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets $ 0 $ 0  
XML 115 R101.htm IDEA: XBRL DOCUMENT v3.20.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Expected Benefit Payments (Details)
$ in Millions
Oct. 31, 2020
USD ($)
Pension Plan | U.S. Plan  
Defined Benefit Plan Disclosure [Line Items]  
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year $ 0
Future benefit payments [Abstract]  
2021 33
2022 31
2023 33
2024 34
2025 33
2026 - 2030 152
Pension Plan | Non-U.S. Plans  
Defined Benefit Plan Disclosure [Line Items]  
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year 22
Future benefit payments [Abstract]  
2021 33
2022 34
2023 36
2024 36
2025 37
2026 - 2030 192
Post-Retirement Benefit Plan | U.S. Plan  
Future benefit payments [Abstract]  
2021 8
2022 8
2023 7
2024 7
2025 7
2026 - 2030 35
Other Postretirement Benefits Plan [Member] | U.S. Plan  
Defined Benefit Plan Disclosure [Line Items]  
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year $ 0
XML 116 R102.htm IDEA: XBRL DOCUMENT v3.20.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Assumptions (Details)
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
U.S. Plan | Pension Plan      
Assumptions used to calculate the net periodic cost      
Discount rate (in hundredths) 3.25% 4.50% 3.75%
Expected long-term return on assets (in hundredths) 7.00% 7.00% 7.00%
Assumptions used to calculate the benefit obligation      
Discount rate (in hundredths) 2.75% 3.25%  
U.S. Plan | Post-Retirement Benefit Plan      
Assumptions used to calculate the net periodic cost      
Discount rate (in hundredths) 3.00% 4.25% 3.50%
Expected long-term return on assets (in hundredths) 7.00% 7.00% 7.00%
Current medical cost trend rate 6.25% 6.00% 6.00%
Ultimate medical cost trend rate 4.50% 3.50% 3.50%
Medical cost trend rate decreases to ultimate rate in year 2029 2029 2029
Assumptions used to calculate the benefit obligation      
Discount rate (in hundredths) 2.50% 3.00%  
Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year 6.25% 6.25%  
Defined Benefit Plan, Ultimate Health Care Cost Trend Rate 4.50% 4.50%  
Non-U.S. Plans | Pension Plan | Minimum      
Assumptions used to calculate the net periodic cost      
Discount rate (in hundredths) 0.22% 0.83% 0.67%
Average increase in compensation levels (in hundredths) 2.25% 2.25% 2.00%
Expected long-term return on assets (in hundredths) 4.00% 4.00% 4.00%
Assumptions used to calculate the benefit obligation      
Discount rate (in hundredths) 0.07% 0.22%  
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase 2.00% 2.25%  
Non-U.S. Plans | Pension Plan | Maximum      
Assumptions used to calculate the net periodic cost      
Discount rate (in hundredths) 1.81% 2.68% 2.52%
Average increase in compensation levels (in hundredths) 3.00% 3.25% 3.25%
Expected long-term return on assets (in hundredths) 5.75% 5.75% 6.00%
Assumptions used to calculate the benefit obligation      
Discount rate (in hundredths) 1.54% 1.81%  
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase 3.00% 3.00%  
XML 117 R103.htm IDEA: XBRL DOCUMENT v3.20.4
GUARANTEES (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Summary of standard warranty accrual activity    
Beginning balance $ 32 $ 35
Accruals for warranties including change in estimates 49 54
Settlements made during the period (49) (57)
Ending balance 32 32
Standard Product Warranty Accrual, Balance Sheet Classification [Abstract]    
Accruals for warranties due within one year 30 32
Accruals for warranties due after one year 2 0
Bank Guarantees $ 43 $ 40
XML 118 R104.htm IDEA: XBRL DOCUMENT v3.20.4
COMMITMENTS AND CONTINGENCIES (Details)
$ in Millions
Oct. 31, 2020
USD ($)
Loss Contingencies [Line Items]  
Other Purchase Commitments $ 85
Penalty reduce over period of time  
Loss Contingencies [Line Items]  
Other Purchase Commitments $ 23
XML 119 R105.htm IDEA: XBRL DOCUMENT v3.20.4
SHORT-TERM DEBT - Credit Facility and Commercial Paper (Details) - USD ($)
$ in Millions
 12 Months Ended
Aug. 23, 2019
Mar. 13, 2019
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
May 26, 2020
Oct. 21, 2019
Aug. 07, 2019
Line of Credit Facility [Abstract]                
Short-term Debt     $ 798 $ 805 $ 483      
Repayments     1,413 $ 702 $ 693      
5 yr unsecured credit facility | Line of Credit                
Line of Credit Facility [Abstract]                
Credit facility initiation date   Mar. 13, 2019            
Maximum borrowing capacity     $ 1,000          
Short-term debt terms (years)     five          
Short-term Debt     $ 798          
Repayments     913          
Line of credit facility expiration date   Mar. 13, 2024            
Outstanding balance     0          
Short-term Loan Facility | Line of Credit                
Line of Credit Facility [Abstract]                
Maximum borrowing capacity               $ 500
Amount borrowed $ 500              
Repayments     500          
Additional Incremental Term Loan Facility | Line of Credit                
Line of Credit Facility [Abstract]                
Maximum borrowing capacity             $ 500  
Outstanding balance     0          
Commercial Paper | Line of Credit                
Line of Credit Facility [Abstract]                
Maximum borrowing capacity           $ 1,000    
Outstanding balance     $ 75          
Short-term Debt, Weighted Average Interest Rate, at Point in Time     0.17%          
weighted average maturity date at a point in time     5 days          
XML 120 R106.htm IDEA: XBRL DOCUMENT v3.20.4
SHORT-TERM DEBT - Senior Notes (Details) - USD ($)
$ in Millions
Sep. 17, 2019
Aug. 09, 2011
Jul. 13, 2010
Senior Notes 2020      
Short-term Debt [Line Items]      
Issuance date of debt     Jul. 13, 2010
Debt Instrument, Face Amount     $ 500
Percentage Of Face Amount Of Senior Note Instrument Issued     99.54%
Maturity date     Jul. 15, 2020
Fixed interest rate per annum (in hundredths)     5.00%
Debt Instrument, Redemption Period, End Date Sep. 17, 2019    
Early Repayment of Senior Debt $ 500    
Early repayment of senior notes including prepayment penalty 512    
Early repayment of senior notes prepayment penalty 12    
accelerated amortization of interest rate swap gain 4    
Amortization of Debt Issuance Costs and Discounts 1    
Debt Instrument, Increase, Accrued Interest $ 4    
Senior Notes 2020      
Short-term Debt [Line Items]      
Interest Rate Derivatives Terminated Date   August 9, 2011  
Notional Amount Of Terminated Interest Rate Fair Value Hedge Derivatives   $ 500  
Terminated Interest Rate Fair Value Hedge Derivative Assets At Fair Value   $ 34  
XML 121 R107.htm IDEA: XBRL DOCUMENT v3.20.4
LONG-TERM DEBT - Carrying Value (Details) - USD ($)
$ in Millions
Oct. 31, 2020
Oct. 31, 2019
Debt Instrument [Line Items]    
Senior Notes Amortized principal $ 2,284 $ 1,786
Senior Notes 2022    
Debt Instrument [Line Items]    
Senior Notes Amortized principal 400 399
Senior Notes 2023 [Member]    
Debt Instrument [Line Items]    
Senior Notes Amortized principal 598 597
Senior Notes 2026    
Debt Instrument [Line Items]    
Senior Notes Amortized principal 298 298
Senior Notes 2029    
Debt Instrument [Line Items]    
Senior Notes Amortized principal 493 492
Senior Notes 2030 [Member]    
Debt Instrument [Line Items]    
Senior Notes Amortized principal $ 495 $ 0
XML 122 R108.htm IDEA: XBRL DOCUMENT v3.20.4
LONG-TERM DEBT - Senior Notes (Details) - USD ($)
$ in Millions
Jun. 04, 2020
Sep. 16, 2019
Sep. 22, 2016
Jun. 21, 2013
Sep. 13, 2012
Oct. 31, 2020
Aug. 01, 2019
Sep. 15, 2016
Feb. 01, 2016
Jul. 01, 2012
Senior Notes 2022                    
Debt Instrument [Line Items]                    
Issuance date of debt         Sep. 13, 2012          
Aggregate face amount of debt         $ 400          
Issue rate percentage of principal amount         99.80%          
Maturity date         Oct. 01, 2022          
Fixed interest rate per annum (in hundredths)         3.20%          
Interest payment frequency         semi-annually          
Date payments commenced         Apr. 01, 2013          
Senior Notes 2023 [Member]                    
Debt Instrument [Line Items]                    
Issuance date of debt       Jun. 21, 2013            
Aggregate face amount of debt       $ 600            
Issue rate percentage of principal amount       99.544%            
Maturity date       Jul. 15, 2023            
Fixed interest rate per annum (in hundredths)       3.875%            
Interest payment frequency       semi-annually            
Date payments commenced       Jan. 15, 2014            
Senior Notes 2026                    
Debt Instrument [Line Items]                    
Issuance date of debt     Sep. 22, 2016              
Aggregate face amount of debt     $ 300              
Issue rate percentage of principal amount     99.624%              
Maturity date     Sep. 22, 2026              
Fixed interest rate per annum (in hundredths)     3.05%              
Interest payment frequency     semi-annually              
Date payments commenced     Mar. 22, 2017              
Senior Notes 2029                    
Debt Instrument [Line Items]                    
Issuance date of debt   Sep. 16, 2019                
Aggregate face amount of debt   $ 500                
Issue rate percentage of principal amount   99.316%                
Maturity date   Sep. 15, 2029                
Fixed interest rate per annum (in hundredths)   2.75%                
Interest payment frequency   semi-annually                
Date payments commenced   Mar. 15, 2020                
Senior Notes 2030 [Member]                    
Debt Instrument [Line Items]                    
Issuance date of debt Jun. 04, 2020                  
Aggregate face amount of debt $ 500                  
Issue rate percentage of principal amount 99.812%                  
Maturity date Jun. 04, 2030                  
Fixed interest rate per annum (in hundredths) 2.10%                  
Interest payment frequency semi-annually                  
Date payments commenced Dec. 04, 2020                  
Treasury Lock | Senior Notes 2029                    
Debt Instrument [Line Items]                    
Derivative, Notional Amount             $ 250      
Remaining gain loss to be amortized on derivative           $ 5        
Treasury Lock | Senior Notes 2022                    
Debt Instrument [Line Items]                    
Derivative, Notional Amount                   $ 400
Remaining gain loss to be amortized on derivative           1        
Treasury Lock | Senior Notes 2026 | Cash Flow Hedges                    
Debt Instrument [Line Items]                    
Derivative, Notional Amount                 $ 300  
Remaining gain loss to be amortized on derivative           $ 6        
Interest Rate Swap                 $ 300  
Notional Amount Of Terminated Interest Rate Fair Value Hedge Derivatives               $ 10    
XML 123 R109.htm IDEA: XBRL DOCUMENT v3.20.4
STOCKHOLDERS' EQUITY Stock Repurchases (Details) - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Nov. 19, 2018
May 28, 2015
Share Repurchase Program [Line Items]          
Stock Repurchased and Retired During Period, Value $ 469 $ 723 $ 422    
2015 Repurchase Program [Member]          
Share Repurchase Program [Line Items]          
Stock Repurchase Program, Authorized Amount         $ 1,140
Stock Repurchased and Retired During Period, Shares     6.4    
Stock Repurchased and Retired During Period, Value     $ 422    
Remaining authorized repurchase amount   $ 188      
2019 Repurchase Program [Member]          
Share Repurchase Program [Line Items]          
Stock Repurchase Program, Authorized Amount       $ 1,750  
Stock Repurchased and Retired During Period, Shares 5.2 10.4      
Stock Repurchased and Retired During Period, Value $ 469 $ 723      
Remaining authorized repurchase amount 558        
Retained Earnings          
Share Repurchase Program [Line Items]          
Stock Repurchased and Retired During Period, Value 398 580 335    
Additional Paid-in Capital          
Share Repurchase Program [Line Items]          
Stock Repurchased and Retired During Period, Value $ 71 $ 143 $ 87    
XML 124 R110.htm IDEA: XBRL DOCUMENT v3.20.4
STOCKHOLDERS' EQUITY STOCKHOLDERS EQUITY DIvidends (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Nov. 18, 2020
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Dividends [Abstract]        
Cash Dividends Declared (per common share)   $ 0.720 $ 0.656 $ 0.596
Cash dividends declared   $ 222 $ 206 $ 191
Aggregate cash dividends paid   $ 222 $ 206 $ 191
Subsequent Event        
Dividends [Abstract]        
Cash Dividends Declared (per common share) $ 0.194      
Cash dividends declared $ 59      
Dividends Payable, Date Declared Nov. 18, 2020      
Dividends payment date Jan. 27, 2021      
Dividends date of record Jan. 05, 2021      
XML 125 R111.htm IDEA: XBRL DOCUMENT v3.20.4
STOCKHOLDERS' EQUITY -Accumulated other comprehensive income (Details) - USD ($)
$ in Millions
Oct. 31, 2020
Oct. 31, 2019
Nov. 01, 2018
Oct. 31, 2018
Foreign currency translation, net of tax expense of $(6) and $(5) for 2020 and 2019, respectively $ (194) $ (204) $ (214) $ (214)
Foreign currency translation, tax 6 5    
Unrealized losses (including prior service benefit) on defined benefit plans, net of tax benefit of $154 and $153 for 2020 and 2019, respectively (317) (306)    
Unrealized losses on defined benefit plans, tax 154 153    
Unrealized gains (losses) on derivative instruments, net of tax benefit of $6 and $3 for 2020 and 2019, respectively (11) (4) 6 7
Unrealized gains (losses) on derivative instruments, tax 6 3    
Accumulated other comprehensive loss $ (522) $ (514) $ (415) $ (408)
XML 126 R112.htm IDEA: XBRL DOCUMENT v3.20.4
STOCKHOLDERS' EQUITY - Changes in accumulated other comprehensive income (Details) - USD ($)
$ in Millions
 12 Months Ended
Nov. 01, 2018
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Beginning Balance $ (408) $ (514) $ (408)  
Other Comprehensive Income (Loss), before Reclassifications   (67) (163)  
Amounts Reclassified out of Accumulated Other Comprehensive Income   56 23  
Tax (expense) benefit   3 41  
Other Comprehensive Income (Loss)   (8) (99) $ (62)
Ending Balance (415) (522) (514) (408)
Foreign Currency Translation        
Beginning Balance (214) (204) (214)  
Other Comprehensive Income (Loss), before Reclassifications   11 0  
Amounts Reclassified Amounts Reclassified out of Accumulated Other Comprehensive Income   0 0  
Tax (expense) benefit   (1) 10 (7)
Other Comprehensive Income (Loss)   10 10  
Ending Balance (214) (194) (204) (214)
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax [Abstract]        
Beginning Balance 134 131 134  
Other Comprehensive (Income) Loss, before Reclassifications   0 0  
Amortization of prior service benefit   7 (8)  
Tax (expense) benefit   1 2 2
Other Comprehensive (Income) Loss   (6) (6) (6)
Ending Balance 137 125 131 134
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax [Abstract]        
Beginning Balance (335) (437) (335)  
Other Comprehensive Income (Loss), before Reclassifications   (66) (157)  
Amounts reclassified out of accumulated other comprehensive income   61 39  
Tax (expense) benefit   0 25  
Other comprehensive income (loss)   (5) (93) (7)
Ending Balance (344) (442) (437) (335)
Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax [Abstract]        
Beginning Balance 7 (4) 7  
Loss on interest rate swap   (12) (6)  
Amounts Reclassified out of Accumulated Other Comprehensive Income   2 (8)  
Tax (expense) benefit   3 4  
Other Comprehensive Income (Loss)   (7) (10)  
Ending Balance 6 $ (11) $ (4) $ 7
Revision of Prior Period, Accounting Standards Update, Adjustment        
Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax [Abstract]        
Cumulative Effect of New Accounting Principle in Period of Adoption, Increase (Decrease) to AOCI. (7)      
Accumulated Foreign Currency Adjustment Attributable to Parent | Revision of Prior Period, Accounting Standards Update, Adjustment        
Foreign Currency Translation        
Ending Balance 0      
Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent | Revision of Prior Period, Accounting Standards Update, Adjustment        
Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax [Abstract]        
Cumulative Effect of New Accounting Principle in Period of Adoption, Increase (Decrease) to AOCI. (3)      
Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent | Revision of Prior Period, Accounting Standards Update, Adjustment        
Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax [Abstract]        
Cumulative Effect of New Accounting Principle in Period of Adoption, Increase (Decrease) to AOCI. (9)      
AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent | Revision of Prior Period, Accounting Standards Update, Adjustment        
Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax [Abstract]        
Cumulative Effect of New Accounting Principle in Period of Adoption, Increase (Decrease) to AOCI. $ (1)      
XML 127 R113.htm IDEA: XBRL DOCUMENT v3.20.4
STOCKHOLDERS' EQUITY - Reclassifications out of accumulated other comprehensive income (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Unrealized gains (losses) on derivatives reclassification out of AOCI to cost of sales $ (2) $ 8  
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 0 (2) $ 1
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax (2) 6 $ (3)
Other Comprehensive Income Defined Benefit Plan Amortization Of Net Actuarial Loss (61) (39)  
Amortization of prior service benefit 7 (8)  
Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax (54) (31)  
Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, Tax 16 12  
Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax (38) (19)  
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax $ (40) $ (13)  
XML 128 R114.htm IDEA: XBRL DOCUMENT v3.20.4
SEGMENT INFORMATION Profitability (Details)
$ in Millions
 12 Months Ended
Oct. 31, 2020
USD ($)
segment
numberOfCustomers
Oct. 31, 2019
USD ($)
numberOfCustomers
Oct. 31, 2018
USD ($)
numberOfCustomers
Segment Reporting [Abstract]      
Number of operating segments | segment 3    
Select income statement components      
Net revenue $ 5,339 $ 5,163 $ 4,914
Income from operations 846 941 904
Depreciation expense 119 111 102
Share-based compensation $ 83 $ 72 $ 70
Number of customers representing 10 percent or more of total net revenue | numberOfCustomers 0 0 0
Life Sciences and Applied Markets      
Select income statement components      
Net revenue $ 2,392 $ 2,302 $ 2,270
Income from operations 548 542 543
Depreciation expense 43 41 38
Share-based compensation 35 33 33
Diagnostics and Genomics      
Select income statement components      
Net revenue 1,047 1,021 943
Income from operations 192 185 173
Depreciation expense 39 35 33
Share-based compensation 17 14 14
Agilent CrossLab      
Select income statement components      
Net revenue 1,900 1,840 1,701
Income from operations 516 475 388
Depreciation expense 37 35 31
Share-based compensation 29 25 24
Segment Total      
Select income statement components      
Net revenue 5,339 5,163 4,914
Income from operations 1,256 1,202 1,104
Depreciation expense 119 111 102
Share-based compensation $ 81 $ 72 $ 71
XML 129 R115.htm IDEA: XBRL DOCUMENT v3.20.4
SEGMENT INFORMATION Reconciliation of Reportable Results (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Reconcilitation between statement results and enterprise results [Abstract]      
Total reportable segment income from operations $ 1,256 $ 1,202 $ 1,104
Amortization (184) (125) (105)
Acquisition and integration costs (41) (48) (23)
Transformational initiatives (53) (44) (25)
Share-based Payment Arrangement, Accelerated Cost (2) 0 0
Asset impairment charges 99 0 21
Business exit and divestiture costs (2) 0 (9)
NASD Site costs 0 (12) (8)
Special compliance costs 0 (2) (4)
Other (29) (30) (5)
Interest income (8) (36) (38)
Interest Expense (78) (74) (75)
Other income (expense), net 66 16 79
Income before taxes $ 842 $ 919 $ 946
XML 130 R116.htm IDEA: XBRL DOCUMENT v3.20.4
SEGMENT INFORMATION Segment Assets (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Segment Reporting Information [Line Items]      
Segment Reporting Reconciliation Item Assets $ 7,033 $ 7,153  
Cash and cash equivalents 1,441 1,382  
Prepaid expenses 106 94  
Investments 158 102  
Long term and other receivables 114 100  
Deferred Tax Assets, Net of Valuation Allowance 424 402  
Right-of-use asset 175 0  
Other 220 211  
Total assets 9,627 9,452  
Capital expenditures 119 155 $ 177
Other Assets      
Segment Reporting Information [Line Items]      
Right-of-use asset 175    
Other Noncurrent Assets [Member]      
Segment Reporting Information [Line Items]      
Deferred Tax Assets, Net of Valuation Allowance 380 410  
Life Sciences and Applied Markets      
Segment Reporting Information [Line Items]      
Total assets 3,143 3,202  
Capital expenditures 44 59  
Diagnostics and Genomics      
Segment Reporting Information [Line Items]      
Total assets 2,515 2,620  
Capital expenditures 34 48  
Agilent CrossLab      
Segment Reporting Information [Line Items]      
Total assets 1,375 1,331  
Capital expenditures 41 48  
Segment Total      
Segment Reporting Information [Line Items]      
Total assets 7,033 7,153  
Capital expenditures $ 119 $ 155  
XML 131 R117.htm IDEA: XBRL DOCUMENT v3.20.4
SEGMENT INFORMATION - Entity-Wide Disclosures Revenue (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Revenue by geography      
Net revenue $ 5,339 $ 5,163 $ 4,914
UNITED STATES      
Revenue by geography      
Net revenue 1,752 1,619 1,414
CHINA      
Revenue by geography      
Net revenue 1,087 1,019 1,015
Rest Of World      
Revenue by geography      
Net revenue $ 2,500 $ 2,525 $ 2,485
XML 132 R118.htm IDEA: XBRL DOCUMENT v3.20.4
SEGMENT INFORMATION - Entity-Wide Disclosure Long-Lived Assets (Details) - USD ($)
$ in Millions
Oct. 31, 2020
Oct. 31, 2019
Segment Reporting Information [Line Items]    
Long-Lived Assets $ 1,391 $ 1,147
UNITED STATES    
Segment Reporting Information [Line Items]    
Long-Lived Assets 727 621
GERMANY    
Segment Reporting Information [Line Items]    
Long-Lived Assets 126 122
Rest Of World    
Segment Reporting Information [Line Items]    
Long-Lived Assets $ 538 $ 404
XML 133 R119.htm IDEA: XBRL DOCUMENT v3.20.4
Schedule II Valuation and Qualifying Accounts (Details) - SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Oct. 31, 2018
Movement in valuation and qualifying accounts [Roll Forward]      
Balance at Beginning of Period $ 134 $ 135 $ 138
Additions Charged to Expenses or Other Accounts 6 9 4
Deductions Credited to Expenses or Other Accounts (8) (10) (7)
Balance at End of Period $ 132 $ 134 $ 135
EXCEL 134 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 136 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 137 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 541 729 1 false 139 0 false 8 false false R1.htm 000010001 - Document - Document And Entity Information Sheet http://www.agilent.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 100010002 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS Sheet http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS CONSOLIDATED STATEMENT OF OPERATIONS Statements 2 false false R3.htm 100020003 - Statement - CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME Sheet http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME Statements 3 false false R4.htm 100030004 - Statement - CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Parenthetical) Sheet http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOMEParenthetical CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Parenthetical) Statements 4 false false R5.htm 100040005 - Statement - CONSOLIDATED BALANCE SHEET Sheet http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET CONSOLIDATED BALANCE SHEET Statements 5 false false R6.htm 100050006 - Statement - CONSOLIDATED BALANCE SHEET (Parenthetical) Sheet http://www.agilent.com/role/CONSOLIDATEDBALANCESHEETParenthetical CONSOLIDATED BALANCE SHEET (Parenthetical) Statements 6 false false R7.htm 100060007 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS Sheet http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS CONSOLIDATED STATEMENT OF CASH FLOWS Statements 7 false false R8.htm 100070008 - Statement - CONSOLIDATED STATEMENT OF EQUITY Sheet http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY CONSOLIDATED STATEMENT OF EQUITY Statements 8 false false R9.htm 100080009 - Statement - CONSOLIDATED STATEMENT OF EQUITY (Parenthetical) Sheet http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITYParenthetical CONSOLIDATED STATEMENT OF EQUITY (Parenthetical) Statements 9 false false R10.htm 210011001 - Disclosure - OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 210051002 - Disclosure - NEW ACCOUNTING PRONOUNCEMENTS Sheet http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTS NEW ACCOUNTING PRONOUNCEMENTS Notes 11 false false R12.htm 210081003 - Disclosure - ACQUISITIONS (Notes) Notes http://www.agilent.com/role/ACQUISITIONSNotes ACQUISITIONS (Notes) Notes 12 false false R13.htm 210141004 - Disclosure - REVENUE (Notes) Notes http://www.agilent.com/role/REVENUENotes REVENUE (Notes) Notes 13 false false R14.htm 210201005 - Disclosure - SHARE-BASED COMPENSATION Sheet http://www.agilent.com/role/SHAREBASEDCOMPENSATION SHARE-BASED COMPENSATION Notes 14 false false R15.htm 210281006 - Disclosure - INCOME TAXES Sheet http://www.agilent.com/role/INCOMETAXES INCOME TAXES Notes 15 false false R16.htm 210361007 - Disclosure - NET INCOME (LOSS) PER SHARE Sheet http://www.agilent.com/role/NETINCOMELOSSPERSHARE NET INCOME (LOSS) PER SHARE Notes 16 false false R17.htm 210391008 - Disclosure - INVENTORY Sheet http://www.agilent.com/role/INVENTORY INVENTORY Notes 17 false false R18.htm 210421009 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET Sheet http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNET PROPERTY, PLANT AND EQUIPMENT, NET Notes 18 false false R19.htm 210451010 - Disclosure - LEASES Sheet http://www.agilent.com/role/LEASES LEASES Notes 19 false false R20.htm 210531011 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Sheet http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETS GOODWILL AND OTHER INTANGIBLE ASSETS Notes 20 false false R21.htm 210591012 - Disclosure - INVESTMENTS Sheet http://www.agilent.com/role/INVESTMENTS INVESTMENTS Notes 21 false false R22.htm 210621013 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.agilent.com/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 22 false false R23.htm 210661014 - Disclosure - DERIVATIVES Sheet http://www.agilent.com/role/DERIVATIVES DERIVATIVES Notes 23 false false R24.htm 210721015 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS Sheet http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANS RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS Notes 24 false false R25.htm 210831016 - Disclosure - GUARANTEES Sheet http://www.agilent.com/role/GUARANTEES GUARANTEES Notes 25 false false R26.htm 210861017 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.agilent.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 26 false false R27.htm 210891018 - Disclosure - SHORT-TERM DEBT Sheet http://www.agilent.com/role/SHORTTERMDEBT SHORT-TERM DEBT Notes 27 false false R28.htm 210921019 - Disclosure - LONG-TERM DEBT Sheet http://www.agilent.com/role/LONGTERMDEBT LONG-TERM DEBT Notes 28 false false R29.htm 210961020 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.agilent.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS' EQUITY Notes 29 false false R30.htm 211031021 - Disclosure - SEGMENT INFORMATION Sheet http://www.agilent.com/role/SEGMENTINFORMATION SEGMENT INFORMATION Notes 30 false false R31.htm 211101022 - Disclosure - Schedule II Valuation and Qualifying Accounts Sheet http://www.agilent.com/role/ScheduleIIValuationandQualifyingAccounts Schedule II Valuation and Qualifying Accounts Notes 31 false false R32.htm 220022001 - Disclosure - OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 32 false false R33.htm 230033001 - Disclosure - OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 33 false false R34.htm 230063002 - Disclosure - NEW ACCOUNTING PRONOUNCEMENTS (Tables) Sheet http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTSTables NEW ACCOUNTING PRONOUNCEMENTS (Tables) Tables http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTS 34 false false R35.htm 230093003 - Disclosure - ACQUISITIONS (Tables) Sheet http://www.agilent.com/role/ACQUISITIONSTables ACQUISITIONS (Tables) Tables http://www.agilent.com/role/ACQUISITIONSNotes 35 false false R36.htm 230153004 - Disclosure - REVENUE (Tables) Sheet http://www.agilent.com/role/REVENUETables REVENUE (Tables) Tables http://www.agilent.com/role/REVENUENotes 36 false false R37.htm 230213005 - Disclosure - SHARE-BASED COMPENSATION (Tables) Sheet http://www.agilent.com/role/SHAREBASEDCOMPENSATIONTables SHARE-BASED COMPENSATION (Tables) Tables http://www.agilent.com/role/SHAREBASEDCOMPENSATION 37 false false R38.htm 230293006 - Disclosure - INCOME TAXES (Tables) Sheet http://www.agilent.com/role/INCOMETAXESTables INCOME TAXES (Tables) Tables http://www.agilent.com/role/INCOMETAXES 38 false false R39.htm 230373007 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables) Sheet http://www.agilent.com/role/NETINCOMELOSSPERSHARETables NET INCOME (LOSS) PER SHARE (Tables) Tables http://www.agilent.com/role/NETINCOMELOSSPERSHARE 39 false false R40.htm 230403008 - Disclosure - INVENTORY (Tables) Sheet http://www.agilent.com/role/INVENTORYTables INVENTORY (Tables) Tables http://www.agilent.com/role/INVENTORY 40 false false R41.htm 230433009 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Tables) Sheet http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETTables PROPERTY, PLANT AND EQUIPMENT, NET (Tables) Tables http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNET 41 false false R42.htm 230463010 - Disclosure - LEASES (Tables) Sheet http://www.agilent.com/role/LEASESTables LEASES (Tables) Tables http://www.agilent.com/role/LEASES 42 false false R43.htm 230543011 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Sheet http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Tables http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETS 43 false false R44.htm 230603012 - Disclosure - INVESTMENTS (Tables) Sheet http://www.agilent.com/role/INVESTMENTSTables INVESTMENTS (Tables) Tables http://www.agilent.com/role/INVESTMENTS 44 false false R45.htm 230633013 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.agilent.com/role/FAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.agilent.com/role/FAIRVALUEMEASUREMENTS 45 false false R46.htm 230673014 - Disclosure - DERIVATIVES (Tables) Sheet http://www.agilent.com/role/DERIVATIVESTables DERIVATIVES (Tables) Tables http://www.agilent.com/role/DERIVATIVES 46 false false R47.htm 230733015 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables) Sheet http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTables RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables) Tables http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANS 47 false false R48.htm 230843016 - Disclosure - GUARANTEES (Tables) Sheet http://www.agilent.com/role/GUARANTEESTables GUARANTEES (Tables) Tables http://www.agilent.com/role/GUARANTEES 48 false false R49.htm 230933018 - Disclosure - LONG-TERM DEBT (Tables) Sheet http://www.agilent.com/role/LONGTERMDEBTTables LONG-TERM DEBT (Tables) Tables http://www.agilent.com/role/LONGTERMDEBT 49 false false R50.htm 230973019 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.agilent.com/role/STOCKHOLDERSEQUITYTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.agilent.com/role/STOCKHOLDERSEQUITY 50 false false R51.htm 231043020 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://www.agilent.com/role/SEGMENTINFORMATIONTables SEGMENT INFORMATION (Tables) Tables http://www.agilent.com/role/SEGMENTINFORMATION 51 false false R52.htm 240044001 - Disclosure - OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables 52 false false R53.htm 240074002 - Disclosure - NEW ACCOUNTING PRONOUNCEMENTS - (Details) Sheet http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTSDetails NEW ACCOUNTING PRONOUNCEMENTS - (Details) Details http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTSTables 53 false false R54.htm 240104003 - Disclosure - ACQUISITIONS - Text (Details) Sheet http://www.agilent.com/role/ACQUISITIONSTextDetails ACQUISITIONS - Text (Details) Details 54 false false R55.htm 240114004 - Disclosure - ACQUISITIONS - Assets and Liabilities Assumed (Details) Sheet http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails ACQUISITIONS - Assets and Liabilities Assumed (Details) Details 55 false false R56.htm 240124005 - Disclosure - ACQUISITIONS ACQUISITIONS - Intangible Assets (Details) Sheet http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails ACQUISITIONS ACQUISITIONS - Intangible Assets (Details) Details 56 false false R57.htm 240134006 - Disclosure - ACQUISITIONS ACQUISITIONS - Proforma Operating Results (Details) Sheet http://www.agilent.com/role/ACQUISITIONSACQUISITIONSProformaOperatingResultsDetails ACQUISITIONS ACQUISITIONS - Proforma Operating Results (Details) Details 57 false false R58.htm 240164007 - Disclosure - REVENUE - Revenue by Region (Details) Sheet http://www.agilent.com/role/REVENUERevenuebyRegionDetails REVENUE - Revenue by Region (Details) Details 58 false false R59.htm 240174008 - Disclosure - REVENUE - Revenue by End Markets (Details) Sheet http://www.agilent.com/role/REVENUERevenuebyEndMarketsDetails REVENUE - Revenue by End Markets (Details) Details 59 false false R60.htm 240184009 - Disclosure - REVENUE - Revenue by Type (Details) Sheet http://www.agilent.com/role/REVENUERevenuebyTypeDetails REVENUE - Revenue by Type (Details) Details 60 false false R61.htm 240194010 - Disclosure - REVENUE - Contract Balances (Details) Sheet http://www.agilent.com/role/REVENUEContractBalancesDetails REVENUE - Contract Balances (Details) Details 61 false false R62.htm 240224011 - Disclosure - SHARE-BASED COMPENSATION General Disclosures (Details) Sheet http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails SHARE-BASED COMPENSATION General Disclosures (Details) Details 62 false false R63.htm 240234012 - Disclosure - SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details) Sheet http://www.agilent.com/role/SHAREBASEDCOMPENSATIONAllocatedSharebasedcompensationexpenseDetails SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details) Details 63 false false R64.htm 240244013 - Disclosure - SHARE-BASED COMPENSATION-Fair Value Assumptions (Details) Sheet http://www.agilent.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionsDetails SHARE-BASED COMPENSATION-Fair Value Assumptions (Details) Details 64 false false R65.htm 240254014 - Disclosure - SHARE-BASED COMPENSATION Stock Option Activity (Details) Sheet http://www.agilent.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails SHARE-BASED COMPENSATION Stock Option Activity (Details) Details 65 false false R66.htm 240264015 - Disclosure - SHARE-BASED COMPENSATION Shares Authorized by Exercise Price Range (Details) Sheet http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails SHARE-BASED COMPENSATION Shares Authorized by Exercise Price Range (Details) Details 66 false false R67.htm 240274016 - Disclosure - SHARE-BASED COMPENSATION Non-vested award activity disclosure (Details) Sheet http://www.agilent.com/role/SHAREBASEDCOMPENSATIONNonvestedawardactivitydisclosureDetails SHARE-BASED COMPENSATION Non-vested award activity disclosure (Details) Details 67 false false R68.htm 240304017 - Disclosure - INCOME TAXES INCOME TAXES- Provision (Details) Sheet http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails INCOME TAXES INCOME TAXES- Provision (Details) Details 68 false false R69.htm 240314018 - Disclosure - INCOME TAXES INCOME TAXES Effective tax rate and tax holidays (Details) Sheet http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails INCOME TAXES INCOME TAXES Effective tax rate and tax holidays (Details) Details 69 false false R70.htm 240324019 - Disclosure - INCOME TAXES INCOME TAXES - Deferred Taxes and other (Details) Sheet http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails INCOME TAXES INCOME TAXES - Deferred Taxes and other (Details) Details 70 false false R71.htm 240334020 - Disclosure - INCOME TAXES - Carryforwards (Details) Sheet http://www.agilent.com/role/INCOMETAXESCarryforwardsDetails INCOME TAXES - Carryforwards (Details) Details 71 false false R72.htm 240344021 - Disclosure - INCOME TAXES - Current and long-term income tax assets and liabilities (Details) Sheet http://www.agilent.com/role/INCOMETAXESCurrentandlongtermincometaxassetsandliabilitiesDetails INCOME TAXES - Current and long-term income tax assets and liabilities (Details) Details 72 false false R73.htm 240354022 - Disclosure - INCOME TAXES INCOME TAXES - Uncertain Tax Positions (Details) Sheet http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails INCOME TAXES INCOME TAXES - Uncertain Tax Positions (Details) Details 73 false false R74.htm 240384023 - Disclosure - NET INCOME (LOSS) PER SHARE (Details) Sheet http://www.agilent.com/role/NETINCOMELOSSPERSHAREDetails NET INCOME (LOSS) PER SHARE (Details) Details http://www.agilent.com/role/NETINCOMELOSSPERSHARETables 74 false false R75.htm 240414024 - Disclosure - INVENTORY (Details) Sheet http://www.agilent.com/role/INVENTORYDetails INVENTORY (Details) Details http://www.agilent.com/role/INVENTORYTables 75 false false R76.htm 240444025 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Details) Sheet http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails PROPERTY, PLANT AND EQUIPMENT, NET (Details) Details http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETTables 76 false false R77.htm 240474026 - Disclosure - LEASES - Future Minimum Lease Payments (Details) Sheet http://www.agilent.com/role/LEASESFutureMinimumLeasePaymentsDetails LEASES - Future Minimum Lease Payments (Details) Details 77 false false R78.htm 240484027 - Disclosure - LEASES - Lease Costs (Details) Sheet http://www.agilent.com/role/LEASESLeaseCostsDetails LEASES - Lease Costs (Details) Details 78 false false R79.htm 240494028 - Disclosure - LEASES - Supplemental Cash Flow Information (Details) Sheet http://www.agilent.com/role/LEASESSupplementalCashFlowInformationDetails LEASES - Supplemental Cash Flow Information (Details) Details 79 false false R80.htm 240504029 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details) Sheet http://www.agilent.com/role/LEASESSupplementalBalanceSheetInformationDetails LEASES - Supplemental Balance Sheet Information (Details) Details 80 false false R81.htm 240514030 - Disclosure - LEASES - Maturities of Lease Liabilities (Details) Sheet http://www.agilent.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails LEASES - Maturities of Lease Liabilities (Details) Details 81 false false R82.htm 240524031 - Disclosure - LEASES - Textual (Details) Sheet http://www.agilent.com/role/LEASESTextualDetails LEASES - Textual (Details) Details 82 false false R83.htm 240554032 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Roll forward (Details) Sheet http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSRollforwardDetails GOODWILL AND OTHER INTANGIBLE ASSETS Roll forward (Details) Details 83 false false R84.htm 240564033 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Other Intangibles (Details) Sheet http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDisclosuresandComponentsofOtherIntangiblesDetails GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Other Intangibles (Details) Details 84 false false R85.htm 240574034 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Text (Details) Sheet http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails GOODWILL AND OTHER INTANGIBLE ASSETS Text (Details) Details http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables 85 false false R86.htm 240584035 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Amortization Expense and Future Amortization Expense (Details) Sheet http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationExpenseandFutureAmortizationExpenseDetails GOODWILL AND OTHER INTANGIBLE ASSETS Amortization Expense and Future Amortization Expense (Details) Details 86 false false R87.htm 240614036 - Disclosure - INVESTMENTS (Details) Sheet http://www.agilent.com/role/INVESTMENTSDetails INVESTMENTS (Details) Details http://www.agilent.com/role/INVESTMENTSTables 87 false false R88.htm 240644037 - Disclosure - FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) Sheet http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) Details 88 false false R89.htm 240654038 - Disclosure - FAIR VALUE MEASUREMENTS FAIR VALUE MEASURMENTS - Fair value of assets and liabilities measured on non recurring (Details) Sheet http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails FAIR VALUE MEASUREMENTS FAIR VALUE MEASURMENTS - Fair value of assets and liabilities measured on non recurring (Details) Details 89 false false R90.htm 240684039 - Disclosure - DERIVATIVES (Details) Sheet http://www.agilent.com/role/DERIVATIVESDetails DERIVATIVES (Details) Details http://www.agilent.com/role/DERIVATIVESTables 90 false false R91.htm 240694040 - Disclosure - DERIVATIVES, Disclosures and derivative instrument aggregated notional amounts by currency and designations (Details) Sheet http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails DERIVATIVES, Disclosures and derivative instrument aggregated notional amounts by currency and designations (Details) Details 91 false false R92.htm 240704041 - Disclosure - DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details) Sheet http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details) Details 92 false false R93.htm 240714042 - Disclosure - DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details) Sheet http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details) Details 93 false false R94.htm 240744043 - Disclosure - RETIREMENT PLANS AND POST RETIEMENT PENSION PLANS - Deferred Profit Sharing Plan (Details) Sheet http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIEMENTPENSIONPLANSDeferredProfitSharingPlanDetails RETIREMENT PLANS AND POST RETIEMENT PENSION PLANS - Deferred Profit Sharing Plan (Details) Details 94 false false R95.htm 240754044 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS Defined Contribution (Details) Sheet http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS Defined Contribution (Details) Details 95 false false R96.htm 240764045 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Components of Net Periodic Costs (Details) Sheet http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Components of Net Periodic Costs (Details) Details 96 false false R97.htm 240774046 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Funded Status (Details) Sheet http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Funded Status (Details) Details 97 false false R98.htm 240784047 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Financial Statement Location (Details) Sheet http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Financial Statement Location (Details) Details 98 false false R99.htm 240794048 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS , Target Allocations (Details) Sheet http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS , Target Allocations (Details) Details 99 false false R100.htm 240804049 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Fair Value of Plan Assets (Details) Sheet http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Fair Value of Plan Assets (Details) Details 100 false false R101.htm 240814050 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Expected Benefit Payments (Details) Sheet http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Expected Benefit Payments (Details) Details 101 false false R102.htm 240824051 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Assumptions (Details) Sheet http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Assumptions (Details) Details 102 false false R103.htm 240854052 - Disclosure - GUARANTEES (Details) Sheet http://www.agilent.com/role/GUARANTEESDetails GUARANTEES (Details) Details http://www.agilent.com/role/GUARANTEESTables 103 false false R104.htm 240884053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.agilent.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.agilent.com/role/COMMITMENTSANDCONTINGENCIES 104 false false R105.htm 240904054 - Disclosure - SHORT-TERM DEBT - Credit Facility and Commercial Paper (Details) Sheet http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails SHORT-TERM DEBT - Credit Facility and Commercial Paper (Details) Details 105 false false R106.htm 240914055 - Disclosure - SHORT-TERM DEBT - Senior Notes (Details) Notes http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails SHORT-TERM DEBT - Senior Notes (Details) Details 106 false false R107.htm 240944056 - Disclosure - LONG-TERM DEBT - Carrying Value (Details) Sheet http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails LONG-TERM DEBT - Carrying Value (Details) Details 107 false false R108.htm 240954057 - Disclosure - LONG-TERM DEBT - Senior Notes (Details) Notes http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails LONG-TERM DEBT - Senior Notes (Details) Details 108 false false R109.htm 240984058 - Disclosure - STOCKHOLDERS' EQUITY Stock Repurchases (Details) Sheet http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails STOCKHOLDERS' EQUITY Stock Repurchases (Details) Details 109 false false R110.htm 240994059 - Disclosure - STOCKHOLDERS' EQUITY STOCKHOLDERS EQUITY DIvidends (Details) Sheet http://www.agilent.com/role/STOCKHOLDERSEQUITYSTOCKHOLDERSEQUITYDIvidendsDetails STOCKHOLDERS' EQUITY STOCKHOLDERS EQUITY DIvidends (Details) Details 110 false false R111.htm 241004060 - Disclosure - STOCKHOLDERS' EQUITY -Accumulated other comprehensive income (Details) Sheet http://www.agilent.com/role/STOCKHOLDERSEQUITYAccumulatedothercomprehensiveincomeDetails STOCKHOLDERS' EQUITY -Accumulated other comprehensive income (Details) Details 111 false false R112.htm 241014061 - Disclosure - STOCKHOLDERS' EQUITY - Changes in accumulated other comprehensive income (Details) Sheet http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails STOCKHOLDERS' EQUITY - Changes in accumulated other comprehensive income (Details) Details 112 false false R113.htm 241024062 - Disclosure - STOCKHOLDERS' EQUITY - Reclassifications out of accumulated other comprehensive income (Details) Sheet http://www.agilent.com/role/STOCKHOLDERSEQUITYReclassificationsoutofaccumulatedothercomprehensiveincomeDetails STOCKHOLDERS' EQUITY - Reclassifications out of accumulated other comprehensive income (Details) Details 113 false false R114.htm 241054063 - Disclosure - SEGMENT INFORMATION Profitability (Details) Sheet http://www.agilent.com/role/SEGMENTINFORMATIONProfitabilityDetails SEGMENT INFORMATION Profitability (Details) Details 114 false false R115.htm 241064064 - Disclosure - SEGMENT INFORMATION Reconciliation of Reportable Results (Details) Sheet http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails SEGMENT INFORMATION Reconciliation of Reportable Results (Details) Details 115 false false R116.htm 241074065 - Disclosure - SEGMENT INFORMATION Segment Assets (Details) Sheet http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails SEGMENT INFORMATION Segment Assets (Details) Details 116 false false R117.htm 241084066 - Disclosure - SEGMENT INFORMATION - Entity-Wide Disclosures Revenue (Details) Sheet http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosuresRevenueDetails SEGMENT INFORMATION - Entity-Wide Disclosures Revenue (Details) Details 117 false false R118.htm 241094067 - Disclosure - SEGMENT INFORMATION - Entity-Wide Disclosure Long-Lived Assets (Details) Sheet http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosureLongLivedAssetsDetails SEGMENT INFORMATION - Entity-Wide Disclosure Long-Lived Assets (Details) Details 118 false false R119.htm 241114068 - Disclosure - Schedule II Valuation and Qualifying Accounts (Details) Sheet http://www.agilent.com/role/ScheduleIIValuationandQualifyingAccountsDetails Schedule II Valuation and Qualifying Accounts (Details) Details http://www.agilent.com/role/ScheduleIIValuationandQualifyingAccounts 119 false false All Reports Book All Reports a-20201031.htm a-10312020xexx211.htm a-10312020xexx231.htm a-10312020xexx311.htm a-10312020xexx312.htm a-10312020xexx321.htm a-10312020xexx322.htm a-20201031.xsd a-20201031_cal.xml a-20201031_def.xml a-20201031_lab.xml a-20201031_pre.xml a-20201031_g1.jpg http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 http://xbrl.sec.gov/currency/2020-01-31 true true JSON 139 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a-20201031.htm": { "axisCustom": 2, "axisStandard": 36, "contextCount": 541, "dts": { "calculationLink": { "local": [ "a-20201031_cal.xml" ] }, "definitionLink": { "local": [ "a-20201031_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "a-20201031.htm" ] }, "labelLink": { "local": [ "a-20201031_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "a-20201031_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-ref-2020-01-31.xml" ] }, "schema": { "local": [ "a-20201031.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 1124, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 4 }, "keyCustom": 93, "keyStandard": 636, "memberCustom": 43, "memberStandard": 91, "nsprefix": "a", "nsuri": "http://www.agilent.com/20201031", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000010001 - Document - Document And Entity Information", "role": "http://www.agilent.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210011001 - Disclosure - OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "shortName": "OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i9e6674ce473f43fbb2b9d5d0eb6d83de_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240804049 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Fair Value of Plan Assets (Details)", "role": "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "shortName": "RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Fair Value of Plan Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i9e6674ce473f43fbb2b9d5d0eb6d83de_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i9e6674ce473f43fbb2b9d5d0eb6d83de_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240814050 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Expected Benefit Payments (Details)", "role": "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails", "shortName": "RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Expected Benefit Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i9e6674ce473f43fbb2b9d5d0eb6d83de_I20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i69b166fbd605401087b1b7eb37e89c4e_D20191101-20201031", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240824051 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Assumptions (Details)", "role": "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "shortName": "RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i69b166fbd605401087b1b7eb37e89c4e_D20191101-20201031", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i9733cc0892814e7e9926939b6dc261be_I20191031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StandardProductWarrantyAccrual", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240854052 - Disclosure - GUARANTEES (Details)", "role": "http://www.agilent.com/role/GUARANTEESDetails", "shortName": "GUARANTEES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i739a2f87f26b4665b0c1e86b48a21a66_I20181031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:StandardProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherCommitment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240884053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://www.agilent.com/role/COMMITMENTSANDCONTINGENCIESDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherCommitment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromLinesOfCredit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240904054 - Disclosure - SHORT-TERM DEBT - Credit Facility and Commercial Paper (Details)", "role": "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails", "shortName": "SHORT-TERM DEBT - Credit Facility and Commercial Paper (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i07e1272adcc9499eb5bef444fe136476_D20190313-20190313", "decimals": null, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityInitiationDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R106": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i98ccf4d48c93469894472d3132bb6f90_D20100712-20100713", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentIssuanceDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240914055 - Disclosure - SHORT-TERM DEBT - Senior Notes (Details)", "role": "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails", "shortName": "SHORT-TERM DEBT - Senior Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i98ccf4d48c93469894472d3132bb6f90_D20100712-20100713", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentIssuanceDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R107": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240944056 - Disclosure - LONG-TERM DEBT - Carrying Value (Details)", "role": "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails", "shortName": "LONG-TERM DEBT - Carrying Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R108": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "ib6d18871a5124c7ab7c7b1b7afa97182_D20120913-20120913", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentIssuanceDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240954057 - Disclosure - LONG-TERM DEBT - Senior Notes (Details)", "role": "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails", "shortName": "LONG-TERM DEBT - Senior Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "ib6d18871a5124c7ab7c7b1b7afa97182_D20120913-20120913", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentIssuanceDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R109": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240984058 - Disclosure - STOCKHOLDERS' EQUITY Stock Repurchases (Details)", "role": "http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails", "shortName": "STOCKHOLDERS' EQUITY Stock Repurchases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i173afbeec6914fedba9ae05f99201be0_I20150528", "decimals": "-7", "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210051002 - Disclosure - NEW ACCOUNTING PRONOUNCEMENTS", "role": "http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTS", "shortName": "NEW ACCOUNTING PRONOUNCEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R110": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240994059 - Disclosure - STOCKHOLDERS' EQUITY STOCKHOLDERS EQUITY DIvidends (Details)", "role": "http://www.agilent.com/role/STOCKHOLDERSEQUITYSTOCKHOLDERSEQUITYDIvidendsDetails", "shortName": "STOCKHOLDERS' EQUITY STOCKHOLDERS EQUITY DIvidends (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3a8bb528b0804825a8b933154f8d8577_D20201118-20201118", "decimals": "3", "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R111": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241004060 - Disclosure - STOCKHOLDERS' EQUITY -Accumulated other comprehensive income (Details)", "role": "http://www.agilent.com/role/STOCKHOLDERSEQUITYAccumulatedothercomprehensiveincomeDetails", "shortName": "STOCKHOLDERS' EQUITY -Accumulated other comprehensive income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "lang": "en-US", "name": "a:ForeignCurrencyTranslationTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R112": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i739a2f87f26b4665b0c1e86b48a21a66_I20181031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241014061 - Disclosure - STOCKHOLDERS' EQUITY - Changes in accumulated other comprehensive income (Details)", "role": "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails", "shortName": "STOCKHOLDERS' EQUITY - Changes in accumulated other comprehensive income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R113": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241024062 - Disclosure - STOCKHOLDERS' EQUITY - Reclassifications out of accumulated other comprehensive income (Details)", "role": "http://www.agilent.com/role/STOCKHOLDERSEQUITYReclassificationsoutofaccumulatedothercomprehensiveincomeDetails", "shortName": "STOCKHOLDERS' EQUITY - Reclassifications out of accumulated other comprehensive income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R114": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241054063 - Disclosure - SEGMENT INFORMATION Profitability (Details)", "role": "http://www.agilent.com/role/SEGMENTINFORMATIONProfitabilityDetails", "shortName": "SEGMENT INFORMATION Profitability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R115": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "a:Segmentincomelossfromoperations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241064064 - Disclosure - SEGMENT INFORMATION Reconciliation of Reportable Results (Details)", "role": "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails", "shortName": "SEGMENT INFORMATION Reconciliation of Reportable Results (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "a:Segmentincomelossfromoperations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R116": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "a:AssetsAndCapitalExpendituresDirectlyManagedByEachSegmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "a:SegmentReportingReconciliationItemAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241074065 - Disclosure - SEGMENT INFORMATION Segment Assets (Details)", "role": "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails", "shortName": "SEGMENT INFORMATION Segment Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "a:AssetsAndCapitalExpendituresDirectlyManagedByEachSegmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "a:SegmentReportingReconciliationItemAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R117": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241084066 - Disclosure - SEGMENT INFORMATION - Entity-Wide Disclosures Revenue (Details)", "role": "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosuresRevenueDetails", "shortName": "SEGMENT INFORMATION - Entity-Wide Disclosures Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "if82501345a1947279e650e3fe2c8be05_D20191101-20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R118": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241094067 - Disclosure - SEGMENT INFORMATION - Entity-Wide Disclosure Long-Lived Assets (Details)", "role": "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosureLongLivedAssetsDetails", "shortName": "SEGMENT INFORMATION - Entity-Wide Disclosure Long-Lived Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R119": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "ic0c839a6ee2741fdb2515d7269ac3b77_I20191031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241114068 - Disclosure - Schedule II Valuation and Qualifying Accounts (Details)", "role": "http://www.agilent.com/role/ScheduleIIValuationandQualifyingAccountsDetails", "shortName": "Schedule II Valuation and Qualifying Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7ed6a7f8ad864c5a8b873acd8fa796f2_I20171031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210081003 - Disclosure - ACQUISITIONS (Notes)", "role": "http://www.agilent.com/role/ACQUISITIONSNotes", "shortName": "ACQUISITIONS (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210141004 - Disclosure - REVENUE (Notes)", "role": "http://www.agilent.com/role/REVENUENotes", "shortName": "REVENUE (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210201005 - Disclosure - SHARE-BASED COMPENSATION", "role": "http://www.agilent.com/role/SHAREBASEDCOMPENSATION", "shortName": "SHARE-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210281006 - Disclosure - INCOME TAXES", "role": "http://www.agilent.com/role/INCOMETAXES", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210361007 - Disclosure - NET INCOME (LOSS) PER SHARE", "role": "http://www.agilent.com/role/NETINCOMELOSSPERSHARE", "shortName": "NET INCOME (LOSS) PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210391008 - Disclosure - INVENTORY", "role": "http://www.agilent.com/role/INVENTORY", "shortName": "INVENTORY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210421009 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET", "role": "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNET", "shortName": "PROPERTY, PLANT AND EQUIPMENT, NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210451010 - Disclosure - LEASES", "role": "http://www.agilent.com/role/LEASES", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010002 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS", "role": "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS", "shortName": "CONSOLIDATED STATEMENT OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210531011 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS", "role": "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETS", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210591012 - Disclosure - INVESTMENTS", "role": "http://www.agilent.com/role/INVESTMENTS", "shortName": "INVESTMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210621013 - Disclosure - FAIR VALUE MEASUREMENTS", "role": "http://www.agilent.com/role/FAIRVALUEMEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210661014 - Disclosure - DERIVATIVES", "role": "http://www.agilent.com/role/DERIVATIVES", "shortName": "DERIVATIVES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210721015 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS", "role": "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANS", "shortName": "RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210831016 - Disclosure - GUARANTEES", "role": "http://www.agilent.com/role/GUARANTEES", "shortName": "GUARANTEES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210861017 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.agilent.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210891018 - Disclosure - SHORT-TERM DEBT", "role": "http://www.agilent.com/role/SHORTTERMDEBT", "shortName": "SHORT-TERM DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210921019 - Disclosure - LONG-TERM DEBT", "role": "http://www.agilent.com/role/LONGTERMDEBT", "shortName": "LONG-TERM DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210961020 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://www.agilent.com/role/STOCKHOLDERSEQUITY", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020003 - Statement - CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME", "role": "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME", "shortName": "CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211031021 - Disclosure - SEGMENT INFORMATION", "role": "http://www.agilent.com/role/SEGMENTINFORMATION", "shortName": "SEGMENT INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211101022 - Disclosure - Schedule II Valuation and Qualifying Accounts", "role": "http://www.agilent.com/role/ScheduleIIValuationandQualifyingAccounts", "shortName": "Schedule II Valuation and Qualifying Accounts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "220022001 - Disclosure - OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "shortName": "OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230033001 - Disclosure - OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "shortName": "OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230063002 - Disclosure - NEW ACCOUNTING PRONOUNCEMENTS (Tables)", "role": "http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTSTables", "shortName": "NEW ACCOUNTING PRONOUNCEMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230093003 - Disclosure - ACQUISITIONS (Tables)", "role": "http://www.agilent.com/role/ACQUISITIONSTables", "shortName": "ACQUISITIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230153004 - Disclosure - REVENUE (Tables)", "role": "http://www.agilent.com/role/REVENUETables", "shortName": "REVENUE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230213005 - Disclosure - SHARE-BASED COMPENSATION (Tables)", "role": "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONTables", "shortName": "SHARE-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230293006 - Disclosure - INCOME TAXES (Tables)", "role": "http://www.agilent.com/role/INCOMETAXESTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230373007 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables)", "role": "http://www.agilent.com/role/NETINCOMELOSSPERSHARETables", "shortName": "NET INCOME (LOSS) PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030004 - Statement - CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Parenthetical)", "role": "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOMEParenthetical", "shortName": "CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230403008 - Disclosure - INVENTORY (Tables)", "role": "http://www.agilent.com/role/INVENTORYTables", "shortName": "INVENTORY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230433009 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Tables)", "role": "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETTables", "shortName": "PROPERTY, PLANT AND EQUIPMENT, NET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230463010 - Disclosure - LEASES (Tables)", "role": "http://www.agilent.com/role/LEASESTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230543011 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "role": "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230603012 - Disclosure - INVESTMENTS (Tables)", "role": "http://www.agilent.com/role/INVESTMENTSTables", "shortName": "INVESTMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230633013 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230673014 - Disclosure - DERIVATIVES (Tables)", "role": "http://www.agilent.com/role/DERIVATIVESTables", "shortName": "DERIVATIVES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230733015 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables)", "role": "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTables", "shortName": "RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230843016 - Disclosure - GUARANTEES (Tables)", "role": "http://www.agilent.com/role/GUARANTEESTables", "shortName": "GUARANTEES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230933018 - Disclosure - LONG-TERM DEBT (Tables)", "role": "http://www.agilent.com/role/LONGTERMDEBTTables", "shortName": "LONG-TERM DEBT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040005 - Statement - CONSOLIDATED BALANCE SHEET", "role": "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "shortName": "CONSOLIDATED BALANCE SHEET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230973019 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "role": "http://www.agilent.com/role/STOCKHOLDERSEQUITYTables", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "231043020 - Disclosure - SEGMENT INFORMATION (Tables)", "role": "http://www.agilent.com/role/SEGMENTINFORMATIONTables", "shortName": "SEGMENT INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "us-gaap:AdvertisingCostsPolicyTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240044001 - Disclosure - OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "role": "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "shortName": "OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "us-gaap:AdvertisingCostsPolicyTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240074002 - Disclosure - NEW ACCOUNTING PRONOUNCEMENTS - (Details)", "role": "http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTSDetails", "shortName": "NEW ACCOUNTING PRONOUNCEMENTS - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i517b5c2808ed40ebb1d41b71e6460659_I20191101", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherAssetsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i82c87e393254440fb2f3f736e614c4fd_D20181114-20181114", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240104003 - Disclosure - ACQUISITIONS - Text (Details)", "role": "http://www.agilent.com/role/ACQUISITIONSTextDetails", "shortName": "ACQUISITIONS - Text (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i82c87e393254440fb2f3f736e614c4fd_D20181114-20181114", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240114004 - Disclosure - ACQUISITIONS - Assets and Liabilities Assumed (Details)", "role": "http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails", "shortName": "ACQUISITIONS - Assets and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "id780bf00f9454ac09bca8ce8358849ae_I20190823", "decimals": "-6", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240124005 - Disclosure - ACQUISITIONS ACQUISITIONS - Intangible Assets (Details)", "role": "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails", "shortName": "ACQUISITIONS ACQUISITIONS - Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "id780bf00f9454ac09bca8ce8358849ae_I20190823", "decimals": "-6", "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "ia7313b73ffa04f5ba8c8f7e93644d703_D20181101-20191031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240134006 - Disclosure - ACQUISITIONS ACQUISITIONS - Proforma Operating Results (Details)", "role": "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSProformaOperatingResultsDetails", "shortName": "ACQUISITIONS ACQUISITIONS - Proforma Operating Results (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "ia7313b73ffa04f5ba8c8f7e93644d703_D20181101-20191031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240164007 - Disclosure - REVENUE - Revenue by Region (Details)", "role": "http://www.agilent.com/role/REVENUERevenuebyRegionDetails", "shortName": "REVENUE - Revenue by Region (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i441c948aa8d146968e4911e730bd946e_D20191101-20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240174008 - Disclosure - REVENUE - Revenue by End Markets (Details)", "role": "http://www.agilent.com/role/REVENUERevenuebyEndMarketsDetails", "shortName": "REVENUE - Revenue by End Markets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i06a7df2eead64d0cbd10faba77daa86a_D20191101-20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050006 - Statement - CONSOLIDATED BALANCE SHEET (Parenthetical)", "role": "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEETParenthetical", "shortName": "CONSOLIDATED BALANCE SHEET (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240184009 - Disclosure - REVENUE - Revenue by Type (Details)", "role": "http://www.agilent.com/role/REVENUERevenuebyTypeDetails", "shortName": "REVENUE - Revenue by Type (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "ifc9d1cf68de34dc2bdb77cabc7916b89_D20191101-20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240194010 - Disclosure - REVENUE - Contract Balances (Details)", "role": "http://www.agilent.com/role/REVENUEContractBalancesDetails", "shortName": "REVENUE - Contract Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240224011 - Disclosure - SHARE-BASED COMPENSATION General Disclosures (Details)", "role": "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails", "shortName": "SHARE-BASED COMPENSATION General Disclosures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240234012 - Disclosure - SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details)", "role": "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONAllocatedSharebasedcompensationexpenseDetails", "shortName": "SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i6b0939fbe2564ebd9d205e0ca2d0d986_D20191101-20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "a:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyTextBlock", "a:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i847e3b3289704ac9bf84acdc98efe859_D20191101-20201031", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240244013 - Disclosure - SHARE-BASED COMPENSATION-Fair Value Assumptions (Details)", "role": "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionsDetails", "shortName": "SHARE-BASED COMPENSATION-Fair Value Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "a:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyTextBlock", "a:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i847e3b3289704ac9bf84acdc98efe859_D20191101-20201031", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i9733cc0892814e7e9926939b6dc261be_I20191031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240254014 - Disclosure - SHARE-BASED COMPENSATION Stock Option Activity (Details)", "role": "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails", "shortName": "SHARE-BASED COMPENSATION Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240264015 - Disclosure - SHARE-BASED COMPENSATION Shares Authorized by Exercise Price Range (Details)", "role": "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails", "shortName": "SHARE-BASED COMPENSATION Shares Authorized by Exercise Price Range (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "a:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i9733cc0892814e7e9926939b6dc261be_I20191031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240274016 - Disclosure - SHARE-BASED COMPENSATION Non-vested award activity disclosure (Details)", "role": "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONNonvestedawardactivitydisclosureDetails", "shortName": "SHARE-BASED COMPENSATION Non-vested award activity disclosure (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "a:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240304017 - Disclosure - INCOME TAXES INCOME TAXES- Provision (Details)", "role": "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails", "shortName": "INCOME TAXES INCOME TAXES- Provision (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240314018 - Disclosure - INCOME TAXES INCOME TAXES Effective tax rate and tax holidays (Details)", "role": "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails", "shortName": "INCOME TAXES INCOME TAXES Effective tax rate and tax holidays (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060007 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS", "role": "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS", "shortName": "CONSOLIDATED STATEMENT OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240324019 - Disclosure - INCOME TAXES INCOME TAXES - Deferred Taxes and other (Details)", "role": "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails", "shortName": "INCOME TAXES INCOME TAXES - Deferred Taxes and other (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240334020 - Disclosure - INCOME TAXES - Carryforwards (Details)", "role": "http://www.agilent.com/role/INCOMETAXESCarryforwardsDetails", "shortName": "INCOME TAXES - Carryforwards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "a:CurrentAndLongTermTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxesReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240344021 - Disclosure - INCOME TAXES - Current and long-term income tax assets and liabilities (Details)", "role": "http://www.agilent.com/role/INCOMETAXESCurrentandlongtermincometaxassetsandliabilitiesDetails", "shortName": "INCOME TAXES - Current and long-term income tax assets and liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "a:CurrentAndLongTermTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxesReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i9733cc0892814e7e9926939b6dc261be_I20191031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240354022 - Disclosure - INCOME TAXES INCOME TAXES - Uncertain Tax Positions (Details)", "role": "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails", "shortName": "INCOME TAXES INCOME TAXES - Uncertain Tax Positions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "id52192e4523a4e60ab860f53bfcedb2f_I20171031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240384023 - Disclosure - NET INCOME (LOSS) PER SHARE (Details)", "role": "http://www.agilent.com/role/NETINCOMELOSSPERSHAREDetails", "shortName": "NET INCOME (LOSS) PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240414024 - Disclosure - INVENTORY (Details)", "role": "http://www.agilent.com/role/INVENTORYDetails", "shortName": "INVENTORY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240444025 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Details)", "role": "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails", "shortName": "PROPERTY, PLANT AND EQUIPMENT, NET (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i9733cc0892814e7e9926939b6dc261be_I20191031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240474026 - Disclosure - LEASES - Future Minimum Lease Payments (Details)", "role": "http://www.agilent.com/role/LEASESFutureMinimumLeasePaymentsDetails", "shortName": "LEASES - Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i9733cc0892814e7e9926939b6dc261be_I20191031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240484027 - Disclosure - LEASES - Lease Costs (Details)", "role": "http://www.agilent.com/role/LEASESLeaseCostsDetails", "shortName": "LEASES - Lease Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePaymentsUse", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240494028 - Disclosure - LEASES - Supplemental Cash Flow Information (Details)", "role": "http://www.agilent.com/role/LEASESSupplementalCashFlowInformationDetails", "shortName": "LEASES - Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePaymentsUse", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i1c1cac44d9ca46efbcc2dbc8b952584f_I20171031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070008 - Statement - CONSOLIDATED STATEMENT OF EQUITY", "role": "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "shortName": "CONSOLIDATED STATEMENT OF EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i1c1cac44d9ca46efbcc2dbc8b952584f_I20171031", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "a:AssetsAndCapitalExpendituresDirectlyManagedByEachSegmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240504029 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details)", "role": "http://www.agilent.com/role/LEASESSupplementalBalanceSheetInformationDetails", "shortName": "LEASES - Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "a:LesseeAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240514030 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)", "role": "http://www.agilent.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails", "shortName": "LEASES - Maturities of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "a:OperatingLeasedAssetsOriginalCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240524031 - Disclosure - LEASES - Textual (Details)", "role": "http://www.agilent.com/role/LEASESTextualDetails", "shortName": "LEASES - Textual (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "a:OperatingLeasedAssetsOriginalCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i9733cc0892814e7e9926939b6dc261be_I20191031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240554032 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Roll forward (Details)", "role": "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSRollforwardDetails", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS Roll forward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i739a2f87f26b4665b0c1e86b48a21a66_I20181031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240564033 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Other Intangibles (Details)", "role": "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDisclosuresandComponentsofOtherIntangiblesDetails", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Other Intangibles (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240574034 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Text (Details)", "role": "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS Text (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240584035 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Amortization Expense and Future Amortization Expense (Details)", "role": "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationExpenseandFutureAmortizationExpenseDetails", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS Amortization Expense and Future Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240614036 - Disclosure - INVESTMENTS (Details)", "role": "http://www.agilent.com/role/INVESTMENTSDetails", "shortName": "INVESTMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:TradingSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240644037 - Disclosure - FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details)", "role": "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails", "shortName": "FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i72430a60ef1f43258da890b0c4acf6d3_I20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240654038 - Disclosure - FAIR VALUE MEASUREMENTS FAIR VALUE MEASURMENTS - Fair value of assets and liabilities measured on non recurring (Details)", "role": "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails", "shortName": "FAIR VALUE MEASUREMENTS FAIR VALUE MEASURMENTS - Fair value of assets and liabilities measured on non recurring (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100080009 - Statement - CONSOLIDATED STATEMENT OF EQUITY (Parenthetical)", "role": "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITYParenthetical", "shortName": "CONSOLIDATED STATEMENT OF EQUITY (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "a:Interestrateswappayments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240684039 - Disclosure - DERIVATIVES (Details)", "role": "http://www.agilent.com/role/DERIVATIVESDetails", "shortName": "DERIVATIVES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DerivativeNetLiabilityPositionAggregateFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "ia1e3cc48142e4b6281ae24cb9e634d51_I20201031", "decimals": "INF", "first": true, "lang": "en-US", "name": "a:NumberOfForeignExchangeForwardContractsDesignatedAsCashFlowHedge", "reportCount": 1, "unique": true, "unitRef": "contracts", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240694040 - Disclosure - DERIVATIVES, Disclosures and derivative instrument aggregated notional amounts by currency and designations (Details)", "role": "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails", "shortName": "DERIVATIVES, Disclosures and derivative instrument aggregated notional amounts by currency and designations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "ia1e3cc48142e4b6281ae24cb9e634d51_I20201031", "decimals": "INF", "first": true, "lang": "en-US", "name": "a:NumberOfForeignExchangeForwardContractsDesignatedAsCashFlowHedge", "reportCount": 1, "unique": true, "unitRef": "contracts", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240704041 - Disclosure - DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details)", "role": "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails", "shortName": "DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i3c06d859462e402eb523809fdc204521_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240714042 - Disclosure - DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details)", "role": "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "shortName": "DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "ie47c3c7f52474f28bbe1fdc49aaea551_D20181101-20190131", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i2220c86bbd4342f4b7db32df9b6ab98b_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240744043 - Disclosure - RETIREMENT PLANS AND POST RETIEMENT PENSION PLANS - Deferred Profit Sharing Plan (Details)", "role": "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIEMENTPENSIONPLANSDeferredProfitSharingPlanDetails", "shortName": "RETIREMENT PLANS AND POST RETIEMENT PENSION PLANS - Deferred Profit Sharing Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i2220c86bbd4342f4b7db32df9b6ab98b_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240754044 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS Defined Contribution (Details)", "role": "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails", "shortName": "RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS Defined Contribution (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i7eff6790c4db4facb67bfc44b077505a_D20191101-20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240764045 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Components of Net Periodic Costs (Details)", "role": "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails", "shortName": "RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Components of Net Periodic Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i69b166fbd605401087b1b7eb37e89c4e_D20191101-20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i2b59bf985c8e425bb5827106e150155d_I20191031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240774046 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Funded Status (Details)", "role": "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails", "shortName": "RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Funded Status (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "idf3dda50b2e84329af4eefcef78c080c_D20191101-20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i8c4de28714544cfeaf8e9afd4bba4350_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240784047 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Financial Statement Location (Details)", "role": "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails", "shortName": "RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Financial Statement Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "i8c4de28714544cfeaf8e9afd4bba4350_I20201031", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "if83bd415d93042cbafc41847cb81607e_I20201031", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240794048 - Disclosure - RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS , Target Allocations (Details)", "role": "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails", "shortName": "RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS , Target Allocations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a-20201031.htm", "contextRef": "if83bd415d93042cbafc41847cb81607e_I20201031", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } } }, "segmentCount": 139, "tag": { "a_A2015RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2015 Repurchase Program - On May 28, 2015 we announced that our board of directors had approved a new share repurchase program. The new share repurchase program authorizes the purchase of up to $1.14 billion of our common stock through and including November 1, 2018. The new program will commence, at the option of the company, on either November 1, 2015, or the date on which we complete the purchase of $365 million of common stock under the existing stock repurchase program in fiscal 2015. Upon commencement, the new program replaces our existing stock repurchase program, which authorized the repurchase of shares to reduce or eliminate share dilution from equity programs.", "label": "2015 Repurchase Program [Member]", "terseLabel": "2015 Repurchase Program [Member]" } } }, "localname": "A2015RepurchaseProgramMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails" ], "xbrltype": "domainItemType" }, "a_A2019RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Repurchase Program [Member]", "label": "2019 Repurchase Program [Member]", "terseLabel": "2019 Repurchase Program [Member]" } } }, "localname": "A2019RepurchaseProgramMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails" ], "xbrltype": "domainItemType" }, "a_A5YrUnsecuredCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5 yr Unsecured Credit Facility", "label": "5 yr Unsecured Credit Facility [Member]", "terseLabel": "5 yr unsecured credit facility" } } }, "localname": "A5YrUnsecuredCreditFacilityMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "domainItemType" }, "a_ACEABiosciencesInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ACEA Biosciences, Inc. [Member]", "label": "ACEA Biosciences, Inc. [Member]", "terseLabel": "ACEA Biosciences, Inc." } } }, "localname": "ACEABiosciencesInc.Member", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSTextDetails" ], "xbrltype": "domainItemType" }, "a_AcademiaandGovernmentMarketMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Academia and Government Market [Member]", "label": "Academia and Government Market [Member]", "terseLabel": "Academia and Government Market" } } }, "localname": "AcademiaandGovernmentMarketMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/REVENUERevenuebyEndMarketsDetails" ], "xbrltype": "domainItemType" }, "a_Acceleratedamortizationofinterestrateswapgain": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "accelerated amortization of interest rate swap gain", "label": "accelerated amortization of interest rate swap gain", "terseLabel": "accelerated amortization of interest rate swap gain" } } }, "localname": "Acceleratedamortizationofinterestrateswapgain", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "a_AccumulatedBenefitObligationwhereFairValueofplanAssetsexceedsABO": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated benefit obligation for defined benefit pension plan where the fair value of plan assets exceeds accumulated benefit obligation.", "label": "Accumulated Benefit Obligation where Fair Value of plan Assets exceeds ABO", "terseLabel": "Accumulated Benefit Obligation where Fair Value of plan Assets exceeds ABO" } } }, "localname": "AccumulatedBenefitObligationwhereFairValueofplanAssetsexceedsABO", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "a_AdditionalIncrementalTermLoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional Incremental Term Loan Facility", "label": "Additional Incremental Term Loan Facility [Member]", "terseLabel": "Additional Incremental Term Loan Facility" } } }, "localname": "AdditionalIncrementalTermLoanFacilityMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "domainItemType" }, "a_AdvancedAnalyticalTechnologiesIncAATIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advanced Analytical Technologies, Inc (AATI)", "label": "Advanced Analytical Technologies, Inc (AATI) [Member]", "terseLabel": "Advanced Analytical Technologies, Inc (AATI)" } } }, "localname": "AdvancedAnalyticalTechnologiesIncAATIMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails" ], "xbrltype": "domainItemType" }, "a_AggregateparticipantscontributionstoESPP": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate participant contributions to employee stock purchase plan for the purchase of shares of the company's common stock not yet issued to participants at the end of the period. Shares are excluded from the available for issuance balance at the end of the period.", "label": "Aggregate participants contributions to ESPP", "terseLabel": "Aggregate participants contributions to ESPP" } } }, "localname": "AggregateparticipantscontributionstoESPP", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "a_AgilentCrossLabMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agilent CrossLab [Member]", "label": "Agilent CrossLab [Member]", "terseLabel": "Agilent CrossLab" } } }, "localname": "AgilentCrossLabMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSRollforwardDetails", "http://www.agilent.com/role/REVENUERevenuebyRegionDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONProfitabilityDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "domainItemType" }, "a_AssetsAndCapitalExpendituresDirectlyManagedByEachSegmentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the total assets and capital expenditures for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Assets And Capital Expenditures Directly Managed By Each Segment [Table Text Block]", "verboseLabel": "Assets and capital expenditures directly managed by each segment" } } }, "localname": "AssetsAndCapitalExpendituresDirectlyManagedByEachSegmentTableTextBlock", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "a_BalanceBeginningOfYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets, usually stocks, bonds, and other investments, that have been segregated and restricted (usually in a trust) to provide benefits, at their fair value as of the measurement date. Plan assets include amounts contributed by the employer (and by employees for a contributory plan) and amounts earned from investing the contributions, less benefits paid. If a plan has liabilities other than for benefits, those non-benefit obligations may be considered as reductions of plan assets.", "label": "Balance, beginning of year", "periodStartLabel": "Balance, beginning of year" } } }, "localname": "BalanceBeginningOfYear", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "a_BalanceEndOfYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets, usually stocks, bonds, and other investments, that have been segregated and restricted (usually in a trust) to provide benefits, at their fair value as of the measurement date. Plan assets include amounts contributed by the employer (and by employees for a contributory plan) and amounts earned from investing the contributions, less benefits paid. If a plan has liabilities other than for benefits, those non-benefit obligations may be considered as reductions of plan assets.", "label": "Balance, end of year", "periodEndLabel": "Balance, end of year" } } }, "localname": "BalanceEndOfYear", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "a_BioTekMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BioTek [Member]", "label": "BioTek [Member]", "terseLabel": "BioTek" } } }, "localname": "BioTekMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails", "http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails", "http://www.agilent.com/role/ACQUISITIONSTextDetails" ], "xbrltype": "domainItemType" }, "a_BioTekandACEAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BioTek and ACEA Biosciences [Member]", "label": "BioTek and ACEA [Member]", "terseLabel": "BioTek and ACEA" } } }, "localname": "BioTekandACEAMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails" ], "xbrltype": "domainItemType" }, "a_ChangeInDeferralsFromCustomerCashAdvancesNetOfRevenueRecognized": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of prepayments by customers for goods and services to be provided at a later date net of revenue recognized.", "label": "Change in deferrals from customer cash advances net of revenue recognized", "terseLabel": "Contract with Customer, Refund Liability" } } }, "localname": "ChangeInDeferralsFromCustomerCashAdvancesNetOfRevenueRecognized", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/REVENUEContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "a_ChangeinassetsandliabilitiesduetoTaxAct": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in assets and liabilities due to Tax Act", "label": "Change in assets and liabilities due to Tax Act", "terseLabel": "Change in assets and liabilities due to Tax Act" } } }, "localname": "ChangeinassetsandliabilitiesduetoTaxAct", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "a_ChemicalandEnergyMarketMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chemical and Energy Market [Member]", "label": "Chemical and Energy Market [Member]", "terseLabel": "Chemical and Energy Market" } } }, "localname": "ChemicalandEnergyMarketMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/REVENUERevenuebyEndMarketsDetails" ], "xbrltype": "domainItemType" }, "a_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoptionIncreaseDecreaseToAOCI": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cumulative Effect of New Accounting Principle in Period of Adoption, Increase (Decrease) to AOCI.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption, Increase (Decrease) to AOCI.", "terseLabel": "Cumulative Effect of New Accounting Principle in Period of Adoption, Increase (Decrease) to AOCI." } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoptionIncreaseDecreaseToAOCI", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "a_CurrentAndLongTermDeferredTaxAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Current And Long Term Deferred Tax Assets And Liabilities [Abstract]", "label": "Current And Long Term Deferred Tax Assets And Liabilities [Abstract]", "terseLabel": "Long Term Deferred Tax Assets And Liabilities [Abstract]" } } }, "localname": "CurrentAndLongTermDeferredTaxAssetsAndLiabilitiesAbstract", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails" ], "xbrltype": "stringItemType" }, "a_CurrentAndLongTermTaxAssetsAndCurrentAndLongTermTaxLiabilitiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description containing the entire income tax comparison of temporary differences on current and long term deferred tax assets and liabilities disclosure. This element may be used as a single block of text to encapsulate the entire disclosure including data and tables.", "label": "Current And Long Term Tax Assets And Current And Long Term Tax Liabilities Disclosure [Text Block]", "verboseLabel": "Long-term deferred tax assets and deferred tax liabilities" } } }, "localname": "CurrentAndLongTermTaxAssetsAndCurrentAndLongTermTaxLiabilitiesDisclosureTextBlock", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "a_CurrentAndLongTermTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the breakdown between current and long term income tax payable and receivable and their location in the consolidated balance sheet.", "label": "Current and Long Term Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Current and Long Term Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "CurrentAndLongTermTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "a_Currentmedicalcosttrendrate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average rate of current medical cost trend rate used to determine net periodic benefit cost of defined benefit plan.", "label": "Current medical cost trend rate", "terseLabel": "Current medical cost trend rate" } } }, "localname": "Currentmedicalcosttrendrate", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails" ], "xbrltype": "percentItemType" }, "a_DeferredTaxAssetsLeaseObligations": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease arrangements.", "label": "Deferred tax assets - lease obligations", "terseLabel": "Deferred tax assets - lease obligations" } } }, "localname": "DeferredTaxAssetsLeaseObligations", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails" ], "xbrltype": "monetaryItemType" }, "a_DefinedBenefitPlanAccumulatedBenefitObligationTotalAggregateBenefitObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "If aggregate disclosures are presented for the accumulated benefit obligation, the aggregate fair value of assets.", "label": "Defined Benefit Plan Accumulated Benefit Obligation Total Aggregate Benefit Obligation", "terseLabel": "Total accumulated benefit obligation - aggregate benefit obligation" } } }, "localname": "DefinedBenefitPlanAccumulatedBenefitObligationTotalAggregateBenefitObligation", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "a_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetActuarialGainLossBeforeTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net increase or decrease of changes in the value of either the benefit obligation or the plan assets resulting from experience different from that assumed or from a change in an actuarial assumption, or the consequence of a decision to temporarily deviate from the substantive plan, recognized in other comprehensive income.", "label": "Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Net Actuarial Gain Loss Before Tax", "negatedTerseLabel": "Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Net Actuarial Gain Loss Before Tax", "terseLabel": "Actuarial (gains) losses" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetActuarialGainLossBeforeTax", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "a_DefinedBenefitPlanAnalysisOfBenefitObligationsInRelationToFairValueOfPlanAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan Analysis Of Benefit Obligations In Relation To Fair Value Of Plan Assets [Abstract]", "label": "Defined Benefit Plan Analysis Of Benefit Obligations In Relation To Fair Value Of Plan Assets [Abstract]", "verboseLabel": "Projected benefit obligation and fair value of plan assets [Abstract]" } } }, "localname": "DefinedBenefitPlanAnalysisOfBenefitObligationsInRelationToFairValueOfPlanAssetsAbstract", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "a_DefinedBenefitPlanProjectedBenefitObligationTotalAggregateBenefitObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "If aggregate disclosures are presented for the projected benefit obligation, the aggregate benefit obligation value.", "label": "Defined Benefit Plan Projected Benefit Obligation Total Aggregate Benefit Obligation", "terseLabel": "Total projected benefit obligation - aggregate benefit obligation" } } }, "localname": "DefinedBenefitPlanProjectedBenefitObligationTotalAggregateBenefitObligation", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "a_DefinedBenefitPlanUsPortfolioEquitySecuritiesPercentageOfAlternativeInvestments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Actual percentage of alternative investments that the US equity portfolio consist.", "label": "Defined Benefit Plan Us Portfolio Equity Securities Percentage Of Alternative Investments", "terseLabel": "Defined Benefit Plan Us Portfolio Equity Securities Percentage Of Alternative Investments" } } }, "localname": "DefinedBenefitPlanUsPortfolioEquitySecuritiesPercentageOfAlternativeInvestments", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "percentItemType" }, "a_DefinedBenefitobligationwhereFairValueexceedsPensionbenefitobligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit obligation for defined benefit plan where fair value of plan assets exceeds pension benefit obligation", "label": "Defined Benefit obligation where Fair Value exceeds Pension benefit obligation", "terseLabel": "Defined Benefit obligation where Fair Value exceeds Pension benefit obligation" } } }, "localname": "DefinedBenefitobligationwhereFairValueexceedsPensionbenefitobligation", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "a_DenominatorsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Denominators [Abstract]", "label": "Denominators [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "DenominatorsAbstract", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/NETINCOMELOSSPERSHAREDetails" ], "xbrltype": "stringItemType" }, "a_DerivativeContractsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Contracts [Abstract]", "label": "Derivative Contracts [Abstract]", "terseLabel": "Derivative Contracts [Abstract]" } } }, "localname": "DerivativeContractsAbstract", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails" ], "xbrltype": "stringItemType" }, "a_DescriptionOfTypesAndTermsOfFairValueHedgingInstrumentsUsed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the types and terms of derivatives designated as fair value hedging instruments. For example, interest rate swaps, forward contracts, and so forth.", "label": "Description Of Types And Terms Of Fair Value Hedging Instruments Used", "verboseLabel": "Hedging contracts general maturity" } } }, "localname": "DescriptionOfTypesAndTermsOfFairValueHedgingInstrumentsUsed", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "durationItemType" }, "a_DiagnosticsAndGenomicsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Diagnostics and Genomics segment includes; DNA mutation detection; genotyping; gene copy number determination; identification of gene rearrangements; DNA methylation profiling; gene expression profiling; and automated gel electrophoresis-based sample analysis systems.", "label": "Diagnostics and Genomics [Member]", "terseLabel": "Diagnostics and Genomics" } } }, "localname": "DiagnosticsAndGenomicsMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSRollforwardDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails", "http://www.agilent.com/role/REVENUERevenuebyRegionDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONProfitabilityDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "domainItemType" }, "a_DiagnosticsandClinicalMarketMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Diagnostics and Clinical Market [Member]", "label": "Diagnostics and Clinical Market [Member]", "terseLabel": "Diagnostics and Clinical Market" } } }, "localname": "DiagnosticsandClinicalMarketMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/REVENUERevenuebyEndMarketsDetails" ], "xbrltype": "domainItemType" }, "a_Earlyrepaymentofseniornotesincludingprepaymentpenalty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the extinguishment of long-term borrowing (including prepayment penalty), with the highest claim on the assets of the entity in case of bankruptcy or liquidation, before its maturity.", "label": "Early repayment of senior notes including prepayment penalty", "terseLabel": "Early repayment of senior notes including prepayment penalty" } } }, "localname": "Earlyrepaymentofseniornotesincludingprepaymentpenalty", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "a_Earlyrepaymentofseniornotesprepaymentpenalty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Early repayment of senior notes prepayment penalty", "label": "Early repayment of senior notes prepayment penalty", "terseLabel": "Early repayment of senior notes prepayment penalty" } } }, "localname": "Earlyrepaymentofseniornotesprepaymentpenalty", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "a_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsOnNonvestedEquityOtherThanStockOptionAwardsWeightedAveragePeriodOfRecognition": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average period over which unrecognized share-based compensation costs on equity other than stock options are expected to be reported", "label": "Employee Service Share Based Compensation Unrecognized Compensation Costs On Nonvested Equity Other Than Stock Option Awards Weighted Average Period Of Recognition", "verboseLabel": "Weighted-average period non-vested restricted stock awards are expected to be amortized over (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsOnNonvestedEquityOtherThanStockOptionAwardsWeightedAveragePeriodOfRecognition", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONNonvestedawardactivitydisclosureDetails" ], "xbrltype": "decimalItemType" }, "a_EmployeeStockPurchasePlanAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan [Abstract]", "label": "Employee stock purchase plan [Abstract]", "terseLabel": "Employee stock purchase plan [Abstract]" } } }, "localname": "EmployeeStockPurchasePlanAbstract", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails" ], "xbrltype": "stringItemType" }, "a_EmployeecompensationandbenefitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee compensation and benefits [Member]", "label": "Employee compensation and benefits [Member]", "terseLabel": "Employee compensation and benefits [Member]" } } }, "localname": "EmployeecompensationandbenefitsMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "domainItemType" }, "a_Employeecompensationandbenefitsassumed": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer) assumed at the acquisition date.", "label": "Employee compensation and benefits assumed", "terseLabel": "Employee compensation and benefits" } } }, "localname": "Employeecompensationandbenefitsassumed", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "a_EndMarketsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End Markets [Axis]", "label": "End Markets [Axis]", "terseLabel": "End Markets [Axis]" } } }, "localname": "EndMarketsAxis", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/REVENUERevenuebyEndMarketsDetails" ], "xbrltype": "stringItemType" }, "a_EndMarketsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for End Markets [Axis]", "label": "End Markets [Domain]", "terseLabel": "End Markets [Domain]" } } }, "localname": "EndMarketsDomain", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/REVENUERevenuebyEndMarketsDetails" ], "xbrltype": "domainItemType" }, "a_EntityClosingStockPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair market closing stock price for entity share at end of fiscal year as reflected on national stock exchange.", "label": "Entity Closing Stock Price", "verboseLabel": "Closing stock price basis for aggregate intrinsic value (in dollars per share)" } } }, "localname": "EntityClosingStockPrice", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "perShareItemType" }, "a_EntityWideDisclosureOnGeographicAreasAttributedToIndividualForeignCountriesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Entity Wide Disclosure On Geographic Areas Attributed To Individual Foreign Countries [Line Items]", "label": "Entity Wide Disclosure On Geographic Areas Attributed To Individual Foreign Countries [Line Items]", "terseLabel": "Entity Wide Disclosure" } } }, "localname": "EntityWideDisclosureOnGeographicAreasAttributedToIndividualForeignCountriesLineItems", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosuresRevenueDetails" ], "xbrltype": "stringItemType" }, "a_EntityWideDisclosureOnGeographicAreasAttributedToIndividualForeignCountriesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Entity Wide Disclosure On Geographic Areas Attributed To Individual Foreign Countries [Table]", "label": "Entity Wide Disclosure On Geographic Areas Attributed To Individual Foreign Countries [Table]", "terseLabel": "Entity Wide Disclosure On Geographic Areas Attributed To Individual Foreign Countries [Table]" } } }, "localname": "EntityWideDisclosureOnGeographicAreasAttributedToIndividualForeignCountriesTable", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosuresRevenueDetails" ], "xbrltype": "stringItemType" }, "a_EnvironmentalandForensicsMarketMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Environmental and Forensics Market [Member]", "label": "Environmental and Forensics Market [Member]", "terseLabel": "Environmental and Forensics Market" } } }, "localname": "EnvironmentalandForensicsMarketMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/REVENUERevenuebyEndMarketsDetails" ], "xbrltype": "domainItemType" }, "a_EquitySecuritiesWithReadilyDeterminableFairValueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Securities with Readily Determinable Fair Value", "label": "Equity Securities with Readily Determinable Fair Value [Member]", "terseLabel": "Equity Securities with Readily Determinable Fair Value" } } }, "localname": "EquitySecuritiesWithReadilyDeterminableFairValueMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/INVESTMENTSDetails" ], "xbrltype": "domainItemType" }, "a_EquitySecuritiesWithoutReadilyDeterminableFairValueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Securities without Readily Determinable Fair Value", "label": "Equity Securities without Readily Determinable Fair Value [Member]", "terseLabel": "Equity Securities without Readily Determinable Fair Value" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails", "http://www.agilent.com/role/INVESTMENTSDetails" ], "xbrltype": "domainItemType" }, "a_FairValueAssetsMeasuredOnRecurringBasisDerivativeInstrumentsForeignExhangeContracts": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails": { "order": 2.0, "parentTag": "a_FairValueAssetsMeasuredOnRecurringBasisTotalAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents a certain statement of financial position asset which includes foreign exchange contracts derivative instruments, measured at fair value on a recurring basis.", "label": "Fair Value Assets Measured On Recurring Basis Derivative Instruments Foreign Exhange Contracts", "verboseLabel": "Derivative instruments (foreign exchange contracts)" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisDerivativeInstrumentsForeignExhangeContracts", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails" ], "xbrltype": "monetaryItemType" }, "a_FairValueAssetsMeasuredOnRecurringBasisTotalAssets": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents total assets, measured at fair value on a recurring basis.", "label": "Fair Value Assets Measured On Recurring Basis Total Assets", "totalLabel": "Total assets measured at fair value" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTotalAssets", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails" ], "xbrltype": "monetaryItemType" }, "a_FairValueLiabilitiesMeasuredOnRecurringBasisDeferredCompensationLiability": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails": { "order": 2.0, "parentTag": "a_FairValueLiabilitiesMeasuredOnRecurringBasisTotalLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents a certain statement of financial position liability which deferred compensation liability, measured at fair value on a recurring basis.", "label": "Fair Value Liabilities Measured On Recurring Basis Deferred Compensation Liability", "verboseLabel": "Deferred compensation liability" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisDeferredCompensationLiability", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails" ], "xbrltype": "monetaryItemType" }, "a_FairValueLiabilitiesMeasuredOnRecurringBasisTotalLiabilities": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents total liabilities, measured at fair value on a recurring basis.", "label": "Fair Value Liabilities Measured On Recurring Basis Total Liabilities", "totalLabel": "Total liabilities measured at fair value" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTotalLiabilities", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails" ], "xbrltype": "monetaryItemType" }, "a_FairValueOfPlanAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value of plan assets [Abstract]", "label": "Fair value of plan assets [Abstract]", "terseLabel": "Fair value of plan assets [Abstract]" } } }, "localname": "FairValueOfPlanAssetsAbstract", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "a_FairValueofplanassetswherefairvalueexceedspensionbenefitobligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of plan assets for defined benefit plan where fair value of plan assets exceeds pension benefit obligation.", "label": "Fair Value of plan assets where fair value exceeds pension benefit obligation", "terseLabel": "Fair Value of plan assets where fair value exceeds pension benefit obligation" } } }, "localname": "FairValueofplanassetswherefairvalueexceedspensionbenefitobligation", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "a_Fairvaluelowerthancarryingvalue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of fair value of long term debt is lower than of carrying value.", "label": "Fair value lower than carrying value", "terseLabel": "Fair value lower than carrying value" } } }, "localname": "Fairvaluelowerthancarryingvalue", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "a_Fairvalueoflongtermdebtinexcessofcarryingvalue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of fair value of long term debt in excess of carrying value.", "label": "Fair value of long term debt in excess of carrying value", "terseLabel": "Fair value of long term debt in excess of carrying value" } } }, "localname": "Fairvalueoflongtermdebtinexcessofcarryingvalue", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "a_FairvalueofplanassetsfordefinedbenefitpensionplanwherethefairvalueofplanassetsexceedsABO.": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of plan assets for defined benefit pension plan where the fair value of plan assets exceeds accumulated benefit obligation.", "label": "Fair value of plan assets for defined benefit pension plan where the fair value of plan assets exceeds ABO.", "terseLabel": "Fair value of plan assets for defined benefit pension plan where the fair value of plan assets exceeds ABO." } } }, "localname": "FairvalueofplanassetsfordefinedbenefitpensionplanwherethefairvalueofplanassetsexceedsABO.", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "a_Fairvalueofplanassetsfordefinedbenefitplanwithbenefitobligationinexcessofplanassets.": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of plan assets for defined benefit plan with benefit obligation in excess of plan assets.", "label": "Fair value of plan assets for defined benefit plan with benefit obligation in excess of plan assets.", "terseLabel": "Fair value of plan assets for defined benefit plan with benefit obligation in excess of plan assets." } } }, "localname": "Fairvalueofplanassetsfordefinedbenefitplanwithbenefitobligationinexcessofplanassets.", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "a_FoodMarketMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Food Market [Member]", "label": "Food Market [Member]", "terseLabel": "Food Market" } } }, "localname": "FoodMarketMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/REVENUERevenuebyEndMarketsDetails" ], "xbrltype": "domainItemType" }, "a_ForeignCurrencyTranslationTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tax effect on the change in the balance sheet adjustment that results from the adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into reporting currency as of the balance sheet date.", "label": "Foreign currency translation, tax", "terseLabel": "Foreign currency translation, tax" } } }, "localname": "ForeignCurrencyTranslationTax", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYAccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "a_Fullydepreciatedassetsnolongerinuse": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fully depreciated assets no longer in use retired in the period", "label": "Fully depreciated assets no longer in use", "terseLabel": "Fully depreciated assets no longer in use retired" } } }, "localname": "Fullydepreciatedassetsnolongerinuse", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "xbrltype": "monetaryItemType" }, "a_GainLossOnInvestmentsMarketableSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gain (Loss) on Investments, Marketable Securities [Abstract]", "label": "Gain (Loss) on Investments, Marketable Securities [Abstract]", "terseLabel": "Amounts included in other income (expense), net [Abstract]" } } }, "localname": "GainLossOnInvestmentsMarketableSecuritiesAbstract", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/INVESTMENTSDetails" ], "xbrltype": "stringItemType" }, "a_ImpairmentOfLongLivedAssetsIncludedInNetIncomeTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For long-lived assets of an entity, disclosures may include a description of the impaired long-lived asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired long-lived asset is reported.", "label": "Impairment of Long-lived assets included in net income [Text Block]", "verboseLabel": "Impairment of Long-lived assets included in net income" } } }, "localname": "ImpairmentOfLongLivedAssetsIncludedInNetIncomeTextBlock", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "a_IncometaxreconciliationchangeinUSdeferredtaxreserves": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation change in US deferred tax reserves", "label": "Income tax reconciliation change in US deferred tax reserves", "terseLabel": "Change in unrecognized tax benefits" } } }, "localname": "IncometaxreconciliationchangeinUSdeferredtaxreserves", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails" ], "xbrltype": "monetaryItemType" }, "a_InstrumentationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Instrumentation [Member]", "label": "Instrumentation [Member]", "terseLabel": "Instrumentation" } } }, "localname": "InstrumentationMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/REVENUERevenuebyTypeDetails" ], "xbrltype": "domainItemType" }, "a_InterestRateDerivativesTerminatedDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap Terminated Date", "label": "Interest Rate Derivatives Terminated Date", "terseLabel": "Interest Rate Derivatives Terminated Date" } } }, "localname": "InterestRateDerivativesTerminatedDate", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "normalizedStringItemType" }, "a_InterestRateSwap": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period recorded in debt.", "label": "Interest Rate Swap", "terseLabel": "Interest Rate Swap" } } }, "localname": "InterestRateSwap", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "a_InterestRateSwapOnSeniorNotesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pertinent information about each long-term debt arrangement including the carrying amount as of the balance sheet date, by type of long-term debt. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Interest Rate Swap On Senior Notes [Axis]", "terseLabel": "Interest Rate Swap On Senior Notes [Axis]" } } }, "localname": "InterestRateSwapOnSeniorNotesAxis", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails", "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "stringItemType" }, "a_InterestRateSwapOnSeniorNotesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Interest Rate Swap On Senior Notes [Domain]", "terseLabel": "Interest Rate Swap On Senior Notes [Domain]" } } }, "localname": "InterestRateSwapOnSeniorNotesDomain", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails", "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "a_Interestrateswappayments": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "interest rate swap payments", "label": "interest rate swap payments", "negatedTerseLabel": "Treasury lock agreement payment", "terseLabel": "interest rate swap payments" } } }, "localname": "Interestrateswappayments", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.agilent.com/role/DERIVATIVESDetails" ], "xbrltype": "monetaryItemType" }, "a_LTPPRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LTPP & RSU [Member]", "label": "LTPP & RSU [Member]", "terseLabel": "LTPP & RSU" } } }, "localname": "LTPPRSUMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "xbrltype": "domainItemType" }, "a_LasergenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lasergen [Member]", "label": "Lasergen [Member]", "terseLabel": "Lasergen" } } }, "localname": "LasergenMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "domainItemType" }, "a_LesseeAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Assets and Liabilities balances and classification.", "label": "Lessee Assets and Liabilities [Table Text Block]", "terseLabel": "Lessee Assets and Liabilities" } } }, "localname": "LesseeAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "a_LifeSciencesandAppliedMarketsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Life Sciences and Applied Markets [Member]", "label": "Life Sciences and Applied Markets [Member]", "terseLabel": "Life Sciences and Applied Markets" } } }, "localname": "LifeSciencesandAppliedMarketsMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSRollforwardDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails", "http://www.agilent.com/role/REVENUERevenuebyRegionDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONProfitabilityDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "domainItemType" }, "a_LongLivedAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long -Lived Assets [Abstract]", "label": "Long -Lived Assets [Abstract]", "terseLabel": "Long -Lived Assets" } } }, "localname": "LongLivedAssetsAbstract", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "a_LtppMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Performance Plan.", "label": "LTPP [Member]", "terseLabel": "LTPP" } } }, "localname": "LtppMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "xbrltype": "domainItemType" }, "a_Netassetvalueexcludedfromfairvaluebyinput": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents investments for which fair value is measured using net asset value (NAV) per share practical expedient, and excluded from the fair value schedule by input.", "label": "Net asset value excluded from fair value by input", "terseLabel": "Net asset value excluded from fair value by input" } } }, "localname": "Netassetvalueexcludedfromfairvaluebyinput", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "a_NonInstrumentationandOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-Instrumentation and Other[Member]", "label": "Non-Instrumentation and Other [Member]", "terseLabel": "Non-Instrumentation and Other" } } }, "localname": "NonInstrumentationandOtherMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/REVENUERevenuebyTypeDetails" ], "xbrltype": "domainItemType" }, "a_Noncashchangesininvestmentsinpropertyplantandequipmentincreasedecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Changes to the cost of fixed assets that are not the result of cash capital expenditures.", "label": "Non-cash changes in investments in property, plant and equipment increase (decrease)", "terseLabel": "Net change in property, plant and equipment increase (decrease)" } } }, "localname": "Noncashchangesininvestmentsinpropertyplantandequipmentincreasedecrease", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "a_NotionalAmountOfTerminatedInterestRateFairValueHedgeDerivatives": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate notional amount of all interest rate derivatives designated as hedging instruments in fair value hedges that were terminated. Notional amount refers to the monetary amount specified in the interest rate derivative contract.", "label": "Notional Amount Of Terminated Interest Rate Fair Value Hedge Derivatives", "terseLabel": "Notional Amount Of Terminated Interest Rate Fair Value Hedge Derivatives" } } }, "localname": "NotionalAmountOfTerminatedInterestRateFairValueHedgeDerivatives", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails", "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "a_NumberOfForeignExchangeForwardContractsDesignatedAsCashFlowHedge": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of foreign currency exchange forward contract derivatives held by the entity at the reporting date and designated as cash flow hedges.", "label": "Number Of Foreign Exchange Forward Contracts Designated As Cash Flow Hedge", "terseLabel": "Number Of Foreign Exchange Forward Contracts Designated As Cash Flow Hedge" } } }, "localname": "NumberOfForeignExchangeForwardContractsDesignatedAsCashFlowHedge", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "integerItemType" }, "a_NumberOfForeignExchangeForwardContractsNotDesignatedAsHedges": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of foreign currency exchange forward contract derivatives held by the entity at the reporting date and not designated as hedges.", "label": "Number Of Foreign Exchange Forward Contracts Not Designated As Hedges", "terseLabel": "Number Of Foreign Exchange Forward Contracts Not Designated As Hedges" } } }, "localname": "NumberOfForeignExchangeForwardContractsNotDesignatedAsHedges", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "integerItemType" }, "a_NumberOfSignificantCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Customers representing 10 percent or more of the balance.", "label": "Number of Significant Customers", "terseLabel": "Number of customers representing 10 percent or more of total net revenue", "verboseLabel": "Number of customers representing 10 percent or more of accounts receivable." } } }, "localname": "NumberOfSignificantCustomers", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONProfitabilityDetails" ], "xbrltype": "integerItemType" }, "a_NumeratorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Numerator [Abstract]", "label": "Numerator [Abstract]", "verboseLabel": "Numerator:" } } }, "localname": "NumeratorAbstract", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/NETINCOMELOSSPERSHAREDetails" ], "xbrltype": "stringItemType" }, "a_OperatingLeasedAssetsOriginalCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Original costs for operating leased assets.", "label": "operating leased assets - original cost", "terseLabel": "operating leased assets - original cost" } } }, "localname": "OperatingLeasedAssetsOriginalCost", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/LEASESTextualDetails" ], "xbrltype": "monetaryItemType" }, "a_Operatingleasedassetsnetbookvalue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating leased assets net book value.", "label": "Operatingleasedassetsnetbookvalue", "terseLabel": "Operating leased assets net book value" } } }, "localname": "Operatingleasedassetsnetbookvalue", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/LEASESTextualDetails" ], "xbrltype": "monetaryItemType" }, "a_OtherAccruedAndLongTermLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other accrued and long-term liabilities", "label": "Other accrued and long-term liabilities [Member]", "terseLabel": "Other accrued and long-term liabilities [Member]" } } }, "localname": "OtherAccruedAndLongTermLiabilitiesMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "a_OtherComprehensiveIncomeDefinedBenefitPlanAmortizationOfNetActuarialLoss": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails": { "order": 2.0, "parentTag": "a_OtherComprehensiveIncomeDefinedBenefitPlansPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The change in other comprehensive income due to the amortization of the net actuarial gains (losses) into net periodic pension costs.", "label": "Other Comprehensive Income Defined Benefit Plan Amortization Of Net Actuarial Loss", "terseLabel": "Other Comprehensive Income Defined Benefit Plan Amortization Of Net Actuarial Loss", "verboseLabel": "Amortization of net actuarial loss" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlanAmortizationOfNetActuarialLoss", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYReclassificationsoutofaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "a_OtherComprehensiveIncomeDefinedBenefitPlansPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amounts recognized in other comprehensive income (but not yet recognized in net periodic benefit cost), including the net gain (loss) and net prior service cost (credit) arising during the period.", "label": "Other Comprehensive Income Defined Benefit Plans Period Increase Decrease", "totalLabel": "Total recognized in other comprehensive (income) loss" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansPeriodIncreaseDecrease", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails" ], "xbrltype": "monetaryItemType" }, "a_OtherComprehensiveIncomelosspensionandotherpostretirementbenefitplansamortizationofnetlosstax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (loss) pension and other post retirement benefit plans, amortization of net loss, tax", "label": "Other Comprehensive Income (loss) pension and other post retirement benefit plans, amortization of net loss, tax", "negatedLabel": "Tax (expense) benefit" } } }, "localname": "OtherComprehensiveIncomelosspensionandotherpostretirementbenefitplansamortizationofnetlosstax", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "a_OtherPlanAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets held in a defined plan not otherwise previously defined.", "label": "Other Plan Assets [Member]", "terseLabel": "Other Investments" } } }, "localname": "OtherPlanAssetsMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "domainItemType" }, "a_PenaltyreduceoverperiodoftimeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Penalty reduce over period of time [Member]", "label": "Penalty reduce over period of time [Member]", "terseLabel": "Penalty reduce over period of time" } } }, "localname": "PenaltyreduceoverperiodoftimeMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "a_PercentageOfFaceAmountOfSeniorNoteInstrumentIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Proceeds obtained expressed as a percentage of debt instrument face value.", "label": "Percentage Of Face Amount Of Senior Note Instrument Issued", "terseLabel": "Percentage Of Face Amount Of Senior Note Instrument Issued", "verboseLabel": "Issue rate percentage of principal amount" } } }, "localname": "PercentageOfFaceAmountOfSeniorNoteInstrumentIssued", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails", "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "percentItemType" }, "a_PharmaceuticalandBiopharmaceuticalMarketMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmaceutical and Biopharmaceutical Market [Member]", "label": "Pharmaceutical and Biopharmaceutical Market [Member]", "terseLabel": "Pharmaceutical and Biopharmaceutical Market" } } }, "localname": "PharmaceuticalandBiopharmaceuticalMarketMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/REVENUERevenuebyEndMarketsDetails" ], "xbrltype": "domainItemType" }, "a_Remaininggainlosstobeamortizedonderivative": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Remaining gain loss to be amortized on derivative", "label": "Remaining gain loss to be amortized on derivative", "terseLabel": "Remaining gain loss to be amortized on derivative" } } }, "localname": "Remaininggainlosstobeamortizedonderivative", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "a_RestOfWorldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A specified country or group of countries about which segment information is provided by the entity. This element is used for a group of countries not specifically disclosed.", "label": "Rest Of World [Member]", "terseLabel": "Rest Of World" } } }, "localname": "RestOfWorldMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosureLongLivedAssetsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosuresRevenueDetails" ], "xbrltype": "domainItemType" }, "a_RetirementandpostretirementbenefitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Retirement and post-retirement benefits [Member]", "label": "Retirement and post-retirement benefits [Member]", "terseLabel": "Retirement and post-retirement benefits" } } }, "localname": "RetirementandpostretirementbenefitsMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "domainItemType" }, "a_RetirementofTreasurySharesaccountingpolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the accounting policy for the retirement of the company's treasury shares. [Policy Text Block]", "label": "Retirement of Treasury Shares accounting policy [Policy Text Block]", "terseLabel": "Retirement of Treasury Shares" } } }, "localname": "RetirementofTreasurySharesaccountingpolicyPolicyTextBlock", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "a_RevisionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revisions [Abstract]", "label": "Revisions [Abstract]", "terseLabel": "Revisions [Abstract]" } } }, "localname": "RevisionsAbstract", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "a_RiskAndUncertaintiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risk and Uncertainties", "label": "Risk and Uncertainties [Policy Text Block]", "terseLabel": "Risk and Uncertainties" } } }, "localname": "RiskAndUncertaintiesPolicyTextBlock", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "a_ScheduleofProductWarrantyLiabilityclassificationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Product Warranty Liability classification [Table Text Block]", "label": "Schedule of Product Warranty Liability classification [Table Text Block]", "terseLabel": "Schedule of Product Warranty Liability classification" } } }, "localname": "ScheduleofProductWarrantyLiabilityclassificationTableTextBlock", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/GUARANTEESTables" ], "xbrltype": "textBlockItemType" }, "a_SegmentReportingOtherReconcilingItemsForOperatingProfitLossSegmentToConsolidated": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of an item in the reconciliation of total profit or loss from reportable segments to the entity's consolidated income before income taxes, extraordinary items, discontinued operations.", "label": "Segment Reporting Other reconciling items for operating profit loss segment to consolidated", "negatedTerseLabel": "Other" } } }, "localname": "SegmentReportingOtherReconcilingItemsForOperatingProfitLossSegmentToConsolidated", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "a_SegmentReportingReconciliationItemAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amounts of assets held by an entity, and used in a reconciliation of assets by segment to the entity consolidated balance sheet.", "label": "Segment Reporting Reconciliation Item Assets", "terseLabel": "Segment Reporting Reconciliation Item Assets" } } }, "localname": "SegmentReportingReconciliationItemAssets", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "a_SegmentReportingReconciliationItemCashAndCashEquivalents": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amounts of cash, cash equivalents and short term investments held by an entity, and used in a reconciliation of assets by segment to the entity consolidated balance sheet.", "label": "Segment Reporting Reconciliation Item Cash And Cash Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "SegmentReportingReconciliationItemCashAndCashEquivalents", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "a_SegmentReportingReconciliationItemInvestments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments held by an entity, and used in a reconciliation of assets by segment to the entity consolidated balance sheet.", "label": "Segment Reporting Reconciliation Item Investments", "terseLabel": "Investments" } } }, "localname": "SegmentReportingReconciliationItemInvestments", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "a_SegmentReportingReconciliationItemLongTermAndOtherReceivables": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term and other receivables held by an entity, and used in a reconciliation of assets by segment to the entity consolidated balance sheet.", "label": "Segment Reporting Reconciliation Item Long Term And Other Receivables", "terseLabel": "Long term and other receivables" } } }, "localname": "SegmentReportingReconciliationItemLongTermAndOtherReceivables", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "a_SegmentReportingReconciliationItemOtherAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets and assets not otherwise identified in other reconciliation balances, and used in a reconciliation of assets by segment to the entity consolidated balance sheet.", "label": "Segment Reporting Reconciliation Item Other Assets", "terseLabel": "Other" } } }, "localname": "SegmentReportingReconciliationItemOtherAssets", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "a_SegmentReportingReconciliationItemPrepaids": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prepaid expense balance held by an entity, and used in a reconciliation of assets by segment to the entity consolidated balance sheet.", "label": "Segment Reporting Reconciliation Item Prepaids", "terseLabel": "Prepaid expenses" } } }, "localname": "SegmentReportingReconciliationItemPrepaids", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "a_SegmentTotalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reportable amounts associated with all reporting segments included in a reconciliation from segment reporting to consolidated income from operations, before taxes.", "label": "Segment Total [Member]", "terseLabel": "Segment Total" } } }, "localname": "SegmentTotalMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONProfitabilityDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "domainItemType" }, "a_Segmentincomelossfromoperations": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting segment operating expenses from segment operating revenues.", "label": "Segment income (loss) from operations", "terseLabel": "Total reportable segment income from operations" } } }, "localname": "Segmentincomelossfromoperations", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "a_SeniorNotes2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes Payable with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), including current and non-current portion. Senior note holders are paid off in full before any payments are made to junior note holders.", "label": "Senior Notes 2020 [Member]", "terseLabel": "Senior Notes 2020" } } }, "localname": "SeniorNotes2020Member", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "a_SeniorNotes2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured ( general) creditors.", "label": "Senior Notes 2022 [Member]", "terseLabel": "Senior Notes 2022" } } }, "localname": "SeniorNotes2022Member", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "a_SeniorNotes2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2023 [Member]", "label": "Senior Notes 2023 [Member]", "terseLabel": "Senior Notes 2023 [Member]" } } }, "localname": "SeniorNotes2023Member", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "a_SeniorNotes2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2026", "label": "Senior Notes 2026 [Member]", "terseLabel": "Senior Notes 2026" } } }, "localname": "SeniorNotes2026Member", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "a_SeniorNotes2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2029 [Member]", "label": "Senior Notes 2029 [Member]", "terseLabel": "Senior Notes 2029" } } }, "localname": "SeniorNotes2029Member", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "a_SeniorNotes2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2030", "label": "Senior Notes 2030 [Member]", "terseLabel": "Senior Notes 2030 [Member]" } } }, "localname": "SeniorNotes2030Member", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "a_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardMaximumContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reflects the duration as to when the share-based award expires as specified in the award agreement, which may be presented in a variety of ways (for example, in years, months, quarter of a year).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Maximum Contractual Term", "verboseLabel": "Maximum contractual term (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardMaximumContractualTerm", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails" ], "xbrltype": "durationStringItemType" }, "a_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIncrementalIssuanceInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The issuance in the number of non-vested shares under a share-based award plan made during the period on other than stock option plans (for example, phantom stock plan, stock appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Incremental Issuance In Period", "terseLabel": "Change in LTPP shares vested in the year due to performance conditions" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIncrementalIssuanceInPeriod", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONNonvestedawardactivitydisclosureDetails" ], "xbrltype": "sharesItemType" }, "a_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsLTPPIncrementalIssuanceNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value of incremental issuance associated with LTPP nonvested awards on share-based plans excluding option plans (for example, phantom stock plan, stock appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options LTPP Incremental Issuance Nonvested Weighted Average Grant Date Fair Value", "terseLabel": "Change in LTPP shares vested in the year- Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsLTPPIncrementalIssuanceNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONNonvestedawardactivitydisclosureDetails" ], "xbrltype": "perShareItemType" }, "a_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForwardTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of components of non-vested stock option or other award plan under which share-based compensation is awarded to employees, typically comprised of the amount of unearned compensation, compensation expense, and changes in the quantity and fair value of the shares granted, exercised, forfeited, and issued and outstanding pertaining to that plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Roll Forward [Text Block]", "verboseLabel": "Non-vested award activity disclosure" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForwardTextBlock", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "a_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, and long-term performance plan grants.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Text Block]", "verboseLabel": "Share-based compensation arrangement by share-based payment award fair value assumptions and methodology schedule" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyTextBlock", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "a_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPeerCompanySharesPriceWiseCorrelationyRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The measure of the percentage amount of share price correlation during the period with a selected group of peer companies. Pair-wise correlations with selected peers is calculated as the correlation between each pair and the sum of correlations divided by the number of pairs to produce the average correlation between each pair.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Peer Company Shares Price Wise Correlationy Rate", "verboseLabel": "Pair-wise correlation with selected peers (in hundredths)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPeerCompanySharesPriceWiseCorrelationyRate", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "a_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionspeercompaniesVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The measure of the percentage amount by which a share price fluctuates during a period for peer companies - maximum range. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionspeercompaniesVolatilityRateMaximum", "terseLabel": "Volatility of peer-company shares -Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionspeercompaniesVolatilityRateMaximum", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "a_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionspeercompaniesVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The measure of the percentage amount by which a share price fluctuates during a period for peer companies - minimum range. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionspeercompaniesVolatilityRateMinimum", "terseLabel": "Volatility of peer-company shares -Minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionspeercompaniesVolatilityRateMinimum", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "a_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueIntrinsicValueOptionsExercisedTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of grant date fair value of stock options granted and the intrinsic value of a stock option exercised during the period under share-based compensation plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Intrinsic Value Options Exercised [Text Block]", "verboseLabel": "Schedule of intrinsic value of options exercised and the fair value of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueIntrinsicValueOptionsExercisedTextBlock", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "a_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncentiveCompensationPlanPercentOfMarketPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may opt to disclose the percent of market value on offering date that participants pay for options granted.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Incentive Compensation Plan Percent Of Market Price", "verboseLabel": "Percentage market value of the common stock option exercise price is generally not less than (in hundredths)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncentiveCompensationPlanPercentOfMarketPrice", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails" ], "xbrltype": "percentItemType" }, "a_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodAggregateIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "As of the balance sheet date, the total dollar difference between fair values of the underlying shares reserved for issuance and exercise prices of the options exercised in period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value of Stock options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodAggregateIntrinsicValue", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "a_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInMoneyExercisableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of Stocks options eligible for exercise and at an exercise price below the closing market price of the underlying stock on the last trading day of the fiscal year as reflected on the national stock exchange.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options In The Money Exercisable Number", "verboseLabel": "In-the-money awards exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInMoneyExercisableNumber", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "sharesItemType" }, "a_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePricePeriodEnd": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Period End", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Period End", "periodEndLabel": "Non-vested at October 31, 2020 -Weighted Average Grant Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePricePeriodEnd", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONNonvestedawardactivitydisclosureDetails" ], "xbrltype": "perShareItemType" }, "a_ShareBasedCompensationArrangementByShareBasedPaymentStockPlanAwardTermsOfAward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of pertinent provisions of share based compensation awards that have actual or potential impact upon the company's financial statements.", "label": "Share Based Compensation Arrangement By Share Based Payment Stock Plan Award Terms Of Award", "verboseLabel": "Term of the 2018 Stock Plan (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentStockPlanAwardTermsOfAward", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails" ], "xbrltype": "stringItemType" }, "a_ShareBasedCompensationArrangementMaximumPayoutRange": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum payout range for participants of the original target grant based upon the company's attainments of pre-established operating ratio targets.", "label": "Share Based Compensation Arrangement Maximum Payout Range", "verboseLabel": "Maximum final share award percentage of the target award based on performance metrics (in hundredths)" } } }, "localname": "ShareBasedCompensationArrangementMaximumPayoutRange", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails" ], "xbrltype": "percentItemType" }, "a_ShareBasedCompensationArrangementMinimumPayoutRange": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum payout range for participants of the original target grant based upon the company's attainments of pre-established operating ratio targets.", "label": "Share Based Compensation Arrangement Minimum Payout Range", "verboseLabel": "Minimum final share award percentage of the target award based on performance metrics (in hundredths)" } } }, "localname": "ShareBasedCompensationArrangementMinimumPayoutRange", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails" ], "xbrltype": "percentItemType" }, "a_ShareBasedCompensationArrangementPerformanceStockAwardVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the period of time over which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, which may be expressed in a variety of ways (for example, in years, month and year).", "label": "Share Based Compensation Arrangement Performance Stock Award Vesting Period", "verboseLabel": "Time period after which participants of the performance stock award plan are entitled to receive unrestricted share of the company's stock, if specified performance targets are met" } } }, "localname": "ShareBasedCompensationArrangementPerformanceStockAwardVestingPeriod", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails" ], "xbrltype": "durationStringItemType" }, "a_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange01Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range 01 [Member]", "verboseLabel": "Range of Exercise Prices - $25.01 - $30" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange01Member", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "domainItemType" }, "a_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange02Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range 02 [Member]", "terseLabel": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range 02" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange02Member", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "domainItemType" }, "a_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange03Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range 03 [Member]", "terseLabel": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range 03" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange03Member", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "domainItemType" }, "a_ShareRepurchaseProgramLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Repurchase Program [Line Items]", "label": "Share Repurchase Program [Line Items]", "terseLabel": "Share Repurchase Program [Line Items]" } } }, "localname": "ShareRepurchaseProgramLineItems", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails" ], "xbrltype": "stringItemType" }, "a_ShareRepurchaseProgramTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Repurchase Program [Table]", "label": "Share Repurchase Program [Table]", "terseLabel": "Share Repurchase Program [Table]" } } }, "localname": "ShareRepurchaseProgramTable", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails" ], "xbrltype": "stringItemType" }, "a_ShareRepurchasesAuthorizationProgramDateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date upon which the share repurchase authorization agreement was approved.", "label": "Share Repurchases Authorization Program Date [Domain]", "terseLabel": "Share Repurchases Authorization Program Date [Domain]" } } }, "localname": "ShareRepurchasesAuthorizationProgramDateDomain", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails" ], "xbrltype": "domainItemType" }, "a_ShareRepurchasesProgramAuthorizationDateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share repurchases programs by authorization date.", "label": "Share Repurchases Program Authorization Date [Axis]", "terseLabel": "Share Repurchases Program Authorization Date [Axis]" } } }, "localname": "ShareRepurchasesProgramAuthorizationDateAxis", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails" ], "xbrltype": "stringItemType" }, "a_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Nonvested Additional Disclosures [Abstract]", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Nonvested Additional Disclosures [Abstract]", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAdditionalDisclosuresAbstract", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONNonvestedawardactivitydisclosureDetails" ], "xbrltype": "stringItemType" }, "a_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionPlanByExercisePriceRangeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sharebased Compensation Arrangement By Sharebased Payment Award Stock Option Plan By Exercise Price Range [Abstract]", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Stock Option Plan By Exercise Price Range [Abstract]", "terseLabel": "Sharebased Compensation Arrangement By Exercise Price Range [Abstract]" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionPlanByExercisePriceRangeAbstract", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "stringItemType" }, "a_ShortTermLoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short-term Loan Facility", "label": "Short-term Loan Facility [Member]", "terseLabel": "Short-term Loan Facility" } } }, "localname": "ShortTermLoanFacilityMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "domainItemType" }, "a_Specialcompliancecosts": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Special compliance costs", "label": "Special compliance costs", "negatedTerseLabel": "Special compliance costs" } } }, "localname": "Specialcompliancecosts", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "a_TaxHolidaysAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Holidays [Abstract]", "label": "Tax Holidays [Abstract]", "terseLabel": "Tax Holidays [Abstract]" } } }, "localname": "TaxHolidaysAbstract", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails" ], "xbrltype": "stringItemType" }, "a_TaxInterestandPenaltiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Interest and Penalties [Member]", "label": "Tax Interest and Penalties [Member]", "terseLabel": "Tax Interest and Penalties" } } }, "localname": "TaxInterestandPenaltiesMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "domainItemType" }, "a_TerminatedInterestRateFairValueHedgeDerivativeAssetsAtFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The asset value of interest rate swap contracts upon termination.", "label": "Terminated Interest Rate Fair Value Hedge Derivative Assets At Fair Value", "terseLabel": "Terminated Interest Rate Fair Value Hedge Derivative Assets At Fair Value" } } }, "localname": "TerminatedInterestRateFairValueHedgeDerivativeAssetsAtFairValue", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "a_ThirdPartyTechnologyandLicensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third-Party Technology and Licenses [Member]", "label": "Third-Party Technology and Licenses [Member]", "terseLabel": "Third-Party Technology and Licenses [Member]" } } }, "localname": "ThirdPartyTechnologyandLicensesMember", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDisclosuresandComponentsofOtherIntangiblesDetails" ], "xbrltype": "domainItemType" }, "a_TotalIncomeTaxPayableNetOfIncomeTaxReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.", "label": "Total income tax payable, net of income tax receivable", "terseLabel": "Total" } } }, "localname": "TotalIncomeTaxPayableNetOfIncomeTaxReceivable", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCurrentandlongtermincometaxassetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "a_TransformationalPrograms": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The charge against earnings in the period, comprised of costs associated with restructuring activities not otherwise specified in the taxonomy that are not part of a specific plan as required by GAAP.", "label": "Transformational Programs", "negatedLabel": "Transformational initiatives" } } }, "localname": "TransformationalPrograms", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "a_Transitionalcompanycontributiontoemployee401k": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional transitional company contribution to employee 401(k) plans for certain employees.", "label": "Transitional company contribution to employee 401(k)", "terseLabel": "Transitional company contribution to employee 401(k)" } } }, "localname": "Transitionalcompanycontributiontoemployee401k", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails" ], "xbrltype": "percentItemType" }, "a_Ultimatemedicalcosttrendrate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average rate of ultimate medical cost trend rate used to determine net periodic benefit cost of defined benefit plan.", "label": "Ultimate medical cost trend rate", "terseLabel": "Ultimate medical cost trend rate" } } }, "localname": "Ultimatemedicalcosttrendrate", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails" ], "xbrltype": "percentItemType" }, "a_UnrealizedGainsLossesOnDerivativeInstrumentsTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax effect on the change in the balance sheet adjustment that results from the unrealized gains (losses) on derivative instruments as of the balance sheet date.", "label": "Unrealized gains (losses) on derivative instruments, tax", "terseLabel": "Unrealized gains (losses) on derivative instruments, tax" } } }, "localname": "UnrealizedGainsLossesOnDerivativeInstrumentsTax", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYAccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "a_UnrealizedLossesOnDefinedBenefitPlansTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The tax effect of the total net gains (losses) and changes in benefit cost which haven't yet been recognized as components of periodic benefit costs, as of the balance sheet date.", "label": "Unrealized losses on defined benefit plans, tax", "terseLabel": "Unrealized losses on defined benefit plans, tax" } } }, "localname": "UnrealizedLossesOnDefinedBenefitPlansTax", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYAccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "a_Unrecognizedtaxbenefitincludinginterestandpenalties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrecognized tax benefit including interest and penalties.", "label": "Unrecognized tax benefit including interest and penalties", "terseLabel": "Unrecognized tax benefit including interest and penalties" } } }, "localname": "Unrecognizedtaxbenefitincludinginterestandpenalties", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "a_Unrecognizedtaxbenefitsthatwouldnotimpacttheeffectivetaxrate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would not affect the effective tax rate.", "label": "Unrecognized tax benefits that would not impact the effective tax rate", "terseLabel": "Unrecognized tax benefits that would not impact the effective tax rate" } } }, "localname": "Unrecognizedtaxbenefitsthatwouldnotimpacttheeffectivetaxrate", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "a_WeightedAverageMaturityDateAtAPointInTime": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average maturity date at a point in time", "label": "Weighted average maturity date at a point in time", "terseLabel": "weighted average maturity date at a point in time" } } }, "localname": "WeightedAverageMaturityDateAtAPointInTime", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "durationItemType" }, "a_WeightedAvergeSharesUsedInComputingNetIncomeLossPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Averge Shares Used In Computing Net Income Loss Per Share [Abstract]", "label": "Weighted Averge Shares Used In Computing Net Income Loss Per Share [Abstract]", "terseLabel": "Weighted Averge Shares Used In Computing Net Income Per Share" } } }, "localname": "WeightedAvergeSharesUsedInComputingNetIncomeLossPerShareAbstract", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS" ], "xbrltype": "stringItemType" }, "a_WriteOffOfFullyAmortizedIntangibleAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Write-off of gross carrying amount and related accumulated amortization of fully amortized intangible assets that are no longer in use.", "label": "Write-off of fully amortized intangible assets", "terseLabel": "Write-off of fully amortized intangible assets" } } }, "localname": "WriteOffOfFullyAmortizedIntangibleAssets", "nsuri": "http://www.agilent.com/20201031", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails" ], "xbrltype": "monetaryItemType" }, "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "CHINA" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosuresRevenueDetails" ], "xbrltype": "domainItemType" }, "country_DE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GERMANY", "terseLabel": "GERMANY" } } }, "localname": "DE", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosureLongLivedAssetsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosuresRevenueDetails" ], "xbrltype": "domainItemType" }, "country_JP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JAPAN", "terseLabel": "JAPAN" } } }, "localname": "JP", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosureLongLivedAssetsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosuresRevenueDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "U.S. Plan", "verboseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosureLongLivedAssetsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosuresRevenueDetails" ], "xbrltype": "domainItemType" }, "currency_AUD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Australia, Dollars", "terseLabel": "Australian Dollars" } } }, "localname": "AUD", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "domainItemType" }, "currency_CAD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Canada, Dollars", "terseLabel": "Canadian Dollars" } } }, "localname": "CAD", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "domainItemType" }, "currency_CHF": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Switzerland, Francs", "terseLabel": "Swiss Franc" } } }, "localname": "CHF", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "domainItemType" }, "currency_CNY": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "China, Yuan Renminbi", "terseLabel": "China, Yuan Renminbi" } } }, "localname": "CNY", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "domainItemType" }, "currency_DKK": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Denmark, Kroner", "terseLabel": "Danish Krone" } } }, "localname": "DKK", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Euro Member Countries, Euro", "terseLabel": "Euro" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "domainItemType" }, "currency_GBP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United Kingdom, Pounds", "terseLabel": "British Pounds" } } }, "localname": "GBP", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "domainItemType" }, "currency_INR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "India, Rupees", "terseLabel": "India, Rupees" } } }, "localname": "INR", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "domainItemType" }, "currency_JPY": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Japan, Yen", "terseLabel": "Japanese Yen" } } }, "localname": "JPY", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "domainItemType" }, "currency_KRW": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Korea (South), Won", "terseLabel": "Korean Won" } } }, "localname": "KRW", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "domainItemType" }, "currency_MYR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Malaysia, Ringgits", "terseLabel": "Malaysian Ringgit" } } }, "localname": "MYR", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "domainItemType" }, "currency_SEK": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sweden, Kronor", "terseLabel": "Sweden, Kronor" } } }, "localname": "SEK", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "domainItemType" }, "currency_SGD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Singapore, Dollars", "terseLabel": "Singapore, Dollars" } } }, "localname": "SGD", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "domainItemType" }, "currency_TWD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Taiwan, New Dollars", "terseLabel": "Taiwan, New Dollars" } } }, "localname": "TWD", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "domainItemType" }, "currency_XXX": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "No currency", "terseLabel": "Other Currency" } } }, "localname": "XXX", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r889", "r890", "r891" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r892" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r887" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r893" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r893" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r893" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r894" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r893" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r893" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r893" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r893" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r889", "r890", "r891" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r886" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r888" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilent.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_AmericasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Continents of North and South America.", "label": "Americas [Member]", "terseLabel": "Americas" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/REVENUERevenuebyRegionDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region of Asia Pacific.", "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/REVENUERevenuebyRegionDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r647", "r648", "r655", "r656", "r884", "r896" ], "lang": { "en-us": { "role": { "documentation": "Information by consolidated entity or group of entities.", "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r647", "r648", "r655", "r656" ], "lang": { "en-us": { "role": { "documentation": "Entity or group of entities consolidated into reporting entity.", "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r220", "r233", "r234", "r235", "r236", "r238", "r240", "r244" ], "lang": { "en-us": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r220", "r233", "r234", "r235", "r236", "r238", "r240", "r244" ], "lang": { "en-us": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by currency.", "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "stringItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Continent of Europe.", "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/REVENUERevenuebyRegionDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r502", "r512", "r769", "r770", "r771", "r772", "r773", "r774", "r794", "r851", "r854" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum", "verboseLabel": "5 Percent" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r502", "r512", "r769", "r770", "r771", "r772", "r773", "r774", "r794", "r851", "r854" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum", "verboseLabel": "3 Percent" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r246", "r386", "r390", "r795", "r850", "r852" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://www.agilent.com/role/REVENUERevenuebyTypeDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONTables" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r246", "r386", "r390", "r795", "r850", "r852" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://www.agilent.com/role/REVENUERevenuebyTypeDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONTables" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r434", "r502", "r512", "r769", "r770", "r771", "r772", "r773", "r774", "r794", "r851", "r854" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails", "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r434", "r502", "r512", "r769", "r770", "r771", "r772", "r773", "r774", "r794", "r851", "r854" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails", "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r158", "r159", "r160", "r161", "r164", "r165", "r170", "r171", "r172", "r174", "r175", "r176", "r177", "r178", "r196", "r278", "r279", "r558", "r603", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866" ], "lang": { "en-us": { "role": { "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Revision of Prior Period [Axis]", "terseLabel": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTSDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYAccumulatedothercomprehensiveincomeDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r158", "r159", "r160", "r161", "r164", "r165", "r170", "r171", "r172", "r174", "r175", "r176", "r177", "r178", "r196", "r278", "r279", "r558", "r603", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866" ], "lang": { "en-us": { "role": { "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Revision of Prior Period [Domain]", "terseLabel": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTSDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYAccumulatedothercomprehensiveincomeDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "domainItemType" }, "srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember": { "auth_ref": [ "r164", "r165", "r172", "r278", "r279", "r558", "r603", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866" ], "lang": { "en-us": { "role": { "documentation": "Cumulative increase (decrease) to previously issued financial statements for retrospective application of amendment to accounting standards and adjustment for reclassification from amendment to accounting standards.", "label": "Revision of Prior Period, Accounting Standards Update, Adjustment [Member]", "terseLabel": "Revision of Prior Period, Accounting Standards Update, Adjustment" } } }, "localname": "RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYReclassificationsoutofaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r156", "r898" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "verboseLabel": "Schedule II - Valuation and Qualifying Accounts" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/ScheduleIIValuationandQualifyingAccounts" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r247", "r248", "r386", "r391", "r853", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://www.agilent.com/role/REVENUERevenuebyRegionDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosureLongLivedAssetsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosuresRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r247", "r248", "r386", "r391", "r853", "r870", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r895", "r897" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://www.agilent.com/role/REVENUERevenuebyRegionDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosureLongLivedAssetsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosuresRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r340", "r507", "r762" ], "lang": { "en-us": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]", "terseLabel": "Statement, Scenario [Axis]", "verboseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYReclassificationsoutofaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/srt/2020-01-31", "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r156", "r898" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.agilent.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingGuidanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Previous accounting guidance and the new accounting guidance.", "label": "Accounting Guidance [Domain]", "terseLabel": "Accounting Guidance [Domain]" } } }, "localname": "AccountingGuidanceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201601Member": { "auth_ref": [ "r713" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.", "label": "Accounting Standards Update 2016-01 [Member]", "terseLabel": "Accounting Standards Update 2016-01" } } }, "localname": "AccountingStandardsUpdate201601Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INVESTMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r741" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02- Leases" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Receivable Additional Disclosures [Abstract]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r7", "r32", "r252", "r253" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "verboseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent": { "auth_ref": [ "r814", "r841" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them.", "label": "Accrued Employee Benefits", "terseLabel": "Employee compensation and benefits accrued" } } }, "localname": "AccruedEmployeeBenefitsCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r24", "r809", "r833" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Current income tax liabilities (included within other accrued liabilities)" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCurrentandlongtermincometaxassetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "auth_ref": [ "r26", "r809", "r833" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.", "label": "Accrued Income Taxes, Noncurrent", "terseLabel": "Long-term income tax liabilities (included within other long-term liabilities)" } } }, "localname": "AccruedIncomeTaxesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCurrentandlongtermincometaxassetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "terseLabel": "Accrued Liabilities [Member]" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember": { "auth_ref": [ "r82", "r87", "r91", "r653" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to prior service cost (credit) component of defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]", "terseLabel": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember": { "auth_ref": [ "r80", "r87", "r91", "r653" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]", "terseLabel": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r47", "r324" ], "calculation": { "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax": { "auth_ref": [ "r79", "r84", "r86" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change, net of tax, in accumulated gains and losses from derivative instruments designated and qualifying as the effective portion of cash flow hedges. Includes an entity's share of an equity investee's Increase or Decrease in deferred hedging gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Unrealized gains (losses) on derivative instruments, net of tax benefit of $6 and $3 for 2020 and 2019, respectively" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYAccumulatedothercomprehensiveincomeDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r81", "r87", "r455" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "verboseLabel": "Unrealized losses (including prior service benefit) on defined benefit plans, net of tax benefit of $154 and $153 for 2020 and 2019, respectively" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYAccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [ "r76", "r84", "r86", "r87", "r709" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Foreign currency translation, net of tax expense of $(6) and $(5) for 2020 and 2019, respectively" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYAccumulatedothercomprehensiveincomeDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r35", "r84", "r86", "r87", "r836", "r862", "r866" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/STOCKHOLDERSEQUITYAccumulatedothercomprehensiveincomeDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r722", "r723", "r724", "r725", "r726", "r729" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r83", "r87", "r91", "r158", "r159", "r161", "r653", "r857", "r858" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss", "verboseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r77", "r87", "r91", "r653", "r723", "r724", "r725", "r726", "r729" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Accumulated Foreign Currency Adjustment Attributable to Parent" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r33", "r558" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r158", "r159", "r161", "r554", "r555", "r556" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r128", "r311" ], "calculation": { "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "negatedTerseLabel": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r164", "r165", "r166", "r168", "r272", "r273", "r274", "r275", "r278", "r279", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r558", "r600", "r601", "r602", "r603", "r797", "r798", "r799", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.agilent.com/role/INVESTMENTSDetails", "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails", "http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTSDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYAccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r514", "r516", "r560", "r561" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "verboseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r565" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising costs expensed as incurred" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r516", "r545", "r559" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "verboseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONAllocatedSharebasedcompensationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AlternativeInvestment": { "auth_ref": [ "r697", "r705" ], "calculation": { "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails": { "order": 4.0, "parentTag": "a_FairValueAssetsMeasuredOnRecurringBasisTotalAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund.", "label": "Alternative Investment", "terseLabel": "Other investments" } } }, "localname": "AlternativeInvestment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r128", "r735" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of Debt Issuance Costs and Discounts" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r128", "r303", "r311" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "verboseLabel": "Amortization of intangible assets during the period" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationExpenseandFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive shares excluded from EPS computation (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/NETINCOMELOSSPERSHAREDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember": { "auth_ref": [ "r87", "r695" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, attributable to parent.", "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member]", "terseLabel": "AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent" } } }, "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentParentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r141", "r228", "r235", "r242", "r269", "r647", "r655", "r712", "r807", "r832" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets", "verboseLabel": "Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r9", "r71", "r141", "r269", "r647", "r655", "r712" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:", "verboseLabel": "Assets, Short-term [Abstract]" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r698" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Fair value of assets, nonrecurring" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "verboseLabel": "Assets, Long-term [Abstract]" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r518", "r548" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionsDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails", "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails", "http://www.agilent.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails", "http://www.agilent.com/role/LEASESSupplementalBalanceSheetInformationDetails", "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONAllocatedSharebasedcompensationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r671", "r676" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails", "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails", "http://www.agilent.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails", "http://www.agilent.com/role/LEASESSupplementalBalanceSheetInformationDetails", "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONAllocatedSharebasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r11", "r323" ], "calculation": { "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and Improvements, Gross", "terseLabel": "Buildings and leasehold improvements" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r494", "r508" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails", "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSProformaOperatingResultsDetails", "http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails", "http://www.agilent.com/role/ACQUISITIONSTextDetails", "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r494", "r508", "r625", "r626" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails", "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSProformaOperatingResultsDetails", "http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails", "http://www.agilent.com/role/ACQUISITIONSTextDetails", "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Business Acquisition, Transaction Costs", "terseLabel": "Acquisition transaction costs" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSTextDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionDateOfAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Acquisition, Date of Acquisition [Abstract]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionDateOfAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails", "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSProformaOperatingResultsDetails", "http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails", "http://www.agilent.com/role/ACQUISITIONSTextDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": { "auth_ref": [ "r623", "r624" ], "lang": { "en-us": { "role": { "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic", "terseLabel": "Proforma net income per share - basic" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSProformaOperatingResultsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": { "auth_ref": [ "r623", "r624" ], "lang": { "en-us": { "role": { "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted", "terseLabel": "Proforma net income per share - diluted" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSProformaOperatingResultsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r623", "r624" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Proforma operating results" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r623", "r624" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Proforma net income" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSProformaOperatingResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r623", "r624" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Proforma net revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSProformaOperatingResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r621" ], "calculation": { "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails": { "order": 12.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "negatedLabel": "Acquisition and integration costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r635", "r636", "r637" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Purchase price for acquisition" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSTextDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r634", "r635", "r636", "r639" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "terseLabel": "Liability incurred to pay for acquisition" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSTextDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r628" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "terseLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r628" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "auth_ref": [ "r628" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "terseLabel": "Other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r628" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivables" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r628" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "auth_ref": [ "r628" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "auth_ref": [ "r628" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "terseLabel": "Other accrued liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r628" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r627", "r628" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r628" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt", "terseLabel": "Long-term debt" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r627", "r628" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant, and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r628" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "terseLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": { "auth_ref": [ "r622" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain", "negatedLabel": "Gain on step acquisition", "verboseLabel": "Remeasurement Gain on step acquisition" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r136", "r620" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r4", "r157", "r214" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Business Description and Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessExitCosts1": { "auth_ref": [ "r128", "r331", "r333", "r334" ], "calculation": { "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails": { "order": 10.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Business Exit Costs", "negatedLabel": "Business exit and divestiture costs" } } }, "localname": "BusinessExitCosts1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CaliforniaFranchiseTaxBoardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of the state of California.", "label": "California Franchise Tax Board [Member]", "terseLabel": "State" } } }, "localname": "CaliforniaFranchiseTaxBoardMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r885" ], "calculation": { "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Capitalized Computer Software, Gross", "terseLabel": "Software" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r43", "r130" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails": { "order": 1.0, "parentTag": "a_FairValueAssetsMeasuredOnRecurringBasisTotalAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents (money market funds)" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r15", "r131", "r136", "r804" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents and Short-Term Investments and Restricted Cash and Restricted Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r123", "r130", "r134" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year", "terseLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r123", "r719" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "auth_ref": [ "r694" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months", "terseLabel": "Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months" } } }, "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r666" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedges" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails", "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.", "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]", "terseLabel": "Schedule of Funded status of Defined Benefit and Post-Retirement Benefit plans" } } }, "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r139", "r141", "r184", "r188", "r189", "r190", "r192", "r203", "r204", "r205", "r269", "r712" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTSDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYSTOCKHOLDERSEQUITYDIvidendsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYSTOCKHOLDERSEQUITYDIvidendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollectiveBargainingArrangementAxis": { "auth_ref": [ "r502", "r512" ], "lang": { "en-us": { "role": { "documentation": "Information by arrangement collectively bargained between employer and its employees represented by union.", "label": "Collective-Bargaining Arrangement [Axis]", "terseLabel": "Collective-Bargaining Arrangement [Axis]" } } }, "localname": "CollectiveBargainingArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollectiveBargainingArrangementDomain": { "auth_ref": [ "r502", "r512" ], "lang": { "en-us": { "role": { "documentation": "Arrangement collectively bargained between employer and its employees represented by union.", "label": "Collective-Bargaining Arrangement [Domain]", "terseLabel": "Collective-Bargaining Arrangement [Domain]" } } }, "localname": "CollectiveBargainingArrangementDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r62", "r339", "r815", "r840" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 17)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r336", "r337", "r338", "r346" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Aggregate cash dividends paid (per common share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYSTOCKHOLDERSEQUITYDIvidendsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Cash Dividends Declared (per common share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITYParenthetical", "http://www.agilent.com/role/STOCKHOLDERSEQUITYSTOCKHOLDERSEQUITYDIvidendsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r158", "r159" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r31", "r363" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r31" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock; $0.01 par value; 2\u00a0billion shares authorized; 306\u00a0million shares at October\u00a031, 2020 and 309\u00a0million shares at October\u00a031, 2019 issued and outstanding" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Accumulated benefit obligation and fair value of plan assets" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r135", "r522" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Employee Compensation and Benefits" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "terseLabel": "Components of Deferred Tax Assets" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Liabilities [Abstract]", "terseLabel": "Components of Deferred Tax Liabilities" } } }, "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Provision (benefit) for income taxes" } } }, "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r94", "r96", "r97", "r103", "r819", "r845" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Components of comprehensive income, net of tax:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r94", "r96", "r102", "r643", "r661", "r818", "r844" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r208", "r826" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r136", "r649" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "auth_ref": [ "r136", "r654", "r657", "r658" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "terseLabel": "Variable Interest Entity" } } }, "localname": "ConsolidationVariableInterestEntityPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Contract with Customer, Asset and Liability" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/REVENUETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r372", "r374", "r387" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "terseLabel": "Contract with Customer, Asset, after Allowance for Credit Loss" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/REVENUEContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r372", "r373", "r387" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Contract Liability ending balance", "periodStartLabel": "Contract Liability ending balance" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/REVENUEContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": { "auth_ref": [ "r375" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.", "label": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination", "terseLabel": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination" } } }, "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/REVENUEContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r388" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/REVENUEContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r107", "r795" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of Product and Services", "verboseLabel": "Cost of Sales [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONAllocatedSharebasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r105" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Faciity [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r142", "r597", "r609" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "U.S. federal taxes - current" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r146", "r597" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Non-U.S. taxes - current" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r142", "r597", "r609" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State taxes, net of federal benefit - current" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships", "verboseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDisclosuresandComponentsofOtherIntangiblesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r22", "r24", "r25", "r808", "r811", "r828" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails", "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails", "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentDateOfFirstRequiredPayment1": { "auth_ref": [ "r60", "r823" ], "lang": { "en-us": { "role": { "documentation": "Date the debt agreement requires the first payment to be made, in CCYY-MM-DD format.", "label": "Debt Instrument, Date of First Required Payment", "terseLabel": "Date payments commenced" } } }, "localname": "DebtInstrumentDateOfFirstRequiredPayment1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r734", "r737" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt Instrument, Face Amount", "verboseLabel": "Aggregate face amount of debt" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails", "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": { "auth_ref": [ "r60", "r823" ], "lang": { "en-us": { "role": { "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).", "label": "Debt Instrument, Frequency of Periodic Payment", "verboseLabel": "Interest payment frequency" } } }, "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "auth_ref": [ "r144" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.", "label": "Debt Instrument, Increase, Accrued Interest", "terseLabel": "Debt Instrument, Increase, Accrued Interest" } } }, "localname": "DebtInstrumentIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Fixed interest rate per annum (in hundredths)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails", "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentIssuanceDate1": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Date the debt instrument was issued, in CCYY-MM-DD format.", "label": "Debt Instrument, Issuance Date", "terseLabel": "Issuance date of debt" } } }, "localname": "DebtInstrumentIssuanceDate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails", "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r58", "r702" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails", "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails", "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails", "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodEndDate": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "documentation": "End date of debt instrument redemption period, in CCYY-MM-DD format.", "label": "Debt Instrument, Redemption Period, End Date", "terseLabel": "Debt Instrument, Redemption Period, End Date" } } }, "localname": "DebtInstrumentRedemptionPeriodEndDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodStartDate": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "documentation": "Start date of debt instrument redemption period, in CCYY-MM-DD format.", "label": "Debt Instrument, Redemption Period, Start Date", "terseLabel": "Debt Instrument, Redemption Period, Start Date" } } }, "localname": "DebtInstrumentRedemptionPeriodStartDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Debt Instrument, Redemption Price, Percentage" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r60", "r143", "r364", "r367", "r368", "r369", "r733", "r734", "r737", "r825" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "auth_ref": [ "r733", "r734", "r735", "r736", "r737" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount (premium).", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "terseLabel": "Senior Notes Amortized principal" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain": { "auth_ref": [ "r403", "r404" ], "lang": { "en-us": { "role": { "documentation": "Deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.", "label": "Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]", "terseLabel": "Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]" } } }, "localname": "DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIEMENTPENSIONPLANSDeferredProfitSharingPlanDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis": { "auth_ref": [ "r403", "r404" ], "lang": { "en-us": { "role": { "documentation": "Information by type of deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.", "label": "Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]", "terseLabel": "Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIEMENTPENSIONPLANSDeferredProfitSharingPlanDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r142", "r598", "r609" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "U.S. federal taxes - deferred" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r142", "r598", "r609" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Non-U.S. taxes - deferred" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r128", "r142", "r598", "r609", "r610", "r611" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r27", "r28", "r587", "r810", "r827" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Subtotal" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredProfitSharingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a share in the profits, as defined in the agreement, of the entity or portion thereof. Employer contributions may be discretionary or may be based on a fixed formula related to profits, compensation, or other factors. It is a form of incentive compensation to employees in addition to their regular salary and bonuses.", "label": "Deferred Profit Sharing [Member]", "terseLabel": "Deferred Profit Sharing" } } }, "localname": "DeferredProfitSharingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIEMENTPENSIONPLANSDeferredProfitSharingPlanDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "verboseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenuePeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred revenue.", "label": "Deferred Revenue, Period Increase (Decrease)", "terseLabel": "Deferred Revenue, Period Increase (Decrease)" } } }, "localname": "DeferredRevenuePeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/REVENUEContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r142", "r598", "r609" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State taxes, net of federal benefit - deferred" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": { "auth_ref": [ "r595", "r596" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.", "label": "Deferred Tax Assets, Capital Loss Carryforwards", "terseLabel": "Capital loss carryforwards" } } }, "localname": "DeferredTaxAssetsCapitalLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r595", "r596" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred Tax Assets, Deferred Income", "verboseLabel": "Deferred revenue" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Intangibles" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r588" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Subtotal" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r590" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "terseLabel": "Deferred Tax Assets, Net", "totalLabel": "Deferred tax Assets, net" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r590" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "terseLabel": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Deferred Tax Assets, Net of Valuation Allowance", "verboseLabel": "Long-term deferred tax assets ( included within other assets)" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r595", "r596" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "verboseLabel": "Net operating loss, capital loss and credit carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsAlternativeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards, Alternative [Abstract]", "terseLabel": "Capital Loss Carryforward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsAlternativeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]", "terseLabel": "Net Operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "auth_ref": [ "r595", "r596" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic", "terseLabel": "Federal net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "auth_ref": [ "r595", "r596" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign", "terseLabel": "Foreign net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration", "terseLabel": "Net operating loss carryforwards, not subject to expiration" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r595", "r596" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "terseLabel": "State net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "Net operating loss carryforwards, subject to expiration" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r595", "r596" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "verboseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Credit Carryforwards [Abstract]", "terseLabel": "Tax Credit Carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": { "auth_ref": [ "r595", "r596" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits", "verboseLabel": "Employee benefits, other than retirement" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits": { "auth_ref": [ "r595" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from postretirement benefits.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Postretirement Benefits", "verboseLabel": "Pension benefits and retiree medical benefits" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r595", "r596" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "verboseLabel": "Share-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r589" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Tax valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r570", "r590" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "terseLabel": "Long-term deferred tax liabilities ( included within other long-term liabilities)" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "auth_ref": [ "r595", "r596" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.", "label": "Deferred Tax Liabilities, Leasing Arrangements", "negatedTerseLabel": "Deferred Tax Liabilities, Leasing Arrangements" } } }, "localname": "DeferredTaxLiabilitiesLeasingArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r595", "r596" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "negatedLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r595", "r596" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedTerseLabel": "Property, plant and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilityIntraEntityTransferAssetOtherThanInventory": { "auth_ref": [ "r595" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to intra-entity transfer of asset within consolidated group. Excludes intra-entity transfer of inventory.", "label": "Deferred Tax Liability, Intra-entity Transfer, Asset Other than Inventory", "terseLabel": "Deferred Tax Liability, Intra-entity Transfer, Asset Other than Inventory" } } }, "localname": "DeferredTaxLiabilityIntraEntityTransferAssetOtherThanInventory", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax": { "auth_ref": [ "r87", "r455" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax": { "auth_ref": [ "r87", "r455" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax", "negatedPeriodEndLabel": "Ending Balance", "negatedPeriodStartLabel": "Beginning Balance" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "auth_ref": [ "r424", "r485" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "terseLabel": "Actual return on plan assets" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod": { "auth_ref": [ "r439", "r485" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets sold.", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Sold", "negatedTerseLabel": "Realized gains/(losses)" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld": { "auth_ref": [ "r439", "r485" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets still held.", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held", "negatedTerseLabel": "Unrealized gains/(losses)" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r416" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "terseLabel": "Actuarial (gain) loss" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r409", "r450", "r479", "r485", "r486" ], "calculation": { "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedLabel": "Amortization of net actuarial loss" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r409", "r451", "r480", "r485", "r486" ], "calculation": { "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "terseLabel": "Amortization of prior service benefit" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]", "terseLabel": "Amounts recognized in the consolidated balance sheet" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]", "terseLabel": "Amounts Recognized in Accumulated Other Comprehensive Income (loss): [Abstract]" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetGainLossBeforeTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax [Abstract]", "terseLabel": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax [Abstract]", "verboseLabel": "Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetGainLossBeforeTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": { "auth_ref": [ "r82", "r84", "r454" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income from prior service cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax", "terseLabel": "Prior service costs (benefits)" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax [Abstract]", "terseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax [Abstract]" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanAmountsThatWillBeAmortizedFromAccumulatedOtherComprehensiveIncomeLossInNextFiscalYearAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Expected Amortization, Next Fiscal Year [Abstract]", "terseLabel": "Accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year [Abstract]" } } }, "localname": "DefinedBenefitPlanAmountsThatWillBeAmortizedFromAccumulatedOtherComprehensiveIncomeLossInNextFiscalYearAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "auth_ref": [ "r19", "r407", "r408", "r432", "r485", "r806", "r831" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.", "label": "Assets for Plan Benefits, Defined Benefit Plan", "terseLabel": "Assets for Plan Benefits, Defined Benefit Plan" } } }, "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "terseLabel": "Discount rate (in hundredths)" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "terseLabel": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "terseLabel": "Discount rate (in hundredths)" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "auth_ref": [ "r459", "r484" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets", "terseLabel": "Expected long-term return on assets (in hundredths)" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "terseLabel": "Average increase in compensation levels (in hundredths)" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r411" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation", "periodEndLabel": "Benefit Obligation Balance, end of year", "periodStartLabel": "Benefit Obligation Balance, Beginning of year", "terseLabel": "Benefit Obligation" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "auth_ref": [ "r418", "r491" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "terseLabel": "Benefits paid" } } }, "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": { "auth_ref": [ "r415" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation.", "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant", "verboseLabel": "Participant's contributions" } } }, "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement": { "auth_ref": [ "r413" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment, which decreases benefit obligation of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract. Excludes decreases to benefit obligation for remeasurement due to settlement.", "label": "Defined Benefit Plan, Benefit Obligation, Payment for Settlement", "terseLabel": "Settlement" } } }, "localname": "DefinedBenefitPlanBenefitObligationPaymentForSettlement", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "auth_ref": [ "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r442", "r462", "r485" ], "lang": { "en-us": { "role": { "documentation": "Information by defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]" } } }, "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "terseLabel": "Change in benefit obligation: [Roll Forward]" } } }, "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "terseLabel": "Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]", "verboseLabel": "Change in fair value of plan assets: [Roll Forward]" } } }, "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r426", "r435", "r437", "r483", "r485", "r486" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Employer contributions" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIEMENTPENSIONPLANSDeferredProfitSharingPlanDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": { "auth_ref": [ "r435", "r485" ], "lang": { "en-us": { "role": { "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.", "label": "Defined Benefit Plan, Equity Securities [Member]", "terseLabel": "Defined Benefit Plan, Equity Securities" } } }, "localname": "DefinedBenefitPlanEquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]", "terseLabel": "Future benefit payments [Abstract]" } } }, "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear": { "auth_ref": [ "r468" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount included in accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan expected to be recognized in net periodic benefit (cost) credit for fiscal year following most recent annual statement of financial position.", "label": "Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year", "terseLabel": "Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year" } } }, "localname": "DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear": { "auth_ref": [ "r468" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount included in accumulated other comprehensive (income) loss for prior service cost (credit) expected to be recognized in net periodic benefit cost (credit) for fiscal year following most recent annual statement of financial position.", "label": "Defined Benefit Plan, Expected Amortization of Prior Service Cost (Credit), Next Fiscal Year", "terseLabel": "Amortization of net prior service cost (benefit)" } } }, "localname": "DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "terseLabel": "2026 - 2030" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "terseLabel": "2021" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "terseLabel": "2025" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "terseLabel": "2024" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "terseLabel": "2023" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "terseLabel": "2022" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": { "auth_ref": [ "r445", "r486" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year", "terseLabel": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year" } } }, "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r409", "r449", "r478", "r485", "r486" ], "calculation": { "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "auth_ref": [ "r423", "r435", "r437", "r438", "r485" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.", "label": "Defined Benefit Plan, Plan Assets, Amount", "periodEndLabel": "Fair Value Balance, end of year", "periodStartLabel": "Fair Value Balance, beginning of year", "terseLabel": "Fair Value of Plan Assets" } } }, "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIEMENTPENSIONPLANSDeferredProfitSharingPlanDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "auth_ref": [ "r417" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "terseLabel": "Currency impact" } } }, "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "auth_ref": [ "r407", "r432", "r485" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "negatedTerseLabel": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "terseLabel": "Funded status of plan" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan [Abstract]", "terseLabel": "Funded status of plan [Abstract]" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlanAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.", "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year", "terseLabel": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year" } } }, "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r409", "r414", "r448", "r477", "r485", "r486" ], "calculation": { "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost", "verboseLabel": "Interest cost on benefit obligation" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r446", "r475", "r485", "r486" ], "calculation": { "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Total periodic benefit cost (benefit)" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]", "terseLabel": "Net periodic benefit cost (benefit) [Abstract]" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets": { "auth_ref": [ "r471" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets", "terseLabel": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets" } } }, "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": { "auth_ref": [ "r471", "r472", "r485" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation", "terseLabel": "Accumulated benefit obligation in excess of fair value of plan assets - aggregate benefit obligation" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": { "auth_ref": [ "r471", "r472", "r485" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets", "terseLabel": "Accumulated benefit obligation in excess of accumulated benefit obligation - aggregate fair value of plan assets" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": { "auth_ref": [ "r471" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation", "terseLabel": "Projected Benefit Obligation" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIEMENTPENSIONPLANSDeferredProfitSharingPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "auth_ref": [ "r428", "r491" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "terseLabel": "Benefits paid" } } }, "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": { "auth_ref": [ "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "terseLabel": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant" } } }, "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r425" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "verboseLabel": "Currency impact" } } }, "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": { "auth_ref": [ "r434", "r485" ], "lang": { "en-us": { "role": { "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.", "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage", "terseLabel": "Target Allocation Percentage of Plan Assets" } } }, "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements": { "auth_ref": [ "r440", "r485" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, measured using unobservable input, of increase (decrease) in plan asset of defined benefit plan from purchase, sale and settlement of trade associated with underlying investment.", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement", "terseLabel": "Purchases, sales, issuances, and settlements" } } }, "localname": "DefinedBenefitPlanPurchasesSalesAndSettlements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "auth_ref": [ "r410", "r453", "r482" ], "calculation": { "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails": { "order": 4.0, "parentTag": "a_OtherComprehensiveIncomeDefinedBenefitPlansPeriodIncreaseDecrease", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "negatedLabel": "Pension settlement gain", "verboseLabel": "Gain due to settlement" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1": { "auth_ref": [ "r410", "r453", "r482" ], "calculation": { "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment", "terseLabel": "Curtaliment and settlement" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r412", "r447", "r476", "r485", "r486" ], "calculation": { "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost - benefits earned during the period", "verboseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "auth_ref": [ "r431" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "terseLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanSettlementsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels": { "auth_ref": [ "r441", "r485" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan, for assets transferred into (out of) Level 3 of fair value hierarchy. Includes, but is not limited to, transfer due to change in observability of significant inputs.", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3", "terseLabel": "Transfers in (out)" } } }, "localname": "DefinedBenefitPlanTransfersBetweenMeasurementLevels", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan.", "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate", "terseLabel": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate" } } }, "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]", "terseLabel": "Assumptions used to calculate the benefit obligation" } } }, "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]", "terseLabel": "Assumptions used to calculate the net periodic cost" } } }, "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Year ultimate health care cost trend rate is expected to be reached, in CCYY format.", "label": "Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate", "terseLabel": "Medical cost trend rate decreases to ultimate rate in year" } } }, "localname": "DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails" ], "xbrltype": "gYearListItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPostretirementHealthCoverageMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide postretirement health benefits to retiree or beneficiary. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Postretirement Health Coverage [Member]", "terseLabel": "Post-Retirement Benefit Plan" } } }, "localname": "DefinedBenefitPostretirementHealthCoverageMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r492" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "401(k) Plan employer expense" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Contribution Plan Disclosure [Line Items]", "terseLabel": "Defined Contribution Plan Disclosure [Line Items]" } } }, "localname": "DefinedContributionPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Maximum employer matching contribution in the 401(k) plan (in hundredths)" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Maximum employee contribution to 401(k)" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanTable": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.", "label": "Defined Contribution Plan [Table]", "terseLabel": "Defined Contribution Plan [Table]" } } }, "localname": "DefinedContributionPlanTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r128", "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONProfitabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r128", "r223" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]", "verboseLabel": "Derivative Contract Type [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails", "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r72", "r75", "r674", "r776" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "verboseLabel": "Derivative Asset, Fair Value" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r72", "r75", "r674", "r776" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "verboseLabel": "Derivative Liability, Fair Value" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative, Fair Value, Net [Abstract]", "terseLabel": "Derivative, Fair Value, Net [Abstract]" } } }, "localname": "DerivativeFairValueOfDerivativeNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r673" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Gain (loss) recognized in other income (expense), net within continuing operations" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentDetailAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instrument Detail [Abstract]", "terseLabel": "Derivative Instruments", "verboseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentDetailAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r672", "r675", "r679", "r684" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]", "verboseLabel": "Derivative Instrument Risk [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails", "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r696" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "verboseLabel": "DERIVATIVES" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVES" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r668", "r672", "r679" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails", "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": { "auth_ref": [ "r678", "r683" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net", "negatedLabel": "Unrealized gains (losses) on derivatives reclassification out of AOCI to cost of sales", "terseLabel": "Gain(loss reclassified from accumulated other comprehensive income (loss) into cost of sales" } } }, "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYReclassificationsoutofaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r73", "r74", "r711" ], "calculation": { "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails": { "order": 1.0, "parentTag": "a_FairValueLiabilitiesMeasuredOnRecurringBasisTotalLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative instruments (foreign exchange contracts)" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails", "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNetLiabilityPositionAggregateFairValue": { "auth_ref": [ "r687" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate fair value amounts of derivative instruments that contain credit-risk-related contingent features that are in a net liability position at the end of the reporting period. For nonderivative instruments that are designated and qualify as hedging instruments, the fair value amounts are the carrying value of the nonderivative hedging instrument, including the adjustment for the foreign currency transaction gain (loss) on that instrument.", "label": "Derivative, Net Liability Position, Aggregate Fair Value", "terseLabel": "Aggregate fair value , net liability position" } } }, "localname": "DerivativeNetLiabilityPositionAggregateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r663", "r665" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r662", "r664", "r665", "r668", "r670", "r677", "r679", "r688", "r690", "r692" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails", "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r136", "r147", "r662", "r664", "r668", "r670", "r689" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r668" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Derivatives Designated as Hedging Instrument", "verboseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails", "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r633" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Purchased technology", "verboseLabel": "Developed product technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDisclosuresandComponentsofOtherIntangiblesDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.", "label": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]", "terseLabel": "Difference between Revenue Guidance in Effect before and after Topic 606" } } }, "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/REVENUEContractBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/REVENUERevenuebyEndMarketsDetails", "http://www.agilent.com/role/REVENUERevenuebyRegionDetails", "http://www.agilent.com/role/REVENUERevenuebyTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r386", "r390", "r391", "r392", "r393", "r394", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/REVENUERevenuebyEndMarketsDetails", "http://www.agilent.com/role/REVENUERevenuebyRegionDetails", "http://www.agilent.com/role/REVENUERevenuebyTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/REVENUETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "SHARE-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based compensation disclosures" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONAllocatedSharebasedcompensationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r518", "r548" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Summary of stock option award activity" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendPayableDateToBePaidDayMonthAndYear": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Date the declared dividend will be paid, in CCYY-MM-DD format.", "label": "Dividends Payable, Date to be Paid", "terseLabel": "Dividends payment date" } } }, "localname": "DividendPayableDateToBePaidDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYSTOCKHOLDERSEQUITYDIvidendsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DividendsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dividends [Abstract]", "terseLabel": "Dividends [Abstract]" } } }, "localname": "DividendsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYSTOCKHOLDERSEQUITYDIvidendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r370" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Cash dividends declared", "terseLabel": "Cash dividends declared" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.agilent.com/role/STOCKHOLDERSEQUITYSTOCKHOLDERSEQUITYDIvidendsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableDateDeclaredDayMonthAndYear": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Date the dividend to be paid was declared, in CCYY-MM-DD format.", "label": "Dividends Payable, Date Declared", "terseLabel": "Dividends Payable, Date Declared" } } }, "localname": "DividendsPayableDateDeclaredDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYSTOCKHOLDERSEQUITYDIvidendsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DividendsPayableDateOfRecordDayMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date the holder must own the stock to be entitled to the dividend, in CCYY-MM-DD format.", "label": "Dividends Payable, Date of Record", "terseLabel": "Dividends date of record" } } }, "localname": "DividendsPayableDateOfRecordDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYSTOCKHOLDERSEQUITYDIvidendsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarlyRepaymentOfSeniorDebt": { "auth_ref": [ "r119" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the extinguishment of long-term borrowing, with the highest claim on the assets of the entity in case of bankruptcy or liquidation, before its maturity.", "label": "Early Repayment of Senior Debt", "terseLabel": "Early Repayment of Senior Debt" } } }, "localname": "EarlyRepaymentOfSeniorDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]", "verboseLabel": "Net income per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r104", "r170", "r171", "r172", "r173", "r174", "r182", "r184", "r190", "r191", "r192", "r196", "r197", "r820", "r846" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income per share - basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r104", "r170", "r171", "r172", "r173", "r174", "r184", "r190", "r191", "r192", "r196", "r197", "r820", "r846" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net income per share - diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r136", "r193", "r194" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r193", "r194", "r195", "r198" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "NET INCOME (LOSS) PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/NETINCOMELOSSPERSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r719" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rate movements" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r572" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate (in hundredths)" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "auth_ref": [ "r562", "r572" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount", "negatedTerseLabel": "Excess tax benefits from stock-based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r55" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "verboseLabel": "Employee compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities [Abstract]", "terseLabel": "Employee Compensation and Benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r546" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Amount Capitalized", "verboseLabel": "Share-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONAllocatedSharebasedcompensationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONAllocatedSharebasedcompensationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r547" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r547" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "verboseLabel": "Unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONNonvestedawardactivitydisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Share-based Payment Arrangement, Option", "verboseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionsDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONTables" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r158", "r159", "r161", "r165", "r175", "r178", "r202", "r275", "r363", "r370", "r554", "r555", "r556", "r602", "r603", "r722", "r723", "r724", "r725", "r726", "r729", "r857", "r858", "r859" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYAccumulatedothercomprehensiveincomeDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r44", "r229", "r266" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r708" ], "calculation": { "http://www.agilent.com/role/INVESTMENTSDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Equity investments - with readily determinable fair value" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INVESTMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGain": { "auth_ref": [ "r264" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain", "terseLabel": "Unrealized gain on non-marketable equity securities" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails", "http://www.agilent.com/role/INVESTMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r264", "r848" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "terseLabel": "Net unrealized gains on our equity securities with RDFV", "verboseLabel": "Unrealized gain on equity securities, net" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.agilent.com/role/INVESTMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r16", "r23", "r261", "r830", "r867", "r868", "r869" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Equity Securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r262" ], "calculation": { "http://www.agilent.com/role/INVESTMENTSDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity investments - without readily determinable fair value", "verboseLabel": "Carrying amount of non-marketable equity securities without readily determinable fair values" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails", "http://www.agilent.com/role/INVESTMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount": { "auth_ref": [ "r263" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount", "terseLabel": "Impairments in non-marketable securities without readily determinable fair value" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "Extinguishment of Debt, Amount", "terseLabel": "Extinguishment of Debt, Amount" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails", "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r698", "r699", "r700", "r704" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails", "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r435", "r437", "r438", "r439", "r440", "r441", "r442", "r485", "r699", "r766", "r767", "r768" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails", "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r698", "r699", "r701", "r702", "r706" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails", "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r703" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r435", "r437", "r442", "r485", "r699", "r766" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r435", "r437", "r442", "r485", "r699", "r767" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r435", "r437", "r438", "r439", "r440", "r441", "r442", "r485", "r699", "r768" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails", "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r435", "r437", "r438", "r439", "r440", "r441", "r442", "r485", "r766", "r767", "r768" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails", "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r703", "r706" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r136", "r707", "r710" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r744", "r752" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Repayments of finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r259", "r260", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails", "http://www.agilent.com/role/INVESTMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Components of intangible assets acquired" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "verboseLabel": "Finite Lived Intangible Assets Useful Life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r310" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDisclosuresandComponentsofOtherIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "verboseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationExpenseandFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r312" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationExpenseandFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r312" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationExpenseandFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r312" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationExpenseandFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r312" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationExpenseandFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r312" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationExpenseandFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r304", "r306", "r310", "r314", "r796", "r803" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDisclosuresandComponentsofOtherIntangiblesDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign exchange translation impact to other intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]", "terseLabel": "Future Amortization Expense Schedule" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationExpenseandFutureAmortizationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r310", "r803" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount", "verboseLabel": "Finite-lived intangible assets acquired" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDisclosuresandComponentsofOtherIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDisclosuresandComponentsofOtherIntangiblesDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r304", "r309" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDisclosuresandComponentsofOtherIntangiblesDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r310", "r796" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Total amortizable intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDisclosuresandComponentsofOtherIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]", "terseLabel": "Schedule of Other Intangible Assets By Major Class [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDisclosuresandComponentsofOtherIntangiblesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)", "terseLabel": "Additions and adjustments to other intangibles" } } }, "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FixedIncomeSecuritiesMember": { "auth_ref": [ "r435", "r485" ], "lang": { "en-us": { "role": { "documentation": "Investment that provides a return in the form of fixed periodic payments and eventual return of principal at maturity.", "label": "Fixed Income Securities [Member]", "terseLabel": "Fixed Income Securities" } } }, "localname": "FixedIncomeSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCarryforwardsDetails", "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "auth_ref": [ "r716", "r718" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Realized", "terseLabel": "Foreign currency translation net gain (Ioss)" } } }, "localname": "ForeignCurrencyTransactionGainLossRealized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r136", "r731" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignCurrencyTranslationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Foreign Currency Translation [Abstract]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTranslationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r435", "r682" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign Exchange Contracts" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignPlanMember": { "auth_ref": [ "r493", "r497", "r511" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Foreign Plan [Member]", "terseLabel": "Non-U.S. Plans" } } }, "localname": "ForeignPlanMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForwardContractsMember": { "auth_ref": [ "r680" ], "lang": { "en-us": { "role": { "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.", "label": "Forward Contracts [Member]", "terseLabel": "Forward Contracts Buy/(Sell)" } } }, "localname": "ForwardContractsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails", "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r128", "r357", "r358" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographic Areas, Revenues from External Customers [Abstract]", "terseLabel": "Revenue by geography" } } }, "localname": "GeographicAreasRevenuesFromExternalCustomersAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosuresRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r293", "r295", "r805" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r296" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill arising from acquisitions", "verboseLabel": "Goodwill Additions" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSRollforwardDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Asset Impairment [Abstract]", "terseLabel": "Goodwill and Intangible Asset Impairment [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetImpairmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "verboseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r136", "r299", "r307" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Purchased Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation impact" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r128", "r294", "r297", "r300" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill - Rollforward" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GuaranteesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Guarantees [Abstract]", "terseLabel": "Guarantees [Abstract]" } } }, "localname": "GuaranteesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r668", "r685" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails", "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r668" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails", "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r668" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails", "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset": { "auth_ref": [ "r320", "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount on the books of the entity of the impaired asset to be disposed of by a method other than sale.", "label": "Impaired Assets to be Disposed of by Method Other than Sale, Carrying Value of Asset", "terseLabel": "Carrying value of long-lived asset" } } }, "localname": "ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "The name of the impaired assets to be held and used by the entity.", "label": "Impaired Long-Lived Assets Held and Used, Asset Name [Domain]", "terseLabel": "Impaired Long-Lived Assets Held and Used, Asset Name [Domain]" } } }, "localname": "ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails", "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "This element represents the categories used to group impaired long-lived assets held and used by the type of asset.", "label": "Impaired Long-Lived Assets Held and Used by Type [Axis]", "terseLabel": "Impaired Long-Lived Assets Held and Used by Type [Axis]" } } }, "localname": "ImpairedLongLivedAssetsHeldAndUsedByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails", "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r128", "r315" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Asset impairment charges" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r128", "r315" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Impairment of finite-lived intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r128", "r315" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "verboseLabel": "Impairment of indefinite-lived intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r128", "r321", "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment of Long-Lived Assets Held-for-use", "terseLabel": "Long-lived assets held for use impairment", "verboseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r128", "r320" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Long lived assets held for sale Impairment" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In Process Research and Development" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r145", "r612" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "U.S. operations" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract]", "terseLabel": "Income before income tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r145", "r612" ], "calculation": { "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Non-U.S. operations" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r145", "r228", "r234", "r238", "r241", "r244" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income before taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS", "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONAllocatedSharebasedcompensationexpenseDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONAllocatedSharebasedcompensationexpenseDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCarryforwardsDetails", "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails", "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCarryforwardsDetails", "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails", "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails", "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails", "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r573", "r585", "r592", "r607", "r613", "r617", "r618", "r619" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r142", "r177", "r178", "r226", "r571", "r608", "r615", "r849" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense (benefit)", "totalLabel": "Income tax expense (benefit)", "verboseLabel": "Provision (benefit) for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS", "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails", "http://www.agilent.com/role/INCOMETAXESINCOMETAXESProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]", "terseLabel": "Effective Income Tax Rate Reconciliation" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxHolidayAggregateDollarAmount": { "auth_ref": [ "r613" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of income taxes from which a reporting entity is exempt or for which it will receive a reduction in income taxes as a result of the income tax holiday granted by the taxing jurisdiction.", "label": "Income Tax Holiday, Aggregate Dollar Amount", "terseLabel": "Impact of the income tax holidays" } } }, "localname": "IncomeTaxHolidayAggregateDollarAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare": { "auth_ref": [ "r613" ], "lang": { "en-us": { "role": { "documentation": "Per share amount effect of the income tax benefit resulting from the income tax holidays granted by taxing jurisdictions.", "label": "Income Tax Holiday, Income Tax Benefits Per Share", "terseLabel": "Benefit of income tax holidays on net income per share" } } }, "localname": "IncomeTaxHolidayIncomeTaxBenefitsPerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeTaxHolidayLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Holiday [Line Items]", "terseLabel": "Income Tax Holiday [Line Items]" } } }, "localname": "IncomeTaxHolidayLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxHolidayTable": { "auth_ref": [ "r613" ], "lang": { "en-us": { "role": { "documentation": "Income tax-exemptions and reductions which may be granted by a taxing authority for a specified period. Such \"tax holidays\" are typically granted to induce business investment in the tax jurisdiction.", "label": "Income Tax Holiday [Table]", "terseLabel": "Income Tax Holiday [Table]" } } }, "localname": "IncomeTaxHolidayTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r98", "r136", "r568", "r569", "r585", "r586", "r591", "r599", "r871" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Taxes on Income" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r572" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Valuation allowances" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r572" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Non-U.S. income taxed at different rates" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r572" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Profit before tax times statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r572" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Adjustments to earnings of foreign subsidiaries" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": { "auth_ref": [ "r572" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount", "terseLabel": "Extension of the tax incentive in Singapore" } } }, "localname": "IncomeTaxReconciliationOtherReconcilingItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r572" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State income taxes, net of federal benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r125", "r132" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income tax payments, net" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r65", "r813", "r842" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Current", "terseLabel": "Current income tax assets (included within other current assets)" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCurrentandlongtermincometaxassetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivableNoncurrent": { "auth_ref": [ "r19", "r829" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Noncurrent", "terseLabel": "Long-term income tax assets (included within other assets)" } } }, "localname": "IncomeTaxesReceivableNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCurrentandlongtermincometaxassetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r127" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r127" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r127" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Increase (Decrease) in Contract with Customer, Liability" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/REVENUEContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r127" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Employee compensation and benefits" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r127" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r127" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedTerseLabel": "Other assets and liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r185", "r186", "r187", "r192" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Potential common shares - stock options and other employeee stock plans" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/NETINCOMELOSSPERSHAREDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "In-Process R&D" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDisclosuresandComponentsofOtherIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit, from purchase accounting adjustments.", "label": "Indefinite-lived Intangible Assets, Purchase Accounting Adjustments", "terseLabel": "Indefinite-lived Intangible Assets, Purchase Accounting Adjustments" } } }, "localname": "IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSRollforwardDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Information about effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Axis]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Axis]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/REVENUEContractBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Domain]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/REVENUEContractBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Gross Book Value", "verboseLabel": "Total intangible assets acquired - excluding goodwill" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDisclosuresandComponentsofOtherIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r302", "r308" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Other intangible assets, net", "verboseLabel": "Other intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDisclosuresandComponentsofOtherIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Including Goodwill) [Abstract]", "terseLabel": "Intangible Assets, Including Goodwill)" } } }, "localname": "IntangibleAssetsNetIncludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r100", "r222", "r732", "r735", "r821" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 }, "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails": { "order": 11.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "negatedTerseLabel": "Interest Expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS", "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r121", "r124", "r132" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest payments" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossReclassifiedToEarningsNet": { "auth_ref": [ "r678" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of net gains or losses on interest rate cash flow hedges reclassified during the period to earnings from accumulated other comprehensive income upon the hedged transaction affecting earnings.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net", "terseLabel": "Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net" } } }, "localname": "InterestRateCashFlowHedgeGainLossReclassifiedToEarningsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateDerivativesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest Rate Derivatives [Abstract]", "terseLabel": "Terminated Interest Rate Swaps" } } }, "localname": "InterestRateDerivativesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r681" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap [Member]" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InternalUseSoftwarePolicy": { "auth_ref": [ "r136", "r316", "r318" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.", "label": "Internal Use Software, Policy [Policy Text Block]", "terseLabel": "Capitalized Software" } } }, "localname": "InternalUseSoftwarePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.", "label": "Inventories [Member]", "terseLabel": "Inventories" } } }, "localname": "InventoriesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONAllocatedSharebasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryCurrentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.", "label": "Inventory, Current [Table]", "terseLabel": "Inventory, Current [Table]" } } }, "localname": "InventoryCurrentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INVENTORYDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "verboseLabel": "INVENTORY" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INVENTORY" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INVENTORYDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INVENTORYDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r6", "r68" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "verboseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/INVENTORYDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r14", "r69", "r136", "r201", "r289", "r291", "r292" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryWorkInProcessAndRawMaterials": { "auth_ref": [ "r67" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.", "label": "Inventory, Work in Process and Raw Materials", "terseLabel": "Purchased parts and fabricated assemblies" } } }, "localname": "InventoryWorkInProcessAndRawMaterials", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INVENTORYDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r290" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Inventory-related excess and obsolescence charges", "verboseLabel": "Excess and obsolete inventory related charges" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.agilent.com/role/INVENTORYDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r109", "r221" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 }, "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "negatedTerseLabel": "Interest income", "verboseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS", "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r268", "r847" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTextBlock": { "auth_ref": [ "r261", "r265", "r270", "r271" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investment.", "label": "Investment [Text Block]", "terseLabel": "INVESTMENTS" } } }, "localname": "InvestmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INVESTMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_Land": { "auth_ref": [ "r10", "r46" ], "calculation": { "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Total rent expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r756", "r758" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Lease, Cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r756" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease, Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails", "http://www.agilent.com/role/LEASESSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails", "http://www.agilent.com/role/LEASESSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r746" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r757" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Rent Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r757" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "terseLabel": "Total undiscounted future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r757" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r757" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r757" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r757" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r757" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r757" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r757" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: amount of lease payments representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r759" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Lessee, Operating Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Bank Guarantees" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GUARANTEESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r54", "r141", "r236", "r269", "r648", "r655", "r656", "r712" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r38", "r141", "r269", "r712", "r812", "r838" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r56", "r141", "r269", "r648", "r655", "r656", "r712" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Liabilities, Short-term [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Liabilities, Long-term [Abstract]" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Abstract]", "terseLabel": "Line of Credit Facility [Abstract]" } } }, "localname": "LineOfCreditFacilityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAverageOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Average amount borrowed under the credit facility during the period.", "label": "Line of Credit Facility, Average Outstanding Amount", "terseLabel": "Amount borrowed" } } }, "localname": "LineOfCreditFacilityAverageOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r52", "r143" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Date the credit facility terminates, in CCYY-MM-DD format.", "label": "Line of Credit Facility, Expiration Date", "terseLabel": "Line of credit facility expiration date" } } }, "localname": "LineOfCreditFacilityExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": { "auth_ref": [ "r711" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of the amount outstanding under the credit facility.", "label": "Line of Credit Facility, Fair Value of Amount Outstanding", "terseLabel": "Outstanding balance" } } }, "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityInitiationDate1": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Date the credit facility first became available, in CCYY-MM-DD format.", "label": "Line of Credit Facility, Initiation Date", "terseLabel": "Credit facility initiation date" } } }, "localname": "LineOfCreditFacilityInitiationDate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r52" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r52", "r143" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates an ownership position in, or purchase of, a security.", "label": "Long [Member]", "terseLabel": "Buy" } } }, "localname": "LongMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term Debt, Unclassified [Abstract]", "terseLabel": "Long-term Debt, Unclassified [Abstract]" } } }, "localname": "LongTermDebtAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r60" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "verboseLabel": "LONG-TERM DEBT" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBT" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r44" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.agilent.com/role/INVESTMENTSDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "totalLabel": "Long-term investments", "verboseLabel": "Long-term investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/INVESTMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r60", "r356" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r347", "r348" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingencies by Nature of Contingency [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r347", "r348" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r347", "r348" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r11", "r323" ], "calculation": { "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment, Gross", "terseLabel": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and Equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Marketable Securities [Abstract]", "terseLabel": "Long-Term [Abstract]" } } }, "localname": "MarketableSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INVESTMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Marketable Securities [Table Text Block]", "verboseLabel": "Equity Investments" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INVESTMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketingAndAdvertisingExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Marketing and Advertising Expense [Abstract]", "terseLabel": "Advertising Expense" } } }, "localname": "MarketingAndAdvertisingExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r3", "r640" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "terseLabel": "Acquisitions Disclosure" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "auth_ref": [ "r370", "r645", "r646" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "terseLabel": "Purchase of non-controlling interests" } } }, "localname": "MinorityInterestDecreaseFromRedemptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestPeriodIncreaseDecrease": { "auth_ref": [ "r642" ], "lang": { "en-us": { "role": { "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.", "label": "Noncontrolling Interest, Period Increase (Decrease)", "terseLabel": "Non-controlling interest" } } }, "localname": "MinorityInterestPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Standard Product Warranty Accrual [Roll Forward]", "terseLabel": "Summary of standard warranty accrual activity" } } }, "localname": "MovementInStandardProductWarrantyAccrualRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GUARANTEESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "terseLabel": "Movement in valuation and qualifying accounts [Roll Forward]" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r123" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r123" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r123", "r126", "r129" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r667" ], "lang": { "en-us": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedging" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails", "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues \"Accounting Standards Updates\" to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Adjustments for New Accounting Pronouncement [Member]", "terseLabel": "Adjustments for New Accounting Pronouncement" } } }, "localname": "NewAccountingPronouncementMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]", "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r162", "r163", "r166", "r167", "r179", "r180", "r181", "r276", "r277", "r397", "r398", "r400", "r401", "r557", "r604", "r605", "r606", "r800", "r801", "r802", "r861", "r862", "r863", "r864", "r866" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "terseLabel": "NEW ACCOUNTING PRONOUNCEMENTS" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Non-US" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r158", "r159", "r161", "r370", "r641" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-controlling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r248" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Long-Lived Assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosureLongLivedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r668" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Derivatives Not Designated as Hedging Instruments" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails", "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfBusinessesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of businesses acquired by the entity during the period.", "label": "Number of Businesses Acquired", "terseLabel": "Number of Businesses Acquired" } } }, "localname": "NumberOfBusinessesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONProfitabilityDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Costs and expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r228", "r234", "r238", "r241", "r244" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations", "verboseLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS", "http://www.agilent.com/role/SEGMENTINFORMATIONProfitabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r748", "r758" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating Lease, Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "verboseLabel": "Future Minimum Lease Payment Due" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESFutureMinimumLeasePaymentsDetails", "http://www.agilent.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r743" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of future minimum lease payments" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r743" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedTerseLabel": "Less: Current liabilities", "terseLabel": "Operating lease liabilities - Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails", "http://www.agilent.com/role/LEASESSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r743" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term lease liabilities", "verboseLabel": "Operating lease liabilities - Long-term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails", "http://www.agilent.com/role/LEASESSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePaymentsUse": { "auth_ref": [ "r745", "r752" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments, Use", "terseLabel": "Operating cash flow from operating leases" } } }, "localname": "OperatingLeasePaymentsUse", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r742" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESSupplementalBalanceSheetInformationDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r755", "r758" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r754", "r758" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r738", "r739" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r738", "r739" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r738", "r739" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r738", "r739" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r738", "r739" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r738", "r739" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCarryforwardsDetails", "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails", "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCarryforwardsDetails", "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails", "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrderOrProductionBacklogMember": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Orders, production or production backlog arising from contracts such as purchase or sales orders acquired in a business combination.", "label": "Order or Production Backlog [Member]", "terseLabel": "Backlog" } } }, "localname": "OrderOrProductionBacklogMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDisclosuresandComponentsofOtherIntangiblesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r70" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "verboseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r671", "r691" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other Assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESSupplementalBalanceSheetInformationDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "Other Commitment", "terseLabel": "Other Purchase Commitments" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]", "terseLabel": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]", "terseLabel": "Other Commitments [Domain]" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": { "auth_ref": [ "r82", "r84", "r454" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax", "terseLabel": "Other Comprehensive (Income) Loss, before Reclassifications", "verboseLabel": "Prior service cost (benefit)" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax": { "auth_ref": [ "r82", "r84", "r454" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 5.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax", "negatedLabel": "Other Comprehensive (Income) Loss", "negatedTerseLabel": "Change in net prior service benefit, net of tax benefit of $(1), $(2) and $(2)" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax [Abstract]", "terseLabel": "Net defined benefit pension cost and post retirement plan costs:" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r80", "r84", "r454" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax", "terseLabel": "Other comprehensive income (loss)", "verboseLabel": "Change in actuarial net loss, net of tax expense (benefit) of $0, $(25) and $(3)" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax": { "auth_ref": [ "r85" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax", "terseLabel": "Change in actuarial net loss, tax expense (benefit)" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOMEParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r643", "r644", "r652" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss), attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent", "terseLabel": "Other Comprehensive Income (Loss)" } } }, "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r643", "r644", "r652" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Other Comprehensive Income (Loss)" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r78", "r84", "r714", "r715", "r721" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Foreign currency translation, net of tax expense (benefit) of $1, $(10) and $7" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r76", "r84", "r714", "r715", "r721" ], "calculation": { "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails": { "order": 5.0, "parentTag": "a_OtherComprehensiveIncomeDefinedBenefitPlansPeriodIncreaseDecrease", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax", "negatedTerseLabel": "Foreign currency" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": { "auth_ref": [ "r84", "r88", "r90", "r454" ], "calculation": { "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails": { "order": 3.0, "parentTag": "a_OtherComprehensiveIncomeDefinedBenefitPlansPeriodIncreaseDecrease", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax", "terseLabel": "Amortization of prior service benefit", "verboseLabel": "Amortization of prior service benefit" } } }, "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYReclassificationsoutofaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTax": { "auth_ref": [ "r101", "r267", "r722", "r727", "r729", "r817", "r843" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Tax", "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax": { "auth_ref": [ "r79", "r85" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax", "terseLabel": "Tax (expense) benefit" } } }, "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "auth_ref": [ "r76", "r84" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax", "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax": { "auth_ref": [ "r84", "r88", "r89", "r90", "r720" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax", "terseLabel": "Amounts Reclassified Amounts Reclassified out of Accumulated Other Comprehensive Income" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "auth_ref": [ "r76", "r85", "r717", "r728" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "negatedTerseLabel": "Tax (expense) benefit", "verboseLabel": "Foreign currency translation, tax expense (benefit)" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOMEParenthetical", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r93", "r96", "r99", "r101", "r363", "r722", "r727", "r729", "r817", "r843" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other Comprehensive Income (Loss)", "totalLabel": "Other comprehensive loss", "verboseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME", "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": { "auth_ref": [ "r81", "r84", "r454", "r485" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax", "terseLabel": "Total" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect": { "auth_ref": [ "r85", "r643" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax (expense) benefit for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Tax", "negatedLabel": "Tax (expense) benefit", "terseLabel": "Change in net prior service benefit, tax (benefit)" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOMEParenthetical", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": { "auth_ref": [ "r80", "r84", "r454" ], "calculation": { "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails": { "order": 1.0, "parentTag": "a_OtherComprehensiveIncomeDefinedBenefitPlansPeriodIncreaseDecrease", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax", "negatedLabel": "Net actuarial (gain) loss", "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax": { "auth_ref": [ "r84", "r88", "r90", "r678" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax", "terseLabel": "Amounts Reclassified out of Accumulated Other Comprehensive Income" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax": { "auth_ref": [ "r84", "r88", "r90", "r669" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax", "negatedLabel": "Amounts reclassified into earnings related to derivative instruments, net of tax expense (benefit) of $0, $(2). and $1", "terseLabel": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME", "http://www.agilent.com/role/STOCKHOLDERSEQUITYReclassificationsoutofaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax": { "auth_ref": [ "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax", "terseLabel": "Amounts reclassified into earnings related to derivative instruments, tax expense (benefit)", "verboseLabel": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOMEParenthetical", "http://www.agilent.com/role/STOCKHOLDERSEQUITYReclassificationsoutofaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax": { "auth_ref": [ "r84", "r88", "r90", "r454" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net period benefit cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax", "terseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYReclassificationsoutofaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": { "auth_ref": [ "r84", "r88", "r90", "r454" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax", "terseLabel": "Amounts reclassified out of accumulated other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationBeforeTax": { "auth_ref": [ "r84", "r88", "r90", "r454" ], "calculation": { "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for transition asset (obligation) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Transition Asset (Obligation), Reclassification Adjustment from AOCI, before Tax", "totalLabel": "Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax": { "auth_ref": [ "r84", "r88", "r90", "r454" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net periodic benefit cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax", "terseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYReclassificationsoutofaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax": { "auth_ref": [ "r85", "r643" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax (expense) benefit for reclassification adjustment from accumulated other comprehensive (income) loss of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, Tax", "terseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, Tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYReclassificationsoutofaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r85", "r101", "r571", "r614", "r616", "r722", "r725", "r729", "r817", "r843" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "terseLabel": "Tax (expense) benefit" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeMember": { "auth_ref": [ "r683" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which reported facts about other comprehensive income have been included.", "label": "Other Comprehensive Income (Loss) [Member]", "terseLabel": "Other Comprehensive Income (Loss) [Member]" } } }, "localname": "OtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r79", "r84", "r693" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax", "negatedTerseLabel": "Loss on interest rate swaps recognized in other comprehensive income (loss)", "terseLabel": "Loss on interest rate swap", "verboseLabel": "Gain (loss) recognized in accumulated other comprehensive income(loss)" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r79", "r84", "r693" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax", "terseLabel": "Gain (loss) on derivative instruments, net of tax expense (benefit) of $(3), $(2) and $1" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax": { "auth_ref": [ "r79", "r85" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), before reclassification adjustments, related to increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax", "terseLabel": "Gain (loss) on derivative instruments, tax expense (benefit)" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOMEParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r671", "r691" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other Current Assets [Member]" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other Current Liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails", "http://www.agilent.com/role/LEASESSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Expenses [Abstract]", "terseLabel": "Amortization Expense" } } }, "localname": "OtherExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationExpenseandFutureAmortizationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeMember": { "auth_ref": [ "r686" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other revenue.", "label": "Other Income [Member]", "terseLabel": "Other income (expense) [Member]" } } }, "localname": "OtherIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r12", "r13", "r55" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "verboseLabel": "Other accrued liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r61" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "verboseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r129" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Noncurrent Assets [Member]" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESDeferredTaxesandotherDetails", "http://www.agilent.com/role/LEASESSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r110" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 }, "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails": { "order": 13.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS", "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r406", "r407", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r442", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r457", "r459", "r460", "r462", "r465", "r470", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r492", "r493", "r494", "r495", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "terseLabel": "Other Postretirement Benefits Plan [Member]" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Total Stockholders Equity" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r118" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Treasury stock repurchases" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r120" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r118" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedTerseLabel": "Payment of dividends", "terseLabel": "Aggregate cash dividends paid" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.agilent.com/role/STOCKHOLDERSEQUITYSTOCKHOLDERSEQUITYDIvidendsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r118" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Payment of taxes related to net share settlement of equity awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r113", "r638" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash payment to acquire business" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSTextDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r113" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisitions of businesses and intangible assets, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r114" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Payment to acquire intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireNotesReceivable": { "auth_ref": [ "r112" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.", "label": "Payments to Acquire Notes Receivable", "negatedTerseLabel": "Payment in exchange for convertible note" } } }, "localname": "PaymentsToAcquireNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherInvestments": { "auth_ref": [ "r115" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investments classified as other.", "label": "Payments to Acquire Other Investments", "negatedTerseLabel": "Payments to acquire fair value investments" } } }, "localname": "PaymentsToAcquireOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r114" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Investments in property, plant and equipment", "terseLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r434", "r436", "r442", "r461", "r463", "r464", "r465", "r466", "r467", "r485", "r487", "r490", "r492", "r513" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "verboseLabel": "RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANS" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r26", "r407", "r408", "r432", "r485" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "verboseLabel": "Retirement and post-retirement benefits" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementPlansPolicy": { "auth_ref": [ "r136", "r469", "r488", "r489", "r492", "r498" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.", "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]", "terseLabel": "Retirement and Post-Retirement Plans" } } }, "localname": "PensionAndOtherPostretirementPlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r405", "r407", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r457", "r459", "r460", "r462", "r465", "r470", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r492", "r493", "r508", "r509", "r510", "r511" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension Plan", "verboseLabel": "401(k) Additional company contribution" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanAssetCategoriesDomain": { "auth_ref": [ "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r442", "r462", "r485" ], "lang": { "en-us": { "role": { "documentation": "Defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]" } } }, "localname": "PlanAssetCategoriesDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PositionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by position taken for a security.", "label": "Position [Axis]", "terseLabel": "Position [Axis]" } } }, "localname": "PositionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PositionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates position taken for a security.", "label": "Position [Domain]", "terseLabel": "Position [Domain]" } } }, "localname": "PositionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock, Shares Issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred Stock, Shares Outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r30" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommercialPaper": { "auth_ref": [ "r117" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from borrowing by issuing commercial paper.", "label": "Proceeds from Issuance of Commercial Paper", "terseLabel": "Proceeds from commercial paper" } } }, "localname": "ProceedsFromIssuanceOfCommercialPaper", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "auth_ref": [ "r117" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).", "label": "Proceeds from Issuance of Senior Long-term Debt", "terseLabel": "Issuance of senior notes" } } }, "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r116", "r549" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "terseLabel": "Issuance of common stock under employee stock plans", "verboseLabel": "Amount of cash received from the exercise of share-based awards granted" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r117", "r144" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Short-term Debt", "verboseLabel": "Proceeds from credit facility and short-term loan" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsToMinorityShareholders": { "auth_ref": [ "r148" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.", "label": "Proceeds from (Payments to) Noncontrolling Interests", "terseLabel": "Payments to Noncontrolling Interests" } } }, "localname": "ProceedsFromPaymentsToMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r111" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from the sale of property, plant and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Products" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS" ], "xbrltype": "domainItemType" }, "us-gaap_ProductWarrantiesDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Product Warranties Disclosures [Abstract]", "terseLabel": "Product Warranties Disclosures [Abstract]" } } }, "localname": "ProductWarrantiesDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GUARANTEESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProductWarrantyDisclosureTextBlock": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.", "label": "Product Warranty Disclosure [Text Block]", "verboseLabel": "GUARANTEES" } } }, "localname": "ProductWarrantyDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GUARANTEES" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r92", "r95", "r122", "r141", "r164", "r177", "r178", "r228", "r234", "r238", "r241", "r244", "r269", "r643", "r650", "r651", "r660", "r661", "r712", "r822" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME", "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS", "http://www.agilent.com/role/NETINCOMELOSSPERSHAREDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAdditions": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Additions", "negatedTerseLabel": "NASD Site costs" } } }, "localname": "PropertyPlantAndEquipmentAdditions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r47", "r325" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r330", "r872", "r873", "r874" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "verboseLabel": "PROPERTY, PLANT AND EQUIPMENT, NET" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNET" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r46", "r323" ], "calculation": { "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Total property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r17", "r18", "r325", "r839" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r45", "r136", "r325", "r872", "r873" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r17", "r325" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r17", "r323" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to prospectively adopted accounting guidance.", "label": "Prospective Adoption of New Accounting Pronouncements [Axis]", "terseLabel": "Prospective Adoption of New Accounting Pronouncements [Axis]" } } }, "localname": "ProspectiveAdoptionOfNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INVENTORYDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INVENTORYDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RealEstateMember": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Property consisting of land, land improvement and buildings.", "label": "Real Estate [Member]", "terseLabel": "Real Estate" } } }, "localname": "RealEstateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReasonablyPossibleSignificantChangeInUnrecognizedTaxBenefitsByItemAxis": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Information by nature of uncertainty related to unrecognized tax benefits.", "label": "Nature of Uncertainty [Axis]", "terseLabel": "Nature of Uncertainty [Axis]" } } }, "localname": "ReasonablyPossibleSignificantChangeInUnrecognizedTaxBenefitsByItemAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r136", "r254", "r256", "r257", "r258" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable, net" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "auth_ref": [ "r87", "r91", "r722", "r726", "r729" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "terseLabel": "Amounts Reclassified out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r87", "r91", "r99", "r722", "r726", "r729" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "terseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYReclassificationsoutofaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r234", "r238" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "verboseLabel": "Reconciliation of segment results to total enterprise results" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfCommercialPaper": { "auth_ref": [ "r119" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow due to repaying amounts borrowed by issuing commercial paper.", "label": "Repayments of Commercial Paper", "negatedTerseLabel": "Repayments of commercial paper" } } }, "localname": "RepaymentsOfCommercialPaper", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r119", "r144" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedTerseLabel": "Repayments of debt and credit facility", "terseLabel": "Repayments" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r119" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Repayments of Short-term Debt", "terseLabel": "Repayments" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r566", "r885" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONAllocatedSharebasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r48", "r136", "r316", "r317", "r885" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Research, Development, and Computer Software, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r134", "r804", "r835" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted Cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r34", "r370", "r558", "r837", "r861", "r866" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings (accumulated deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/INVESTMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r158", "r159", "r161", "r165", "r175", "r178", "r275", "r554", "r555", "r556", "r602", "r603", "r857", "r859" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings", "verboseLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanNameAxis": { "auth_ref": [ "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r457", "r458", "r459", "r460", "r462", "r465", "r470", "r471", "r472", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r512" ], "lang": { "en-us": { "role": { "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Axis]", "terseLabel": "Retirement Plan Name [Axis]" } } }, "localname": "RetirementPlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanNameDomain": { "auth_ref": [ "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r457", "r458", "r459", "r460", "r462", "r465", "r470", "r471", "r472", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r512" ], "lang": { "en-us": { "role": { "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Domain]", "terseLabel": "Retirement Plan Name [Domain]" } } }, "localname": "RetirementPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r457", "r458", "r459", "r460", "r462", "r465", "r471", "r472", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r493", "r497", "r511" ], "lang": { "en-us": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r457", "r458", "r459", "r460", "r462", "r465", "r471", "r472", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r493", "r497", "r511" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r405", "r406", "r407", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r457", "r459", "r460", "r462", "r465", "r470", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r492", "r493", "r494", "r495", "r496", "r497", "r508", "r509", "r510", "r511" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r405", "r406", "r407", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r457", "r459", "r460", "r462", "r465", "r470", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r492", "r493", "r494", "r495", "r496", "r497", "r508", "r509", "r510", "r511" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSDefinedContributionDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r219", "r220", "r233", "r239", "r240", "r246", "r247", "r250", "r385", "r386", "r795" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS", "http://www.agilent.com/role/REVENUERevenuebyEndMarketsDetails", "http://www.agilent.com/role/REVENUERevenuebyRegionDetails", "http://www.agilent.com/role/REVENUERevenuebyTypeDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosuresRevenueDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONProfitabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r376", "r377", "r378", "r379", "r380", "r381", "r383", "r384", "r389", "r402" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue from Contract with Customer" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/REVENUENotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r137", "r138" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r382" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue, Remaining Performance Obligation, Amount" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/REVENUEContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Net revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r753", "r758" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Non-cash right of use assets obtained in exchange for operating lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeLeaseLeaseReceivable": { "auth_ref": [ "r760" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type lease.", "label": "Sales-type Lease, Lease Receivable", "terseLabel": "Sales-type Lease, Lease Receivable" } } }, "localname": "SalesTypeLeaseLeaseReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r87", "r727", "r729" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "terseLabel": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.", "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "terseLabel": "Schedule of Allocation of Plan Assets" } } }, "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts related to pension plans and/or other employee benefit plans in accumulated other comprehensive income (loss) expected to be recognized as components of net periodic benefit cost over the next fiscal year, including the net gain (loss), net prior service cost or credit, and net transition asset or obligation.", "label": "Schedule of Amounts in Accumulated Other Comprehensive Income (Loss) to be Recognized over Next Fiscal Year [Table Text Block]", "terseLabel": "Amounts in accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year" } } }, "localname": "ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.", "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]", "terseLabel": "Amounts recognized in the consolidated balance sheet" } } }, "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.", "label": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Amounts recognized in accumulated other comprehensive income (loss)" } } }, "localname": "ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "terseLabel": "Assumptions used to calculate the net periodic cost and benefit obligation" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r471", "r485" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]", "terseLabel": "Combined projected benefit obligation, accumulated benefit obligations and fair value of plan assets" } } }, "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r625", "r626" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails", "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSProformaOperatingResultsDetails", "http://www.agilent.com/role/ACQUISITIONSAssetsandLiabilitiesAssumedDetails", "http://www.agilent.com/role/ACQUISITIONSTextDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r599" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "verboseLabel": "Provision for income taxes from operations" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r60", "r143", "r364", "r367", "r368", "r369", "r733", "r734", "r737", "r825" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "verboseLabel": "Long-term debt - Senior Notes" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r590" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "verboseLabel": "Significant components of deferred tax assets and deferred tax liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r469", "r470", "r473", "r474", "r485" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIEMENTPENSIONPLANSDeferredProfitSharingPlanDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSAssumptionsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSComponentsofNetPeriodicCostsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSExpectedBenefitPaymentsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFinancialStatementLocationDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFundedStatusDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTargetAllocationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": { "auth_ref": [ "r469", "r470", "r473", "r474", "r485" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.", "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r672", "r679", "r685" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Effect of derivative instruments for foreign exchange contracts in the consolidated statement of operations" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r677" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r662", "r664", "r665", "r668", "r670", "r677", "r679", "r688", "r690" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Aggregated notional amounts by currency and designation" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "verboseLabel": "Reconciliation of the numerators and denominators of the basic and diluted net income per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/NETINCOMELOSSPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period.", "label": "Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]", "terseLabel": "Defined benefit plans assets measured at fair value using significant unobservable inputs (level 3)" } } }, "localname": "ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r572" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "verboseLabel": "Tax rate reconciliation, U.S. federal statutory rate to effective tax rate from operations" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r516", "r544", "r559" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONAllocatedSharebasedcompensationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r516", "r544", "r559" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "verboseLabel": "Allocated Share-based compensation expense disclosure" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "terseLabel": "Schedule of expected benefit payments" } } }, "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r698", "r699" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "verboseLabel": "Fair Value Assets And Liabilities Measured On Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r304", "r309", "r796" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDisclosuresandComponentsofOtherIntangiblesDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r740" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r299", "r301" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r299", "r301" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Goodwill balances and movements for each reportable segments during the period" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "verboseLabel": "Income before income taxes domestic and foreign" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r14", "r40", "r41", "r42" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "verboseLabel": "Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INVENTORYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Investments [Abstract]", "terseLabel": "Schedule of Investments [Abstract]" } } }, "localname": "ScheduleOfInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of Net Benefit Costs" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r169", "r172", "r199", "r200" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]", "terseLabel": "Accounting Standards Update and Change in Accounting Principle -Leases" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Standard Warranty" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GUARANTEESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r47", "r325" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of the fair value of assets and liabilities assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r15", "r134", "r804", "r835" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Restricted Cash and Cash Equivalents" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r106", "r249" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Revenue and assets by geographic areas" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r228", "r231", "r237", "r299" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosureLongLivedAssetsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONProfitabilityDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r228", "r231", "r237", "r299" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Segment profitability" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r518", "r548" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionsDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "terseLabel": "Schedule of share-based compensation, shares authorized under stock option plans, by exercise price range" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]", "terseLabel": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r63", "r139", "r203", "r204", "r360", "r361", "r362", "r364", "r365", "r366", "r367", "r368", "r369", "r370" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYSTOCKHOLDERSEQUITYDIvidendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Future Amortization expense for the next five years and thereafter" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r215", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r233", "r234", "r235", "r236", "r238", "r239", "r240", "r241", "r242", "r244", "r250", "r850" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSRollforwardDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails", "http://www.agilent.com/role/REVENUERevenuebyRegionDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONProfitabilityDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentOperatingActivitiesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operations of an entity including continuing and discontinued operations.", "label": "Operating Activities [Domain]", "terseLabel": "Operating Activities [Domain]" } } }, "localname": "SegmentOperatingActivitiesDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.agilent.com/role/INVENTORYDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONAllocatedSharebasedcompensationexpenseDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r215", "r217", "r218", "r228", "r232", "r238", "r242", "r243", "r244", "r245", "r246", "r249", "r250", "r251" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "SEGMENT INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONEntityWideDisclosureLongLivedAssetsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONProfitabilityDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting Information, Operating Income (Loss) [Abstract]", "terseLabel": "Reconcilitation between statement results and enterprise results [Abstract]" } } }, "localname": "SegmentReportingInformationOperatingIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting Information, Profit (Loss) [Abstract]", "terseLabel": "Select income statement components" } } }, "localname": "SegmentReportingInformationProfitLossAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONProfitabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r108" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONAllocatedSharebasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceOtherMember": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, financial service, and other financial service, classified as other.", "label": "Service, Other [Member]", "terseLabel": "Services and Other" } } }, "localname": "ServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r127" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.agilent.com/role/SEGMENTINFORMATIONProfitabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]", "terseLabel": "Share-based Payment Arrangement, Noncash Expense [Abstract]" } } }, "localname": "ShareBasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount" } } }, "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONAllocatedSharebasedcompensationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "auth_ref": [], "calculation": { "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails": { "order": 9.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.", "label": "Share-based Payment Arrangement, Accelerated Cost", "negatedTerseLabel": "Share-based Payment Arrangement, Accelerated Cost" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]", "terseLabel": "Incentive compensation plans [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Number of years from the date of grant generally vest (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]", "terseLabel": "Aggregate instrinsic value of options [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONNonvestedawardactivitydisclosureDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Foreited- Weighted Average Grant Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONNonvestedawardactivitydisclosureDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONNonvestedawardactivitydisclosureDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted - Weighted Average Grant Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONNonvestedawardactivitydisclosureDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Non-vested ending (in shares)", "periodStartLabel": "Non-vested beginning (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONNonvestedawardactivitydisclosureDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONNonvestedawardactivitydisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodStartLabel": "Non-vested at October 31, 2019 -Weighted Average Grant Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONNonvestedawardactivitydisclosureDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONNonvestedawardactivitydisclosureDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r536" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Total fair value of restricted stock awards vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONNonvestedawardactivitydisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested- Weighted Average Grant Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONNonvestedawardactivitydisclosureDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions", "terseLabel": "Post-vest restriction discount for all executive awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility of Agilent shares (in hundreths)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionsDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Compensation percentage maximum eligible contribution to purchase shares of common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "verboseLabel": "Maximum number of shares authorized for issuance under the ESPP (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Common stock available for future awards under the 2018 Stock Plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Options Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted-average exercise price per share, cancelled, expired and forfeited (in dollars per shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r525", "r548" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, ending balance (in shares)", "periodStartLabel": "Outstanding, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r537" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "verboseLabel": "Aggregate Intrinsic Value - Options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "terseLabel": "Total number of share-based awards issued (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/NETINCOMELOSSPERSHAREDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r515", "r521" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionsDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted-average exercise price per share, exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r136", "r518", "r523" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]", "terseLabel": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionsDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]", "terseLabel": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionsDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "terseLabel": "Minimum price of options outstanding in the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "terseLabel": "Number Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "terseLabel": "Number Outstanding (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "verboseLabel": "Maximum price of options outstanding, end of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Percentage which rate options generally vest per year (in hundredths)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r548" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "verboseLabel": "Aggregate Intrinsic Value - Options Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "ESPP eligible employee common stock purchase price ratio" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted Average Remaining Contractual Life (in years)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "verboseLabel": "Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted Average Remaining Contractual Life (in years)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONSharesAuthorizedbyExercisePriceRangeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates the sale of a borrowed security or written option.", "label": "Short [Member]", "terseLabel": "Sell" } } }, "localname": "ShortMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDisclosuresandderivativeinstrumentaggregatednotionalamountsbycurrencyanddesignationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r20", "r808", "r834" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt", "terseLabel": "Short-term debt" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermBorrowingsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Short-term Debt [Abstract]", "terseLabel": "Short-term Debt [Abstract]" } } }, "localname": "ShortTermBorrowingsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]", "terseLabel": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTerms": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Description of the short-term debt arrangement, and disclosures pertaining to the underlying arrangements, including repayment terms, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements.", "label": "Short-term Debt, Terms", "terseLabel": "Short-term debt terms (years)" } } }, "localname": "ShortTermDebtTerms", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTextBlock": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for short-term debt.", "label": "Short-term Debt [Text Block]", "verboseLabel": "SHORT-TERM DEBT" } } }, "localname": "ShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBT" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermDebtWeightedAverageInterestRate": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of short-term debt outstanding calculated at point in time.", "label": "Short-term Debt, Weighted Average Interest Rate, at Point in Time", "verboseLabel": "Short-term Debt, Weighted Average Interest Rate, at Point in Time" } } }, "localname": "ShortTermDebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHORTTERMDEBTCreditFacilityandCommercialPaperDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r749", "r758" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term Lease, Cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleNatureOfUncertaintyDomain": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "The nature of the uncertainty for which it is reasonably possible that the total amount of the unrecognized tax benefit will significantly increase or decrease within twelve months of the balance sheet date.", "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Nature of Uncertainty [Domain]", "terseLabel": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Nature of Uncertainty [Domain]" } } }, "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleNatureOfUncertaintyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internally developed software for sale, licensing or long-term internal use.", "label": "Software Development [Member]", "terseLabel": "Software Development" } } }, "localname": "SoftwareDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StandardProductWarrantyAccrual": { "auth_ref": [ "r352" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability.", "label": "Standard Product Warranty Accrual", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "StandardProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GUARANTEESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualBalanceSheetClassificationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Standard Product Warranty Accrual, Balance Sheet Classification [Abstract]", "terseLabel": "Standard Product Warranty Accrual, Balance Sheet Classification [Abstract]" } } }, "localname": "StandardProductWarrantyAccrualBalanceSheetClassificationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GUARANTEESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StandardProductWarrantyAccrualCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability that is expected to be paid within one year or the normal operating cycle, if longer. Does not include the balance for the extended product warranty liability.", "label": "Standard Product Warranty Accrual, Current", "terseLabel": "Accruals for warranties due within one year" } } }, "localname": "StandardProductWarrantyAccrualCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GUARANTEESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability that is expected to be paid after one year or beyond the normal operating cycle, if longer. Does not include the balance for the extended product warranty liability.", "label": "Standard Product Warranty Accrual, Noncurrent", "terseLabel": "Accruals for warranties due after one year" } } }, "localname": "StandardProductWarrantyAccrualNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GUARANTEESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualPayments": { "auth_ref": [ "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product warranty. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Decrease for Payments", "negatedLabel": "Settlements made during the period" } } }, "localname": "StandardProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GUARANTEESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r350" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Increase for Warranties Issued", "terseLabel": "Accruals for warranties including change in estimates" } } }, "localname": "StandardProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GUARANTEESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r136", "r351" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Standard Product Warranty, Policy [Policy Text Block]", "terseLabel": "Warranty" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r1", "r215", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r233", "r234", "r235", "r236", "r238", "r239", "r240", "r241", "r242", "r244", "r250", "r299", "r329", "r332", "r335", "r850" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]", "verboseLabel": "Business Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSRollforwardDetails", "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTextDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails", "http://www.agilent.com/role/REVENUERevenuebyRegionDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONProfitabilityDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONReconciliationofReportableResultsDetails", "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r29", "r30", "r31", "r139", "r141", "r184", "r188", "r189", "r190", "r192", "r203", "r204", "r205", "r269", "r363", "r712" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTSDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYSTOCKHOLDERSEQUITYDIvidendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r64", "r158", "r159", "r161", "r165", "r175", "r178", "r202", "r275", "r363", "r370", "r554", "r555", "r556", "r602", "r603", "r722", "r723", "r724", "r725", "r726", "r729", "r857", "r858", "r859" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYAccumulatedothercomprehensiveincomeDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS", "http://www.agilent.com/role/INVESTMENTSDetails", "http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTSDetails", "http://www.agilent.com/role/REVENUEContractBalancesDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYAccumulatedothercomprehensiveincomeDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYReclassificationsoutofaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by continuing and discontinuing operations.", "label": "Operating Activities [Axis]", "terseLabel": "Operating Activities [Axis]" } } }, "localname": "StatementOperatingActivitiesSegmentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.agilent.com/role/INVENTORYDetails", "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://www.agilent.com/role/RETIREMENTPLANSANDPOSTRETIREMENTPENSIONPLANSFairValueofPlanAssetsDetails", "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONAllocatedSharebasedcompensationexpenseDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r158", "r159", "r161", "r202", "r795" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS", "http://www.agilent.com/role/INVESTMENTSDetails", "http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTSDetails", "http://www.agilent.com/role/REVENUEContractBalancesDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYAccumulatedothercomprehensiveincomeDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYReclassificationsoutofaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Granted or Issued, Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based awards issued" } } }, "localname": "StockIssuedDuringPeriodSharebasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/NETINCOMELOSSPERSHAREDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r30", "r31", "r363", "r370" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Number of shares purchased under ESPP (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r30", "r31", "r363", "r370" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Share-based awards issued (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r30", "r31", "r363", "r370", "r527" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r30", "r31", "r363", "r370" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Aggregate Value stock issued under Employee Stock Purchase Plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SHAREBASEDCOMPENSATIONGeneralDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r30", "r31", "r370", "r517", "r535" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Share-based awards issued" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock Repurchase Program, Authorized Amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Remaining authorized repurchase amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r30", "r31", "r363", "r370" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Stock Repurchased and Retired During Period, Shares", "negatedTerseLabel": "Stock Repurchased and Retired During Period, Shares", "terseLabel": "Stock Repurchased and Retired During Period, Shares" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r30", "r31", "r363", "r370" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "negatedTerseLabel": "Stock Repurchased and Retired During Period, Value", "terseLabel": "Stock Repurchased and Retired During Period, Value" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r31", "r36", "r37", "r141", "r255", "r269", "r712" ], "calculation": { "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r141", "r158", "r159", "r161", "r165", "r175", "r269", "r275", "r370", "r554", "r555", "r556", "r602", "r603", "r641", "r642", "r659", "r712", "r722", "r723", "r729", "r858", "r859" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Total equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEET", "http://www.agilent.com/role/CONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]", "terseLabel": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r140", "r370", "r371" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "STOCKHOLDERS EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITY" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r751", "r758" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedTerseLabel": "Sublease Income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]", "terseLabel": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsConsolidationItemsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.", "label": "Subsegments Consolidation Items [Axis]", "terseLabel": "Subsegments Consolidation Items [Axis]" } } }, "localname": "SubsegmentsConsolidationItemsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.", "label": "Subsegments Consolidation Items [Domain]", "terseLabel": "Subsegments Consolidation Items [Domain]" } } }, "localname": "SubsegmentsConsolidationItemsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]", "terseLabel": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/SEGMENTINFORMATIONSegmentAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r730", "r761" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYSTOCKHOLDERSEQUITYDIvidendsDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r730", "r761" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYSTOCKHOLDERSEQUITYDIvidendsDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r730", "r761" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYSTOCKHOLDERSEQUITYDIvidendsDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYStockRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "auth_ref": [ "r575", "r584", "r586" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Summary of Income Tax Contingencies [Table Text Block]", "terseLabel": "Income tax contingencies rollforward" } } }, "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Cash Flow Information [Abstract]" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TangibleAssetImpairmentCharges": { "auth_ref": [ "r0", "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.", "label": "Tangible Asset Impairment Charges", "terseLabel": "Asset impairment charges" } } }, "localname": "TangibleAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r593" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforwards" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit": { "auth_ref": [ "r599" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of income tax expense (benefit) for remeasurement of deferred tax from change in tax rate pursuant to Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)", "terseLabel": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)" } } }, "localname": "TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit": { "auth_ref": [ "r599" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of income tax expense (benefit) from effect of Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Income Tax Expense (Benefit)", "terseLabel": "Tax Cuts and Jobs Act, Income Tax Expense (Benefit)" } } }, "localname": "TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense": { "auth_ref": [ "r599" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of income tax expense from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense", "terseLabel": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense" } } }, "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESEffectivetaxrateandtaxholidaysDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]", "terseLabel": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]", "terseLabel": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks and Trade Names [Member]", "terseLabel": "Tradenames and trademarks" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ACQUISITIONSACQUISITIONSIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Trademark/Tradename" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDisclosuresandComponentsofOtherIntangiblesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradingSecurities": { "auth_ref": [ "r816" ], "calculation": { "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails": { "order": 3.0, "parentTag": "a_FairValueAssetsMeasuredOnRecurringBasisTotalAssets", "weight": 1.0 }, "http://www.agilent.com/role/INVESTMENTSDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI", "terseLabel": "Trading securities" } } }, "localname": "TradingSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFairvalueofassetsandliabilitiesmeasuredonarecurringbasisDetails", "http://www.agilent.com/role/INVESTMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized holding gain (loss) recognized in the income statement for investments in debt and equity securities and other forms of securities that provide ownership interests classified as trading.", "label": "Trading Securities, Change in Unrealized Holding Gain (Loss)", "terseLabel": "Net unrealized gains on trading securities" } } }, "localname": "TradingSecuritiesUnrealizedHoldingGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INVESTMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r259", "r260", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/FAIRVALUEMEASUREMENTSFAIRVALUEMEASURMENTSFairvalueofassetsandliabilitiesmeasuredonnonrecurringDetails", "http://www.agilent.com/role/INVESTMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease": { "auth_ref": [ "r84", "r727" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cumulative translation adjustment, after tax, from translating foreign currency financial statements into the reporting currency.", "label": "Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease)", "terseLabel": "Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease)" } } }, "localname": "TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/REVENUEContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryLockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customized agreement that fixes the yield or price on a specified treasury security for a specific period.", "label": "Treasury Lock [Member]", "terseLabel": "Treasury Lock" } } }, "localname": "TreasuryLockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/DERIVATIVESDetails", "http://www.agilent.com/role/DERIVATIVESEffectofderivativeinstrumentsonConsolidatedStatementofOperationsDetails", "http://www.agilent.com/role/DERIVATIVESFairvalueofderivativeinstrumentsandConsolidatedBalanceSheetlocationDetails", "http://www.agilent.com/role/LONGTERMDEBTSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r164", "r165", "r166", "r168", "r272", "r273", "r274", "r275", "r278", "r279", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r558", "r600", "r601", "r602", "r603", "r797", "r798", "r799", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Accounting Standards Update [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.agilent.com/role/INVESTMENTSDetails", "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails", "http://www.agilent.com/role/NEWACCOUNTINGPRONOUNCEMENTSDetails", "http://www.agilent.com/role/STOCKHOLDERSEQUITYAccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax [Abstract]", "terseLabel": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax [Abstract]" } } }, "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/STOCKHOLDERSEQUITYChangesinaccumulatedothercomprehensiveincomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r567", "r578" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance, end of year", "periodStartLabel": "Balance, beginning of year" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r579" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "terseLabel": "Reductions for tax positions from prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r581" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedLabel": "Settlements with taxing authorities" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r574" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Interest and penalties accrued related to unrecognized tax benefits accrued and reported" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued [Abstract]", "terseLabel": "Unrecognized Tax Benefits Rollforward" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r574" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r580" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions for tax positions related to the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r579" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Additions for tax positions from prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r582" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "terseLabel": "Statute of limitations expirations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r583" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/INCOMETAXESINCOMETAXESUncertainTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r206", "r207", "r209", "r210", "r211", "r212", "r213" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.", "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]" } } }, "localname": "ValuationAllowanceOfDeferredTaxAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r149", "r154" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Balance at End of Period", "periodStartLabel": "Balance at Beginning of Period" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r152" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "verboseLabel": "Additions Charged to Expenses or Other Accounts" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r153" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedLabel": "Deductions Credited to Expenses or Other Accounts" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r149", "r150", "r151", "r153", "r154" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r149", "r150", "r151", "r153", "r154" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Variable Interest Entity, Not Primary Beneficiary, Disclosures [Abstract]", "terseLabel": "Variable Interest Entity" } } }, "localname": "VariableInterestEntityNotPrimaryBeneficiaryDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Not Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity, Not Primary Beneficiary" } } }, "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/OVERVIEWANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r750", "r758" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable Lease, Cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LEASESLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/LONGTERMDEBTCarryingValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r183", "r192" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "verboseLabel": "Diluted weighted average shares" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS", "http://www.agilent.com/role/NETINCOMELOSSPERSHAREDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r182", "r192" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic weighted average shares", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.agilent.com/role/CONSOLIDATEDSTATEMENTOFOPERATIONS", "http://www.agilent.com/role/NETINCOMELOSSPERSHAREDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(ColumnA))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r157": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693" }, "r181": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e725-108305" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e765-108305" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r251": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714" }, "r265": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "321", "URI": "http://asc.fasb.org/topic&trid=75115024" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r271": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "325", "URI": "http://asc.fasb.org/topic&trid=2197064" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r292": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19379-109286" }, "r319": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r338": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r346": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1),(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r354": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "460", "URI": "http://asc.fasb.org/topic&trid=2155896" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r359": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r371": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r402": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(b)(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(s)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2919-114920" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r513": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944" }, "r563": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e39076-109324" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r619": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "2AA", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759068-111685" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "c", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3),(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "4F", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624186-113959" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624258-113959" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121558989&loc=d3e80720-113993" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994" }, "r696": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "54B", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117332851&loc=SL7495116-110257" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=SL116692626-108610" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=120240428&loc=SL75039408-165497" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30304-110892" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30755-110894" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=116633155&loc=d3e31531-110899" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r731": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28567-108399" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r759": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919379-209981" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r823": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r825": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5)(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r845": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r846": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r849": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580" }, "r850": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r857": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r867": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r868": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r869": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r870": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r872": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r873": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r875": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r876": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r877": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r878": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r879": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580" }, "r880": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r881": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r882": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r883": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r884": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r885": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r886": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r887": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r888": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r889": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e709-108580" }, "r890": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r891": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r892": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r893": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r894": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r895": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r896": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r897": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r898": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" } }, "version": "2.1" } ZIP 140 0001090872-20-000020-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001090872-20-000020-xbrl.zip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

9YT]8A79]@V;V2_=*/:[\IAS]*1+HH8TFF MYZ=Z6VI($Q&[^H7BY:7L=56#JR&PJF/KM,WZ>:6+/%1?0*?OL+HN+[_9Z3?> M[S6U&U_5B,(I>UGJ]I5L!CY1=;T^C99N$#R8G4.P^GWM MNM:$UR@O.:M>$F,"(_J5I/CU]>]Z*LHG8\<$<'00"ZP$_%W]:MF04W+IZ=1E M^K:\17Z]S/5]XRI'"C)Q%QFI\#D<2RV,9T6NZEY D%W]L\R96,.@YLOMM5?- MWOI;YO6O1KN(^([>//8X2M*QB'6".JIZ?Y)0:YT$M"VBB:T(%-,R<;^EM>^- M&=>+#WC5=\^7Z,U27T9N&>1"):$5XR8I;1(%*D)#FW-W'+H2!TVC1'))0!CKA1$RS9CZ]'G6&Z9O?6NW.7J M V?M?J4N5T_=\&B=Y4Y0\E0BK#NWE?U^VV*LE_K,(I1R9'@!@YX]93+,14%H0.BHV]T!-I0UY1:U2N?D[Q5 M KCC2@JC4ITSG30K5>UB :W6Z? .BV2F78Y*F9E[UF#V3)B5G%@3(E?OQ9>4 M&Z.:Q%&%GVL=&]M^_<@-S-4-4)QCWFGAK.TH"DQS9WIST],8DS3HVHY-9*.0 MZC("6]L7\!F#J.*5B JKKG,>!?\((8%<3-BFEY;"M_Q>S.^QV(T46J&H"YFK M=R1A0L,Y""J6SCF:VC ^.>8Z89CHLH#UO)?OV6Z+,?,'_Y!HL\2^V@!_@@N5 M@9.(I)S?+<[=OU4&+L$X<]3!Y;#ED6DZC,ZPX5$3,W2G#QO$=H@WA.F<8T)A M1C@8FYVD-DQ'!6"IX)XAFU5!>HB^IZ\1$RSL='8YV'-2L7-5)D1-;PB7E167/6+F66LL'.C=4P[FA\D"?QG&ZRZ*+JMH] M[^<*=%H5AH*&,ZY'O.)S6 M! :'%#-(&NLZH3=QYS.8E>I@;LJMQG MF9FYRT^<+@;V?K?3)P<<_VPU]I M]L_>!>KB"?B&0WY.DSC!_3ME[_%D$A>_2.G]GFC,MG['.\.!G3!LF3.=,].- MQA7$AI"=4MJPK_"$-,R.8?022*([^NYR.Z#XRB.)[N5>B^XO8'L"%=Y[.D?\ MQ0D)ZR?;)8/:WV;*_U<'DFF7&W/:[)+@-;5L^H[A9$;_MJ[_2+'65ZRUG7U5 M>EZYZ :/7(4=8GT*)X+-T*'A/;V6X++*HT_AO+-;9?V]4_\"S#^Z5B.7![%E M8PN$;BT$TSQR9,$=$.J+F\>I#E-E.#YJ3:5.Q @=&X;E(X/'>0?'(1@-97.V MJ69^&A50D\>%,BY*5(W833G3&RI7V[)T4[J$]65K'"3+8\$V(,4)U"^,*VQ_ MP$G%L2,GD9\6F)*L3;F"ODW6Z4<* MO(2XC@99HCP"Y8BA++@ )S,L5=:H@BA$//.)#,;2V;&:+?0;W6/ ML%Z$BM-AUT@V:M.0(P8$Z^\B3RD3S2G80N5DL[4VR8JLS_E.^H)<1B <6:4. M1+ZUSM3\;4YO,AI1OHE9GY(*T65B>$$_3KBO0YWSG77:D5.E&ZAQ*>%U;2"" M.*[OA[!1(C*?@7,X^O,: 8FPD3SVK% =&4'P9'S.\LC2\X86!1THWG7T.H50 MI%B8546CMA.(%@O=IT)465[;II\Q&M>V3R&G'%MGL\(39-Y785&>T*>Q1I1F,D L\ M%;9AA4IFU^V[UAA7&WL +PGIOKM-=[V53;=RZEN;3RU&P-+KUIOEUZW;K.[0 MK&Y[2=M>TK:7M,WS_4/=#U(X\I.Q3)[!@7RA"?\.YM(?; /MILL9P/P\3V8_ M%C7#NX[$[R^2/^A]O@S";16+Q8Q@33?2CMVHLI:U1T8 31Q#S MBE?$-OY:Z:#AL'MS<8-J*$_A_P/]8J6ANJ2A_IH']>\NA]U^O[_TZXMN;^EW MJX:][=[T!SN-NOJ[J\O+EM8#H;77AV&O#XG8VXV&_2OM,6,^&$7"^QZA:2/4 M$G\[NSRS)D: (,<_]F??O1YL:$?Q17)4V^"\MQ];%]ZN4X47#?:S8H:94^]J MDTFQK;A/T_K_Z%K^Y\:XT-+)UA?P F=ZUOQHFLSYW_W#9!'%#:E^#.-D=-YY M[\GU7,6@%;,^;F;UAH99MQ[\7P.K3EI3V#DI\P>-(YB21Q$P3Y-W8*O>OWBL M":_:'>5QE"58'^J8& L:IV7LDS#V=M?S3:FOXU=5CE%S/"O_&E.4N2XN>_-( M)LX#F71@8M'RYFV3.;-LYCJ8$2<4?%S!H_;)IW]RS6)A#Q%L^Q$'YTJ@?%_* MT6@_1'1]N/E"A^W4U>6/FU@/QS#GS:WN=;/=1)FU'&LYMH<<>TYKJ^79<_)L MZV-K1/]7G;B'_WO#U[3[O-,^,]!C5I6;;:9[X1V"3GGUH"FZ4TMQU+V:VV5G M.+QL5@"[R.T6L]U*1U1>6=4SKF>M=WQZ\S!UO5.]J-ROT9/G5NWB@&;K> M]MX[_?25\/1C>W^WK3]9SN"YA+T<) 6FW&^=PG-L"OWQ&;3?Q\%5Y_)RN%M0 MXO%XM.=AM':WM+M%[Y;>]8Y7%>UN:7?+B>V606?8&YSX;CF9\&_+K^T<._)3 M_DHUJPT5L7N#.+T,$$*1T5;NEK\[I K3EM:VMW&TK=]O*W;9RMZW<;2MW M]ZYR]R@8]Q*5NJO#V*(I._$/1@]1[H075<^U][>5#%)"T[6W:V[&S9 M>?#L;(O*RE/O;S?UQENL_;NLN;EZD=*$%[&=GO3BHA6/5CQ.3SQ>IK#I^,3C MZ*X]__,_;ON]_FX&VLDR[77OC3>;Y6U]U:KZJHU4ZJ8U"/NG9_K;GKB/DZ5_ M."IU4_>M%8]6/$Y//+9-O&O%XT0*9AYBD)TLTWH/-\<..RI&)4[9^$+;L- MKM6M/$K'\U)W^6><*A6ZO!N'$5#Q0^;F4V&2U2LJD=;- #;O(1[&NA/WI6ZX M76\*SCVUU[0L=UN2-[4B'U4:?/>8DO4MR?GMJV;>N[XT,[<3NC(3"F,:I''H MVPTF!C_=8F+]YHEE2U[_.()XR$*M5K@XE$_RPZUO5T-T@>=*82 M*AIWQ*;;J;-,>LV[2!1AH\Q%I@0(>X\O:/1QE-S!%-Y_^M\//YV#S,%2!'(: M^KKC^%3U)_RU(YK$WFXA,ZK;2-7J[ MWJ]I,L\G-,D )HW]RH%F7T81KQ5V_[XK,J0]ZWBB ,J%ZI^M5H'N4^ W<>%' M$E@@?+""J)$Q]4_7/^YZ7R?2+)FFL_E%V+A\EL(N34&$-5VJ8SM,_DX-3=) M4F7[>C,]N?.JP(.IXH\#/2#<&4B3/^EZ MK09X[)W8&S;OQ%N6ES&+9VCDS6B:ZK:T)+#"43MQE31/11A;^5HB6ZFDV;@B MUO4^Q!Z:7:RWJI2-[99R"01MEX!@,76:,JOE2.+6["%X"GB4AR("LI/1*(/S M%48V+)'B&V\?'CT*@690I9,4-VTR3L5LLNAX8]1!E<\:'P4&P6"@D'P@?2KS M=$%$J@\R/YDMC BTAV/##;-[3C:;.G"^X&K43J&-QNI=U.RF^F"W*P=# 0SY MK%IRA*,@Y9-42JN=,SDFF^M';>IY[T$9!Z"NK$D"V@'Y&(7T7.8R$!^"#O[*":F].AGJD1?2PA7>CQDOAG/X262""@@[@5"9@JZ.>3*(HF>/^A7%@QQAC4N]B/TJR M J;M ?$P\U2_$B>#=DX"1BB.#C\XQS%AJ(S-^1$L'%BD9**".2-VWV,W1['! M5IZ+&^^P-+1Z8DJ._G?U' MV+\:#'UQ?75Q/0@&H]'U[:WH#6XO[X:#0(A^EHYJE41.^A%#_]ODS0^5M3[YL64\R/9/NLMYU2B08HG+ZBL+:R?W:QT M/B&<CV-N;!A;;F6AZK5D:]T6M4#]VQTLXWI\5,&I%1%09YR/,,8$*,R]K]*?Q+" 8XS_?OSXWGM]]H\P M^2J_G;UQ U1KP@>[,W:%M>02[%RWN('9J0BD'F(;.W97L_7));_YC, VN#I* M^H\%+ 4%2Y[%-V[1\\K?'1+*6TMKBY[7HN>UZ'DM>EZ+GM>BY[7H>6NVR/.# MP"E+L#[4,3'V)=#U3H.Q3X6^=SRJRC%JCF?E7V,V'"=\9F\>R<1Y(),.3"Q: MWCP0/NP T3A_=Q*G,76,8T@/0N,\I.GO!P9?R[&68R_(L>.J>&IY]H 3[+!+ M_3^NNVIZ",C;D?9T.Z"N;/W.Y;#_(FA]CUERV@F]W;#JZ:8K[K:-[G8O!S8L M%3ZF,]S*W(')7+_7REPK<\\XM^'@\N E[GA#?OT6078K?MT^T!(][/!HM02P MC88>X1U&"5N8.2^9N!ZW,M3+WO#)W<[&MU[-_,G>\T;W+-AKZ MK#;H 6; ?*UV>][6F7QB*.F]8]C6$85'9-!^GP8$:;M;1.)%4;:?,X+6[I9V MM^C=TKO>,7[7[I9VMYS8;AETAKT=FX\=S6XYWMCOCG[*R?+KJL%/J75/T$2= M#.[F'X\ ;C.H(?-NWUT!>P_$"55D(_*3!L*)7?2=54-[[US '-7)0(]6[V<0 M5R$!DY%W4T,K9 Y8/'4#2DU0F6IPBV9%6+L3D4Z%+PN&ZB<.^@(AXP5GR^#/ M8L*K5QSM&LP;#7]M(8[6+P?!SZL"\%Q$> MITE @,<&W52#3XV21)/8B+L=2)]!_<.X"=E)QOJ?HF%VAGE:WV1B>AO)R=E0M26N<7LDQ.$HM]6&9' M!0/;"X._G:U'!^_U^F=_;Q'<7X"6%L%]!8+[;[OX91A:^GG[S-P M"6564T:' "T,.[-[P;MS6VSAP45WT%_^]>X8N-?#JR>!E6UI/11:>[WN9?]I ML(6?@-A^]WHP;+&%6VSA%ENXQ1;>A%DMMG"++?P\$+A'P;B7P X^#L:UV, E MG-R.)[_[ H>8'(Q2;8N8\E6X\MANTKG^.5IU"R\"MUO%3;(C%-X6NH M+6;^_>WFWY@KNG\ID5=7W6WK_1ZG_O\E)ONT"8)'*B#7W9>!P6D%Y$ $Y*:[ M8TYU*R#'GF+\NO_&F\U6'*HMUYJXUB.N/062R4&99%FM]>A.QMFF1?_[IVT& M-]VK%RF,/QS5NFF5^=$*R+;5?ZV G)2 7+4"TN)4+&LG<=OO]=]Z+=>V0N2K M&[2G$"YCA(^Q8Z&=6J#LLOLRT*R'HTE// XRV/JH;07DQ 1D6V^N%9 3#OFT M3-O,@#VY.-D?,I,B]2=<_R/O993,L!:EA?L]9!C,P?!E8GTM\.K)2MS%MA=W MK<2U$O<@B*;;;7,)]D_BCCBTM6.WB9-E6!."UI'' ;_("#X<=U1IN4*_":9A M'&9Y2I7&;=^S0^X'U.L,AM<'WQ&HE;D#D[GKE\E";67N=&7N\G9'G/$]DKGC M#>ZUG<^>UQ8]P#CHIQF"&P&U#[F1/MS!TGF2(.]QZ430=)IQ B-DKDD M+,PP"1@=-Q7W,N)W=KV=UP.Q-Q%/'&A>!L+9,'8J1Y%$=EO6(^?!7AGY]+]*0?CP3BXZNX/:F MX7>SC&I9RRL"OX(QW;5K$@6-V%],6&)I?>J?ZN1 M)S3F;L=[!>)5^A#^1M:_ZE]7/@I#))Y[+R9 MWWC3\,+JN.I]M_77/<("'+(&9R6P+)W(;AX')]X"Q6^LZY>B+F_^6MN(0:E[ M=V/JXD#>HJ0_PI0QB4&07@VMB%34 SQP3/YKP*[8J0EDZ1Y(6@/Z(LT?345!-:+:A-0&LVZ2!\G;!]*Y""?X3)5_EMA>(/P@Q> M3H."^-.H\ XXW(A348%FDGK4/1A6Z]GMUN%JR]5?!0N_^5O-FEMQH"7Q,F(! MS!HXB&>LQO!P.8VHSVI]';A^A(-6*]2X?.[)LLEZTEKB!->T!&A8!XN@76.5 MF=\>*:R7.WJ\#>Z>&W76IB#TY0V.]<=;O(_Z2]25P::&IVN-P-AQ1GCG2N+@ MA2!)I?=UUN#)/ZG*V'$AKFHH\W6]L./0-16QS$A4+(873\,L8X@L]5DDQ\[N M-A^[:AK'@X648X:R=KC5N'3.PF66ZJ;E2CB4S?I%6]"AFD$F[H$E:U?EE'4# M^R=)Y4+ <3.;^DIM:L%TEBF,Z@5$S2O=S$RI.IU/HS&>7TTL613C:VYJ0S3S M_W;E"TS#KO5^XZ;[?%NG')6-@OEIYS]'#*-7JO#^PW=NK5&S6:]@4GNEK-1^6_LR.'7 M&!'O]9=%Q$%:[\-,G=)P5$J-P:<W9&[:1E?^890G8.$@ ->(#$C+IP/ZE$@B<@9VA'B"# MVKS3NDQ@-*P0)0[4&T;@)VRC)-SI;P1^.+B$$;>/1,N:[F7!3\O-+4)Y([_J MWY2,0H>W_:6\!=LICRC2J^/1''#R(Q%./4$D ??F(?SW'V&B.G3# 9+.U&'4 M6OH;;@H,&1S4IF#7PMZ3DB&OQ!-X#T9Z$683+3N!O'N(LW\"PN I.;C=4 XX M28/U F_CBZ7;.)>S\V*F]S!'=2)'7^!A_A$D ?P]]!][QE]DSX?H<&^.\):' M'+T$N]H!?UQ-06I1P(O#-#A'5PS]3.^5'1.G$Q)6JOD-3:)*=7$'JY<7*L"$ M.K7L0%+4\D[&\*_<##J+8'4\F!=8LR!_Z,VA.4R_^6\!*X[J^I\R&J&F_JQ^ M]"'.BI0ZM7X4\ZIZ?-)=UO7V<%,L&VO3WJ179_MLP7W@=?@JOL.8VQN<^]TI ML=V?NN:!+;$7E]N1M A- I:OWO;]H4' MLI1M>[F]:B^GSH_Z4,?$V)=H/W<:C+T]3?WCG"3'LYQNG[TWVZSK40#!?#;^ MVFOE-KZA:U?EF>7H$;1(, >-D-!_&3SC%I/C5"7N=>^J7^M.VDI;*VU/,K?K MRQ?$''K"HM"7NQK'@#Q?2>9TQS<%&A8_9(Y-8#*T*-$*3A@3#N9(=XRYCYQ2 M18]3@E R\GJ#[K7.X.UZ6UR-%FG3B#J;*I59$>5<**K-F:H1PX5F;CXI/ &S MCMVG D_D*G^/TO9VOZH[@@P)%@.\A%LJ!OJF@<7@JK^A&+SN77>OWFPK"'0= M^%B"D '#PQ'LZSB/%B6QH)L4SJ269H)TF30<+KOU@ 53UR;J*D9QB^K(;]YF M1"D0 ;-%NL'C^ )$BAE(X#8B=B02=;NI8@'5OJ%$75]OIEC<&\5G%B7.'25) MNKI:>G\F8_BUOB'&#_ZG^Z6+%S/>^T*EZO]WXW?HXCU+][B$_ 9 M_=5[^P83,;,P(_IIP[TAWMF2Z%<#1YKA;WH-I;JK:CH8C]*4DU3G97IA+J=T MGQU(.968)3L3>KL^E$22.QG; <_&5RD7=G%/6IU_M5O.FPA,H!DG.7,;^3/!"(Y8 M9%PQ=T]%6T$(^R-%8?RS2,,L"/V<2ZVF2997Y=[5:90<5!J5-E$@W<.5)%Q\ M5^G$L>>#H85WWGXD,BZJT)N-4[*I-).*/I("[_I! F#X0#UH\WSP:3F=1A]B[R?IRREJ#*NPG F5IDO*"MAD&4HD MX)F J@$D/@:YY==,KE3HX MR>]<-M]08L]GJLZ:;RJ"<,Z_&BU4K6M*(C"[/9M@!L'K(,2<[.!-0^[DJXMN M_Q+3*;J]:T48?')3)FDI19^8"OIU$VF6D1L0IY(U.VQB !E#!:*D!M3C.[4 M)K6#-:%1/,]T_!^=2OJGS18L;4!S"*,>[P"WL4X?Y3Z)P=-:>+,DRZB@+I^ MO8Z90 +.Z MWJ\@?&J>!:DVH)A+:Y#?\)E,4;/"5LUEFC%SX06HD^$D_Q/V(7'BNS!%(/"- MT<= 9/64$+$8\YQA_8J8LCYP!!#"*9W+:&?A"A%4B%Y49]%H'XJ(TI!4IM;2 M-7Q\0_HD"U5Z;:'*?M#2%JH\:J'*BYC;(O*+R!P5J+Y<71Y2ZO)]$J'!$DB! MB GL^12Q,H;5,URJQZITM.F M$GL*!WB1\GDP30(9=9375BDKA(.+"^QC^UJ:I=:FY+Y,9:YL=\<3H$,5:Q## MF(]M[36X1L&?13 F(N"DM4<4&?TXZY3Y8#S0W3G3H0<0N8;\40L=T'!6SJ5G MSC68*.YA3"9V184&JY@%;%R$65:@%T".@:I--8>LY6C'V%5DL-)I3L9(Q\7% MX475I?-4WZEM%;"%V"U J:+!X6L\U[3I"Q2517<*KA)[D6PMS]&F &. :][1 M;]1T!AH*A0TYY2&Q$,/7*65GFV! /6($ZS>J3=QYS.4D.J-L8,"D(IF1K<.K M:V9&/FB&DH&IVJ,BI95301PR@U2@2MN=2M0"(D3><\F)[Q>VZ'B4C[&>ZDYA6^E>S;.XGRZEA.2JD2C:]-,ZMN]SJ3^(EFW?+K'M'7N^2C[BT7]RE?:>6]C=>VA/:-I^PA'!C4=>!U,PU!\]'B5_@SM&' ML7+>56&4AR6):6&CHUDRRN>HT>DI&2L8F@R<5G+\$Q S-$!&<.S\JQ#T+Z8* M#(3%O_ETF$T6&=Z+TQ=W(57%X9] X ROS#G02A5+PDQ+0_O!F8JW)V!6B*Q. M@#J<$(3)O*',HM3@#F)82&$TR31-Q@1%(= TSCP.#H&Q&4FTP_DD]N&M]$>$ M<(5=+#LRF+/ 3CE.TM @)LD?X<5PKL//0+O!&8V(A3!S[_79Q_=G;[QLD5$H MD*]*IK,D1B:_7?*CJ4"%AP%-^%CF*0_SVQ<[T%MO#-.IO>O75>]J^$73BWZM MO @DOU"15;2Y@&$!5HIE4]'X\P_O/Y_3 (XPO04.HYKU,+R1SL@,?'WV[EWU M*7@D3>:H_/D%Y^IG4H&W5=ZEKK1^^WS^[N=GL7FQ&K MR@TJMP^]/N_[TRDM.:CJD8V+%% L;>[GF]MO>PAK_SR M>MG=39P',NG Q*+E34-GO>7Z0 M6+=B?71BW;_9$;KAD,3ZD>RN/>R2/OC+3EWE3Y9?O;_4W=YCPP[YZ*1I MK4YD4S:[Z:5EFSX.3(/)>J^^7U2=6T/?U9&"+?$F(L!<99LMKE\%,C3/)_4V M= 2M+:8F'3H264Z5<5WOG6TGE]' P-*$JJ,CIX7;TE7[[)0>)\%5V$O^3U58'"N<'6.E!)(S99-#E-GXQP[G?3G M9'+I!L/)VX)N&WS5DA/!%(*<@:Y0$CALU-EEQU1QQ MDUZJ55,@HQ!^01EZ(#WP/VH7FP*.B8#7^[+(35KJ*$F"I@&PP(FP)XS.6=7F MUY\ T7I([)@[7JC14RPL5P3+^#X$LG!"EFIGUP0RFX6JK-;=WFI[DK"___2_ M'WXZQ[+_BJ;2168K&-@P_;4\K71(3*D$&6:L&.PNJ:J06[55D<*/L$Z_/N/LZ=N*P&YI+ELK37$JW.9X(N\!I#<]-(V YQCR*TC[ DTQN MI71.>E?O:![TAHT'2[V5[%KS $:JG.(K#D(4R::.PQN8%$S.PZV'RTVLAS5- MY4^RCKW?UK'O!RUM'?M.=>POM&\V\#;Z3^=M#)9Y&Z)!$:[4W&2<-'LQ=5]D M6Y+AG$%K1)BZ(2QQ"NAGEF-H0)3L'6,Z9"*R'LU&U3M-UD2EZS1UW@WO5/E7 MHV.C'#15-N(41V+UL+%/K54Z![U(9[$BM='AZC3,8#O?S*VYL?9>\R%WRK:3 MXQ'5/"$P:RJ>4-U?Z2PS[NOELZ7*.^N$+'>4RH9+I^*JK/:+"/*G[O_8E^E= MC+_-6,3_,AJUI&+U;#"&PX6)#LH6EKR6X$D8 MMA!_)+\C,W&92$E/J%S/G7=5[_:1=I4ST!/L*AIQ\V*_ M7XEKOU&5'2W3)VYL"]SB#Y^>7>42OV'Y1F3/U!(&94!THV2.'%)UC9-DGFT) M_O"#Q[,&F5:8+-K0:6HQ;&\)4+4561D#<^A\NN+0>.&J3' [NQ?L>FY;ECE MM,W!$Y0/#BYVJYU;5Y&W6^?!U;1>[UB8VM*ZIBSSYOI@B.UWKP>;%;R>=+%5 M6Y9YQ)6&;5EF6Y;9EF7N75GF43#N); ME!T^EFP]MABVKWR.5YY"X=/7!&/K8X[5E0-,55;VMYMY8_+\_B607PV[.Y9% M/# ]_"4F^[2YUL][LOTAFP%Y& $Y&6:(Q^?@!Q=M0;VJIO-\EKW\Y9K MJ[A&+:_Z;[VFP,CF4Q_1_QV4-?:'022FS*-[&24S3'_86+$TS/G8BAB;IKC? M.K/?&VYY/C2+[I,6(%9>N7%=;2MQ>REQUZW$M1+WG!+7W]9)VC^)>R2K8@\- MJMYN9OO)\NMU[TU#F?61AP*_R B;QW6P[PUU;J:$J6 :QF&6IU3D\Q ']]AT M=-,4]UM'7U^]3"#K.?%=6HG;I[E=#[:U0UN):R7N01)W>?@Z[G@#>SO:H2?+ MK\L'6J$'& *U]0X/N([>-$2P?_JKW^^^3+#P<"Z3-O5*CU1 +KM7K8"T K)* M0%H-TL:UEL6U\#JZ9=H.M]$G%P_\T%C[V(8 #]D]OAK<'KQ[W$K<84G+/.E$+@-V*!-F+SVQQKZ9QI^I^&G B0-'H=) M9+F7"03JR2H30#2N421R \]5Q^NL/<]$PB/P=I=X_=X)L%RF%N6$\#L5AK2 MA1LUP[@MA[';5=0NKP\?%6M9OJYE[Q(H.FC3J$JTU:K.89,H MZ04=A_X:"%CC4L-68)AC%WFJ482C9 XC!V$&KZ01TP6B[5F8-,EH*HKMB MAH94N_\K;$.,NF;DVJ6#VK$4L];.2#2)N^7(&MZ6T1(S1@^#_ZVMT3WL-]8- M8G&JX'*]J\TRCS;;4?7-M./03[^MMMTU]'J67* ;I)L.CFSG&5[6]E5]2VTU M-#4U<$^?E?*^"3<1:BZ51&-I3S6QTP2H8"QUF"[?R@\\N0Y\R_6;KEF;-*Z% ML5V^OYK&*1E=.ZXQKIUKOHQ+AAT/7;?;MI&,%<"\M4FA+:2!SF'P-399_?>I M'$4$?ED=I(+5WD0_R(;>M83[N\6>7"[A)XGF?MFBN>\'+2V:^TYH[B< ?^K> M.7VJW3F]A-9XV*INH 8/UH1HOA]L:,4&A]BK:XW%XR5I^2MKQ3?ZP]C11-0Z M"* ^>#6\T(-R=Q[WF%P"W$KXYB*,+>0]!85,**C9@([O4'9]N\[;EU M^$\5K/I?99Q,X8_'X],^*-_5'D"1UB#[QXH-MH,22&%4!)+QE/77'2\N_$@B M0+N/#1K@72E*'=!4C. ?1:HC*>F2H$P'3-U\ C,=+SJ\#V+<+0X]V ,#3#%0 M"V@4@ZF;3<(9#7,7)M,$S.DB$JGM96';4#RBL.^]#MYP$;F901JB?@+5D&$L M&-4'ZPE03 CN3FCQ' /SR8VHM&J#;T!9A12,>'WV[O.'[.P-(6$GP)GD_(ZT M'S8M%#/Z22GX9='F\PDY3R16>HUAM<,8W)=BRG]DR2B?(_(^]9& 7Q53M (1 M<9YBTS)6CAL#\!M4^5++B3+ZMY5$FCCAYL,AG"9CQ+C/Q'2&_52 -!H'J%;B MA1TCM+!%*,!=/N=_"=,,Q)BZKRS?-2)-P7D@+OWT^SMO6N1T;L!6R*7/'2CQ MU_EB9GPZCUJ8Q,7T#H.4$C'RPUAUJPQ1WK#E#(\"JT>_@!G!>^*Q5.RC5\E\ MLHCX.5C946B]1O0/T66N?.6L5@S2K1Q,&B"3_RJ C2@;K\]^__4++'P.GJU$ M:']PPB>FNQ_^!ALW(, >J@/!-"DL=9@+O%BQ("NH@X-9:SS#G7W,??,,(ROR MHP5 KW<$7BBM*3-H02R@>!.%SK(L\4,*.5!;$T,E; @\0^E>1$8S^""E9@;8 M$R55LKS .!C(8,"+7=)\EBI#-N\BH!A8%L[,Y-$E!]\^0[AZ$%O"/N_H"W%+TJR6DTL+ MG&_FP?;UJ,. !PN$,8HQ,!,[ZP A05J,%9\+;/SP;UF>M=H0D@?43#3<@F5, M%;.,DF_B5)@U\ (#']3DA0=7*U%5<2!8.6XYYP7S)/TVBI)YQK9@0X,/.[*1 MJG Z+>($Q"Y/J'M,ANV$7I]]^*_W9V\Z%&T)\\*;+.Y24(S_9KF%K[_\%WX- M/P JOB\BU:E!)C Q^/J__A.4R=N?@?49-D/11R%V*,+[/OTA]ADL4NQS@^TV M4-A]Q/B_2ZBSC6HII=0 4#\5?R8U 5 GIR395\U4++P[Z=$RN1L,.,]' 77XB,)O:-O" W>PMT:A"F<+GC7V MR&)]84X(D)-?PA'.'O5MTU'ORHG0VXI8H0\-)@K%!(3_#E;(MH-"2?#\1JRPMJM0W3^JQ#4 M1X4LIL3IQ 6S*BL6/H_46>-]T<<3'8GP&]012.\8AX0%R3GPAV_D=_#?.38W M#4%WDX#(&*.D\ *_ "U!W5Q&*('2.<(,15K!H_;)IW^R7:P#>O(4( TP()M6 K(;%H>6S;5+4*M! M4F" M4FO'FD1\'8\V.\JX5[G8G"S6YWP5FS8\]+U5JR/3JS[O5:L6[$^+K$> M[HKI<$A"?;P@!OT6]&$K?MTVX+X>&]Y#-06[GD5I,^&K%04&%**A(O&7Y26T MF()#(TT$YI#1W8F(HB:0AR2NUN8E(T\=K+7RR%HV/^8T96(JDK_*9)R*V01%#1.2JNG^[N145NN[*8SB8WHF)H7%2;5@L;.L)OKG(DUF M5I89)P!$HKU$0!_K1<3JDK5/7C-H6P60KM'/#I]Y_^]\-/ MY[VAJ6&%%5I0(F M:8A3_:!7LZ-9J06'*U+6I[5I;E3K2QMGI7B4V=%KC"&:7#GI5'=,60+JO'[, M1/XG*M >=OM7+P:+\$'I/17!?\XQ!9^Y"QS#G$LK MU" 4@I*G9\FL4-GV.C.2I,4M>LF\K,#\2&!30HG3DG7P; *"SQ46NAAC#T3_ M8"P#$"U[BMTNLPQN-[ ,8*0=+8/+9LL@6P964[4"VD)]MU!_T!;J[P]$-Y@JY$JSD=_M?,A&F 5XVN MBJ2MA;/:*['/+:_P6E*FNH$AZQCO6.J3B7G]O;@T:^QW:U-A38DJ,RR5Y2XW MS?FQ)JM\ \UE/R\G;,2YGPM"6_4G%3U=YF&+NEAGG%SG\: MF=S,,F:K6!G%F29T.UNXB"=21/ED\:Q6\:$;P1^3Y!LR$R1A+K">$EF8%.,) MZ1 )_S])TIQ]$]Z25..UW)_2*!'&'U,PGR%Z6*,1UKTR&)0<]:[TA;PE326\1@E>JGAOH86+"^!ZHPR?E=V"R06"$ M&6$5'OR%([@59:JJ3ONGIL*SZ_U3:N>-35ZLAS.DEE5\B:2,2U55_:DM&144 M1_8^_?;[AR\=[_-/YQ][6$F,]=Q(PQ?P17_Y\.6_2O,9*]]1QF-4M7AVX>"E M0G6SRY+85\$09WX=&ISV_/(B['KQM>6(2\X=L"" I9-!U_N-MS*XS'STKO+Z M'4?+Q3;4E?U5U15 M.P72(_B*:B>!\E_ E\+S_%L';$W8CC!'(Z@4,= ^#U,..Q!D89IP[ "G/75Y M09)#VZ!9,I=A6+ D2OF-:BM)?%F2U,L]0L.CQZF\&J0IQZ@$%POKJFLEAG75 M=G35D Q5_!LCXB$/+$S>;^56;]MJZ0OWB#]8C8\G,FB>B,]55;TY2>;99I&^ M'Q38(&Q" [2HC.PFX")S%W(/:JG(R";A[4O6B?WT=D?1?.%ZU.&P>W7=V[$< M]?KB\@G*)F\N;Y^D$G'0TGH@M&(YZNVN!#T[L?UN_WJSVMF3+C)KRU&/N,*R M+4=MRU';FPQ M;%_Y'*\\A8*OKTF..(E.\XBEVV)5-_!-^SSN7^+\56_K;N"/TPWQ)2;[M%GF M1RH@@^Z.97"M@)R&@%QW7Z:?ZO$)R-'5J;R^?./-9GFM*7S+M95AR'^G NE3;U M38]60/JM@+0"LDI 7N;:X?@$Y.BB6TU&19FTS#:NM$ MY_NK4X:"",L*^^ZR!FV7& #DR M]4;A=XG2E.55B!_$[(&!XV($XQ4I(5"M0]YI0I6.DCF\1\&?XYOS5-S+B-]9 MF8!E11WE+[-X:B#IW0$+2 OD@-7H6L@@W5J[ MBX2723]!A#P7P6@) _.)R#6/Q@2H1EZ'>FTF(I"U^R0JI@_ OKZ\/F@D'-HH MR_*$+;"-%9FABQRY:L]L,ZBSV-FDR(-D;I"J% H7K)<[AH+"4G)40K@.P@R& MQ;]$NN"7@?B 2*%H^U%!F&?EW;&>5 ?B\ZK,@.4[I0S73UN#IZGE643V!8Y6 MF,$>3JE[P0\9B/>_BI#QK;*.EMPY;%<&&[H7:E/22!C<'2;#K MMEQL&\<08:# 507B2#(:I7G0+B.#8$K"!M1"-ZY8)TCVDMJJ$Y&IPBKVXT-HP'IKL),#0? MH-C11-3ZD.&6>-6_UN-T&[P'XUC7?5D^N;@5#D4"&HY> N0%ESA>>;XY 0%S M$J]B1:D;#+*BUW=Y<;.2%['%S:WFQU)4J3W]9NZTU$W0C-4L/;\W&1SR\ MP^!O9^MU9J]_<[;-VYY;?[X;AQ$RZ#TR^:.X.R',>)3*ZO0MEC=2Q%C"\'T( M>R^";PFK.P3G2T%R@XOCPUXJIG@L*M];IO>A+QVL]8XRFT/T C-@!&\@!FV7 M!NW<2XH<-RHX;+]A,$V!;UN$=?@];+0@0:3P CRLJ.--I8A1#^AI^,A%PN\F M4HK9#':3A5-/Y5BD0<3],7#T,(5]B5$[#LL4L'5PB_J3!*< ._>+ 1=/$9R0 ME8@_D0AN;]"YZ3WXAT(/I^ES'&*4SQ%F?"(C0O6&!X!?,:+GESG;]?ZO7)@8 MHR]R.::>9(0 [W"8?6'I_?J>7O#Q/0;YBRE&5S(QG5&<4H(B8?M>C8>='X@' M+N4=%7V*$!P>R(ZDKZ.4IBG:PN6.GB5ZOFJ.FIHL!]55S#I6O>+BP!*%L8;H M1]49A=2D @>"1>U8]J #ICE7:N0F,M2#(.F@[PR(.O$CRMG#-ORF:"GRV6I: M(UD:&)ZZ0GCOF1?JEW9(8C%L@#@@6<;C1H2P%5E\VR$J-RWFPYM03!=])TU; +^.Q? M!<@.C?3LC2Z&>V3J_0[+HCI[[BNX.+AAW0MVQ79 %Q_TEW^].PKV]?#J28"E M6UH/A59$%^]O!MB]!\3VN]>#88LNWJ*+M^CB+;KX)LQJT<5;=/'G 1>1?1/T]6< [S\PL6AYLU7YE8YFQ E=P*[@ M4?ODTS_9+M8!/=DNU@$]>0I5J-RH(J9>V^70]X95/64+^Q).PB I,";>=!0> M:?76=CS8\_*NSO#B8K<"KZW8L.67VW?+,.YM/6LW579.:V_6\7Y(47@)? M%6E*Q473Y%ZJ=*,DY?$F FMLZ79,1%&IR)5K2S"/J5>KK5WZSE\E5C/.)BAL MT:)CZ,=$5UWE@FE,[Z98"XS979C8))I>X=)BIL!$=1P^]-T2M9^+-)G)%8,N M';)2R^D,>),NO*@ 0<.2J@(+8:,01&]!);+Q>2"GI;117I,, M_-N(4^OT-SJ-U,PXE3[*,!*N) Q^ 9H/GHA&FM=8B(J9A(;B2-SA%@.1B;M8 MQ5'F*@Q$3#"E4<#W/.5Z*YTP:#:J\#DS&]F9RC&EB1(+,B2/0\N<[)Y/B"E) MD=-R@FA,$R ;V3$5?\+&E#&6@:??)"9K4MKK1*13X?<^CNX\ 3U<*A2X75T6T%VOAF&XC=1P$]K#DG>^ MD5(4HF9N? +3657YU;J)TS%HE/2D28BB!98KH " MK9*:2QO:36$V"=TKC@[+ZE+!_N.>(E?+3Y&KK0:MG".]BW4'27U5UQPDR[/T MQ5QM^>I2PJM1K+[)15FYJ-[/BIM!*,8QZ*_05PNE:^KY^95K (0XF M\M/_S][;/[61*VV@_XJ+FWM/4H78^=!\9<^;*C:0'+8"9!.R.>27+E##Z%3L3@#8N3+G@'/V? @ ! MEE;[$&BJI0N!T,Q^B+;$NWG##9B8%;SF6CLU2H>4^[A2]!?F$OCD)7#_"2Z! M3UN'=;_OJPBB#M45282:FCGAL$V8_^!7?U?VJA]L31 C2OQ7 <]Y?E5,W\E* MQ/J7OG4JW09]#U?[.M-NU%89!H2W4:$<1?R^_$O]C^$MN+0P=JSU_1[/O]LE MC$VYAV+&:N[WX/T>SW+-_1YSO\?<[S'W>\S]'G._9W7N]VR$X)[B_LYF",[< MSVG=5:DRR"6C(!NR>>ZO+$NWEJV&YI6/\=MGK%Y9F^,^_1^W;1K%=.FN-IXZ2WJ.RRG@^]"('%+/UBC<$;AC,(9A9NE M:UYSU6-R&Y+!:+(BF>7#IS> M?=1D -N*I5->09Y!\]EZ MD[R0='6R^;=N%3T<,'CEMFQVKP8ENTTWFS[K MQN"\U;99\E:R_BAER7#4Y'QLDDJ5O"4[G9/SO!"MWLJ*B!'&B71**;:5CJ\[ M3/90F$*]I_I\3[#WC8EAMH ;;'"37&\5A]YT;K76*ZZ40!0#)8SX'!8;92W9 M*B^Q][= G"%_F.27 ^O,DDP.7$U:2VIB?2KQ:%(73:%UEM5\<&V1PUR1 M64PHJI?9TO^,$8\DX,15F"IY/8\KD(IZD_X'[)^M2/"D\K29]/Y?(@OYED!"R[-%I14/I-G0R2813;*VUX]C2WY%H.;^=#Z65P1\MVJM2@A M5>^C^'-9]Q9IZ9DIP&%-"L\>XR7WZ&V$2<]!W^CYX(SULU],42_K;55^@I1^65&H M&]AR: W3P6O8,XU&;\#2)''7S9"9< 82+RB&&8S<-]G:0L^78];CTX)N&%9> M'7!6/U!9MM%@MB5M2V)4_9!Y3;KT)\KY%K.ER3K3?8ET)B/P"I T/JEACY]3 MS^$[W;Q_E;^7OM/%((/'PJA+!9+DIQ5%;L55?YYUA3(X',F$JZ2<.ZFZ-VU@ MLZUP>P[;NT$2TWB@;[&TEBB007;\Z4T*9P5"=W$N-8'IS0XF3%]2!G3243?- MNEVY_]7>),I2[?WU+Q[!+'0(2S"O]-KUVT'LM$<3.UPATLOFR<+QY,G"4F=[ M/X!Q[9VGPY?I!S!3NFN $;R@=DET @K;(!^?"C=($LPF.,L1!U[X5OF<-<>D MFZ37XL1'Z85!4WK.S>U*PAO$9[O1#?+;0-!J68AA2IYD2@YF,R7C<#/^?UN9 MX]$H8;YG^933-/7#D-DT=..(T"X ^S(KW>EKE(!A_!_J"Z /1!4IWAE>C" 'LPFW-$N\H'LC5 .N"\$ ME[-6_]G>:QMM@^K8=!O6+I=-""Y N;GJ033"H#<&I2C% M)Y,"0ST+\"K D"]T2)TA6&,;( A?5>,9V&VYB(?;C8UKND ZK"AR@(1AN7VB M[!I[7-7\8XKN.;;C.=%#1HLP%FV(O['1 E67')OR1;":ANS+TKZMG-*0$"Y&(05^V7$#/I1AUAQ--O2YT M)PWY<*FIS98>H(_9$!46-1_]".6%Z%1!]9 >NU8#RU7KCUIYX'=IA=EJ"%/< MCC7GJ]\'D>4@0WAOUAMU1P58]UE6Z(Y@TH=&X7%]*G3=Z&:F\M,7V'4-Y5U* M5'8U.Y1Y6'W0\67G\XYJT/&4^OPV'X!C?ID-8(Z[&=^&?0:0-5566HGALTA& M ]3 75"2EUMO=S_M?\:_;[V2PA!]I>(PWQOF\N"KAL=V8$3J<(C]Q+,'F(J< MR1ER]K(T%7)^H)B@I[C,LKD>6-XX ME[3NEO>4*RK!H%R@QN0:(M#'IS"#T;! B97Z"*C/)19)VVGT5]ZG+]\RU^GI\/]&XV87 #0_,[0-V-]1 MJ)%7YQW2FWU2;,)T+KJ\,CV]?4OKTQWLRER]AB@V*%$J85CZ@,X: Q1B&G*K MG\."JC9-XWYA$^'.1F"5N:R.T/%6@6D2\..DPS :@C?\"VT?#R#$4+;)3$=] MZ7[*$Q+8"%7_+-%'FX;7@_.+PX:W=OD5SDE.&B;*+EG654<1Y>%^4B=P=&'& M$+^)GJO@*W 4\70Z!\('KVM;!2G@=JC,7(;9)$R?@:3!]QLRV8MM"%"KE@1= M:JUT59O/CNS#I7MUR;5H./?@IE]*S25]<98/M18-8. L44L#NY]4EJNL _U M\P@6J?DYQ".XI\)(I7/)!089N#-<# 2NM\[PRW=7*G9S -0,,#!H&&1Z*+7B M8A%(/EB%PZH'U9"9J8+I.G,$0GZ+"_Q1N3XRRJB/<795\5*V(DF#I[.MH\H0 M&G*J#Z18)2?ISKZ(G'H/+?/TDWNIU?A6]=PR,8V:B]]II*3'OA-*O+U@X'&- M[2A!E7SN /!B@G?4. _6)4GHH%ZJ@@_X\=F ]:HSA>WQP3+X _ MJ#8/)N/M*RW%?G\D0V[=Z:N *)A4_\C4VO*\+UJ+I*98*P@^"=^O>XQ!'*&U M8FR17']21UJEAE@BD6-;+X1RG061*^"X]2]+'UEOXQ)GL6\E? \S*-VN4*AX M@=UA!S(%4"^K&F*AQRA'+E?8B\;6L%I<9W)QW^E*NFO9(4=,[9"C+4!W4MO6 M2:ZA7C2I$BKN1K0=.DT*7^J%P.PJ'R0!I&S]7(DWR _=2'HF$[4XK?1NSJQ>.[\^R(-AO MP"_5\E85HO"N_O6_"CVT$DU@+)]AL@QF)+9K5[TU$MN?M)>#$F/1+5'G@645 M+\@*?6?5=!TEG+)LH%NXPN/0Y9&%Q)>P6KTJ9'/"^JAQVL/[STNBN)\-.3Y5163%# @0G$5A6@1M0VL(R_4(Y46FI6KHE$ ME/%]%T+W6A]MEVK4^?&[80YGOWIZ> B]$/P,!]?-A&=/I MC2]K&*0^DP:(>]L<;-J0[&S!-D0JRVYN$NJTG;@YB78J?VSXF^Z+S_(H;4]6 M==26VM@'62(SP8BFB8! "]VB,<[,M,A?3)_7#*P]T)Z:F'AU.\V(/J>7*6L*F>JXKH MTHA!]R.WTQ16"Q2CH#,ALOK'K6^&$Q)6&\?MQHNSNA(-9$'@KB711>"6R9>> M$"KK4C4 EX=_X\S38F M*6!W;"<0Y=+D?LCVVR:L>:_\_5]._NFFO]HAV4 QG(F3SKM#QKTXDKQG.L5;H,_3J; M!JW@K;I5(#_<]B*KD^7471C>?)7-%5WGQD4]&F M?+L0L@*\_CX^]84W+6%42:/657AF>2+7S!$U,T-2_9U:]UL94J<.;V G[ZI; ML8TUF9*5>7HK>+(JVSGA7%U M*''.!ES=/AH(Z?AWSID^:+V41W/%.9/T!!40EXGPEPCW6_+9DY]NO5+ADOQX MYB/8:'B>#V!2JKBV^AS&,[I0H=2.33OQ6,U0WNMABE4N.AN.G5[4UZBJ,@]] MWJIKPX_P0B_F_U06&'>>:J13QEB&I[H2H_DV50JO_AD$!5%,EF9)IS^2C\?= M#R>NT]?YJ,M5N6 L!-8L%1\QQ1O+9H PPM#T5U M =?%A1B&C1^=^SM5ZK\O#-B75]YK5YQTV11$HF=T:! M/HSI=B2(IB(!Q.L%R =]RF:B 5:S?P;>IU0(Y%U 2Q#=K =[YQ#30EV5*AD[ M;\V*8E0F.=K*T40!T;OHYM="U(>)576$KHRH\&G:H.="IL"[,S))_@)P \#A M3[.?N!186=A7%J)N/-PT.IZ+8AF@A+<78E%C$2[0'* T/R9%-V*2;9#HW^>+71M#'=6!![%V3TO$61<35P[Z%]GP5=Q;WR MEM:S$,Z-HKASX<'8?3=UDED[#'B&V3BE51%V5(?8FHHEXV7JND;&YAEM4[O' M3PL:6YH:J1UN5QD4+I*NC*)8YW\C-@!$Q7RY'JT6 MU!SK"Y(: MV&IR456Z:@9#6SOHS-S@9"G<3)ZD:&'";@7N"%E>J"5=:'.0[U M@6-9QBGK5I3_PP#,*WI M1@Q T=J);G7?XGPPR*^$S(2%K6T&"T(!C5]$]J3;*,8'=HN/UO2DT5D##UV] M6%69-C:J&][0P9UJ=W0&>J.>'\Q7JZ!3Z^*IMSU@/S[(:GFH^&!+$ M>7EOP)$-52MP50Q4[_)'E)^)'*WF/@M5;GB2A+2O3Y>]ON(4G M=^G6)XX]6T-!>W*YH\TI@X%(P24X%[Q97%]?GY*2J8_#9@[SN->N!C'@7P",*YK%+BOD!+IHWP-U M(0YKC]4*@I^E+DQCT*ORD)%VMQ208E_"N"H;J8K):Z56!1U[WCW06) M*4QY?L,REIZJ$#<_2RVLZZNB/T46@)YLIO+VW4PF(RKY)."? J8.&]2[8\#( MYP];%_'"EK*KK=8>#[ZY&,C=Z2.#!=D@\H2R-%9FZ"NK+;#V*)/HQLJ;!)4( M+E $98R_K1%$66S34#&E@RDR4=&.U7OT=G.;@"1._+;.DE5[!,:[K? <_= :EG$0S7E@H8ONQM*H M ICBO]T\MYOVWY7()JW2D>R'O'^F\&5/Q,,E;$.KO)_=N'N!?CB=S^H:R!'" MR.;KRFW'49_%Q;"9O%.1JS.V!>#FQ25PS]Z)Y)U!JW4SHG5AZ.66%'_SW^H3 MZ;$/M#NG7SOL1-%.:/V_>DO(!A,O5X_1/\7X5N*3C&];(*$PPE'75&)5,JUQ M$$]3],%/"8GN#DA)YB81-'MEL;'^05;?)FG?ULVU_Z]?6<:;^,KV8,I/\'Y= M5<.-7ZNN,$D E.>"8P^5J^0^UUM,NCZP\^>H>ZW5=?JN5MN\85R=TJYT MWK@UMI)!0FM]F1B>>(3*_3LJ"R!D\OJL+^]LLOKZW9FZ=XXWGD:]D:I_5V>[ M:,P#<8XW3"^K6[ ONWE1O"HOJ18P.9G0[H%+*I\L;VIK(6BF^ YR,2E&E"P5 M=2@W)@8UT]ICD -3XJL?/W&%?,::@7%.O]?VP"<.$:WO4T?AW5L;ZC*N"0*R_^:9R-KG::I0=L4 M$G5]&GM5??V.M,IQ0= M-M 2_RY&Z]YFM/XLH_5O,UK?N:/13IT>O&].R[7N:+CJI,=Q^BKI47L6\I_F ML=W&$9=>DV 5+/=IG=!W(AY(0%0J.NF(GH,;@U[G%1MPB-VQ;0#V@V/7:F5_ M4]?M1C%77! MU)_C+=%;BN;PEK1%*?8&>>U"H?IDP@M]&UG0*RFSS@4_$_=(&/J-6N&9^4*Y M\>>$;.U3O=7L0 MTDH,HO/O=.5O6DOSE-56J^SE+E@"<)RFG3]85Y;%?3Y'^K7=9L NCR81YI]' MQ7;5RZ+F=,?,0MDI);Y6?7$TZ])VI\"]#K2XYFV.%;]='XQOT$-RZOY9CMM4 MH\NCOAC6:CXT_J"LT-TAT^X(N9+5+QO;FFJLU1&ZETUY0U"V]E+D5-)=B-72 M-OFSAOI"G>S74';ZJ5L8C'%IR?8'.YT/L@-#H]F*;KF0J4[0UQ7!O:*RJIN/ M84/FL:&4/'_R7Q6_GZKN*S85JB )_K$7>["9N2HHFRT#KI@=O MZPK 9P8?E:M>3/1X14-L\<*QQFW?"EAJ H06 &3]9MLX^%2W*MN>2M$*,^Z* MJKU%1;<),V1GNDZ_[&VK[ZNA<\%^-AI4E!NR+$@LF[-MMRBWTUF=],I@J-OJ M_%AV;QF4G1_5-07IGJ@Z[@(+7Y%_ 5WZ/NM>_U)W(> UWT?]1D FK?^9M-"X MF5JEV4"Q,U1NV*B'#,B_A.(25*T29JW4S#@(X^(RBFXJ,5)L_93$Y45UP5'= MF51K-=%/2Z,_+"U"_TO<=Y237+QZ?;/$%UXGU8B=#/.+UPIBM4#*U#IV'R9H M&^RB$*_+O_S.L^*BRZY?9WTI8/FCW_6S=#X>$]"P \H6EEH3Y!#5QSHW#8XZ ME17C_QX.X/]Y^6*=N=Z1F>O?AGSR,^KO^!&=^;&U8\_\[*;'VO8.M69_?--C M;_[,L ^TL__;EN*0J_BA*A?+^T)B# :F%<[PW.7QF&NFN3U9XGC%@R)6?(#+S;W.=$C3A(ATO3W&Z30 M%>G$_OLP,KC=[[+*.V_E%:>2$!E]8GCP"/U2\&EU=%F,\)*EF%29V\2AW15T M9D :'>E0=;O[->0_PE2LU<8_:8ZS1RQ8 ?KJ@(&X HUOM M#.#'-7I7:G0RW[Y8]7**6"E=V"LQKUCME[7HKHP6YZ/L+*U'*\YTUF: M@%;;7'V/WNO 9PD26H_C36,KS]Y6[-"8BC$58RH/7A)C+,58RG.QE&54W3RA MOY59Y?7DWN'$Z4YW\NR_.K:Z1/<8U3J5/5B*I9 M4G21]Q5/$=XF9I(04J@>&]7- CF148$$')>ZKS6N0P!?:#3%KKI1& ^:!["(E;^L*T!;L!%(1(.AV MR&I]RD'W8-#G,)=SP:IF4%QT,_A4M9W2!$ L1F*!^NKIQ4#(GE9E8YAVYQG5 M"TOTIX\,!U.+4?9@DZW?D7+@6@Q5"WC-QE%/FH&&O,E>"UV*[LG9J<"S[J"G4KFW&TKTE!5003+0X)1:-P,4#: M%WE%:= KIZBHERZZ+,'!@UYI[@3\VJB;2G:8O!B6JS*MD$UJ1'V!'">:]:N^ M78]P]?I9$FG:ZT.DN;I[@*K._%@J=6-+J$F]GF)U90R=SWO;.4S M2TFWFMPO#98WA!R EA0P0!WG52!>01#@Y?4%N@+=:PG1 #@:=.H'J3UGGJ?) M5R(C"J IZZI68:HQ:"Y'7(Y,HBAR74C>%ODZ>0M_XN>23 *^QQI\=;)KJ1 E M,4N!W9,'$X!4][LOD$Y#;5#8/U,]3/,;*)$AVXMJ8:DGHC<&23^%#X)!_ZMH M#4 W%8Q%FLL.S?J+2Z;]0%HI/V\ M3^1_<)'"6-!L^O"W\M&29D;]!#;B(6F\NR!G82_YM:R!R MIVM\!\T]ZUV@0LMGX12TM[G3V9?L77A)&?LWVIIC'-S&K*N[L;I6V?SI2BBU M+[VU=IO18;-NHB3 ;8I(P9)FL0*G]2Q#R!.]BVY^C7!6-3-TRWYZVQU:M=:# MWWKU?V"W^.JG_RK*[GS54_']HE\HK.(C47)=RE484\5R-4IG$**(7^(>Y%7K M8;ZW[[^RT2]JR0 ;">9I2MHT-2WN^ALZ"^+23?G CC9=Q(LZ8_T;N 8W7%0/ M2^"DX\'IVKD0]]*:4"R%GGL7BB77WW'#N['RW,BMX^Y$X<,0 3EFL.LU6-=0 M+)T9BB5#L60HE@S%TOU/VCXWJ,P-=])#S7_S3ULWI?C */.:*[.];95M(HPJ M&U5>9U4VN&R4>6.4V=YV5Q:7G\.E5#RD$H,$$_$7[$+,S@ELY@VLP) GK?@* M/?D=.;-,9IG,,JW8C=.5WE,/QEIL/C/R)#\R="^KO4*VLRC%AEFBQS:BP*S0 M:J^0;3_A$CV'T+3F2\+N>,\L,'UR1\WXTW/E#\P"K?8"^8OR$)@5>N05HHN& M"R8:78PHO^I:VQ6LF"SGV' W[:ZL2E;;!%=?/^ M&4$JH$XW8W'6S20ISDW\#\AO,I4 HI/UD^Z(B\X+UW$KYA[\.OQ#6/Z#9'^[ M4"PER-+4X'JJQP)/RGL"3R";P]KI=(Y332ZDV?"V.R_L**I>UGC8J%^2D^!3 M2DJT+SJ\]B>ZE*"D)-<>*R*2. MX)?$SXMLH A8D*X%E)4-1T-)BMC->MFPY&88P&?X$C;B,(-"#(==27FAF P' MH@K3.JI'W"E>BYCJ;T_ S_G]; MF>/1*&&^9_F4TS3UPY#9-'3CB'+&'![\8[ONUEPF_N#F/'IKSP5#TE+X& MNSM-1J3FGP_,TB2?.(TB9?J0_QJ!NDK507I+,#OXAV[YWWM9D73S8@0VU]F- MD4;MD U^B&'G4U;\6 !QUYTN1:,,V%]>*&1#CC88: ? 9B#ZR35\IDR^@^#3 M&8!\T+81( -,L664K NC*E!N8;,F["!9A<2,.7'FHRS *M5-%9-(P0YY)(O M#KZ=52_'3W(-$DS!20K(6_)&E2/4?)O%*"XRGB&A:R'Q\USP,_P%TK5V$E:< M=])N?G7/ER%/Z)F>,,H*GHMD8!<2/UHPER'EU27RQ2A2.RED'(KD!9LBU**# M^ 5@#,O*SA0W*5)78>WI!7Q'D"NDTHI9D4GN5OA!,<0'G,&PAEE7,MR WY-= M*B5/88Y]>0\DZ\,71WIEU$:*L]#+'^A>- MB=8*CU%^ M<0AKA@/4_RAEH-P$M2JW+HJD.\/=?Z186''SD2MT,1J@9>)RYWJG'"IRWIJ> M49/:5NR,^"S6[6[C=GF1#^36N:UIT%@"W]6[&JA4(J;,6E))7BG12=W#"=7 M4*EN@Z(R+^D-)1T>:+,:8"7&7GY94?N"?Y+U+I#[4=$G*L)<_+O<<9FTN$VG M^[K9=T:S4$?\Z/6<@4_@W MCDK!KC416Y]+946&*<7!5WZTTSGHUQ!>TUT68M)&&J]7#^Q<9B (^,%ECNK< MS12_MESN2B/D=BOUK*%CBR(99#&HO"*O'N8:,N4^4+T#%7&< MQM-SFL2 BA-:B@K'C1[Z=L?3W1MN^A[$(SA7SYWCJZ&B'RV744I(,3PBF]= MTW#GDK6["T"8LLM\(+U^(0D7\:FEUST=A1M[":PXV'4?EPW)LE%@&%B,NI65 M >B(_AF2=:E-HR\#&:R^VVGR&?I!(KKZG8N[") MJVT;AR&I;/\W I,!O6PIKF;)1/K.7&]X. :(C"21I/X.:H8B$)??5O2WQ93( M8>F8]BS9O1W#[GT'MQ^T$DREAQ@*@;2,="\1J %'N]?@Y:"G/NJA@;#.^?4% M>L:*$M:VVI@'/J[ !@:E\39M=\SV=(A=.FD-7$=W:987.(;V@.BWY(]4.D4: M9SD9$'F6J.2-SF_ B%O34AM2TU.1V0_TYR2].*OI34M85K$/S$+F%^73:^^N M-*1M#;^J64.UJV_+'(<2&.([[+\#<8[K<"G*!!52X%9[Z[/VB'28*AWY1JR: ME;?RJBBJR=_;RPI8,H#R6$!@IC)E]4_T13YT0-!IUHO9S27)\A 6\B=N@%)M M2^W$7B$2Z =E\XWJ:5>B;&NA&HO@NFVKU4/O_!+"Q=+A4C%F<0Z>>9F.O(1' M:+>K9+.7[3]X(_3@(AZ.>PZH(9/.>SW\EGP:#2^D=)2^@_;R,G>I/'*9_(*Y M:57NG\E!Q:*;B0\Q 2PWW\V"O:URYS)!$S6JZ"_C%SS&VV@K:URGL;W>Q#?SYWM^RV2 M?/>W5M5C?/)\?[@FZ?YWE>?UN72L&AW)Y'^SP75GCPW9NC)U!U9P%Z;NR-J) MPKM1--]&_#P?0_,B@_5WK-!;)N_S:M6&3.>G/0"L_ZD;Z]6QQ#2-?L8DOA\! MCZ>1]H[M?ZZRS66)9HZOSD5:UGK.(]U1@Q$]&079+7K\>@Y%OON%D V[[C>E M0NJ1+F@H#6IL@OKW!+\,6'US@5&:/IA0U,"Y2'*53WFM@@[X%@R'K4&=X,37G4_41WJZ?>/,0SVI5&LK)3W^N\/G"C@E!CX?0U.\ M8%GP:9RQ55_N\";X?-LZK#M0AW5W!-+.VF-HN 0,-2[H,S$J+S0NZ#-9;H^. M86B[82D;;I8OB=-=]_'K ]?UGH0=&8?>H-,\FN+-TA3CT&_:YY0Z=K4LG&EN;5%-\V MGN=S6>YHZ\U1KF^_S%'?97POHU&W:Y3O&-_K>2RWXX>2RP0OHW:O.Y]'O1[6 M,;\<]24)CN"OC--AE&@>);)M]R;0N!NAV;.\=4)7[<;QY^.7/SX?=P:?#>>Y=M>8U0XAS?/C8:J@98?[(D;<'8NZ];" @I![H:R_# M//EQGG#?C)Y->V.UQ\?3C'FOPID>[(] M2M97?'$JZS#S:I#LZHE4*N"7#P=Y5Y)P-+ZNZG%A1WL$1K#'QS(IJ_*^L78F M-).&IH/1E_3KD$7S)G4*/,*]1:T4&Y">!+^,SI>/0P9M]'=M[ MR5Z]=%YU7N(]M9)T$@:;BH%FDF)%I[%4,T@.:IF7BZB(*R7AUKA:Z>7^5Z'N MQTH*HZ;=U8\=E'8W0R6VZZOLR2"35W,[HD#_)0/-E 0[3W4Y<;J530 -D=AS MIOB W@U83USE@Q\//.@;A]AY"3;FOBJ)!^+KQ7R_SY^-5B%_+7#$(/%'5$KG:=;4UK=HN] MM&U-LE@!1A4(I7BK'+EK\?)YMUO3CFA^V$*]89)II%P&;6>+P&E%4()XW: > M*R%\B0 I&1?S/K(3(/Q*BC]6WV?1Y%7(KJ@(LR2+%<27%YHY2U)6];/J$$+M M0CUX9<)V.KN(/-F4!2F%@@R+2&8H^$T"5@PO:KZ#?2SM9ZTE<>.\=XL.SXID5!3*?C"[WG%*3HY;D;>-!XIOAFM* MG'Y?,A%VKLXS0+ALV/;#5+/%DBBP@L_;?E:RZ"EBH+SDO)+(![,8@C[$O"V?*1??B@HFJ:[\F:LE]:Z6$U8YA^ M>=&U/W\(/CV0B785MW(E0<4VFA6*9!E=JJ)T!*I\0"/NM(/?BSF<-="7>IM.$%I-NC!SZMKOQ6[LK[_6X)7 _>/D=@(U4WG M@UZV?"0(]#Z^W3W^XY7BX!XC#8Y17>K[QO)MVAG?954V?UF#*'(RZ.AJ&64K.XT88\;G^/7YCO^00;$05 MY2/EI&9#9H.R15KIVH/(5XD*?)3@TM;*-&M90(/['+2A$JV25^?D/"^:GVIE MJ%BE+[I,R5C3B*GE4Z_"O@^QI .OND<(R28VD.]FDDS_ZEQ4O1WFL*X!;HXJ MQJR<<5SJ\BO;U0/+UA&# 0 6LM\-8%B:+4Y_Y2Z^^Q4K&I'!S,#@23@8GTC5 MCFOM*BEP;UW("N^UWJB +D\$ET2>,JN$^TM%$U[,7/*Y7SJ7;LP8#ZJ[VCFX M CHT"SFNG)G!>B<(KV=@614U ML6[.(CGB&YTG=#A[ZQS5'J=7@ZD0MQR-3B%6),C3(ND1;C\R]]AHY +#EG3. MJ/E<PD'.B5+'*TU:D]0VBURO!?DBW1_R$K5AWL,#U5J^?D#X7*&#E+50MVF]W MH%J\G&I8R)$HB2QG+GQ#I27]I:(5;2BL7$&Y(J"3N-/W10)/QN*!4N^R03+J MH?@2W3&CQ?+9V%_@L:C9DDN\ OVX\MX;V9:%,'+U(''! &9/@&IE50+_0[-7 M46J.ER!6[R1CSO8")H_<]5*ABT*;EFYRH;5QJ@/21MZ!*+O,7#I9I@F0F.Y7(4<.,L9$7>H/X=9D<;(@;UI=13_<>H4,9G#D*..B@7*H M*0*SS+//'IYE]8JW:M4K*X=:\T#!/8R^/'F1WF2P4=3;'+G7=J<$X&P$4#)H'/W5S@ ME>NM1PLZMV\Q"8\#2;!>F#\"K7.*&DZFK@]$!SF,'6&+=54O,8E$6(K2 M"$W+#:(YE1N.L=/TX2I:U3'V4YZASS@993]$7S4-NSK/NW4?#E0)D.\VIHD: MBZ*CK.E6(PUE6WL3JM5$H?PJ,;$D4Q^05]TA9ZIK7I^Y:NW>4(B>OHI?JC;4 M)^QGYV,99JVU"&X]^Z_:095G__X=S_[/9:-$'3HVN]%BF#^KPS> T N'6G4' M\JEE/[*OB=945:+23*[*(UO%RG72O?E4= MKLN%1Z_FJ4JWU6)6G MKP,A>7@%HQ\(<$#[LG^@:B4N(Q0I$VQ=J=\U]G1YVTD.\"H?='E[.N<2,/NC M7JSZ!:IB.!Q1N3\ID%+]R6>,<:'Q-(*ANE/-C"[MLSNTW[$/^^PV['J>90]Z M;#JJMG[5"UBV;&RT%=7CJ3-T9;&T'K7T87C=3(X-,.^O3GP&S?/D]<;\6YW2 MJJ%GEB@R,CE$J1I'),/_&:!T2D9SM]0V;RC!AEC^YI4]]*!&DCG6K] M58Y.E6Y,?6FS:IYUSF'^C7!-(R5.K88PK2S99=7N#>Q/#-!49$5_&ZZD:Z/U M5:=?+G)LI)RICJ&MN3".2Z[QL-T_5;77U044 M I*UI1!KJT%47K L6NG//C?50;6H.K1A^@>/EN6@JP.(,CW;Z0F&'E)YDCI# M[&44+TV_%;:K9:^.,]DER[HR$22;]%[(ZATYE+%=ZJ:=,RNJ95&[AXYF6K(? M$U=Y#0%4&[,&94U2.:X,D1W644J]>]V**JJR$S45*?4Z-I&-RE3N "2="EE7 MPKJZ+$\'+1(RBQ\(9_BT'_W\JHMMQ#<8;W8Y'S2.1;7A5V*;KJ!C1Z%CRJ-R M,GV=%I3R+9\AHS-]GGQ#E#;C*/E$ELE-.Z,OSVBG%K!56:7QQG53#$IOGLQ29N\P>JLM5&TKQ!:8PRVJ)MO3?[4]K;9"NJ)E MS6!]7T61;]>;>YW1U>HZ'/>J=SH?%P9\U<%]5)17XXJLJ#J>MS?.=HGH[$"M MV\K:M6.MULC1>UG^?M-N9C?9^.LIVMN%GGN7]G:>NQ-:=.F-Z*B[$T7^YG:B MF]YJZK?B-[Q"DH@KS/^>@SLMWN98RU1T/GSX>-?N<],[M=GV [9JVZ U^0RO M_#/' ].W>#\XARB8W7,E-D$L>R(1,N-B!RKGMF3MI$8[YUF&DD ?GZI*G"F M93/+N Y<8/ ?[2AJ7'2ZB^PFR&K&?M+DH6I58I,6-]7\4=D\'"'/NJK(7THG M9NI4'#1KS*2#W8)F^EQZD;'I:<,+"V=X80^[EM.I=G;?'WQ ^MUF]6?X-OCH\_''P[V=D_V]SJ?3^!_#G&^Q^\ZQQ_W M/^V>',#G4UAQUL8CCG8=L MR%[=KV/\/3E]GR(7<22&)=O*ZWF 9!/F//\&O(K,ST9B:RJQ)36JZ.#_!HTT MW8I*X.,@1]:-8EQK%IFNU5F'M7YQKRDVIR;YVU=J;O_.?K[NY_UW W5YM#/J M9\-/2*$^*OB6K+" T_/GCR [A&5\NO_7_//_VZ^+'D0//_'[J??O. ML].3,^OH^ZY]^O5O^/67ZV]?_[H^W#MS#G]].S_Z'%FG7_\LOIU<9,?O/W6_ MX?B<_5]'>_O6D7-X=?S^T#OM'<+[O_WX]OWL"GY_=7JM?_/?/\_C'N\>]P[H MM_=__SC^"F\\.;1@;.[IKUUZ^JN;G?XZM8]ZGWK'>W]\_W;RQ_?__OIK>/C9 M^OGA9']XN/N/:]- N&Y DL1)"0VH()'-+>([?A *BSHA%UMOW.THLHX:'Q8/(C0&F MA.530B.;D2B(T,UR?2>)8^8&%@)60/T5 JPE9J&_#BH9RK>1.6S]["1>)Z M+/7BQ'%#&C K\IAO)U:26+'/F$M-^+1F%EZ'3WZ2NI:P(S!NRR'4=0+"DM@A MS(' *:$TB"P++=P)C85OL(6[%@T#-_'\B 64>S9+X\BQ+!QD?A"GL(W%5A!XEL=,++)..';: MC$6<@(<6"V*2)BXGE+L>88P[)'4\GWI.S&W,FWC;KALM*6^R2%'44V:!#3;, MA0TL<&TW#MPT91:%:(:%29@&(G)]2GE@N2:*63-LJ*.8F,6)Y[*8^"SR"<"] M(#&G @#""WEH)QY@!F*#[2_KU-I@PT9A@\4=CU-+6&X00R1LAS2"O4:XMIW& M 8]M$_^L%S8TXI_$]U,*<2R)[-@C%$"?A([-2<2%$T6^%0LJMM[0[-)G?P11,U;*IP342,U7+2P08S7 WM7IY$<]ILYVCQRSWQ54Y3M_G M.2]V^[P\AO^<=[GQ@1;R@/:Z. M>]3G+@8S]K8?6L:0-]>0'[,\U!CRT@RYD940F&OR140H"WQ"A>_#WBP"XD4L M3BR/IQY/T)"]R%LA0WYF5:!EB%"8:M#'K 8U^/,@^/.C&1$@V*1)2DD<)!:A M;LQ(3'U*_,!!1P)/R=*M-X%EJKXVV%:74-=I;/6A;+5V^L,D9J'MV,2S: C1 M.W=)G$((GU J8@_)ARSP(WA=.8$^JD(6&IB$@:I98?II$#[@MB@.O=.[(P&+") M&/"859,& Y:( 5\J#/#M,(GB)":!\!U"K20B+&()X9%P16K;W'-L2SGP2A6 #;+W:YV!@'V5=VJ@:?% MX.EG,TQ)G%1XL(,01Z0 3W$8X9T.GPB>.E'@ATU]K]YP'LL)'+B! !E@&D8*\L\4D<8%FA[U WB;?>N.&]N3/-<<7= MJ>BZV+9[NW,F^MC16_KYC/>R?E8,![)GHKFZL HG%7JAWJME JS:;2V2@:L[ MP=5U,QR@-DT383LDI;%+J!TQ$@8T(:D;^B*V4YJ$-E9-4G./89.M^C'/'HQ5 M/Y!5UT&#"-P8^5N(Y8>44,?V26B%":&<1HF5"">T92TT];PX#ZU4"VN MA?L<'CSC ]''+HS"HU"-584!J\7 ZEUE^HP@JB:)0"$&BF/N$^GY MF!_&)'8\+W)#CX4I0\MWG'L70AK+WT3+?^PB*&/Y][+\1NF3%XL(?#-B.Q[L M^2QU2"BBE 2A@Y?I@SBD 5H^;/_K8OE+.AI9Z9#EH)_D/=%)!WFODU\(#-CS MOKG)L2*E4,=J1?IG:ID^Y(4!J05!RFH&)FYBPYZ2NH12X6(''IN$;L1(;#F, M!N!C>B&X)^'2>H6MC'-B*K17)"PQ]KU\^Z[##R=(+,N%>"/E;D2H%5O@A(0! M26W/\P+/ML-(;+V)J&WLV]CW(Y1:&?M>AGW704;HAJ$=)0F)PX@3:@(AQE ,1#'L9-((S$V*1PL?#OJ7('>L[E3X M4ZZ$P:#%,,AN7:*PTC#$R,%SA2!4$K\R"_Y(;<=++2_RTP!BB!4J\30EV:L> M!QA#79JAUL% FH8\9M0FW'61:(HC8CM.>#0"5O80;KUQC6<;!MLJ4OW MZ(VE+LU2:[<^]M+8BH.$)!Z#L-UF-HF=P"7"B:/(\6.D6\=[$RMDJ<_C;$ [ M[KJ.Z9E=C'CYM*Z[DKVIG;P3O#A-C]VSG4@$@468AS3O;DA)%%LNB2/ %3=E MW$_IUILIA(^O3"7T)ACG [CKQCCO9YR-.\XL@IRD)W#!P MTB1DL$9@G),9/6.<&V&<#^"A&^.\GW$V+C3'/&*N;1$GP$+>F#N$N59 7/!K M6,2%L!P/C'.2+^1)C/,Y)-./L5^"SJ1W7FK'_-4V-KLWB?7'J\O!53C*^WG[ M?,] SIT@QVTZZRST0SO@C'A6&A :!0$!I F(Y49)'#NV8V$=H6^R=AMLK\NO MLS'VNEQ[;93!'X SAQ<3C;UNL+TNOV[& MV.MR[?5+HT0NC:,P3 D%!XA0*PI(Y#L6X8(%OA4&7B1\<.DWL*/"2OOUN@X_ M%FD^$)TA^WG'6\.FB.\!4O%E[=Z[0=Y["^_*^B.0WW%U7>(/N6KJ>R>X=(=9 M/Q]DP^LR%[';Y^VG[/]O!!\?BN%YSNLC15,B+-!N^0L* \D3E M[H'7LTCT/%!L!1BF4SM_J#4QN+08+GG-.,@.0Q8G3DA2C@20D>^2V*VLRSN)9.27<6ZBB6$,P5,&/YF;/:A;+:.03P>^+XG*$EL-R34 M88S$BC8MYG'$F; % YOU)G,7\U=:&'-=W8WU@8((8Z3W-]+:X1>V$\?424EH M.SZA;F*16'B4!(YO%L&1.3N9S\Z.Q*R[Q0^;ME@Y0;QXN/EO M#-(N/82!B!* U5 [+ RN!ZT6VKY-+3\2";%8"E%+*AP2IRPF+O69:X5^S/#T M)GAV65@#80;"GI =UZ#;/="M<P& M2-]O!<^-FLK@F\&WAPZC= \0:/4AB.Z*!H,0!5YE0)PS 10M2XK DI78@ M&'>14./^M;Z/?.!5#J345T\"U+)S7',\HS%A%Z;$\U'<%1,SOL\;S"AO&.7S MRI5T+@1H_CD;B-ZLM ME_!C.TV90R+*4CQDMK$FA)' MF)8+IL[#MUZX^RX&U@98N!GP^'GGDE1 S\/ M!#^-QL1>$B2QQXGC>A&!7<(FL1^8L#?P\$/PTN(PL)TR9[Q,KIC&A$4])'(N 1)X3QSYGD1,E6V^LG6@#:4;7 M)G3#W88_:-/B<-L6-@\^'#AZU7AD 70Q 6\W3PI3[U&8^<2+&"(5X MD3#JN,06S(E]C"G#0(:/]ZY_7"(GW".=4AL 6J6YK6#X: #HK@!4!Y"P&]@^ M>-.$,3Q_YFY,F),FA"9,4-L*4XO'&$"Z@0$@ T!K!D /'4 : +HK #4+8 !D M! \!@%PDD@\<$GI.1&+7"CW!*+622(:0JP1 JU;D8IXQQS.>0RG*5_D?@G<8 MC(J="56,4G1&!?Q;UH=Y]RY&2/Z'Y,:F:,648!B)F:*5QRU:J2;^S"XH*R1^ MZ)MSY0:PJ_#_:-2+Q> XE>YJ<3P:%D/61Y&VSSY,Y?9>@3*BS/]E+AT0@<5]=:)=97PS&P?!->.L>A,>&'->'(_]3T' MPL[$9S:AGN^1V'($26.>N*F5^O#_>/GBWJW/C0FOM DO_7*4,>&'->$Z?>1Y M 14!,A+S(";4=2(2>2PDL>5%GH/W. 3>Y'#M>Y:2-^ MK&# &/'2C+C!'Q[[C@@2FZ2"^X3&D4, E%,2^Y;O)$$8!IZ'X ML>AA\F]#%G?%HX.:4Q\O-?^L=)=GEV_^#7^40^JQP5G6)TKK7H?P>/TO2.00 MMM$[$=CNX/&!6L[IY%QT6()GU*Q_+0^I\R$\'0"R X/)8&1G ];M7+#!L).G MG>&Y* 2"MV0Q87CLG69]UD\R^!+ Z5#(A@P[,P6C7TZ=G0!CZ(N\R! +7@]$ MEPVS2_'[5<:'Y^4NTOBA%J55_X3%, C \YD_6149>T%;',T_<;ARRW$\&B7, M]RR?0AR3^F'(;!JZ<40Y8PX/_H'_VBI_=5Y!UP5L;R0>"/:#L!2F^)IUK]AU ML?5;6QU!\\8D/RXT)9HW_XX'\-,IPWU2N093Y=KI[+X_^+!_=-(YV7_[GZ/C M#\?O#_8_;RO3/#AZ.UL+5V4&;X^//A]_.-C;/=G?ZWP^@?\YQ.DQO0\05C#H9\G_I8 MVU84[82>B^:E$X_ZQ=KR=J3EC7D]ZK/ W7&"8.;'UHX]\[.;'NOO0%AUIZ?> M_)GGWNVIFS16;ZZGWI*&OM5ULKV)[TX)!Y6^/TX\&-Z&"G*#.15L4'3V^QS\ MA>-DF$,TUG'M[44J==:\#FF& [P -=QJKS!FR)[">S[!;]_U#AV8S=ZW7I6@+I/-W__X\>WK%_OP^]_9MY,? M/T]_?>H=?CTZ/X0Y?7L/[_QZ^NO;]^3JJ'=J__=7>5JT/SS<_<=/.#97B(G/ M64 H#1(2P:H0)TYLET5"A'ZPE.X*JU<]9J!F0Z'FV;=!6!,4NJY0*++#%!;' M(EZ(!(21FQ+FQS:!1<)>E1YL$\Z2NB 8'#(X9-H5/#NP.:I='ML6EN.%#O$2 M%A$J/$9"'D0D[AV(<]$OLDM17NY] MV06=?[64F[W+N+FYL<^X1HQKF=E[%JG?L*/WBQ2 ON)>1" M9K3@EACZM@FAJM_OE_Y @,1_"8[S10_BN+]73;78'60%K-K>: !_?H1_S_D) M^VF??8U&\)S>T3+_3PUYE]].O3 M]^.3O\]/'93!7][AK_,?1U@PN/?#^N^O_:OCDQ_VX;II='O[[\XPOJ M"D^$A%/&":5A3)AM^X1'+$VY;2>1AWT#)O6RP_J\\^(I0RFCD!NGD-_/_K&] M.+!]EQ,O]6U"DR0DC/L6<>PHC@2/$CL%A9S,(8V5YSV/Z\6;YK$%Q:JSQ M#M;8. Z*PH0F,;9^22Q"4TY)['@I"5(KM4,'UMZ!$&'R,.C5&N=?C9FOE0-H MS/RN9EZ?MWB4>XGK."01=HB<(2&) N83WTF],(S],(J\K3>3C"'&S%?6S#?# MF3;&?4?C;IQOA#R,+%@];.3F$>HS <8=1,1)XC!-(YO[J;OUYCF?;CQ9LG&W M![,8%IV!2+JL*+(TDXRFP[PC-"MS1U[;@G^%?[MS+O(IR[)F80%:_Z=JV@G# M@>WR[Z-BB+-Z-\A[N\=O#UKX8'!@41PXFQU9]_[\<;AWU#O^"G/X^F=VO/>7 M=7KR1W8(XSI\_RT[VOO6/=P[H*6<"(;/(;)!A\KGX$T>KF^>KEW^D_ (V%9D44L$<6$\@@KAP0C$+E& M3AI[%H^3-4M!&HU<5XVD\/=_$L=!)\LC89)((M6(A"Z-2)1Z-L);8'%WR3G( M#60U6844Y!T,T<0O=[7&.GX)4KRU[T#\8D6"T,AV24BY2P(:)&$@G,"/TVF0 M;AB,5MO6']D/-#:^)R"9$S#J,9O$,6Z2-DU)F J;>($3.3:WPICR:3F* M^1.0QKQ7=RM?@BMMMO*5-?-&*M(2#O>=("%6R&W8SWU*(A8PDG#&:1*D#NST MTPJ7GIS';//K'M_E _C/?B<9#0:BGUQWA@-X6E=:QAJG&/6TWNI9G=23JLW= M&/6B1OWCIHJ=[E'OKY]'WP^N3WL'[N&O3S^.?B4>S-,Y[!UXAS#F;R?[UT?. MZ?5D"=GA/XR'GNNZ#O&MP(%H.74(X'U(4H^[;AJRD(?.M&AY+?**1AG72!F_ MG_W#PR@)62Q(R'A$*+@BA 5!0!C@%K+P1Z$/D:<]F>5>\6RBT<-UTL/=?WB< MX.9(24A=B] D= FS/8)B X40)IA,3'I+(LBCQ$R>P(NZ%3NQ-Q?.UOU-N;/[1 M,XG&YI_0YNO,(A61<)) $)N!X=/8#0E+N8>WIBSJ6R+U>6!L?@UM?I%P[_$3 MC,;ZG\[Z&PE'-[&"T+-\XH2N3ZA#(\(2+R'"!E#P[" -.-MZXTVV/WF2RN;G MP.J 5'][_FF:\]Y1A_:'&^1&L!H^MOL"/W%M=PDZSC]UYRBX]E_S]WY3_Y\_N-Z=[&7^'<;\_M(Y^_;B"__]UB/-] M?WI]?/(N.][[\_SHZS?X_%,7Y&4==L.?AWL_O*,3[$9TX![O)>X_J>/;MIN MPYJXE( /ZQ((12*2I!"^.M2"S3U,WL4F"F4@:I!&) MK9B2P$OA?T/8)BPLM)WL2:5SXZOMOALUW00U/;7^\5.+2[U,A>]B89%#(HM' MQ+$M+_"#T XM>RI5RK/,G:\V!VS+HEL.OY<2+ A"P?V0 2X9'( M34(2>HX=!H[P 7HAFEZ-8-IDT5:P"-=8_#I8?-T_V+; \PH9)R'W&:&QS<#8 MT>+#P(Y/]_9AW%^NC[^"G+X>T&\G,&_GT#[^"G)\-Y$>W \&SH8EWEFF3 M=5(3EM@+P] A@8^DU:[C ?([$?'3@,5>0AT>).;J\<;:^J/5 QM;?RI;K].9 M;L2]V(UMDGJ>1RA-/!(Z\ <+'!9;PF7@E1E;WUA;?[1+=L;6G\K6ZSRFDW+J M! DL)> XH1:-"?,BAX2I;7FVRV*61BMCZ\^AR?>T?FY8:SFSHG>.XY>YVJEO M*)H]3:K68-/=L.E7*^9@D>7Z,5Y+2 &;@AABCL".(9)GE@4Q?9HF;.O-$FXE MS&T?:W3D^IQM_FG2W<;F[VSS=>R16 Y-19H0/Z$,\PP.82QU"0W=E,>)L+T@ MV'H3+:&7BC'ZS3+ZISDP,$9_9Z.O@Q#?=G@887]&GR<0A*0,J^1=$@.(0Q02 M)\P3$(3X':"LG MN1=/**#51OJG/'>: NTEK,-_=4 MA0F='< 8!Z(P9[\+;@56,^:+>10YPA/$=K"4UJ&4Q&D4$8<+-Z!I$M/$VWH# MV_B2V"^79V!/G, V4&N@=O5I@ S4/C74UJ&V8UE1&/L6$8P*0K'Y!G.92X*( MP=YJN<)B%H3:P;)Z!ABH-5!KH/;13ET-U#XUU-8)#B_E+&%I0MS(\@CE+B.A MFX!K&[(H<1*?)Q2;LWB3O6/7%6IE'N0WJ5%E"65U*^3-O^/!;V.TJ_!'.:O& MBQ*!VO?XQNO(-,>YZ+ $TQRL?PWRZ/3S(3R=#>"?^]A_4IP-6+=SP0;J/LFY M* 3:M!2F[$:99GW63Y QIQC"/\A&E#L3\YY+*'IDU-D)/!C]15YDJ!^O9>-+ M,/#?KS(^/"]AI_%#K0-6_1,6PPA'P]D_694%0,*Q5@UNXT\"_2 LA2F^9MTK=EUL M_=:21"_KDS')CPMM]NI-K&&/#<[@@7I%0GB8_A2J;4BB)8RNRRX*\;K\R^\\*RZZ[/IUUI?OD#_ZO2T% MU)DQI)124!]K=8JBG=!S4:-TZEB_6"O;CE2V,?!7GP7.CA\Y,S^V=NR9G]WT M6-O>\=W@3H^]^3//?:#!1G,]]I;T_&IFX2=T6(+/=,^@FE0TSZ24$3[.M,*Y M9G6<#/-8##JNO=V:VCHLW'PSO&7=&G'I C[::B\JIN&7->%YF!Q;WN_DHS9) ML';T/,TDVD S>9GU._#4+CCIQ79'_$S$Q5#ZE1!B="Y9=X2!!Y?_4IQC& )1 M!GNUR/K?I4+V,>4TY]:W^_GS_LGG.W'?9M-.::5/C M[P?>X?^]^_/?7EV:G*LOW8COQ?!+& M5D"HYT_YY!I@U%IBAPW22QPL@);2H" M$46.'[D1UD8[OAT+1*;IM38&F9X6F>I^6I;C4ROR(I(D84PHB[$793^"Z.(&[20*3&1:=@4@$&$'<%9(=\$Y7;=>7&V"U MG*9R43Y5:W(DACJR-8BT$"(E35_)<[D(;)\1+Q: 2'8B2.C%'A$B]CV+4SM, M&2*2Y4Y>J+U;$P9"[Z_%> MP,/$=]S \Y!*_-Z=.%>/EF-=W(:#_B4H>3ZXO@\EQV:CS-W]A#;*5*(&<#&H MLA"JG#4W_\!Q[2@. N()+R T2FW"HL0F=N0R-_6C(&!BZTW@F/Z^&VR4R]KZ MC5'>QRCKK9ZYW*&PW1.1A#ZAEI>0V/9LX@=^$(>V$SD,MGH_F.2Z,!F"QR7C M:IVKFNS 0^_Z4NJ[4M@FHK@+S/QH[OU)&+#8L01$% 'V]O,CP@)&05NXY_JV M$$%(M]XX]B3'GPG[-\8TE[7W&].\OVG6'D"4)KX;.P$1GIT2ZE&7A X5)'5C M2ITT\.S0VGIC1ZN4D5MFL.]XJ^\":+*;^[L &TK1M6*G!P::[@Q-^U=-(A;+ M2>+8H3[Q4Y\2&CF4,$=XQ/9=WTD$ X1B6V_<;6I/=C*]6WRR,M?_#2'?FI0Q M&&N_G[777""""S<5,2.I+P1X(BDG+$D3(@(P=NY@DI"CM=OALK(1AHEO">;X M<9!?P'"NMSL778;N29_+8M8+O&IN:AD>)5M1K@'V+QCN]OE^*7^3'ET8DUI] MU!EE3APG ?$=<#ZHDS@D$G9,O-AQ& NYQ5VD_Z;W]C],XF)UK719B0MCI4NU MTF;OX)%J&4NYJ[0E!![[/S4/IP&>NP%/JUU8 MF*1N[,42H ML%+"+' !W,!W;$%7B1XLO4F",P]B TVSP>X!V',\Q[FV0SZ73OR MO)C840!!/V=@F4X0$L^S[93RR.81]@!>6N/'%0KYU^PNQ'07X&$KH5=.% MS MU3W#EF:/=M_# .]BP.LT_2*;T4 (SDD4!8Q09EDDBE-.;)Z(. PC.W$ >*-M MW[EWMG7-+GH82#.0]E276@RD+0QIM2])TR@..6"82V5-J@7@YJ0^2:*86YXK M?">)$-)@$UH72'N #-,*-O;X<+#[Q\&'@Y.#_<^=W:.]SOY?7PY.3N]#[=]8 MF"EM,-13>_%@+FVKL0_8)) M>^C_?L77]9AS0K= YC3'793H(QU>6;:H-,*W)8&#&+P.H( M"$]2ET0V#XEE49NY5B1\:H&INO?V%U:O@G5=_(4]D0I0=-X9B$O1'TUD=4S% MW+*]@U+BGY3 #<[<"6=:!%DNB-05S"<\IA:AB6>3D*,PR@"CV#K3; LCFZ3%5A!VUR6"V!L9?DD\?T8R3$YB2W+(1X/+!8"HL9HH)1N M(%OVFMUR32;KI$W;KU6]!FI0ZKXHU>+'\GUA>Y[O$^;$#)DT!6&6YY/4BFW. MA/C_V?OVY[2.;-U_A>).W3NGRBNGWX_,O50IEI.C4['D.')RG%]<_5AM82/0 M /+KK[_=6P^093E" FD#G9F2$2#8NU=_7Z_WXFA,:< GEI9ML"XEH17R;2F3 MK)!? N2?SXW[8YZ[1$!S3[.]8 386#*LO8LFFN"]]MER>$+,O563-2Z9;)VN M,FO(>>?PQ5;81 ^A@YSW =S-@J@]@>Y*2E=:=J%VQ&-F(298 )'/%'#4YF-B)!QZRP%AB8* M:KU@I:$7?:+M!K;T:K72\!*G_3$>X_G T)/19 KCV7.U8N+!1H?B<)*_:F<8 M&U_KBRR(F1QVLQ"&&'\ZDT:96SB9LWDJ2=V5I*XTO_*< \%U[QQCEM#2@T"03E)?YI M$ QQ43",3M"2$:V6Y<.H;HI%TBP&E\Z*FFCQB(D6E6ONRC7\2D&F(]:PJ($( M*T 0X\!YPZ$<($)Q[22FDMU571,;C-%5Y5I4C-X#HW,5& :I==YF>$H/0O(( MGG$.,@DO8G*EEKK;$_K>DTC;YX%8LW2+FF:Q#B&.F9 J+2U&2^**U\%P[;5E M$-")DJ9I(#^E(&;!T1@S+3F1:>F)OG]+F9I?L8E8?]C\BHKUA;$^4T$8D8'J MR$"9*$%HIL GY< TP1'1](1HL$[6!NO;X+%X.CH^[I]-\VN") 5^^=IQ&#(@ M.O_<'TWQ3#I4_\>2^E/?+*P+EER-,O!ITO]QV!_\O^YT?(I?T\#<.NP,X]/Y M5:AD5-;"58SFA^E;#F+0%72-^[.;0BFZ;7INDWM=68CL+[H]$@'QZ3_W,OP*RAZMB.01UKOF(/?9S$_H>+ MSS[_""CO_Y&:1@*/L2HOQA=-ZB8%3O_ZQ_'[\G^N_ E7S?]Z]T>._CE55ZW5^3@\#T] M^-E\>K[[7NX?YK5[M\M_8Y2$54I4P;B$P?AN,_600B0 F6.FZ"((]T>^8%<3^>]]D3G MQ(T['XJ<_]6Y<0].BOPG#^_YO+HQFUTXV3F='HW&F;QC=8:V8D.^__R&$I-Y M)E&('!4(I R,DP8<(66/,*8<_0[%?7-[/4 0K6ZO]=A>'*,05@H(7 4044IP MI4!2:,8"L212Q;L]RJ[W4KG!CY]5Q$'9@6<;K^,N9;XH!RYEDV:M-)2-^G$T MCA,Z:RX!4]!4Z1Y+R2JX_<,U%;MK4I>+=Q@R>7#D5D* M*JF2GQWS5DO2 T6>-Y>+W%'=[>7-A7^OP-W"HNTW_-+D"HQFV^'2IQG['VKI MU:J2%K_@>!3=Y.C[6&W\2A6?"^-SEKY@&*..<@G1QZQP&NO <2N )2V4MTF$ M4E[UO_^7R7^E[P. MASOB^9?7\OGA*_+ZW6^?#W8'[_/OGU[_^?7K][N?!P1]?J;YYG=X$ M'V0DEH#EV< 2S"CPGC!(7F=XDJ2)5X\;_*O;:8VV4PJ4",T(""<\")I/$AMC MA!@D&N:UL!I;&_FS"X1FYG;EC7$96W?C(^[&UY_>,)4U#*\<9"[*Y":M!6^S M76\2]VB9C*CY WF]Z][:L+V%R2#%E/5CZG7>6Z58AU('2FF3E64A#-/='KL% MS?E6!?L6W)K55]ZB;1GX&Z6\3OG(!1>IR@:<"<5K;D!2BI19:4WQN[1_7U4_ M>0LWE\^J7,-Y2NI\GF;9G\V,H0Y3%)3+*&VWQ\GU*5776>_K%(=IYR!,1Q[' M9TX$3I]TRJYJO.2MR_NJV[7UV[5D?27.J;4)0F8L$+&TW9$IJW]*N:S]6<)< M>I2X83UCUWI?19+RD5@RI#4O9H43X!CA8)CET1+B4DJ%!J]W@KPC#5*[_)CA M5O1<6E9?M#E(UAC#W; X"PWJR)@1#@$Y]2"09*L\$@9<)6:M-]:8;)6WJ<]2 M[876FJ!@Q>62<3F+_9E$B';! (T%E](G\,(9L%H8SP+3)HIVX7*9_<^H;7GE MXTZ^YK+>;M Y!["U*WJ7A=Z9 M'D$E9TX2"8&6EH4E?!%_0RO:R1D"W*(%H/7>(E3ET9,=!! M-Q[FJY]T_NE".#T^'93@%F68^%"$,_.Y; SD\+NF1 J M%2U&15=FMF@M,?]/@;;<@2"!@C669\4YBTZ(X!P+W9YITU2IZFNX#53_^2!J MQ"3?9WY40?L H)WS0W!K740%*F2HBA@#>*H3."I55] M$,OV0E ML3?,PL%?LTCV<7J0#MVG2DN+T=*5(2ZE%9*FRH%BI0I5.\RZ!&% B N4LORB M--FL8==3OF[/2]4;T6+T+EV/J.A=-7IG2H5$E-H; BG("%F1:$;,YAULD#-" MJ%:E/X'\Q@BF1T'O,KT1ZS/99?*-7J#W\4%L\=B'!XA\S'=N?=;(JC+48@QU M9=(+,RDQ'SA8I0T(5IKF4:(A*Q;H"=?2*U6F/YBEC:!JS:27)?HRMACR#Q N MJ9!? N1G2@GAQJ5D!63MI,R@3<4]&2)H0CUWTGA?1DJ+)UI<=W:T%/);/Y*N M2=&\C2)SR]D\9W?W(\]K$D>G?H"7XKH?U;5N)?_QB NT,6? PT[VVQG&>B+< M\T3X[=/5S!=)6!0!J/,.A$ "/A &EG@FE68R^=CMV2>*+2MVOCP4/;*GJO)I MY=-UU*DKGRZ=3V<:-J)R06=3FC:3UR,+X+0.F4^)-?FHU-JFPJ?Y;-P8/FU4 M\/^>+?SMNTJ7'T\XH=:9'.,&" M[V;-FR!FZ@_=,/0;WV-^HAD/]\/5JJJYM3N_','.[)*3T:1)'OQQC ,W[7_ M?WWLQ^G1!'Y:I/9GSB?+^)T>O.?7!/#(ZVZM%\5F[%7QV-9ZVSWB+X,;KWX%*^Q1_=X*/[/.G^ MY]4=FS?G5RO_]:*=+4WO__IQ_M-O7.YW]__#K[3^YDKO_++WZ[/]P\[ALZ?_ MM7_P:Z;#9[\_.=OH>_M/;]Z5;;G^IP?[OQ_\NK>[<_ALM_/[8?[G>;F=@Y\[ M3W=^_Z_.S[\>_/G[C3 M4_:'K!O<^#+YX>;7OO>Q)G^JN-.G?O\UR?G67ZN\U:?^C2>KG4/3KB'S-F/F MJ+S-79TK P]R7^96M_4:W7C2>985DWA1-=WA],DBP^%:(<7;W>WM9P4NH&"V M6\#%5[6L&[[-@,0KJOOUC]JDA:6V+NQJ%M9L)__,'2*;(\Y_]H<7'3HF_[&( M7#=B./%3-SGJI,'HXZ23QJ/CSN@$QZZ,3>\4#\F'QF559UO7V=9UQ5HTW'B] MIX'OX[33;S)?[U/+L6D!FF_=XL:$6'1&J=*6!!&]2"YXI7T*0GBBM232O=EM M0BR44+A=3>6+\2CUIR5SNCVADW<[YZ&3D_>OW[VBS]GK+_N[03S?W2'[O[R6 MKX_SW[P;O'_-_NC_M?O'T<'N;^ROR]#)R?OR7?M?7LG]P[?\.?N-'.S^W#\X M_.G]7W_^1EZ_>R:>?WE/GG\)Y/)O+D(GQ[_E^WK/]\ODH]WPY:_=_#U_[LGG MO[P#O[GRV_G89-GT^<[;U2(RF+PH*+3($0)FF2I M /.!UDI9H-I1JG.>5>\Y0<$4EZ9X))&BU70D1->$,U MYIQJ[CT:NK+075GH\R4+65I:1P@"TK@$PO($3GD*64@I&B'S,<&Z/?J$Z VL MX:X\M*$\1"*341 D7'NA,^4(2YQ&GC>UU]'3AH?T!0^9JO*LD&SV9RH/I4B8 M- QD< M^J7ZPQV/\M5]:9ZH+;0>S.\S+X?\>(#EP3N9L_ZMA%[3+.G$<%/10)/YP10R7RN\*"N(6)PM M_%FOWT/WZ=FG0CGX$PXQM6F*P%JPSOMY'=Z;R 2-%#0+#D00%JQ/"%DU4-$D M(Q65W1[;P.S5#"5A(V8[Y'Q6URT;M$G3ZBMH'0>V\EL\%#\X3L,+2$K#@X+R20(00 M*:OZ7#+;[7TC=7+MA_:L@8+_[%/ R5EGVE'I.X53[/2''W X'8T_=YKN5<5_ MGTW?MW?4_[?"V;!T_7_O0@9_COM3W!U]K(Z&Q2CHV!;XS J2 J)N? QH@@#'%@J+'@='0AHA$"BY%W/;6E M1;ZFZA)N>^2F@G8)H)VU9%7"NFBC@>"L R%1@$W6@O*!R6SH6<]2%?@&"3P4 M87BN()+2TSP%DXV$$,MTFQ"CL=K'S-+?*"2O++VY++WTP%T%[1) ^VJF6JE@ M6*(1,B=S$"&PC%>965IRQV0FZ:A<%?@&"3QZ0B,5#+@669>V:,"C,R"UHV7. M*56&9EWZN@.G12R]97';7UQ_V!F5K\63C@O_/NV?-1>O$=P5&O3S#4"^X'@4 MW>3H:VKZZ722KW(R>3HZ]OUADT'R>Y;1SDQ$9Z,=]DJ_0YQ,]X;-2V/$EWB, M;G(Z;CK1%_E63EN,TZY,TTGYR))*,G B94[+9Q<8S?,AYES^?S*14%8J6 VC M[%\U$KRYN%]RXY^*^S;B?F9QBH D4A]+]-B :,)27%.0P6B) 94UHN)^77'_ MP+'D"O'V0'QFKNB8Q9D(!RUI F$,@BGM"6TV4S"2X+0I62+7LTIKO/D!&O9, M)J4SS_&)ZX_+;J^AY8>/-%XN_D'*7.2&;_M^@(U@)L\^A<%I6O7>F:?5FMQ>^#V1? M5%"O%M0S"\*D0!6+>1?SZ$#P),$'H4%Z1&M19&23I5D0%=GM1?;RPQ85PRO% M\,Q$8%JHD&D9@K$$!&H&)GD%DHK(J'4)9=-#HT7PW;( QJOA&/-E?,'8>7L> MR\#&>NY,,)R.FV:=3TI?SRV+:"SBX5BZY7#FO_C]4@ _?]COSP15'!>US_#B MS/1E9C(\)_MOW[!$@HS*0N8FF14,$\$&%H$S19!%2835WTQ=K$4N&P';I2>M M5=BN"+;/YV&K,$C&6,EE4RP;^]J#\T%EV-*L5C"%7F5C_[I*45';6M0^K#%P M&S._0GE%4'XU#^4DE,]FO@+C4$/6G@(8X5@V#R)F'D8/CLBHP.TFZ64*6I M.QL*.V^(UY9SHL B52"DTV"%(Z")#L$'2V-TU0VY!6A>72>+"N#5F0P[;QRC M384+2":RF>\3!>=T+%7RI?6V#3IE -?8X 9#]X&,AHKCU=D+.V]XM@FTR"9_ M;#(*0\IV/TD*I,(0K,H@E[Z-!W'MR5T7H2["W;NSKW=\[6!ZA.,MBYT]K(E\ M@U+=+/S^:%C&$9XUFSKO-%4/X<4.87ZEW0=WTEJ'8#E%$$)F:]@I"=8[Y9@1 MVCO>[=5!-AL,V=79P16RRX/LS/XES'E,*$$2PT @,> )%Y !C"I@3%[%;D]7 MR&XN9%?7SK%"=GF0G6L$P)*22M(R5L&!<-2 H8R ,DE&-!9)&?/8IL;)6Q81 M>WKDAF_SQ_6''=>DC3:-'0=]Y_N#YGV*+FNJM;4KHV [ JZ"%;(K@"R<[8EZB0B%>!% M3" 4(OCD>/Y52B:LEHCV7:E:W7\B_;*6Y92F7+U/H+,60SOC+-0DRS=Z4U MO-7>LR09&"PS?(618*0/$)1*7J%C/M+,-/>IKZI)5RV&Z@.H\Q6J]X'JG![O MN6>!.E#4"1#2DPS:TD_%A, <9C$JT>WQ^ZCQ%:HMANH#J/$5JO>!ZIS^[K-= MS;+^'E6VNX56'"R/$K1-&*3B(0C3[1G>#JANIY?^Q'TN=NJ6>>?;I<5?"./% MF2PJYRS&.5>:.,NLN!EE$&(LDPATB&""HD!"3%$&P?+YT>VQ%L6CJZ>O?5E? M%;&K1NQ,H8^6BJRW2V#))Q N6/ N(Y:)%'00RMI49V]O.&0?T#=?(7M7R,XI M]MG0-DDX(,9*$%$:,"Y9X,*)Q%7(IKCO]L3U=LJ;D?75>NW^V?')8/09,=_I M<4EQ;!J/-WE?_FQV=>VM_)CZ_H5X7IZ-4OYUEHM766DQ5KK26IGQ3$1.:V#& M"A H!?C(%*3H;,R6@):4+$.1J.[!]J+W 73_BMXEHG=F!C!EK%=2 HK@0=C( MP/'DP 8J.1+)M<*,WNO.PHK>C4'O Y@!%;U+1._,(DA&'V[FIC,0%24@^A:E4D)4I!I8S!&DI(ZFU*V*5J_57&$ MPW$S@_1S9S *[SON[1B;<:0E::C\6X,(CV8D7 R,';LI3CZZDW.)5"?&@GQ$ MYJT"@9P8K1RD:!%$/D4R'SD/*1\G05'CN:UCW-86OH]2#U"1ND2DSC3^E%C& M8R(@!8\@9%+@-8V 1DG%HW("7;=7:P#6")[MZ9%<,;M$S+Z:*]SQQD5#P3/F M0%B5'V&B0%0D(A^IQFK5QM.UML+=MF!)TRGNACC)E@5&6E;OW$CFX 0S,>>% M?.I.^E,WV,?JAEF0F-F\V1,,<66 1$>S%804C'<(4B>&GCM'5.KVQ'WJ*RMN M6XS;!TB7JKA=&F[GRB>H]M0@ T:E!,$\!2=L FE,YF'#N.<:#4\/8ZC MZ?GKE1$>D!'F"K<%Y;*T9XR!935&B !.&@U,)Q(#IS[0;'[0)Z1R0N6$!XCC M5$YX+$Z8F3;*1BZHH) I/'-",!9,4A(D,VB82=26";:9$\R]I_@\%"$'G'QE[]QM3L@:+L:W]^%2?5=UQ>J*?;UB6S:7 M:*^AF":MHE2EG8R+CV7Z^4GG9."&TR;LBO\^[9]L8:+IHP9=7YSGNAR.=D)> M_S&^.)?,BR*7G6%\=B&5JB@MIBA=F2 3-,K # >:F *1=5XP0C((299$4X+< MLZPHT>O=*FH.VT8 =^E!UPK<%0)WKO^T8,IQEG=K*#-*-0^0-RJ")=IH'3P) M7F3@ROM,I:C ;3%PEQYUKI\M1R>.KYU5DTGC!'-('$? 2AREA)]!:(9]0+9-ZH,JBN136Q-;.K MW<'2KPM<*J(? M%SK>V()]ZB!N\2@HC!@N,. 0-3UG#TWLO:GV(+<+U\TZ$B M>(4(GMD.7B-:S10$6>9/)J+!T> @!*$,$S(;_[I=9W*M6JN+4!?A[O6+ZQU< M.W MM"VYPUE0D"6856L:@N,D&6O\-[N]5[AN!%Q7'T2K<+TW7&?V+Y?&<%>"WEG1 M 8$BGZXQ"? D4L8D!^Q_J#+[%*?E*UY9\8FHKT J$D!DQ0D\$QJR M&>2%%$BB2-W>?=(':R2AQ6!=O;U3P7I?L,YU:M%$>TX8I!2SD:-%F4H="?#$ MI GHI Z\VZN-6C84K*NW=BI8[PO6F;%C621)8LFX\::TI:?@9:20!4)2<%DX M,GYKA'P;V[.TSRZI(:ZV&'P;%^+J#Z?9[FM,O;/FG5L6WFK/@((;SZF]2Q'M M-!*J!]5B!]75&C)E%4]<@(WH07!+P!&;0!GGG,VZI6.FC1V5JSM]_:S!"MQ[ M W=F#E*22=8Q I(E#L)AAK#'!)RYF+)TG)7?3/&NP:_6HK4]XPLJA%<'X9F1 MB$RA(=[F8U<@"&9YR0@-@.B9#OF%&):7TUW+RNX*RV;K3_IET2>EF,R?3O)[ M\O8_:^Q_S6)XTAGBM+RQ:0%Z;EC$+0L:K8$=\=.E'/=Q>I!*_Z+S5V*EM85H M[;)^-"S/J(*RW%4?IL4E +J"*F*%+R6$M5UA;8#VQ2W+HY7X7W2N$] M,SRD#.>2 M\+)*I0F)8'CT(*@*&;?&@K?&Y^-8HT+5[4EZG[&'#Q>9VMS! :<3+);%-YMH MUJ$!CY:;-LDWG!_=LC'PWH7P:F/@NY+7IWG#(I*8#Q//@ F7-0\1LF%A9)86 M12*Y]\(FDC4/L83N.[5+^&9A?PF6R"7V[]LOO-+",FAA+A)"759II(.@N0.A ME0%K:7YD O.)HO"<%X-$VB54[E5BV"QB6((I4Y6"AT?_S*(QT6OJ5(8[E66F M4++@@M39HDF1H,W,4,J*-%E"+\TZ)F %8P)2?^B&H8X)J$WOZXK5,0&K&1,P MF9QFCFDZ@8;1\?&H7,$HO,]Z0>;S#AZ?#$:?$<^?+!U":];GX_0$O9#40?K] MR(UQ\JH(:"\_,7U6KQ52K+_/^%D>D4(J;K%4YE7]$F;4JZZ&DAFH4@MBHNCUUW:JJ::$; M _?E9X56N+<*[G/]5% F$8T#RR(KEI0 [X6#5(:N6219\*+;D]=G2E>X;PS< M5]I=M,+]\>$^YSBQ1'D? DB2RIC%?+!;0R4X)PE1+-ID=8;[]4AP33Q]X/*T M;+9,W:?\N6,2:CP]&A^_1G?WIT-!J4=?QY-/XVNU4.6XS#KG1LE.BT3"P"45%D#J,) MO(L?]O6Z2C%39")J"7 MEQ(X2$^;F%3CV*@,M!@#T7EK@!&2J&8$#%79&HA4@[.H@% ?B8X1F='=GE!U M'O*& G9EYD %[!(!.Y^Y29*T3(!T66\0@2 XIC40H@.QBJ881;>G:POW307L MRC3_"M@E G:FXSN*D28; &7I01JL HM"@S21A& R8C'K^(+=I[%AC1%A# (^AWA^DW8OEK\1S9^*YTJE<,JICBAQ2&1DAJ."0Q20@(1+T67(Q MD&Z/W8MXJH^PQ6!=F6I?P;HDL,[Y\YFF(BD*24:5P9KU!1>4 4T]\4Y[:[$T M/R;5H;^A8%V96E_!NB2PSE1Z@E0ZE0@PE2$JLIS C+\A"_$JI@2(B M1B: !R]!)$_!EPDGW,>H-442J>SVA+WNNJ_)QQL#W8>J-:C0O3]TY[1]%R6+ M2H O^!7&Z!+W1T 1N>;>^,!+U,U>3\*KT-T8Z#Y4/^H*Z%4!>LXB4$%D1!#<:=_81^$T>2.LVJVPR6Q2F=_%L0% M&3TM8JCLLQC[B'E+( 6I#%,,F"DAQD@"&,(0DK:2:08Z2@M"2))Q2K+%3FVD*)QA5E6A M[P:=$W>"XQH(>>1 R--+@;PH\JBTO! MOYIK-$@2SM5XP0AC#=1F]J!?6:FDP5U"L!]:MY4!MOO):6@4%!06C/P0@:L_V4 MQ:DT0R679S_5$,E=T?D23V8E$4NQ'-;7N?.HP9)+04PJ%=V3BC[/&0QR?^<- MQ>0I"1048QJ$D@Y,EA=X9:)64:$L-91M>"!;H2)XF0A^/H]@ MQI3TA$C@4F>3'ZD$'X6!( FE7@R=XP#XUI(A<:S):9.U:J*I=@%9P-HL#/ V@[I8:V"G\]6_M>R M\"_&_6'HGQ0>.N.F2D5WMPL:OR-#8[WS()R,( QFK2(H"='Q)"UE03%^O_R, MZFQLKRKQ0%9!1?"*[(*"8&MU"@HU4.D<"!XU6%0,/#I-M4PVZ-A&)V,%\WK: M!17,*[(,"IA+7T(JLE&03"I@3A1,\!2LXSI(1@TQLHU@WK*(P8OSEF'%,,@" M@(+#\6@P*/,I^QF28YQ,MRQP\+ 6PJ(AS@M^.AP][P]'X_[T<]/:N71ZQG%E MK059Z^-\)88PD2;#"=A4@IQ)!_#.&>!E$E0^DY"YY5%6]4NVV/)?@C5QPY#L M"N450GE6K,&#*Y15B>:X\ M.UHBO>!95J4\6X0 AEL%T;LL5>)$BKZ-Q_*6Q1B^*EL88^Q/.UDG[@^:^6S# MO.A'H_$4LDUQW!F,W'#+(@]MJ63X-5]9"80V JK$=.?JA=+VT0D;T8$GUH%P MB8/Q):TAZJ)LH @Q='O:FA:Y-ZJOLGV!AXK551T7! M,GI-2PP6,D%,72F*DH^%\I_5L6-WC@U*)Y#\7P]#B. MIN>O?R_]L9+4(!/YH!<*5#0$!!H%WI?ZY&RB6^4LD9 M;+_*OX_33G"3H\[I!&.G/SRO(RB)0D4,'_K3_OVJ"?QH''$,T]')CV5=)J-! M/W8N[FO#*6H)]L -"0=9;$^SU%Z,1V6.3/SI\ZLLOKWASQ?"V[F4726OQ9EPJQDT.M-X1>N/[@U3M;([[C-V%]= MLE'%_@JQ/S,P$C4>%2.@;<@&ALBP=R0QT!RS56%9\"B[/?:-62X5^UN._268 M)A7[#X_]F=&2G \^,SBX0/.YCUSE MI82AB5K@IW#DAF^Q,W93[!R//F!CT6]9T.(QLY+.9'&0GIU+XF46Q,&PL-;. M,)9_GOW[M/\A4U,MQUJ8I,B\<9*E01"#!^:#!J$I!R^"!*8R15DML[:2C9/K M_L]:TK QX%UZK**"=Z7@G5D7+JL00BH--)76]9:&K%S8!)SJ&%+2)0>Z@G?] MP-L.,Z'">*4PGAD*$DW&L6= HJ$9QB:?P=XR< X%R__I+,EN[U[^P1K)>3PYBWS@# M-OE,ICA[WPQ1C\WHM:'@PTZ$P MTU?L]/)2&.?L=?6)N7>^R/<[BGOGXMX]%W;^?7!:9#!/A6?T6(EO,>*C\\:' M%B8P*S64DLQL?!@#1AL'FNI$O$M6:=[MR3KH>MWPWXX81V6"EC/!7%&V<&A5 M"""#4" "$K!<1R@M)%TD*J20NCVC5.W1MIDLL#HSIK) RUE@9@@I[1(UQ9\A MFJ.>S%?);+% MB(S-&S8H\QG%$H'$+8+PFH!W- &35L2LW=K@::D X>;>!>#5.=M>C&MN'4M& M)Z:\4&6R0:!H\F/C&'5*-1C_VQXS%>,MPOC2E=[ 4+1F!]Y!4F+ MY'DF2ZIB?&,P'F7>" R%9-P)5,1YHTB2W*> T;/48%Q7C*\1 MQN=F@W,J!8D)L)@APJ*&#&L*-'AN=6!<.5HPKLQUQ\3:=Y?:(+L$\],W6"2K M34%MW;K]8W7WOS&4S@-1T615765>)PQ]YG9#;,J6&6)"2,LZ6Y,I[X(*MBPNYV/9G/+=L)^ M M/F/NAGF^I3@Z]0.\=L?W^89ZE=^YRFUP"?U^>G(R:"KUW.#,\Y,&HX^=_O", M@3-8?[PQ'+V,))[Z&5O7ZW)O&$;'V)FZ3YV+MD]/.D.\-A;KWB&2UMWY[77& M;]WBYJB%R\Y>/]M1A^X33EZX?JQJW4)JW>LK0[L<$4IKM$"16!!!"C#$!G!2 M44&I2YKZ;H\KVJ+8S9+4B4HX&THX2R_6K81S7\*9Z_;#.?I *02K$42*#DRR M!H)FF+@F.NC4[='[%[14PJF$LZZ#$2KAW)=PYAQ7CD3NLDK#G1 @#$KP@@H( MCCEMI#*,8B:<;_0O7OOLE/4Q$<\F)5\:B/>I5-@TYOS6+6X,B3 F,3@HV)4B6RY(@H35DWK_2X\LV&\LT* M3,/*-_?CFSG34"LL^>"0.)8^:T1"UMLH*,6%U2QY$[$,F:M\4_EF3?AF!99A MY9O[\5!:J%!V%M!"NU N6\%#0H:B1I&=]L6>RP&9IQUF:V/^R< MC$(^/^F<#-SP;&9>*6PX:2;I]9N& V>S-5P(>1&FDV)0NA+X+V_-3XY/ M\^N#OO-EP%X?)_"-IE4U+KG.7KO'G1KB?MP?#4M:Q=FFG?2'_>&'S-:-4Z,_ MO-C S?;-6_)R\UYLPXM-6&E],5J_,EK029MEE866=+98LVP)Y(-5 U59U==4 M4I]XMW?=:EWG<665I#:5I);?^JN2U*.1U,S6M2&*;-*:3%)4@"@CV[R*'!*Q MP5J.@03?[;'*4I6EUH&EEM^:K++4H['47+,Q$1S10H.GCH$H'4BMB23S%28A M%2?<9):2[2"IQC;^SVFQ]_*_L?^A]W_SCXNOGONL@,6).H,-Q;$9UC4;^ABG"X1=?6P?:"5UM]< MZ9U?]GY]MG_8.7SV]+_V#WX]^&7OV>]/SOQN>_M/;]Z5;;G^IP?[OQ_\NK>[ M<_ALM_/[8?[G>;F=@Y\[SWY[M7?X>N$;6)262@E3X_JZ1%U3$)/O?^!.)OCC MQ8-_Q?XD'Z*??^P/F[MH_NA?5S=&V65?46_S?6.Z?//_B M\^WY0[,]OSH/SE[CY@?!V(TODQ_HC:]][V/E#]3J.WWJ]U_CHE[KNERK_D$: M5:]UZ=>J?M!T7?: _$$ROB;7*GXPYG;79N;.M?/6W1;3T?'Q]F0_GTZ"N]O46>Y0 GBYLAVL=L?CSY>:[)XINF< MZRY_6SK>[AVS$\+I\>F@V&>- GB0[;9Q\RCOI9,Q'N%PDHVMYIE?1Y.;YV]^ M>ZWJ#JNWOP6W_^W#DF_'8:?WX_<&+]+?XLL MPFV*_O_FF-FVILXNI'_K3:Z&)NI*7*WDX*FUA M&NOD:#3(]S7Y/YW2/VOZN2[:S4?1: CG"OEP.AX-\CO>-K]?I.K6M?O^ACO# M[?5M]C>YKINCH FY@1K:/_O#3O[403[5)D\Z^"E@OI]AH[:5\..D4==*KN[T M:'2:OR=._F,1Z;>[&]?72_3M!(N?W, - W;O/[W.G_OZ\+>K?'U'[_.UY.\(9/]+'+S^\S7=/_QIL/_G7O[,G_KY M>CZ]OI9#\L?@K\-7Y."7DG?R6NQ_^8WOLS^._BIY++^\HOD:WC__I=S[ST?_ M\^4BR^W9]'GI&\FCH@0A&L- 4$O *K2@*<:%AMBC';4WXZ?,E/R7AG4//@!B1^2D& 38Y!HY&KF5*@@J;^:DR4V6FM6 F M)FE0PAH7-!5YHC-H3%$Y%$U%SY[F2CG"5 MV,W,=<-4\\I3CZ-!Y5-ORQ+ M$,(;,**IR/0*A,34XQ[)AR1-GV' MH*KQUW;*FE5E1FFECYJ (J'T9;0ALQ4ET)C[B:2H#>OVQ!/#:VO&RESKP5RH M-3-9N7+!1%$:PG/E9?&L$\]CB+HZU%M.3V%&3SH*B@6'Q5 G.P)D4P6FOF1;*ALC/E*HV92G\39;416UWOEC\/MG5=]9W MKO*=2VI9LKM^JW+XX M:97C8.N"U06K"U87K"Y87;"Z8)NY8)LR-.UV"U!:XY]IE=M5*/*__Y=AE/UK M[9V%54I52E5*54I+=54G*JQSW 05O6#*61:)M2G1X)4A1BX\;NC%>)3ZT])8 MJ#J7%W(NO[Z2!IED"-:P")%H"X*H"$X&#TJJ1&-@-";=[7%Z/ ["4P:")PDN M'W*@B8]$,8Q6D,J@:XC-RJ#K(*7'''E9&?0>##I+< A2.Y&8 ,9YIE'D"#90 M#LXQRREQTDO7-@;=E'&7MP-9T]OUJ\#QX'L]7;]'-;<=J=0ZJKG;@="^85=5 M2E5*54I52E5*FR&E10I%94 N2-*:45$2X"VBH,RGK&-%GA7DQ-+D4&28+/*$&H40"3Y&"5VBBH38% M*[H]Q=HQ\ZXB=\G(78+_KR+W(9$[?M>O_5J')G1))_WX!6L<\]TB;O6TXIZY87;&Z8G7%UGW%;A&6OO7P MB?502Q\SZ^<;>FC50>^D@[Z]8N,3RAD52+)1SV)I>*3 )IF &F3*42,-FFZ/ MR65U%UED'DLKLD_:\AF5;AXR1:;2S3+I9F;RQDB3%-Z!U>A J,PY-E *UF?# MUS%+K?9K13 K89LD_/NN/OO\OWD+__K_\Y M(N'XCZ'[TYX>'/_WT4&^U[_>/?MX\.=S\=?N;VS_S_Q9N^'37[O__2[?HS@X M#!^?'^_1__F2WW/XGCX_S/?Z+HCG7UZ],4EI3HP"8TP @4& H\J"TY;E+2$5 M+^WVR0_27D^>ZYR_-+*N9-ZP!QW:XB*LCOTJI2JE*:7NDM$A0;.EE MFY=JQ9RJ452B:@PLJE7,%7$RFPPU)I_]PD@03A/P/CA@WFC--$=M4[='[?6F MRS7!H*THW48NW3"_RP-G=U6B71'1SIR\1ABA>'+ J90E!9.!55&"L4@(1T&% M\DLBVM;X=RL+5Q;>%A9>NON[LO#26'CF^[:.2R6) Z=E "%<2:S-I$P]1JL- M)MLRIMV"F8TO\>1T'([R5C^?V=BD:1=H;%?3S9O#M^UP1\_D%'>&\25.^^-O M>:>K'WHQBOHR[X?6G%$O)('$-6:&4A2,\A$4"U8:(U1*O-M33P2_[H>N&8YM M1?8".L9]4?W5Q/,O.![%)@OC+H!N%)&J:EDZ&T!)PS M'K*![F,R*:GD+BV%^ZH=%=9M.; ?*FA1$;PB!,^B%91%JE/3QQ M"$TU&$84 M&)HHD5(ALM#M&5V/XXW$[=++@BIN5ZI)?[HT]J.1Q),LER@2!8%:@\52*F2C M3SJSK[6TV^/\NK6_$O7+D"-WCA^G%O^-2=]*=NT#">_SK-XB7^^[0_Z4_Q=QQ_Z <\._)?8AB] M'3:?4D__.YS^9-ZORKSRW(< .@4%@CH-5B2$&&C*)[]E5F?C2I,6Y6)4P%=: MKE*J4FKCX;ET+V,]/%MW>,ZY)A7S:*PF0)!GTYF[;+7)J$ IA02=TVA8/3W7 M#_&5E]=!2H_IG:R\W#Y>GKDT+=3-+3@& MPQ(GC%'O#&%9&7VS=__$\^9[STID:F+Y8LQ$YQ/+?91$QE2Z.(H2R^8:3" & M;- IGT;14)>Z/4[U$TWO7?^R9HT=5PORMI'A/U8FQ@7$UR9NNZZTW9'8OAU) M/AH-\O)-GF7E:_IY;Q@&IV7!7HS&Y2IVIM-QWY].G1_@X6A_-"S7,1X-\N6_ MWB#=*4\EP5 MD5%V,R-.\FWF1Y7_6L)_^Y[$>9#1S5GQK+(O4!*K&:9YD(BDA 1F*C,MS;,]^62^;):'[G0 M%$C4'D0I23&D&L%K3(6SW!D4-&'6][+^)S0(1B6X2#,?&LF]YE89R3(5/I'J M>E%_M8(K(VX1(PJ&S,B"$\\%1>Z4B=%'366D(257 R%MISU^27M,$B\QTYY2 MJ3C_) ?+5 #OM0M4>V%+FUE1*:]2WC937E8 '$M&)Z:\4$IZ$BB:_-@X1IU2 M50E<8S:<)>I180UC24(^Q4A)U%/@LHD,C@\2JE*J4II,Z6T M2'T<$U*8X A*ED][9KE"Z17APE@JPG?"N55W>WS=CEQ'\-$J\ E1"V*LY+$$0XI4X\,,F4\Y0*H8/1RG%-E0C< M**QQRC7"]I=Y;#,T-C'4X,M 5F&Y!V\9!T:T9E(D%HGJ]N[3<+>BNK7GM+%: MT,0]%3Y3?$@F1*:S9>Z3C]PK6L_IMF.9SF-9<8T4*0%*99GUB09,# 22-1:L#E5>,T17^V@=I+1(TA?3*D0=N#12.!J-TU*KQ#270=+O%0!4WFT' M[\IYWHV:"J93!&LY!Y&TS#I4)$ 4$F*S'8PIMHQWMZ .O71C& U+ZX;S26J"U06K"U87 MK"Y87; E94@TZJW^0G(M>KVZ!-R_US5BMS*KU5*]RD?("33JXN$H13) M:B,T#]8H1F3I*.(JO[:%7V<%H4E2&22G(!D&$+941FG*@7M>RN/S45F2R2J_ MKB%R*[^N@Y06X%>G.2U5VJ5L1R3IG0DF:;1<"1$UX95?V\*O":&EHU)X%9$Y*Y56XA89\0WU,HR,\ MG5<1]IKP8M&0]W%ZD [=IZHI+Z8IBRM=^J3WD0A!H(@*A!()K(P.D!)/*/4N M^=3M6=N.@>@5NLNN:+N_\[!"]T&A.W,BDD =H1FUR:,$06("XTDV@&=/A:.H&WZQBN5.6ZM\O0.NHYQXYN;>-]]05JRM65ZRNV+JO MV"WBUMLR2WNM0H8L (3G6B MWGD3LA*JV9("V:UIH[P"9ESI9U2^6:T97/EFA7PS,WJ=R2+B*D#,T@"1: 1C MHP1N5/2)*B:X6BN^>>@N#['_X7%:/;C)42=_>3_B,$X*> 9NC+'SSW]\#Z_ 7&WSP[T[RW[V7^1H^/S_>^_+7N]_R=>3O?/?7X/F7/;:_ M^YJ^9J_%ZW>!_/6'^?1\-[_W,*_?NSU^L/N53$N]8HY7:/H1-4<6%BMF*L$S=H?%T11,#3;!$*3!#Y("=$%Z:(H M0UM]M\?($N875YA6,EV9E#;,]?+ .5Z5:5?%M#-'KZ1E'#R7D- Y$($$<,Y* MT-)9S8DGT=$E,6UK?+R5ABL-;PL-+]T%7FEX>30\5SI*DE%<<3 !%0@AL^HK MM 6'GDN?316">EUH> M2PEZ6_OVHRN-B"H4JI2 MJE*J4JI2JE*J4JI26F\I+6)W(K$IHHS9U'3"<&*E#,PY1[D@$KFX>P72\_YP M-&[F[9SIV;L8QIAU\9_'H^.7&/&X&9==6QDM:(^6X N_M$=U**Q=!_+]%L&BP9P MFIK\JV4F1F($=ZT![Q:,PVKR#<'G;1X[[J,;QTFG/YF<8MRNIF,W$E"3K#?Y MBH.DB&A1!AM=%((KX[AS9>(U3R((3?^.@_@"#1 ;)_9>(Y+=TW%>U1?Y!D>Q MD=ND^?E3$5[)_L;AQ)6KOV0H7AGJ-@SU^9R=,E/MO)&&,R.] >&E!J&5A#+_ M%I"AE(1D_HJL-$K4]M[YWNL=N%H_D&]C>'']I+2 +AABI-:E)*+5(ECC?-0N M,!DD&DO<;0RY6Y'M'VYPBG_#M54;O"W7OKKDVLAB2F@H:!FS)6=L!*-U "6= M-XB1H\2L#))*M.L%X4JT54I52NM?PEZ/PX

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

=PRO8&E(\07%B$OS9L07C(:BZ!LZJV/D:>'G8 MO KD3Z_*UH1Y^/,)BJUU$["F1+_*"4?R8BJD&=^P:?!:OV3#F3/,+J\=X(0_ M0:0AQ^.C[.3A[/7VNJ]-LF^H$JKO/7NK;)T:>1-".FQA?+\"ST[-3'K&&^<< M[%5Y]"+.1*0V_H+I#YL2##\T.4\AR,7-#X',.7 QV.MSZVD&270TR MA,NBND;I7<7J.:&!-WPM+:P27XJW5*J3/T<[V?^+[0>JN3/&291=P=J*^,N[3^R/$BE!R;?=P">&Q-<>&\SVT _1\^05@ M=9_R>50T9.A^+"D\XR6["4M^2:I2+*6-038H"[Q"Z2N(/$?T5*!XH'1_Z9K9 MV ?F7K47.?,K9'AUQC9Q3ZKA537+0X>F/GT08X329$Q:/V&VH<8XNY7MK0'A M0AEBY\84("' !J_4$]]\T[EY M ON9T19,"B4X&,5X7;14]?J;[FIQWY^(OX$QH676N[^'IKIQ?OXY.!<.PRQB M6Q$< ]9MD,W474)((0*PVUQ1'MW.D"DZ$I'09%;2.^RQ-#R^DL/0%K0EK1SO M#HH96-(@P79N)T#70"B@"GF* 8/@?OU.'*BVN!I)MVI#BH2+/<2*B#:&42NE M0?_EZL#)ZI+B\IJ;-4,VH7Z"LQUJF8&]_0*>;PZAU\F.K#UEY&0\J'ST-TMZ M:@[>MNM7L]/,X&]'+T;8:D7O=SM]-D8M8 MC&#)9))_TU0 #:IC*QPTM3_W[@MF'RIBSB5^TWX+EDQ0 'X]'G7?]P7$+ M%D0$5<=:(1_W'CM_K8GGC2N8WTD<=\F32V9IA]\ \%7VIKD:T0PEX-U^)S8] MVOCI(!#(>)C,$4RE1Y!QB0CR$XCEFR0U\0$N[82=^4Y@\S/4N5-?:;0:1O_- M Q<2+<&[T,0S;GFDT"S#T1-W-"H3R= EC9FPL5OE0\H,)'")2\?)9N3XGOBA+E;BBPM"G!5NV37;%A M1H_E4D/W5%\W>30MIN>BN9KXHXF3&Z()TGOK^N\YG1](GB=J+$'!HH;G5(ZHQ_[;SUG-['TP%RK&- MH CHQ]X>Y$59V<8[#M\.ME!0U&N;N:E8VZ2IDJ:FF'7V@LV[9V*#$"#NMZ%! MA')'.("C:04SS;"M<*(OEH]E_P$@QI7_TD\RF=7*D_$\0OUK9]$>*)?[:H+% M<:C)^*!T39:Z_:TF 4T+MI M T ,1Y"O[ =<$FWW1M'*H6K44#([N\@T6\'C1&-M[K5Z6TJ:9D?1806!@A=Y M?^(6&4^A/T]&0YH;K<"900*.@U-IZ^=&+50PGW.\Y&HR.^ZE=D^&K-WN2_72 M4H\+3!_X8JOCFZ5QR\NVXGS&\238WT@7Z-95S@11B!L2!>>"6]463')37W"6 M=03$T;T6CXU9B ) D&_BVOR3'>K8Z+" L4NCYL MJ:!RYN:=.,V^_055!I(JXUNPQ_#:1=;K3&@$)IQ"V4=0<;E,*]";ZAA/)+^$ M W8'YYZ$2.X #8"B;Y(W;N6D7\_]8(6?.Y\Q;H)^T/-,[-OZA#Y',)RN3N(( M=M,1' CIF6>7W2_65J("K6K'.(HHIL-7ZYB5.F>W*4\'O_"@BD_U!X7BM%4] MS@X+"%CO#6'B.B]ZJ8Z@$6%^%)%[4Z='"H[5$AN_#HS<5&S)&!)0F>7_U/5K MI7"\LMU1?LE+981(_ETI-D@!OT_X43KQ9],M5N^0@-@S*1[CU44X1BZFEEE_ M#)Z. $YPLW!+6=(F'$$'YEVT(_L)QP")UATV-P,:AI<#\P=%0&6&6?,%RLCP M%TV#Z\XZ@CT+!\TNQ=3++Q ]R_[0(;UT0LSK02J-9!*;O",0)S=0H"/]7ZU MH/CIE!\M<(+LV,6Q=[H#!1VWNB:F5,_(.YJ27'6A>\P1 M6Z,BCM?1;=K7X^]U)[T-KF7KK@>OY3A6Y7UOH]N8Z\E:B3L>0/0UFH9D@>N0 M=1]C7:>;K.(A[Z/U>),B)3 _G\3/DOOP80RM1DG.3_2-GO1 TKZT2K_?VZ>8 M6G5X/K_GS*W#%"(7J6 81G+ \=\-\;\3%7[8%QIX[H/I^#]VNV_>6F&0ISW1-T&/19B&D58)[! M?)G4CWMK?GS68*0F,Y1B+U!>;IX@*QGO\_7T%!$U84;_^@ 98!,>:+CA81VF M8"=J/OZMU>?3IT^T]!7DH-PJ#Q.)OLA.()*'Q1*V8+L)?->_+A7JY%.#UY*+ M R]V2P:D1H9YAZKUPBGI^^ZBZ_:\C56HO4=:G6'NYTQ8Z($F3&',*!XX$SJQ M&R*MF'U 5^Z5U^@K8.QKL-&J'B%^>^:4F5VMY9TATM$!(".T]DCYR%7;E/NO M;';!X!]&7"APUIY,)@+,YPB4,J^RE*&W^H(9\%*LPMLH&=37@C'DY(\W7Y*N M?U+-TX[AV_]RF?>#G>J%7GOA,.%/\V6_##@"?A!!N G4KV91B)#C4@T._3(& M2ZX2=.ABR;=G#@>G54:B!\+U5/H4_)4S I23OM[T\+$4GW=])/9"LR@)]C_1 MM+^+@?K=K.?5C(=;L"JL"2I)>ZU;EFTV?+RB46CA2,;3[S7[6'\A>?(2&1LJ! MZY..F@N\<63:!R!%X2V!]^I8^!NVHWUA3?URK+\PW^2S@RZ:;&TY8 *\8M\# 5.55L M#3 Q@Q9[=@<7EOD!T6Y3EYY8^PH.J@:_??4 W<@?MCN[KR;UP_97Q)>;3GR+ MW;1D[B8>V,Z\A&VU)TAPJ;$>-EA,#,2Z@#977G@L%2FI^8DC:$9"S=JW5GE<*-+-,)=N0G71Y L&2S#!LQZ#F&V*D$A\SA] M,+[IPO.^NR6H[/&6=S:'4>I)'H$)PZ9R-V8K=*D[7(21M%.:/-1*4*.4);E] MD"$$5'8AX '$73JU6[!4[)Y?R3,>70CQ$-:!MK;1A;M^N7OKWLGMZZRY-=T[ M[]!RUS6Z?WM1:32G#P$$K^.(OD10 ]G%#<\JC&=&!!RIR*4746?=6/;A0)SM MXO"=-ZJM5SU]WDX-&PIE.\3?--N0QI0.'8,_PM<-KN;3N_\%7NS\J;^J -0S M)J.Q4M.H+@AGQ7[1$&WUN]46FM5?E]G?^ZO\I"*DZ;7?H4NO<@LU4RZ_B)7) M7>EFV3&14$<,$ $'XL._>!J<[L<1*&<>]9^% 9VU-02#S/;1OYYOA]VU7QQ+ M+UTN^>V;=?Y%B/@[,\%H;4;WG$T+*09;X]<^18+418D@]\/K ##Z[/RL/T;Y MJTIC7?KC-9N)O7N/U,E?NO+XOB7OM:8M&#=F-0+3O5OV^957]L#UHTCF_F7M M@OU?.X_,OX=K>=4#^?)D'K5KSBTPMF%_MN^AKWT*L/$X*9P3[_Y;W M*_C-LX_G!S2T/\,X0A"9X(71Y5@R'HQ,P)&F^QPS?@KZ/JZQ#/S9B,? M_@@($]W1^NP4[+70F%F#9*IC-$'6HSXQN/Q%735=_>.K2\L-J2\DO?N3A,J6 MKF7SDWANG>PM?_#HAO8(U.U$:/9!W;Z'P(ZUV(>.HO-U(B:QMF )A32I-^R/ M#J=D@\'JZ0]TLL+=7WW!O>_QU5[V*M:!MZY>2*W(,#?)QGW? M>6'J;ZHU#(/&MEICR7&S6NP&;! ^&ED;$4L,U#5I81"W(QTRVPB[&L!PBXJ0 MPL\,[7=Z(?D7'A2X/;>F\.SX[)8XX.X(*A,[N /_"@ZXOD8$*>Z:X<>T8>#Z M;4LG;!PY_9S/&X0)]EN/SQM;L+L+?SPBMF!]1XFZ44SHCZ-8)R'Q54#(36GU M_*4/[B>NSC.O]I ]MF"R/U1.T>OC*YKDE$I5NAF:0;/V\M\+G 5VFZ'<3J>? M>M\;V]N;&]FWM_=23#6*/L=!*XQD/1-W+-A5.NAMWL)O9LY(BB!(XJV(<9>I8?' ME5'.O@F8?+XA._-]@]6AX!,K;B=5MC-RZ+J.;H!LKO3;YP6?1;Z@O_\VT3I&H\2^(<=7"5R2T4#')C3L[%,'J^ MA =[4,]DOEH:(XAE4DY\F9IH1TSDB62F7LE- MD5@2O[FQD?H< ?A=.M8)(-'BBU"SH4E%HS\4MF"Q&>,5.:\\%(JE/SAX.5K M-S^:6#T9IUTZU;0(>6?>"-#X)Y5O-8 IQHIB)S89,%$!1P;BNX/W*RB48WY3 M>-,'BE^EN?KZI(9G5($W(SMNQ[:J&D'> MN1]-A/[1/(KBP2QK+%#IW.WR,"TUJF10=Z@IS=>EL<$E6QN?>^:"FX&"ME80 MO5 -ZBL!UBEV,48>,XBL6J>5,T^C(CKA E@_1ZW;S?!V"]%"R')U27AT*C8_ M=7^8Z=FGV!00*MFQ(OC^D?D3_QYGXDMN=.MO&L0[>.TARL*MM[P/M.'2B&%L M8(%"VR&T0HY=9GNA1 [E84.TIX*N9>7[F[>,7 \IG=3>.)GOHNBH\0:LANY^ M.K:)!;5B*UDR88P3X//GJ$"J; DEP% L04F!?B;&:#:3:BM\L%/QD[]&FH?; M%ZL04?/.F]MOE$8B)KF@2^L!"(_ILN]FZ6H!D0P MPH"(#GPTZ9U?*U)ZR;MMZ4V Q6&Z_# 2.:83(CTCE%P6\Z8]3*=:-7_\@YLK M8;=[N UTOWLHH<0R-XDYQM2U);W20> M9_E>MN2-UF[?Q(-JZZMJSW^TM]US;-'V-S<7[S)7SEMXSHZ?5WJO>& Z*J7C M;C_F8GOFQA>^5J0\]NIZ$AZX/X">PXFP @%]Y-8XE\[$,#92@FT+KL$+<5T MJFPGXHB"S^IQCF#,"U1 Y\MG[P893ZJ#0MSMO65:,UR?V*N3C*TO4QXX?M$5 MLQI"&Q1-HD+;[UE7X$L#&$-3KJZN4V^=IHXGR:BD2N\X<0&V@UNHJ1P"I5'X MNS%:ZAQN MO)V<$N@NA@($X7MT\ M"8C=7QA:I*O-E:FZ-.0/W+WY8/M[?]J<*M\=LS;,*GL( EMN'JLZEHPGPK'> M8J VL5O7JX\Q/,;192'&6/H1D7.'P[4#G!41'3GN+PQ<)_KV?<@P2P:#AI=* M?/B]TZ@BGXIN\VP*,?K83\S5F &87HXY.\L\K-PK( ^9QC*Y67)IV1UUSNAY M.L;ND8GPV;:ZK^W!K2M>B2\#CEQ,O&;(5CA=7U,ORJUXX7WL<^=$W2L>M2?O MC_:H;ESOA$%=SZU)O0_KCY\PX0@T4W&@!N21WPC(XV1%4APBV@G"S8YQ!.NZ MU. R1_,Q%SEQH77COU%CDI!#BI4\L>>U9+B%/?"5(]($/H"^!/;1I3@"!Z] MH&&R&]Z!4)I$I:UT2:+W/O)TUW%V[6?T\8_>,5ZZO>*L.FW\.NO4^W ?MA,W M)IF@AFWE14O1H4=LHR! M5!(S]-6WLRP$ <'R)#.(!X2VG5C1]2O\%:Y-4]3 MS\X/ZCAKYIY(^J/DL>/*%#>"&T'&D^K]5KLI2"$4#Z.56ZJ>V"DFS+*HM0_= M 4:>!#("(D=-4PX8%]_QN5N9O6L\@1*DZ6NG6.*#\YL8<>++Y4Q /K;>%NPZ M:4*!ZK?:-=OE6F617'5,_&%W2MCY3KV+:9>.^(1:' MKPYE23>2'5OM]2=66HAUB/M-G@$O P1>_L"*H[%DA=*QVS\N'MQMU'%QK"ST M==\NGL#ZB;Y@I$&_60&GK.B^!8SNPE)H9"JMX &[34AHEQ\QWT:0#4S/>?&LZRU3B%@MD!9!Q,1CU?"5U("KN2>G%QNI%MA1M M1\IVIY(L_6SIO+W?GXED(ZRA2_T@<$NUX)Y[T<#:#T2T-(9.%I\&PRA(OD#M M-^Z=6S#!C>!KC+NC$[3'1NW7'^FU9!SNSG;-.#2]ASUE#;O;O9H.!'9CJR'B M028]@(M;*"]Y[?\(A,:M&MI[AMH!(WG.TU.3'C:A"DV2GM/4XRK3';9R&K&[ M*FT@SQ1T_\K@A?ZYG*7%_H#V9IY@<=W$-Y9E+#-Z7;7N*E'(0@]EO.+Q_HMW M>I7NZ@F3T05-*F]"AR-,^X%FUH,[O_'Q7#AE2U'J.\5VHIWK<5WN.=T":]? MQG*O22$L; MG:%7KJM>5SCK[1L65"F?,6P5N/."HKRP;>\->?AR@R;/]] )R,9'RK7AINJI M?BQI$B.&_CF7BDLF26PR@]7Y-T74[8]JM.>=%OKK::'Q8*)GMWM5]SI_N%_$Z8#V"UR&]KRWS^.>#A;S)OV@N MKYZ)#82":A$L<0,JGB4EQ2#2NVF>)9SI(QK<9(>K4Y>LJ*%BTRR5[(YM1LLS MV?4%X8G"I^7=3FX^NO*']W[@*S 4ZJ1S(!Y8X0@I4DF@=B>1EEPTO:RD5UW8 MM=Y2#M2=C]8^^3YZ6%7.ZJ*.I_5;T<_>[8_ \]/&G/N0ZXG' _;ZX+[/S=!3 MEL!F>CM5(PU24P<5ZITL^O<_A;H "R^"/"71L^AE>^+6%BQ@FD=*:&FHV.G^9,UU8W3&>VBXQVBL]"N)!YKWV1;FT-B= M9]T#.9B]**MNN0Q2=]D21\I3?=VV*4PZVK7^TK0.X3R#\=/F@_"A \&]E(OZ MH+H?]RB.979LDUHI9P O022_O(5J)./BPXT;A\P57H"R9B(G4?T+-P/4G_VT MUY%-U9I1E8^R88/A*K8J;Y[1P!;NP; MP0S3#^%-91(" 8G+L]0X3S$(PXG[DE(Y]P=J$]P-=O4%]/5=$7ZBQV@SC7FNQ92#IA@8X[ M$=K"5;9 JYGJV('B@^R!CA,WK*.:K:5A9_\'VG]Q!&04]C]%()_?QKH"7;V- MR?XO#F5#WD?\I^/;1OY'A/L_:7W_1>1+P9[T@=U]TDF?>@6KGD:+'1?!N'-F MX6+!W&3A&LR>,4@!<(F%,N!7,FX7RR3_!!C%5"7&C;F-*M&*^R M39 OB7)?<$U(](E1[NS]DU MZL?T;$Z12_=2&VC@ZTV8^G3<"=98;WSH^R.Q*?M_(BY (A;_1WG+I[<3P7V#ZHKU &I8*EUPNW):F3>+S6%;2:&(JY40JEN;IC<[X M2/0<;G'8X&L+N3"IY+ %NS #:2@B /D "?A%W">H@C;4:]7P9)9=Q32X>ZPS MX-X6+.1KS3JMP!J6%K1VO.X.WOS MI["6]1/;ZH6X@I^H)&NP%'R9!]&1X 6 HPOOY!S(;_V+2ZEMU"H\;&YU\[6_ M2/D/WLFZLC@EF.- M0XNR'V'469J@'+79&?+<]K"NT-?R*21!T$NHQ .G'ODX;<[IT>7'T=*Z/7#S M6!5>WUR+$]"-(-0!'L0@,5!MK%L?8C7M<-A;%M\;?[APA09,=AQ%B M:0X-QAN*F'18:-0,E]_NR0]/.DJ*3_,.,!%O??I.PYQS?AMS(<=XN)\Q-*UB M)_MO:V'P=-K$BX^--57)GYL^IDE/[_QS2;/GQZ% (!X)7J#HCYMP1!= 2Z"= M@8QR.39DCB5;YW35A:V,1917V!NEO5'+7K;/]745X[H'O8S#A_F"[;Z8BF]O@TNB!:*>H82HKC/!AQOM[.\Z1L<6;8K MW+[L?P?KZ2W]1[#>*SX:#0W9:3X8AD2JQ;*D%!C'ZMAOL=<*;%I=KNE+N_J/ MS<+I\7%Z>J-G;]3S]F=:WMUV7/"D<=:5^],;![G9:>*@"F3J=[)SMV!7*D&_ M05 S]7&Q%U"9N!:,E@D/HWI$.4< ?Y+DZI/J$6Q_$E ) MFNMSG-CZ["P1J2W8L89G8@CP)_0P;I'C(@Z$;66\R:_K62!P(U M!O?HPI-0_P$7!T%5E]5&('END88M0CF2B?$LDY>!CU#G6I6VY3#]SH='NWK+ M'8D=^-F1DNZ@Z9P]96+KEI[@4(L@UQ E*>Q";-#Z>#*'_P]0V3+YD,C;^3G5 M^".P?GKD2@**P%^9T=MM]S%CV76N4#EX"AWV2=+OP\[CMLXP1*#NFNX:Q2/? M;=AUVE9I3$0.L6?6)/BSB7>%05?@QKD6SAY(X ?8 M5@..'F<24<<7B[AV ;S+-$.R5(AT7#L11@K\>Z'CGDUR4,W*U?ZZ(U']0U/6 M-TT)V4A-FJ]K\N7[?#V(*KX6TI0)XR_T)$M4(.,^.Y.P'97LSBY]"0Z$4WNP M_FRKSCS%YN]C-[P&>";S7U=F_[DL6W@>ZXO"?.ZX$>MZ$,9)#'AM+FD+=!\R MZ+)Y\N"!=GIZ^E02"_*Y8A)I!,C;:!] 7+%GB[+-!>@*71'N1XD)E;=SW"1% MG*Y/WMOW:+MW@ZM:5MOZ;,G)P^>2V,?8]XGD1T@8EER 5[+0PGR!"V"TT"?H MHN7TRQ/U"2KT[L2=19*VNUT"'L899;BI9KA[!JQFKN=D*+YSFWJ^U[#*A$=U_RN_JV]2VN>) MH(;)OX+>W,798K1$#./+*$<-I4]VO(\^>_,P&$YN5FE%3#64=SZ\57-\X^_& MVNW3U<4/79\=^R0#"AML;,%82H/%:,LF=CQ&1@Q+HB@:6LTM$M-DK;Y MI[.8< 1=M&1YE"2_B/]"!%75RXOM()U)9A?4(G@"5E"/T,+ E#Q;X\&; KH8EP>8YLBP(ZZ-QH!1'4)%2.9<^'8>V>.?ZM?H*.G1O;N3-S5"X9!R*L=J[5.&=:CUOV/< MDKD6XC2V%2(X/L%\#"6@KH#L*(0^_743+P 9CI99V3J/HV;NU3D7.8-ID0:06$HQ4>0HH?"7\:]1QH%3,[)\ MVGZZ';,R),,XB0W9])X(TSXS@SW9JL/0;+]!2?O-$8(S;Z/U"<@:5*#C6&W! MD>[VWWS]5?752/&9MKHE(5_9?;L$WHDTGCR8ILGSVYA*G1V6_=A0H)RZT\MN MU_Y7OS5*S,5;#CVRW".!'(0\,")3C+6332#H8:80.Q'7CYIY,WWL(E5WTH^]-?.$=XC/V*C)]1N'1!%YW!$MF!L(O$Z] RMP=4'X4Q7SO!D?'2Y,$&+./36'$&& M*/&TN\[QF>!/N0N%&[>^YSP*%BS><9>\^!X:-.86K%^C=+/'V2P V>=,CV.;T2%,HU3YR1>'3B70'!^%<^!;[5/U?^1 M-&<3.Y78LYD/>G[O/;?RQQ5Z+HHSJ 3[EW@T.+D^%]\MM 7[C\RCA)SU$*.90GD=*2& MZ.]"57>X*,&PLB4_DU=T#QMYNHKI78[8)WM'RW^78F]Y*^]VF,6O?R'TY)?X M6D>6))'A!932#C+U9D"I\YZ.5!%B;'B46"D_?^-^QO$U M[_MVIFN!?Z:@UQSEM)&J'5?G(.6A87JW8/(8<;1%LC7=)BD<*7 )U7WQ?>Y< MJ/@,$@P\2\A;_F,Y%79HH,E:-;]PUT*VX3[%!W_/<80\F>[H$T S;G4'4R!@ M[EQ^"URZ%)CI[J#QV#8G32*EQVV,LT+RK.QUWI]\UZO^U#3#.B4[X:-@W'U$ M<'!(>>AECS+M)PN)G-5T4]^C'U3*[9!YI/?QJ^%,+S0W[_LEVH5^#_/I(DEL M"^8+3_;B3]+UH%24O?V1Z3:Y,N0QU3%V<*E.SJ!]5X%S>.;ECD+_@&W[/[#F MZ8ZMKQ#D+#S@@9##MII8:($5XV@!]NL@G=LT#22=]^7&^K&AT%J1'L6:84E& MMV>;.I]NKHE5 MFU[):'D!W6@W""KK=PR":F()!$,OM#&[NIB^,X>N]_V2_^Z02K*:]\OID]>, M?\O=$GKV.WCWYV5GXWJ7PU=/'B_]X0")<(6IC&VM)UBPT[=@ET/3(+P*C8<\ M)YJ&ZU>"R52K-&=?(VBE&N8/6DEWJ3MM\YV@8V-U46A1]0 MKZ7,F95MB5WFM/5@W8WNT=(2A$U\;'#A' M E4T$A AN"D>,I$V!G@PLI,II []F/JZA8%:+#2Q@I9^?[&\R_@0,+- M)V#;'V!%_5"LE8L99'#/_RMTP64^^$ B;^U,)(,:W_Z5M4LNQVEF&2X,O56% M4?/QY<##?H77DL_6IFDFNYV0W#6GP'-@]N0,D;M>L_B[JQ)4KNQT3"$"+MAM MW$.C0XA!GH+MSH!L04#I!&J_?JQSSXZ!FAO3-@-M\M[E, MVH?!Z_A8XC'4L40L^<4C;*LS-^J05'<"RV>AO"RNXZ7_[IOY?B-/LPL6IUHV M[F*NBU2=2%!-_!9S)/%">E?@9E$2C(SUTW^(.0):DN6^6FBC_48P>U'5YYL# MMV"2J)=_N\Q,UT).J5[1?4M5-S/S23,=VG><=+NQ*:,I S%( MP0H+I<&C>1 MG%@=6[E*+.4,'W%I)XI5$ /*2#-]9'FCY)Z%>K?H(M.1X Q#"W]5Z;#'S&ER M%-8:AHIG2=4SG.FD5013%64"_<)WLK6[OJ 43B:?&C8:,&MS]E_7K?&MNSMT ME/;%;_*\[$6G.YGUA>8J'"$K[EHA0&3)1)P";'#F^^@O?U)*._7CMM/_=4EIBQG* (O%$[B M+G79$J__X!@C05R;"4:NZ=U7A]WSKM. MK8YEV Y-3AO:IM<.V\2\OW3\K70EMUC%'^[.+60,H_>!W8QU]CL+?LQ(X2YV MN>$@SP1ZYX=W'X#2V K"'H>R_-?!E5<@8+)K./)6>+EK5K7E6,OVB(.'*XEO M1VFZRO9_YK)O[DY\$:>E(;4PG-W%F M<*J4(U ,T/\=QHMDE /(-(RT&^F2(T5$B$J*U%[Y;A!;CG"DMB=D&/\3%W M@SKKSD=VY6;PJ9]=LL.NRUZ\<*'Y.-.W#N6U53:*)$:9Q/[N +EU=W7G*5SV M(1AS(PGV!\D1I$"3Y#7(/5[L&ONI+D$8M=A9CY&E\\7_"O\&(8V9D/6''%N" MH--Z0M6?+PU/S2._9+QJ?7 L<'",(Z X-S@IQQ&4 =8Y@BK,*+07T)U86_F0 MH!#=WD(0 VSB2M]]C2O>4S7 +KOUVT3*]C_*LUTXF:3LQBW/=I:[%%QKPY)P MF>/#$O"U=?G %JSSH+_W*;I>/A7."\%+^WXADRJ#8T3_A!#C MSW+>-Y34HCHDLQ L21*'/Y0Z"*KC:/ET;T8%HBZ0=2*&VE]_*W#WQ7JR1 !V M3P;IZ&3OV'ODKN^9MU-4E;_)]/2^1=XA6EXGE+V<6CGB^1EW5ZW-.B($Z&7D MW++<7Z;E[.R:ZV7<2AF*^5?G"88]2@)"$.VDR95N!!Q"_3@V#NLO)@*J>")W M+3$BM*CK_(1R7],/371^^RSQ:4L=$^/5V*+@X1-M;K*V2,TASGML*S21R1DD M$03YT1:L6G>L%2D(SF)E4;@.]X_?FGRI4_D2P0QF0?*>FYW\$04TXIQP^M79U;Y(/K6W!QH_S?HOQEZ-,+TS6KS,:Q M#C-=4=C.T898QO-7**Q7(X@T>MH0/C-RZ:Y'#))WV\YX04QTD/!B=' MG/CFL:O5D,V:A1PA[M&4T7?0H=#GW1_(>DSFFR7\;CW=>7Q'#I+?)RU*XWK1 M:5FUT5,#!-,O>F[&>S*)9C;%: 1T.0]*60Q428'TS1:>AH#+=;H[%+"_;<%B MF\)?H(XM1=R[,)U31;(V.\:UFJI?;1_RI9CK]6QD+KC\N !")S>S1$994-R M7%\?YZ.4LJ0@81YRX^;],U!AE)/$:[/2'R"S>8#TTL/-<[*3\>[W5(6>=QKJ M>;RWU9Z;.L\[UI;I3!N6=#*'WPSB$*W6"&]L+'*'N2?SA$4J'4$>R/ S:AQ M^91JP=/)>PXV.%ZKYWV5'EP^7A.V/:.S&>9\%?%N/J>>9NE!RP' M8NML:!.A=,>NW=<2U?,IB;IHR;QKF5==-0/[RE#7W(P47O+']/LE*,O+R)RN MLB4=XLQ"KQ_JF$PD%V&A@<=V(Z=XV@/IJNC3373/PW2\Z M0R9[Q*>LI>]\>F9KR=0)<>D/\,G<'(:L%_&:?CQ6WD*2)0@LMCOBD+MI&&4P MW^JK7:;5LP!<[!I2/7JLMFW:V"GW??JD:JND@E M2"[;WU8_42=ZPU>[/GJG;2?$-S"'6,H@A9R 44?+@\\A R4#WIF[$7\)6'@O M0BN68?8M=/1_])H[K$A'XN UI.Y*.+95'X+7$KCX[2W8E'>+R1>6/DAC6J(, MN@A"(&V/@U$:?F>!457/"]*''46N^Q(?!GP[;A"KI76;[0AHK'YC'@9C**0T M6I.":/X;4'O.F(!V?&M9=.G5NY'.;UE/#;)0"D%?9G0K<[7X@D@!.7?(BWOE ML3O^Y8@XDB9-J.RQ%L0#1!V\G2MJU]>!F6?^A:IQ=Q/F#?'M'KWZ M]P5,87F;6[ DHAQ&CB4".(QUX%*\$,-H@V<3A]2ZRMZ25,7+&GG3#O2?7%+L M+=K;9W;@ N\C[9\V#/HW!#EW"R:+)9=S@U+'R(Y)7KR 1J=8G,71+=C#Z VF M_=?.?'O?D'Q=EM$>^HEW36,17NX)NRVK3#6<>#-4;S&PM;@.19]Y=S;4@1"]GK6S"I^>$7"T(%U_\7>V\>U433[0LW(B)C1"89HX* (J , MHH($1T34.(*($!6528C*+"&- Z!,45!1$*(RJ0P1F620$$8%$005&20)41$A MIB,06I)T;O.<<\_[G/6^YW[K?/>N]YSON\\?O59#577M5-7>^_?KKMK;.[+@ M*'ZYOK[+">P]55!Z=[/N*( -)^G OR&BX$JW>=T>R'L$]<4Z'@K?GK]O26*^ M?%9SV'7=C,J:Q1[MZC?KJM4] @J]%>4:8+K0%VG' 75'LF7@UWQADX/>A^0, MKV.??FQ,+70_:G?+I;#HU%''M_+7\U=JK6I8NY3#P20S57FX,U1X@QM[W75V M8FM%SUPX@(TEF9R A<^7U=2^TQ @O?MN.@UG+;O.;;I_4T?]*1T*VIM/K9 M$YOY'@(ZW)_;5#1.*,>V\!8QX1SA]OGU87>?Z"579O2_#7QXV?;ZQT'[?WLP39. MFA86'T;D14?[$'V_B[ M2X>2Q=0F\_,?R9(>7=*E_P4$QM8C7H+D45F<[8IWYRZ:3J_-JJ@T_KH\=AC#*,WL8KGUD]W M];RTFO"RE0 //J'+O"-WJ4,'?[GGNP3">="^I^E?ZH25,,!A<@;4&^:+ML_'($7 M)/60;/D*[)FDZ?4&?B$O;+YLJX\H6:=9_J)>-4>/@3Y>L&+8H]_1/.1M2] :\/ M+[LMO3KS=*9QU :Q&EP,:;)&VY:4OR";D>QZ0]\]^B&HR;_3]^QK\<_B?/>' MYQHN.X;.?[A"9\GIXSM+\K^UO_W5.37>L3.OZHZ5[C/G):="#&1V92\T2-HG M^XTI4O<"^[&(_#ADP:8W4C]Q1BA7'0Q(NS-'W.*G*3(1\8RC]S5G]%5*$P0K M;91V_3JRY&5LS8#A#]<#<<[-:Y^6/U0+(G\F*.7/[;1@E5-1_BQ2XS5'F9'U M_;/EWI,U24Y\M=P55?&G[HU6]Y24W.>KJ7KN#1SP6:92]^"-K0F-3K)A6\A' M6.&1UQ 89RTV>E\=')C?[S0_BG*P M":*4R_$Y81FUNI*2CMFO_N5H;6#%&TE+7[XKX =>+3Q_ M(GJD^'#)P_2]5?><4X*5DH3Y)A[MX4>&%IQULT(GX2*_JY$)&X9/L/GQ@B7B M8E%T0<2.&=9HLZ?W(:@]P.V)XO *J&+,(WDCPC@65^='>'NE(S'J>F^[0:0" M(?_BWINYW[7/;EP7FS?8[SZXU"7*9:?&^D?[WQT^!.1\DD_<#XW&5R0*-[FY M=9\M*2D?4\R([NQ\:G_G[0Z%'6_DMCAI+7F 2:"S4-K>CQVA3&2A DW%C7*H M<4;==0%\E];9*HIHSP//9>[EKT,UDD]O"]3]PY7BNZHC>S?QQ4!D.>[O==E:,]!SHZ9?[ MDETT^C7YPAM'7<2+W,^$+E(FQEF4"M@;737W;6BZ3*,OB2WZZS*%IGN4!G9R M;59=::L@Q;_-MD.4212IIB')-E;@0].6Z"<+0"8WQR\9" MQ[(M^-+T)JR*7W]"XYN=#=MSANVH+[N=0CXI-Q?&KK 2!A)0?BE234/D7@N= M0,9>">#+Q0G"Q5EUF^J=!L^/X%2&=S0V.3X;DOX\]$)7ZMT^4L\Z]O$:55MSIO;\5]R#)_&'GBS M8T3JN]K^[<# _;A,">"TG4#H^_L/B@"XY!!:G2P!P+\+ M)NO&PORCP+/ _^SC/[HB"")5)K(SNU@"> ^C-BC/Z&5/G04BQY, AGA7"5#* M8W^HR___+E>+YKEP !@'U8@#XVU4=?O(1[#/UM(],S5=UVQVGBTV MZ_OP[=[M15&I)M+^":)&<1F=-<U F6@1TC&@97[^"G]Z\+VA;!;2](#V_ MZ,J#M'TO!G66(>*:MQO&QGZO%7J#C"$) !WD#9P< >7(;RLS-!F=BW_A5PUC M%09 W_'%IKKS P9O+[7=;;VHL9_GB.WU::,.$ 21XG1[7>8BG"\ON5X#4#.)M+-W\OV2:3X@A\HYN#9WFP_96YG=(0GDO6%:>1]>%T MCD:9QM?$_;\&M[VK"NG*"M9Z0=(_5RD\HHR]W_<%WT"$EX$B#0F R*=S5L#5 M? R;F<#E?-B52;T&ZDYW)+K>Q*QB>1)?9BU\K:1F7L]93M^/+A L;,D1'(## M!7A5\B 3&RH!KLU>#HRLLV6?VKCN%B9B>)_7#_2?@?I#0M1#5G$W2P!9,Y!Q M&B125"1 8RF\E9-(E7+_\>ON67MCR,"_L=&>;:?TM_46$Z- MG%^(&Z:-]0H(XCBZ-^]361,=2B*W,\OBK]8I!;U;^-.X>RJBYP?7">_PY8H- M@Q5L4,HIOE@!D)W)K3C(AR)2S629E/,UN9M&J(M)9_J6#?0,$MX,[$BNNR _ M,%!]K_J'X8N0$XR]#Q J25U,11:0.Q&E1/;HA!B*:G*0[V8S/$T;!PPUUFA( MZ]Q;=EAQN.@"_D( [5&,/8\E.Y$NM$%E@=+ I@TB-0A%373V6O[\&N9U^K.B M;3AB?1IO%_Q=UF[_N>O5E4]_;IC:9?)@7L*_7G__IK!P?/:W-*+ EP F9\4/ M<1/43@F0\^@!AB./UL

7\/P$12?X_4_M;#7*NWU 1"50%WF1"/=(,J#BI( M)U/3FA"_$P]?!#$YD=2U!)QS'-@47> SY#8"),F]<[8[D;)I=T4&\??R7\7'/@U0*?2XH#;1+?)')L8V?>\$(0GB+:UP6/J5J M>!/T+?.)GYOE3V@F*:B>.=\U^7'398V=7W9>3PM8^2ON$([G]@,+K] 4J1&: M"56\1IK:&*A%5L9#O)'1QBXU7"QB&K'*F?3J;(5)W[GL@=U9@E_)+9;.,D<6 MW-S2SL*N)?=B*_M$&O&(7/ (=3[RCE I[F. U[$RHH,<'3WIUEEBDZCB^TFOY,*DUNI#'"X&-K'E.HT0^]-9%;?IC=$NC6M%N_C? MZ$0V)6Y?Q/C^ $_#'V6%KX(L])3Y@42BVHSE_-]#6[_F>VV3[:('T.+"<-!^ M,,5+57SG+$L3IT36@+\UM8":%6?/Z(CWOHJ<#8\;P84Y6=:YA4=(@,-J^W:0 M ZAI[\! )FPT.H$B81DMZ&,ZFS"HR6KVLJCLCGW=W3\=U>%L/7-_Z9V=&0.^ MKX*_.KWN^MRV93/P!7/*QHRB WI<>'!5IEG_L'&=J M[>-E[W'R7VVZY'R%^KU[C/;8IG/4^1(@@/E'O-LGHI,P1:@1(6QT4(.VL.Y^R;Y MVZI8N")KSWHPKBY,2C^*CWI_=*#GG6J MRZYQHA.(GCO:-")^,1?+4D95?*/.3'@@PLDQA$?BF'H2@'TZ&+%&?39JO[Y<_\$4;!K'S1X(^&PZ MBH&-*3'EO@X+?KB.A9)<+;3]2U?:)CG+K6.D#;%WX(/3O% WO-#AI@3 V=)A MC?=2I=N]Y]9B+MC5R4-D*K#0E3'LY"0*52\%.NJHN>)$2V>=1"(4%+,\]O_5 M\J^6?[7\J^5?+?_[M71K 2O#11J)B!Q.**_PTI1CS#U]XC$,=Z$>T:8Z,3&FWET-3WNVRHC4O.+S.C;/% +AC(+L@_WM-R&QKV>/-?GX!JB[!H:&K MVG37/NZPL_HC[FR$.LH8LM"'K@$9*^C>8,5W"G^*Y,S7J_PJ :Y&L4-,GV9Q M# (^\SRLF\XUO#D6_$OW)#WK,8[]&T5LQVB+=0(,81J?B$_EW>48=32M.W!E M"!G=6WGB1UB5'I\0B: (^S2NE:8N3FN6 %7Q7-L\>%=G9=VP.AQ-%.>0VR_F M#.\MG*^\Z8!=[,P#90/!6]0+=](#J8GS>$V$4AJ#IR0RZ?DR=&,\H^1S\)$V MQQ^GMU^##=AG=)&F&Z+@/3)(O+Z1>95L'(&TC\T,P%TC MYD_,LA,#=4+7]0Q;;GT&=MD=/NMS]1L]%],OC2C]_B,W: ON] >R)KESW<:V M:V9AS^&R5A2)!OCK'Q];;MW0%H1 3NK1Y^R5?GQO86#^X^*B2OY]Z?@O*K.=0CV0 M84QGH6/\;/3OI>M29-.NR2*\#^,F:PLI# MRF4-!&@OF(1;@ DMQX'>>3C#5]0Q\$:SHB.:F5JT>SG5R7*##U^%EO:Z]"O M/=@R7]Z@RMDXLV-#N&5JP/@J$^G)N<0LHL4%B((,5,NN*&C$HCP$\G+QU'$L MKXKPCM\COCUE_:(YJ7-U/IN7L>/%S<]?HN+-#%YQ#:PVK"9?$C^0 #X@;"(O MV@II7I< )PF#^"9$'6+&V6\2WQS!S"/M@@P"!!>'Y:_Q@+AYI:!B1 *RV![(!J7^\(/C'0;/4T3\W\UFJS!Z45 MEA6562?\ONT*7,V)'+UEX&)-,_QEG_KZU]5?2@:(W#2?)B#S*2T4^ 2/0L9" M3K'UUA%QH$K K.M+]LH*K3HKVK'FY2_?3^4G_%0S.G?S]9?=13??9A]??95! M<'_GJ!\@Q)+;<0O!$[S^LD;P>5O#2_, @B*\=8_0+,USIW[4$ZT!]Y(SQP&_ MO'M?;K\"@FZPI&(VK?K7/2B-Z,+*E@"_MDT3A?K35/%*FY^WV2B- W\OOU@E MIESL0FYES.SZ/Q;G[[_LHJT1YX.!N'X+@374P >Y>X3;(EP:*HE:4:?Y"\IT MK3Y?>K]YP>XJ)>2-;]N5%O+A/]YV8B9 J(M+UA8G.,A&Q(^$Y<84.2SCRVTT MNIG=LWSCR_<-X4X)RI_\ 7$NC2H!SF+A5>$BU7&!0MD]"> /#N0TUFN_7TZY M"(<2E;X5+VW=,:AS8@5#]E+M<:_(Y?1[V %91('YKV$+LR*:12O@0#ZFN>;8 MQ5JUIM9T7-2=0X[#@E@1@',3YN[PB MG1!N+DF&P!WU:6^KZ_BW>8,5D;=37(IOEUD17QL6-S^S+0:B;PI]T/KCR,(> MASXVY9..P*WVH[%4*D9#M+M:://B1.N77NZQUZNR'Y3S;74+[,G^HIUS)[A M1LC$QA.;=4DG.GYN#_%^UGEJJ)X8?KB MO1MFW<;P3<18NF*]4L26/O8,JKT7-6-#=-0'3S^*"':.:^V1BEESH_%I8G>( MWF/IW\7B))#5B1TLX,CVVSL+CXL.0WV->XSVT-91SG24!*QGW5XI75SDKALT M.?3D[3Z.['2A8"WJEKQ!5BJS=*R\+PA9@$.]F++T_&O34RJK MW_O1$$#MBZR7CWQ]"HCIV!Y>M_N@9\ M21@Y/\_3.>CJJSN,MXIY89#CZR4E/#:EE7I% FB+Y#1;,%>8:B*[$:K2&VQ' M7]VF(D;DF;!H_NBV-S$TON+7J)&8C?ZFC60ED(&GL[*QY;B6U_72(HRXC*P' MY[3PK8HN*E-&?(TROCQ8T5*O$_BV6\YA/PEP9FE/X_]S^[E,I!\]JL9< ;$. M2DCW19F^Z_6*I.V]I*T!)T@?C]XMS9RIU-SUM'5XQ&B>2^26Y[;IRPL#0\^> MN+0>JRD! K']3BS-1-4&NI8#+L*GJ::TS*4C4\_IP.$ 4Z<+UT-#DQ)W:C'V M6[<8K#BRP% 7N!BJ]LGX\H_YU97W#%.V*>E>:RAO:LQU9CFV 7\YC!O.S^2 5^T-%N<+TIN1%17/]M7G M=BU/BNI[P]0 62P:;(!C4-;.Q4J4D8*V"YVHZ8W$X)*?!L\VGCUX9?KMIN_2 M$PFFOP)&ND3Z+JC:YT#&]XB0L)&N;D]<\RK.T[CQH^#.1+0[+>CD3:<>R^C" MK]@!8P03Q@\J8P<>;&(^9TYL(#[R3]?HTD\? 9? #5X*3DMC;WUJ.GNI?1KH MJEK_RF!I#'E< C3M(W=AH6[4N;^F0M7V. F@8(JHH'K2!6^AEQ\4;A7BR%VX M]K?GL\_/5(H^#7;ZD4[ HY"'X")TBJGB8"\Z"C&O6.N0C3[:[R]FG#A;H#7X M;7=['N6TK/$S&KMF5% LSBVA^X[A EZ3U\%)I+UIGAN;(H8W[>G=IYDK 8H7 M/Y&)^!V69(*_H40WB[;](Z6&+G[[S2HO^^E*/UHJ71A!'4N$IDC51Q!M2]839Y835$2^ M?2>&2CMR'$->ZJ[_41P9DNVM..5;_'5K?XW/+U!0AMJP I!5 E9Z%3$QB%Q$ M2A\[Z-Z33D&4F2H[+H/W=.CG^D/"L]FGVS*S!L)80_0=\QS?0%T;_ =^) MW+6%$:W\L+IA#4B=+@C*UJF[X/E&?R3$X?$=+J%0 CSW$:D6"'3%<=:A/>!I M3'\\JNOG,;?-"T_D7P\UO3J5,7MRQ@HS\R4H/P9WE]Z?B2C-)2GIF@LM;;^7 M;"(Z FD\9'4$GMQL(P&2ZFW&51G1P=E%@?==H@VXWT\E'^)/IN1,N_UAC6WH MQWE7P%-\8VXD']=,UPR-J"ROV5.[[GJ.SY.#NLI]EL?YU'*3$Q\V-(BO/8I9 M;]$_(W 79Z)"R=)BP#/42V1U:-V->;_OD)>\6U:N>O/=5]_WUET_?KI3+@2\ M_&\8%%ET4)R/;(H0(G(@JD(F\)4"9%!?JCZ>#;81!Q08V380H M*[ZSQTC<8+:8H;C;8.]3E?LKG5T*QCX73%"$]J3=L!V'IQAA>K""RL#IV._' M)(3RV;77D+;"K?8:4%?N3^[]_[;YLBULF8U]6?_]_9L3!)A0V(S M[2H!VD/LQPDH,)U#270;($QDL6F);KVB!1_JG$)7MW*AZ MROM\7KGEZ^4_+:W6+$@7:7H(%L)*3TC6L%(!N9TN4V?#0I?'&)_9E$%L##S( MN*BK'?WA41'E?'C:V03R:YFBQ4/UFX^(8H/L>.2/N$6AA&14W<^G3["%R\93 M,RERZ(/<"T7X]%UI=\U#GR1_R_*SOQ81:7:5?&J/2,EJ4?#]2%XC!EZOBBS\ M2B-MI@J:Q _I9Q6<16$#VS[JRT,[J*S/03Q$1AQ3E3:]Y5K] MXHS1M[4]7^I#5RQWJGVQCK:6:&ZK!M\Q@4[MFR'7LQ),ZX2OG"MK.N<\?LJS=FD/M0Y"3; M0D1)!.=,FG)9,;D;U*S;"HY0N&J+?P^+/I[52C&+3 M_\I-((YZ\2(=6WY!*VXQR,JJJ6K$:XW/'"T4J<,5-)%]S[1IOTOG.NJIX]D? MW"G[=6W]Y&<-3>S;)QKB],5K5T7RR$D>-E^J -' M N>-R7?FNSPN#U!Q!E7GN J*,YM'Z0F@U"4T0$'5Q6Z0-RD!^#8_W#YJ;,S+S2 7 MG%9OJ2NL/&*SPB-\HAR.^![ YF MFUU8X&P?6.BL,X]\*G+FR:SZ<5![!H1WDU CMODQCO>43X2-*S,++!AFA]WP M,5*R#XX0S,VZG^RW@NW@^B4"Q4 !F'D&5P$]N"$5;37>?"+MX2UA-"6-RD:ZN_ MM&=?3,WMIRF%8AC/6R[CHKC.4;:?#MV%O9$K^T#F(;#1FTV95=HL :(/=TUP M<0H<;CO-K+B:3=<6;D$^,V/1\3R?[H%"OY4 MQTEDY+!$ CQXCYWY< QYVRL!1ENQPBF3/]W.H_ZI#O;?1#L<++3#2P#J$I#7 MG?.WVP?RX%_2_U\LO6DBG,>7 )?6$?:DQ0 ][,(LLV)U5_X^.NKIZ;W_]C] MRT@&",7^0SG=VNAS1!>$EU,95!O[@\(PV&!?ZE(PG&T:D!4<.>7:R[JW-SJ8 M.=RK WX$!4[=TO^Z>NB4VD MI\/_L8$1R3Q4T/#N_C6"(^0Q]":GU S0"'RO\W0 M@AR^0L/L]EL9=XI',DT]?-U"^C15Y^]L>^(=(_N1?F,,QRJ@0^?HW :N9HR# M+2F4CQNX>PG;2%/"GUF2O>[QN\!';?DR1^W(BZ(ONR6 BG9>CS/U>*YPG^S4;[X+(M^&XLEVV/1;&]]6, D?SAO: M2K5DU 7XF76W$8:V<5>*-.K]811QR1X!&>KU6G++WDD WYKF4K"7@$M:*W-%1 M'Z '!D9U)K*H$_%01Y/)[X7(\I?TCX9)44MRRP]$MW,&Z([UJB CFP[MQ,<_ M,N:_K&JFZ]6PVNL-^7>KDKO.)V_4.2.-R%#)TU.CC41XF:9(A<=Z3$$6T6'C MJJ;$._$+-MCC<_7.,_24N!G<"X :Z"H[U'0>;:[;I3#Z,."A(BF\: MX3[+(%P2*13D)D4O=EYZAP4VG"HY$&V***\15QU)=L4/9+:$:48O* @O&O0+ MI/[\7:SW7,C1GQ:'1R^ M#JK_K _;0J1UGB]T_Y7)*>#RH/&F!ZPW]6K=%A6I]0UOSY;-NDW=_L=>5':$ MT@C"5E:(W&-CE#@"=)8I M6I3);KF7,",(2&ON,[),CAXAZOPHVS#_N.CF,:=%..[\^6'+Z=OI_]AH(%'@ M"*98!]'?("#"7HO )DL)\(K Q05A!U],XK[()D7S9DFM]B7GOY$JA*^A]$:F M-%E:9/W.09FDVSU%58X@-&60PC8:7<]K^LKPFZD6*^]T[)YT-IYG_ M5V&0O^3_?R>_3+(X.P^H*7WA[FT8,]YK8[-N_:/8L*W:CV97L0[^[2#X/^6D M^73>EP!EVFLY><#%9'68+SR&ROH-]TRS$5_A"SZG-%(U24??CPP]\W=3D0 G M_)2CUJ2RM;]/OE5Z/HJ-ND]Y@Q](1)0+T;FM)W^LR82-613_7 M&HRKT4K;?]]6GAKP8K)@TDKDBC@;/] SD9Z] 0\*MXFDQ1DB(\1._)!L#7LP MM"T72(#KZ0D5XU$+[Z<\+;8J$7PYX6:8"FC9_*[Z0S F#G+IBMDQOA56Q2;4 MKPW8]_,()6ZJMV",?/P'+3Q"13!KO^9-06F;#=P!X9&%;2/HV?R>^!KJ?6,B?8?+V*$O-UXKI%S\937K+#0 &6D20+IN MK8"PB#P(5IRI'JF]/3 9$=R@L3+?O3 \N:1D?MGN['%=I:D'F#<6L"E3I(L1 M>LR%##9;C>A&I&][!LDV>6[D<5T1&6AZJDQAC-&^)_H<>T^OL1VPDW-P\NR0 MK5LK4WJJ*QFE/R^EG<7WS>SQYSF%6=L-H&8'18\K3U^^>[4_4$ <_IUUONS^ M&?ISZA4JM T/KY!MH,75I#?2 *1Q>%Z@K7NO8>]TP,L %Z3GO?F#F[MJ,@?+ M5C2.;OAM>$Q7G2&MBQ4M[D46*@DU4.%6U:^ Z1QL8]Y[>_Q(,K@ORUJ)V/PN MIXO=N>*M&[[2H#!T\;%SOTP.+]O!:L!VV8I620!XHT)#@798K/#Z($H9.56)TP* MVB_S3DB?'FTB8N:]^"'G(F,_\[I+KS"O!V1QB;"9><:A8=)I*!E9DFJ.8#^9 M1WPGY>Z5/8J4AFY2W?[QQO8B/XTJ?[7''IFA-XY/8]?8:W^;)O8+6>OJBVIX M#(N%P_' FEKH<]$]X(MTC57WI"/VC3X*W&2O@0Q"R%>%, <-PHV[1CR&I2*5 M1_[Q=8-X4V%!#YTU18=7Q29*/2:IPZH7,R\1;1L':M;9Q1P\#*C^V$S[WG18 M'(<[Z1F:. Z6,AL[&@F1MB"FO%^.2,B0[GH9K$T3+2Y#Y&)+5GIZ('(=D!'K MUBI]_-6,M:=E2W0F^K&7'F 8+PT0C*^X_N&@N%9H(L)6MX9'IVYR59SU#N5P MID6F>:@0,UT#9]2E/<2Q=7+GPA0S"6I>C;;A.$N9)][C*P7D/$!9#%IL('#\Y82U#I1'62V'"D5&H:O M42 &M[J:'S:WM!B_LRNVB'0)O?,V)4 M#!SK-TYNMZ8P')$K?CRX6)GMQS^Y 0INM?6[GNU 32;'_&!"9R6 :-&,^X$J MZC/RW9C\7@%>*^#9>0EPEI9.)5=T^C,A?YIH$>_ :K3BJ9>[FE8OU* NMOG6 MIB>;>5&D7R[U:^_4#:3^.G6O;)J?,4Z+L M6U*7YL(#C3$A%Y=NS0.P'G_@M>!T8H2W4\C;B_-J2O C.7DALVXB?5.TD]CW M.S7O,-6++-NMPEF/]UJ]1WZ,S8:+K8[=07'K@L,@P^+GW=>Y(C+,]749]88I M.VX#4\"8(V*8\2V4 %NZ"+#W=K[#!? 2/H[Z,6JJ>HT 0,V&D ?5#C M5_,MV<"^)N*B5,P,&'Y]LXP2K'/196)> M[\C'9",/K;:."Y%M_B)%5!]>TV&3LX:HYT/>@PO,-YR-+IETC4]AAK7,SDS- ME/BXHK]Y+@Q-8<8YHZZ1JH9!DYUXIK$/.( +9;,UUAJZZ#0>+ANXS3)4G'O3XI M+G8YSJO2\AW,_[(J I&Y.W0<39#?^ 5D&%>9Y!/W4J37OVW\K@XYGMRL3D>;H:CDLLQSTDM3&]T$P8>);U@0;\@)R MLP185+?C$-8$+O0L?7>%"AIPM,#\A63@BSRZ5^C\[U>T;\HD("6&(OTY\3FS"*.W[+SXI;'Q9V+IE6TJU\ M0GVJPB6L@R<1Y7/H,'P517V0C;=?)MSID-)W=MM1ITOV*'4MP9\*)IJU?36> MHGWGH=QQ41LB)P<=;"?.!QF;ZK5W0^#3S.:,11]S#W[BO=_-I9*^U=^ -!N[ MXG#RY?0)/+K>E$.P2OW',:7?-VY;=_YXB,ZRP]@\ #3 0D4XUI>N06K6PYYRT5QV>2TNE@[Y\40:!2-%C<(6^H(Z*Q;C MPN# :*N^_?.P#5_*S-*&7F$>F]8.T(M7F4C_;H7WH+J]!>G=2+_%U,,%X>?! M4>NMC*^*;***O-]+G_OH/LN!: 7DN416MW#/W.+M"RE)S I,"TZM25#8+7YX'#?SL_[^7._S>>++#M*_\5" P QV9]][M+1XF,(R<]"Y[!1V M[^3D$N$=XP3!1A,I@^3EF]5VJA\"GN8 F%U'3?[=V;#_YVM5=L6(!0;V[^4B M!GUGIV!9=UI0JB'W\S6]ME%'31.:!9_ I0LU8,5G_#9N%%2[8^4,O8($%GAP M: 3+$]_!59,6ZN@@^-%9J60EQ5 *;,)D](>%:KNE3/ HN_D"GS1<+!!MMYUD M,=(%;T"]Z776YZ:#XMJIQ+A]YVKPL:&9G]NZ=:*,L26FG?9NJ'\Z!S*6V-O1 MA08CM&0;;H&".(VET\Q\:^G0LVQV,@$06SVB+[4_C%:1](0AY'8'.7&QO11;*#;>R:]/)1:5 M?]YS8\A#RK3Y];(MAY[Y#CY<'K/)-<'T5R:B/&XNHKWO@;6!XW!L!>2-!$C(1#0H@O!!A_Z\ 8($:*,+CB%>7161 MX+A.6.=0T #.^H\AF*,^QTE;4:/#89-CLZG]7@O#!_L*!H*,Q-&FDQQ!M;C( M81TR1"BWO0;ZXP8LFL-FJY+J]@6"E38*>S::[OPJM,E==V/$Y/#^\XHJ%M*I MU1L,,P!QI02X-HH;UR3\SL0).PBH\X)<*(-41'^_4 [6$7R4 +&>$F A061$ M'0#YNR5 H 3P%5,F+N9]CA>1(A=%9B(=W\!"SUK!9-5Y9&GAK!C]I*$ TXYRE)5WS78;X_BGGP"R.$3<@2 M_L^G&;%Y*>GY!/\+S:I[4_R^N6;/M-_6O;HC3N_[BIM')FC^XKLXOVACP7TH MO[IX,]35XJ7THF]I1>]$,6-!U+UOJ>O?26F9O086 YN4$WZ#@B7H,KT% M4P2#?(3&2IQ+KDSD:D&7!YUZ' 9F)4 K&-_QR-VS^K:!AZ]6OD_&22VJ?-YA M[Q775FP]RG<3J86U3[8Q5>J6"3ESBQ+-H(L;AR)H.N3"+#6(Y"--A( M-NWAO+?>=+1OF4^L4/VXEMX1RXUK%%.*BJ0.F);\TS?2_28*7J"]]<[9"-Q) MB_)/))+X&6GE@K* VVE-#MB:C?6/:?WZ'U_M@M*ZM;98/)'. &93$T2:XA(< M2T!;X-;GQCSQL?Z=OS^;][ M^0<1A67H"I@+]OXTHI(8B\R#"_@*!SR8MR)T6-FQFVZ=-'JUH/6N?O%R>_ M2/W:]B(IQ:F83$#ZL-#%J@D&BU(1 0K6B._5N7!J/[1OI\&-7.M >UN_Q6JJ MQ_;2)UY4.2!T&?)K].F^HW-YG6]4QZ-(0>\1Q&SJ[SZISYX9X1O-&NX3,5FVW8:7KY.W]%#&TPF+T%2PE7(9VXYP5QLE? ,_28 M>A7(/&._JP=1P7>1>R3\O:?<7]OU1_B&,X9?,GB/I?D4P8XY?(D[28FCGNZC M!TB E/K5,/6Q4T7!N_+#VAJWVN T;NO)WFK/.7B^STKZYI,@7: M-P-7V!9SU:40;5^JK(-RA#$>&HT5;2AH\W[DFW%LWGJSI9MCGMIEYY9V6"U^ MXVR8G? ?[6\K_)%1>?N1>V5.L7^8(&QL9K3FGO?VV;)%,L"11W69K:B?JIJP M@+K"1:O!P:UL7+S )US ;/:T[,/."$)I^GRZ2).&+!R%1&O[Z*R'5.62=;K8 MB3U[IG$=$W[FH#PP^R-!] 6MI8=2T?F[H)1IU!'[;0IN#HJ7L<;%USS_(M0I MC#@D#J;LXO-T0<9W=''N5I(FZ2O!9GPJX3;^]7(8W%-QB\*CCVOK#?H:L;/0J7FC*OA^ M7KUX_ MC[US_)BHDVH=TH8+[Y;:3FI"%3)3G.>P 6EC0KOI"[3U8)XAMF@\80$\/]U9ZR_3S^P_N>"<.-CYZ2F,*+M M>NA H$J=\TT"O#G-IB"N;F-](IUT%&',(SG"_ #^HTE$?@RM) .9)?A2H114 MBP%['Z,K[-:TMTBO,/S&LZUG^X[\*IHY;YQ^2UC[EC>J7=_T+[E$SS\KI1*%/FB"TLH)*=F@QYWY=6[VVUAC M?DAG@+"IK4@U7) ,=^23N^A2]+-$&9C>NK%]:%WZ0QC<9XL_MS3.^>NJ[WD. M1T9N_C[1R,\V_7Y1M!7M=3O(*$*=CDBU2? +CA;ZD+:)G]ICGC:QJJ<75'>7 MZYGSA\?,R\.+]U&!B?\@GFX7Z(S)*-C6[%%HQ M6]J5'==O\I7JFR&<*,V8\G"Q35/%I!%B\H$.V$/&O(.6TYI MMDC00(V4Z.3XL0^AH/JRN)X-*XZ\GR@M=5_'NPG(*UO:G8FQ/]@"0B1*W ,S M["64"6>&]SE24P/=1AYM3HG*O7CV'D?\L&^0:H4Z:OUIX7ZO!1+@JH% %U*^ M#U[]46_XLJY-3U1QQ7ZD2I\ 6\JR"SY?:?:RSK;XB4I*["L()NJ$=)WO^JJ# M+M%==%87"NQPOU"^Q["R=QDYJ/7;BA51TA3,%.(/'DL1"42/I5OGOG?*/D!K M' KMY$=$L2T8>]07+M,?;)R]WT.Y<.:].U[\"Z<]B=< &0-8Z"A511-I@]EL M3]GSZY'7<'2!PW!4]-,-]&-]W\-%JCQ$'N7!\W7$1>C<2I-?@0".E:RO#G7R MDFVTBB9$SB4D:V@(YQ/!S<]RN>;JC@U/+R>)-'F$,@PE1C,#O M4.'X"-SB XL%K./>'9M3UC_ ?!EOPD$$/&Q!;Z$O]IN]7<#=S!%?^&!Q,G5D ML$E_P;/K9Y*/61FM+G*[K+Q^PI$VSG#WW)HS;^&KI=!V,Q#%]3HXUD\>O'I! M.J__3A;=Y?%8WT;C:[2ZP-P!PR]^K@'K%W6& ME#WVB+WGX-NPPGG^E1>B/-0V,+JQD"?VFBVA/\."&R PV+#L[!0F_N+2X.PU M16>S\:]KQ:LH(GLW1'D;_!,WA;H#&*FLYR:O:3?V6\NASS]#C6 MZ)VZ4G_%&:>M[<\,+Q<\7%)\$4#.5A!A:P-V>N/XMU[0%T69J_N:,#*>6]2& M!CSA,/7431TOYIE7N%RPS%VT\XLNYV,BR) "65=Q&$!96]@<6&"PQ3G!I^R1I>D-4K9-09H.S\(,C8.6WV/*(+ MM25F>0:A+IL\#M?>C/RI3-6>G?(>A(!N$#:FB[1UH*Z9X;D@Z>4D?%_NYLGM M.7'91J,]75MNEK7-"!$;X5RJD:1*,64UG97%5%Z-.XY?,JZ_%-X>&/BXB<4E M$)SO_ S9LY?K,SG_W39.X*LLQU.$VSL6K,%SXE%JPVHC)/1= MD;T0ZNP5%[ MNX91C0C>]-,A^_2$EMA4X(/(G1;.WXYV\4:<8&\AU#DJTAH/[4FY)3=F0CX.,5BJT#_.I5R!;#SN5D#]0 M45\FBW17D8VN>%*:+.'JL[N/VO8G7\J2'2@J*?TF?F302)G>)"13^[H(5331 MXC[!RKE4"9O9=A:#INS K@0SD>:F+P.*&LC2NM[F/2'/B@8S>HY\OK1H.R-H M7;%6E&0Z*#OJZ]&YY\HG:S#L:]YV>ELKRBM>KY9NU9#)_6SY_/( ML)-K%DK/-D 4D0X%'0<\M'EK#KFA7B>S0T@?F/WXY+%/4K"@\(D5W#>) F*9 MD=O'5GW$@H&SX(G@1]HLNX&7FH5HJB?D_^CG+X\%4"% 4.VIZO]479L% &]>470%8N M >*CZPX;7X'1#F &P+$0IP.BI]2-A>\)-EQ+>TR<"69D;&@0EDO- MO/R?<:S^T9$PM[[IOP\LYHAM54<;8.G,OSN4^P&6_@?'=_]=O"QL"A8ZB.F? M$72@(WR4_'YXJ9@.GOF\$C$6*<)9_. FAU5P#E32CQ%\RRP9\-IR@+.GP>B$ MG5'/TR64-:9&[]T/3J4+E,3/<*>)@TVL<)&-YL2]D?452@;- RGB2,/XUR_+ MWH]47=8RHYTPO%MBD+!^4=*-_=ZG5B>5,&W)O;AR#->;=2T']=_;D'9]JP]F MY5T#WCM>0K+)]L;FZ5$^--_ D86CSRM]/W[;4!S$N7YG\-2[5?1;*:=/OG&: MBPZ3(TY$EB*=-:-M>'0QJ9+D EC)6SFT%G?183]HI%6@$PM]O9NT??%;P42W M3C_EGC7B4KA,42X R331.OWB6@PBN9$QB^4##ZCB0W M!Z.$0?[H+%30XNN74KUZB%-=BMN?K!A^%)@Q+'OOU!W[U><[+CQ0O"*XW+RX MT.L$A&-1N.ZH^6"$U*\B]PV;B&^1]N23;/B4QFB#Q@'<]5&^\J6EFF%E;8:I MSD2-W!DY%9W+-[6\GWW=L2.Z25 D?BH! C#]XQRW6&ML' ["4]1)Q^#HHK$T M[*((:D.V2:_W^ZD OI%!_(3FK\'<4LL32?47I=+N!^HTV%LAHL$B">KQ;=X:?'[8@.OKO/: $VD15.YEU=L/Y+GW+YC M4$7JS.E?'QX9[;5 E';0W\\E1)E?@-.HVWXQJ(*I1W+CKZ./V/4)^VQ[AIXZ M&^BF.JM8&&?,IK,T&_!Z<(>@%&4!#[!Z]D"V"E\CAZ5#F _C&)V/MX9'YOK> M'':.MD_O]:AMZ O7M- _>>EK@@G7N_FY-:6J$3QE<8E9'B]:'.4$,X0VHN7B MN].\ZUXJ?$U*J(4F29D.?46H2A7I@H25T9H';-W65&1X''-Z<4SFYJFX8R6G M"88QYZE0@/G+)T-($U6=-.]-1TZ$J> N/^@Z.X DNC,;X6'Z4#>Z\G??P>SU M'=B+8@M:)HZ5*@&>G:)#>_&?*$U@6=4U>^<%52-/S$NFZ7KCE0^NT:8+^W?W M6>BSY)(M;^0LRDM5/REEZ-83(I7&*<0M8<([D"XV4NI7,'[ <4=65'30Z3@M MRS5OK_ 4?1)^86%'D/6 .D40R:%F*9 MNH-0'96BP._^W5\?6]3^*O]O7/Z!J@H7-B(+NX-(ASFXQ4?\M#UOD4]_RWOJ MM>)EG9QX-'6+NE/U\GJYN5=-HR!L:#%!%62M8@HNI8UX51-OBA.ARE?^EZYQ M$)R"T^FDZ>8OE*VMC@[E]PX:][+@E'9W6S[B']ED>23T' MZ*8&_.Z9>_8T?H#:1O#OQGGC^@N;'*2>DW*/SB0&4=W?APEN+M^O5&?6^S7T M?E0V4].&*=(L0Q2BG]YMIFHYF/NYN>D^E7T.O5D<]U/V9GX#B@EJ(@0LZ5FS MN<>R0-C(;8(H*+9J RN)<75[2CQ.X^,0O8&L"]]?C.ML*EVSA5/3N3J"]H8P M4(A@/.&*)SI9&,%J<7I(I[GJ[2H^MCFRL_DK_KRW[X^;SW[(O;@9_&&G[B1V M[@T40>@>(9RHD0#<-*$33&!S$]E?N^O,S@X,YZ58Z;S:[0I5$>[IG]N$V27> M-I=@CH6RV[D!S!-X>NR#Y7#-W M,6:'WR&WH_4W*0>1JH=X]K;&:!4O/OYB\ M@1EEMH"5!2+- D3!EC8$&V_ATUNZKE7:+HYTR]:&P;R.TX\:BAL\[A8MMCOW M0)?XPI#U:^B+>(5P!6K?,R0 M!^7)!=80NYEJI#T(,J>] 4!LM7(X(<;YR7 MZL C'B$2H.#^E0\!LT2HX"K)F(7'#$;@&Y EO>6!J]HWW;EXYO9IO9=U"N+W M*6O4G9[-*_>5_M4DV(>"!FVN0R\K9"RLU6W[8^]+F[;$A9 MQ=H=KY'FUA-=!PF/0'E$%O9A$:X^A# ,W/R(K8Q9]2I1U/=A36AHG4:I!*A5 MDW^,6\4S>: (ED8PD2MA!%@1;*7\Z;[RGUQ&-P)9C]&Q"Z6)[ B""7[7Q$$) MH*CUK\"JGXH"J\9WR%NASZ!UK0LZES-(![6C7T"S$'L']=2Y6YR_*)WP#L[)*M(H';Y$ ;&ND5P(D M^ B)0J<)T/N#^02.PWEUY0U30+ 2'^4RJ[)J*?3N!;A/=40)L+G60K0 QW'Z M\Q\>:OO^%Z4' AQL(4*\,V%11*W+LU7G&B?WI:S6]<%:*0_UK2PB?Y S_OB M+Z$4@;N2I: K1:V,:&]=[5,P?&N?+/Y_84GZ[@3@H ,4V-@I7HJX"&&",JOG M73XR+#K4L[Q!5I9W3'FZ ,()^.+K=#^ZKB?)1GP?%P#&ZSOT383TVRB\-&!D M6SU_/QKWSC#%..O.L-/R-9/;\F;/;-?Z%K-)^C\D"0@HJ(BT1B$N2K+S%ON^]>^X]^[QW[N?S?N?W/O?N/Z9^@#7F'&O, M,<;\CCGG&H.):"/'X32 ,9;=Q>'.]_>=[ M'MX+-5(/IV$27; +_\%!>?_'18XFX@>*5J^7J/.);.W@V,_)9TU^Y,ATY/J$ MNA>;SIV;FT"E:6>.X&E+&$#MSD/K2A:FT\Q*)/H:5UAU)F7F9Z4F-'UE[V&X M^[SD;CYL1:&2#VMS!PVB_O8GPU]G7^ I,T3F"9&]$I[,GFE<01NCK_WP%8B1 M2=O#CKM?0)8\3V;:A0G@V\TX.ES/QH,FN F_0DI>6._$[#XPXH/@//P?3C(Z M*:>/J_R+L[_-!11;^HCN"772Q$Q@[3RW6![L';JGR/,[QKX)V?,[) +\@*_N MZZ".\6&@K.50I*M1JK, MOER0[3.9D:7% J-2ZUL-;I!7S$3*ZS22N))X&N[SP;"%5BV?P,;?IS=?R4TX MM) $^ZG_CXPUESK>!,)5>(V@'*Z?#]N!E.4* <>8!YR9)?&F <]G<7(LD9'L M4C>\S^S(SYL=F.!674MUO)&!C<">.)5ZJ>G&'JZR+02?KP]1I-UD ;,2YI9K M7(6PR360_6MM)1_^7>(?F^Z78\Z0[.HA[JL:\R^[LU"4P]<#8SUI"I83>0^7 MZU86B#V&;R!S@-PL5T;SO.8\L5:C.._%:8>W=')\GVSW 8WD]%\S4]%(.A^6 M,&UJQX=94V/Y,-$9/BQ"Z^]_IQUZ&NK-_0&T2@:A.KE MUG-=DBM';[>:<:4!3SI)8BHLOJ=VKD0\+F-X!E\4^FXN)HT'V:I=B]% MPER9RCFZ_A4]'^:A/V;2&4]!5S]8:& V42)H-2?OY<]-J=;>X1[]-:92J_]U M_II269V@H%P7]MT1]0"=- MSRL[Y79OVUU*R'.1ADW$W*<":P]9/5PE2"*;*I@05)U'2&/-6%4_M>CVH$)PZ'$)OFH/6>,$+6)=.H M&$"#T$9:+VCMR2"-<:;)G1A)X&:'.8 W3BB[RKP_\BS I"?*Z]JK;L;NQ9U*O$$)'YT->XA[FPU--O=9O MMV%/_?X:WM'W4>9$K4!"N2$)T1?@U$,H7EXE:;)*N,JYD(;N&6Y^A84S M%6CL5(44G0<1E@7A>R+O<*[Y$)\CBG!W<1,HYK4EKO@TG32OQ@ITY&62KT0V M+26&H$5K?+AR!KA=(S4G9X,/+K@NC B'Z^6J9Q:>/W\^YN WR-_H)X4LWK"'ED"-=#D!,/)^CQL(WHE&%9&!G59<23@;\I0Q MCW!MB1QK[/61H,TL'66#H96H(T&I.R?:2K5O.P]_38'VJY(Q)35"D!^IS*6RD_]I9 M]FZ6A/GI+_$.K-;4:]&KO7KZ'P1Z?K!))7C: Q33G\25^LG&\,@X45P_60JW MQ=L9$=^LP(*?'#;\Y<&:>F1:,69QH_AF(L8@;N+MIZ-I#0+?-JPA(%$?P_42 MF?:$-'(5'];.07^\#D?X'>XJ22G/'PTBQ\LX.O2R[SE[V 1^?I7?3=KV5+]M M?\ (63:(#!@+@L)]K/)50XP8[O7A^92>+9RN5N3 E:#>_2<^N?TB9^1E\K#] MYHC.Z^LW+W\-9UX2$@LUS \%"UVI.*ME='-$OK*E/.J:87C]H MT%1^_I:@W+ 34I9-'B')XBBM7_&,WG8Z^W:K3PFT=N^Q%[%'27NV8 MKN/*I;*TI^L6E*;YL)0!<#(/P00?,984?,>'TQX)1G]MSA@0+FTH2=N%\HV[ MD.EZ[B[LU<%O!_3C\31HO=DT(85COR=C++*-#^\(<:8K2%^;:_-X[S>1_?OK]X!SAXU(TFNEEQY7 M]Q!%N68LMSEV#-!4YA26?+QZV H&@J:T]A[\>B]72LGC3W]R_=O^EWQ1\1@ M\_I'\U9@%[L)3]?E58!::'<%V)QCMVUJX3W-/ M_G+2+]0?)]^"NMCUJX-G<:,'<*]'T)57RXI,O]=,&&$.+ MS;;/)YY6QWW..,A-]GM*/^CC89)TW>2E#0RV ;@WW0>8H=CYK#N9@?E='#C7 M,*-]ULC6D^1K[,BR;E 7M*TH)311E%H !@*$K^^ WOTV@OH(N7T^S L=#2*J MSOXXYD>WM9Y?VSPDA6)1WY!O-A^"!+ )>M00<-HS2V3:X6%OJV&H:G^OYI4Y M=B+:S(2SEK/(-8.>N@L]Y02<$W@">=N#H*#:TU^>C^C7,PUB25896Z[/M,#" M^K@[K,!MFSG6T!.G\9<2R#Z8U/'X._DL<:#GMP&]QQ^JLV(F?]L@O$NL\*;H MV)%#UP,'90T]9&[9]!SM,;6Y-U( ML)VJ88*PPE/3+[K^V\L1 4YEA=J$1ZA\L@A.@JL#'*"3@6.M<*X!DP^+,R!4 MF_)A8V[R_?D5M%?=NS:+34,S OGD(:6Z.6]\BYGHR,>V( ML0-LQ_I1I'B8C)WQV^?&:=7:4L.K3;<2-?:ZHBVTG%2$M\E8F!36J^UY8RVX M[(ZV!KL00GA:N?Q,7'!4*"@T2T./PT$Q7LBB-GJ'+U[(W_!I-6=VH>-7P,4^ M]X3"L+C.1PZ6&IOZ4K8<8B\!<3V@, 17+ _P8=G&'0AN%6D8#1C!V>(0/VWK M1U6@3M@@K6HKPA&K693-=CH=-_9RU'-2[L ]BD(3)@ MN P*07JQ>=U$;W*O 9#=CS?1WI-B5M RP(F!J3U5^YN4YMS6[6 X38!+N#V@(%\8[+S;?Z!"O M[U#>NH1^@KK"(O.V0!@8BI12K]F;0__][6_"KQ,X6\%W2*5AS5%3%$>7JU+1 MTE#OLXC1 15\^D_JO+#QD1O9<2%1/4M3_9[;L 4L4%XP)ABQS3DJMGUD;=>C M+; ?0;S=ET\?OA$MN@<"4/]T /6_\:^;HXS,++7/Y!1UWGQ;_X5A6Z!47_JW MY27^1=OR?];^OZQL8S_*M:<3H9DB=RFK5@Q>HB"#>>-''RJ%WQ24(QFP\ M+ M'&&L&16*S'\N%# ?'?NQ_!5_#6LYJ%L[?8^X/R#EC."+?O0>H D47C_#B66> MAH)9(J!5TOZL-AA\Q3KE?">L#^&Y? !PS +(H"@>8A(19EYMQ_$M+MK/A[U5 M4FMK_-*]:'*P\@<4TG]?+ZO-K62%!CXBGFT>*ED MO%R%Y_?#!!2&)">HCQM$U:%[,' J[A5.DV753HQ'"@S3ATTUO:3&CSS_?C@% M6[;Z*V[J0'7&LVORUO>E=3QTVP17HRXN=?)AR>1MR*W "3P"ZP7DTI>V?G,@ MLY9? (\NQ+0/0#[ (HW9C^-_NAAC8*B4,060\9BF''QTE]6U>TT3\_LW3#K%L[L (4V0QHR"5&6AS7"$Z=, M !>6@M/)P?JPF6G+!K/[VA**2XDU6Y:+DHLW-U\_2+MT8P,GFW,13QE#,6WZ MQNH6G#4[[!3\J#+!K_;'#+9%V$N?W/E-F?VM2T*3H+;M+[M]F,)T-+O MH@<_!M]0A;DJ3,*I!S=B[3/T%R9=!:]H-%C4*H9P]D$.02I*;CWQ#24C3[:2 MH]?""01'?SHNPHR1<@"Z)$%M^]X WN.(E-Y"IGGML;04H>E5";85Q/KZ)I<> M_HI=E2]B(]E]25BORG<#H1-4K_5W/RL>FJZG?RIU@UFGB\P'""_@][?*\NZB M:"UHIK-2Q$2W\V@L3A]K\[+AP?LJEDS:ZNYKU0/IM0%Z8 MVPW9@4, M'%%J,_I0_UU>ZTSL^Z@R+R^O$F>+DEEV!6636 (]1K:]T'O+QJ>*,$'8MHSU M"U&M;KP"/*V:#$&=,>V>PZ0.Q+@ NY=9'LLP$\5H.GZPU\/HZWP>5_"X.]ZE M5NKO>5#MH&HT\O$3\GY0%4_YA&):(C;+"=YIW1TVVL4Y4 V$MAD'A!/MZI(Q MHU)TU/IA#)OZ\=')9<%V(H0[&%FUCL@+HXLK"WN->6LYWPAOHE&^3TDSH0P$ M%R'"BCRS+$%'<25F.B+L["7S5%D+W8^)1QT47#!O48ES;A(L"1 .Q:\Q%0#Y M77([4ARPHEOW'KI:D#3"!^'5SP5/\<>KA MZ;ZHNBU%Q>:_)@3CL?J%LQS!_ QABWLL/;L6W- ?%R-I7S ?17^R+0$U9BP[ ME_>L)A4]?9WD[ODD+&, L]TW]$!KD<;KVC27Y"I8G<:R0I60J( 'C66.>#'\ M!5%MM3#&D09?'XYK3>6JJYH8ZO=M!K!)4)!=@M?C>9*34S/=&"2R#!P5YA,QXTP]_919ZN$ MJRS_28;M3F-5;]/;=;7W#RI[C'UZG9+BI0E3_L*"@Z+KQ=8UL,94Z<<PNB#LL0#C?>_PFD-PSLH8S>]/A$T L7NITO(T]#KW\!-Z_Y4P]<):S M$ZO;+^!U>72Q1O?44SZL]JQS#![>3M;&*8$4?)UFUT(\W6[>A^786:KY*4J0 MOE@44ACQ5XE-?W%LNE>IR^5D8SF/+(-GO8=/I;, M#N9EDVG/#K>4M*'$O6M[.J>4!@UU7>A+=YHUMF1?IM&RC-AW)PJ.[;;Q^-W% M)N2-2ORE>@+O\LWA7S7FB $$=P<>%&Y9/W7D):)HZ60ALA=I',TN3>Z8,F R M1]-(^18TWM6UDX'(EJ>31X7'QU[+36[O/]A!P\!HG^'[_DU_Z.NVQ:[DI1H@ M( S+/&TWWM=CY';P)7#/\]D4.BRBP^&#LZV1B<(WS]02C[C<[??:IMS"M100 M6B04#P+QM#ZT"#A*KIJ)Q?L0-^$I=M?L[C3[Y;M\;[Q?)6L&O/!INF< M>4;WQ'1 [VAJ_$'#1204]<8JXX0GW$%Q$J!EG*0?<1WL8XK4U$;P8;C%BR%< M @F&R"!6>CI]GE_A-FR3NO//]X/3O M;0N&;Z*/VBHL]_3N>Q\!142Q$7@:&;6C?ACEH2\S%5[?QQXE5#]<_AK<-Z[? M@V;TG09(LU:@$ 1 -^4#/M"_"8 $ WX+(8S3!F*[:I&JK+-^H\:XG3%;I^3& M1X1#CCN=$RGR_[!\[]Y(:UD^G%'%'EX/\R#-L%E/WRJH@S,%1_FPJGDW">9( M :GCR81K27)UV1%P0N?LN_3[E0W9]R7K[B^J>;=MBC$G999RLGB-J$OHL0?@ M-F/F]5&:Y@*:-E<6V&$4L2+_SL@AXL7(:3U&DG\-)V2MP MP) *;O7/9QSA2"2_%N16DX$XAM"!00 W)5'W,S('!IK[K8Z"V^MSK,FT4N5] MQQO%$I&;OK_YYHCT!D?[>_M[%*/'IA?&APVT)+.AV8@)P;6C*S%)Q!Y\E=U\*A004>3GL^">N^KH M?=M=)MS,JN[K"^4ZOM/J-M X>2ESTP\M@;'U:GC/LQR="5P)079:1<6-70]H M5LE9IM'') I3%'[6O!]P->S8EZBPY?(QUBQ.\:I"F;VY^(:8L^ MPION7\^0#*C79IVCAHU.&Q6E>+@!W5VA[N787+/#/WOH23S/)]&H?4$8P, 1 MW-I?%"=#A6-#G](N/:(J7]1;C"!J:0Z0=Z&\J8#!'+@M-IQS&GNLCO<([_5> M?I3^!)@^CX"7#.-4?#@3QSGG[O3<")_RGSJ2@M@K^,HDVI!WIM\<\:8U%@*] M(7B*VVI,P9E'=(?,>AH$E.7?3(1WVZ7[:8X29KI"&@6Y+?#.X*&Y'H%-_'\U@*?1".1O"PR+0G-M.N+0U21H[$"K":V M,J RC5#XIBPTL$*6!LKY,'HK$3O>6["YT/ZBFYQ>V=N&K',^Q@Z,$V/* V95CTEOZZ'F9,NJ7B%F? M.T/WKGP]\1@=TS7 4X!UI" MKKC+3N25=+H2XK$:K6-V5+(](H'W7;H?FV!8ZC+Q\G''!->_- MF><5I>)VI[S&R;YS!(#'5*!C%E!,OTY4%1_6385_\IT29[GE70OFZ4TX-K[T M:[JZL]HRTN9*ME3%G6W3-[,5EQ3TZ#;D=") 40.[JW2,&'KSP07 **?DX.-7WN8Z?_]5IGO61$7"]:U.[W/1X>TSOG'V<6<$7E+ M@ :&*Z'0'H?N(#-/4V^-9.QF>+=*SBI[7>0M8^K!X$D@D'V&E]6L5 U8L?V8 M6S*K%%!56 7W+9_<9<=V]$PB[JZ4@TFPTB+O'+U8?[89W+JF\K:[F+/+"[^> MRN@]P_^+"WK^JU*';_:WV:<^L/=)X!WD9H #PEAWTH=F5N>P* M$!EHR6^ZTS8D4V%4,O8(\EE4R:SXV+C8E9^.VY=/W)T4KDEYLPBZM;WKR=CP M?<5Q!CW_Z!GW(G.)JZC+HM+A*2AOM$+8VPXV8F.UF9WE(-;^N=K$;,8GUV-? MDR/#U)*V'I-2OY_JM/CY]VVS* QQ7+B+*D.F/25NP-/N34FQKI8^!@([0>4A M;B0K8N;(4%%5RU"0R_'ZM+>G3B9<\+@CG/Q*T:XB,\]@JZSVP4OP9BW2+:X0 M"W^6%T^F526&5*X:3G7P\Z.%6C;&I*K' MRZP0&1 ;<#S[I&I^Z&0/GF+LC )T!3O0R1#H(W?CE8'*4;L14,UW2@%0@<=C M'2-+-&.K362GDR;.5+GXV%L^UEE2__')Z.N51%E5C1_?!%:*DWX)@ELC.1BN M):\)=5D8KH#%U,=,,V1BL';/PK09F[^\T%8,S_S1LG@,+#Z]\M\Y);3?S(558+^AP'?+OA-$8DZ@$' X')VS*N MS1SC<=TKC?$_1VKWMW,>YVG^NC@=(BJ[ TEBH9.XAV@845>@KJNQV4C>__8N ME[>O>\759^NGZPRY.#SES=1A)J&3!.CBNXGR@(1;[+D!$IZNR-%=K=#0&*.W MZ!EU1RDY15G <$-@.Y%YNU.@MP[>/ MGSHU4^C-Q_P\=QZ_NZ_=IO;\>*CJ9Z^54O9%WE-P$SB.VABD#T%(;U8?5[U5 MB*4_3JXP),^_+455\_*^NUP@!P9+GMTUEI^)])";2,_<2:2+DJ$5UAT-''($ MM^WC"(*O\Z1X:2BO211]DG0'NU._._NI+TXVYSL/'(T*B%1)'Y]Y>^UDX,Z+ MEO5G\C_'6 NN+EO@55OU(S=O#Q(Q*WR! MS)^9:F[JHC+15$"'E%J'O_9'HNPHT47RF,Q>"+\]&+M"0,3!\%Y!XI+25V " M&7Y ( O#E1P$MYE-3W9T$^MFNG/M%5XX4B4-?=24*2+='\RB2;HL3!-C/_FP&JZ] MCW_=[X%?K?>]#\= BDX)0A:6*Y?7!>,Y2-?/#,5ZZG9,R_L(\^ KTD MM/J%>''%[#I<^+"*5A.@H-,DL(Z#H"\6/F+-LI\^GELB8!U_!& >]P70F\CB M+Z(M?*(PU^;2RO:?HLW,"N""3\MZUF=>BMD5&K)!3$8C<1XV9XX8@J]SNH(& M-%KC6Q'"7$5@M.S5@0H& DKC.[G/"6R4[[M\HF1-&G#WOT]L@+JVXG. M!>:(9J0>U L#W.4FK2P @:]@;V<\2F485'\?/E&?UJW,A\VT0((CTU;[ *VO M!0VF4APCK,Q ?Z,A.[O4M9&WE9P8N'H63+L,70,;'9OY<\VHUJ5Y;[? I?0^9 \?/HZB.-&?=/Z7=DH?VJ, MF_;@"A&P-!AE_IZ'8IJ.9/D<_G2B2AA=;?Y47;OJ!B%CB]T)'K66914[3W/Q MLST]HO7ALEJ*_WGE-E$H;I1&51.YBOTLJIHYJVXA_GEB54]<$!^VHZWL$V%% MZX/[2D^- "A$A;A3PX8>9"$HU'''\\NO)_DP(5S+TR--IKG4Z[G[B#AP]2>< M*TD%13\.X@YP18$*CC)6G9>#/4NC[IBR#7@RB]I134RXI5X5IB\95;Q/I-': M^,7QRQZ;!+]'@HO@Z.L%WU52+)G]:.26KP\=[J%]Y3LDWL"4?4=5>V8-D,(";%E MS(W(K5*R6I_WHV@$(M.5F#"N2TR&9!"-%]/WU]=US^G]NMS-?MHG_#1HIVV8 M[$99Y5R>M\ \:BN>DH&NDUKL ^S(?M0X^:O6RZ@*VM!2[=KTN[I85'%4Z<#Z M =,6!RQW*M)-ZQYT+VKV38XH>VS\(?B=QIWA: M+H)IATY U*#OH/PA'ZZLS\SQT;3]X%7WLK:NT=BY)??WN ++C-^DM1,5_2\O M[U2?5B7+/H4B"@N(\V$[);\\14A]1[@ZS*M$_\+7[HQ(UPCJ>>/QS;E#W^]Z M.Z<.X;WRO/-W[_RZEW)3P+#BJLD BU+IX @UI=SL7W95/F M71Y5'TSA+TX?471_YW<^X0>*C.[CP[CRG' _*,2F!(*"KE.]%9U$YKWK(=\. MT'//P8=&OT5!3\BE,W]VXR5J^#!%H ?<9I"#RR[U&PW-BE".9WX[,'%$9W%6 M9ERC%9;I($S4EI-CY\/#_]@^>XRG[#4]\-4%D*#][-:7.$W^_H70L195U!3E MYK>T%T]M9!(2\$PL.O[QLBX(S13E\-+U0/#YX>V\@:8%\P[R]O-]S'CS1.""H8FKG7VV8)7NI]WKF3G<9*:IP.%1 M4-B/M>6L#YTZ+G&,^2JW]H6R/( OWG=HVO?14\T;N'CDZE^_0"D#<7,R")QJ4&5]:W1T81 V:XZ3O:$I_D@$-- +&&BJZECPKB@, MN^$E,RZ.E&; 4_1F^3AS0W\Z+(^;?65V&XPGO0X>OCCC_8IV1O"S6R8G$,(& MB.KN9W[/ 10#M7",<9YSXL3+,&V+X?R8:WM-+@1]M+\@NM?QL9Q@$OB$?)TP M,4A'&R?[P-.7MK/-+=U8,7Q[.>D"?1,H%RXXO,K3#1M_6YTC*9GDX M?)J6,U7.G*/^>R[4S^0ZX_E!IAJX38"S!ZAC'P'Z&+P3/1W(_3$CNJ>7.W[N MLXC<&K.H4.V=YUUD<5E=Z*V::/,9P2_&G7: V4^V[Z!I'W".^K(D+;C9ZPT$ MBY*['"+_1[BC9: 6_]23D@_OAG#X!$C07%] MY3YI/HST47QBI2NRKH,,J%AQ=W#H^ =\V-;1^=TT8:*^ IZN*N/D6?-8+F^ ME.2[M-@;==IO\IH#T1^,.TC @1)02(K6DLIX1$UJU?>D!)#">F7/$W Z_OZO M$&E1.\&5-^3>DL+71^AOF64N?0EAQ)W ;LZK#+V'ONV?B'H[<] M;00%[UHON:7_38Y>/Z[+C>7 /I\:PZALA9 M^[#BL#Z8)2FG]PGO=PA;C]B.8DL=/- M;,"1\%O63PEK\M%\CN-JZ3_(!@S#&R!$(05]0P:TV,WBTY"*"3/Q'?U(8PN? M9[Z.RR7#%K_[_++V^T:X165Z=$X)L=S2ITD(:%!+#^.FFX[. /?Q;_?P1O\\I62TP=,7U#_/!_E4X'7S><@\QO_8#O[)*"]EO67 MY^V8=9UN>T<6I:,<._-4F8:IO"^=SY/E&S(8FBHQJN66!Z5FD9N!8\Q'="S" M$_!BDCM:E1+T^I7CGASQKE_IM"Z0>OR/7MS'_L*?Y^X^(\@@+D"\;(G 6O%> MHKR7Y' $C/:,^)WBQX*O=(P'-?!=RVC+OAJ9QZM=Z:=$G[VXF"'JE6OA!X M 6X1P$H(A3VTX\/(YSEC_VAT;!GTLI!GB/'@KI\GV8'O#Q/F&QB$<3(HG15M M>D2OA!YRCQ)O'25U%?;)18OC_RI#\WYXF\@C-QN[]^0O:XM5^#_/\IDOLD?; M^,]3=,(&GOQ%]1?57U3_6ZCV*"APS$YL"':_4=EMLV&TV-?W7UM0"5P_J\?U MD"L%N9(=M)+;-1.W=X256@.#Q8")-9!)_VPT/G-GT=%5/FK>_H3Y%7'/N[=O M]&=('_]R[M &]1'<&!G;>-=2YF%,T\.WWUQ+'-C2P=-<'Z6 MZ<5V!2+(PN"6,%5="6OC9>HDH?I]8" ^TF0I[\?WKZ'ABXOJF.R9["FK@V\5 MM\$ (@W.?='%XH#OR1WH-:=, N<(8&(/K'^XC\0* E3&UBDS809F_E<98&S9 M?"\!"OFK?Y77"%V>_"!=E[7_>;A[D]PW9 ,S=#U]PEFFS,*QY^#8E RS)/$Q MD%GNT^_DIZQ&9#B0;^CKJFFYUV6,NWRM\[[_)#.EI_H2[6;@&.X#H@I#X%A*.ZZUKY,,2L)N+?&7<5%C^[XR5=5B8A)KD MU),.(QYQIO7'?SJ*_I!E''4X>.Z%_4:*6*CB#^+ZA^IYZ"K];KA2&(&QI:D MB#_1Q&I)D4;O\&_>/2URS+J6Y=FLU=^E7"!2V%]&$:LZ?O&6VG%LR57"YWPX M%"N-(F!^:S)95C%8,\]"[W&S% =GA\SB"1TC=DC_3FMZDL$& M>ZES6F=@,)CVT6C5UI<5P[KJ@ZLF6N6Z7UPK*::7^WL>GZ5(<2_A*:&M2*X& MKYA,*R/*M^IQMSO!XZZR-I<_*'KOG?#R$Q_FY<-N#*KJJHJ5S!BW414;=K6+ M /NU\N$T4?)C$F#4]$<&DTWKR?L2\)3#!GR8&-:=E[F"E^2>93HFZ*^0$F1& MUT8>2PX:U.W_]/']EV,W$U2-,KJVO;3/JGWP[#>_5:B')3Y,W]@; ,WMT8HV,NUE*DXXU?$&_?4B898D0./!@EBQD_=Z9:G+Z/A*E]E[ MS2.)C[T+K%0FCU:$#+[;M5_@3<@(E&Q!T 52#H'0.%LOT)LQ 6%-+@:'+] MF3\7Q)CZ;)_F 5,7NDM'\./O9\-FG!J=-/95>Z:S8 MGZ9#/S=T1G &DXBG#:_?1OB9C+5Z&E;JPLLSG-4/-AF[OJ1NER#__$Z6E=YG M+2),6O-6VW-]2"7R()604-I&FI]C2*E?VL\]/EQI]HLHM7;$ H:#)JY3'9*L M!7E-K74O']9Q"PKENT:_C=XQ5:#W;04P=LR\Y.+NK C7%(>L1-4[GDD&6_/O MO3YHWQ,Q2F4B @[*T N2]W=A*3E#3#LBRX[.<5 MN"N5D:B[+!K5!LOVD=S/K@VI$'><]7 M\9O"QJ-<3E5P9&*K2\G*MG7V(^4'E K5-V^^B_2\NQ&>N;TPB#2#)-?W342" M0CV<]00L5J;:CP$$^QU@&S MHM:1<_O!./+WUCW#!A^?- 3]>/>B5F9O^ N) M/<6V$P*MGS#7N'0^;$<]1+<-]:T;O[P+(/)A64$; $CQMA"Q)WD/F@7YL,V7 MF5\)T/K35CNJK#IJ,-%D%]>J33S;$,]1<([TH7MOM]E#V3_I_#X0MIQQ5..' M:K'Y6!1R@9PX[*7=NX]3^K7S_IE+,'E^MC8@_K?)2_.0ODK](_B+Y MB^1_(8F"HOW1)I54^RBI&[N'_OO=W/YOV/YE%=$OUG4OI2)$4%ZHVTAU8(%U MKVO'MU9I9A8!65+^_5[IWKK:1.%]V_*K*B %D+ZJ-J!LTB<'D]9L8O1H5XG'K:+*N_0GN>?N(CR>$U[>E=W]FV6@.0+I M@J>X-(<6^$[M88UVVGT\R]CUB#G:,:7TP; T]>I(U/YIQX%JWLD%#0QI7GRE MT5QZ*E8P]Y@G2,"2'=*NH"N10K.X)$S"W/K5D^+@J[JGO:Y+U%6-7+,>E;W7'*U5[NP/\*: MXS?'A\F!"+U$SY"OYU+]\Z]FY_DD7,7NR3R?DK4S4\2O"\VTG]#N0V MF?'S MSA@^,!M:!%_N2^I%1JUOUF*L3]&3T()[\&&#A0KL/OR +!N]&4 MT%=]T[;GQX3USE1/)!&#U9_]/.L&$0OI04'?T;@EWDKUA@H+]_5DY*5\V(?' MD(>*TD4P,[[S82M:;GP8]:2Y@J0#BJO>2.9MDR'_'.C_B_8OVK]H_Z+]B_8O MVO\_TCH.8C1;:R0^.=EC1U\AF&C"KV-> M"T)\F >(X2E)P?"RYZ#'(4B)_SN0Z4B#_QD@_;_'^&.1J1DWQ):X^HSEZL>'XS841U3>H$V^#/;Q^#[_QB_TL8&MZ1?6KK7O, M+\\&G1'\@EE(I9-3BDA)%BH]:8A,5VWO7#[SBX M>]N^;1=4'':*6T1I_EM1OPUT/-,._TLUHHY'B.@#[^?\/,$DKV>&33=S 7M: MO/BP$[:11?]A[OZGM'^5+?Q9"T-S):B@=5X9'^8^5<6'%>UJ&6C6_[-SA/^W M8/N_9?M7;EY@HS@AN$]H<:X,QPE0 X5^,C71'[@'&'A%K-DH]P)^6G_'1[.9 M,9T@X)6+B[!GEHKAYW)U_T6.2IH@7N^WHX27?I]1@'8)5_PGC 0@98K>VJ M4:\*U6P?KXMX[&T11*D:- D_'V-=\PB>J*Q6Q]I^X-[7GH@Z_.'7>:%Q8SFP MM650J(L3 !P MVER5,)$GA7:U1_LXN,LW&1\361" MX^CYA-]8E4;#D[<6S__*A@9Y.>$+O1W6G24YD999AAMRTVUA0M8F,";[0NU- MR,2,E?'I_2*X['\+(RGCZ$[$5BJ@[U+?=&?0/KK#-,M8=_N;PMC[P5_LE"S" MX5P3*HW($VDU@=;9-S-<;]B?U&:9^3G_$W*[G8 @YT28R1D@;IJJ$+8VO@87 M]Y6_:54 /,M/?A,3U#7M*B2 M?!BS%L7U)0 W9>8AF[!08!!!Z1X^+/6,X,<8;>Z9KN.*^[%OKELPO22N&J7,M8S$2(7ESAON:F1%FA0>%:=U'W?W M\PC>^4'P6]%?$OSOSRAI'_/?=&*8#_-=DL(J-;*6.B\7>8.R%>2:3%.W]I L MQTL4XEN*VT%9V7QX_PGM:>+?]6W_)YS"./))P,R?B '_GWF-1G8_:3WT]T) M_&=>\^$53TEI^/\D JL_D:C O.]??/YS?/;Q8>-^H) 0QX"K!0@QB FM\BP^ MK#-;?R55MZ3F)%6VJO.=+#S[^*7TOJ?E1 J*:4$8!_*KW&:S MEM]4A'V(V\XJ581KW[IGCKC6_S_#=OXG,8H+YH9 F,(6UXN&X]2Q!LS:^&EJ M0I\_@R316_I+A_PA&M7'=5 &L,6]3!($)J(/2JW:_F^)5*66"0N'./MP M0X>A%WY_C)W >X@[['WX6DY)!P:P,#W)Y,.Z\F0S%GN.I1 MU9!*TC3O\DS-^DTN\ [""HK(E,%.!--./U%9!+C%Y+#+>22L7\GW/#,FBC*! MV!1VH#U"] $["M4>4BR+&W^ODA?2TIK)<)JB.Q^,V?5JFJ(WND( -$>[R6.< M;I0TBA[?:@;@*;MXZ"JSMR5P1]+/LP,YVO5GLMNM--/W M5UH=#H^NE-@/+5/B'P+6+C2D,9]@!=Q'B^UC9X9_AB MH9?/U8;LZ W%65X9CCLW-!Z+W@);>?Y'9=B6-%+A]U#CD(CKSS !1L0;NDN, MF."0VH?=&0F?85]D>]0QU;2%=#O+3=$WJ%5H2JX=S2N:A%5Y/G<&_3J8H;!@ M<;4N-?.\U_WZ4\HT1?D5^?]"O;QFSC0"ZI"!(6 W,#A*OL).7"6&S-#URSE& MNC>*51])IL5KFHYZ,O"20"#%6:0OR=2UW'FV,3AG2T-S\T,KQ4MW"]1_ZAR] M-90!>[WS_-H_J(SWYTV[K_D0T^ML/\I'7QP;\,#YUH)A'_S";+_3BVOJB8^O MG+SW(3;G^U)S."WJ0'<$OB/5JONP*SG!T$\A>5+_6 YHV-Q<>ZO@PMUG M'RHM;0351:T9C0@A[P$@L#W'*[XDVR-2!*D0FKY%X'[JN?3Y .?_VGF\(!'K M#AQXQK5E+46;HMW+CO@A8IN/KJ6^.V#952[9>?9*^H?/,SG_I0E<+_>)9,Y MW5%1OP_>3Z*W:?V?[9< * PA M":UKO,>H>>)[/JS@"8DT]_=7R:-1*7N@YU%X,FT0\^N$UT(H'X9!K&'SR/A2 MIB H8L2'W2_&C>+94&T1UC/GF29^:_IVSH!R>1>P 6 M#?VQCT%(0WFR/' [O[5N&EKBJM:QT=ZII,NUX6+'+VSXM* BX!F:^6G;9\1[ M^$<.N&T]FUD -.YQK$D#@,!SO('2:4)GGYPO@=&7G'>8.94>68;WGI,1LYKY MU$3XU)F0].R+9>^WBEOZ?3F\;1!A&)YR#!183^.#$RCIAL#%I2 M -0NH/7/,5N?9HN/N7::>ZK$^F,W!\O)JF1&(,8"V0?6D[!=PMP)==O&RP'A M0&3;^,YP3'!DJ?5Y]88KSE8Y7^E@N-%G6I/4\0V.OD]A HYL1]X+LA=APIW6 M^HAS!/>6#Y/4,76AFYW/U5W5WO&M_\1#ZJ9^ZU)U\7++;Y_/7]IZD+)I31>; MRQ%9KZ93!H[CJS4[[<;D.<<;FQ'9 MI9=4)Z)\Y,;CA'2/OA&#?\Y*K =4I1QO""MJ:3ZC'$1$HS*Q^SB_X2DNW"B. M!&[R0Y@^.YN7NZH$9U\=?E+!Y!%Z I3G7(V[]+8/Z'X=W:6])2TR;-.[!&GO M72J%]IH9&R8@<1YKW3L1=H#]@I>.% \K7M7E[IO&I#X@3AP]F[!8_F)%Q#)* M;Y*# +(?[;Z+[W/Q3N#4S/!A"GP8C8'^Z,B. $ID;B,UN&9 CS_M67#)P-GI M(+2()F;SZY ,V4)KTMOXAG/I%T[=/::J5%BZ]VL3'M AS<,9^L!NJWD;/FPK MH8VH9/6$:\G,:W*?MKOMIE7;^B-#Y.J' ^;'63^2=6Y:)ZO^KM9\,[!*<&;I MXP2X;8$CPCW*RUX@T_+(3&C5C9?'4U )2"5FI[(D"]^.2%A3?#G;V+RCL_;5 M>*!UJM([\>>[T_9VFUL+?=6RN2BPTM3AI@ZM92G-)B4 N=UYLKRDR+?6WLTG M)S5E3D?&X4=^V)?4H;O?WE!B!6*VJI:/]J&9)\BWQI?F)SE; #5:>87H,Y': M1*.7K?(UH](6+34?/(>7=@WH+DJ;*Q\J&"RL2NUO\_#8T[;#?$WZ_\$"_Z;] M6)KP8RCENEX27(%0C!DVA)K\Q\,([$.\&IQ8!Y/*3F+:)M8 V_U%D:/ M5;@G6"6@AJ9/0 MQC5EU].M-RB5TLO2WD,;6^*<6 Y$N"5E.$TII(W)G7QT2 M3'>5W&>UZ>0F+2FQH\_3VH*D?MC-2SWYCJ_47%!C'0"%!@,*^V1BRZ;0">C- M>K]MX9C*2Q>$4,?ES2\9/:X8RCN:$107\B64KZ(D M+1@V!I9#2T%\V/QJ[8?1W]*LIUY]TEWH_#*=M1L]+RR.U @^A&*>ZP.T'!<4 M.!N_(T4 I/$/C6"5.<:]8]'V4WWEA98BHS&&QQ(N%1?XY"._74\+ZCW>7FI M5&GX':ET3^6BLC#4'RF"*\$WC7HU#(PP8,>8:8=\4H?TLR=O(Z_O2@[;_L2Z M3]SYD\I^RX^[=;S>I;X,U85A"S@ZN$$^K*)G?C/'&WL1D"J#K-VV61-%F3S6 MGJ?(THRI7DI$RR_4"#(7RP*#GT^@9VM#'_S$F+Z/&0DRAHU>$]P/NM)ZZCQ\^QX(_9)6CSM=C=B'@5H8.:I3!.:Y?F;MISFG/2Z^CYE47=8SB:UL"[[R3O+_>;(EG^N6K;=/H&$ MY-1.#[WPGC*8+@X/G*3U/N/#-GLS$836/1_7Z? ^]' MYVO%Q]*>O"(\+84/DX:@^C41=S8#FO7KX!3D?9:F[>1U\,S*ZE>FFEO(CX$L MIU%?U]>7 W0"=+L/-+S"9EPX:O)J<4,OGJ(#"3T?78.ZC;I&@GRC$HI6U+I[ MH-F"Y4+)\6+W1+=JS-I;;7(S[#Y@:P#K]EU"65FT:QA"_$:.D'?]-OUHYD3R0^N>6@ M=MRBD?&^S6E?_*XQ_$-@OD;'S9>QZX O)YA#=X_\#!-I.\RQTT2YJ2(U<* MQX=XYX?V3]V MLK/6FFNN.9]G[;GF!*9BF;5@9[/M\G7M[ M'V&,+@VQ7EJX)@OX)6@)BGRT%-J!,#4TA,!">-.,)Y?QZ.EF(".I(1-LH2"@ M,VB?WEO;'O^VZ F%+)6FD,27&!FS'J\5#8QK1 MAY>_,0RX(GD,*'.&$\<.*PLB0;$[,%KUB52O*DH 9D;S#./D@<3?JF_T,XR^ M3PS3CE!DQVAA#4F)K,YPSKWO" JN M^AH=S,_\TCE547P0VU5I^>A,S\T6XBV)A,X 3BP^%$9T81J!K%*@2P]/KO': MF;S>FQ]S!=1F4 :,"QGRX[9.#2^R-R#C@9DYCMO?+=J=[BTLR9I?PDW7=*OK MCG1L+\:. Z(_+-..]FY !,WUS*>C]O9:(*O]:V"YSP).(-(J&F:T[-[/$*?J M6/>-FX M(.2$%\&W%\3T[-3:Y5SCQLG"7T%.^7%%;5@[OQUPQ&W#($T2S*OU@Q6HR'@V MZM&GJ>,5)-C,IT6HI1#W@ZEJ%O-+C'C\X*FWV3_ZXSK<**%)7+%1JS#RRYOB MR&.3C:]#?Q2>>GO6I[VIR#Q+K\2;;9CZ3&CY<"5Q^0K[T;M-]39[C<^R#+[GG]/[+8((]&5),! M4#_D19$$N'EZ;X31F>@33G\;F0:XT[W:#80Z-1I,[IM=CY&3//3 [X\"UZD<(_OC1PB8:53 -C,==]N3U) RY.\Z!8]&6([Q]E[J**G>\\Z M]4R$[R[R*5(Z:CV7D.Z:+G3I-16_F>^1?A8:@Z>?1<8T8(Z D0'AE!4Y]*WE M19Q4I^JW1_U5:*3S$6=[CPJ:]2'@"F6E%YG":RXT MM+=0A7F14_P3(8->9UHSBNK;PKM6DJ1BFLA4QQ']URRW MVSM=L[N^-E?^@]G<_+![)H!@Y#3/B%JRS@:J[]LLS+"4P]7G%&!-P6;[0H6^ M-JUKITA"H=^U>COO1769^'SY%3!O[#+HMA+\,3+=-]D(MCY/Q M&>_[RY<.;4"JZAC9\4]8AKSIA4XWOE:>><#X&K W,R,?&P$#]178TNLG.2]N M# G.);[:@*CA":%$&4I#P7 \(&E%X9B)H0\$3AYEA8VS18K#;X&KUQ^DE+TE&2.X.)*>PLILQL]A6UL[O?%1\ M\.:ZT&']:<@7NT&@WJ2_@$2T(!MG,* ]M_@79K5C[--T^V9ASKHL3<_Z/%J8 MZ"&DX9WKLD4>N)^9BI]5]YGQK4VR912X(IES,&*5ZP3BTC#Q'MDB"2/%.LHV M+[R"U0-O3A[+=]@AMYI">$J(C.6?]H24[TQ-,U!X*WSQG'E4\>V'U#KV'C)4 M$&WI.!$V++ZP:QJ%3CFC0/RR8+CF]4[3-KOTIO8#PZNE_JW$I.2G_-$&%_\9 M6YF'FV#TZ:A^1+R7)KB' 7.PR(G6*9+,!'\19/4O7BH57C5DG/Y9+^+1]('2@O0)"_T*,]J M/L;26?&"9EMF5JM>I@"J!E5$#8@=\AB-F(CI_H/C9%JIR*LB)'J=LJ- MVK6U8I&)/2:)LU"PBOSR*(74(RYG?E#&.?;U^(TWI6')J_R'T=HB-GDRM^MM M"_1V[-%,L/;54+7I(MW9@/#A0VIBVI"])"BH[!#>E=]N$TFIPBF"9ZHG3R?U M/<^].^W5IWU,>^K,K)E);5M(6DDF!_X_9-DMC1$RNF ?Y']VW]RANKYD_J>W MHR%J$-FE?[9#.(^?OO")+<:PB$.$<%3;B&QX1./PG3,V#Y%DUGR2U_E=BP7" MU.8QBX?9,42&[.7K*$N@ZUBG <^7G<-?A!*3US=U85T-"^-ONDH7(^I7GI0 -7[?MB C=:I+0;;G"$Q.[?D<3H0%S8@ M4_-@1A]J<^.QCWY9,,]=>/#E2-3X6/TNWXO0 M-T MB;;.0G)?P]1H/$QUCT0_-P/M43<"8W+2=+N0*>I*[T-,=H#9I=9',AJO MB!F%7C@?L?IN0/II;O[Q[J&K/#Z^K%:UA(>:(:6P/;-[Q^9;)SK%/TTO_C;Z MLMS[=1QC\,=SHO;:'NF173'[K_AFMD86FGYIVU5S.32Q4^P>583M6' H 2EI M4U*H3W)\T/#R98']UXXSV[2.:?V1MOV06-%)RP$A'R+D#58-=)ZC6B'DOB^[ M!P=.'K]WHNY%OK-O8W.64X[O':20+YJ\IGB-.BN)/NQQ_Q^A< M&/%9K@%[5 MJBR@GIF*%47=$<*!U4X352Z2=(#C7,'83NWS!9NOO MLQFM7C(L0>PLHK%FV8.Q;KM9.PGH\NHX([>28KYUBFX_1\CQM*0:/;U;Y7>5 MIS!/QS4-*X\6CF05IUC:: ^/(UI0<5;(,O31(YRG7(6%<.7$%*Y$X-F@YM_! MR2$X]P]>"!/7D?N "M*OS?9><7M3@\_Z3CY<"Y#XX\YRIS3[R-A]K4Y)<(XR M/6W_7'!J:"QK\=INK52]Q-/9=C]\O/Q8/)ITW,J3=9/[:0,B>8,T-="-?,9] MAQ6DO_4?9E@[.S9.6*'49GU33EI>#P]I7I7+NG B-,$4;U!EMT!JKEBNIK=S M10I8*C9TY]#D]0DO04;/;YT&XW9*XC9/Y(GTI5G01BPN+>6JM( TF>:VIZD- MY@J:TX,HH9DXJ6]M37>,P^RW KO^%V^ M?-$UZ] !USG;N\>E!9P@^I6OMHSD_'=.]*\91GYS.S6_]>!;OM: .V']2.+-_BZX*'B8A\ V(&WT M ?81L&1.)0.ZV+EGLI_8B!/U('IXGD>1WF9^EQF2;$3[1-,O_Z'JK81,Q@[@ MFE9H^UD"&&<&:ID']06:.D%)!@&)-\JH!W M*1BW/1%5'Y?)*L\SMG[TP/*S15L%W?IX('8413]I\K& ^0&L\V8 S ;0R(^Q MC67]/OW>HX!9S;S/M2.4"&6[(I4P_?( U_)%6"2?F+<(9CK:!/N15#>YW,#K MZ&%.KBZ(8-PD#O? %2:KY\:LS*E1(JL6N%.M'QTZRRIF=,CUQLM5S\^,)]=> MNGEN;9TM745U86>L_T<.WQ=P]%Y,$US.3)]@"M\AB[:A:H'[F#WA=*!*-0@;$$KU,&@F%'1RZLF@V9 M#IWH#9:W$XH%'2^1;VRYW7OEPS^(ID6=&6^L5M]7-MYD&>E41-VW/>A.]M:L M=@';R:M*ER]"SKS1Y7_FLH6%9(O4Y1_" M@@+.?B6<3E(7RUD_<]@TMFLWF6[[")H"^ _Y<$7C66YL/S"M&NB"PP]BX* = M&15?M/W>(3HWC8H3)3SQ0F] SC;'Z(7D4P,>WW5UCZB/*MJ;(@TSFDK:*O5# M81G!FSH#3@$0!/"!!H1UF&HGS!WC-<[6] .HI/A;X:F&7\=O!!^;KIHEJIPQ M.&F5A^G52(T_[2%'W$QV(4?#PMG\L=2M18HM]);D[]^_/X-O#SB L86=9!B5 M%!@=L6K#[;G$_&RC^61MAV2G2.UP'ZQ%@2TEPQ7.INLR+1A^?8@XG-@&A.+% MMJ/KY"&2V#(,GQ,3QL@DP3O>@Q-95L.:YLLM"I&:JT)P'X=Z;6N]QBU!7)$F MEBB/.>R>*Q@W8,A4]\EY2X"0Y3;N,,9Q8<;;-I8>FK"&6'[QL:\VJKZS: M&COO)U5^-.E2RC?4[: Y)-&2$AZ#WY/ M2#=X]/2=0HVHQC[XJXG"?Q9@_1G7C*+!GG.'$0U 6J5I-JY5OL073W M]Y+Q>(_W'P]]OKVI-N%:Q8TS'>M2\KJ" Y\.KWBUH/9B1XC&N70$LY@>3M.N M7)1O "WZAWS)L.2<]=-57:I#UR[1OU0S&>&IZ:O1D,?=JJP MW3:W2'EH P[X9VP#\9LR],-H,C9?#ZRB%MN^M@>7$,&;TY39.G5<6*6'1NN- MN&&_G8TY4Y<*\P8S)+L;C#<@S3=(DMRWN):,5YZG"(3.G727WM!$N%YC@<.X MBMT8KL-V[\S,NV__0&LX^]&"65+8=[@61&(CE)\[5B0:*H=& M$8CD"6]Z]?AHOT\$)M/J],"UNNR N"##]HN75^_<,TYW$F'36+NX/8B&R3]+ MTAU]0:]8/EY:$8_1G1N._9U>Q;"GS-[#K :TW2P+>A+P?N%W\J%WI$M95+V? M_C%I3W9,M3H-AM@*YF-?(X01H0A0&Z"E0=DR.+)7,EX![U\-:([SN\V!.U"7)YS^6UI4WC_43? M0++XX+&Z:_#&?X8?:ZH"B$>KKXQNR-NOE.5C7N]6VK,CFIH;^ MTQA[:0CD'DJ-.^MEPIO*;,PU3O$SO,\PJ"O86R/"-O34?371:<0@]69(+>P. MDCZJ]F5FYCFNPLW]1(:,55K%K)U6>JG^#IH^&JC]6:U@Q]!)"Z?0 (>$U6XN MT3YHVO(!H=_*N,S+XAS!0$\C=DSY%XNY+1ZN5),,7,(IWKY*Q<>5#]N,-K6_ M4EYSIU_/^_+>^-)]]FH2U<+YU."I;U6B+:_63 ]9D9A*O,XE(V(Q^Z^S#("N M7*+Z/AQEN-\D<4_!!B1N R)_(WLZK'1&K&7J M^:X]!^]7&&@9"A%V0[YDKW7"@2YI@/P WP@D8R(9XRV6HWNV[;W7;YR\L .?L/L'F4*4(WOL.C M\.I>Z/J#>DW!>PA8@S'M-9U)#"+HZ:S' C&V$X&>5+[D?"Z4B["X>>KZ(547 MMDP5=87&\_8"6SAWYV.Y(E"6/GB=D)/;G'M _:G&!'PR>$X^V3G^IZ6MD\W4 M,U_A3@532]OS=DJN$_NU?W\O$-OMT5-[6/KQCOACQU^=W@?A>W_N'VT0\!=N M0))N>.[]9590?4(JTNCANC.3WVEM/D%&,7O$ZGO8.;"53NPG9[/A-KJV3QR0:*-Q;7 &EA^F-"S M2PJF)@_J# PHITA:G%[63="BI\TO[@:,V$!)B(<74SA MTMQJ4YJ>(*.#&5EZYX!*NXR&$< MI:3@ZKN 8GO5*\T?K"XHTLJ;>VP&B+..<9J:P1?X0LDNM*LL/>P8X6P&,YA3 MVB' $&1MCPE\0R;)NRU='KUYY-?C69N/*H);Z7]!F4=E63C*/V"*(H618/_ZC#:431R=0M?!2P5;[]Z904EI]$GL[ MU8KT)*I"PZZ\LO>2Z2[9@L^A5\BG M!0#Y$> &B+@&VPKVH0BR);ASA-,&*+4C-00*T0%>KAG"\T= M&5]-,WK^W%STU]E=W1&/Y3/$_E 7^[XE55./@9JZSGS)J4!-> \!,C- MI.;A[DB699I.OP?HQ@@_@T/2VX*NVAF^]PH8F<;I;#_87BIAU10Z\T[IX;PH MC21QXR"4&E$3=&M5^/ MR0AB$M8=N4*OJY&; :+Q+!DL$2%O"#?A3@ "S[@:)'^BU,@-<ZU8YRN=- M-.WV$$+*'(<,9&,SV6%O#]0YBZ6_Q6)YFN#T9S':?-"& M"DM%7!@F3A*441EF0&S^PP-1+339L(14,+G;WJEH8L3>\]GJ4H#JW8COET22 MIS)+HS*N3@%=^G ^M $3R3#I1TSE,J,8ZRA($^]IZ??8]>4%'IQ,\$L#]B<9 .,W+ZVBF4IWE_Q MT9WPA!5BZ*MF[Y^%8G=SU$UKS\=/-.:R&HY0[*T""A.O0G;Z9G1ACK,DN9_P M=&L38E4/OG&>+AP*-9N-4 1]+VI@7G*O)! MI>T)T])K1R"X^GY:$,N=.S&KS@#8,NO,/KIO8N(&)!@V]71ULJ](>,S'8!MN M[E+3Q;LDC[9*QX15I:+NSX_C5\-T;C@&,XZNHY([+.GWN"(^+%F=NT5&C,MI M%),[M\1+USS!(-=[=A-&FFL^^?;..8BBV=.,I@Y&V ;$4T;"MD:([O\>"#69 MKB&'TYZ0H5,-U K"C#TE/9:J$JH4").%J\VB0[YZ&+ 0.N**U<0G+WU;@2:# M5Y=C3':@9@U./MV ^(%^W5@%NE?^;XM8]GZ?LJDW46&1VL\+ ^_V35KL>7/U MZFY'B$).A&_V=)55:D]6SWM!!%V4K- -G8JD;$NDJY M;E]A[Z<@)=PX!78C M5UKDTJZY%1;>B;@4?CD\<\"R?<\>^8M([W\4UX8YR)NN$YP2!+D"J,?U(L6P MHZ1Z4I<]3 TC"48^=K#H0PIZG,)/WUJV,$U;/X#!NEDV@L%QK1(6G+K[)4\; M>B \!=*#]N!B=V-G< W]RP.L2PL3OQ.[5I+;$,EF+\QH7M;*#NLIF3\:RGNQ MK<([]]( 5:DW]P/FG46\S"[]6F.V9'*0CKL\ZW ?V!/A#?=.-^N[WO//W3V6#G?3X5^( Y5)\A6W4SN M,QP.C'W]A\GE(FE.,5P"M%[KW4O\DL50&@\V M+,GZ+MR=5NZ<AXGQ8]:VPU$"83X#1LPZ:1YJ$EDK^G.XD=K,6* +OATJ%-4W&\_05 MFIQ_LXD*E0%U[>U#A?Q_/V\U:]/)O%9O.WF@\5AC[[M9P;!@R+O8X_5T+ W!CU-QF0VL^6E^BCY?^SB ^DSP2;O0L M:<'X[/;$%M.G:L_3,BH7_MEKCT?C)AX.H\;FLG5%GZ=?K8H&^8IKE3D6)@E# MZOH@KS]/SKLL%V[6:N;4 +XD8C[T8RA7U(XR)$JXU=\3Y3Q_!M1C'#WT OIH MJO_;.)-\,168O#'+HV= MRUJ7Y^'\&&^>&^7U0?X;5\B/UZ4X1MA*#\#'OO A] ;I-DH]Q.+X]><]'[(/ M^"[W9+4L*)VP';R<'FKP];Z#6,HBCGX&!>HDTCSH:\Q6'FK\L%G/=,)L )GR MYD(.0@:N%&3!+VY W5MTVU&SP;0T_+"4PO5Z@XBK+]"SIKYP$_:Y"8#\#+>5 MK49']:%J=?MJXG'R[/T,!$%]>T-!WRRD+?84O6P"]]0#&5%)_!:L6-]ZV+_E M3)]4SZB2TS&#K-=\/_V6PQ@FO22%3J$ED@C<-"AK ]+=#0*5G] 65+69U 1B MP(KW'3'WAQZGO!6:K[N3^C->&'?/7U-%LF2Y7?@&_+(H_3N/NF] 7CG(G UH M>FF[!-=E())^NIFK^7AU:/H7K7Y'%5UV^N7XQ],]3=:N.*=1MAXE2M=K#'.N M#'VM;_K<>(^FTYA&X[$B^K&RB](O5$H_EL9_.O7>5G'(_Q\FC=JL4>N'M?+@ MOH/5P^\Q$'T.3_KIOTV2X4J-8-/54@?#ZT3^%J.W:Q3L.R^PYDJ6O^D;F M#I[RHUDY8\J/CN^K MB2W2.Z=>06F?=$X.(E2"SCJ=RB$ \M%$1$0(% M-59ZAD$G0(I6[3-.IHR98DP_F%RC3);G;&5"^$\P0B@:U2)QKE6F=6?WV5!N$[9 M(].!.[^+'@]5+U'XW9?5"IU*(2#H9U'@=I.4>4Y!&! +W\)K:%FQHE#B*J#=YA1? V'">=Q[@3G+5 M0#TJ5 Q4F-.-Z3 O^>8NF,[6O5J*I#J<'6"=,0GU&S7QL7N<2O1T\[CL_W[P MPZF;V<15R*T66@9+D,W/>6F6(0IZ,%,\@;/T^82FKJ?X^!\KDL,!Y=_290() ME00I_N]\ZW%7KCZ,S;Y\;OG S<**166,\JE[/N+5U<\,Q)N:.@YK)IM#]/53 M!4Y#(!(0V>:]>]U][Q\(*?"3>_FRPU[N98=4G&VFM9R3C0@$ MD'<6S\1\&C M+O/XM(Z#+!WL-$!W7$E#U=K0?M%7!WIRVX!8JX/5&-4/'85\L6SO'A>6#?E2I]YTC8#/N&C3)Y2Q-SA?L+13X5.NSB#'UB7,:8-K9P, MJX!JCP5WV!VSK18'<(2!RIAI\:-GCZ7*!$3NRSH?$,.$P"AF[5,N19NX)ZY#$*9@Q]YI5=-?\'>+W+KHQ-&QEI)^_+?70@W MB*9@^BP]M7+V0^ !#+\41! "M+"8ZTL$YH#D(@.PB24%#KNG.!2M]RJ<#53F M ?TG#PV/?5+M:+9,>H70.^VH/RC[B3/$4O D8L3![#GHQ\*:N=QCHPUST#@% MJ=?*>FRCRI.#S*N[*/'Q:_:0T[;V'FG[ ,F:0K8)*P 3R2D!+@\K8'MX,JL! MM8'>*JC:-W6EM@_F:+8,V>TG7@1=_?E.IG;CN!%[(/A@82UYQE[UC[T3:ZMX MDTD2;S$LKU^GVS O@Y9T%O6&,K9N+C01(6J&%YU!W^^N'_IJX^LGMY!\6:7G MNGV 3.UKTA=K#VUKB"E6#.B"\V ,,@;1.)P.7#DH@YSX69/4"<_K*Z8BY8(: M J47FZ]T;98QW5H17/C(]]P7:\&9TW:.ASIG_A$JB1BF7<,W:FT6NDAMQ$\= M799BVXXU^HVRE:*J'.HG3^%;?6,L%]/?[)&KNT>3*%:M[SYDHZ4'J6*%@%74 MBMN #S2E:"^H((-/:P02W'^NQ,GO;&D=HX[.9TT&DE="]Y\3_40.KXG'P#:C M-#CQ>'(YJ0X7@PBN 77Q/6F1%(5>(Q?"7:\%0*%#@6K9-*[@>(R?.NW>TSJF M>JI&]>M97VW7.WOKQ)=1]),X4 ^7P34%)QTY,0CR([A("QC%<@#E!^$-Q5G2 MA#YGT;MM$SS3?M/_O)Y?VI[:[QH"8G6@21*/[,*F<[E"O2PG,)?YD*>Z*(QI M+K5BF<.0<3F ZZF9>M?WTVCEATI_?Q[P6%BBCQD/O]CNO?-MYAL(/W8 UM3" M0[\>Z,C-,E](TK1*5XXZC-,(7*X:0"FC=<^D/CL I&6-W4_X/3-^I-3B[B!3 M05O6)/O)GLR(K SP!9\,!*"'<+)P=674&(W M8)+3Z('38#']^QHAW'0*-?5KEW]OR+C#-Z,!SA.O+692$=)UM<@^Y4[R(TA'PX#A\QFWSY>U=E^X,\0'[>9 MJ;P'#=*1(G_#W/]_HFV\)_, [F#"!W0=8@N4?E-&I!BS!1G77X7[G0.1 M#)\C*N90B4#1A--NMJ;$UX>D7YU2O+;KE3*/6Y.S-R M,%HLR]X53"'[T2)8 M^B0PM)\DW/2DPY(ATY_CL@LJ_LVE;D?CM<72W5D!OC9VEY)V](N\T#GT[N[D MQW$7Z_>-2(FIYD(*1WFB>^:YS@M_0]J$UAX'37O#>$>^UL_A-T.>O1N\9F?& M%_A?.38R,#PMR P">:JVU1ND/ .Z'#:S"JK+W',%7:AI[C-X?Y.I.61PYLP; MJS.TCY,D.! ]:Q6'W,DQZ@,2VT'2,$WW4D1[U[@F4 M*$/(7W[?Q'GH,!ATK;:A7W;Z#R^S"'Z9E@B-B8FJXH7\IJFL?"] M ^$A]4(5:2TV^M\%@ZH@3HD:J^+N_X7C2R7,44X*PH\TO5[7WWL.^%UX/52S]."\XGLF5JYC+8LA9, M=\[C4#SY'JJIAI 62IU&^]DTCW-A[*C1^61+CQI1JY6M?AX!YSM-XUB$\>#'!1L:L>,?P:IZ1!5JIC6G:W) F[&(L9CIKN4HI[RI\YO MN>WL_P]CDG9":A(0Y%*>CT.D6 !R-(!<(7HCU[GC?$Z'7D$DHD7"_G$2G$OH]5=>PF %N="%@N_)$'$-:MO6[FV47E>R ME%-E_O)+8[(3-5-1\NU;6XW)K^'=-:+8<3S]"$#,(.#J)[OQB9U&X!3+!(-B MB#$!,:O]I9['KU*AB>ZC-D:C'PT\[97MRTUMS,KMM)SN:&99^_I>O_X[TZG\ MPXV@M(ND'@MEA\9<9LYJ5Q"&KI>O6.9/=/WP^M/3KSM3=N[S498I+(%(C&J/ MZ8P&?QVG[6AI1TL]?Q1S7=]F^Y9K5=EGR:K1O2X:?EO*D/^%@V5K)FS9%JYP M&9D'AV'1C84^-@Q?4C37&"VQO 0(YLL$K$[T*MOO_)17@8RM9S3 M/Z4ERVOE8:468I/UT@RM^A3.\=[4"4N'_T:.J9%!5+J=3K31_Q*V_36:-@KX2S)91SZV]^9069R_R7Z# MBD;\)4_.?^EHWO]5G_^= N<;8J- /'V8K$ XZ#>GVX=4<@,CN[GJ#1;N$TV5 MNR6)1X0$/D7;*FFVW/IUCPOC>=:MP1N0TC@V@D=26_'@S%^ZCCT+=.$1]-!A MMDP55\2(]\#2*!" (KH0O S;&,1SY/8(1D@T,^6:N%FR= W(!L0_J\;D+DP,HPA M%+YY-ZXF"09Z\KQ\SYD-B&0BT*4"+)P ;V] XC^1V,8@.J(%>!]ZPLWPH/G&U ,D#-4(Z6+N^/N *\UOL6-B")[,W6%[8_PKS7V'^*\Q_A?FO,/\5YK_"_%>8_PKS7V'^*\Q_A?E_ MDS"_C6U ?#/ G:1E2U9(T.^:>+POE.A"P!X8,[,T:QNO-ML_4S2A$)5,:[41 M>%&3 E E5S;_01@EB:"W\]I/JDGFC7=X R+D3X+BR26P)MWHCGU9QKCB16"* M*6I6\.FH1(VAOU)[X5/3R/>"/[3_CRK.]+_*1O77/2>>-BBK;;XY^8!8?A1$ M^KW?@,0;]_]XU(<.!G'@-3AR;Q/ZZ=%ES\^?^>[7*&]D*385"X",9J M FN$<6?DX"@KXNA(9!;+?:+)X[;3E5<@D6&;S\I]P<&P%NP T(UA24F,X2IR!_+Q&3< 9;#(P:(/KC,:5FET MD1ZH"+;L650B0#\[G$"BG^+IQ]2*AS.8 M1J%YN-0R:+--_CE>3FD-0SL(H3+V9FFMSGN^)NUNO[:RY2ZTK/+/T/3*\^@2 M0G.13B/=\UU+L'HUX'TUTK?"[)7#P4;HUNLGJL8>'QQJJUL0>PV=E>7#)L]W M&F%L/F E,/H,BUZ2M,=YAPJT"V&RK9>]]_;)&H%&Z)ZGV_3;DXNW:(G-:875 MI /^&:!1V>1R ?UZ]P:$-Z'^>%"GOQ\E@H[L@VO4?C!3&#.QTI\T17G9:.70 M!X+5&T<]&@R1F?HZW2^B*I(AK*+D7VNO\"TFZ3]#B3($6,-\+^FC#[6"\*3# M.R!*)YX*2'DN*.0[CKIW^V6-EX_\M"R1I2FW/S[P)"SM]6MKS84#O#&^P!-A MU*_%=!4R[D[G[D62>!B@@$CX$91F[2!XY$53\E?J/I\ 6)"G@ZR/2"FN('S= M*9T/0MM9H\*S,5'826=22^YR,!E!_#[PZAKZ(DQU\2SJ^*.!)Z)]C4XO.\$OS-?RB$W%>@69H/(:O0(5 !]:\UM MS,QAV]*$TE!UHS32K."Y;]K-I]8]<:3M7,5/# =."A @M &Y ILRH4S2'!1B MIPEO> M,:"JHJKAI T),2WIQYY)D7L<+]E!K'RT%=_B0>N&?JXBG1G7K?3P# MA6J$=BOPS&L_?NJZ,WCX^7,\<+%3>J+I19AP/E&8N.\Y^Z.3RY6W%@+]:BE/ M7"Y S_TOT@WX4!78JL4\L^8(.LW1KE. #" 86AO4J3)A?.-E8#]7;CCI"^O@ M3$>UV(>5C%.7HIZG6AC([7NM=>&]X*1=2WF7M>WS\6(1VD8OMXV.&0X5/9X.I)N#.]?1.28PM'=8]3/1A M;F>LQ#[G:J,[!PB=LI,_."X.$V;.'2]"+K:V->,&FS)]W+1$M;9?DLI4J1-O MW++D;G"79PP9TY2,Y5[ZN5Y8HVX?(&6<30D57&A8RO_R*^UA_]83KO''!RQ; M1"H?Y5QV4LWTTJ9'C+XX8&E=3\K$1(NO2-HJ(E5WJ/^GSK_"@"3(!X0],C?8 37@"#-0-[Z>= MHTS&F=L/0&6^Y6/45?*I?1ZV$_99AM;UQN6NV1\>],K0[52:FR%P\'''"M.1 M4P7?PB62^!M-B$>9P0P:/HFM315R6PXMMDZ;NW$QZZAAR)9>_7WZKU])VOQQ MV +O3\J BW,><(7 E+F:#,,F@R$$@0D/7+QEE/<"/_;=<\(@2,7V\+:@@CN? MDX5\MH;F7#J?^EXP^#BFA"7--VQ'3^_D<;LSNXN!+7H+3PJ>K6]H&2E_D30D42"6>_91^YBZMFF$:-PA1SNS*V]+MRPD M&[S&JG-G\/6DGIJ/-$2HD2@U[1E,S(60JSS.?8E-DQHEMT@8^Q19*=A1T9_O M4+JN[I"%//1[UZ''"Q,#6$S.C_>%+00 M'!SL'? \)$1+6/5,I>&[0;031-J.S'=(YHR7'$\T:SPK%(_AVPPF90NV<1[A M_8)/!32F(.26;LF-O_S(C_9M>O@L9 F^D#]3_=WI5MR+TQ';7D[\?TD+# @( M\J,-2(LQSZ%O_-*ZX)2S'*^&MP ])>H M,AHDTWEO;6L[1;FY3F->NT2V,:A)QFUA>W.J>?ZY)H4DS%7'' DR?X_50B=, M'Q^[$7D]7*$@E#DQ$F;9NMQ2+"96>WM22^X"!#[^N'CTIZBX>[>XRXF7"5\G MOLKE$+_.GF8,J$"H]-,#]!DN"-]>Y/JHH3%#,&JHIZYO;^W9P3+_+=,+-3E8 M^&9"/ZXQ]PULF_DP<0OS/B?6*MB/$BQX(I]U%D]W23*;"?OQXYA1P8NSMF7I M5JEF=5J+,.,O9^PS*AK3SHYZC 2'51]B_\/9OK^M MKO'7UUV'8/BQ_\-KL6Q^_K;@2#3054Q:31B2X;[=]G(#4I+%N_PU22 MQ7\1S]?EW!?G@6<;;0@6Y[(VP+C'A1[F5,"5,%X,%T(0[&/#J_#3Z,B>7.(E MBSWHF)]>EV(H5(E78OQ'+MW^AGH_CLFCPL#M"+:T2F\^9ST98\/: DJLG1Y; MT6['M^>/G%T;TLP-#YT-,[1#N$/8-WCX=Q8(#/V]>V632YQ! ?$PALHPS6$# M8GWP3]0O8K!"KYGD??>'S2;JSZ3]>1>RR07N X28/XE(1NCFPX(\X*[Z"/H: M"J;-,\MY@U+?A/WQ: _IA$-V($^<]4&]G2+Z,;6XX.S M$O2FP2'Y"K2$,_6[GB!Z\M763;8 MX88E5"VT.PU* 7JAT)YU9;,#F-7^0W=?ROZ@%#O-X/<\ MQI&322YYN'>+;\84SUG]53)-_Y'=X<^N[.,.UP:B6M9Y7:$F]D(EC^4J#QZ( M6WU3#D;9OJYO<@QS!#!H;'[+J366R#G[QO5*7^D_!%;MY^M1\/ M?H'1R7^R(\WIS4?Y>(K5OW/+ZA:N9@3G"7ZA?[,1RO$HKAQ''*/*>$GJ(<5Y MR8&9@(_:,^YV^DQZF7FCX8EC:].E9;)%M@)TX1\U>0A*UY]TS:9EDZYMX:VH M=)<)K/I[LU#A!7FX//UKH5HYKMRM-\@[0/+7]@0SH:3.KD-;%@^IHF@NK&.@ M"?,$IX =Q#J!.8Q9]!*CT]Y56/$?2@O;L7VU^FZ1U1M?/6F_*MO'>"7X@6^X M;0AR[@:D<66YBK>(X/1)F@H9*0WBW,>-V08L]Y9XMHL?^O>=R> '@3GU'O!'I2$:\5VD6&+X]]QH7,G MF$:-# X_DC[[_>N[;??L&N5;#L2%RQQ58QT-TUNU5G\+B3DTE(8 ]>:7/96-C$!* EWB M;#OZ.I/*R?U1+4@-)9#B%8I@S2E4P:0?:>>.,/SM;S;5V6$)X7^,-'YXH)$E M['1RM1H&(Q]O!RS8R\Q,<%LC?%XH*?9 M_2#[-(T55EXX;X@T5;C;I6)L1 B./OX>$F7'NL(=P[= EWM9%[C]> &7.=W8 MT!_09.[>W,-@@EE-XHH?O-C\Y>,!K;LO>VGOFV.L+QX[(99)AA[L>A[.Y!&8 M[%3 9YBES;7BK8(#&XIZ6JG]+H[$RXG'=FH-%[WT=KZA\&)9PG\*W8,>XNWIKZB'U':O+C M&>/+,,E WCKK5$6;]-QR2;9"AE+%);;+_LYNT/+R[/@=<]ZV\I6P4$;:U&GP MD7"8R?11JB[-A^$Q9W,;"\5@P-OT?AOPS)Q]QE9_8D4T5F28FA=V\!IQ1+C& MV*0TRI0Y$UR2\^6"O6VJA>#K"/<+#=95:\,T'B<3V Q=;,%L)O731K)0X KE M.XZ>05V)PX0%4W!R;N@"RF=*TX).>U.".!*9ON1D?^Q&JTK'1S]G]!NS"F9%4)[<_*]JBBA4J>26WP[ M1_Y@O!UX0W2Y>'2M1-.P4) M5\'(N1^_%!V80+;@B M)IL'$$D-^#N=.[GO.V48)H2,=(3<#KK.2SK!GG[LY@?TSXX_\V=N0.CI MKN:?^D.KC/)0EX@T8L5^Z8^F;Y:#8_+40_6X21+[8+!.;@6QX5GMQ6 'Y\A4.+EN3_$6SF5T)5R7 M#>74<^6!KFO5B."5.*!A*WM/[XBO),,L)>5/ MQU)R6NP>YEQ([H&\@F$"\[WRG@?D*ALW51R.\(O8TA4>$";R1I9Q(/M2V(6C M>EMCA+JVQJ+R8/2P?O:#]:X-".L 5&0#LKBW#%4Q_NO+!D10&CL(:^JG%; L MV?O!_2P=["!Q.-W[$)TU S#HJ=3% 3(A?;4FHP+*2S+;N6HB::#T]-WU-_M,RHS'5"/<%D] M6949XS1U/<'\5_L<,%W %1%D9#!51H"0#K#'7B;TM%R: -W" XQ@ M;.EN*X\/F(-)>"VZ=V8#1@V>TT>OB]VU?3:Q.B0&M#N M?B9T]Q%BGB'F@31SKO5OKIWIH6NO$XM0>SV2?&WG6C2.#>G7F\3;L&5M"#!Q M?" J'FBVJV7HWFY$B'L-T$.I$<%P<63/7IG%%B,KA8F<'?OFU]U] M?+_F601YV8,0RWBT4\P82*W'4T)DQL'K59&CU%YJ3C _QX6'Q M81[3E>)D6AV"&T.W\> &#UL(,1C(Q(X2$V8%$?Z!64,ST7RSVLKB7D9/>8;3 M?'BPAPC(A0U_1+C34W<1.^S:'?F_$ 2! M&?FS5>LMDHU\']DP3@D^!#>U"89ERK!=0.,*3>HQQI&>T3,@"C" M^;&C"G@1*Q4*,ND6+A:K+"Y(4/8J_4U8_*8\4!5H<[KEP1NQT78A6O50PS.[ MG/OM,7EX1:X SVOH\(2_R-[!J<$@6";HY'E*33Q6:JE3<1)SVNIPL49+1T>^ MW9GX]D!^RMSAQMVN;P8P3U_)G*]ARTR2_6@'>4H?"]YA)#(OWV/Z,4)[:F)G MC<#;D7.HN")]NFP;9E)>Y^<9OP^AY+:V%G_U/;)>Y]G=OS+SYMZ-0\KHHUP1 M41[+F&[@"M%8'B PMQ+W8P9*[>\B"8/KK_ RAF:>U+ZH(\,GVE#-'@99;V3Q MNS[V9*,_P\*#+[-%.2_8AUEJ0)<\XN** ,:P?M08NX/M7T?WB[;:&O: :&\$ M7_J]<\+!^JO9I0#OEHSK#\;OMS<&W%7,',<G6".VIKSO/8N:H M)FP9068?R /!6Q,X#S &Y.&$^2Y2H\5R]5,>15%7ID_>::J&VWM>9-FG.0C2Q6JQ=X"]#(NY\?E>5 P7 MP:#A8KC;W<$20IMO41DE9:#G9O/8\N71X.ILVNUDE*G2B#.?HV'!0SE:&$#L MGX/VXT #A10$N;!H*Y@205\GD"2XTE-@A?.DF>?>OCGG29.:$/E]U#47@UK(A]6[0;]*080:G.]^9, M4A2*#N*0 MZC$R[*YEG$3X.3UX8M'Q=$5XD<2YU.J>_W"F9%!>$:8WB*Z(*C MAK_* '6938Q@N#K;H&'$HQ?'ZD8,_9]D=/O&'"34[]']HR]>)YA MG7#'JBA2QIIO 4&W#R7F@9,RQZN.R]Q3O&_O*RL9_2ZU@6^U",G(3\LJCTD>^_OAF7[;([-XG]^F(3H[&H-4;3&V_,0'' M6T8QE[$COP7C5L*&IZR1H ZB9P-R&VN(ODK>%BNZ,>B1 ATT-IW['B=< Y=%K[LR MFJNH)H)+!W!)9@,L[VO$ML )HZ^++2[;S-]\GA!J]W/ M_ ^XU3(P%LHW]CPO-B/&-V;<\OINMX-E5#KQ?4?X93R!(J3WX"(A=&LN@+F\.GGT$O=\Z?RB3IG#KXK]!;*_-SQXKAO6KBB M=X35I+;CD?=8$JZA&D\;+L:XZN'CMYZW =7 _HXH9R4G"RK.E>+XC M? ,B;))N94)N-T+TM+UN"^B9Y+F:,P;1HUL54VT)UY<_1>B\3/^/+2UN!-84 MZ%I -,X33%)F]<%@'Y8\6F()"D5GL4XF? V5]*H:O'O>ZO!'OFC;DW2S* M*B1Y6"61AXU*2)INE2*MDAAI21Z;'1)YWMT#4G=6R5.E51YV8\S8R(T42@P; MBW*S;*DYM;/Y'?W^^]8?]Q_W/]_?SQ_GO/;:SGE_SJ[/]?E<[^OSN1?K3_(?9.;12RGRWJX M7_RY$3K1FC%Q&Z44^%N@)\Y-EK<29TH"+RL]] Z[G7 MI?;97FL1^:Y:4IB]_&*)X0-7G#V+2,3!S3^M*1;H\:587M2DN3*XD=_<_[A> MS1=(R5^5O+FP\GW1*[/S?Z]]3;RNK]5PW&;-,F<$*76FB M:A"14C): S(2/4G;.AC8R%7=:FYPJ/NRZ"_SLZ$5X-H<!"P,#C _PU M5Q,=]7-Q60RA#QG<3N;G0NH<\0A#>L->0;(%Q+)]XHJ3OP@\(D)QWM7)IR_> M.'W*= 4G@9:(>W9P^H- #W[&0EC2$;)>G/HHV"+9(VM%:XC(:<;ER5U^(8=I M5XN"3B[]:0C I1&O_4H]0 M%?6K]N)Q$V?C:W+$!7&F8]A?=&#V5\J5"E6]QE@%[$+OG@\)\SGG<\N MM.N)S 7K4$\]$=\]%5NXPB,4T)@K4)0$039"-3;N7=O(*"VQ?BND)8H189K: M!'OE RZ:I+?=>GGFT<9O:1I+_GH1>2.BSV +]%4RM^!SMHQD IT1=D(:Q3(5 MC&1C,&XA>BM9'1^%7M%CG,EX:N_TT->OQ?QQ5?DGPII6^^#4*K>[U\WR24=W MDYJEE58,CBD3J4M:#KE);Y"4VOA2U)[JMR? Z\-_TIU"BEK#"CT6RJ$[C092 M5?S,&YT-\08;_\QR1JTX.3$-0)KE/!T6%S1SN-(XMY7H),TDAO+<"4L@CVZB MVP@N#;<\](M$6SB:6<4/"RU^K./E$15ALS%^-_JE2^-A9#N+=#E^LE,F8#F?6J=31A8"+=]EDE^WG+I9JZB1?C6OEW%HZOO(8_ MXCY;45Y\ MA1XNB>1$&^P3C547,N-*P,"&(23]>>(.O [P;C3D$:NPV*WD2:14+(AB@IL%'")C*I%5"'!2UB< M80ZY!SSY*-,G[\=/A5YEEUS5#V)$K-FN=ZW,\-BR)6W M2;$3)_3 \'[5^^KB9U(."@1A*Q5/E:QPM8W:BZS:7\J3Y??G%SIW9[=W1Z,[?2.NVK M0VP,XZW2+5/DX+.))+N4U;1;W]-Y4TRU%!P\H8:48 A %FQ'3PD=QE)Y)I Q M//$P?9(+0J-*C_@,#CI'Q,64N.$-JUKM,PD$S7-.6]LTPUXT'\*WA\4H3K*% M!GP 4F\9F6JA*$*;I7_8NXN,AQEL''* N .,S%>C=W=YH [7)QDPNE *HRSD MZ?2.2SK)8?5K-39%>GL^D?MF))H:,G -Z]WF/Z MSJE9;1ZV(=P*^XVQBUE5GMM>A>6IS60!GK"Y&5^-;FN";=DN!O+O?MVXM(DF MGZFD3W2,U:,S(2L+WCXN<$G).IB].MZ@*#CW"H-WF4;:"&N$#>0L39:9@9U[ MR2,4-E4#!\XB6$,F3Z=U7[8TZ^AL'MPYNEG?WY?]WNE,^Z(/3J9)OPWO_B ( M$9J*'\-W/R%U,E2!DY0L2GE6-2RF??H;7E?B^M58/B_O'1?K;.L/FS[]M.M6 M_YB;1?_G4?_-[?O55SCA%[2EN"H.XE0BI-YL8 EQ^\B=\PZY-3F)@1'1"=L$ M.:[[!_QI[5BM.H^T#7=33R1;[7)63BF0<_R(F#3YWY>7O(<)D"9!MK1+>F\N MDQ@G?<1[DC),Z#-@QHY1>#AU]&W\HV#=P8%POW7WM\TD>D.19GXP<+JX_'J)[SOI^&&(+_B / /#N+",*"!LVU_/7@"5ZH ?N[8F99 M**.";DWUZ]#<--C0,>K'>KWJT>2U72:\S*C4>(TNC0!O26SXOMCWO'_))%UE'%AZ4P3STUBWAW MW?$-T5RR@:CR"E(IGLA-C7KD$Q2VQ:CGQ6TM3KC^#I&C?NE<(!4+*3RO ]TS MY7^0IG\'9'<>/_I X20R,96=D&:@;+%$R)DU=KM&ZAR'TPUUB5%@+YDCT M:_"J!$5JQRVHQ.F!Y2W:VR)O7=@6^S;7GQ R^K=V=VVGN70 @ M_9EO3(Y]ZD7?+&^T.TA^3$K@ORR68(B^(!YN]QH8+G)AUV"@-3BYK8,X-G>9 MO9'P,Y]ER\IY98L_M,G7,2?JJ:^;*>2\RU$40GH)1_]61CE>K,)I)JQD)Z_M?+:VLQM(TKFPUEV M)9\,T]2LUF8>U0',%!3FJI*X, ([.3-B(MQ1*2!&ILR$'^HKZ! H.CB7X98B M!QT!L1:5VG?"2\=#HF?.^?5W;.X;>TR^=*[]OJ'_G+%'-DK[F549!F-Z\SGJX@<99UVK:P*!DDP^M^SS ::$7JY#A0'-2- M+R^U-G:MR_5(^S3(LUG<:QV%/AVEU?#Y97$+HQ\G4PX;08%FL,,PES(U4"#/ MPZE&1[&0Y1&=6?8.97Z0G67'\#C%>]M^]ZU>1ZM[+)8UO([7'UKEEZ>KLVGQ M^T*)WH\ROQ.4Y!KK27-1KWAAN7 F]8L#VF&!1/P[ =F'+2B\[+I.EQ6YD6K^ M9NJ&O"'B8>MF5=3OMU]?],#QO 6' 1ZOSE+\JD*:0W?!-+8!?0V0#64NT<35 M($?5G9+S?CL%N-.V\37;AGPW?OAKVEI#0E_R2K$75XZY0D)'N_!0270KR7[( MN5[2H;8\K_>"(G^(>B5;1O0M*[<\:-FF8TFR451;LN+O69:P36N[-IF$J M $B[&^:#L)F[P<"+O"\1_4_P,"I*+1W%0=MF:NXP$].P/9V4EWB0FI%"K\P0F7(NW.$RH14UJP*;>FL/GK$:K0+KE5/QL6#U M]5VWJG*MVHR>57OIEN^T;*F^=09]5BE#G@OP2F<154.)<[=*KQ&=);LA+"AW MD3^%P N; OBF#I:_564%W:W[,ZU5+IFO8D\P:C1 ],E-5V1[*%G)"F7%IWE?4EOG MF/.Y=>7)";3C(KB'M1=PQ1ES&1)A_;6C!TJ6R5XRGKFP5V/8)(?;N[$"I%X_ MOF9?WGWS)]2 .-/!HVZQ1.8H9TM",&UA^8;F+; 3)?1B]!'$-2(J<^J=9)C2 M0.BC_08F7A1B^90$>BC?MTR'5>.<7=/W,6?:.6R)\6_TJIB \#4FGQ4:ON5A M->50S8Q^7YGRWO5NH2X2]PJVD).7>OYYK7R9/[VU;L LZ0_Y%X! M3/]9Q(DI,JX*U4A.PB"!@#L6*@#,9A?4&^"';(51R?9.P)+EP64J!D?QO[4_ M$;(^GR&K51>T^[HKG)\@2PX3UX)ML($X@U1 :T67BX^)R$UJ"J#=2%8VOS.5 MEH^^QC3,E=B:9/@8_1%)L[1JZ[!OJ^AXKJ_0.%FF@2>M%S8=#3JTB3L^XWW]P=FBH+7.>5[FY;'ZRLE# M3J>GN7TM8H[T3[H_C\NY[E0#=@Q+O8Y*\^F!)>^(F+>0.Z_D@7=Y5?=HC5*$ M:D95NEG94]1-Y1*,=8Y+J[?,%+*4/L4$D$%S( 43BDMB/%=,09N#>B-49@>F MLO^@C(/1D MK)!U81"A1,Q]"%LM4DRA.XRH()CL*F,UV-][VU2JM=K.C]D]KQJ MBWN, _O3UVW/8\):1_LYNRB&(7GM69&RJ[(F7*5^JN0,J06VD4"P0'ZW[1E] M.V%A4:G%S8!I-/O<>*I@AD=8WOY\S1E59GC"']X?J)#&E1&DP%)D*5/](O2> MK!->$;N+K#HS8/I^:ZKIF(Y(=70T+3K:=R@]1>-0_D0G:I5GBTF,>3LN*##U MFLW@$4,,S/">82:;AJ?>U8K=P"C)QFC_@W$[NAM(FA5=^QZ()JW+759,/U%^ M/SEMA%H_\ >A>=\&^9Z07Y:B_;F^0#P&*/DG-4=^KH-;S_BYX %"MFD.32K[ M.7<,M0'Y%>7^.^8ES@0?$+=!)9,F?=6A M%_QTL)ZG:V^VK5P<_[M2@X/$>[AETB0.9I9>L#+8DA <60>NW'O2^J$/>*SW M0'7/NO3#0K^R@4;\NZV77W0OV.W8('!$=FO]"+M2G8;ONS:+>)T#C-F4PT3W M"] $6V+F>\:7 ,JW+#.8ZTKG0J3VSX5C<3'"&)1T9:#,/QTCP[A UIV0/CQ_ M[#XRB[@YTCF+(+]2G/KZ?Q;VM8S#?49M0G$ZQ1=[&(&$M/HUL*_N'P,$EAR> MR-=XDYESKPC7OR]7N]?3+=E/]%=:@^WS]_(9\2[7(31L*@!2W[:/]>H@W);" M>? >GP"/]-N92YN8-8NN7(Q3Q*Z/^ZVK5W!<:_A!PO#-K^JE5M_P__3)P&C_ M)K2^$)?\!;XZVL6YJOO"G?7-IN:6^YY?=E$MH[NJVQ0X#^_??W!'%@)Q\$<^ MI.1OL-JU A_;,-.K8(&(OF.&ZP'>9]SW+9U0BS8 D>9&TYRB$RB@?:XL VY[ M,YLRBT 6R/0^R-2,8-6%&V\/"YQ%M'R4G_F>-@_ZCT ?\D-TE)@L MH@G,)9ISV\ZRM9 > \PM=2F-GF[RW]EM[U(0K-.JW&AQOZKG?GB(B2M_R7[1 MY8-R!Q20>47\P+\]I M5<%24^'$+YK]18,(Z568"<3*7O1_F#2"V:^W&%L+4G4R+E 5WL4E.KZA-,TB MCE=OJQUL?*D=HWY(09Q\D#RZ__=]AR6A;".M&'$0*+DHRK)+--X4EZ%K$LHE,- M&\'O.&F75^'@$^*2K0"Q3%?DN2-BF(\Q8(A:_VU9EO>(HDS;FPM%QF-J^TW! M'?"-3^>B5D9):X#A -C[;@GZQ5?RDKK[C,NH_\0@SX/.@\Z#SH/.@\Z#SH/. M@\Z#SH/.@_Y;H+_:9GNO*--M^O%&>O:/_%39,[.(U0_SUT@+9A%!@'90K_XJ M$;:%HAL<&S= \AM,OC=RN_I>'J;FXV>M$Y/.B+ +L$,!S/;]#U!+ P04 M" )GY%1)Z4-%AY% @!!'A< $@ &$M,C R,#$P,S%?;&%B+GAM;-Q]:7/D M.)+E]_D5V-[YD&4F5/$ KYYC37G5:"$_^?UYP_@;4Y7CSRKP)N"XXHS\"VM M'L#?&"]_!Z+('\'?\N+W]"N&\%_U0V_RI^2Z#B7 $Y"&BG),P2A"]NO\K)W[DA Z!). 8(HP0C'F20#<,"0F3@$:> MHQM=IMGO?U7_$%QR()7+2OWKO_SEH:J>_OK33]^^??OQ.RF6/^;%_4^>X_@_ MM=_^2_/U[SO?_^;K;[M)DORD/UU_M4SW?5$VZ_[T?W[Y\(4^\$<,TZRL<$95 M!V7ZUU+_\4-.<:4Q/RD7./@-]1MLOP;5GZ#K0=_]\7O)_O*O_P! #4>1+_EG M+H#Z[Z^?;PYVF?RDOO%3QN^593_Q(LW9EPH7U0=,^%)*KUNKGI_XO_RE3!^? MEKS]VT/!Q?YFET6QU:J2,E%2NJ&2\G\>ZNRG,\0?2-YJ5]8!A-/J?AQ*QF.8 M?AQ,W#OI'_CX G>Z.5OD^H5ZE[&IWMUU5V>+/K[$0[T6>867$[P6FVXZ(B_5 M'S[(GYIN5$-'G*GNIW'='5'Y]XIGC-?>5W^&V?WO)1C\%;< MX>^?\D)Y^^NJ*E*RJC!9\KO\$R[D3+IP:.)2Y,20$T?.;0%S(?%8!'$D9T(J M1.1$SJ):CXT%S^"O7UHUM*S3"/H7"Z2K QZCX&6^*NAFKGU<[IM Y=RI9MOX MIPP_\O()-P](;5584@/PKUI/L*4HJ#4%KS[D9?G#/_^T@>B"]EW^::RVO+#! MKD!'6[!1%^ 2U I? :DRR 602E^!1FW0U1M4.:@U/VC^G&ZIN%2A6%Z\M$U. M)[/-EHO4=A&X)!K81H2?5/3\$U]69?L7J/X"';<)]_[GZ++^M#.$KHL62%S0 M$^]7\XV?:"X#X:<*;KUJ:N$P+>)5/NWHJ]\T"<)?0%XP7LBEUAY =WS2EP?9 MRFL9W#,EFQ1,KQFNBT(.*ZZ68:^?-U_YA)_5GZZ_X8*]^V.55L\W\#9[9-JHOQ9-E&5-UD=O"P\C[$ 11'TO(1!%+HNQ)@G$''L!CR6KUH4 MV,Q!4PD^MSE)2R=7Q:_2#)1*0=M9:#*+F\U*<[3CR+.4U@>J%34#7:5!1VM MGD'W>XWF0*M^!6KE04=[4,]]E=0?- !<@1H"(%^5&H3A)JRIS3;D!#:9[)-. M:%-;Y.4$-WG__2:\MUSPHN#L,__*LQ6OVY13<<&E7&]Y_=\%BEGLNUX$@\B/ M(/(B G$0($@=Q@,WQC$.K59,1KW.;:IIA0:-U%>-%P&MX.!5*[KE'&1F!+,) M9'!H1_;^@Z!J[:^M4!K2V9IU/*FGM,+BI9NS>]C.1Y5%M?C,RPI7VF%>?T_+ MA>.3Q/4QA[&+9+0<>CZ,N8R;F>_[#N6"HC@T\41[VIZ;OY&0INJ42*V^/TE8 MBW9D_*:D_;]F+F8?AL<=R9G(C.PN^H)B["&.J'_$#\BG.CY _O9R_.]K=I)1 M?D2?=BP?^TKOJ"+-.'O-,_E#]4E:4/W_=5GRJKS#Q3VOKI?+YD!.VH_*7O$] M7Q!"Y;)74$A"/X (N1Y,A& P!O+; MH%;*.NSH8R7C.&1D[,:9W>Z0;I%O''*G6X ID]>E%A;__UB XI+WQ:YL_JT">K7QRUE_61?Z_>IR7%R[]S7"PBGG!$? _&GH@@ M$GJ?R75@) (/Q9'@CDO/"P"M99J;T]L?EK1J@5HOT"H&MC13 _A[!6KE@-+N MW(#1WL1]H\=1#7>14')PFPT06/9&>=PHTUZL"X>0X=B'B"4(QA$+81APDO! >O,D M/L^5FX@Q-^]=RZQ.($GC"_*UV'\%ORG)02.ZX0;?F6;JZXZ'!O\B'GACC?;O M&SU,C3& T[7!%Y(4!"%T"&<0H2P V,G=*#GNL0ACO PQ8NOO""Y MQ=+>0@";4=L58T2G>?O++S=WO[S[>/<%7']\"][($_$K[CK_5;P0'.&-@2'6QD![\IZ8$6?]AE?0_CS>?'VW0)[+&0)IC#!0GLO 9/89=#W(H<'S,-A[)F$?9LF MYQ;"_?SN\R_7'_]NYG,3O:K<9Q64[C$M.?[S/O_[4 M?+D>Q@)%P4T2+#LQRIDZ"_,#,.'=90OI.S@JQ)>[6(_J:,\K.4? M:^EUTG*>YWLQ%@2&Q$40A2R&F'$/LH2Z).;<"SPC=SFMW2ZQS_FD5VSTM"VO M0)G>9ZE(*'$K9#M< M^HAWWVMWTC2KMU QKS>\ D%GK3AVW, MC4M E;F%,O>#OG+YX_D3[W VJB=>K.=2UVEFT@&:GV0F'0Z&=B8=L,5^^SUO M/BYP3!S7Y0Y,0G7,AV(*$Y6[X1&/.!3QQ,=&*;N;)N.VW'W@T^JJCU7L]&MX'V>F2#D^[U;!1XN=?3^<0V!-T;VZX3"E'@TYCZ M"&(GD*.)^A3&H>-#&D2AXR"/LP";Q9='^YG;$'M_:"UODDUH!?"IF&\PV$8> MJ],A9AJ'#8;<1$'660A:Q#Y&N!P(;(X_.U'48J3 )B0Q^[JMV_S"LS0O/N85 M+R5&WB]#8F(_O '3C ;[6,QIYO/RZF'N]L?";R=*]SN#<5(!&92MY ?J[+]9/*9EN>+%C^ FJ]>27U6& M_^8#<)^K[^+L]V+U5%W)!K1%=&,/^5(.[%*N."E7-PG6O\!5[W]F(A=]5."-:S[^M:%.+:^I?*M72[7:/$3R])%7/^,T*]6M M$EY>"^D\[_#WAY4;QX>D%$ M-H/[I9PCCF]^GV:9VM-YC9>*]O;<GZGDE.8HR1(XF.#L"(,W'?F:92=EC01G:@C;"@E7;\W&%S>(9T<@:]3NJ[S%%XZ9(LGNSG:3[SDLN' M'MZJ7*O\21/+9)H+;R4]V9=<5-]PP3_ERY0^;\9&&#F$!L2'<1ARB'P>0NQB M"@,1($?E%D=V1'.]I)C;OD^KA%[_=C2Q\TS]#&+FK$:'>63_UUWN%@^K[>_ M(*]D$N_&"5$_H,)Q"A&$$>$Q81R/XF,N._L MNIV;-]2R=[8,<]'N.VKYP5-G-['6P'0[V,H8IW;/QX)X9$\X$W1-]^#'0GFB MK?D!T;;8W^X#VH%M;ZNF)MH-[Z/>9I.\U],]>$U5GE9SX.2C4/IR/X$B$Q7_A&5%XOVIV;X_ZB1E-9I8K'Y!>.U6)#O]F_OEDL%=+3I#+B:-^YYT_6B+R,LEH_7S$]:2J&\R9HL(O7I>XGCUNW/\IT0G%8M#_C" MPS$/@CB"C+F*W2!R(8E".9FX(0X1#AV(%&IP!Y)?.QCXB:!8Y_,/;M7ZD^3YCV-U1WI(B(B$/21)R!*I M) M4.*HP^K025S*7>;:)H#/U.;S3@V?QMQF\>CL##ARG&J93K[1N^'%TA6*5:F5 M;@BKHJ"79"QRYJA!Z!1F&2Z"G=1L0T:VTP@^:<0[J2U>1L+3=FZ;0O4Y+7^_ MSMBO$L>BDIVI;?B768S$PZ&?^ +Z/(@@HIC!) AD9)OX,?'<1#!B>%'8H+>Y M1:1*9!TX;@EMFK9C N^I7*B!01O9?>_'RRK=LP>&IAE/ V,Y4:*3Y3MHD!'":3%B9*7;)09I.Q9/.0G7-E/%U\J2^%/[?<4A^EE:4_3:B# @_B$ 40 MB81#S%$"(Q83)EUM['N1B3\]U,'<7&@KXX8V3TEI-OP/@GC<:PX!S=@G;W:H M& _J4ZH?X9.2C]9QHOSA97AXL-E)!O3(CEUUC.0ZD(0.8\SWCWH8)V&,,(41C01$ M/(R@8L^#B8A#Q'SFXE@,P7QP-O;3;7=U+-!L@%P!LMX"DT9Y'J!\X7YKN %G MQ*,.#"/?A4@."$C4[.8)/_"$ZX<1&H#%8"!;C+\-M<\27(9RH]K ;&=I!%1' MGC,-JHI?/RJ:P3&) XZ"-"XIP/ZN+WSA_R@>IR_S'W_<=C_C)I,3'"^KS[CB M7[[)#CU*J>]' 0QI3" *$P\FR,>0FZS;BL?4 ("):'I M"GL'M%-;$N= ,;*+&! %TTV%<]"8BJ^Q(;RN$_CHFJT\S<"WAY0^@.I;#IYD M7*)3J.\+KHN2EU(94$^4*07-[9VR9D/#!0V MJ4CE<[5@B@=-N0:F=%'<:8.0F!TRZ8%-D)VO3[3C<4C,S?;&P6^$)8.0FGALD)/$3N>;)*[PTB_5VN[!RM.N.QAM, M=ZJ/AE6^ LN-O+WO;;18FL5MYR$TLO_M"*<.Y[1XHUR_>*'Z2!5'HTB1T!#NWS-I LMH,IVD(E>J#<+HYX.Y2+JN3@=V" MV)H\M(%!/5%3E=*MLW0YP2HL?@ JR\J:_'K\=\:EGIQ:9+2. T7&.F6 L,R<,GL5G*-TW7A*NOAK#_6I553?)"-!(J=6*& MKT_?;9 +O!0CS\HS?1^&H'$ILN5Q5GBR2A3DBH!\/$P1!1 MY,#81R&DU&F^T^]1=A;C.3%%(SO]5GC0D?X*2/F!5@"T&J@K//4%3SD+G(#?VF/W1W!(5]Q#BDE] M;'^47CK/,UH::L7XA5?54E\"+3MG4BAVDMAA%)*8AQ Q^4\B0@H]'PLOQ)@Q M;$7Y8=COW/Q?1\ASP^3]./<->L]&[_)G?^W%='7A9Z/.F-'G4=#&C27W=WWA MR/ H'J?CO../3TS\4=./W&QNFNF0\^X!9[=/>H/E8YY]Y:7TH'_CZ?V#J@_Y ME1?XGO^L2('?XHJOCS87092$(@X2Z"1.#!$7#&**?!AQ'GI(^,PAR#Y%90ZJ MS3/_1.9L1Y:KEG^H@T]QDJB0VH 'G"JSAN0('WD>%$=AD M$,V 7F4$F\^"H&5(O?X<%"\C6'(PDI@Q9.L7/?QGD[2@SL]K;LE%Y$=AXL4> M=%DHH)R\"<2)G,NY[Y/ #3GB06*SD-GM8FYKEE;".J?&CG'T")!FT]-Y\(P\ M65@B8^VG#RL_I-?Z[8H;@[/VJ6DG7U'S0I"S] MG>/B??J5+U"$ Q12#R;84811(H!Q$"$9WY,0>[%PD]"(=?A,.>;F*>0+%IR[ MK6%F@+[;'(/#>I%MCU8+4*NQ^;16Y HH38!29I*XZ;W@339AG CFR?67&\H9 KFQC0)B17;VE;S7=G64OQ!6!F\5)_&$9V1K5@H^04[==Y4$J= M[1ZFY;[9J]T.2VS_=FAU7) MA8IO5M&^J#(4[9PI&/>2B"!(F @AXH$+8\8<&%(9@WFQX]. 6E*Z'NAJ;AYI M(REH1>V=WWT$8,.@9!#8Q@Y0^B'6AU?P!!@#DP$>ZFUJ!K\36N^AW3OUA)V_ MJ._[T>?%VW__]P7B@H>)0V!$7;G\"!"!"<,,N@$5?NA@UQ%&9T#=1N?F ][B M+"T?P+\7>69(UK0%T?&QW5?QT7=;,W43^:K6^C [A_&PW:?G$0:F]NOU"&U_ M>SDZMQJ=9!SN4Z,=<7L_ZS<7*XI+52]8_D?-\5_QDNNT?SEP4[73N?_SFJYM MX;(D(<1Q8$!(H,9D#.,8(9B0R'>= *$86Q&PGR/,W,:R$O*J)L#MR*ICXB\/ M>5'!.UX\@AM]J/ZX_FBC:_WHOK]UFK,+"\ZRM5G@,)4%1W9*:^Q? GZUUT*[ MWYJBY/H06 \9N9PESZ2QS1#(O8Q^!FFSY^Z/JN!W4Y8KSKIE/'0RSOZ$H 4/ M6$2Y2V!(U#7?) A@[#H^I ZE81@YB(16ZRQ[$>;FK[O)A5AE1)4@U?I8[@+9 MV\)P/VA4A$?VIUK $M3B7]6IE5?[\SDWJ6KM[=?W>2%XJ@Y:@ MH[JV=4?YK:HC!RKEC5%N9$*C35%&;TBQ9U%<;P0[F);<&Z-KVV2RZS?OKE^G M>4E3*8*J;4)__(4_$EXL8L1Y'+H4NJZJO!H1#&,2^C#T8AK1,/+]Q#?CYSS8 MQ]RF&24HZ$AZI1S.8=I"8RB/N_>! !K[&&4O-N"W6E#C_+/#()GFH0T"UD3Y M:'U!LTA-.PG'@12UP\]-E*IV4O!-RMKIK]JZO?>KY?*9<>F1::H*0-6$;5F^ MS.6J4KK75&!K*C2_]8OW*V0 M\? UK5;J,MI2A2D'.' M!4;W^"YCM@M3B>Z[FP:VC'PK]&['6D'PX1)&/C717\)TE]O6^K-8S32VN(3U M)@I [F0LT12'.\#@W# HLI4NV*!B#_S"R:J_;3O:>YQF)7BE_"TO?U U%W+] MC4VE!]6X?)KF954.4D]A:!L=B'4&ZV:B@&AH6#91T^ M]TVN_F.E N/W:996 M_(,4@]W(49/=IV3)ZTLG+Q@\?BVY6"T_I((O B?F@1]RZ,JE,41$.##QJ0]# M1&,_0H0P8;0U.(0P9QGV%+LZ.G MJ2PT]B;FJ,;ID3)^/JK#)I6?(<_$:>?G([>;F#Y F_V\<;<8T%LYV7_5]>8W MUS$\%+B>&TNZ$/O"@WX8!)&#(U]$CHW#/='?W'RJRH%-,[W/LUM% MS#*[]1349OYP0 !'=GG;@'5D'>42C"$N0SJM4UU.ZI<,]7_I>DP?ZUD;C$OG MQ6^?U+7_-+O_P+$6EN3MBG_DWZN[;WSYE?^29]6#7.B%GJ!"$,@= M1S%#1SXD$0NAYW,'40XA-CS*.2!2R,4QHD; MQ!.R2A^2TV;X3T<1W1&S6QN=U$6Z-0FT)GXNIV)^/FAFCU$>B4C @(=(<=UX MBG#4@<)- B^,D(.%8UM1?09&'K_V^I:)N?[O'.UK-OE>U&(CS\H#<&ZO6;6W MC%YK.@/>[%-&F 4)]D$A_QR,UJ^F1'XRZ@-+6C''N+$'N)\ F!5$\, M/L<0*A-96@!DNF- X"Z8UY,,NE/H .<<%DM)A^A722_0N ML3):RS#+%=%+A/JNA';:.9<8;DW/WQ#/R5!P4\GZ%RG&JN#L-OO,U54L*9ET MP6FIV9[4Y75]=WU!D9,PG# H,!,0>3R$,4\X=&+B.8P$(D&6!:4'E6]^Z5>; M0B+- 120>H&.8J#5#-QF8*T;T,KUI9\;PM*& ?*EK#=V<-SHI9(Y-B:\:FV( M#]DPW[%APWHW#@'$*/"/PY(WA( 7HM(;$-O#?'M#=M)OIGCW^+3,GSG_PHNO M*3UP*7M=!$8'Y>5=7N%E]_,W>5E]S*N_\VI3.'CA^ *'24"AB*-$56_Q8$P< M'Q(GY&X4NK$7A#8Q\VB2SBVX/LF/L%:R79(KK>1?*_#,*[!1[ K4Y9SM9I3Q MW@BSV646=IYP&V9<$UO/+J/#/^1,,YZPD\XZHV/^<@8:O\.>>3./3UBE[-33 MX5W^FK]-RR<9L+-;\?KY%UX]Y&Q=H>P+7O(WN"B>Y<2H)]%;H9];Q)X7!8GC MP"A6_'38D^L5BAAT"4T$=3!-J+#*KAE"JKG-,JV,X*M>I\B05]WS:3+H]-4? MRSR<04QGF*TSM4'&SNEI]&E7&O6V3ZN3L@UY!K5:W?J62C/%-=@8\C];0UX? MM9Y]#M"0: ^:*32(8-/F$PV)Y4[6T:"-VU[QTY/(9_XD!\6#G$H^%?E]@1]K M[GLG(9X7,PR1DW"( B(],O:97!50[ 8A!JUT>"??R#G]_5].;-9>$%DY(8T0B#!W$"41Q0&"" SGO MA4Z0N#1R&+:JM634Z^SI6&"DYP"35>@H8%#L"&.;V]#$W%[$6$91*QG\"_^C\Z+C@"1?U_MH_ =<+P&.Z M7*IDRSH=%N"57)$7:MOTGT"69[QA'M>3<[Y)>;-S,_L,8N9>SH1Y9+>R05B+ MMV83OSG.UF[M58Z@,*0WV=?-I%[DB)XOO<>QKPYY0Z.FB[]>CXI?,]FB[K/. M U4D"N6[[[R@J5J1BJN*77H^ M#((X]'WBARZ)K(HP9,26*V\\CH#M^N/MKG7='X_RY=+ M7)3J3[5S&R35?Z#WP2=P;W (9%WNQ*P,!]VAYAO.4E+=*GFJ#G3CZM,K(464'92=7Z-\[N MI1>\R:7 M#-O(">3+J"^_E^">9WHW[Q%7JR*MGDVW]\\QSZF#DHD@']F[=[10W'):#YU[ MK#51?^JD)K>&Z:BC:'&,F7_/,8?I:&B,EVZ4_E'5SP#\.WY\4GD!:4L44J@-WU(QJUR! M9NF_&8Q7NN\R5Y]4#X-0T U@LP/G2>>T/-%YTP#*;\ZCAFBLWP+M(__6J>M; MY)G\D>H(L6'W]Z)$8$X=B)CG0:1*2B0TX!!Q@@+L"3=PK"CC3G4XMX72-?NO M55O!4PX=(.4'WKK4YN4FV_D8N$>UXN*(_BV(\#*)@;082( ^,D81"[7H!P M1!./66TS'^]N=@Y(20G2M9B*OE;):7LH=11BTW.IH8 ;_6BJ2PL)-J*"-R? MZW$X98+)L.=31WN<^(C*1/O=4RJCIX:M#*FX=]NJ6W4-+OGW0MW/?W8L .>+-#>G='N8.%NS8/_PUV%J M-5H8SWA4YKJNL"RW[U-K",[PB*$L6W0EP!$28AQ!$2T/'=D%$6$82L MEI@&?<[-G]8BUSD%FV2"08[<3"Q@YCL'QG5DY]A VB012('E>ULG1;)F7U0* M7?-?#9@%:0[1H#F0!MU.FP%ICL-._J/%H[;G/K(!JG9_[_65?,KKS*A;\85G M:5Y\S"N^V5VK\TT6(F(^\5D"<!Z3G;N,A/=+SVJ<@IYZP$.:FPKKS%O\L(MRSKTS/\XL5GG%2=\S,@ ME,ET@#7(,5A_2 ^@50/4>FP^K35IN"*U+L.M8W9Y\-EN2[4DQ>;@CH)XJ$B48'<=12O5QS )$A"&$0BEK$V M\YA+S58^^YJ?FU/KR&BX=WT ME.Q[[E@C.Z(-N*9;!F;0&*>!'8>-)-E=]E! M9)52=1B!@[E2>QZ9+ GJL+C=[*8CWSKCD*]#H?A12EK?FUV(D/K,(S%TU%8 MPH1 0H4/(^ZZV'>(\!-N1V)[N+/YK?[K(R'-\*3R#,%R(W:/$[G]"%N_/LNJJ* ME*PJ3;Z:?\*J]_5,AC##$1>*9XX*N1 4&,9AC& 8,M^)<"(C)J.8:&"YYA9, M61U,7X%&0]!547&CU4I:1R%#&WW S()A33FG]((AK#A.^H$YYI/G(!B(-K]$ M!',\>V4C6#1_F:IQ[_-"\%2MPU66OER9IX5NH;S)ZE2*%\6&MZZQ+2(_IIX3 M$O7>R/ TYC&,G<"#H1LY5(0."T1@66/ADOK,+P)NI86XJ0#.VPNN]5WG=1[% M%:"J;MERJ=B5N5*[H600-2#\P)7GJ^F4U>?YIW:.0I;\BR:1U,]&O5 M047=K*]QV5.Q?OM"]GPJK0UBXSE593M/H1GQM&*-N][NO[=*F2 MS0L9=,BIJ+EK15WJ,R?Q81)Q#!$-8DC\Q(.)AQ%UF!?[R(CU[$#[VA\EBY_LH" >VOO<_ M,]'>]U&!-YO?Q[_6;P7S/LU4Y*J+RWUJL[K:T\"%CWP<(JSJ\:@5!A48)CP, MH? ]CCT>!3["BXS?J[3*._.MJJ.=&KVM2?VV[G0]WAO[F3\U FIRV5H#L%0J M6&Z''X?<+,@^'\%IW&$C9UNF'O.")(A8\;C'4X:TQGI_C+F,GNH MY\:(RK16#:W+5U[3*OVJ=^*_\'L=OGU/RX5P Y_$F$./J&PH^1+!V(L1I"Z) M&$Z0B[!12K1EOW.+H3;U7#?B@M^4I);[U*:X&R[EAT=S['WF'D#:KW[M8!ET MG6K8];0K2CL\=M9^EH_W\TC72SF0,TV17F;G;?1A3+J6SS)^V8^DF4LX'BI. %_QFFF3H9NL_=YP=/[K&;& MI\]O-[Q9'WGUF@OY\1W^OCZO)1$-91B20,1]!R+7"2&.!8$1%EY(G%@Z#RL& M^_-%FILSV6@$E$K-<:ZJ;]SH!5K%0$1P0 _I4 >0:E+O.QR*+UWU@"WW\^OJ F]]/K!FL/VP/$(5VI M3?>3^LP>N+QTCGV:Z%GW6(;)F;3SL_2P"Q_C@'L^AC'#H0Q6:0))@$+HB]#S MF'1R_>H.VC]W6[[ MTY;1W:/93C7ORHDA?_6[N27&2\4D]7^/LBC-S00RB B1L)*.,7.>:1C&\B+TQ\0CS?C^+V M2.[X2!]9TA[G>",[#36EON)U\;L?VKJ0IN?RXUKUN"^:@Z4NGR>NR0!!HVU= M\$I_6RD,-AJO"WYJG:] 5VMU=*O*@ZJFKE2]T'E8WS2[8S9OP419(K-Y&RR2 M3R:QT8$DEG'[GB@99A( -TDUTW0W%-U(\^,M6:;WNK?FO/Y]7GSA5;74DBVP M.C[W97@@(P4&D1-QF#CJ:IEPPT!P&HH8G\\G'&E_VZAQME<#$C3 M;8G! 9UH>V$(8"UV!JQ@.K#"-VMCHI6ZE4*;%;?=8[:^>= BL8[7EJY#)*"$ MJ_K@B+U[][G6$VP4!5K3FEJ_ MN>^LUX_EWF+2P/%,7=PX[\&IN>7BUAT[D6$\PUI/8N-8V'32N[BE)YHDOZR> MGNIE.BZ>09J)O'AL=L_E_U9564G?K2Y@4L.J5*@+&]UF\_J"MV)*T)?!=4/;/!SE(-S; MHQKTP'0^3I\33?^C K8)%\;MIN?UMB:7ZU9LDM4W'*6<$B=R?1\F+*00(1[! MQ(D"Z$<\#)CO.8&P*D)TM+?93?V-L&J8=L3MG=]]'&JS3:;! !Q[=NV/G?TE M-A-,!KVZ=K3#:2^LF>B^/VHW]+:T>KJF<[5=+E26SLZ=> MWF3OOLMIL+P5ZOMUCN'U_7VALVK6&V'=3Q=Q%,0L#A-(Y;H&(B<)8$*DW9+( M#<((43] R7E'A"-K,#>_UU%OG7.0KQ54+$U<:ZC&-C[^70APJSH04O>F@INJ MNR.[E+&4TO_<(\RQ7["^AY\S>FTN!+/>!8FK7,\KQ$[_]@&*XLO/[]=Q!XE/D8,TC *(&+"AXG#"$S< M(*$LYYL8^8)^J MFZ%=MF.[Y/3'^_SK3^W7Z_'=_O9R?&\U.LFPW:=&.QKW?C9,%H8!G_--IBJZ MIE]Y][EZ :EKO=Z*7W#Q.Z]J1GK.!(LCYD$F1 R1GW!%SX,@"I.0DX2'$3,N MV#V-R#;C8YJKU)T:U(]:SLUVHSJOI?GCHYQM2WV.7Q_&OBR#D);@7J[A"[Q< M/H,LK\!2[4I5#SC350\>5ADK.*L>3)>!D[T^_;(Y+OE*7"J]HUNSX'53LZ#Y MWE;- K#6?/MYO279**]JF]?JGRA+<)F7XKP$D$N^'%-Q=TL'(.6OGJ6_>%8N M055F8G6$QK7/:&JF*Q>R[5+4E4O!"Q6OZ\P/Z2,J\(2+*E7DLRIZ?Y)-JMM! M;=K'O82SXFS$#(^Q+&:5\C&X$!?- 1D+TE-)(:/U.W2U^.O.?=%;T6[]?.3? MJ_=R'.&E*L.\$#%QD.<2B!*UTRR(@,2/?"AH',JHAX?,\X:I&6\BSMS6-2>J MG%^_N.>]M5^J- .U:KKL^5 5Z(W,VO=@="QC7>24: %,?"%- M&'D!CSQ!,68VGOA89W/SLVOA>O'1'X75S!,.!=;(?LX8)VM?90+ D)[H:'^3 M^AD3S5]Z$:-GSBQJT3DX<_R$(E= $8+N8UO+:&* MQ.N;6_WX(?8@:3; S\-GY %N"XWU"#^L_9 C?$\ODX[PPUJ^'.%'OMEOA*NB MX+HP7M5'G+P;G[N@XY&#NM3SH2=[5Z.0SW?./,->^=NM2]B#SDQ8F<*"F+(R@#XPC& M7N)!3]6#]03CQ+>[VKK5_-S&8F=%I^7KN\RML;-V6SJ/ MLJJM>[C,BG9+NX.KV>UO69>DKR_+9.P-?DHKO%1;Z!E+JY5\%=ZF!:?5\OD7 MG.%[SEX_O\/TH:FPJ'N]X]^KUU+TWQ<>]1V78 '#*'34 211!73D?(L\YD>Q M@YV$FB96#2/2_!*G:KUT'C*M-0.\HQI@C6[@L59.45APK)@N:OV,*\(/8]+C M[N<29AK9837VD1J!1B70U0FT2H%&*Y78I/0"C6*-GP-*-Z"5,Z:F&!JB8LVNTCE]#=IB56N[(E/#$&52:2'7,&?\J*J>6EJW7\$FSRF M-GFI!)3+;Z792YZ; VV M!8&/]97#U[A'X!*C$LSNEPQ^4;)EM3GCS4%I9*] M??*IR/6M[T*SS\NVOZ;\6^TC=-;E0\H%R-?5C!FGJ2:Z?\2_\T(]]HK4?6EF M\F\J&;/@]PHL^4++QK^FJO\J-VCM"O"O/%.ZJ-S-;=EQ=5KX07*SAGV%#^1> M#=3)1+E5PT*RR9T:N-W>ZXJ,X8)]*G*VHM7?L$K=JIX_Y>PP#T_A+$2TG M: 0%K:17H)85_-;\UV3N[K-<.0W3P*N7(QU.O9@YK?N>M8W!0T,E6=YDJH#CD26N3+A0R-8")\)!U+'+' <4,4)G:%\8YW.+]E2BL=H*HR MCIST=QEGSLU_W$*HFCJ].5;C*G4K\,'%]$CK$B"IU>+RG29?J MH#THKF8N?#BT1O;A^_-"U_"].0;? .F>^U 9-YUSJ\<+IVONT_YT.N;>I^SI M"3018W, *T(BG0.,. D@"K$+8^D?H.L$KL 4>5YDE.&^U>K7_']+E\O7O$FZYNR]%*]#UW2H8)I*R;[)MI.RUSR=E(6">0F#3/BA M#,.\ &(<1Y G09(@&D21>R;=X*CRS\VG=*GAZK*'=*M(8EH72>3M+8LJEU$? MD$O[_#[3Y-RXU$_DF>87;>H@-J51 5OI&WIJYRA3ZR=1W\!XEH#TIG&=^H7K M&RW-YC6Z2/BU]UK.[CV<40AI+V2+<8.^<56X?DQU_S#G'W.E\OW>:$>VIP9<>PP)PC5R:U#(1)! M##$7%'(1T"01<2!\,3HEQGDZS&\/18H+:WGK@@9 <;9][1P=R6!V=!J#,U^, M4^>_?P)CC[U".9O]HH8"=+ =0UKA493!:4$:SR @0TB(#?>APT7^IE&ITD M8[J7:J*C[+=;1]@O@N^->]GBV5$\&/KUJ9V.9O]>Z;(Z3C/FX);JLCY\Y-:@"^?ZP5#JI[,NX?8ZK=5)B? [$6;5]L]-&N%J_KL M_:&NS-(<=_^QPO6YNOILF\!"I_JMZ-BW+E7*Y MJKA[IR3,4WU(K]<,A(J&Y+$?(,"_LT*0A9THU=Q:184 ?@%9D($'Z;>:\ M7I4R)"Y+*3-),RWRY_52_X:I)!>1JL/[YN2?2F$+SJXS]D'^N;DH*S^3DK.: MF;:JOZF56"1)* +&Y4L9^@E$;A3!F"0^#$1,.7/=2-#89N]F7''GME53S_\U MJ5[5JW;#R.8UVRF9C]%&#@);14%'4\6PO=XZZRH+VAS#1ET]5744!HW&5PV) M=[6NT:#5'F[S9!KS#+E7,K+$DVZ-3(/^RYV0B7KMRZ_[[M\7/L>!0QT!J1L+ MB#R?0))$ 10.)A&F+D\2HUM;W4;GYM^_?.,2ZBOP[T6>Y89,4EL@'?>_?54? M>ZELIG4/7MV-F@/RZLI&)^;5W:BQRZO;^:SGQ4@Y[F_%&SF8T^H]IFHH/W?* MHM0;HK>;%=,B9C''/HH@X<*#",6JVI?CPYAZS(\Y"V.*K*Y/6@HPMT';$:TM M2&IYZ=+6 F91UIBXCNP1E.AJA5\+#UKIKX"27]/VZX]K%4!'AP$O>_9$;] K MH;8R3'MQM"=".]=+^[9CY^\83Q?O]%;2ET>\7+8!SP(E# >A)U>DG#"(1$1A M[&!?)1L&"16$>\PHF^! ^W/S5K6(0,L(6B'-_-4A!(^[HP%P&=G;V$%B[$E. M*'XD(I%/UDY"_O#2-QQJ=9*A?T*E=F2?^EI/1J4\*_-ERFJ679WNO3E#\$5( M<$("Z(5,K@Y"/X28!11&KA#403$-[(*28YW-;4A_*M*,ID_+NISYEN263$O' M$#8+.H;";>0AOR7F-!<]3) 9E)GI6'_34%[+)A^>&:HR)Q.>JAAGE5 8%@2\@IH1"X@5Q+/]!0<*M2C3:]#XW3],) MO]>2ZFW*C]?_V9/=SA+@/?4PCB+B7P(3Z$12!SP,_H"$GQHE?(\@WOZ2NC?0@[23L MO!)-W57^OY'+VZSZ?QL<^;6*@AN,[!6$6@=0<>TW5RL MMJ)NHR=8*WI)NYJF4EW8OE,Q?CQ(\_%EG6M7\"?9MC8=7E-SE&L>*KER$FF& MY4(*+\%37J9U75 %3Y,@U9!9:"*0 V,:L+UNX*KEO6 5UM)3+('=9.B>=^( MPGR0S*,1[7L@JVB,'B?*&!H1K$TVT)B=]&3-4,E'G_F3'&T/N.2?BOR^P(]- MH.W$U(_#P(7$<1.(XDC^%/, .I3R,&0A0F:[HB:=S6V54Z?D;H0%C;0]5SA' M<39;T R%WM@'N;V!LZ?-,$!D4-:,8_U-2YIAH/D.9X;),_;'*=?2.S'EH=XO M\?U"^(A2+#@,<.1#1'T78@\3*+V(\/S8<[EO?)"RU?+<_,-:.*"D,S\[V8;K M]*E);Q!&'N:&^EL=E.S5]8PCDNWV)CL _EW( M<.*S8EY;\5)=5'OW70Z$#"_?K,HJ?Y1C8GV7E7!'8$$%#!+%J!(E+HPCXD/N M4)ZP./(L)_8^0LQM0#="*[Z\^T8=2\*L7J8PF_O'!GAD9[$1'VCY5?IKK0%0 M0P>T.H"U$J-<"#X'Q2'CB%YR3!I?G(/4R[CCK+9ZDE&LKT;=BI,W,,I#5S V MQYXNP5Z4T!"Z(B$0A=*DL1.$,'*8%P21ASW7L2*;&%:^N;G2+ZO'1UP\:X+/ M[NVS[9NNEG0/ YO4S.]>T% CN^3MVX-?.O?^#EU4+=74V/WB]DU5"VYC>R:' M<:%K M17V40ZC9I2%!X$2)1Z"#"(4H#M7Y?R)@XD=^@@,1NY%=$H!=_W-S\K7X4,L/ M-@JL[R-I'4!=X4QIT3,UI<6*LX7'W<@G MQ%'5K%V(*$]@'(<(ALCQ"0M]1JA53/J$61:8KVS49/.X+70NC:,(IA1E_\:5AW%3O/NRZ=/X)7*,]%/&*9\ MC6=_B]/F2]ETBB/J$[L=1S<[KL#']7M0ZPDVB@Y\OCV_%!]4R.E/TL? M>._Q^R@=V>8*O\O8+[CX73$X*/+OV*?R_W (*6)41N]N +'GJZQ?Y#(6.IA% M1N457C8\MU!<2@<:\:RHTG< .^Y SX%A9+\W& *F&:;]D9@H.=0"$8O$R_UJ M'\B9?/'EB=(=]XNXR50\\+FMJ^G&S7)-VRYI%MWRU9%E>I8_2-I4,E+@0 M7!T-RK+3'8' M8%W?L\-)>LQJ5ZIZY>8+5QTK8JWO 2L.DK@_!/H'9INSFIYH;AI"_2GJ_'9RI'Z/>=8DIN!67KUY(U:J9&F=IE)V=G#D"(K!%_V *@]P^/U<^=F M^ON"_[%2I()ZG>\DD4-CZD'AA1PBCEP8,S7M.(Y /F4XC*)>O!>'^YS;/STM4UJS^O BS=F;NJ"2#+S?Z0C\3OJW^O*U'A6".SZ//0(9(5B& MNR* Q,$"4BJ\V&\CRT7CK/,UOKRX:X"2@_UZEDJI1R^9*V MC[M8$!Y2B%PW@HA@!Q*/A9"ZB8L1Y[X;6"7H&?8[-X_YKBE;M+TR5$E<;4*/ M+56B&?QF;G $4$?V>ULP-B+K.NOE5&R*5H@-2ZQHUO7$'(M6>.S2+=H]WL]G M:04IMG]K7C?\NYT*$_N9 _E_H^:;']*$^9'G$+B8T]&AJHV M99S(7WG@)+[KQ=@S.B(<0[BY>;^UI%L,5OUN90QJ1#/W>"G3C.Q#>UK%VE>. M =^0#G50^2;UNF,@^](UC])'S[O5.^62VQK?GWFU*K+;3)=0UO=4%G%$I1-V M QA3H5;N#H>Q("Z, ^3A$(>N$]-%QN_57&/FH6VZ-QKF23W,NT*,&(&VY= + M+:SB?M,U./M4<;,RA)F/'1S<692>KV4'KU15[A\4Y/H0[_HXY -4FS^-W;BE MXH_T?^$Z[Z>1.5VDW:"-O@ZN9=_[67I+]=+<9IN_?>35(@H2E\6N!VGBA7(Y MK1+3N.M"A[I.%%'?#XAG10=QJL>YA9)*3/!JJ<=3)XM&_K&N+IS6EZ5>-35] M?[@"F6+03*L'^15%E)EF*\5UF3_Q0B\WK%W?*1.9^KL!@1_=R;5R78$:_[4_ MZWXDA1[2IQGB,ZPC.]7IQ-[+$(-=EV7ZH&U6[:XSK.LCE9UJC9FNN:B6] 5_ MD(-0DXFJ42D[OJ;5"A\T5G>T=_KZ(7#=V791 -T8$HLB+(%%UW7#H M$ =S3D,G,,NY'4_(N7G#M:3@U;V458Y)Y1FY,0?TB.9$CDAB@CET0^:IF2J MA/D)](1 R OCD/JDC;_O_@16W0[6[R8P[K[8LJDY5VX5\$^V^E?*@UE[=*I[!RW)\SKRX[2^WEOC_U-ZFR>#SL/N$J>(J6)4AK&*K MXW)*!HRW/PM0L[V7*M95J:%?VS*4/-5O@_I;DV(,D_XD80)8=J<_VNZ2\^ MU16MFEYEH%/6.1Q:4JST24LE5I6#BC\^Y85\=ODL__XUE7ZU[9:#>PXV,4\-J*_/='/W.)4Q5VR MQ4>SEM=T,CH.ZZGX83"P1@X!#N,$?JN%-;XW>QPPTPEX,."FFD// -!B>C"" MY8"'/_[L1$[:2(&-GS7[^KF;GCO9*\BAW$-4KAQ]+Y9K2$XA=B,7"H\E'DE\ M-Q$]=SOGGB^TO^A3WZW*GFE!P\ UV>;D1*D_IU$99TORL@D^I[4^O DYP;![B2V%Q$K%54"^]: MR1G<0CR&_2RN'NX5\,]QW_ 8MH-=,CS:2=^L].6ROD;_&A?J1"3-[CN2Z)LA M7I)0STT0I"&/FH,)&CG0]5D0,X=&W+>ZTF/0Y]S<^$9DN)%YRRGTN:EC KZ9 M/QX8TI&][-EH]L@^-\9GV,SST]U.G'5NC,-NQKGYH_U\T3M<+)\_\Z?:X]V* M+SQ+\^(M)]5".)@'TME !T<>1.J E,1!!"/&24RCB <^LG%!A[N:F^?1DH*U MJ)KJ0 L+E+1V_N8(P&9N9AC81O8N/1&S]BFGP1C2E1SI;5(/- M8N9EAH)Z9#_3B-EAFU<;:AM1A_,T)H ,Z6N.]C>IMS'1_*6_,7K&GH>W2JOG MOZ6,=PHC92_*Y5U759&2EYRL%$3-'J"M:+@-Z4JT+I:#J\M0/6(O_18/GPIUH:5Z5BE0 MU77&WOVQ2I_JS5=U*[-FVX\]%H4DA)&GJ#A\$D'L(A<&E&$4H)#Y;FBSAC#H MAZY7M/JC,;06\Y<;F'D -=S3/@VGL 'L;H>$2\@S4'W3SA2% M% 8DXM(!Q!PF(L"0A=BC'G-#-W(63_K,]TN%B\K,#1CU;?/&OY1@O)>_$0[@ M"KSF]VFF#PES<2J?X@P3(.KY)(XI#"D3$'$G5DE-,N@+A,^\D,510AH3O,L, M.3!&,D#;_R3PJ\H[HP)OYJL'AW)D[_WEW1OPA3YPMEKR*^!ZT$FNP%H)L-%" MYUVW>EPU-]B&<_)6N WI]LTZGG0BL,+BY=1@][#M%O.7A[RH[GCQ^"''V7M, MU?G+ S04SNW \$TMHI $2![82 MCSTYT8Z@@?";C3V3+_>E'U?'=S+.K'1ZT8>\)NIM: BC((Q=ZB'((R2#91PD M$/,DA"[E,8^P_#]N=')FU-O<_&)SX+R6%K3B]B2(/ ZU66PV&( C>\PSL.M! M\6V R;!,WLLXRI^KUK[S)^DKY)K2'73.5.>2C>NSA(: MWKV(1ISBT(%)Q$*Y B<13 @/(9'15T3=V(N9T>4Y\R[GYED:N<%:<+ MN3ZG M.\7&UQ?^DR'9"*".'9]=$D_CN&T$7"<*XEJN%\6443-U// E4Q=T9$3']:'C ME5YE ^5C;D4U8:J&%D?>"M*CGR9,LV83II=D?*!\VH0 MX@Q;^ ]%CJ;-3!5&6JK5B2EMG^P78'[@LA5^6[,:9O2+"P2>$"U)[8 M#1FRVHHP:1#;$Y^786W?9GIS?O.BX.QUGJW4]N2G(A=II:X.;E_8V:38O,FS MJL"T4J?;MZ)]OGLWL5D*QI%+8IX0R*F#(>+"@3&//1CP( XX0D$46^74CR?J MW+QE*RG0JM8\*UI9T&C;O?UVUX/)!RB.[E?(] M_UJJ2QU-K0PIF[J+JF\H79-2"[2(.7)\"3MT/%?-3VX ,?$%#&+J)\*C/O*L MF$GL19C;O*/$!V*9?RMKHDC1BJY8*!O9_VHW9?2PB]E4,"[:([MX12*KP6[% M5_L)KWZMMQU^ &LEP$8+\%NKQX!NNS^(0[KC'E),ZF;[H_32?9[14D\N)[Z4 MG][_S#.YG%A*AWW-'M,L56WKPI5U%8<%\A!Q'4$APDDD_Y%>,$D<#GWNAXX3 M82HBWXJDR:C;N;F_1NHK<%_+K4,OO"6Y)=>2&?IF#F]X3$??SF[@_+D#Y[;0 MH)%Z0+HC*Y0&Y3$RZWE:@B(K-':8A^R>[N>A#K$'*[;@SYPN<5FFHJF[>\W^ M:U56=>GR_/'Z]LU-M^Y&A_]<,!QJ&F G5#3 C"<0)]*]"3\68< H]845!]$8 M0L[-^W68\!M]%"GY2C-B7%-:%SN6?SK,C6_G'$/ VF&/:8LAW?LHR0RE-L=Y7OVEJ0KQMZD&\SXOV^]?TCU5:J##]]:I,,UZ64B\B M(W9]4$XQXR'E 10>01 Y1$;..&+0H2Q)PH B)[2BFAI%RKE--:W0FD\&M&IN M'66UJH)7K;(_ /D>K+:5>X_SRI/G>3W(%2YN*,LCWS_%"S6GD^%QWJ7>)\,7M]\8 M!\B74^HBY\P7M^&AX^C+"]9O_F_HBJ1DNN1?.TC;JW0><]W$353F: Q1&

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

(O0?L MW&N@UV=+%(.\Y+K,C6>H7 $%%@*P>*MUDL;:-J\Y#Y(TUMZ29K?8,,+O%D:7 MFQ%XXD(F!5':6 ?8,O!H(EA3N$_DT7EL4_GV"%$C&Z2!%+\3G@[0PJA=%R\$ MX_H.%UOSFEG,T5A#0J%(4ZEZW 2S(.B@A2Q-MOFIV?&/?7Z/L#A$?_/!A3DZ M)/Q#7�$@.1'6*-&$U!"))NW(Q.\J0%IX.T R0>^OQQP^]&D!A$F...G/Y1 M,,M+&WJQ^CQ?3/][K:#:6[\VJDQ*X6-BP"-B':=,@M+&@162TV^G$FY/.7CJ M\>K1[QMG$-#P?DI#*7>%G1_8N3QBQ-7VF+ED-&?*49! %[$*]&_><@:!,<<, MVBCXDW/,]_K&3AZO!M3V@X :4/0]06K+R2]752W)F)+09HA^;5=-!F>T!EW( M2#ON);-/+7]^XBO&&0IU J-SE"Q[B(U^+%BY=:@P;]I9^40+*W,1' 0F\OR- M*."]8E!0%6?0<*7:-0@]35\G1NDX--S7M#>P:OI#7'XQR^]Q54<+O;Y83&>? M-O.MUH)=3K1V#CVQ)6/A-85J*1PH!E1*S**T3-]>2]\$=H\2V=?S11/L#:>D M9P/ =9?^Q*)EH@Z"*%G7%0+TB]?>@I,B2&MC#J+)2)8]:.PK[WA*^.VOHO[0 MMQ7;U?"C:_-^_61+J.085 26 MZY:](FM1'4M@I#6%PLP@=9,9A3^2,5P'U_H,O?S^JO9#;((QK[7!R!!<#+59 MDM6:G:P@9IMD1N5SHVKUAVGJH4;N( 0\W%=UG-Q[N#T?*+7@)1+5I-Z"%,$K MYB@&(K$ >:91*,ZTC_#XQ=)G0"\K&VE6E*9(! M%6I&*!@)4F%@T@15N:]I'^/VA:/M"%874=>XVA% #X+H: MQ=?LHJ-C9[2U6N4UW37IK>J:YI'['W@)W+#HJU8=Z:Z?71"MH$+3,# MBD$L*!ZQEGS%VMR98LHN.M7& CU$T<@/S*UNLD$4T &2;M*_/5TZUO? ZIJ1]D]+*NZ1TTJ9TG(YO[W4\3N"=0>8Z(Z*R9[8( \R@ M!N5J:J)0?,&E,M)YEP5KDENZEYIQ%V&U,CK'"[X#]+R>;K,?5Y&I"USD$ *X MA!*4" *\< *,+9K+HH,/3<8 W:%D7',S@'9O#R<_2M0=8.75_,N7^6QC*B]Y M>8>+=7+V=1V&L:A;WZQT%#0D8%H13TQZ\-EKLLVZ6%.8B[I)+\DNQ(V\%/0X M_=^V/D,KHP. 73%R@[FZ>'D2E/2(%&'0#1_J'"U)-[S2P%@*.A17I&VS2>$! M@D;>"SHHD 81>D_@>1>^U[M]7=BU/0BOP_=?Y[/5YQ>S_)\8%A,A360:'6"L M$Y=K.U<09-5C7549!1T;VV;/[.XTCKP\M W$!E9-!ZA[S S74U2[CB9FN/FX;"E TR]*Y-M.8=R%NY#VB)[L3#U)&!P#;[F_F?E/292T&W6LA3"98E@O*ZG*1*3KE#4XJ27A;&H;F_;:^>8/4#CR#M" MFSMF0ZCFV10[W1C7.:_C.M/-<9W3];C.X8J>]OBR-L5/AW([V(#+;0;_K&PF MH1*T[IF/>CT*47MN@HT@>MI@)0'WP[W%_^(E^MRL9J\ MQ^4E[>MWL.(8YT(I8$S+ZA0A&9*@OGLJR:(FBII?,P6-TV]6F'&]$ MAI=]!T"Z?R:C8S%$2]% BO4A5!A',2B3($@\623+$F]2&/?LYN?NI>V=YN?N M(_H.\/,B_[^+Y6J=0OMIOO@-_Z HI+;/U+:OQ7Q&_YK6TMN("WT,PM(Y*]8$ M4$4A4/R:2%P1B>>0A6KR,K,7E2/7LPQGJ-KII@/@U0K5L_(BS]5I18C MRTE**%S5 @Y&AT>86K4:!3.%TQ%JTI=R'S$CKP)JI_OYP(KH $Q7A^Z7JUH@ MIHSQ:"G4E":#4MX6!,-HH945MXF_J0_VR5WU=LS>\%H[385+N "<[;B"B M$X?33[-7%T3B+'W_N BSY?E&8U?'\C>L:^?#GY.9@)=./+4#X778AKYFNAYU!M'#7%4V3#+>A!1!I$+7A>4*?$X* M4D@>?0Z*NZ=FH#WZ!9V$BL?A:$@A/A_3]QI+W>SP$F?T+ZMW]<>DM=GF[[R; M+U>+]62(*MYWYR2/JZ.1ZM+,;!VLASPIDBOXXACXN@"@8';(FHP(;LQ7)\'$ M24WB23!P\)'XAHLX/]I _CY;8#BO@R,JQ[@\F]WBNC)6>8HF>4M<@/%US:4D M44=#=K]8D7GB,:MLGK"5NWY7)X[BL6:SB6B?CP5]M?E#]'NO/H?9)UR^G=$! M^3E,9VMW@^1>B]U^.I__\6^8Z<=OZ&2D:Q=#B6!CL'6B#@5=*C Z0TYYNE;0 M),NRUV5,.WH<=^-6GHUC34^(AU%=SNMC7WE;7I_]Q?3;FOVW,[HY+M9)B\I8 M<+*@R1R$3J'N#Z9[@F)0B$CF0&<92M([&]:=OG+<@K0&]G5X03\?,WM]0%BB M.,Q8,%)03,840K06(4OE8Y'*ZC:;QO>D<]S"M'%,WT$Z>C;5:5MS/IV%4Y:I M'?*M;>K5CN9_K,(UR;R,A:[07,?1>1; 1>D@Q6R55@[1-QGO=>+"M1W/Z"8M MG(K+1O@"7#E?5XU$")D7T$4GIXM0J4U;\3Y$=I*=;("R \WK_JKKX'I__#W> M"!M95!I$,@F4970]&99JX;2W=0\)><-]5KZT>PEL!H:]ZF+VT4P',+N_.,-Z MIJQ,$IAJ2YF']%W@)\;I^[>)Z'M M.WDQH1BC,K 0#,D).81 _VD8TYI)+_,1\GJ8J7D4#AZ^%X=22E]0 MNR=1^L,KY+O%=+[X@(MOTX2OYLO5*Z)V>LFV1&(010(=>9T($&H+D!=@I2B( M4D S]/>ZV'@BL)U/K\T+S[[/P9;Y876:RJA=S-6'0!Z]% !\- \68 M)Y[I!'/,V4AODW--!LP.0?RX+X:CXG@8A?8 XGF:7N=3_W81SJ?E>QTWOUSG MZ-_\FJ[T2_^!P"9)ZYL*(XT6:JY#%$C_OT MV "TIU)@!V"]SDQ\Q46H%:(O$G$]74UQ^0$_737;(%<^REJ/3I(#Y2S6EZ0$ MO'"1/?TB?9,2G/*BP:['(NC$P45G MH9"3+CT/)<.UY0Z@V_G08NZG M97LM#!6UM+F0933&D(W,N8Z=UB"=H7.DZC#J4;OWF_GF)S$NQTB['Z!L45XX M0\=X@*#JAE!.' 19/'$@DY<2K=RI\^BY]_;OI<-'>_OW$>CH:/@VK=729V6= MT]ML3KQNW2-#.\MAD9>_?\UU>?;MS+4N,@M)?IT1*H)"YB 6&T"$0KQS'5C8 MI6][1^@<0VH7.#L$'_-1E-5#A':W!$Q'(9Q3 KP1 92D&S[R.DBX!&0L:!]- MF_TYA_5(-BL,/GWP?Y@..D#1OI5_VK@@N"[D1*(#96*JQY*#]L0T.9"EE"8= MW2VJ,T_9^;@7+(ZLSMQ'1P=#\.MFA_4J+%:# /$QSEYBF2^PLE9?'9)1'J2V MQ)H@)\2Q),&4%!&5\4XVL7 [4===F^0QH!M>'QU8N_=U#/IR23%L6NNE=FOL M<+HV':.KC4-QS7SR1G%E&#@7ZAR\8L$G01(03J0L,?$VTRT&Y:*[ALAC0#N> M?CL ]^.NSI\3$8-D05C(6->3:"<@Q'7..GMQV]M@EVS/(@ M,'QD:LQE X@HQ1BK(G##B"ON&(0Z_SAF+92/D870I(;M:=*Z:T4\!FP#:^+Y MF+B]!A=%RWU)G(,7GJR\P5#;/A/XJ$*)S#/'6]>I_S6&5 T-MQ,,K=I']\\B MO7,?]R3XS9":>V5Q':,Y\G>8\QY82K+.'(FDEQQ Q^!%4MZKT&1K02-^QDTA M-3X,/6"@@_M@"#'<3G1PW<)[A MIW6#9'-4[W\%7[JD[VJ3$/U@M5I,X\6J/JM_G&]:,"8N&,^].E%^^*ZJ'Y;"8+J>S3Z\O%G4ISZU:()LS*SH) M<%*GNF>%[F5$5Q='8'0L&]^FV;HQ7^/FFY_#6>L)6!W<8(\YNB\VPT(>2!$^ MNG?@Y@B2]7ZLIW0[022/6.H")M5\HI$K#8M,Y)-7'9U2 .,FK9_S MR>T:JIT?\9TE<^/?W](GS;]M=Y;]N1F'/R&16*>L )M4K:UU$2++$9BV-G"4 M*I M*UD';[.D)2A>,D21 [@00C;DIY;4I(%G)'Z?=VJ_S=E[#M#KX!9[3$Q/UP+O MF3V]H^F)D9*;Y!!(U:17860=*B$ T7D7I>?,-5E\,"[;SSNA?_KSVAD01]W5 M^I"G)RQTD>K;/?>Y^\5^E?ATDJ+C MG!W(.C9.>4?W.OH"!B4)A*-.HLD$H)9,/>]T^FGOH9.#J /G<,CX%0MW%HGU MPL-Z,T>A"Y9IR(H)&11#E9MT'YXZQ=%MEKS_%,<^$.FD(/['A>Z5G[/9K2: MZUTVU6#L. 2! I3R'H(N$K(VM69$%96:I+N/)WVWE!]K=2 &3FR? M6)4=F/<=FUI>;?X0_=YV;?C;V0US4B.P5V'Y^:?S^1_K!4W+34W&]0R+9*Q- M4H-3-7%IL:YD4@@\B&23)4N#3?!]$N[&S7J?&K*'-46=$#_=)[[OT]@-%3V: M633,&W(9!63K21"A5*4Q1JJB^-MI7WP^:7OY$;R,F[ >^=B,C8T.;I[CDGT_ MB.5:!J%X48+3H*TBY]43DET('$HP)HDLA&VST+D%,^-FB#L]("=#1^-+Q(\(T??!S\B9VS"Y MYG7#Q5GY#?^XWAWVCN*K-/UZ3M+91%EGY46>?ZUX(7F1,I=DA#;__#BO#N=$CX3YD54[V&WQO__U MCM9^H=]8_VC]D_JWWF/YG_6?O[]_^\/GAT_3<_I;_T(G>_/I'SZ>O?J__W;V MR^LW[S^\^=OO;S_^Y^T8:CF_6,U+N+84ZXJ!=--23+>7[RI,SY<_,KRS?(\9OSHZ=1%$ MMCZ"9IG\&FT2*ZX9D0WTYX"1B8@%&D!HT:= MK''&_O.MFM]+MSNMFM]'S!U$Z/>4(1AA,2>*A*0M!90("3Q/"GS4C,N4I!1- MJMH/7,[;?D_EX49E("EW@)/KB.?MC.[?B\K,\C(^NG8\,=_>9/CJ[=O9:KZY MNC=A#7W&-L5%L=/$A(04'T7(GNYN11$W!!88)%&<4E$Y79HL^VO%4"<7X8% MNU,?UX'6NZ[./N!5;UU*FU&C4@52B!&4$QEBL )8()5(%61I4S8W+!N=V.=A ML#ZBAD?U&AOP?Y591:LB?9.$PHT$906%:#E'\$7&[)S*/)ZT[> (7KI;/]P) MU@_2=9<]:/>6J%\U%]5D[.I%6EV0VQ_.JZ F(7JI,7E(2/>7@RN'#R*K3NAI6><@US*RO?+:K^ K[0'H,A+R645-'!\+I"QM4\5+5709/S MR)76*C&91(?QP/Z,=K=N>CPOJC%*.K_5!I3/6C+:9*U3 ?(U/2A56Z>T+1 E MDDYU9$6??$KOL"QVMSO[&9R:/!^&0I M8+,AL)..VFW$9W<[BY[!Z3D((QTWCV]]^.GO_ MZXN/;\]^V[_ [>Y'#%*@]@1E0Q68X:>*KO?XM4:TLT_7&Q.9J)6]!DR=Q:!2 M\>"X,& 3SS8BHO!-QB@^1-#13_6W/O?U=)G.Y\L+B@U(E"_IC_YCHCA:89RC MD,":VDD9(5)0 !1W"Y>,LSPT,5<[T#;RP^@0*+GSK#^P1@;,?;0V,NN:B -J M:1_ZH#8&YSXJFYL=Y0QJI8![1W<*BP*<8PAH6(JQ2%-8DT:N9F8G?<9\<8YG MY9QTY2Z6+[^_6\SS M15HMR=O7FVH:9GGQV0N(03/R*=?%FP&!2:-BR;X4+9M(J04WO9JV/9!X MQ[2-KO61ZVRW/)Q=YK77Y8*JU&&:-@.+J2X]YA*BRP)T->XLDMOH!JNAO(^ MD8$V/B;F RJH#X#=%,BVA%2PX(NEJ$0'M'62&#&A-(4F7&>*5RQ#N\LCW#XH MNTO%>)6ZQROV+DJ.E'('68U]C]QUM!VXLZ6VH+$@ZK9<)L [+4%D5-;*F*-N M$A,<3/'(967=6+G3JKX#C%^+_K9/KHZ.)5Y^M M!".5$DS98)5IZTSN1>_(^&[K+K;37 < K<-*9VEZ/MW6'9U]Q478].;.RW1U MV6V^97/Y3W--35YSS;+1 IT'3G$H'4N-X$HH4%)11F;G(F_RZ#(, M^2-70K: [PAZ';7.)4Q>+)>XOJ9>A:_353A_\^=7G.7IZH+4^7JZP+0Z__YK MF(5/F%]^?Q/2Y\NCNQY'Z2%[=Y&@K$)*120H!Q%.5V475W?(EOO9GFOFT6"^64^^_3+]!OFC:A>?O\9YY\6X>OG M:0KG+^H,A%NR$%+X;$H!FRAJ4,%G"(5SX(85IQ-&DQKGFX9F:>12Q;9>Q*CZ M?S8O?9O;*42ZN%;?#QYOL=O'MDG0/\U!ZW1]M,H+K#5UZ @8)5&(% R!UJ)* MZ+G7[EFEZW^[^!)Q<<.%N71:)EF4XA%3'4L?0:4L(6*)4)QBMDAOTNWM.,-P M^B!%G:;-]T'$;0LVC/0[B'3V#.C6.0['G;>\6"B!#+[BQD"LLWR]TSRHQ +C M;1[<]Z>UTQ#\&.BUUE@/H+PL)7IYL9S.<+F\/%V;%+'TS!>F0?!"PLN.HB^M M/8B00L LG4^V"?P>HZJ7%YM&F'AHSL'1"NHC'ME0OWTPR#YFAI%#$3:!,G0X M0S8>F'))JY1LXFVRC#>IZ&2\P/'ZO;^4Y@!1C]I+^LNTX(LSL#$)Y5Y7:>:BB)F"]QIXW8&MG&1D73D# M:3E]ADVJH'X"$8]]?A?.S5%0&$QZHV+@Q2;^?;68+Y?T45ORA8\)BY.@0ZR[ M6FO=L_*U*C RFQS+DCUE#N[]X"[2\D=I_7AYC:KN2R]JO@KG6]HEX5)Q:P&5 M)5_*<@M!"0V1%VFX\MD'_X2N[WYJ%ZGNHQ1]I*1ZB$0>=J>O7]\5XS'G2)<5 M8QF4YPE"O;:;-W^F\XN\WG:QI+@1\[JQ4,88G I@F8Z@ B$H""E "*V9ST*)TJ@. M8F]:NX7FL )T'.PX+N S8?/),Z7@>QG;57&V7+#!R\A9*XYU.F0H"37 MX,BM!18+5R$[U+()@.XGIXLX\P10&D 9H^8=+M^G"O0>^_QN+ZOC//8!A?ILBHE^K(&=EXU4 M:^C]'I<79$6&*S#:^:O:%!T=QFGK0J00+,-0'!@=&8&*'*# @X3L#!DQ50J* M-A6*S?N&=\_QZ* 5U\Z#HJ,)*J<"3A8%))JL@J/C9MJLP6E407+ZXJ5]4#1$ M!FHCCCZ2']K_7(MO:H+-2T46U?/%DL1;(B"N @*I=6H2Y.5 M%_>3\_QJ1O9"P9V,P]$JZ1)8VQ<2FT0R,7C@3 =0PB*$2+&)"MP5"G"]9DU, MVD,$C0NN(93])'X.D'P'"-K.95N/7OMQWO7VB6_PRWXX(K"?0:T0N302G M7:J3T#1X811D*Z+C6J.Y7:34PDS=0]GS>Z@<[C(\5E&](V][4J,/+*:40&*L MX73!^K)+QU5H^I'-*;=9.+8#;3W9MJ/1L _6#E!-!VA[MYA_Q<7J>V5H]6*6 MW_S7Q?3KNE[U^Y6OH9T0CLFZF*3(.HF!3F9F K#F#QGG@8LF9>([T#9R\O[$ MMFYH9?6,OQM^22XZE:#J]L#:XY$]A^B$!5'(U8TD,)>:C&/9@;9QK=W@>-@5 M;P,Z"0("$%1>_0D&%4"&"VC\9DSC$W*=YY-0\Q>^GVT(68? M4??;]R!TCD9*"2236LIM'-EQ3?RX1$2XF*-Z:F':T7T/)VJ!V4MAN_4][".] MW@KAD0RE]I&#+AE!U9?Z()0 EHW3.M4:?_F$Y@\LA#]1G\MA^CY24MVWOF6I MT"D2B#&F]Z+-F!YDEX@1HHHGU#[4*UO)^I\.0P'0\NR!]=TE]H,&=&C MKWE_YVL:U3-RYXLE=]X9-"B=R'UW2+2;KW-J1W5H=?4-P7N*3Z^>T!5=M"): MXM(8LL 2$;S* HRGD\UC,MHWV25V&+E=.#T#PF9W7 ZEPQY\I>F:A7-BHJMDBCB,"B1%/0,7T;-<.8L OE6W?V[G'@N M97#UV*B00:'FQ"#]0JZQ9,B(ZRQ:@&]W$KL(&$Z)QD;:.Q:>1]Z='Q=AMKR2 M73A_MZ@S(,GA*,I9'2CTDJ'48>M!0)0F4>2$2=EB=)'BB4OSH<_NMBEB^-MR M$/&."I''.SQ>+(C!3YOL[??K/_(N?*^_]>*/L,@O4L+S*M:G1]S VNKGYOVQLKRR5SL3/\VF_XUU1?7/83JK M0GQ]@1_G'W"U.E][)G3@K.5:JN2!6:5!.:'!K7LF,!JF,LLF-(FP#R5XY 7D MIX?L230[C#T[0;+/]2[R?CZ'-\ M0%]%6[-ON,GM;R1+$1>2WE<3QC'0RD+:AOSU K E3E+=ELA9I%"]SC()-I%H:FFI1XDI:!5MF^S+ MCW3LAJN_T@/*,8KH!TYK>_W;?#;_44J73$5ON!1<@PF:K+',=#RJ@%Q6G+3D MHVC3&?4X6;N![:_PY-) 31VD[ZZ%3A])FL>H)>=SM./R5WFIZ!=#A9ZN6>Y]PLM=69YOG@.&F>-W[L6TF=CW- M0>OI7,R[9%W)('.6H)(5X!FAF#ENG2HL4&1^BJ+0,:=S6<%<4IA!1\])!MH" MN3F.S@KS7"A3(F^\0_6Y3^?:!T5#3.?:1V,CN@K+Q6IRG1<@-M:)A'4+G9'% M:Y$VE]/J@* MN@/1MBU'\BQ58@*T*'2OE]KAK5$#9\%FYE#[L$NCR8$P&K-3=2C%/HJ3 Z3< M063R>/-N"M%GC054Y!84=PY<\K;.%3:^6&&B;M/=?'3W?%?3D XQ1L,KJ,/N M>?2:CDL.0&)PE7P!07$/,27'BT?N>9M9I\^E>WXO_3[:/;^/J/OOJ>76&,4T ML*PSR<9&\"%:2%P[)HO*'&_5/CWW=9)[J6^_GMH]9-GO6 4F4W!&<4",Q$4. M))K*#S)M8^"H0 M"YG-I\Q!]^LD#]/Z\?+JH3/TYFR(;(VV213P23&"*ADNQY(":61R!J7$K)[0 M==_K) ]3])&2ZB$2N8C+FZZ/"9: R#58Y06!5-?(3!4@]R=(D5.4L'[S"(^*-HY00E\8NIQ%$HP)QDE ;E4=/U4@9#)U.8<@4D"+NC6*NH@RCM'K MPQ@Y0,A]H>2!K)!2+A%^8"F% XA&@_*!@8^2@3OBDPD)UYNY^?: :P'TS6,RG? MT0'R[P!)ZV*_36'+-G;5%.7*7+/==9.RBG6"6\X*8O3,2?J)84T&"]RAI#_< M'*+B^XHK#Y9W+X#Y;3Y+%XO%54W49=HC)Y-+'0R;,YEF;BR$$HDSZUS*CHD@ MF[PI/4+3N-GCEB :0 <=P&FG"7XQZX2J2'!1DZR,-W6&-0=K;#$Y%%GX2:K? M#I[3V6[8PZG#PJ'5U4..^XJ;'S>S5F8V1VL2F2;#;!F(7$>K% IQG X&#*-_ M1Z4T"SN.07SRN[IX^1Q0OP]V[PTB[,[A\RHL/[^8Y?J/6O+]+9ROR[QE]CK( MK(&+%(A#K\%)E:&0W5:V,'O'1S\ 3O=_=Q>OJ>/ :P!E= ZW=PO\&J9Y.2$! MIAS(IKMZ]2O'$,BW<* 9G2$9C15//LGO_FU=/-6. ZF#!-XYB&[VH[@:(=M: M41F2(F?21HA(S31UQ\(<-[ MV:Z/9'K)#ZVBC-Q$D2 (:TF4T8 G*4+T4GH3K4\V'XVN1PCH=NQ@>[0-I98. M(LC7VZ_]&/[<.)"_X6JBI0Y193+%1#$H'00$XQA@"#X9DX(O33(1]Q'3[3C MXV VF/P[P-!5[^@O&);X?OKI\^JL_+[@;':4JTBUEF7#EBI=42%UQ$,=$VS1 $M%^BS M:K(R?0_HC#%3;QCSKI,Y_/E M!7W3>_R&LPL<;DK$+M_29FC$WORUGB$AN:_-_QDXKUD%%.232R, ?0@RQ83Z M]A+,/F=(A,E]HCV;_8QU0<37S]/T8D%.XXO5:C&-%W6"U?SM+$^_3?-%./]I MOL#II]FK^<6,?HS+[9.8\DEICG2$74VXR 3.1*S[ZTI*GHF4TA..U] T]?4. M=!"(KOVQ414V\E" JR[3:W;#^;H"B3EMBC42HO$:5, $WF@+3BLRZ;[*PK3.Q*B$KY),X7C?+&:F)G2JE%*LC MX9+ANY1S[0:RAZ@8;_;$0-J=#RWJ$?&2UN?F^^3W#Q/O8A A4M";ZRP_SA4$ M41RDB#Q+&:Q-]^P:75ZB8XGI7S[-O_WK]A,W -G^QVU\7'_KB& 81G7SH^0X MZBR(2YI?_39!:Y%KI"B"^TR,,@=12PO!HC)%LZ#-/8TV1^G^U6_CE!^TT_V> MEZNS\O?YXCQ?]IY3Z"B5KA/<61UQ4=^O!?EVS@1K?(D4Q)HGW-X[ M'SI.-<#P&CY67AT8^']_-RE>*.T$)W/D"RC+ WBM%?!8N)1"AU#N<3&/.N3_ M_FZ<5_QVAWQ/.7:@^==O)IH3IZE.OQ(9ZV!HHCU;!S98Z273)EQ/7A](\Z_? MC/.BWD[S>\IQ5/,^8$!U(\$9LRE)T.5F=*F##"SX0C&_YZDP+C4:'I^X(5K0 M-8X;T4G0VH&J.WCKN,7M-K&ZF:[\)WW-+)R_NEBNYE_H&Z^R5\4%&XV-X"PS MH!@R",$%8!0#BB!UYC'=-8K'IT /(?8OD)@Y$%SS$VNZ S1OF;J<,%Y9^/MT M]?F2KZLEFO5=DOZ_%MM,@DA6%,/ !P#-3ZO-9_W&5TL/?YE^PSST0/@]ONQT+WZ[<-OZX8\7D;4/!GQFGOS>M%Z8 MKH L;RXL&_KM)F_]/0V/5X4B]"01M*H;((HP$)3DY,9S&0TF@6UV5OYUAL?O M@Z(AAL?OH[&Q7U\>?&0("I6(9-4SSXG\^\+ DZP@6<,M8RQ$YG> W7-\XCN9 M[G=ZR]M'$6.CZ<%41@J!&9%((NM6-14M>2\O;2[L[ MO>7M(^H.$GZ_?YA8H0WZ&F)E94'9DB 6E0%%T=H;X3S^<[SE[:6ZNV]Y^\BQ MB[>\?W\WR4RZD@('GFK[H9(9 G>5>2N<-9J9^Z9*G2+-?^*WO&-TOZ<<.SCU MK]],$F=$;R:@2E/HIJP;PR@T!1X4794R,G[?FHA3I/E/_,9WC.;WE&-GK[BF MB%!2UI!B!2TCO 95R$\7:&-"*Y*^M5QFH%?<$S_A':+A8^7506IPIT+T'*5& M)+RF8$@VS'N(6@4PHBYLY\DX%W?P#,>;D-/5TIA#PH]FZNH @K='34VTXLKD MX,!I$HO200*=30\Z"^$]U]S()KU'MPGI*U5RO*KG \J]UR3Q]CR^??L?X?QB M_6EAEO]V$NOU>/5U+^[[NJMD72C2 MLY+K.%ZMR()I"9$%!BIY# 8=79Z[3$S;*5.P&TE'942N;/CCWW6==O](HGY) M?_T?$Q-U]"0-<')MRU%!5"%!LM+IXKAE>3!)'$'G>(%T T3]D&(YD>X&#,7' M,7@'/X3M^?FG-'\MGKOVP*SPW">="+-2VEIU4("@6B!)%7RTQE@_6(-->RNX M\_E9^[ NA:2%T\ THRC'Q@"^< ?%12N1B\CU+GL4!N#]%F7=6[I]4'/3TK73 M3PCC X/=R.L5>D=A8]Y<4=W#;YL@4CY[Q$(\430$"GV X%PM]\W) M&JM=-DW&!.]"W+B1:@M0[(6[ S34)>K.RIUQ5]NL(L;LA.1UF5.LBYAR!E]# M\Y1M2J%ZS[;)8H\]:.P9@X< Y$D$#J.MDY@]NKJP.C^.O\V[H(X^WL\1/]?GY>"\+_ M"(L\X<*'%+T"9.1-*Q$9W2F^MLMFS4V@WU1-W,(#:.W?1SP0.?/3JK$#I#[. MV'8WQR08[^IH4W Q$"NUO=/7)C]4/'I; H]\ER3!P%[CEKIQK^SF&-G+ASQ$ M80>C\"LNIO/\8146JQ-@\=7GL/A4>VE>S9?KT5]_?L79$BNV8+U+]Z9+\)8V6 MH0'O>095.V0,/X75]L^> MYE)'F1!E3=KJ=;^^H7.&3A"(I,]*:&7]B:+Q0R_U9EL.^H+B(0H[\E)_,\N[ M//9M?U!_B6&)_^=__']02P$"% ,4 " (GY%1Y6K><,(# #9&@ %0 M @ $ 82TQ,#,Q,C R,'AE>'@R,3$N:'1M4$L! A0#% M @ ")^145<>!L-H P @H !4 ( !]0, &$M,3 S,3(P M,C!X97AX,C,Q+FAT;5!+ 0(4 Q0 ( B?D5&94*\0=0@ ",K 5 M " 9 ' !A+3$P,S$R,#(P>&5X>#,Q,2YH=&U02P$"% ,4 M" (GY%1QE>;4GX( ! *P %0 @ $X$ 82TQ,#,Q,C R M,'AE>'@S,3(N:'1M4$L! A0#% @ ")^14<=/CW%M!0 [1@ !4 M ( !Z1@ &$M,3 S,3(P,C!X97AX,S(Q+FAT;5!+ 0(4 Q0 ( M B?D5%NL9AZ3P4 ,P6 5 " 8D> !A+3$P,S$R,#(P M>&5X>#,R,BYH=&U02P$"% ,4 " (GY%121=@,T.L!0!* 40 #@ M @ $+) 82TR,#(P,3 S,2YH=&U02P$"% ,4 " (GY%1P'=X M1<&UL4$L! A0#% @ "9^147 V"R3S1 $ VY,. !( M ( !?R4& &$M,C R,#$P,S%?9&5F+GAM;%!+ 0(4 Q0 ( M F?D5'KB6-RO& ! (?Q 0 1 " :)J!P!A+3(P,C Q,#,Q M7V%P 2 M " 8W+" !A+3(P,C Q,#,Q7VQA8BYX;6Q02P$"% ,4 " )GY%1REN M%IUU 0#G;1$ $@ @ ';$ L 82TR,#(P,3 S,5]P&UL 64$L%!@ - T 20, *B&# $! end

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˲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�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�V1:=Y )C)=<< SU0\%BRL1>J;)&,'21[1=[TP%*#?X M("&G\*P%VUY*"R%$.MZ'J3&AX4)*$5Y/RMW"J&2ZPE#W0I1J6+*'2=URY)A^ M:"\[Z(VH\51?82SXR#2:0;5